<SEC-DOCUMENT>0001564590-18-021372.txt : 20180813
<SEC-HEADER>0001564590-18-021372.hdr.sgml : 20180813
<ACCEPTANCE-DATETIME>20180813084511
ACCESSION NUMBER:		0001564590-18-021372
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20180630
FILED AS OF DATE:		20180813
DATE AS OF CHANGE:		20180813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arsanis, Inc.
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		181010390

	BUSINESS ADDRESS:	
		STREET 1:		890 WINTER STREET, SUITE 230
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		781-819-5704

	MAIL ADDRESS:	
		STREET 1:		890 WINTER STREET, SUITE 230
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>asns-10q_20180630.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
asns-10q_20180630.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, DC 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-Q</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:MS Gothic;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:MS Gothic;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended June 30, 2018</p>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-family:MS Gothic;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:MS Gothic;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:MS Gothic;font-size:12pt;"><font style="font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from _______________ to _______________</p>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number: <font style="Background-color:#FFFFFF;color:#000000;">001-38295</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">ARSANIS,&#160;INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">27-3181608</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4.5pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">890 Winter Street, Suite 230</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Waltham, MA </p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">02451</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <font style="Background-color:#FFFFFF;color:#000000;font-size:9pt;">(781)&#160;819-5704</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-size:8.5pt;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font>&#160;&#160;&#160;&#160;No <font style="font-size:10pt;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-size:8.5pt;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-size:10pt;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9746;</font><font style="font-family:Times New Roman;">&#160;&#160;(Do not check if a small reporting company)</font></p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Small&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth Company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9746;</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-size:8.5pt;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-size:10pt;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-size:8.5pt;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of July 31, 2018, the registrant had 14,315,410 shares of common stock, $0.001 par value per share, outstanding.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IFINANCIAL_INFORMATION"><font style="text-decoration:underline;">FINANCIAL INFORMATION</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">Financial Statements (Unaudited)</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Condensed Consolidated Balance Sheets as of June 30, 2018 and December 31, 2017</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2018 and 2017</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"><font style="text-decoration:underline;">Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2018 and 2017</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2018 and 2017</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to Unaudited Condensed Consolidated Financial Statements</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IIOR_INFORMATION"><font style="text-decoration:underline;">OTHER INFORMATION</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><font style="text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
</table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><font style="text-decoration:underline;">Exhibits</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Signatures"><font style="text-decoration:underline;">Signatures</font></a></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own or have rights to trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. Other trademarks, service marks and trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this Quarterly Report on Form 10-Q are listed without the <font style="font-size:7.5pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></font> and &#8482; symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade names. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><a name="PART_IFINANCIAL_INFORMATION"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IFINANCIAL_INFORMATION"></a>PART I&#8212;FINANCI</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AL INFORMATION</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_FINANCIAL_STATEMENTS"></a><a name="ITEM_1_FINANCIAL_STATEMENTS"></a>Item 1. Financial Statements.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARSANIS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>CONDENSED CONSOLIDATED BALANCE SHEETS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Amounts in thousands, except share and per share amounts) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,940</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,793</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant and incentive receivables</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,178</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,608</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,393</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,129</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,562</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,530</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">353</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">355</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">948</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,210</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,254</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders&#8217; Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,137</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,893</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,879</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,779</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unearned income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">694</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loans payable, net of discount</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,486</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,314</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,214</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,680</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loan payable, net of discount and current portion</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,706</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,922</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unearned income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,519</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,936</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,446</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,547</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 10)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.001 par value; 200,000,000 shares authorized as of June 30,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 2018 and December 31, 2017; 14,315,410 and 14,294,383 shares issued and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding as of June 30, 2018 and December 31, 2017, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,601</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,830</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income (loss)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(115,028</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,265</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,764</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,707</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,210</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,254</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARSANIS, INC. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Amounts in thousands, except share and per share amounts) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,930</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,906</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,063</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,297</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,686</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,738</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,503</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,174</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,616</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,644</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,566</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,471</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,616</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,644</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,566</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,471</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant and incentive income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">516</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">862</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">961</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,562</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(259</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(444</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(526</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,463</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">762</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(462</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(462</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">483</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">803</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,133</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,705</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,763</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,090</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of redeemable convertible preferred stock to redemption</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,133</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,718</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,763</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,110</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders&#8212;basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.85</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11.13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.59</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.62</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,304,102</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,299,288</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARSANIS, INC. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"></a><a name="CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"></a>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Amounts in thousands) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,133</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,705</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,763</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,090</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation gain (loss)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(297</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(379</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,863</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,713</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,469</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited notes are an integral part of these condensed consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARSANIS, INC. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Amounts in thousands) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,763</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,090</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,618</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">397</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,377</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash rent expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">462</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(762</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant and incentive receivables</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(635</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(547</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,394</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,708</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(563</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,434</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unearned income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(336</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,095</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,657</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,874</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of redeemable convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,053</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible promissory notes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,935</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of loans under funding agreements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">666</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repayments of loans payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,167</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,165</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments of issuance costs of convertible promissory notes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments of issuance costs of redeemable convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(197</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of initial public offering costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,058</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,275</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Effect of exchange rate changes on cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(120</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,862</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,415</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,148</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,429</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at end of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,286</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,844</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of redeemable convertible preferred stock upon extinguishment</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;of convertible promissory notes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivative liability in connection with issuance of convertible promissory notes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of convertible promissory notes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,405</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of derivative liability in connection with extinguishment</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;of convertible promissory notes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,234</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of redeemable convertible preferred stock to redemption value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited notes are an integral part of these condensed consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-weight:bold;font-size:10pt;">ARSANIS, INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Nature of the Business and Basis of Presentation </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis, Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody, or mAb, immunotherapies to address serious infectious diseases. The Company possesses a deep understanding of the pathogenesis of infection, paired with access to what the Company believes to be some of the most advanced mAb discovery techniques and platforms available today. The Company&#8217;s pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including <font style="font-style:italic;">Staphylococcus aureus</font> (&#8220;<font style="font-style:italic;">S. aureus</font>&#8221;) and respiratory syncytial virus (&#8220;RSV&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 28, 2018, the Company announced the discontinuation of its Phase 2 clinical trial of ASN100 for the prevention of &nbsp;&nbsp;&nbsp;&nbsp; <font style="font-style:italic;">S. aureus</font> pneumonia in high-risk, mechanically ventilated patients following the completion of a planned interim analysis of unblinded trial data for 118 patients by an independent data review committee (&#8220;DRC&#8221;). Based on the results of this analysis, the DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion, and recommended that trial enrollment be discontinued. The Company intends to conduct follow-up visits on patients dosed in the trial per the study protocol and to evaluate the complete dataset from the 154 patients that were enrolled in the trial to better understand the basis for this result. The Company expects to complete this evaluation in the fourth quarter of 2018 and has ceased further clinical development of ASN100, pending the results of this analysis. The Company currently does not expect to incur material costs for this program beyond the fourth quarter of 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In light of the discontinuation of the clinical development of ASN100, the Company is considering strategic options that may potentially result in changes to its business strategy and future operations. Pending any decision to change its strategic direction, the Company&#8217;s current operating plan provides for its ongoing review of the data from the ASN100 clinical trial, the continued development of its ASN500 program, as well as supporting its collaborators across its ASN200 and ASN300 programs, both of which were outlicensed to subsidiaries of Bravos Biosciences, LLC during the first half of 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, the Company&#8217;s ability to successfully execute on its strategic plans, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Any product candidates will require significant research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 3, 2017, the Company effected a one-for-3.4130 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s redeemable convertible preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 20, 2017, the Company completed an initial public offering (&#8220;IPO&#8221;) of its common stock, and issued and sold 4,000,000 common shares at a price to the public of $10.00 per share. Concurrent to the IPO, (i) the Company issued an additional 600,000 common shares at a price of $10.00 per share pursuant to the exercise of the underwriters&#8217; over-allotment option and (ii) New Enterprise Associates 16, L.P., or NEA, purchased 2,000,000 shares of the Company&#8217;s common stock at the initial per share public offering price of $10.00 in a private placement. The aggregate net proceeds to the Company from the IPO, inclusive of the over-allotment exercise, and the private placement were $58.1 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. Upon the closing of the IPO, all of the outstanding redeemable convertible preferred stock of the Company automatically converted into 7,180,483 shares of the Company&#8217;s common stock.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had an accumulated deficit of $115.0 million at June 30, 2018. During the six months ended June 30, 2018, the Company incurred a net loss of $22.8 million and used $25.7 million of cash in operations. The Company expects to continue to generate operating losses for the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on its current operating plan, the Company expects that its cash and cash equivalents of $49.9 million as of June 30, 2018, will be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments for at least 12 months from the issuance date of these condensed consolidated financial statements. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis is incorporated under the laws of the State of Delaware and is headquartered in Waltham, Massachusetts, with a wholly-owned subsidiary that is primarily focused on discovery research </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in Vienna, Austria. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include the accounts of the Company and its wholly owned subsidiary, Arsanis Biosciences GmbH. All intercompany balances and transactions have been eliminated. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Summary of Significant Accounting Policies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unaudited Interim Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed balance sheet at December&#160;31, 2017 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying condensed financial statements as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017 are unaudited. The accompanying unaudited interim financial statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2017 included in the Company&#8217;s&#160;Annual Report on Form 10-K as filed with the SEC on March&#160;9, 2018. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#8217;s condensed financial position as of June 30, 2018 and condensed results of its operations for the three and six months ended June 30, 2018 and 2017 and cash flows for the six months ended June 30, 2018 and 2017 have been made. The results of operations for the three and six months ended June 30, 2018 and 2017 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2018.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of common stock and stock options. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk506359613"></a>The carrying values of cash equivalents, other current assets, accounts payable, and accrued expenses approximate their fa<a name="_Hlk506359613"></a>ir values due to the short-term nature of these assets and liabilities. The carrying value of the Company&#8217;s loan and security agreement with Silicon Valley Bank (&#8220;SVB&#8221;) approximates its fair value because the debt bears interest at a market rate. The carrying value of the loans received under the funding agreements with &#214;sterreichische Forschungsf&#246;rderungsgesellschaft mbH (&#8220;FFG&#8221;) approximates their fair value because the Company records imputed interest expense based on rates that approximate market rates of interest as of the issuance date of each FFG loan. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gain (</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Loss</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive gain (loss) includes net gain (loss) as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. Comprehensive gain (loss) included $0.3 million and $(0.3) million for the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $(0.4) million for the six months ended June 30, 2018 and 2017, respectively, of foreign currency translation gain (loss) adjustments. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Income (Loss) per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, options to purchase common stock, redeemable convertible preferred stock, warrants to purchase common stock and warrants to purchase redeemable convertible preferred stock are considered potential dilutive common shares.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s redeemable convertible preferred stock contractually entitled the holders of such shares to participate in dividends but contractually did not require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers </font>(&#8220;ASU 2014-09&#8221;), which supersedes most existing revenue recognition guidance under GAAP. The FASB also issued several amendments and updates to the new revenue standard (collectively, &#8220;Topic 606&#8221;). The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance. These judgments and estimates include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows as the Company does not currently have any revenue-generating arrangements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2016, the FASB issued ASU No.&#160;2016-15, <font style="font-style:italic;">Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments</font> (&#8220;ASU 2016-15&#8221;), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The Company adopted the standard retrospectively to all periods presented on the required effective date of January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2016, the FASB issued ASU No.&#160;2016-16, <font style="font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory</font> (&#8220;ASU 2016-16&#8221;), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2016, the FASB issued ASU No.&#160;2016-18, <font style="font-style:italic;">Statement of Cash Flows (Topic 230): Restricted Cash</font> (&#8220;ASU 2016-18&#8221;), which requires restricted cash to be presented with cash and cash equivalents on the statement of cash flows and disclosure of how the statement of cash flows reconciles to the balance sheet if restricted cash is shown separately from cash and cash equivalents on the balance sheet. The Company adopted this standard on January 1, 2018. The adoption of ASU 2016-18 resulted in the Company's cash, cash equivalents and restricted cash being included in the beginning and ending amounts for the periods shown on the statement of cash flows and was applied retroactively and reflected in the balances presented for any prior periods. The Company believes that the adoption of this guidance did not have a significant impact on its condensed consolidated financial statements and related disclosures. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The restricted cash as of June 30, 2018 and December 31, 2017 is held as letters of credit for the benefit of the landlords in connection with the Company&#8217;s office leases.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,940</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,143</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash &#8211; current</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,361</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash &#8211; non-current</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the statement of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; cash flows</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,286</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,844</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, FASB issued ASU No.&#160;2017-01, <font style="font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font> (&#8220;ASU 2017-01&#8221;). The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill and consolidation. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU No.&#160;2017-09, <font style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Scope of Modification Accounting</font> (&#8220;ASU 2017-09&#8221;), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2018, the FASB issued ASU 2018-05, <font style="font-style:italic;">Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118</font> ("ASU&#160;2018-05"). This standard amends ASC 740, Income Taxes (&#8220;ASC 740&#8221;) to provide guidance on accounting for the tax effects of the Tax Cuts and Jobs Act pursuant to Staff Accounting Bulletin No. 118, which allows companies to complete the accounting under ASC 740 within a one-year measurement period from the Tax Act enactment date. This standard was effective upon issuance. <font style="color:#000000;">The Company will continue to assess the impact that various provisions will have on its business. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the FASB issued&#160;ASU 2018-07,&#160;<font style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting </font>(&#8220;ASU 2018-07&#8221;), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The new standard specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&#8217;s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. ASU 2018-07 is required to be adopted for annual periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2018-07 will have on its consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the FASB issued&#160;ASU 2017-11,&#160;<font style="font-style:italic;">Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</font> (&#8220;ASU 2017-11&#8221;).&#160;Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480&#160;with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU 2017-11 is required to be adopted for annual periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2017-11 will have on its consolidated financial statements. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No.&#160;2016-02</font><font style="font-style:italic;">, Leases (Topic 842)</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (&#8220;ASU 2016-02&#8221;), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leas</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 1</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 months or less will be accounted for similar to existing guidance for operating leases today. ASU 2016-02 (Accounting Standards Codification (&#8220;ASC&#8221;) (Topic 842) supersedes the previous leases standard, ASC 840, Leases. The standard is effective for publi</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c entities for annual periods beginning after December&#160;15, 2018 including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial statements. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Fair Value of Financial Assets and Liabilities<font style="font-weight:normal;"> </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents - Money Market Funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,576</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,576</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,576</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,576</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents - Money Market Funds</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,891</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,891</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,891</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,891</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes to the valuation methods during the six months ended June 30, 2018 and the year ended December 31, 2017. There were no transfers within the fair value hierarchy during the six months ended June 30, 2018 and the year ended December 31, 2017. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Accrued Expenses<font style="font-weight:normal;"> </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,335</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,317</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and benefits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,539</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,454</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">563</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">510</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,879</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,779</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration, License and Funding Arrangements</font><font style="font-weight:normal;"> </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Adimab Option and License Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, the Company entered into an option and license agreement with Adimab, LLC (&#8220;Adimab&#8221;), a related party (see Note&#160;11) (the &#8220;Adimab Option Agreement&#8221;). Under the Adimab Option Agreement, Adimab has provided to the Company certain proprietary antibodies against RSV (&#8220;RSV antibodies&#8221;) for its evaluation during a specified option period and has granted the Company an exclusive, non-sublicensable license in a specified field under certain Adimab patent rights and know-how during the option period. Under the Adimab Option Agreement, the Company has an exclusive option, exercisable during the option period upon payment of an option fee to Adimab, to require Adimab to assign to the Company all rights in up to a specified number of RSV antibodies selected by the Company and certain patent rights owned by Adimab that cover these antibodies, and to obtain from Adimab a non-exclusive license in a specified field, with the right to grant sublicenses, under certain other patent rights and know-how owned by Adimab. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, the Company entered into a grant agreement with the Bill &amp; Melinda Gates Foundation (the &#8220;Gates Foundation&#8221;) pursuant to which the Company has no payment obligations under the Adimab Option Agreement with respect to sales of products based on licensed RSV antibodies to the extent they are sold at cost in developing countries. However, if such products are sold in developing countries for an amount that exceeds cost, then the amount of such excess will be subject to certain royalty payment obligations described in the agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized research and development expenses of $14,000 and $58,000 during the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $0.1 million during the six months ended June 30, 2018 and 2017, respectively, in connection with the Adimab Option Agreement, which consisted of reimbursement for services performed by Adimab. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">February 2017 and August 2018 Amended and Restated Gates Foundation Grant Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, the Company entered into the above-referenced grant agreement with the Gates Foundation, under which the Gates Foundation agreed to provide the Company up to $9.3 million to conduct preclinical development of mAbs for the prevention of RSV infection in newborns (the &#8220;RSV project&#8221;).&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, the Company received a payment of $1.6 million from the Gates Foundation under the grant agreement. The funds received from the Gates Foundation were incurred on qualifying expenses attributable to the RSV project, and the Company recognized grant income of $1.6 million under the grant agreement during the year ended December 31, 2017.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company entered into an amended and restated grant agreement which replaces the February 2017 grant agreement in its entirety. The amended and restated grant agreement includes amendments to conform to current Gates Foundation audit, reporting, and other administrative requirements, as well as to make the perpetual Gates Foundation license grant described below irrevocable.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized grant income of $0 during the three and six months ended June 30, 2018, and $0.6 million during the three and six months ended June 30, 2017, under the grant agreement with the Gates Foundation upon incurring qualifying expenses. As of June 30, 2018 and December 31, 2017, unearned income under the grant agreement with the Gates Foundation was $0. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Gates Foundation Grant Agreement&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk520994072"></a>In August 2018, the Company entered into an additional grant agreement with the Gates Foundation pursuant to which the Gates Foundation granted to the Company up to $1.1 million to conduct preclinical development activities for the RSV project that were not included in the February 2017 grant agreement, as amended and restated in August 2018. In return, the Company has agreed to conduct the RSV project in a manner that ensures that the knowledge and information gained from the project will be promptly and broadly disseminated, and that the products, technologies, materials, processes and other intellectual property resulting from the RSV project (collectively referred to as the funded developments) will be made available and accessible at an affordable price to people most in need within developing countries. These obligations survive any expiration or termination of the grant agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk520994086"></a>To this end, the Company has granted to the Gates Foundation a non-exclusive, perpetual, irrevocable, royalty-free, fully paid up, sublicensable license to make, use, sell, offer to sell, import, distribute, copy, modify, create derivative works, publicly perform and display the funded developments and, to the extent incorporated into a funded development or required to use a funded development, any other technology created outside of the RSV project that was used as part of the RSV project, for the benefit of people in developing countries. The Company has also agreed to seek prompt publication of data and results developed under the RSV project under &#8220;open access&#8221; terms and conditions. This license and these publication obligations survive any expiration or termination of the grant agreements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The August 2018 grant agreement expires on August 31, 2018. The Gates Foundation can modify, suspend or discontinue any payment under the grant agreement, or</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> terminate the grant agreement, if it is not reasonably satisfied with the Company&#8217;s progress on the RSV project; if there are significant changes to the Company&#8217;s leadership or other factors that the Gates Foundation reasonably believes may threaten the R</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SV project&#8217;s success; if the Company undergoes a change in control; if there is a change in the Company&#8217;s tax status; or if the Company fails to comply with the grant agreement. Any grant funds that have not been used for, or committed to, the RSV project </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon the expiration or termination of the agreement must be returned to the Gates Foundation or otherwise used as directed by the Gates Foundation.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not recognize grant income or record any unearned income under the August 2018 grant agreement with the Gates Foundation in any periods presented.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gates Foundation Letter Agreement and Investment&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2017, the Company entered into a letter agreement with the Gates Foundation. In connection with the letter agreement, the Gates Foundation purchased 2,464,799 shares of the Company&#8217;s Series D preferred stock, which converted into <font style="color:#000000;">722,179 </font>shares of our common stock in connection with our November 2017 initial public offering after giving effect to a one-for-3.4130 reverse-stock-split. The Company committed to use the proceeds of $8.0&#160;million from the investment by the Gates Foundation solely to advance the development of a specified monoclonal antibody program that involves the monoclonal antibodies ASN-1, ASN-2 and ASN-3 and the Company&#8217;s product candidate, ASN100. Under the letter agreement, in addition to the initial project funded by the Gates Foundation with its initial investment, the Company also agreed to conduct up to four additional projects to be proposed and to be funded by the Gates Foundation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU123"></a>The letter agreement contains certain global access obligations as well as requirements relating to the Company&#8217;s use of the funds received from the Gates Foundation investment. In the event that the Company fails to comply with these obligations or requirements or any related U.S. legal obligations set forth in the letter agreement, the Gates Foundation will have the right, after expiration of a specified cure period, to require the Company to redeem all of the shares owned by the Gates Foundation or to locate a third party that will purchase such shares. For any redemption or purchase resulting from such default, the shares of the Company&#8217;s stock held by the Gates Foundation will be redeemed at an amount equal to the greater of the original purchase price (plus specified interest) or the fair market value of such stock on the date of such redemption. The term of the letter agreement continues in perpetuity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this letter agreement, the Company has granted to the Gates Foundation and/or Gates Foundation-supported entities certain licenses, including a non-exclusive, non-terminable, royalty-free (except as required under the Adimab Collaboration Agreement), sublicensable license to products, technologies, materials, processes and other intellectual property developed using funds provided by the Gates Foundation or a Gates Foundation-supported entity, or developed in connection with the Company&#8217;s conduct of any funded project or additional funded project, as well as all of the Company&#8217;s background intellectual property, to utilize and exploit products and services directed at pathogens or other targets subject to any funded project or additional funded project.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The proceeds received from the Gates Foundation in connection with the Company&#8217;s sale and issuance of Series D preferred stock were incurred on qualifying expenses under the letter agreement during the year ended December 31, 2017.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred qualifying expenses of $<font style="color:#000000;">0</font> during the three and six months ended June 30, 2018, and $<font style="color:#000000;">0.7</font> million during the three and six months ended June 30, 2017, under the letter agreement with the Gates Foundation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding Agreements with FFG </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Between September 2011 and March 2017, the Company entered into a series of funding agreements with FFG that provided for loans and grants to fund between 50% and 70% of qualifying research and development expenditures of the Company&#8217;s subsidiary in Austria on a project-by-project basis, as approved by FFG. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">FFG Grants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For grants under the funding agreements with FFG, the Company recognized grant income of $0 and $0.2 million during the three months ended June&#160;30, 2018 and 2017, respectively, and $0 and $0.3 million during the six months ended June&#160;30, 2018 and 2017, respectively. As of June 30, 2018 and December&#160;31, 2017, the Company recorded grant receivables from FFG of $0.1 million and $0.1 million, respectively, for qualifying expenses incurred that were reimbursable under the funding agreements. As of June 30, 2018 and December&#160;31, 2017, there were no amounts recorded as unearned income in connection with the FFG grants. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">FFG Loans </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loans under the funding agreements with FFG bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged by FFG as additional grant funding from FFG. On the date that FFG loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is recognized as additional grant income over the term of the funding agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized grant income of $0.1 million and $0.2&#160;million during the three months ended June 30, 2018 and 2017, respectively, and $0.3&#160;million and $0.3&#160;million during the six months ended June 30, 2018 and 2017, respectively, related to the recognition of the unearned income recorded for the imputed benefit of FFG loans at below-market interest rates. Unearned income (current) related to the imputed benefit of FFG loans at below-market interest rates was $0.7 million and $0.7&#160;million as of June 30, 2018 and December 31, 2017, respectively, and unearned income (non-current) related to such benefit was $1.5 million and $1.9&#160;million as of June 30, 2018 and December&#160;31, 2017, respectively.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Incentive <font style="font-weight:normal;font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses incurred by the Company&#8217;s subsidiary in Austria. Under the program, the reimbursement rate for qualifying research and development expenses incurred by the Company through its subsidiary in Austria was 12% for the year ended December 31, 2017, and is 14% for the year ended December 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes incentive income from Austrian research and development incentives when qualifying expenses have been incurred, there is reasonable assurance that the payment will be received, and the consideration can be reliably measured. Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each reporting date, management estimates the reimbursable incentive income available to the Company based on available information at the time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized incentive income of $0.3 million and $0.1 million during the three months ended June 30, 2018 and 2017, respectively, and $0.6 million and $0.5 million during the six months ended June 30, 2018 and 2017, respectively, in connection with the Austrian research and development incentive program. As of June 30, 2018 and December&#160;31, 2017, the Company recorded receivables for amounts due under the program of $2.1 million and $1.5 million, respectively, which amounts were included in grant and incentive receivables in the condensed consolidated balance sheet. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Loans Payable </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate principal amount of debt outstanding as of June 30, 2018 and December 31, 2017 consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term loans under 2012 Loan Agreement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,667</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FFG loans</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,937</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,225</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,437</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,892</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current and non-current debt obligations reflected in the condensed consolidated balance sheets as of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2018 and December 31, 2017 consisted of the following (in thousands): </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term loans under 2012 Loan Agreement</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,333</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FFG loans</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loans payable, net of discount</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,486</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,314</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term loans under 2012 Loan Agreement</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,334</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FFG loans</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,937</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,225</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,231</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,637</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loans payable, net of discount and current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,706</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,922</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loans payable, net of discount</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,192</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,236</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2012 Loan Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 7, 2012, the Company entered into a loan and security agreement (the &#8220;2012 Loan Agreement&#8221;) with SVB, and borrowed an aggregate of $2.5 million in two separate tranches: $0.5 million in December 2012 (the &#8220;2012 Term Loan A Advance&#8221;), and $2.0 million in February 2013 (the &#8220;2012 Term Loan B Advance&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the 2012 Loan Agreement, the Company issued a Series A-2 warrant to SVB, which became exercisable with respect to 2,202 shares of Series A-2 preferred stock on December 12, 2012 in connection with the 2012 Term Loan A Advance, and with respect to 8,811 shares of Series A-2 preferred stock on February 25, 2013 in connection with the 2012 Term Loan B Advance. At the time of grant, the Series A-2 warrant was exercisable at a price of $4.54 per share. The Series A-2 warrant expires on December 6, 2022.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 19, 2016, the Company entered into the First Amendment to the 2012 Loan Agreement (the &#8220;First Amendment&#8221;). The First Amendment provided for an additional borrowing of $3.5 million (&#8220;2016 Term Loan A Advance&#8221;), with a requirement that a portion of the proceeds be used to pay in full, all amounts then outstanding, under the 2012 Term Loan A Advance and the 2012 Term Loan B Advance.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The First Amendment provided for two additional advances not to exceed, in the aggregate, $3.5 million, with each advance being for a minimum of $0.5 million (collectively the &#8220;2016 Term Loan B Advance&#8221;), and total borrowings under the 2012 Loan Agreement not to exceed $7.0 million. The Company borrowed the full $7.0 million available in two separate tranches: $3.5 million under the 2016 Term Loan A Advance, which was borrowed on February 29, 2016, and $3.5 million under the 2016 Term Loan B Advance, which was borrowed on August 23, 2016. Following these borrowings in February and August 2016, no additional amounts were available to be borrowed under the 2012 Loan Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the First Amendment to the 2012 Loan Agreement, the Company issued a Series B warrant to SVB which became exercisable with respect to 7,251 shares of Series B preferred stock on February 29, 2016 in connection with the 2016 Term Loan A Advance, and with respect to 7,251 shares of Series B preferred stock on August 23, 2016 in connection with the 2016 Term Loan B Advance. At the time of grant, the Series B warrant was exercisable at a price of $7.24 per share. The Series B warrant expires on February 18, 2026.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO in November 2017, the Series A-2 warrant converted into a common stock warrant to purchase up to 3,940 shares of common stock at an exercise price of $12.70 per share. The Series B warrant converted into a common stock warrant to purchase up to 6,474 shares of common stock at an exercise price of $16.22 per share. At June 30, 2018, these warrants to purchase up to 3,940 shares of common stock at an exercise price of $12.70 and 6,474 shares of common stock at an exercise price of $16.22 remained outstanding.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings under the 2016 Term Loan A Advance and 2016 Term Loan B Advance (collectively, the &#8220;2016 Term Loan Advance&#8221;) bear interest at a rate per annum equal to the greater of 3.25% and The Wall Street Journal prime rate, in each case minus 0.25%; provided, however, that in an event of default, as defined in the 2012 Loan Agreement, the interest rate applicable to borrowings under the First Amendment will be increased by 4.0%. As of June 30, 2018 and December 31, 2017, the interest rate applicable to borrowings under the 2016 Term Loan Advance was 4.75% and 4.25%, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk511920908"></a><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to make equal monthly payments o</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f principal as well as accrued interest beginning January 1, 2017 through December 1, 2019 (the &#8220;First Amendment Maturity Date&#8221;), when all unpaid principal and interest become due and payable. The First Amendment also provided that the Company could volunt</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arily prepay all (but not less than all) of the outstanding principal at any time prior to the maturity date, subject to a prepayment fee, which ranges from 0% to 2% of the outstanding principal if paid prior to the First Amendment Maturity Date. The Compa</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ny has not accrued for this prepayment fee as it had not intended to prepay the outstanding balance and the prepayment fee is 0% as of June 30, 2018. A final payment of 5.0% multiplied by the principal amount of the borrowings under the 2016 Term Loan Adva</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nce is due upon the earlier to occur of the First Amendment Maturity Date or prepayment of all outstanding principal. The final payment is being accreted to interest expense through </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the First Amendment Maturity Date</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In connection with the First Amendment,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Company paid an arrangement fee of $20,000 to SVB and incurred legal costs of $7,000, both of which were recorded as a debt discount. The debt discount is reflected as a reduction of the carrying value of the loan payable on the Company&#8217;s consolidated</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> balance sheet and is being amortized to interest expense over the term of the loan using the effective interest method.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was in compliance with all covenants under the 2012 Loan Agreement as of December 31, 2017. In March 2018, the Company entered into an Option and License Agreement with BB100, LLC, a subsidiary of Bravos Biosciences, LLC, under which BB100, LLC secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license, to mAbs targeting <font style="font-style:italic;">E. coli</font> that were discovered by the Company in its ASN200 program. In June 2018, the Company entered into an Option and License Agreement with BB200, LLC, a portfolio company of Bravos Biosciences, LLC, under which BB200, LLC secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license to selected mAbs targeting <font style="font-style:italic;">K. pneumoniae</font> that were discovered by the Company in its ASN300 program, including lead preclinical development candidate, ASN-5. As a result of entering into such Option and License Agreements without obtaining prior written consent of SVB, and subsequently delivering compliance certificates under the 2012 Loan Agreement that did not disclose these violations, the Company is currently in default under the 2012 Loan Agreement. On August 8, 2018, the Company and SVB entered into a Forbearance Agreement (the &#8220;Forbearance Agreement&#8221;), pursuant to which SVB has agreed to forbear from exercising its rights and remedies with respect to such default until the earlier to occur of (i) another event of default under the 2012 Loan Agreement or (ii) October 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the default in connection with the Option and License Agreements, the Company has discussed with SVB whether its decision to discontinue its Phase 2 clinical trial of ASN100 may be considered a material adverse change in the business, operations or condition (financial or otherwise) of the Company and, accordingly, an event of default under the terms of the 2012 Loan Agreement. To date, SVB has not agreed that the discontinuation of the trial does not constitute an event of default. If the trial discontinuation does constitute a material adverse change in the Company&#8217;s business, operations or condition, SVB will have the right to accelerate the Company's outstanding obligations under the 2012 Loan Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the Company&#8217;s obligations under the 2012 Loan Agreement may be accelerated at the election of SVB upon the expiration of the Forbearance Agreement, or earlier if another event of default occurs, including but not limited to if the ASN100 Phase 2 clinical trial discontinuation constitutes a material adverse change in the Company&#8217;s business, operations or condition, the Company has presented the SVB loan payable as current on the consolidated balance sheet as of June 30, 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized interest expense under the 2012 Loan Agreement, as amended, of $0.1 million and $0.1 million during the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $0.3 million during the six months ended June 30, 2018 and 2017, respectively. As of June 30, 2018 and December&#160;31, 2017, the unamortized debt discount was $14,000 and $26,000, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made aggregate principal payments in connection with the 2012 Loan Agreement of $0.6 million and $0.6 million during the three months ended June 30, 2018 and 2017, respectively, and $1.2 million and $1.2 million during the six months ended June 30, 2018 and 2017, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FFG Loans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the funding agreements with FFG (see Note 5), the Company received loans from FFG. Loans from FFG were made on a project-by-project basis and had an aggregate principal amount outstanding of $9.9 million and $10.2 million as of June 30, 2018 and December&#160;31, 2017, respectively. Amounts due under the FFG loans bear interest at rates ranging from 0.75% to 2.0%&#160;per annum and mature at various dates between June 2020 and March 2023. Interest on amounts due under the loans is payable semi-annually in arrears, with all principal and remaining accrued interest due upon maturity. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company has recorded a discount to the carrying value of each FFG loan for the portion of the loan proceeds allocated to grant funding, which is being a</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mortized to interest expense over the term of the loan using the effective interest method. As of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2018 and December&#160;31, 2017, the unamortized debt discount related to FFG loans was $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and $2.6&#160;million, respectively. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized interest expense of $0.2&#160;million and $0.2 million during the three months ended June 30, 2018 and 2017, respectively, and $0.4&#160;million and $0.3 million during the six months ended June 30, 2018 and 2017, respectively, related to the FFG loans. There were no principal payments due or paid under the FFG loans during the three and six months ended June 30, 2018 and 2017. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may be required to return all or a portion of the FFG loans and/or grants (see Note 5) if it does not comply with the terms of the related FFG funding agreements and related guidelines, including specified requirements as to continued operations with respect to certain locations and funded projects. To date, FFG has not requested the return of any amounts received by the Company under the funding agreements.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Common Stock </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2018 and December 31, 2017, the Company had reserved 2,738,039 shares and 2,187,252 shares of common stock, respectively, for the exercise of outstanding stock options, the number of shares remaining available for grant under the Company&#8217;s 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan and the exercise of outstanding warrants to purchase shares of common stock.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Stock-Based Compensation </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) provides for the grant by the Company of incentive stock options, non-qualified options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. Incentive stock options may be granted only to the Company&#8217;s employees, including officers and directors who are also employees. Awards other than incentive stock options may be granted to employees, officers, members of the board of directors, advisors and consultants of the Company. Following the adoption of the 2017 Plan, no further grants will be made under the Company&#8217;s 2010 Special Stock Incentive Plan (&#8220;Special Plan&#8221;) and 2011 Stock Incentive Plan (&#8220;2011 Plan&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon its adoption, the number of shares of the Company&#8217;s common stock initially reserved for issuance under the 2017 Plan was the sum of 585,994 shares, plus the number of shares of the Company&#8217;s common stock available for issuance under the Special Plan and the 2011 Plan immediately prior to the effectiveness of the 2017 Plan. In addition, the number of shares of the Company&#8217;s common stock subject to outstanding awards under the Special Plan and 2011 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will be available for future grant under the 2017 Plan. The number of shares of common stock reserved for issuance under this plan will automatically increase on January 1 of each year, through January 1, 2027, in an amount equal to the lowest of 1,025,490 shares of the Company&#8217;s common stock, 4% of the number of shares of the Company&#8217;s common stock outstanding on January 1 of each year and an amount determined by the Company&#8217;s board of directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares that are expired, terminated, surrendered or canceled under the 2017 Plan without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">439</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">616</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">614</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,053</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,618</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2018 and December&#160;31, 2017, total unrecognized compensation cost related to the unvested stock-based awards was $11.4 million and $4.0 million, respectively, which is expected to be recognized over weighted average periods of 3.07 and 2.76 years, respectively.  </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s stock option activity since December&#160;31, 2017 (in thousands, except share and per share amounts): </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,403,119</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.26</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.81</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,128</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">829,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.19</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,027</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.06</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of June 30, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,099,615</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of June 30, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,178</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.06</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.47</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options unvested as of June 30, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,559,437</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.79</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant-date fair value per share of stock options granted during the three and six months ended June 30, 2018 was $11.66 and $11.77, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Net Loss per Share </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per Share Attributable to Common Stockholders </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,133</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,705</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,763</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,090</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of redeemable convertible preferred stock to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; redemption value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,133</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,718</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,763</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,110</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding&#8212;basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,304,102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,900</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,299,288</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,900</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders &#8212; basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.85</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11.13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.59</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.62</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potentially dilutive securities, which include options to purchase common stock, redeemable convertible preferred stock, warrants to purchase common stock and warrants to purch</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ase redeemable convertible preferred stoc</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">k</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three and Six</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months&#160;Ended June 30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,099,615</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,198,291</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redeemable convertible preferred stock (as converted to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common stock)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,729,121</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,414</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase redeemable convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock (as converted to common stock)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,414</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,110,029</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,937,826</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Commitments and Contingencies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lease Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2010, the Company entered into a lease agreement for office, laboratory, parking and storage space in Vienna, Austria (&#8220;Vienna Lease&#8221;), which expires on April&#160;30, 2021. The Company has the option to extend the lease agreement for an additional year. The Vienna Lease includes a rent escalation clause based on an inflation index.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, the Company entered into a lease agreement for an animal-use facility in Vienna, Austria (&#8220;Animal-use Lease&#8221;). The lease initially had a one-year noncancelable term, which expired in June 2016, after which the lease became cancelable by either party upon six months&#8217; prior written notice. Base rent for the Animal-use Lease is approximately $0.4 million annually, accordingly, rent expense is being recognized on a straight-line basis over the lease term.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2015, the Company entered into a lease agreement for office and laboratory space in Waltham, MA (&#8220;Waltham Lease&#8221;), which expires on January 31, 2019. The Waltham Lease includes a rent escalation clause, and accordingly, rent expense is being recognized on a straight-line basis over the lease term.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company entered into a lease agreement for office space in Waltham, MA (&#8220;Lease Agreement&#8221;). The term of the Lease Agreement commences on the earlier of (a) the later to occur of (x) the date on which the premises are ready for occupancy and (y) December 1, 2018, or (b) the date on which the Company commences occupancy (the &#8220;Commencement Date&#8221;) and expires approximately five years from the Commencement Date. The Company currently anticipates that the term will begin on December 1, 2018. The Lease Agreement includes a rent escalation clause, and accordingly, rent expense will be recognized on a straight-line basis over the lease term.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes rent expense over the respective lease period and has recorded deferred rent for rent expense incurred but not yet paid.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded rent expense <font style="color:#000000;">of $0.3 million and $0.3 million during the three months ended June 30, 2018 and 2017, respectively, and $0.6 million and $0.6 million during the six months ended June 30, 2018 and 2017.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the future minimum lease payments due under </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company&#8217;s </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operating leases as of </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 201</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (in thousands)</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.64%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk520382914"></a>2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">881</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">996</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">648</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">479</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,114</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 10, 2018<font style="color:#000000;">, the Company entered into an amendment to the Lease Agreement (&#8220;Amended Lease Agreement&#8221;) with BP Bay Colony LLC (the &#8220;Lessor&#8221;). Under the terms of the Amended Lease Agreement, the Company will relocate its Waltham, MA premises to a new premises with 5,711 square feet of office space as compared to the 10,290 square feet premises in the original Lease Agreement. The annual base rent obligation is approximately $0.3 million, with a total cash obligation for the base rent over the initial five-year term of the Amended Lease Agreement is approximately $1.3 million. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, in accordance with the terms of the Amended Lease Agreement. The Company will provide a security deposit in the amount of $0.3 million as well as a relocation payment of $0.1 million to the Lessor. The entry into this Amended Lease Agreement reduces the minimum lease payments presented in the table above from $4.1 million to approximately $3.2 million.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into the Adimab Option Agreement in February 2017 under which it is obligated to make contingent and non-contingent payments should the Company exercise its option to obtain rights to certain RSV antibodies (see Note 5). If the Company chose to exercise its option, it would be obligated to pay Adimab an option fee of $0.3 million and make clinical and regulatory milestone payments of up to $24.4 million, as well as royalty payments on a product-by-product and country-by-country basis of a mid single-digit percentage based on net sales by the Company, its affiliates, licensees or sublicensees of products based on certain RSV antibodies during the applicable term for such product in that country. The Company may choose to exercise its option under the terms of the Adimab Option Agreement at any time on or before August 31, 2019. As of June 30, 2018 and December 31, 2017, the Company had not exercise its option under the Adimab Option Agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Manufacturing Commitments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2016, the Company entered into an agreement with Boehringer Ingelheim International GmbH (&#8220;BI&#8221;), a contract manufacturing organization, for the manufacture and supply of ASN100 drug product for the Company&#8217;s completed Phase 1 and discontinued Phase 2 clinical trials. In March 2016, the Company entered into an agreement with Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;) for process development and the manufacture and supply of ASN100 drug product. Under such agreements, the Company is obligated to pay BI and Cytovance development and manufacturing milestones, in addition to reimbursement of certain material production-related costs. Additionally, the Company is required to make prepayments for process development services and manufacture and delivery of ASN100 material. The terms of these agreements require future delivery and formal acceptance of the clinical material upon delivery from BI and Cytovance. Formal acceptance includes validation of the clinical material and that established specifications and good manufacturing practices, or GMP, standards have been followed during the manufacture. It is only after acceptance that title and risks and rewards of ownership pass to the Company and at that time advance payments will be applied to the purchase of clinical materials required to be produced under the agreements. The purchase of the clinical material will, at the point of delivery, be charged to research and development expense. The Company&#8217;s policy is to expense research and development costs as incurred (i.e., as services are provided by the Company&#8217;s vendors or as qualifying materials are delivered).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not terminate the agreements with BI and Cytovance following its decision to discontinue the Phase 2 clinical trial for ASN100. Amounts recorded as of June 30, 2018 represent advance payments to BI and Cytovance for the development and manufacturing of ASN100 drug product that is expected to be completed in the second half of 2018. As of June 30, 2018 and December&#160;31, 2017, the Company had committed to minimum payments under this agreement totaling $<font style="color:#000000;">3.2</font> million and $4.7 million, respectively. As of June 30, 2018 and December 31, 2017, prepaid clinical manufacturing expenses totaled $2.4 million $0, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party Transactions </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreements with Adimab, LLC </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made payments to Adimab of $0.1 million and $0 during the three months ended June 30, 2018 and 2017, respectively, and $0.1 million&#160;and $0 during the six months ended June 30, 2018 and 2017, respectively, under the Adimab Option Agreement. The Company recognized $14,000 and $58,000 during the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $0.1 million during the six months ended June 30, 2018 and 2017, respectively, of research and development expense under the Adimab Option Agreement. As of June 30, 2018 and December 31, 2017, the Company owed $14,000 and $21,000, respectively, to Adimab under the Adimab Option Agreement. The chairman of the Company&#8217;s board of directors is a co-founder of Adimab and currently serves as Adimab&#8217;s Chief Executive Officer. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Services and Facilities Agreement with EveliQure Biotechnologies GmbH </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s wholly owned subsidiary, Arsanis Biosciences GmbH, leases office and lab space in Vienna, Austria from a third party. In February 2015, Arsanis Biosciences GmbH entered into a services and facilities agreement with EveliQure Biotechnologies GmbH (&#8220;EveliQure&#8221;) under which the Company provides certain laboratory services and sublets office and lab space to EveliQure. Tamas Henics, the husband of Eszter Nagy, the Company&#8217;s former Chief Scientific Officer, serves as Chief Scientific Officer at EveliQure. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 28, 2018 and in accordance with the terms of this agreement with EveliQure, the Company provided EveliQure with written notice that the services and facilities agreement will terminate and EveliQure will vacate the sublet space no later than December 31, 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three and six months ended June 30, 2018, the Company received payments from EveliQure under the agreement of $0 and $0.1 million, respectively, and less than $0.1 million and $0.1 million during the three and six months ended June 30, 2017, respectively. During the three and six months ended June 30, 2018 and 2017, the Company recognized other income under the agreement of less than $0.1 million in each period. As of June 30, 2018 and December 31, 2017, amounts due from EveliQure totaled less than $0.1 million and $0.1 million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Subsequent Events </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Amended and Restated Gates Foundation Grant Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 8, 2018, the Company entered into an amended and restated grant agreement with the Gates Foundation which replaces the February 2017 grant agreement in its entirety. The amended and restated grant agreement includes amendments to conform to current Gates Foundation audit, reporting, and other administrative requirements, as well as to make the Company&#8217;s grant of a perpetual license to the Gates Foundation irrevocable. See Note 5 for further discussion.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Gates Foundation Grant Agreement&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> On August 8, 2018, the Company entered into an additional grant agreement with the Gates Foundation pursuant to which the Gates Foundation granted to the Company up to $1.1 million to conduct preclinical development activities for the RSV project that were not included in the February 2017 grant agreement, as amended and restated in August 2018. In return, the Company has agreed to conduct the RSV project in a manner that ensures that the knowledge and information gained from the project will be promptly and broadly disseminated, and that the products, technologies, materials, processes and other intellectual property resulting from the RSV project will be made available and accessible at an affordable price to people most in need within developing countries. These obligations survive any expiration or termination of the grant agreement. See Note 5 for further discussion.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Forbearance Agreement with Silicon Valley Bank&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 8, 2018, the Company and SVB entered into a Forbearance Agreement to address the Company&#8217;s ongoing default under the 2012 Loan Agreement as a result of the Company&#8217;s failure to obtain SVB&#8217;s written consent prior to entering into certain Option and License Agreements. Under the terms of the Forbearance Agreement, SVB has agreed to forbear from exercising its rights and remedies with respect to such defaults until the earlier to occur of (i) another event of default under the 2012 Loan Agreement or (ii) October 31, 2018. See Note 6 for further discussion.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lease </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amendment</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 10, 2018, the Company entered into an amendment to its Lease Agreement (&#8220;Amended Lease Agreement&#8221;) with BP Bay Colony LLC (the &#8220;Lessor&#8221;). Under the terms of the Amended Lease Agreement, the Company will relocate its premises in Waltham, MA to a new premises with 5,711 square feet of office space as compared to the 10,290 square feet premises in the original Lease Agreement. The term of the Amended Lease Agreement commences on January 1, 2019 and expires December 31, 2023. The Company has the option to extend the term for one additional five-year period upon the Company&#8217;s written notice to the Lessor at least nine months and no more than 12 months in advance of the extension. The Amended Lease Agreement terminates the Company&#8217;s one-time right of first offer, subject to certain terms and conditions, for additional space containing approximately 4,000 square feet specified in the Lease Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The annual base rent obligation is approximately $0.3 million, with a total cash obligation for the base rent over the initial five-year term of the Amended Lease Agreement is approximately $1.3 million. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, in accordance with the terms of the Amended Lease Agreement. The Company will provide a security deposit in the amount of $0.3 million as well as a relocation payment of $0.1 million to the Lessor. See Note 10 for further discussion.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Reduction in Force</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> On August 10, 2018, the Company&#8217;s board of directors approved a reduction in workforce to reduce operating costs and better align the company&#8217;s workforce with the needs of its business following the Company&#8217;s discontinuation of the clinical development of ASN100. As part of this reduction in workforce, the Company plans to eliminate 19 positions across the company, representing approximately 44% of its workforce. The Company anticipates that it will substantially complete the implementation of the reduction in workforce by the fourth quarter of 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently estimates that it will incur total expenses relating to the reduction in workforce of approximately $0.6 million, which is comprised of notice and severance payments. The Company expects to record these charges in the third and fourth quarters of 2018.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="I_Item2"></a><a name="_AEIOULastRenderedPageBreakAEIOU23"></a><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 2. Management&#8217;s Discussion and Analysis of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Condition and Results of Operations.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes and the other financial information included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the Securities and Exchange Commission on March 9, 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. There are a number of important risks and uncertainties that could cause our actual results to differ materially from those indicated by forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in the section entitled &#8220;Risk Factors&#8221; in Part II, Item 1A that could cause actual results or events to differ materially from the forward-looking statements that we make. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report on Form 10-Q, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company focused on applying monoclonal antibody, or mAb, immunotherapies to address serious infectious diseases. We possess a deep understanding of the pathogenesis of infection, paired with access to what we believe to be some of the most advanced mAb discovery techniques and platforms available today.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 28, 2018, we announced the discontinuation of our Phase 2 clinical trial of ASN100 for the prevention of <font style="font-style:italic;">S. aureus</font> pneumonia in high-risk, mechanically ventilated patients following the completion of a planned interim analysis of unblinded trial data for 118 patients by an independent data review committee, or DRC. Based on the results of this analysis, the DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion, and recommended that trial enrollment be discontinued. We intend to conduct follow-up visits on patients dosed in the trial per the study protocol and to evaluate the complete dataset from the 154 patients that were enrolled in the trial to better understand the basis for this result. We expect to complete this evaluation in the fourth quarter of 2018 and have ceased further clinical development of ASN100, pending the results of this analysis. We do not expect to incur material costs for this program beyond the fourth quarter of 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 10, 2018, our board of directors approved a reduction in workforce to reduce operating costs and better align our workforce with the needs of our business following our discontinuation of the clinical development of ASN100 pending the completion of our evaluation of the complete dataset from our Phase 2 trial. As part of this reduction in workforce, we plan to eliminate 19 positions across our company, representing approximately 44% of our workforce. We anticipate that we will substantially complete the implementation of the reduction in workforce by the fourth quarter of 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In light of the discontinuation of the clinical development of ASN100, we are considering strategic options that may potentially result in changes to our business strategy and future operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending any decision to change our strategic direction, our current operating plan provides for our ongoing review of the data from the ASN100 clinical trial, the continued development of our ASN500 program, as well as supporting our collaborators across our ASN200 and ASN300 programs, both of which were outlicensed to subsidiaries of Bravos Biosciences, LLC during the first half of 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2010, we have devoted substantially all of our resources to building our business to support discovery, research and development activities for our programs. We do not have any products approved for sale and have not generated any revenue from product sales. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have received significant proceeds from outside sources to fund our operations. We have funded our operations through </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 20</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18 primarily with proceeds from the following sources: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">net cash proceeds of $75.1&#160;million from sales of our preferred stock; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">net cash proceeds of $39.5&#160;million from sales of our common stock in our initial public offering; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">net cash proceeds of $18.6&#160;million from sales of our common stock in our private placement to New Enterprise Associates 16, L.P., or NEA; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">gross proceeds of $14.4&#160;million from borrowings under convertible promissory notes; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">proceeds of $9.5&#160;million from borrowings under a loan and security agreement with Silicon Valley Bank, or SVB, which, as amended, we refer to as the 2012 Loan Agreement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">proceeds of $9.2&#160;million and $9.9&#160;million of grant and loan proceeds, respectively, from our funding agreements with &#214;sterreichische Forschungsf&#246;rderungsgesellschaft mbH, or FFG; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">proceeds of $4.9&#160;million of research and development incentive payments received from the Austrian government; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">proceeds of $1.6&#160;million from a grant agreement with the Bill&#160;&amp; Melinda Gates Foundation, or the Gates Foundation. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 20, 2017, we closed an initial public offering of our common shares, in which we issued and sold 4,000,000 common shares at a price to the public of $10.00 per share. Concurrent with the initial public offering, (i) we issued an additional 600,000 common shares at a price of $10.00 per share pursuant to the exercise of the underwriters&#8217; over-allotment option and (ii) NEA purchased 2,000,000 shares of our common stock at the initial per share public offering price of $10.00 in a private placement. The aggregate net proceeds to us from the initial public offering, inclusive of the over-allotment exercise, and the private placement were $58.1 million after deducting underwriting discounts and commissions and offering expenses payable by us.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates and programs. Our net losses were $12.1 million and $5.7&#160;million for the three months ended June 30, 2018 and 2017, respectively, and $22.8&#160;million and $11.1&#160;million for the six months ended June 30, 2018 and 2017, respectively. As of June 30, 2018, we had an accumulated deficit of $115.0&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over the next several quarters we expect that our research and development expenses related to ASN100 will be reduced due to the discontinuation of our clinical development of ASN100. Pending any change in our strategic direction, we expect to continue to incur significant expenses to advance our ASN500 program. We also expect to continue to incur additional costs associated with operating as a public company. As a result, we will need substantial additional funding to support our continuing operations and pursue our business strategy, until such time as we can generate significant revenue from product sales, if ever. We expect to finance our operations with proceeds from outside sources, with a majority of such proceeds to be derived from the sale of equity. We also plan to pursue additional funding from outside sources, including proceeds from our existing grant and potential future grant agreements with the Gates Foundation; our expansion of, or our entry into, new borrowing arrangements; grants and loans under our existing funding agreements with FFG; research and development incentive payments from the Austrian government; and our entry into potential future collaboration agreements for one or more of our programs. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with product development, as well as the uncertainties regarding the outcomes from our ongoing review of strategic alternatives, if any, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2018, we had cash and cash equivalents of $49.9 million. We believe our existing cash and cash equivalents will enable us to fund our operating expenses, capital expenditure requirements and debt service payments into the first quarter of 2020. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;&#8212;Liquidity and Capital Resources.&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Developments</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">February 2017 and August 2018 Amended and Restated Gates Foundation Grant Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, we entered into a grant agreement with the Gates Foundation, under which the Gates Foundation agreed to provide us with up to $9.3 million to conduct preclinical development of mAbs for the prevention of RSV infection in newborns, which we refer to as the RSV project.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, we entered into an amended and restated grant agreement which replaces the February 2017 grant agreement in its entirety. The amended and restated grant agreement includes amendments to conform to current Gates Foundation audit, reporting, and other administrative requirements as well as to make the perpetual Gates Foundation license grant described below irrevocable.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Gates Foundation Grant Agreement&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, we entered into a grant agreement with the Gates Foundation pursuant to which the Gates Foundation granted us up to $1.1 million to conduct preclinical development activities for the RSV project that were not included in the February 2017 grant agreement, as amended and restated in August 2018. In return, we have agreed to conduct the RSV project in a manner that ensures that the knowledge and information gained from the project will be promptly and broadly disseminated, and that the products, technologies, materials, processes and other intellectual property resulting from the RSV project (which we collectively refer to as the funded developments) will be made available and accessible at an affordable price to people most in need within developing countries. These obligations survive any expiration or termination of the grant agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To this end, we have granted the Gates Foundation a non-exclusive, perpetual, irrevocable, royalty-free, fully paid up, sublicensable license to make, use, sell, offer to sell, import, distribute, copy, modify, create derivative works, publicly perform and display the funded developments and, to the extent incorporated into a funded development or required to use a funded development, any other technology created outside of the RSV project that was used as part of the RSV project, for the benefit of people in developing countries. We have also agreed to seek prompt publication of data and results developed under the RSV project under &#8220;open access&#8221; terms and conditions. This license and these publication obligations survive any expiration or termination of the grant agreements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The August 2018 grant agreement expires on August 31, 2018. The Gates Foundation can modify, suspend or discontinue any payment under the grant agreement, or terminate the grant agreement, if it is not reasonably satisfied with our progress on the RSV project; if there are significant changes to our leadership or other factors that the Gates Foundation reasonably believes may threaten the RSV project&#8217;s success; if we undergo a change in control; if there is a change in our tax status; or if we fail to comply with the grant agreement. Any grant funds that have not been used for, or committed to, the RSV project upon the expiration or termination of the agreement must be returned to the Gates Foundation or otherwise used as directed by the Gates Foundation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Forbearance Agreement with Silicon Valley Bank&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 7, 2012, we entered into a loan and security agreement with Silicon Valley Bank, or SVB, which we refer to as the 2012 Loan Agreement. We entered into the First Amendment to the 2012 Loan Agreement on February 29, 2016. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were in compliance with all covenants under the 2012 Loan Agreement as of December 31, 2017. During the six months ended June 30, 2018, we failed to comply with the covenants under the 2012 Loan Agreement when we entered into separate option and license agreements for our ASN200 and ASN300 programs with subsidiaries of Bravos Biosciences, LLC without obtaining prior written consent of SVB, and then delivered compliance certificates to SVB that did not disclose these violations. As a result, we are currently in default under the 2012 Loan Agreement and SVB may, at its option, declare all of our obligations under the 2012 Loan Agreement to be immediately due and payable. On August 8, 2018, we and SVB entered into a Forbearance Agreement pursuant to which SVB has agreed to forbear from exercising its rights and remedies with respect to such defaults until the earlier to occur of (i) another event of default under the 2012 Loan Agreement or (ii) October 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the default in connection with the option and license agreements, we have also discussed with SVB whether our decision to discontinue our Phase 2 clinical trial of ASN100 may be considered a material adverse change in our business, operations or condition (financial or otherwise) and, accordingly, an event of default under the terms of the 2012 Loan Agreement. To date, SVB has not agreed that the discontinuation of the trial does not constitute an event of default. If the trial discontinuation does constitute a material adverse change in our business, operations or condition, SVB will have the right to accelerate our outstanding obligations under the 2012 Loan Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lease Amendment</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;&nbsp; </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 10, 2018, we entered into an amendment to our June 2018 lease agreement with BP Bay Colony LLC, or Lessor, which we refer to as the Amended Lease Agreement. Under the terms of the Amended Lease Agreement, we will relocate our premises in Waltham, MA to a new premises with 5,711 square feet of office space as compared to the 10,290 square feet premises in the original lease agreement. The term of the Amended Lease Agreement commences on January 1, 2019 and expires December 31, 2023. We have the option to extend the term for one additional five-year period upon our written notice to the Lessor at least nine months and no more than 12 months in advance of the extension. The Amended Lease Agreement terminates our one-time right of first offer, subject to certain terms and conditions, for additional space containing approximately 4,000 square feet specified in the original lease agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The annual base rent obligation is approximately $0.3 million, with a total cash obligation for the base rent over the initial five-year term of the Amended Lease Agreement is approximately $1.3 million. In addition to the base rent, we are also responsible for our share of operating expenses, electricity and real estate taxes, in accordance with the terms of the Amended Lease Agreement. We will provide a security deposit in the amount of $0.3 million as well as a relocation payment of $0.1 million to the Lessor.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Reduction in Force</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> On August 10, 2018, our board of directors approved a reduction in workforce to reduce operating costs and better align our workforce with the needs of our business following our discontinuation of the clinical development of ASN100 pending the completion of our evaluation of the complete dataset from our Phase 2 trial. As part of this reduction in workforce, we plan to eliminate 19 positions across our company, representing approximately 44% of our workforce. We anticipate that we will substantially complete the implementation of the reduction in workforce by the fourth quarter of 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently estimate that we will incur total expenses relating to the reduction in workforce of approximately $0.6 million, which is comprised of notice and severance payments. We expect to record these charges in the third and fourth quarters of 2018.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of Our Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_Hlk520998000"></a>Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the near future. If our development efforts for any product candidates are successful and result in regulatory approval or license agreements with third parties, we may generate revenue in the future from product sales. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize proceeds received from grants under our funding agreements with FFG, our research and development incentives from the Austrian government and our grant agreement with the Gates Foundation as other income, rather than as revenue. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;Research and development expenses consist primarily of costs incurred in connection with the discovery and development of product candidates. These expenses include: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expenses incurred under agreements with contract research organizations, or CROs, that are primarily engaged in the oversight and conduct of our clinical trials, if any; contract manufacturing organizations, or CMOs, that are primarily engaged to provide preclinical and clinical drug substance and product for our research and development programs, as well as investigative sites and consultants that conduct any clinical trials, preclinical studies and other scientific development services; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of acquiring and manufacturing preclinical and clinical trial materials, including manufacturing validation batches; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">costs related to compliance with regulatory requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">facilities-related expenses, which include direct depreciation costs and allocated rent and maintenance of facilities and other operating costs; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">payments made under third-party licensing or option agreements. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize external development costs b</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ased on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activitie</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our direct research and development expenses are tracked on a program-by-program basis for our product candidates and programs and consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and central laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses by program also include fees incurred under license or option agreements. We do not allocate employee costs or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes our research and development expenses incurred by program: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN100</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,482</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,903</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,719</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,385</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN200</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN400</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unallocated research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,702</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,691</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,557</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,930</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,906</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,063</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,297</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of our ASN500 program or any of our potential future product candidates or when, if ever, material net cash inflows may commence from any potential future product candidates. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successful enrollment and completion of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a safety, tolerability and efficacy profile that is satisfactory to the U.S. Food and Drug Administration, or FDA, or any non-U.S. regulatory authority for marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">timely receipt of marketing approvals from applicable regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the performance of our future collaborators, if any; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establishment and maintenance of arrangements with third-party manufacturers for both clinical and any future commercial manufacturing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">adequate ongoing availability of raw materials and drug product for clinical development and any commercial sales; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and internationally; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">protection of our rights in our intellectual property portfolio; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successful launch of commercial sales following any marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a continued acceptable safety profile following any marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">commercial acceptance by the patient community, the medical community and third-party payors; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to compete with other therapies. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><font style="font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may never succeed in achieving regulatory approval for any product candidates. We may obtain unexpected results from clin</font><font style="font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others</font><font style="font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any changes in the outcome of any of these variables with respect to the development of </font><font style="font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</font><font style="font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our plann</font><font style="font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significa</font><font style="font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt additional financial resources and time on the completion of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical development of that product candidate. Drug commercialization will take several years and millions of dollars in development costs. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;General and administrative expenses consist primarily of salaries and benefits, travel and stock-based compensation expense for personnel in executive, director, finance and administrative functions. General and administrative expenses also include professional fees for legal, patent, consulting, accounting and audit services. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses incurred during this period include increased accounting, audit, legal, compliance and director and officer insurance costs as well as investor and public relations expenses associated with our becoming a public company in November 2017. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income (Expense), Net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Grant and Incentive Income.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;Grant and incentive income consists of grant income recognized in connection with grants we receive under our funding agreements with FFG, or the FFG Grants, including the imputed benefit of FFG loans at below-market interest rates; incentive income received in connection with the research and development incentive program provided by the Austrian government; and grant income received under our grant agreement with the Gates Foundation. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest Expense.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;Interest expense consists of interest on outstanding borrowings under the 2012 Loan Agreement, convertible promissory notes and loans from FFG as well as amortization of debt discount and debt issuance costs. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2017, in connection with the sale of our Series D convertible preferred stock, all of the outstanding principal and accrued interest under the convertible promissory notes that we issued in 2016 and 2017 was automatically converted into shares of Series D convertible preferred stock. As a result, in periods subsequent to this conversion, we incurred no interest expense related to convertible promissory notes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest Income.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;Interest income primarily consists of interest earned on cash equivalents. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Change in Fair Value of Warrant Liability.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;In connection with the 2012 Loan Agreement, we issued to SVB warrants to purchase shares of our preferred stock. We recognized the non-cash changes in the fair value of the warrants as a component of other income (expense), net in our consolidated statement of operations. Upon the closing of our initial public offering, these warrants became exercisable for shares of common stock instead of convertible preferred stock. The warrants met the criteria to be classified in stockholders&#8217; equity and the fair value of the warrant liability as of the initial public offering date was reclassified to stockholders&#8217; equity (deficit). As a result, we no longer recognize any changes to the fair value of the warrants through other income (expense). </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Change in Fair Value of Derivative Liability.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;We issued convertible promissory notes that contained a contingent put option and a conversion feature, each of which met the definition of a derivative instrument. We recognized the changes in the fair value of the derivative liability as a component of other income (expense), net in our consolidated statement of operations. The convertible promissory notes converted into shares of Series D preferred stock in connection with the sale of our Series D convertible preferred stock in April 2017. As a result, no convertible promissory notes remained outstanding and we no longer recognize changes in the fair value of the derivative liability through other income (expense). </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Loss on the Extinguishment of Debt.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;In April 2017, in connection with the sale of our Series D convertible preferred stock, all of the outstanding principal and accrued interest under the convertible promissory notes that we issued in 2016 and 2017 was automatically converted into shares of Series D convertible preferred stock. We recorded a loss on extinguishment of debt related to this conversion. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income (Expense).<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;Other income (expense), net consists primarily of realized and unrealized foreign currency transaction gains and losses. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of the Three Months Ended June 30, 2018 and 2017 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the three months ended June 30, 2018 and 2017:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,930</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,906</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,024</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,686</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,738</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,948</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,616</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,644</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,972</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,616</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,644</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,972</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant and incentive income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">516</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">862</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(346</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(259</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(444</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">225</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(462</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">462</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">483</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,133</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,705</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,428</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct research and development expenses by program:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,482</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,903</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,579</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN200</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN300</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN400</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">253</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unallocated research and development expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel related (including stock-based compensation)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,525</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,265</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">575</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,930</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,906</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,024</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $8.9 million for the three months ended June 30, 2018, compared to $3.9 million for the three months ended June 30, 2017. The increase of $5.0 million was primarily due to an increase of $3.6&#160;million in direct costs for our ASN100 program, an increase of $0.1 million in direct costs for our ASN500 program, and an increase of $1.4 million in unallocated research and development expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in direct costs for our ASN100 program was primarily due to CMO and CRO fees for process development and establishment of manufacturing capabilities for the supply of our clinical materials, the oversight and conduct of our Phase 2 clinical trial and investigator fees for that same clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 28, 2018, we announced that the DRC for our ASN100 Phase 2 clinical trial recommended that trial enrollment be discontinued based on the DRC&#8217;s conclusion that the trial was not likely to meet its primary end-point upon completion. Based on the DRC recommendation, we decided to discontinue the Phase 2 clinical trial of ASN100. We expect that direct costs for ASN100 will remain reasonably consistent for the third quarter of 2018 when compared to the second quarter of 2018 as we and our CMO and CROs complete and close the trial and CMO activities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ASN500 program was initiated in March 2017. Direct costs for our ASN500 program during</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the three months ended </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 30</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2018 were primarily due to third-party fees for the oversight and conduct of preclinical research, facility costs and preclinical program expenses associated with internal lab consumables. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our direct costs fo</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r our ASN500 program will increase as we advance </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN500 </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">program </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">through preclinical developmen</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in unallocated research and development expenses was due primarily to an increase of $1.3 million in personnel-related costs (including increases in salaries and wages of $0.7 million and stock-based compensation of $0.4 million) primarily due to the hiring of new personnel and increased employee compensation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160; General and administrative expenses were $3.7 million for the three months ended June 30, 2018, compared to $1.7 million for the three months ended June 30, 2017. The increase of $1.9 million was primarily related to additional costs associated with operating as a public company, including increases of $0.9 million in personnel costs (which included increases in salaries and wages of $0.1 million and stock-based compensation of $0.5 million) primarily due to an increase in headcount and employee compensation, $0.1 million in Board of Directors fees, $0.2 million in insurance fees and $0.7 million in professional fees primarily due to legal and accounting costs.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income (Expense), Net.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160; Other income, net was $0.5 million for the three months ended June 30, 2018, compared to $0.1 million of other expense, net for the three months ended June 30, 2017. The increase of $0.5 million in other income, net was primarily due to a decrease in loss on extinguishment of debt of $0.5 million in connection with the April 2017 conversion of our 2016 and 2017 convertible promissory notes into shares of our Series D convertible preferred stock, a decrease of $0.2 million in interest expense primarily associated with our convertible promissory notes, and an increase in interest income of $0.2 million, primarily from the bank interest earned on the cash received from the initial public offering and concurrent private placement of our common stock. These increases in other income, net were partially offset by a decrease in grant and incentive income of $0.3 million primarily associated with our grant agreement with the Gates Foundation.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of the Six Months Ended June 30, 2018 and 2017 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the six months ended June 30, 2018 and 2017:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,063</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,297</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,766</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,503</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,174</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,329</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,566</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,471</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,095</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,566</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,471</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,095</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant and incentive income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">961</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,562</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(601</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(526</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,463</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">937</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of derivative liability</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">762</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(762</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on extinguishment of debt</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(462</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">462</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense), net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">803</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">422</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,763</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,090</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,673</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct research and development expenses by program:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,719</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,385</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,334</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN200</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN300</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN400</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASN500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">615</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">281</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unallocated research and development expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel related (including stock-based compensation)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,536</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,614</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,922</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,155</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,063</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,297</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,766</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $17.1 million for the six months ended June 30, 2018, compared to $8.3 million for the six months ended June 30, 2017. The increase of $8.8 million was primarily due to an increase of $6.3&#160;million in direct costs for our ASN100 program, an increase of $0.3 million in direct costs for our ASN500 program, and an increase of $2.1 million in unallocated research and development expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in direct costs for our ASN100 program was primarily due to CMO and CRO fees for process development and establishment of manufacturing capabilities for the supply of our clinical materials, the oversight and conduct of our Phase 2 clinical trial and investigator fees for that same clinical trial. Based on our decision to discontinue the Phase 2 clinical trial of ASN100, we expect that direct costs for ASN100 will decline in the second half of 2018 when compared to the first six months of 2018 as we and our CMO and CROs complete and close the trial and CMO activities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct costs for our ASN500 program during the six months ended June 30, 2018 were primarily due to third-party fees for the oversight and conduct of preclinical research, facility costs and preclinical program expenses associated with internal lab consumables. We expect that our direct costs for our ASN500 program will increase as we advance our ASN500 program through preclinical development.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in unallocated research and development expenses was due primarily to an increase of $1.9 million in personnel-related costs (including increases in salaries and wages of $0.9 million, stock-based compensation of $0.5 million and personnel travel costs of $0.3 million) primarily due to the hiring of new personnel and increased employee compensation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160; General and administrative expenses were $6.5 million for the six months ended June 30, 2018, compared to $3.2 million for the six months ended June 30, 2017. The increase of $3.3 million was primarily related to additional costs associated with operating as a public company, including increases of $1.3 million in personnel costs (which included increases in salaries and wages of $0.3 million and stock-based compensation of $0.8 million) primarily due to an increase in headcount and employee compensation, $0.3 million in Board of Directors fees, $0.3 million in insurance fees and $1.3 million in professional fees primarily due to legal and accounting costs associated with being a public company.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income (Expense), Net.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160; Other income, net was $0.8 million for the six months ended June 30, 2018, compared to $0.4 million for the six months ended June 30, 2017. The increase of $0.4 million in other income, net was primarily due to a decrease of $0.9 million in interest expense primarily associated with our convertible promissory notes, a decrease in loss on extinguishment of debt of $0.5 million in connection with the April 2017 conversion of our 2016 and 2017 convertible promissory notes into shares of our Series D convertible preferred stock, and an increase in interest income of $0.4 million, primarily from the bank interest earned on the cash received from the initial public offering and concurrent private placement of our common stock. These increases in other income, net were partially offset by a decrease of $0.8 million in gains recognized as a result of decreases in the fair value of the derivative liability associated with our convertible promissory notes and a decrease in grant and incentive income of $0.6 million primarily associated with our grant agreement with the Gates Foundation.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 20, 2017, we closed an initial public offering of our common shares, in which we issued and sold 4,000,000 common shares at a price to the public of $10.00 per share. Concurrent with the initial public offering, (i) we issued an additional 600,000 common shares at a price of $10.00 per share pursuant to the exercise of the underwriters&#8217; over-allotment option and (ii) NEA purchased 2,000,000 shares of our common stock at the initial per share public offering price of $10.00 in a private placement. The aggregate net proceeds to us from the initial public offering, inclusive of the over-allotment exercise, and the private placement were $58.1 million after deducting underwriting discounts and commissions and offering expenses payable by us.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have not generated any revenue from any sources, including from product sales, and have incurred significant operating losses and negative cash flows from our operations. We have funded our operations to date primarily with proceeds from our initial public offering and concurrent private placement, the sale of preferred stock, borrowings under convertible promissory notes, borrowings under the 2012 Loan Agreement, proceeds received from loans and grants under funding agreements with FFG, research and development incentive payments received from the Austrian government and proceeds from a grant agreement with the Gates Foundation. Through June 30, 2018, we had received net cash proceeds of $75.1&#160;million from sales of our preferred stock, net cash proceeds of $58.1 million from the sale of our common stock, gross proceeds of $14.4&#160;million from borrowings under convertible promissory notes, proceeds of $9.5&#160;million from borrowings under the 2012 Loan Agreement with SVB, $9.2&#160;million and $9.9&#160;million of grant and loan proceeds, respectively, from our funding agreement with FFG, $4.9&#160;million of research and development incentive payments received from the Austrian government and $1.6&#160;million of proceeds from our grant agreement with the Gates Foundation. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for each of the periods presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,657</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,874</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,058</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,275</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of exchange rate changes on cash</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(120</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,862</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,415</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Activities.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160; During the six months ended June 30, 2018, operating activities used $25.7&#160;million of cash, resulting from our net loss of $22.8 million and changes in our operating assets and liabilities of $5.0 million, partially offset by net non-cash charges of $2.1&#160;million. We expect the discontinuation of the clinical development of ASN100 to result in a decline in cash used in operating activities in the second half of 2018 and 2019, as we expect our expenses associated with ASN100 to decline substantially.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in our operating assets and liabilities for the six months ended June 30, 2018 consisted primarily of a $1.6 million decrease in accounts payable and accrued expenses, a $2.4 million increase in prepaid expenses and other assets, a $0.6 million increase in grant and incentive receivables and a $0.3 million decrease in unearned income. The decrease in accounts payable and accrued expenses was primarily due to the payment of the 2017 annual bonuses in March 2018 and the timing of vendor invoices and payments. The increases in prepaid expenses and other assets were primarily due to prepayments for the supply of clinical materials. The increase in grant and incentive receivables was primarily due to income earned under the Austrian research and development incentive program during the six months ended June 30, 2018. The decrease in unearned income was primarily due to the amortization of the discount associated with the FFG loans. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the six months ended June 30, 2017, operating activities used $9.9 million of cash, resulting from our net loss of $11.1 million and net cash used by changes in our operating assets and liabilities of $0.3 million, partially offset by net non-cash charges of $1.5 million. Net cash used by changes in our operating assets and liabilities for the six months ended June 30, 2017 consisted primarily of a $1.7 million increase in prepaid expenses and other assets and a $0.5 million increase in grant and incentive receivables, partially offset by a $0.9 million increase in accounts payable and accrued expenses and a $1.1 million increase in unearned income. The increase in unearned income was primarily due to the payment of $1.6 million we received in March 2017 under our grant agreement with the Gates Foundation, of which $0.6 million was recognized as grant income as we incurred qualifying expenses under the agreement. The increase in accounts payable and accrued expenses was primarily due to increases in clinical trial costs associated with our Phase 2 clinical trial of ASN100. The increase in prepaid expenses and other current assets was primarily due to prepayments for clinical materials related to our Phase 2 clinical trial of ASN100. The increase in grant and incentive receivables was due to an increase in the amount of our qualifying expenditures as well as the timing of receipt of cash from FFG Grants. The decrease in accounts payable was a result of the timing of vendor invoices and payments.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investi</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ng Activities.</font><font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160; During the </font><font style="font-weight:normal;font-style:normal;">six</font><font style="font-weight:normal;font-style:normal;"> months ended </font><font style="font-weight:normal;font-style:normal;">Jun</font><font style="font-weight:normal;font-style:normal;">e</font><font style="font-weight:normal;font-style:normal;"> 30</font><font style="font-weight:normal;font-style:normal;">, 2018</font><font style="font-weight:normal;font-style:normal;"> and 2017, </font><font style="font-weight:normal;font-style:normal;">we used less than $0.1 million of cash in investing activities, consisting primarily of purchase of property and equipment.</font><font style="font-weight:normal;font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financing Activities.<font style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160; During the six months ended June 30, 2018, cash used in financing activities was $1.1 million, consisting primarily of principal repayments under the 2012 Loan Agreement</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the six months ended June 30, 2017, net cash provided by financing activities was $39.3 million, consisting primarily of net cash proceeds of $34.9 million from our issuance of Series D convertible preferred stock in April 2017, proceeds of $4.9 million from our issuance of convertible promissory notes in January 2017 and proceeds of $0.7 million from loans under our funding agreements with FFG, partially offset by $1.2 million of principal repayments under the 2012 Loan Agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2012 Loan Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;7, 2012, we entered into the 2012 Loan Agreement with SVB, which, as amended, provided for aggregate borrowings of up to $7.0&#160;million in the form of term loans. In February and August 2016, we borrowed the full $7.0&#160;million available to us under the agreement. Following the August 2016 borrowing, no additional amounts remained available for borrowing under the 2012 Loan Agreement. As of June 30, 2018 and December&#160;31, 2017, the outstanding principal amount under the 2012 Loan Agreement was $3.5&#160;million and $4.7&#160;million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings under the 2012 Loan Agreement bear interest at a rate per annum equal to the greater of 3.25% and The Wall Street Journal prime rate, in each case minus 0.25%; provided, however, that in an event of default, as defined in the 2012 Loan Agreement, the interest rate applicable to borrowings under the agreement will be increased by 4.0%. Under the agreement, we were required to make monthly interest-only payments through December&#160;1, 2016 and are required to make 36 equal monthly payments of principal, plus accrued interest, from January&#160;1, 2017 through December&#160;1, 2019, when all unpaid principal and interest becomes due and payable. We may voluntarily prepay all, but not less than all, of the outstanding principal at any time prior to the maturity date, subject to a prepayment fee, which ranges from 0% to 2% of the outstanding principal. A final payment of $0.4&#160;million is due upon the earlier to occur of the maturity of the loan or the prepayment of all outstanding principal. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the 2012 Loan Agreement, between December 2012 and August 2016, we issued to SVB a warrant to purchase an aggregate of 11,013 shares of Series A-2 convertible preferred stock at an exercise price of $4.54 per share and a warrant to purchase an aggregate of 14,502 shares of Series B convertible preferred stock at an exercise price of $7.24 per share. The warrants became exercisable in connection with our borrowings under the 2012 Loan Agreement and are fully exercisable. The warrant to purchase shares of Series A-2 convertible preferred stock expires on December&#160;6, 2022, and the warrant to purchase shares of Series B convertible preferred stock expires on February&#160;18, 2026. In November 2017, in connection with the closing of the initial public offering, the warrants for the purchase of convertible preferred stock converted into warrants for the purchase of common stock. See Note 6 to our condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q for additional information on the conversion of the warrants.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings under the 2012 Loan Agreement are collateralized by a pledge of substantially all of our assets other than our intellectual property, including 65% of the outstanding capital stock of our subsidiary in Austria. The 2012 Loan Agreement contains customary affirmative and negative covenants, including restrictions on our ability to pay dividends and encumber our intellectual property, but does not contain any financial covenants. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were in compliance with all covenants under the 2012 Loan Agreement as of December 31, 2017. During the six months ended June 30, 2018, we failed to comply with the covenants under the 2012 Loan Agreement when we entered into separate option and license agreements for our ASN200 and ASN300 programs with subsidiaries of Bravos Biosciences, LLC without obtaining prior written consent of SVB, and then delivered compliance certificates to SVB that did not disclose these violations. As a result, we are currently in default under the 2012 Loan Agreement and SVB may, at its option, declare all of our obligations under the 2012 Loan Agreement to be immediately due and payable. On August 8, 2018, we and SVB entered into a Forbearance Agreement pursuant to which SVB has agreed to forbear from exercising its rights and remedies with respect to such defaults until the earlier to occur of (i) another event of default under the 2012 Loan Agreement or (ii) October 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the default in connection with the option and license agreements, we have also discussed with SVB whether our decision to discontinue the Phase 2 clinical trial of ASN100 may be considered a material adverse change in our business, operations or condition (financial or otherwise) and, accordingly, an event of default under the terms of the 2012 Loan Agreement. To date, SVB has not agreed that the discontinuation of the trial does not constitute an event of default. If the trial discontinuation does constitute a material adverse change in our business, operations or condition, SVB will have the right to accelerate our outstanding obligations under the 2012 Loan Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because our</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> obligations </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the 2012 Loan Agreement </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be accelerated at the election of SVB upon the expiration of the For</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bearance Agreement, or earlier if another event of default occurs, including but not limited to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the ASN100 Phase 2 clinical trial discontinuation constitutes a material adverse change in </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business, operations or condition</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we have</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> presented the SVB l</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oan payable as current on the consolidated bal</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ance sheet as of June 30, 2018.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FFG Loans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Between September 2011 and March 2017, we entered into a series of funding agreements with FFG that provided for loans and grants to fund qualifying research and development expenditures of our Austrian subsidiary on a project-by-project basis, as approved by FFG. As of June 30, 2018 and December&#160;31, 2017, the outstanding principal amount under loans from FFG was $9.9&#160;million and $10.2&#160;million, respectively, based on our actual spending for qualified expenditures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts due under the FFG loans bear interest at varying fixed rates ranging from 0.75% to 2.0% per annum. Interest is payable semi-annually in arrears, with all accrued interest and principal due upon maturity. The FFG loans mature at varying dates between June 2020 and March 2023. In the event that the underlying program research results in a scientific or technical failure, the principal then outstanding under any loan may be forgiven by FFG and converted to non-repayable grant funding on a project-by-project basis. The FFG loans contain no affirmative, negative or financial covenants and are not secured by any of our assets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2018, the funding agreements with FFG are expected to provide us additional loans of approximately $1.0&#160;million and additional grants of approximately $0.1&#160;million if and when we incur specified amounts of qualifying expenditures.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be required to return all or a portion of the FFG loans and/or grants if we do not comply with the terms of the related FFG funding agreements and related guidelines, including specified requirements as to continued operations with respect to certain locations and funded projects. To date, FFG has not requested the return of any amounts received by us under the funding agreements.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Promissory Notes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Between December 2015 and January 2017, we issued an aggregate of $14.4&#160;million of convertible promissory notes, all of which were subsequently converted into shares of our convertible preferred stock. A description of each issuance and conversion is provided below. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2015, we issued an aggregate of $4.0&#160;million of convertible promissory notes, or the 2015 Notes. The 2015 Notes accrued interest at a rate of 0.56% per annum, with a maturity date of December&#160;16, 2016, unless earlier converted under the terms of the 2015 Notes. All principal and interest accrued under the 2015 Notes was converted into shares of Series C convertible preferred stock in connection with our sale of Series C convertible preferred stock in April 2016. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, we issued an aggregate of $5.5&#160;million of convertible promissory notes, or the 2016 Notes, which accrued interest at a rate of 0.7% per annum and had a maturity date of October&#160;12, 2017, unless earlier converted under the terms of the 2016 Notes. All principal and interest accrued under the 2016 Notes was converted into shares of Series D convertible preferred stock in connection with our sale of Series D convertible preferred stock in April 2017. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, we issued an aggregate of $4.9&#160;million of convertible promissory notes, or the 2017 Notes. The 2017 Notes accrued interest at a rate of 0.96% per annum, with a maturity date of October&#160;12, 2017, unless earlier converted under the terms of the 2017 Notes. All principal and interest accrued under the 2017 Notes was converted into shares of Series D convertible preferred stock in connection with our sale of Series D convertible preferred stock in April 2017. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending any decision to change our strategic direction, our current operating plan provides for the completion of our ongoing review of the cumulative unblinded data from the ASN100 Phase 2 clinical trial, the continued development of our ASN500 program as well as the continued support of our collaborators across our ongoing ASN200 and ASN300 programs, both of which were outlicensed to subsidiaries of Bravos Biosciences, LLC during the first half of 2018. We have ceased further clinical development of ASN100 pending the completion of our ongoing review of the cumulative unblinded data from the discontinued ASN100 Phase 2 clinical trial and currently do not expect to incur material costs for this program beyond 2018.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently expect to continue to incur significant expenses for at least the next several years as we advance</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ASN500</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> program</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> through preclinical development and clinical trials and seek regulatory approval of any product candidates. In addition, we expect to</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> continue to</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> incur additional costs associated with operating as a public company. Our expenses could increase over the lo</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng-term as we</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">advance our ASN500 program; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">advance potential future product candidates into preclinical and clinical development;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">conclude our ongoing review of strategic options for our business that may potentially result in changes to our current business strategy and future operations, which in turn could result in significant future research and development and general and administrative expenses based on the outcome of this strategic review; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek regulatory approvals for any product candidates that successfully complete clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own or jointly; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">hire additional clinical, quality control and scientific personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintain, expand and protect our intellectual property portfolio; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">acquire or in-license other product candidates and technologies. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on this current operating plan, we believe that our existing cash and cash equivalents will enable us to fund our operating expenses, capital expenditure requirements and debt service payments into the first quarter of 2020. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We expect that we will require additional funding to complete the clinical development of any successful product candidate from our ASN500 program, commercialize any product candidate, if we receive regulatory approval, and pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for any potential future product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize such product candidate ourselves. Also, in light of the discontinuation of the Phase 2 clinical trial of our lead product candidate ASN100, we are considering strategic options for our business that may potentially result in changes to our current business strategy and future operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to successfully consummate one or more strategic transactions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to eliminate all material ASN100-related expenses by the end of the fourth quarter of 2018;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, progress, results and costs of researching and developing any product candidates, and conducting preclinical studies and clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs, timing and outcome of regulatory review of any product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any product candidates for which we receive marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of manufacturing commercial-grade products and necessary inventory to support commercial launch; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability to receive additional non-dilutive funding, including grants from organizations and foundations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the revenue, if any, received from commercial sale of our products, should any product candidates receive marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain collaborations on favorable terms, if at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we acquire or in-license other product candidates and technologies; and </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the timing, receipt and amount of sales of, or milestone payments related to or royalties on, product candidates, if any. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, government funding, collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, additional debt financing would result in increased fixed payment obligations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise funds through governmental funding, collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, reduce or eliminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration, License and Funding Arrangements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, we entered into a collaboration agreement with Adimab, LLC, or Adimab, pursuant to which we have agreed to pay royalties of a mid single-digit percentage based on net sales by us or our affiliates of products that use or are based on any antibody discovered or optimized under the agreement, any derivative or modified version of any such antibody, or any sequence information as to any such antibody. In addition, if we sell or license to any third party, or otherwise grant rights to any third party to, any of the products for which we are obligated to pay Adimab royalties, either alone or as part of a package including specified patents not directed to these antibodies, we are obligated to pay Adimab either the same royalties on net sales of such products by such third party, or a percentage, ranging from the low double digits to a maximum of less than 30%, of the payments we receive from such third parties that are attributable to such grant of rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we (or one of our affiliates with rights under the agreement) undergo a change in control and, at the time of such change in control, we have not sold or licensed to third parties all of our rights in antibodies for which we are obligated to pay Adimab royalties under the agreement, then we are obligated to either pay Adimab a percentage, in the mid double digits, of the payments we receive from that change in control that are reasonably attributable to those rights and certain patents arising from the collaboration, or require our acquirer and all of its future third-party collaborators to pay to Adimab royalties at a mid single-digit percentage of net sales based on those rights. If we grant rights to a third party under certain patents that are not directed to the antibodies for which we are obligated to pay Adimab royalties, we are also obligated to pay Adimab, in place of royalties or a percentage of payments received from the third party, a lump sum in the high six digits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our option and license agreement with Adimab, if we exercise our option to obtain rights to certain RSV antibodies, we are obligated to pay Adimab an option fee of $0.3&#160;million and make clinical and regulatory milestone payments of up to $24.4&#160;million as well as royalty payments on a product-by-product and country-by-country basis of a mid single-digit percentage based on net sales by us, our affiliates, licensees or sublicensees of products based on certain RSV antibodies during the applicable term for such product in that country. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, we entered into a grant agreement with the Gates Foundation, under which the Gates Foundation agreed to provide us up to $9.3 million to conduct preclinical development of mAbs for the prevention of RSV infection in newborns, which we refer to as the RSV project. In August 2018, we entered into an amended and restated grant agreement which replaces the February 2017 grant agreement in its entirety, and includes amendments to conform to current Gates Foundation audit, reporting, and other administrative requirements as well as to make the perpetual license that is granted to the Gates Foundation with respect to any funded developments resulting from the grant agreement irrevocable. In August 2018, we entered into an additional grant agreement with the Gates Foundation pursuant to which the Gates Foundation granted us up to $1.1 million to conduct preclinical development activities for the RSV project that were not included in the February 2017 grant agreement, as amended and restated in August 2018. Pursuant to both grant agreements, as amended, we have no payment obligations under the Adimab option and license agreement with respect to sales of products based on licensed RSV antibodies to the extent they are sold at cost in developing countries. However, if such products are sold in developing countries for an amount that exceeds cost, then the amount of such excess will be subject to the royalty payment obligations described in the preceding paragraph. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a>In April 2017, we entered into a letter agreement with the Gates Foundation pursuant to which we licensed to the Gates Foundation certain rights under our ASN100 program. We have no payment obligations under the Adimab collaboration agreement with respect to sales of certain antibody products if they are sold at cost in developing countries under our letter agreement with the Gates Foundation. However, if such products are sold in developing countries for an amount that exceeds cost, then the amount of such excess over cost will be subject to the royalty payment obligations described above. In addition, if the Gates Foundation terminates the agreement for certain specified uncured material breaches by us, we will be required, among other remedies, to redeem </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> then-held shares of our stock purchased by the Gates Foundation pursuant to the agreement or to facilitate the purchase of such stock by a third party. For any such redemption, the Gates Foundation stock will be valued at the greater of the original purch</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ase price (plus specified interest) or the fair market value of such stock</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the&#160;three and six months ended June 30, 2018, there were no material changes to our critical accounting policies. Our critical accounting policies are described under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results&#160;of Operations&#8212; Critical Accounting Policies and Significant Judgments and Estimates&#8221; in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March&#160;9, 2018&#160;and the notes to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on&#160;Form&#160;10-Q. We believe that of our critical accounting policies, the following accounting policies involve the most judgment and complexity: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Government contracts, grant agreements and incentive programs</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Prepaid and accrued research and development expenses</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Determination of the fair value of common stock prior to the initial public offering</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Valuation of derivative liability</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company Status </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Jumpstart Our Business Startups Act of 2012 permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to &#8220;opt out&#8221; of this provision and, as a result, we will comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the six months ended June 30, 2018, there were no material changes to our contractual obligations and commitments described under the caption &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2017 that we filed with the Securities and Exchange Commission on March 9, 2018, other than the Amended Lease Agreement with respect to our office space in Waltham, MA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the Amended Lease Agreement commences on January 1, 2019 and expires December 31, 2023. We have the option to extend the term for one additional five-year period upon our written notice to the Lessor at least nine months and no more than 12 months in advance of the extension. The Amended Lease Agreement terminates our one-time right of first offer, subject to certain terms and conditions, for additional space containing approximately 4,000 square feet specified in the original lease agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The annual base rent obligation is approximately $0.3 million, with a total cash obligation for the base rent over the initial five-year term of the Amended Lease Agreement is approximately $1.3 million. In addition to the base rent, we are also responsible for our share of operating expenses, electricity and real estate taxes, in accordance with the terms of the Amended Lease Agreement. We will provide a security deposit in the amount of $0.3 million as well as a relocation payment of $0.1 million to the Lessor.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Issued Acco</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">unting Pronouncements </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2 to our condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="I_Item3"></a><a name="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"></a><a name="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"></a>Item 3. Quantitative and Qualitative Disclosures About Market Risk.</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest Rate Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risk related to changes in interest rates. As of June 30, 2018, we had $3.5&#160;million of borrowings outstanding under the 2012 Loan Agreement. Borrowings under the 2012 Loan Agreement bear interest at a rate per annum equal to the greater of 3.25% and The Wall Street Journal prime rate, in each case minus 0.25%, which resulted in an applicable interest rate of 4.75% as of June 30, 2018. Based on the principal amounts outstanding as of June 30, 2018, an immediate 10%&#160;change in the interest rate would not have a material impact on our debt-related obligations, financial position or results of operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2018, we had $49.6 million of cash equivalents consisting of money market funds held in our sweep account. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates. Because of the short-term nature of the instruments in our portfolio, we would not expect an immediate 10% change in market interest rates to have a material impact on our financial position or results of operations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Currency Exchange Risk </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk506915920"></a><a name="_Hlk506358905"></a>We are also exposed to f<a name="_Hlk506915920"></a><a name="_Hlk506358905"></a>oreign exchange rate risk. Our headquarters are located in the United States, where the majority of our general and administrative expenses are incurred in U.S. dollars. Research and development costs are incurred by our subsidiary in Austria, whose functional currency is the Euro. During the three and six months ended June 30, 2018 and 2017, we recognized a foreign currency transaction loss of less than $0.1 million in each period. This loss primarily related to unrealized and realized foreign currency losses as a result of transactions entered into by our U.S. entity in currencies other than the U.S. dollar. These foreign currency transaction losses were recorded as a component of other income (expense), net in our condensed consolidated statements of operations. We believe that a 10% change in the exchange rate between the U.S. dollar and the Euro would not have a material impact on our financial position or results of operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to grow our business, our results of operations and cash flows will be subject to fluctuations due to changes in foreign currency exchange rates, which could adversely impact our results of operations. To date, we have not entered into any foreign currency hedging contracts to mitigate our exposure to foreign currency exchange risk.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="I_Item4"></a><a name="ITEM_4_CONTROLS_PROCEDURES"></a><a name="ITEM_4_CONTROLS_PROCEDURES"></a>Item 4. Controls and Procedures.</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_699"></a><a name="_cp_text_1_701"></a><a name="_cp_text_1_704"></a><a name="_cp_text_1_713"></a><a name="_cp_text_4_714"></a><a name="_cp_text_1_715"></a><a name="_cp_text_4_716"></a><a name="_cp_text_1_717"></a><a name="_cp_text_1_720"></a><a name="_cp_text_4_721"></a><a name="_cp_text_1_722"></a><a name="_cp_text_1_724"></a>We maintain &#8220;<a name="_cp_text_1_701"></a>disclosure controls and procedures&#8221; <a name="_cp_text_1_704"></a>as defined in Rules 13a-15(e) and 15d-<a name="_cp_text_1_713"></a>15(e) <a name="_cp_text_4_714"></a>under the Securities <a name="_cp_text_1_715"></a>Exchange Act <a name="_cp_text_4_716"></a>of 1934, as amended<a name="_cp_text_1_717"></a>, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports we file and submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and f<a name="_cp_text_1_720"></a>orms<a name="_cp_text_4_721"></a>. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required <a name="_cp_text_1_722"></a>to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our <a name="_cp_text_1_724"></a>management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_726"></a><a name="_cp_text_4_727"></a><a name="_cp_text_1_728"></a><a name="_cp_text_4_729"></a><a name="_cp_text_1_730"></a><a name="_cp_text_4_731"></a><a name="_cp_text_1_732"></a><a name="_cp_text_4_733"></a><a name="_cp_text_1_734"></a><a name="_cp_text_4_735"></a><a name="_cp_text_1_736"></a><a name="_cp_text_4_737"></a><a name="_cp_text_1_738"></a><a name="_cp_text_4_739"></a><a name="_cp_text_1_740"></a><a name="_cp_text_1_726"></a>Our management, with the participation of our Chief Executive Officer and Chief <a name="_cp_text_4_727"></a>Operating Officer and Chief <a name="_cp_text_1_728"></a>Financial Officer, <a name="_cp_text_4_729"></a>who serve as our principal executive officer and principal financial officer, respectively, has evaluated the e<a name="_cp_text_1_730"></a>ffectiveness of our disclosure controls and procedures as of June 30<a name="_cp_text_4_731"></a>, 2018. Based on such evaluation, our <a name="_cp_text_1_732"></a>Chief Executive Officer and Chief <a name="_cp_text_4_733"></a>Operating Officer and Chief <a name="_cp_text_1_734"></a>Financial Officer <a name="_cp_text_4_735"></a>have <a name="_cp_text_1_736"></a>concluded that <a name="_cp_text_4_737"></a>our disclosure controls and procedures were effect<a name="_cp_text_1_738"></a>ive <a name="_cp_text_4_739"></a>at the <a name="_cp_text_1_740"></a>reasonable assurance level as of such date.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended June 30, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="I_Item4T"></a><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><a name="PART_IIOR_INFORMATION"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IIOR_INFORMATION"></a>PART II&#8212;OTHER</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> INFORMATION</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="II_Item1A"></a><a name="ITEM_1A_RISK_FACTORS"></a><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Risk Factors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Quarterly Report on Form 10-Q and other filings with the Securities and Exchange Commission, press releases, communications with investors, and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Financial Position and Need for Additional Capital</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.34%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company with a limited operating history. We have incurred significant losses since inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have incurred significant net losses. Our net loss was $22.8&#160;million and $11.1 million for the six months ended June 30, 2018 and 2017, respectively. As of June 30, 2018, we had an accumulated deficit of $115.0&#160;million. We have funded our operations to date primarily with proceeds from our initial public offering and concurrent private placement, the sale of preferred stock, convertible debt financings, borrowings under a loan agreement, proceeds received from governmental loans and grants and proceeds received under a non-governmental grant. To date, we have devoted substantially all of our resources to building our business to support discovery, research and development activities for our programs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have devoted a significant portion of our financial resources and efforts to the development of ASN100. On June 28, 2018, we announced that the DRC for our ASN100 Phase 2 clinical trial recommended that trial enrollment be discontinued based on the DRC&#8217;s conclusion that the trial was not likely to meet its primary end-point upon completion. Based on the DRC recommendation, we decided to discontinue the Phase 2 clinical trial of ASN100 and have taken steps to notify health authorities and clinical investigators participating in the trial. We are in the process of performing analyses of the cumulative unblinded data from the trial to better understand the basis for this outcome. We have ceased further clinical development of ASN100 pending the completion of our ongoing review of the cumulative unblinded data from the trial. We expect to complete our assessment of the ASN100 Phase 2 clinical trial during the fourth quarter of 2018. Our determination as to our next steps will necessarily impact the amount of expenses we incur and the size of our operating losses for the foreseeable future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending any decision to change our strategic direction, we expect to continue to incur significant expenses and operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we or any current or potential future collaborators must develop and eventually commercialize at least one product candidate with significant market potential. This will require that we or our collaborators be successful in a range of challenging activities, including completing preclinical studies and clinical trials of one or more product candidates, obtaining marketing approval for one or more these product candidates, manufacturing, marketing and selling those products for which we or our collaborators may obtain marketing approval and satisfying any post-marketing requirements. We or our collaborators may never succeed in any or all of these activities and, even if we or our collaborators do succeed, we or our collaborators may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.34%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, obtaining funding from government entities and non-government organizations, developing and securing our technology, identifying potential product candidates, undertaking preclinical studies and clinical trials of our most advanced product candidates and entering into licensing and funding agreements. We have not yet demonstrated the ability to initiate or complete later-stage clinical trials of any product candidates, obtain marketing approvals, manufacture a commercial-scale product or conduct sales and marketing activities necessary for successful commercialization. Consequently, any evaluation of our business to date or predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discontinua</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of ou</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of ASN100 has required us to reevaluate our future development plans for </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product candidates and </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs and </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has significantly decreased the</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> likelihood that we will commercialize any product candidate</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the near term. We may never be successful in developing or commercializing any product candidates</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.34%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, reduce or eliminate certain of our product development efforts or other operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending any decision to change our strategic direction, we plan complete our ongoing review of the cumulative unblinded data from the ASN100 Phase 2 clinical trial, continue the development of our ASN500 program as well as support our collaborators across our ongoing ASN200 and ASN300 programs, both of which were outlicensed to subsidiaries of Bravos Biosciences, LLC during the first half of 2018. We will need substantial additional funds to support our planned operations. In the absence of additional funding or business development activities, we believe that our existing cash and cash equivalents at June 30, 2018 will be adequate to satisfy our capital needs into the first quarter of 2020 based on our current operating plans, which do not include material ASN100 expenses beyond the fourth quarter of 2018. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our estimate as to how long we expect our existing cash and cash equivalents to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, our current changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate. Our future funding requirements, both short-term and long-term, will depend on many factors, including, but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to </font><font style="color:#000000;font-family:Times New Roman;">successfully consummate one or more strategic transactions</font><font style="font-family:Times New Roman;">;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to eliminate all material ASN100-related expenses by the end of the fourth quarter of 2018;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope, progress, results and costs of researching and developing our ASN500 program and any product candidates, and conducting preclinical studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs, timing and outcome of regulatory review of any product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any product candidates for which we receive marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of manufacturing commercial-grade products and necessary inventory to support commercial launch;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability to receive additional non-dilutive funding, including grants from organizations and foundations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the revenue, if any, received from commercial sale of our products, should any product candidates receive marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain collaborations on favorable terms, if at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we acquire or in-license other product candidates and technologies; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future product candidates, if any. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if any are approved, may not achieve commercial success. Our product revenue, if any, and any commercial milestones or royalty payments under our collaboration agreements will be derived from or based on sales of products that may not be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to technologies or product candidates. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, government funding, grants, collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize product candidates. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Our issuance of additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our common stock to decline, and our stockholders may not agree with our financing plans or the terms of such financings. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, additional debt financing would result in increased fixed payment obligations. In addition, if we elect to obtain any additional debt financing, our ability to do so may be limited by covenants we have made under our loan and security agreement with Silicon Valley Bank, or SVB, as amended, which we refer to as the 2012 Loan Agreement. For example, we have made a negative pledge in favor of SVB with respect to our intellectual property under the 2012 Loan Agreement, meaning that we will not pledge any of our intellectual property to a third party as collateral for a loan while the 2012 Loan Agreement is in effect. This negative pledge could further limit our ability to obtain additional debt financing on favorable terms. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If <font style="color:#000000;">we raise funds through government funding, collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to u</font>s. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy, and we could be forced to delay, reduce or eliminate certain of our research and development programs or any future commercialization efforts.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our existing and any future indebtedness could adversely affect our ability to operate our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under <font style="color:#000000;">our </font>2012 Loan Agreement<font style="color:#000000;"> with SVB, principal amounts outstanding totaled $3.5&#160;million as of June 30, 2018. We are required to repay outstanding indebtedness under the </font>2012 Loan Agreement<font style="color:#000000;"> in monthly installments through December 2019. </font>I<font style="color:#000000;">n addition, borrowings under the </font>2012 Loan Agreement<font style="color:#000000;"> are collateralized by a pledge of </font>substantially all of our assets other than our intellectual property, including <font style="color:#000000;">65% of the outstanding capital stock of our subsidiary in Austria.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were in compliance with all covenants under the 2012 Loan Agreement as of December 31, 2017. During the six months ended June 30, 2018, we failed to comply with the covenants under the 2012 Loan Agreement when we entered into separate option and license agreements for our ASN200 and ASN300 programs with subsidiaries of Bravos Biosciences, LLC without obtaining prior written consent of SVB, and then delivered compliance certificates to SVB that did not disclose these violations. As a result, we are currently in default under the 2012 Loan Agreement and SVB may, at its option, declare all of our obligations under the 2012 Loan Agreement to be immediately due and payable. On August 8, 2018, we and SVB entered into a Forbearance Agreement pursuant to which SVB has agreed to forbear from exercising its rights and remedies with respect to such defaults until the earlier to occur of (i) another event of default under the Loan Agreement or (ii) October 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the default in connection with the option and license agreements, we have also discussed with SVB whether our decision to discontinue the Phase 2 clinical trial of ASN100 may be considered a material adverse change in our business, operations or condition (financial or otherwise) and, accordingly, an event of default under the terms of the 2012 Loan Agreement. To date, SVB has not agreed that the discontinuation of the trial does not constitute an event of default. If the trial discontinuation does constitute a material adverse change in our business, operations or condition, SVB will have the right to accelerate our outstanding obligations under the 2012 Loan Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the obligations may be accelerated at the election of SVB upon the expiration of the Forbearance Agreement, or earlier if another event of default occurs, including but not limited to if the ASN100 Phase 2 clinical trial discontinuation constitutes a material adverse change in our business, operations or condition, we have presented the SVB loan payable as current on the consolidated balance sheet as of June 30, 2018.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our loans from &#214;sterreichische Forschungsf&#246;rderungsgesellschaft GmbH, or FFG, principal amounts outstanding totaled $9.9&#160;million as <font style="color:#000000;">of June 30, 2018. We are required to pay interest on our loans from FFG semi-annually, with payment of principal due at the maturity dates of the loans, which range from 2020 to 2023. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be required to return all or a portion of the FFG loans and/or grants if we do not comply with the terms of the related FFG funding agreements and relate</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d guidelines, including specified requirements as to continued operations with respect to certain locations and funded projects. To date, FFG has not requested the return of any amounts received by us under the funding agreements.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could in the future incur additional indebtedness beyond our borrowings from SVB and FFG.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our outstanding indebtedness, combined with our other financial obligations and contractual commitments, including any additional future indebtedness beyond our borrowings from SVB and FFG, could have significant adverse consequences, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">requiring us to dedicate a portion of our cash and cash equivalents resources to the payment of interest and principal, and prepayment and repayment fees and penalties, thereby reducing money available to fund working capital, capital expenditures, product development and other general corporate purposes; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">subjecting us to restrictive covenants that may reduce our ability to take certain corporate actions or obtain further debt or equity financing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">placing us at a competitive disadvantage compared to our competitors that have less debt or better debt servicing options; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">increasing our vulnerability to adverse changes in general economic, industry and market conditions. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">may not have sufficient funds, and may be unable to arrange for additional financing, to pay the amounts due under our existing debt. Failure to make payments or comply with other covenants under our existing debt instruments could result in an event of default and acceleration of amounts due. While we currently have sufficient resources to pay our existing debt in the event that repayment was accelerated under the existing SVB and FFG loans, that may not be the case in the future. If we are unable to make payments when due under the </font>2012 Loan Agreement<font style="color:#000000;">, SVB would have the right to foreclose on the collateral under the agreement, which would result in it becoming the majority stockholder of our Austrian subsidiary</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Development of Product Candidates </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business to date has been almost entirely dependent on the success of ASN100, which recently had its Phase 2 clinical trial discontinued in connection with the Data Review Committee, or DRC, determination that the trial had a low probability of meeting its primary end-point upon completion. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 28, 2018, we announced that the DRC for our ASN100 Phase 2 clinical trial recommended that trial enrollment be discontinued based on the DRC&#8217;s conclusion that the trial was not likely to meet its primary end-point upon completion. Based on the DRC recommendation, we decided to discontinue the Phase 2 clinical trial of ASN100 and have taken steps to notify health authorities and clinical investigators participating in the trial. We are in the process of performing analyses of the cumulative unblinded data from the trial to better understand the basis for this outcome. We have ceased further clinical development of ASN100 pending the completion of our ongoing review of the cumulative unblinded data from the trial. We expect to complete our assessment of the ASN100 Phase 2 clinical trial during the fourth quarter of 2018.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In light of the discontinuation of the Phase 2 clinical trial of our lead product candidate ASN100, we are considering strategic options for our business that may potentially result in changes to our current business strategy and future operations. However, we cannot provide any commitment regarding when or if this strategic review process will result in any type of transaction, and there can be no assurance that such activities will result in any agreements or transactions that will enhance stockholder value.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we determine to pursue an alternative strategy or engage in a strategic transaction, our future business, prospects, financial position and operating results could be significantly different than those in historical periods or projected by our management. Because of the significant uncertainty regarding our future plans, we are not able to accurately predict the impact of a potential change in our existing business strategy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pending any decision to change our strategic direction, our current operating plan provides for the completion of our ongoing review of the cumulative unblinded data from the ASN100 Phase 2 clinical trial, the continued development of our ASN500 program as well as the continued support of our collaborators across our ongoing ASN200 and ASN300 programs, both of which were outlicensed to subsidiaries of Bravos Biosciences, LLC during the first half of 2018.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">approach to the discovery and development of product candidates based on our targeted mAbs is unproven, and we do not know whether we will b</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">e able to successfully develop any products.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are focused on the discovery, development and commercialization of monoclonal antibody, or mAb, immunotherapies to address serious infectious diseases. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates, including those that we are directly developing and those being developed under collaboration with subsidiaries of Bravos Bioscience, LLC, in future clinical trials or in obtaining marketing approval thereafter. For example, we have not yet advanced a product candidate beyond Phase 2 clinical development. In June 2018 we discontinued our Phase 2 clinical trial of ASN100, based on the results of a planned interim analysis of unblinded trial data conducted by the DRC. The DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion, and recommended that trial enrollment be discontinued.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have never had a product candidate receive approval from the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, or other regulatory authority. The regulatory review process may be more expensive or take longer for our product candidates than we expect, and we may be required to conduct additional studies and/or trials beyond those we anticipate. If it takes us longer to develop and/or obtain regulatory approval for product candidates than we expect, such delays could materially and adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical drug development is uncertain. Our preclinical programs, such as our ASN500 program, may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize any product candidates on a timely basis or at all, which would have an adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we explore strategic options, we are continuing to develop our ASN500 program, which is currently in preclinical development. We have outlicensed two preclinical product candidates, ASN200 and ASN300, to subsidiaries of Bravos Biosciences, LLC during the first half of 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to obtain FDA approval to market a new biological product we must demonstrate proof of safety, purity and potency or efficacy in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned Investigational New Drug application, or IND, in the United States. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of these product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C<font style="color:#000000;">onducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity, novelty and intended use of the product candidate, and often can be several years or more per product candidate. Delays associated with product candidates for which we are directly conducting preclinical testing and studies may cause us to incur additional operating expenses. Moreover, we may continue to be affected by delays associated with the preclinical testing and studies of certain product candidates conducted by our potential partners over which we have no control. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including, for example:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">inability to generate sufficient preclinical or other&#160;</font><font style="font-style:italic;font-family:Times New Roman;">in vivo</font><font style="font-family:Times New Roman;">&#160;or&#160;</font><font style="font-style:italic;font-family:Times New Roman;">in vitro</font><font style="font-family:Times New Roman;">&#160;data to support the initiation of clinical studies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays in reaching a consensus with regulatory agencies on study design; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA not allowing us to rely on previous findings of safety and efficacy for other similar but approved products and published scientific literature. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, even if clinical trials do begin for any product candidates, our development efforts may not be successful, and clinical trials that we conduct or that third parties conduct on our behalf may not demonstrate sufficient safety, purity and potency or efficacy to obtain the requisite regulatory approvals for any of our product candidates or product candidates employing our technology. Even if we obtain positive results from preclinical studies or initial clinical trials, we may not achieve the same success in future trials. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">future clinical trials of our product candidates may not be successful. If we or our collaborators are unable to commercialize any product candidates or if we experience significant delays in doing so, our business could be substantially harmed</font><font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">currently have no products approved for sale and have invested a significant portion of our efforts and financial resources in the development of ASN100. In June 2018, we discontinued our Phase 2 clinical trial of ASN100, based on the results of a planned interim analysis of unblinded trial data conducted by the DRC. The DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion, and recommended that trial enrollment be discontinued</font>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we are exploring strategic options, we are continuing to develop our ASN500 program, which is currently in preclinical development. The success of any product candidates we may develop will depend on several factors, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">initiation and successful enrollment and completion of clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a safety, tolerability and efficacy profile that is satisfactory to the FDA, EMA or other regulatory authorities for marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">timely receipt of marketing approvals from applicable regulatory authorities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establishment and maintenance of arrangements with third-party manufacturers for both clinical and any future commercial manufacturing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">adequate ongoing availability of raw materials and drug product for clinical development and any commercial sales; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and internationally; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">protection of our rights in our intellectual property portfolio;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successful launch of commercial sales following any marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a continued acceptable safety profile following any marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">commercial acceptance by the patient community, the medical community and third-party payors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the performance of our future collaborators, if any; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to compete with other therapies.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of these factors are beyond our control, including clinical development, the regulatory review process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. If we are unable to develop, receive marketing approval for and successfully commercialize any product candidates, on our own or with any future collaborator, or experience delays as a result of any of these factors or otherwise, our business could be substantially harmed.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical <font style="color:#000000;">drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of any product candidates are prolonged or delayed, we or our collaborators may be unable to obtain required regulatory approvals, and therefore will be unable to commercialize our product candidates on a timely basis or at all, which will adversely affect our business</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a>Before <font style="color:#000000;">obtaining marketing approval from regulatory authorities for the sale of any product candidates, we or our collaborators must conduct extensive clinical trials to demonstrate the safety and efficacy of the produc<a name="_AEIOULastRenderedPageBreakAEIOU39"></a>t candidates. Clinical testing is expensive, time-consuming, difficult to design and implement and uncertain as to outcome. We cannot guarantee that clinical trials will be conducted as planned, completed on schedule, if at all, or yield positive results. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays in reaching a consensus with regulatory authorities or collaborators on trial design; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays in opening clinical trial sites or obtaining required institutional review board or independent ethics committee approval at each clinical trial site; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">delays in recruiting suitable subjects to participate in clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">imposition of a clinical hold by regulatory authorities, including as a result of a serious adverse event or after an inspection of our clinical trial operations or trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure by us, any CROs we engage, clinical investigators, our collaborators or any other third parties to adhere to clinical trial requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure to perform in accordance with good clinical practices, or GCP, or applicable regulatory requirements in the European Union, the United States, or in other countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays or failures in demonstrating the comparability of product manufactured at one facility or with one process to product manufactured at another facility or with another process, including clinical trials to demonstrate such comparability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays in having subjects complete participation in a trial or return for post-treatment follow-up; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinical trial sites or subjects dropping out of a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from product sales, regulatory and commercialization milestones and royalties. In addition, if we or our collaborators make manufacturing or formulation changes to any product candidates, we may need to conduct additional trials to bridge our modified product candidates to earlier versions. Clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could encounter delays if a clinical trial is suspended or terminated by us, by the institutional review boards of the institutions in which such trials are being conducted or ethics committees, by the Data Review Committee, or DRC, or Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including those relating to the class of products to which our product candidate belongs. In June 2018,<font style="color:#000000;"> </font>we discontinued our Phase 2 clinical trial of ASN100, based on the results of a planned interim analysis of unblinded trial data conducted by the DRC. The DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion, and recommended that trial enrollment be discontinued.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates or result in the development of our product candidates being stopped early.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results from preclinical studies or previous clinical trials are not necessarily predictive of future clinical trial results, and interim results of a clinical trial are not necessarily indicative of final results. Any product candidates we develop may fail to show the desired safety and efficacy in clinical development despite demonstrating positive results in preclinical studies or having successfully advanced through initial clinical trials.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There can be no assurance that</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the success we achieved in precl</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inical studies and early</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical trial</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ultimately will result in success in potential future clinical trials of product candidates. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, on June 28, 2018, we announced that the DRC for our ASN100 Phase 2 clinical trial recommended that trial enro</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">llment be discontinued</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> based</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on the DRC&#8217;s conclusion that the </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was not likely to meet its primary end-point upon completion. Based on the DRC recommendation, we decided to discontinue the Phase 2 clinical trial of ASN100. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we cannot assure</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> you that we </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or our collaborators </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will be able to achieve success in our preclinical studies </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or any future</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical trials of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product candidates.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a high failure rate for drugs and biologic products proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical studies and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could materially and adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may find it difficult to enroll and dose patients in clinical trials, which could delay or prevent our collaborators and us from proceeding with clinical trials of any product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying and qualifying patients to participate in any future clinical trials of any product candidates is critical to our success. The timing of any future clinical trials will depend on our ability to recruit patients to participate as well as to subsequently dose these patients and complete required follow-up periods. In&#160;addition, we may experience enrollment delays related to increased or unforeseen regulatory, legal and logistical requirements at certain clinical trial sites outside of the United States. These delays could be caused by&#160;regulatory reviews by non-U.S. regulatory authorities and contractual discussions with individual clinical trial sites, for example. Any delays in enrolling and/or dosing patients in any future clinical trials could result in increased costs, delays in advancing any product candidates, delays in testing the effectiveness of such product candidates or termination of the clinical trials altogether.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to identify, recruit, enroll and dose a sufficient number of patients, or those with required or desired characteristics, to complete any future clinical trials in a timely manner. Subject enrollment and trial completion is affected by a number of factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">coordination between us, CROs and any future collaborators in our efforts to enroll and administer the clinical trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">size of the patient population and process for identifying patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">design of the trial protocol; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">eligibility and exclusion criteria; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">perceived risks and benefits of the product candidate under study; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">availability of competing commercially available therapies and other competing drug candidates&#8217; clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">time of year in which the trial is initiated or conducted; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">variations in the seasonal incidence of the target indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">severity of the disease under investigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ability to obtain and maintain subject consent; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ability to enroll and treat patients in a timely manner; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">risk that enrolled subjects will drop out before completion of the trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">patient referral practices of physicians; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ability to monitor subjects adequately during and after treatment. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may <font style="color:#000000;">conduct clinical trials for product candidates at sites outside the United States. The FDA may not accept data from trials conducted in such locations and the conduct of trials outside the United States could subject us to additional delays and expense</font>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future conduct one or more clinical trials with one or more trial sites that are located outside the United States. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qu</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alified investigators in accordance with GCP. The FDA must be able to validate the data from the trial through an onsite inspection if necessary. The trial population must also have a similar profile to the U.S. population, and the data must be applicable </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful, except to the extent the disease being studied does not typically occur in the United States. In addition, while these clinical trials are subject to the app</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of th</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which would be costly and time-consuming and delay or permanently halt our development </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of any future</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the conduct of clinical trials outside the United States could have a significant adverse impact on us. Risks inherent in conducting international clinical trials include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinical practice patterns and standards of care that vary widely among countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">non-U.S. regulatory authority requirements that could restrict or limit our ability to conduct clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">administrative burdens of conducting clinical trials under multiple non-U.S. regulatory authority schema; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">foreign exchange fluctuations; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">diminished protection of intellectual property in some countries. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We or our collaborators may fail to demonstrate safety and efficacy of any product candidates to the satisfaction of applicable regulatory authorities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the results of any clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with any product candidates, we may: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be delayed in obtaining marketing approval for our product candidates, if at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain approval for indications or patient populations that are not as broad as intended or desired; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to changes in the way the product is administered; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a risk evaluation and mitigation strategy; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to the addition of labeling statements, such as contraindications or warnings, including a black box warning; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be sued;&#160;or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">experience damage to our reputation. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If serious adverse or undesirable side effects are identified during the development of any product candidate, we or our collaborators may need to abandon or limit our development of that product candidate. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="color:#000000;"> any product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause side effects or raise other safety issues that delayed or prevented further development of the compound.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our collaborators elect or are forced to suspend or terminate any clinical trial of any product candidates, the commercial prospects of such product candidates will be harmed and our ability to generate product revenue from such product candidates will be delayed or eliminated. Any of these occurrences could materially harm our business, financial condition, results of operations and prospects.<font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The manufacture of biologic products is complex and manufacturers often encounter diffi</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">culties in production. If we or any of our third-party manufacturers encounter any loss of our master cell banks or if any of our third-party manufacturers encounter other difficulties, our ability to provide </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">any</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">product candidates for clinical trials or products, if approved, to patients could be delayed or halted. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">manufacture of biologic products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. We and our collaborators and our third-party manufacturers must comply with current good manufacturing practices, or cGMP, regulations and guidelines for the manufacturing of biologics used in clinical trials and, if approved, marketed products. Manufacturers of biotechnology products often encounter difficulties in production, particularly in scaling up and validating initial production. Furthermore, if microbial, viral or other contaminations are discovered in any product candidates or in the manufacturing facilities in which such product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Delays in raw materials availability and supply may also extend the period of time required to develop any product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a>All of our mAbs are manufactured by starting with cells that are stored in a cell bank. We have one master cell bank for each antibody manufactured in accordance with cGMP and multiple working cell banks and believe we would have adequate backup should any cell bank be lost in a catastrophic event.&#160;However, it is possible that we or our third-party manufacturers could lose multiple cell banks and have our manufacturing severely impacted by the need to replace the cell banks. We cannot assure you that any stability or other issues relating to the manufacture of any product candidates or products will not occur in the future. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the supply of product candidates or products. We may also have to take inventory write-offs and incur other&#160;charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of any product candidates or products and could have an adverse effect on our business, prospects, financial condition and results of operations.<font style="color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the market opportunities for any product candidates are smaller than we believe they are, even assuming approval of a drug candidate, our business may suffer. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our projections of both the number of people who are affected by disease within our target indications, as well as the subset of these people who have the potential to benefit from treatment with any product candidates we may develop, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, healthcare utilization databases and market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If approved for the prevention of respiratory syncytial virus, or RSV, infection, products from our ASN500 program would compete with palivizumab, which is marketed by MedImmune as Synagis, the only approved therapy in this indication. Any ASN500 products may also compete with other mAb product candidates currently in clinical development in this indication, including MedImmune&#8217;s MEDI8897, which is in Phase 2 clinical development and Merck&#8217;s MK-1654, which is in Phase 1 clinical development</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many </font><font style="color:#000000;">of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources, such as larger research and development,</font><font style="color:#000000;"> clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could b</font><font style="color:#000000;">e reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Competitors also may obtain F</font><font style="color:#000000;">DA or other regulatory approval for their products more rapidly or earlier than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies </font><font style="color:#000000;">developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors. In addition, the availability of our competitors&#8217; products could limit </font><font style="color:#000000;">the demand and the prices we are able to charge for any products that we may develop and commercialize</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Dependence on Third Parties </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may enter into collaborations with third parties to develop product candidates. If these collaborations are not successful, our business could be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our strategy, we intend to seek to enter into collaborations with third parties for one or more of our programs or product candidates. For example, we outlicensed our preclinical-stage ASN200 and ASN300 programs to subsidiaries of Bravos Biosciences, LLC during the first half of 2018. Our likely collaborators for any such collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any collaborations we enter into in the future, may pose several risks, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may not perform their obligations as expected; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the clinical trials conducted as part of these collaborations may not be successful; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may not pursue development and/or commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product candidates developed in collaboration with us may be viewed by any collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product candidate; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development of any product candidates, may cause delays or termination of the research, development or commerci</font><font style="font-family:Times New Roman;">alization of such product candidates, may lead to additional responsibilities for us with respect to such product candidates or may result in litigation or arbitration, any of which would be time-consuming and expensive; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If <font style="color:#000000;">our collaborations do not result in the successful development and commercialization of products, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed and we may need additional resources to develop our product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a>In addition, if any future collaborator terminates its agreement with&#160;us, we may find it more difficult to attract new collaborators and the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this Quarterly Report on Form 10-Q also apply to the activities of any future collaborators<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are not able to establish additional collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">may seek additional collaborations to advance the development of product candidates. We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, the terms of any existing collaboration agreements, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations are complex and time-consuming to negotiate, document and execute. In addition, there have been a significant number of business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We <font style="color:#000000;">expect to rely on third parties to conduct any future clinical trials and we currently rely on third parties for some aspects of our research and preclinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a>We <font style="color:#000000;">do not expect to independently conduct any future clinical trials of any product candidates. We expect to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct any future clinical trials. In addition, we currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical studies. Any of these third parties may terminate their engagements with us, some in the event of an uncured material </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">breach and some at any t</font><font style="color:#000000;">ime for convenience. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or to do so on commercially reasonable terms. Switching or adding additional third parties inv</font><font style="color:#000000;">olves additional cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays may occur in our product development activities. Although we seek to carefully mana</font><font style="color:#000000;">ge our relationships with our third parties, we could encounter similar challenges or delays in the future and these challenges or delays could have a material adverse impact on our business, financial condition and prospects.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our reliance on third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our responsibility to comply with any such requirements and standards. We and these third parties are required to comply with GCP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA, or comparable regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a U.S. government-sponsored database, clinicaltrials.gov, within certain timeframes. Similar requirements are applicable outside the United States. Failure to comply can result in fines, adverse publicity and civil and criminal sanctions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a>Furthermore, third parties on whom we rely may also have relationships with other entities, some of which may be our competitors. In&#160;addition, these third parties are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our clinical, non-clinical and&#160;preclinical programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to&#160;the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product&#160;candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our products. As a result, our results of operations and the commercial prospects for our products would be harmed, our costs could increase and our ability to generate revenue could be delayed.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">reliance on third parties to manufacture product candidates will increase the risk that we will not have sufficient quantities of product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">do not, and do not plan to, own or operate manufacturing facilities for the production of clinical or commercial supplies of any product candidates. We have limited personnel with experience in drug manufacturing and lack the resources and the capabilities to manufacture any product candidates on a clinical or commercial scale. We currently rely on third parties for supply of product candidates, and our strategy is to outsource all manufacturing of any product candidates and products to third parties.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to conduct any future clinical trials of any product candidates, we will need to have them manufactured in potentially large quantities. Our third-party manufacturers may be unable to successfully increase the manufacturing capacity for any product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities and at any other time. For example, ongoing data on the stability of product candidates may shorten the expiry of such product candidates and lead to clinical trial material supply shortages in any future clinical trials, and potentially clinical trial delays. If these third-party manufacturers are unable to successfully scale up the manufacture of a product candidate in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained, which could significantly harm our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our use of new third-party manufacturers increases the risk of delays in production or insufficient supplies of product candidates as we transfer our manufacturing technology to these manufacturers and as they gain experience manufacturing our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even after a third-party manufacturer has gained significant experience in manufacturing certain product candidates or even if we believe we have succeeded in optimizing the manufacturing process, there can be no assurance that such manufacturer will produce sufficient quantities of such product candidates in a timely manner or continuously over time, or at all<font style="color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We </font><font style="color:#000000;">do not currently have any agreements with third-party manufacturers for the long-term commercial supply of any product candidates. In the future, we may be unable to enter into agreements with third-party manufacturers for commercial supplies of product ca</font><font style="color:#000000;">ndidates, or may be unable to do so on acceptable terms. Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails risks, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reliance on the third party for regulatory compliance and quality assurance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the possible breach of the manufacturing agreement by the third party; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party <font style="color:#000000;">manufacturers may not be able to comply with cGMP requirements or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and/or criminal prosecutions, any of which could significantly and adversely affect supplies of product candidates.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a>Any product candidates and products that we develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP&#160;requirements particularly for the development of mAbs, and that might be capable of manufacturing for us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the third parties that we engage to supply any materials or manufacture product for our preclinical tests and clinical trials should cease to continue to do so for any reason, we likely would experience delays in advancing these tests and trials while we identify and qualify replacement suppliers or manufacturers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the substances used to manufacture them, it will be more difficult for us to develop such product candidates and compete effectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and anticipated future dependence upon others for the manufacture of product candidates may adversely affect our future profit margins and our ability to develop product candidates and commercialize any products that receive marketing approval on a timely and competitive basis<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our agreements with Adimab, LLC raise the potential for conflicts of interest. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">have entered into two agreements with Adimab, LLC, or Adimab, under which we were granted exclusive options to obtain ownership or exclusive worldwide licenses under specified patents relating to the development and commercialization of monoclonal antibodies. These agreements are important to our business and we have exercised certain of these options to a number of antibodies. Dr. Tillman U. Gerngross, the chairman of our board of directors, is the Chief Executive Officer of Adimab. If there is a dispute between us and Adimab, Dr.&#160;Gerngross would have a conflict of interest because he simultaneously has a financial interest in and owes a fiduciary duty to both Adimab and us</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Commercialization of Product Candidates </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If <font style="color:#000000;">we or our collaborators are unable to establish sales, medical affairs and marketing capabilities or enter into agreements with third parties to market and sell product candidates, we may be unable to generate any product revenue</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">do not currently have a sales and marketing organization and have never commercialized a product. To successfully commercialize any products that may result from our development programs such as our ASN500 program, we will need to develop these capabilities, either on our own or with others. The establishment and development of our own commercial and medical science liaison teams or the engagement of a contract sales force to discuss any products we may develop will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We may seek to enter into collaborations with entities regarding product candidates to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any future collaborators do not commit sufficient resources to commercialize our products, or we are unable to develop the necessary capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We compete with many well-funded and profitable pharmaceutical and biotechnology companies that currently have extensive and experienced medical affairs, marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. We also face competition in our search for third parties to assist us with the sales and marketing efforts of product candidates. Without an internal team or the support of a third party to perform marketing, sales and medical affairs functions, we may be unable to compete successfully against these more established companies</font>. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The </font><font style="color:#000000;">hospital formulary approval, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or </font><font style="color:#000000;">maintain adequate hospital formulary approval, insurance coverage and reimbursement for our products, if approved, could limit our ability to market those products and decrease our ability to generate product revenue</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">expect that hospital formulary approval, insurance coverage and reimbursement of our products, if approved, by hospital, government and other third-party payors will be essential for most patients to be able to access these treatments. Accordingly, sales of any product candidates, if approved, will depend substantially on the extent to which the costs of such product candidates will be paid by hospitals, health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors. Hospital formulary approval, insurance coverage and reimbursement by other third-party payors may depend upon several factors, including the third-party payor&#8217;s determination that use of a product </font>is: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a necessary and covered benefit under its health plan; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">safe, effective and medically necessary; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">appropriate for the specific patient population; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">cost-effective; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">neither experimental nor investigational. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining <font style="color:#000000;">hospital formulary approval, insurance coverage and reimbursement for a product from third-party payors is a time-consuming and costly process that will require us to provide to the hospitals and payors supporting scientific, clinical and cost-effectiveness data. We may not be able to provide data sufficient to gain acceptance with respect to hospital formulary approval, insurance coverage and reimbursement. If hospital formulary approval, insurance coverage and reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize any product candidates.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to hospital formulary approval, insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including government payors such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered and reimbursed. It is difficult to predict what third-party payors will decide with respect to the insurance coverage and reimbursement for product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, international operations generally are subject to extensive government price controls and other market regulations, and increasing emphasis on cost-containment initiatives in the European Union, Canada and other countries may put pricing pressure on us. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries may use different methods to keep the cost of medical products artificially low. Foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable product revenue.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by hospital, government and other third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for product candidates. We expect to experience pricing pressures in connection with the sale of any product candidates due to the trend toward reducing hospital costs, managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes<font style="color:#000000;">. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The </font><font style="color:#000000;">commercial success of any product candidates will depend upon its degree of market acceptance by physicians, patients,</font><font style="color:#000000;"> hospitals, third-party payors and others in the medical community</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even with the requisite approvals from the FDA in the United States, EMA in the European Union and other regulatory authorities internationally, the commercial success of product candidates, if approved, will significantly depend on the acceptance of physicians, hospitals and healthcare payors of product candidates as medically necessary, cost-effective and safe. Any product that we commercialize may not gain acceptance by physicians, hospitals, healthcare payors and others in the medical community. If these commercialized products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of any product candidates, if approved for commercial sale, will depend on several factors, including<font style="color:#000000;">: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the efficacy and safety of such product candidates as demonstrated in clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential and perceived advantages of our product candidates over other treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost effectiveness of treatment relative to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the clinical indications for which the product candidate is approved by the FDA, the EMA or other regulatory body; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the willingness of physicians to prescribe new therapies over the existing standard of care and future new therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the prevalence and severity of any side effects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product labeling or product insert requirements of the FDA, EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling, including any black box warning; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">relative convenience and ease of administration; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to educate the medical community and third-party payors about the benefit of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the strength of marketing and distribution support; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of market introduction of competitive products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">publicity concerning our products or competing products and treatments; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">sufficient third-party payor insurance coverage and reimbursement. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is launched. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we obtain approval to commercialize any product candidates outside of the United States, a variety of risks associated with international operations could materially adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that we will be subject to additional risks in commercializing any product candidates outside the United States, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">different regulatory requirements for approval of drugs and biologics in foreign countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reduced protection for intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unexpected changes in tariffs, trade barriers and regulatory requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">workforce uncertainty in countries where labor unrest is more common than in the United States; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods and fires. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business Operations </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of our objectives. Any of our executive officers could leave our employment at any time, as all of our employees are &#8220;at-will&#8221; employees. We currently do not have &#8220;key person&#8221; insurance on any of our employees. The loss of the services of one or more of our current employees might impede the achievement of our research, development and commercialization objectives.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, also will be critical to our success. Competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials (such as the discontinuation of our Phase 2 clinical trial of ASN100) or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations and prospects<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product <font style="color:#000000;">liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">face an inherent risk of product liability exposure related to the testing of product candidates in clinical trials and may face an even greater risk if we commercialize any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in</font>: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">decreased demand for any product candidates that we may develop; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">loss of revenue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">substantial monetary awards to trial participants or patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">significant time and costs to defend the related litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of clinical trial participants; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability to commercialize any product candidates that we may develop; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injury to our reputation and significant negative media attention. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">insurance coverage may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">internal computer systems, or those of any collaborators or contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">internal computer systems and those of any collaborators, contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed</font>. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our </font><font style="color:#000000;">employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and re</font><font style="color:#000000;">quirements and insider trading</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">provide accurate information to the FDA, the EMA and other regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">comply with healthcare fraud and abuse laws and regulations in the United States and abroad; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">comply with the U.S. Foreign Corrupt Practices Act, or FCPA, or other anti-corruption laws and regulations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">report financial information or data accurately; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">disclose unauthorized activities to us. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <font style="color:#000000;">particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations regulate a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Other forms of misconduct could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA, EMA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct and implemented other internal controls applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The United Kingdom&#8217;s &#8220;Brexit&#8221; vote in favor of withdrawing from the European Union could adversely impact our operations, make it more difficult for us to do business in Europe and impose additional regulatory costs and challenges in securing approval of our candidate products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <font style="color:#000000;">June&#160;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as &#8220;Brexit.&#8221; Thereafter, on March&#160;29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The withdrawal of the United Kingdom from the European Union will take effect either on the effective date of the withdrawal agreement or, in the absence of agreement, two years after the United Kingdom provided its notice of withdrawal.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It appears likely that this withdrawal will involve a process of lengthy negotiations between the United Kingdom and European Union member states to determine the future terms of the United Kingdom&#8217;s relationship with the European Union. This could lead to a period of considerable uncertainty and volatility, particularly in relation to United Kingdom financial and banking markets. Weakening of economic conditions or economic uncertainties tend to harm our business, and if such conditions emerge in the U.K. or in the rest of Europe, it may have a material adverse effect on our operations and sales.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currency exchange rates in the pound sterling and the euro with respect to each other and the U.S. dollar have already been adversely affected by Brexit and that may continue to be the case. In addition, depending on the terms of Brexit, the United Kingdom could lose the benefits of global trade agreements negotiated by the European Union on behalf of its members, which may result in increased trade barriers which could make our doing business in Europe more difficult.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also face new and additional regulatory costs and challenges from Brexit that could have a material adverse effect on our operations. Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, the referendum could materially impact the regulatory regime with respect to the approval of our product candidates in the United Kingdom or the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for our product candidates, which could significantly and materially harm our business<font style="color:#000000;">. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We might not be able to utilize a signifi</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">cant portion of our net operating loss carryforwards and research and development tax credit carryforwards. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of <font style="color:#000000;">December&#160;31, 2017, we had U.S. federal and state net operating loss carryforwards of $24.2&#160;million and $20.4&#160;million, respectively, which begin to expire in 2031 and 2036, respectively. In addition, as of December&#160;31, 2017, we had foreign net operating loss carryforwards of $56.3&#160;million, which do not expire. As of December&#160;31, 2017, we also had U.S. federal and state research and development tax credit carryforwards of $0.3&#160;million and $0.1&#160;million, respectively, which begin to expire in 2032 and 2031, respectively. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset our future income tax liabilities. In addition, under Section&#160;382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income may be limited. We have not determined if we have experienced Section&#160;382 ownership changes in the past and if a portion of our net operating loss and tax credit carryforwards are subject to an annual limitation under Section&#160;382. In addition, we may experience ownership changes in the future as a result of subsequent changes in our stock ownership, some of which may be outside of our control. If we determine that an ownership change has occurred and our ability to use our historical net operating loss and tax credit carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The recently passed comprehensive tax reform bill could adversely affect our business and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 22, 2017, <font style="color:#000000;">President Trump signed into law new legislation that significantly revised the Internal Revenue Code of 1986, as amended.&#160;The newly enacted federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain and our business and financial condition could be adversely affected.&#160;In addition, it is uncertain how various states will respond to the newly enacted federal tax law. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock</font>.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are <font style="color:#000000;">subject to taxation in numerous U.S. states and territories. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including passage of the newly enacted federal income tax law, changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements</font>.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If <font style="color:#000000;">we are unable to obtain and maintain patent protection for our products and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">success depends, in part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to product candidates and technology. We and our licensors have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to product candidates and technology that are important to our business.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a>The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates. Since patent applications in the United States and most other countries are </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the first to file a patent application relating to any particular aspect of a product candidate. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be initiated by such third party, or by </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the United States Patent and Trademark Office, or USPTO, itself, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a>Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO, and various government patent agencies outside of the United States over the lifetime of our licensed patents and/or applications and any patent rights we own or may own in the future. We rely, in&#160;part, on our outside counsel or our licensing partners to pay these fees due to the USPTO and to non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to&#160;our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could have a material adverse effect on our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from infringing our patents in all countries outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. For example, there can be no assurance that our issued patents contain and pending applications will contain, if granted, claims of sufficient breadth to cover all antibodies alleged to be biosimilar versions of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes <font style="color:#000000;">in patent law could diminish the value of patents in general, thereby impairing our ability to protect product candidates</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As <font style="color:#000000;">is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, and these decisions have narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors&#8217; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on future decisions by the U.S. Congress, the federal courts and the USPTO, as well as similar bodies in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that may weaken our and our licensors&#8217; ability to obtain new patents or to enforce existing patents and patents we and our licensors or any collaborators may obtain in the future.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent reform legislation enacted in the United States in 2011 could increase </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the uncertainties and costs surrounding the prosecution of our and our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents. On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switch the U.S. pa</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tent system from a &#8220;first to invent&#8221; system to a &#8220;first inventor to file&#8221; system. The USPTO has developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leahy-Smith Act, and in particular, the first inventor to file provisions, became effective on March&#160;16, 2013</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> However</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Leahy-Smith Act an</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents, all of which could have a material adverse effe</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ct on our business and financial condition</font><font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">rights to develop and commercialize product candidates are subject, in part, to the terms and conditions of licenses granted&#160;to us by others, and, if we fail to comply with our obligations under these arrangements, we could lose such intellectual property rights or owe damages to the licensor of such intellectual property</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">are a party to several intellectual property license and option agreements, including agreements with the Bill&#160;&amp; Melinda Gates Foundation, or the Gates Foundation, and Adimab, that are important to our business, and may need to obtain additional licenses from others to advance our research or allow commercialization of any product candidates that we may develop. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. It is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses. In that event, we may be required to expend significant time and resources to redesign our product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, development and commercialization timelines, milestone payments, royalties and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we have entered into two agreements with Adimab under which we were granted exclusive options to obtain ownership or exclusive worldwide licenses under specified patents relating to the development and commercialization of monoclonal antibodies, and we have exercised certain of those options to a number of antibodies. Our agreements with Adimab impose specified diligence, milestone payment, royalty, asset transfer payment, acquisition payment, prosecution, insurance and other obligations on us. If we fail to comply with our obligations under the licenses, Adimab may have the right to terminate the license agreements, in which event we might not be able to market, and may be required to transfer to Adimab our rights in, any product that is covered by the Adimab agreements, including ASN100. Termination of the license agreements may also result in our having to negotiate a new or reinstated license with less favorable terms, which would have a material adverse impact on our business. Further, under our agreements with Adimab, under certain circumstances, Adimab is permitted to transfer to third parties antibody libraries that may include antibodies that we have licensed from Adimab, as well as certain information regarding certain attributes of such antibodies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our existing license agreements, and we expect in future agreements, patent prosecution of our licensed technology is in certain cases controlled solely by the licensor, and we are in certain cases required to reimburse the licensor for their costs of patent prosecution. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products covered by the intellectual property. Further, in each of our license agreements we are responsible for bringing any actions against any third party for infringing the patents we have licensed. Certain of our license agreements also require us to meet development thresholds to maintain the license, including establishing a set timeline for developing and commercializing products and minimum yearly diligence obligations in developing and commercializing the product. Disputes may arise regarding intellectual property subject to a licensing agreement<font style="color:#000000;">, including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which our technology and processes infringe the intellectual property of the licensor that is not subject to the licensing agreement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the sublicensing of patent and other rights under any collaborative development relationships; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the inventorship or ownership of inventions and </font><font style="font-family:Times New Roman;">know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the priority of invention of patented technology. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If <font style="color:#000000;">disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The <font style="color:#000000;">exercise by the Gates Foundation of its licenses to certain of our intellectual property and its development and commercialization of products that we are also developing and commercializing could have an adverse impact on our market position</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2017, we entered into a letter agreement with the Gates Foundation. In connection with the letter agreement, the Gates Foundation purchased $8.0&#160;million of shares of our Series D convertible preferred stock, and we committed to use the proceeds from the investment by the Gates Foundation solely to advance the development of a specified antibody program, which involves the monoclonal antibodies ASN-1, ASN-2 and ASN-3 and our product candidate ASN100. We agreed to grant to the Gates Foundation three non-exclusive, sublicensable licenses to research, develop, manufacture, seek regulatory approval for and commercialize antibodies that we or our research contractors discover in specified areas of global health that the Gates Foundation has identified as underinvested or disproportionately impacting poor and vulnerable populations, including ASN100, for the treatment of neonatal sepsis caused by <font style="font-style:italic;">S. aureus</font>. Two of these non-exclusive licenses will only be granted upon request from the Gates Foundation, and the third, although it has already been granted, would only be exercisable by the Gates Foundation upon certain &#8220;trigger events,&#8221; as described further in the agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, we entered into a grant agreement with the Gates Foundation, which was amended and restated in August 2018. In connection with the grant agreement, the Gates Foundation granted us certain funds, which we are obligated to use to conduct preclinical development of monoclonal antibodies for the prevention of RSV infection in newborns, which we refer to as the RSV project.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, we entered into a second grant agreement with the Gates Foundation pursuant to which the Gates Foundation granted us up to $1.1 million to conduct preclinical development activities for the RSV project that were not included in the February 2017 grant agreement, as amended and restated in August 2018. In connection with the grant agreements, we have granted the Gates Foundation a non-exclusive, sublicensable license to research and develop, manufacture, seek regulatory approval for and commercialize antibodies developed under the agreements for the benefit of people in developing countries.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exercise by the Gates Foundation of any of its non-exclusive licenses to certain of our intellectual property (or its right to obtain such licenses), and its development and commercialization of product candidates and products that we are also developing and commercializing, could have an adverse impact on our market position. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We <font style="color:#000000;">may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors <font style="color:#000000;">may infringe our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. To counter infringement or unauthorized use claims or to defend against claims of infringement can be expensive and time consuming. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, many companies have en</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">countered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other intellectual property, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceeding</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent app</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our effort</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own, develop or license</font><font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Issued <font style="color:#000000;">patents covering any product candidates we develop could be found invalid or unenforceable if challenged in court. We may not be able to protect our trade secrets in court</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If <font style="color:#000000;">one of our licensing partners or we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type double patenting, which, if successful, could result in a finding that the claims are invalid&#160;for obviousness-type double patenting or the loss of patent term, including a patent term adjustment granted by the USPTO, if a terminal disclaimer is filed to obviate a finding of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review,&#160;</font><font style="font-style:italic;color:#000000;">inter</font><font style="color:#000000;">&#160;</font><font style="font-style:italic;color:#000000;">partes</font><font style="color:#000000;">&#160;review and equivalent proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which the patent examiner and we or our licensing partners were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect, and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third <font style="color:#000000;">parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a>Our <font style="color:#000000;">commercial success depends upon our ability and the ability of any collaborators to develop, manufacture, market and sell product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current manufacturing methods, product candidates or future methods or products, resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including interference proceedings, post grant review and&#160;</font><font style="font-style:italic;color:#000000;">inter partes</font><font style="color:#000000;">&#160;review before the USPTO. The risks of being involved in such litigation and proceedings may also increase as any product candidates that we develop approach commercialization and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their pa</font><font style="color:#000000;">tent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercia</font><font style="color:#000000;">lize any product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high</font><font style="color:#000000;"> one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Others <font style="color:#000000;">may claim an ownership interest in our intellectual property and product candidates, which could expose us to litigation and have a significant adverse effect on our prospects</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While <font style="color:#000000;">we are presently unaware of any claims or assertions by third parties with respect to our patents or other intellectual property, we cannot guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. For example, a third party may claim an ownership interest in one or more of our, or our licensors&#8217;, patents or other proprietary or intellectual property rights. A third party could bring legal actions against us and seek monetary damages or enjoin clinical testing, manufacturing or marketing of the affected product candidate or product. If we become involved in any litigation, it could consume a substantial portion of our resources and cause a significant diversion of effort by our technical and management personnel. If any such action is successful, in addition to any potential liability for damages, we could be required to obtain a license to continue to manufacture or market the affected product candidate or product, in which case we could be required to pay substantial royalties or grant cross-licenses to patents. We cannot, however, assure you that any such license would be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases, which may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If <font style="color:#000000;">we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade <font style="color:#000000;">secrets and know-how can be difficult to protect. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, there can be no assurance that such inventions will not be assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitive position and may materially harm our business, financial condition and results of operations. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade se</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> independent discovery. For example, a public presentation in the scientific or popular press on the properties of our product candidates could motivate a third party, despite any perceived difficulty, to assemble a team of scientists having backgrounds si</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">milar to those of our employees to attempt to independently reverse engineer or otherwise duplicate our antibody technologies to replicate our success</font><font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We <font style="color:#000000;">may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many <font style="color:#000000;">of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals, or we, have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or current employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a>In addition, while it is our policy to require our employees&#160;and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims&#160;that they may bring against us, to determine the ownership of what we regard as our intellectual property<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If <font style="color:#000000;">our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">have not yet registered trademarks in our potential markets. Any registered trademarks or trade names may be challenged, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage</font>. For example: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">others may be able to make products that are similar to product candidates we develop but that are not covered by the claims of the patents that we own or license or may own in the future; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we, or any partners or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we, or any partners or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">others may independently develop </font><font style="font-family:Times New Roman;">similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may not develop additional proprietary technologies that are patentable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the patents of others may have an adverse effect on our business; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may choose not to file a patent for certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Regulatory Approval and Other Legal Compliance Matters </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA, the EMA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for any product candidates, our business will be substantially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">time required to obtain approval by the FDA is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval</font>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidates that we develop could fail to receive regulatory approval for many reasons, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA may disagree with the design or implementation of our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe, pure and potent or effective for its proposed indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">results of clinical trials may not meet the evidentiary standards required by the FDA for approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">FDA may disagree with our interpretation of data from preclinical studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">data collected from clinical trials of our product candidates may not be sufficient to support the submission of a biologics license application, or BLA, to the FDA or other submission or to obtain regulatory approval in the United States; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any product candidates, which would significantly harm our business, results of operations and prospects. The FDA has substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for product candidates. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We, or any future collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory <font style="color:#000000;">authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain orphan drug exclusivity for that product candidate. Generally, a product with orphan drug designation only becomes entitled to orphan drug exclusivity if it receives the first marketing approval for the indication for which it has such designation, in which case the FDA or the EMA will be precluded from approving another marketing application for the same drug for that indication for the applicable exclusivity period. The applicable exclusivity period is seven years in the United States and 10 years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a>Even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because the FDA has taken the position that, under certain circumstances, another drug with the&#160;same active moiety can be approved for the same condition.&#160;Specifically, the FDA&#8217;s regulations provide that it can approve another drug&#160;with the same active moiety&#160;for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 3, 2017, Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted<font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A Fast Track designation by the FDA may not actually lead to a faster development, regulatory review or approval process. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If <font style="color:#000000;">a product is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet needs for this condition, the treatment sponsor may apply for FDA Fast Track designation. Fast Track designation does not ensure that we will experience a faster development, regulatory review or approval process compared to conventional FDA procedures. Additionally, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even <font style="color:#000000;">if we complete the necessary preclinical and clinical studies, the marketing approval process is expensive, time consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of drug products are subject to extensive regulation by the FDA, EMA and other regulatory authorities, and regulations may differ from country to country. We, and any future collaborators, are not permitted to market product candidates in the United States or in other countries until we, or they, receive approval of a BLA from the FDA, approval of a marketing authorization application, or MAA, from the EMA, or marketing approval from other applicable regulatory authorities. We are in the early stages of product candidate development and are subject to the risks of failure inherent in that process. We have not submitted an application for or received marketing approval for any product candidate in the United States, Europe or in any other jurisdiction. We have not yet been successful at conducting and managing the clinical trials necessary to obtain marketing approvals, including FDA approval of a BLA and EMA approval of an MAA.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the typ</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e, complexity and novelty of the product candidates involved.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical studies could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or any future collaborators, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability or that of any future collaborators to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Failure <font style="color:#000000;">to obtain marketing approval in foreign jurisdictions would prevent any product candidates we develop from being marketed abroad</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <font style="color:#000000;">order to market and sell our products in the European Union and many other jurisdictions, we, and any future collaborators, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. We, and any future collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In many countries outside the United States, a product candidate must also be approved for reimbursement before it can be sold in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. Obtaining non-U.S. regulatory approvals and compliance with non-U.S. regulatory requirements could result in significant delays, difficulties and costs for us and our collaborators and could delay or prevent the introduction of product candidates in certain countries. In addition, if we or our collaborators fail to obtain the non-U.S. approvals required to market product candidates outside the United States or if we or our collaborators fail to comply with applicable non-U.S. regulatory requirements, our target market will be reduced and our ability to realize the full market potential of product candidates will be harmed and our business, financial condition, results of operations and prospects may be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as &#8220;Brexit.&#8221; On March 29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, Brexit could materially impact the regulatory regime with respect to the approval of any product candidates in the United Kingdom or the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing any product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for our product candidates, which could significantly and materially harm our business<font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even <font style="color:#000000;">if we, or any future collaborators, obtain marketing approvals for any product candidates we develop, the terms of approvals and ongoing regulation of our products may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once <font style="color:#000000;">marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation. We, and any future collaborators, must therefore comply with requirements concerning advertising and promotion for any product candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we and any future collaborators will not be able to promote any products we develop for indications or uses for which they are not approved.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We,</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our third-party manufacturers, any future collaborators and their third-party manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, assuming we, or any future collaborators, receive marketing approval for any product candidates, we, and any future collaborators, and our and their third-party manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we, and any future collaborators, are not able to comply with post-approval regulatory requirements, we, and any future collaborators, could have the marketing approvals for our products withdrawn by regulatory authorities and our, or any future collaborators&#8217;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any <font style="color:#000000;">product candidates for which we, or any future collaborators, obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we, or any future collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any <font style="color:#000000;">product candidates for which we, or any future collaborators, obtain marketing approval in the future, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such product, among other things, will be subject to continual requirements of and review by the FDA, EMA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a Risk Evaluation and Mitigation Strategy, or REMs.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we, or any future collaborators, do not market any product candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state healthcare fraud and abuse laws and state consumer protection laws<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, later discovery of previously unknown side effects or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on such products, manufacturers or manufacturing processes; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on the labeling or marketing of a product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on product distribution or use; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">requirements to conduct post-marketing studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">warning letters or untitled letters; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of the products from the market; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal to approve pending applications or supplements to approved applications that we submit; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recall of products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on coverage by third-party payors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fines, restitution or disgorgement of profits or revenue; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">suspension or withdrawal of marketing approvals, including license revocation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal to permit the import or export of products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product seizure; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Under <font style="color:#000000;">the CURES Act and the Trump Administration&#8217;s regulatory reform initiatives, the FDA&#8217;s policies, regulations and guidance may be revised or revoked and that could prevent, limit or delay regulatory approval of product candidates, which would impact our ability to generate revenue</font><font style="font-style:normal;">. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <font style="color:#000000;">December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation, but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.&#160;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a>We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of executive orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. An under-staffed FDA could result in delays in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all. Moreover, on January 30, 2017, President Trump issued an Executive Order, applicable to all executive agencies, including the FDA, which requires that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017,&#160;the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the &#8220;two-for-one&#8221; provisions. This Executive Order includes a budget neutrality provision that requires the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the Executive Order requires agencies to identify regulations to&#160;offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within the Office of Management and Budget on February 2,&#160;2017, the administration indicates that the &#8220;two-for-one&#8221; provisions may apply not only to agency regulations, but also to significant agency guidance documents. In addition, on February 24, 2017, President Trump issued an executive order directing each affected agency to designate an agency official as a &#8220;Regulatory Reform Officer&#8221; and establish a &#8220;Regulatory Reform Task Force&#8221; to implement the two-for-one provisions and other previously issued executive orders relating to the review of federal regulations, however it is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted<font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our relationships <font style="color:#000000;">with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, <font style="color:#000000;">physicians and third-party payors will play a primary role in the recommendation and prescription of any drugs for which we obtain marketing approval. Our future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. </font>These include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Anti-Kickback Statute&#8212;</font><font style="font-family:Times New Roman;">the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</font><font style="font-style:italic;font-family:Times New Roman;"> </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-style:italic;font-family:Times New Roman;">False Claims Act</font><font style="font-family:Times New Roman;">&#8212;the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented false or fraudulent clai</font><font style="font-family:Times New Roman;">ms for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandato</font><font style="font-family:Times New Roman;">ry treble damages and significant per-claim penalties, currently set at $5,500 to $11,000 per false claim; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">HIPAA</font><font style="font-family:Times New Roman;">&#8212;the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters, and, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms and technical safeguards, with respect to maintaining the privacy, security and transmission of individually identifiable health information; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Transparency Requirements</font><font style="font-family:Times New Roman;">&#8212;federal laws require applicable manufacturers of covered drugs to report payments and other transfers of value to physicians and teaching hospitals; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Analogous State and Foreign Laws</font><font style="font-family:Times New Roman;">&#8212;analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, can apply to sales or marketing arrangements and claims involving healthcare items or services and are generally broad and are enforced by many different federal and state agencies as well as through private actions. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some <font style="color:#000000;">state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union Member States, such as the U.K. Bribery Act 2010, or the Bribery Act. Infringement of these laws could result in substantial fines and imprisonment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collection and use of personal h</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ealth data in the European Union is governed by the provisions of the Data Protection Directive. This directive imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the indiv</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iduals, notification of data processing obligations to the competent national data protection authorities and the security and confidentiality of the personal data. The Data Protection Directive also imposes strict rules on the transfer of personal data ou</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t of the European Union to the United States. Failure to comply with the requirements of the Data Protection Directive and the related national data protection laws of the European Union Member States may result in fines and other administrative penalties.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The draft Data Protection Regulation currently going through the adoption process is expected to introduce new data protection requirements in the European Union and substantial fines for breaches of the data protection rules. If the draft Data Protection</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Regulation is adopted in its current form it may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. Th</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is may be onerous and adversely affect our business, financial condition, results of operations and prospects</font><font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently <font style="color:#000000;">enacted and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize product candidates and affect the prices we, or they, may obtain</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <font style="color:#000000;">the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any future collaborators, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for any approved products.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or Medicare Modernization Act, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result in a similar reduction in payments from private payors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, then-President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA. Among the provisions of the ACA of importance to our business, including, without limitation, our ability to commercialize and the prices we may obtain for any product candidates that are approved for sale<font style="color:#000000;">, are the following: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of federal healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">extension of manufacturers&#8217; Medicaid rebate liability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of eligibility criteria for Medicaid programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">new requirements to report financial arrangements with physicians and teaching hospitals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ddition, </font><font style="color:#000000;">other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduc</font><font style="color:#000000;">tion, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These change</font><font style="color:#000000;">s included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2024 unless additional Congressional action is taken. The American Taxpayer Relief Act of </font><font style="color:#000000;">2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in</font><font style="color:#000000;"> Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a>We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Since enactment of the ACA, there have been numerous legal challenges and Congressional actions to repeal and replace provisions of the law.&#160;In May 2017, the U.S. House of Representatives passed legislation known as the American Health Care Act of 2017.&#160;Thereafter, the Senate Republicans introduced and then updated a bill to replace the ACA known as the Better Care Reconciliation Act of 2017. The Senate Republicans also introduced legislation to repeal the ACA without companion legislation to replace it, and a &#8220;skinny&#8221; version of the Better Care Reconciliation Act of 2017.&#160;In addition, the Senate considered proposed healthcare reform legislation known as the Graham-Cassidy bill.&#160;None of these measures was passed by the U.S. Senate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Trump Administration has also taken executive actions to undermine or delay implementation of the ACA.&#160;In January 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices.&#160;In October 2017, the President signed a second Executive Order allowing for the use of association health plans and short-term health insurance, which may provide fewer health benefits than the plans sold through the ACA exchanges.&#160;At the same time, the Administration announced that it will discontinue the payment of cost-sharing reduction, or CSR, payments to insurance companies until Congress approves the appropriation of funds for such CSR payments. The loss of the CSR payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA.&#160;A bipartisan bill to appropriate funds for CSR payments was introduced in the Senate, but the future of that bill is uncertain.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More recently, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by the President on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221;&#160;The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, will become effective in 2019.&#160;According to the Congressional Budget Office, the repeal of the individual mandate will cause 13 million fewer Americans to be insured in 2027 and premiums in insurance markets may rise.&#160;Further, each chamber of Congress has put forth multiple bills designed to repeal or repeal and replace portions of the ACA. Although none of these measures has been enacted by Congress to date, Congress may consider other legislation to repeal and replace elements of the ACA. Congress will likely consider other legislation to replace elements of the ACA during the next Congressional session.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will continue to evaluate the effect that the ACA and its possible repeal and replacement could have on our business.&#160;It is possible that repeal and replacement initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in individuals having insurance coverage with less generous benefits.&#160;Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop and commercialize product candidates.&#160;While the timing and scope of any potential future legislation to repeal and replace ACA provisions is highly uncertain in many respects, it is also possible that some of the ACA provisions that generally are not favorable for the research-based pharmaceutical industry could also be repealed along with ACA coverage expansion provisions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs of prescription pharmaceuticals in the United States has also been the subject of considerable discussion in the United States, and members of Congress and the Administration have stated that they will address such costs through new legislative and administrative measures. The pricing of prescription pharmaceuticals is also subject to governmental control outside the United States. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired. In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical drugs. We cannot be sure whether additional legislative </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition, increased scrutiny by Congress of the F</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us and any future collaborators to more stringent drug labeling and post-marketing testing and other requirements</font><font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We <font style="color:#000000;">are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">operations are subject to anti-corruption laws, including the Bribery Act, the FCPA and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA and these other laws generally prohibit us, our officers and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials&#160;or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international&#160;operations might be subject or the manner in which existing laws might be administered or interpreted.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, which we collectively refer to as Trade Control Laws.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control Laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control Laws by U.K., U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If <font style="color:#000000;">we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Although we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions<font style="color:#000000;">. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of Our Common Stock </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The price of our common stock is volatile and may fluctuate substantially, which could result in substantial losses for purchasers of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price is volatile. The stock market in general, and the market for biopharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">results of clinical trials of our product candidates or those of our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the success of competitive products or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">commencement or termination of collaborations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory or legal developments in the United States and other countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the recruitment or departure of key personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the level of expenses related to any of our product candidates or clinical development programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the results of our efforts to discover, develop, acquire or in-license additional product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">variations in our financial results or those of companies that are perceived to be similar to us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in the structure of healthcare payment systems; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">market conditions in the pharmaceutical and biotechnology sectors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">general economic, industry and market conditions; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the other factors described in this &#8220;Risk Factors&#8221; section. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If <font style="color:#000000;">any of the foregoing matters were to occur, or if our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. For example, following our announcement of the discontinuation of our Phase 2 clinical trial of ASN100 as a result of the DRC&#8217;s futility determination, the closing price of our common stock declined from $18.19 on June 27, 2018 to $2.41 as of August 1, 2018. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management&#8217;s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">executive officers, directors and principal stockholders maintain the ability to control all matters submitted to stockholders for approval</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">executive officers and directors, combined with our stockholders who own more than 5% of our outstanding common stock and their affiliates, in the aggregate, beneficially own shares representing more than a majority of our outstanding common stock. In addition, three of our directors are affiliated with stockholders who each own more than 5% of our outstanding common stock. If these stockholders were to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in management of our company that our public stockholders disagree with</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is performing well. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales <font style="color:#000000;">of a substantial number of shares of our common stock in the public market could occur at any time, subject to compliance with applicable securities law. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock</font>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If </font><font style="color:#000000;">securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <font style="color:#000000;">trading market for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our business. We do not currently have, and may never obtain, research coverage by industry or financial analysts. If no, or few, analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">An active trading market for our common stock may not be sustained.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">shares of common stock began trading on the Nasdaq Global Market on November 16, 2017.&#160;Given the limited trading history of our common stock, there is a risk that an active trading market for our shares will not be sustained, which could put downward pressure on the market price for our common stock and thereby affect the ability of our stockholders to sell their shares. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration</font>.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If <font style="color:#000000;">we fail to continue to meet the requirements for continued listing on the Nasdaq Global Market, our common stock could be delisted from trading, which would decrease the liquidity of our common stock and our ability to raise additional capital</font>.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">common stock is listed for quotation on the Nasdaq Global Market. We are required to meet specified financial requirements, including requirements for a minimum amount of capital, a minimum price per share and continued business operations so that we are not characterized as a &#8220;public shell company.&#8221; Additionally, if we conduct a reverse merger, the combined company following such transaction will need to meet Nasdaq&#8217;s initial listing standards. If we are unable to comply with Nasdaq&#8217;s listing standards, Nasdaq may determine to delist our common stock from the Nasdaq Global Market or other of Nasdaq&#8217;s trading markets. If our common stock is delisted for any reason, it could reduce the value of our common stock and its liquidity</font>.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If <font style="color:#000000;">we commit certain material breaches under our agreement with the Gates Foundation, and fail to cure them, we may be required to redeem shares of our stock held by the Gates Foundation and its affiliates</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In <font style="color:#000000;">the event the Gates Foundation terminates our agreement for certain specified uncured material breaches by us, we will be obligated, among other remedies, to redeem the then-held shares of our stock purchased by the Gates Foundation pursuant to the agreement or to facilitate the purchase of such stock by a third party. For any such redemption, the Gates Foundation stock will be valued at the greater of the original purchase price (plus specified interest) or the fair market value of such stock. If we are required to redeem such shares or to compensate the Gates Foundation, our financial condition could be materially and adversely affected</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">are an &#8220;emerging growth company,&#8221; or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company for up to five years. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies</font>. These exemptions include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reduced disclosure obligations regarding executive compensation; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors </font><font style="color:#000000;">may find our common stock less attractive as a result of our reliance on these exemptions. If some investors find our com</font><font style="color:#000000;">mon stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We <font style="color:#000000;">will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As <font style="color:#000000;">a public company, and particularly after we are no longer an EGC, we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and the Nasdaq Global Market have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If <font style="color:#000000;">we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock</font>. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective <font style="color:#000000;">internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section&#160;404 of the Sarbanes-Oxley Act, or Section&#160;404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal control over financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a>Pursuant to Section&#160;404, we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent&#160;registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to&#160;a loss of confidence in the reliability of our financial statements<font style="color:#000000;">. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Provisions <font style="color:#000000;">in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions <font style="color:#000000;">in our corporate charter and our by-laws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things</font>, these provisions: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish a classified board of directors such that not all members of the board are elected at one time; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">allow the authorized number of our directors to be changed only by resolution of our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">limit the manner in which stockholders can remove directors from the board; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">establish advance notice requirements for stockholder proposals that can be acted </font><font style="font-family:Times New Roman;">on at stockholder meetings and nominations to our board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">limit who may call stockholder meetings; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a shareholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or by-laws. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, <font style="color:#000000;">because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or stockholders</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <font style="color:#000000;">certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty owed by our directors, officers, other employees or stockholders to the company or our stockholders, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law or as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware, or any action asserting a claim arising pursuant to our certificate of incorporation or our by-laws or governed by the internal affairs doctrine. This provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, other employees or other stockholders, which may discourage such lawsuits against us and our directors, officers, other employees or other stockholders. Alternatively, if a court were to find this provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition</font>. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Because <font style="color:#000000;">we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be&#160;your sole source of gain</font>. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We <font style="color:#000000;">have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, our ability to pay cash dividends is currently restricted by the terms of our 2012 Loan Agreement with SVB and may be restricted by any future indebtedness. Our ability to pay cash dividends may also, under certain circumstances, be limited under the terms of a letter agreement we have entered into with the Gates Foundation. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future, and investors seeking cash dividends should not purchase shares of our common stock</font>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="II_Item2"></a><a name="_AEIOULastRenderedPageBreakAEIOU78"></a><a name="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 2. Unregistered Sales of Equ</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"></a>i</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ty Securities and Use of Proceeds.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_216"></a>Use of Proceeds from Initial Public Offering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 20, 2017, we closed our initial public offering, in which we issued and sold 4,000,000 shares of common stock at a public offering price of $10.00 per share, and issued an additional 600,000 shares of common stock at a price of $10.00 per share pursuant to the exercise of the underwriters&#8217; over-allotment option. The aggregate gross proceeds to us from our initial public offering, inclusive of the over-allotment exercise, were $46.0 million. The offering commenced on November 15, 2017, and did not terminate until the sale of all shares offered. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_217"></a>All of the shares of common stock issued and sold in our initial public offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (Registration No. 333-221050), which was declared effective by the SEC on November 15, 2017. Citigroup Global Markets Inc., Cowen and Company, LLC and Piper Jaffray &amp; Co. were joint book-running managers for the initial public offering. The aggregate net proceeds to us from the public offering, inclusive of the over-allotment exercise, were approximately $39.5 million, after deducting underwriting discounts and commissions and offering expenses payable by us of approximately $6.5 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_218"></a><a name="_cp_text_4_219"></a><a name="_cp_text_1_220"></a><a name="_cp_text_4_219"></a>No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to <a name="_cp_text_1_220"></a>any other affiliates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_221"></a><a name="_cp_text_4_222"></a><a name="_cp_text_1_223"></a><a name="_cp_text_4_224"></a>As of June 30, 2018, we estimate that we have used approximately $<font style="color:#000000;">25.3 </font><a name="_cp_text_4_222"></a>million of <a name="_cp_text_1_223"></a>our existing cash and cash equivalents at the time of the initial public offering, together with the net proceeds from our initial public offering, to advance our product candidates through<a name="_cp_text_4_224"></a> clinical trial programs and for working capital and general corporate purposes. There have been no material changes in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC on November 17, 2017 pursuant to Rule 424(b).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_OR_INFORMATION"></a><a name="ITEM_5_OR_INFORMATION"></a>Item 5. Other Information.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bill &amp; Melinda Gates Foundation Grant Agreements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Amended and Restated Gates Foundation Grant Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 8, 2018, we entered into an amended and restated grant agreement with the Bill &amp; Melinda Gates Foundation, or the Gates Foundation, which we refer to as the Amended Grant Agreement. The Amended Grant Agreement replaces in its entirety the grant agreement that we entered into with the Gates Foundation in February 2017, under which the Gates Foundation agreed to provide us with up to $9.3 million to conduct preclinical development of monoclonal antibodies, or mAbs, for the prevention of <font style="color:#000000;">respiratory syncytial virus </font>infection in newborns, which we refer to as the RSV project. The Amended Grant Agreement includes amendments to conform to current Gates Foundation audit, reporting, and other administrative requirements, as well as to make the perpetual Gates Foundation license grant described below irrevocable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Amended Grant Agreement expires on October 31, 2019. The Gates Foundation can modify, suspend or discontinue any payment under the Amended Grant Agreement, or terminate the Amended Grant Agreement, if it is not reasonably satisfied with our progress on the RSV project; if there are significant changes to our leadership or other factors that the Gates Foundation reasonably believes may threaten the RSV project&#8217;s success; if we undergo a change in control; if there is a change in our tax status; or if we fail to comply with the Amended Grant Agreement. Any grant funds that have not been used for, or committed to, the RSV project upon the expiration or termination of the agreement must be returned to the Gates Foundation or otherwise used as directed by the Gates Foundation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Gates Foundation Grant Agreement&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 8, 2018, we entered into a grant agreement with the Gates Foundation pursuant to which the Gates Foundation granted us up to $1.1 million to conduct preclinical development activities for the RSV project that were not included in the Amended Grant Agreement. We refer to this grant agreement as the 2018 Grant Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2018 Grant Agreement expires on August 31, 2018. The Gates Foundation can modify, suspend or discontinue any payment under the 2018 Grant Agreement, or terminate the 2018 Grant Agreement, if it is not reasonably satisfied with our progress on the RSV project; if there are significant changes to our leadership or other factors that the Gates Foundation reasonably believes may threaten the RSV project&#8217;s success; if we undergo a change in control; if there is a change in our tax status; or if we fail to comply with the 2018 Grant Agreement. Any grant funds that have not been used for, or committed to, the RSV project upon the expiration or termination of the agreement must be returned to the Gates Foundation or otherwise used as directed by the Gates Foundation.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In return</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the Gates Foundation funding</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under both the Amended Grant Agreement and the 2018 Grant Agreement, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we have agreed to con</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">duct the RSV project in a manner that ensures that the knowledge and information gained from the project will be promptly and broadly disseminated, and that the products, technologies, materials, processes and other intellectual property resulting from the</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> RSV project (which we collectively refer to as the funded developments) will be made available and accessible at an affordable price to people most in need within developing countries. These obligations survive any expiration or termination of the grant a</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">greement</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To this end, we have granted the Gates Foundation a non-exclusive, perpetual, irrevocable, royalty-free, fully paid up, sublicensable license to make, use, sell, offer to sell, import, distribute, copy, modify, create derivative works, publicly perform and display the funded developments and, to the extent incorporated into a funded development or required to use a funded development, any other technology created outside of the RSV project that was used as part of the RSV project, for the benefit of people in developing countries. We have also agreed to seek prompt publication of data and results developed under the RSV project under &#8220;open access&#8221; terms and conditions. This license and these publication obligations survive any expiration or termination of the grant agreements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing is a summary of the Amended Grant Agreement and the 2018 Grant Agreement, and is qualified in its entirety by reference to the Amended Grant Agreement and the 2018 Grant Agreement, as applicable, copies of which are attached to this Quarterly Report on Form 10-Q as Exhibit 10.3 and Exhibit 10.4, respectively, and are incorporated into this Item 5 by reference.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the above-described grant agreements, we are also party to <font style="color:#000000;">a letter agreement with the Gates Foundation that we entered into in April 2017,</font> pursuant to which we licensed to the Gates Foundation certain rights under our ASN100 program. <font style="color:#000000;">In connection with the letter agreement, the Gates Foundation purchased 2,464,799 shares of our Series D preferred stock, which converted into </font>722,179 <font style="color:#000000;">shares of our common stock in connection with our November 2017 initial public offering after giving effect to a one-for-3.4130 reverse-stock-split. </font>See Note 5 to our condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q for additional information on the letter agreement with the Gates Foundation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">August 2018 Forbearance Agreement with Silicon Valley Bank&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 8, 2018, we entered into a Forbearance Agreement with Silicon Valley Bank, or SVB, in respect of certain events of default under the Company&#8217;s loan and security agreement with SVB dated December 7, 2012. We refer to this loan and security agreement, as amended to date, as the 2012 Loan Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were in compliance with all covenants under the 2012 Loan Agreement as of December 31, 2017. During the six months ended June 30, 2018, we failed to comply with the covenants under the 2012 Loan Agreement when we entered into separate option and license agreements for our ASN200 and ASN300 programs with subsidiaries of Bravos Biosciences, LLC without obtaining prior written consent of SVB, and then delivered compliance certificates to SVB that did not disclose these violations. As a result, we are currently in default under the 2012 Loan Agreement and SVB may, at its option, declare all of our obligations under the 2012 Loan Agreement to be immediately due and payable. Pursuant to the Forbearance Agreement, SVB has agreed to forbear from exercising its rights and remedies with respect to such defaults until the earlier to occur of (i) another event of default under the 2012 Loan Agreement or (ii) October 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing is a summary of the Forbearance Agreement, and is qualified in its entirety by reference to the Forbearance Agreement, a copy of which is attached to this Quarterly Report on Form 10-Q as Exhibit 10.5 and is incorporated into this Item 5 by reference.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">August 2018 Lease Amendment&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 10, 2018, we entered into an amendment to our June 2018 lease agreement with BP Bay Colony LLC, or Lessor, which we refer to as the Amended Lease Agreement. Under the terms of the Amended Lease Agreement, we will relocate our premises in Waltham, MA to a new premises with 5,711 square feet of office space as compared to the 10,290 square feet premises in the original lease agreement. The term of the Amended Lease Agreement commences on January 1, 2019 and expires December 31, 2023. We have the option to extend the term for one additional five-year period upon our written notice to the Lessor at least nine months and no more than 12 months in advance of the extension. The Amended Lease Agreement terminates our one-time right of first offer, subject to certain terms and conditions, for additional space containing approximately 4,000 square feet specified in the original lease agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The annual base rent obligation is </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately $0.3 million, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a total cash obligation for the base rent over the ini</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tial five-year term of the Amended Lease Agreement is approximately $1.3 million. In addition to the base rent, we are also responsible for our share of operating expenses, electricity and real estate taxes, in accordance with the terms of the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leas</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e Agreement. We will provide a security deposit in the amount of $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3 million</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as well as a relocation payment of $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.1 million</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to the Lessor.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing is a summary of the Amended Lease Agreement, and is qualified in its entirety by reference to the Amended Lease Agreement, a copy of which is attached to this Quarterly Report on Form 10-Q as Exhibit 10.2 and is incorporated into this Item 5 by reference.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">August 2018 Reduction in Force</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> On August 10, 2018, our board of directors approved a reduction in workforce to reduce operating costs and better align our workforce with the needs of our business following our discontinuation of the clinical development of ASN100 pending the completion of our evaluation of the complete dataset from our Phase 2 trial. As part of this reduction in workforce, we plan to eliminate 19 positions across our company, representing approximately 44% of our workforce. We anticipate that we will substantially complete the implementation of the reduction in workforce by the fourth quarter of 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently estimate that we will incur total expenses relating to the reduction in workforce of approximately $0.6 million, which is comprised of notice and severance payments. We expect to record these charges in the third and fourth quarters of 2018.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><a name="ITEM_6_EXHIBITS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_EXHIBITS"></a>Item 6. E</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">xhibits</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td colspan="5" valign="bottom"  style="width:26.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporation by Reference</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="top"  style="width:0.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="top"  style="width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:9.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SEC Filing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top"  style="width:0.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Number</p></td>
<td valign="top"  style="width:0.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:7.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed&#160;with</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">this&#160;10-Q</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">3.1</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312517348213/d495338dex31.htm"><font style="text-decoration:underline;">Restated Certificate of Incorporation of the Company</font></a></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/20/2017</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="middle"  style="width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">3.2</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501697/000119312517348213/d495338dex32.htm"><font style="text-decoration:underline;">Amended and Restated By-laws of the Company</font></a></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/20/2017</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="middle"  style="width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.1</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501697/000119312518190522/d604970dex101.htm"><font style="text-decoration:underline;">Indenture of Lease, dated June 6, 2018, by and between the Registrant and BP Bay Colony LLC</font></a></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/12/2018</p></td>
<td valign="top"  style="width:0.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="middle"  style="width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.2</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="asns-ex102_204.htm"><font style="text-decoration:underline;">First Amendment to Lease, dated August 10, 2018, by and between the Registrant and BP Bay Colony LLC</font></a></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="middle"  style="width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.3</font><font style="Background-color:#FFFFFF;font-size:10pt;"><sup style="font-size:85%; vertical-align:top">&#8224;</sup></font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="asns-ex103_186.htm"><font style="text-decoration:underline;">Amended and Restated Agreement, dated August 8, 2018, by and between the Registrant and the Bill &amp; Melinda Gates Foundation</font></a></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="middle"  style="width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.4</font><font style="Background-color:#FFFFFF;font-size:10pt;"><sup style="font-size:85%; vertical-align:top">&#8224;</sup></font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="asns-ex104_185.htm"><font style="text-decoration:underline;">Grant Agreement, dated August 8, 2018, by and between the Registrant and the Bill &amp; Melinda Gates Foundation</font></a></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="middle"  style="width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">10.5</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="asns-ex105_184.htm"><font style="text-decoration:underline;">Forbearance Agreement, dated August 8, 2018, by and between the Registrant and Silicon Valley Bank</font></a></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="middle"  style="width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
</table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.1</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="asns-ex311_9.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.2</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="asns-ex312_6.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">32.1</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="asns-ex321_7.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">32.2</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="asns-ex322_8.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:7.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.INS</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.SCH</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.CAL</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.DEF</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.LAB</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.PRE</font></p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:9.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:7.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">&#8224;</sup></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p></td>
<td valign="top" style="width:93.33%;">
<p style="margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="Signatures"></a><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis, Inc.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 13, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Ren&#233; Russo</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ren&#233; Russo, PharmD</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 13, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Michael Gray</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Gray</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Operating Officer and Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>asns-ex102_204.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
asns-ex102_204.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FIRST AMENDMENT TO LEASE</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS FIRST AMENDMENT TO LEASE dated as of this _<font style="text-decoration:underline;">10th_</font> day of __<font style="text-decoration:underline;">August</font>__, 2018 by and between BP BAY COLONY LLC, a Delaware limited liability company (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;), and ARSANIS, INC., a Delaware corporation (&#8220;<font style="font-weight:bold;">Tenant</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">RECITALS</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, by Lease dated June 6, 2018 (the &#8220;<font style="font-weight:bold;">Lease</font>&#8221;), Landlord did lease to Tenant and Tenant did hire and lease from Landlord certain premises containing 10,290 square feet of rentable floor area on the third (3<sup style="font-size:85%; vertical-align:top">rd</sup>) floor of the building (the &#8220;<font style="font-weight:bold;">Building</font>&#8221;) known as and numbered 950 Winter Street, Waltham, Massachusetts (hereinafter referred to as the &#8220;<font style="font-weight:bold;">Original Premises</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, as of the date hereof, Landlord has not delivered the Original Premises to Tenant and the Commencement Date (as defined in Section 1.1 of the Lease) has not occurred.  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Landlord has agreed to relocate the premises leased to Tenant under the Lease from the Original Premises to certain premises containing 5,711 square feet of rentable floor area on the fourth (4<sup style="font-size:85%; vertical-align:top">th</sup>) floor of the Building (the &#8220;<font style="font-weight:bold;">Relocated Premises</font>&#8221;) shown on <font style="text-decoration:underline;">Exhibit A</font> attached hereto upon the terms and conditions contained in this First Amendment to Lease (the &#8220;<font style="font-weight:bold;">First Amendment</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Landlord and Tenant are entering into this instrument to set forth said relocation and to otherwise amend the Lease as set forth herein.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW THEREFORE, in consideration of One Dollar ($1.00) and other good and valuable consideration in hand this date paid by each of the parties to the other, the receipt and sufficiency of which are hereby severally acknowledged, and in further consideration of the mutual promises herein contained, Landlord and Tenant hereby agree to and with each other as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Relocation Premises</font>. From and after the date hereof, the Relocated Premises shall constitute the &#8220;Premises&#8221; demised to Tenant under the Lease and the Original Premises shall no longer be deemed to be a part of and shall be deleted and removed from the &#8220;Premises&#8221; demised to Tenant under the Lease. In connection therewith, the Lease is hereby amended as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)<font style="margin-left:36pt;"></font>Section 1.1 of the Lease is hereby amended by deleting the definition of &#8220;Tenant&#8217;s Premises&#8221; contained therein and replacing it with the following:</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.38%;width:85.77%;">
<tr>
<td style="width:30.96%;"></td>
<td style="width:54.81%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Tenant&#8217;s Premises:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A portion of the fourth (4<sup style="font-size:85%; vertical-align:top">th</sup>) floor of the Building as shown on the floor plan annexed to the First Amendment as <font style="text-decoration:underline;">Exhibit A</font> and incorporated in this Lease by reference.&#8221;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 1</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-style:italic;;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, </font><font style="text-decoration:underline;">Exhibit D</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> attached to the Lease is hereby deleted in its entirety, and any reference to such exhibit in Section 1.3 of the Lease is hereby deleted and replaced with the following reference: &#8220;Intentionally Omitted&#8221;.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)<font style="margin-left:36pt;"></font>Section 1.1 of the Lease is hereby amended by deleting the definition of &#8220;Number of Parking Spaces&#8221; contained therein and replacing it with the following:</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.38%;width:85.77%;">
<tr>
<td style="width:30.96%;"></td>
<td style="width:54.81%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Number of Parking Spaces:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seventeen (17) (being three (3) spaces per 1,000 square feet of the Rentable Floor Area of the Premises).&#8221;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(C)<font style="margin-left:36pt;"></font>Section 1.1 of the Lease is hereby amended by deleting the definition of &#8220;Annual Fixed Rent&#8221; contained therein and replacing it with the following:</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.38%;width:85.77%;">
<tr>
<td style="width:30.96%;"></td>
<td style="width:54.81%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Annual Fixed Rent:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&nbsp;&nbsp;During the Original Term of this Lease, Annual Fixed Rent shall be payable by Tenant at the annual rate of $262,706.00 (being the product of (x) $46.00, and (y) the Rentable Floor Area of the Premises (being 5,711 square feet)); and </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) During the extension option period (if exercised), as determined pursuant to Section 9.18.&#8221;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(D)<font style="margin-left:36pt;"></font>Section 1.1 of the Lease is hereby amended by deleting the definition of &#8220;Rentable Floor Area of the Premises&#8221; contained therein and replacing it with the following:</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.38%;width:85.77%;">
<tr>
<td style="width:30.96%;"></td>
<td style="width:54.81%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:4.49%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Rentable Floor Area of the Premises:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,711 square feet.&#8221;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Condition of the Relocation Premises</font><font style="font-weight:bold;">. </font>Tenant shall accept the Relocation Premises in their as-is condition without any obligation on the Landlord&#8217;s part to perform any additions, alterations, improvements, demolition or other work therein or pertaining thereto and Landlord shall have no responsibility for the installation or connection of Tenant's telephone or other communications equipment or systems. In connection therewith, the Lease is hereby amended as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)<font style="margin-left:36pt;"></font>Section 1.1 of the Lease is hereby amended by deleting the definition of &#8220;Estimated Commencement Date&#8221; and the definition of &#8220;Outside Completion Date&#8221;, each in their entirety.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)<font style="margin-left:36pt;"></font>Section 1.1 of the Lease is hereby amended by deleting the definition of &#8220;Commencement Date&#8221; contained therein and replacing it with the following:</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.38%;width:85.77%;">
<tr>
<td style="width:30.96%;"></td>
<td style="width:54.81%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Commencement Date:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2019&#8221;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 2</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-style:italic;;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(C)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 2.4 of the Lease is hereby deleted in its entirety and replaced with the following:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&#8220;2.4<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Habendum</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall have and hold the Premises for a period commencing on the Commencement Date and continuing for the Term, unless sooner terminated as provided in Article VI or Article VII or unless extended as provided in Section 9.18.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, <font style="text-decoration:underline;">Exhibit E</font> attached to the Lease is hereby deleted in its entirety, and any reference to such exhibit in Section 1.3 of the Lease is hereby deleted and replaced with the following reference: &#8220;Intentionally Omitted&#8221;.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(D)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exhibit B-1</font> attached to the Lease is hereby deleted in its entirety and replaced with <font style="text-decoration:underline;">Exhibit B-1</font> attached to this First Amendment. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(E)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exhibit B-2</font> attached to the Lease is hereby deleted in its entirety, and any reference to such exhibit in Section 1.3 of the Lease is hereby deleted and replaced with the following reference: &#8220;Intentionally Omitted&#8221;.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Relocation Payment</font><font style="font-weight:bold;">.</font> Concurrently with the execution of this First Amendment, Tenant shall make a one-time lump sum payment to Landlord in the amount of One Hundred Thousand and 00/100 Dollars ($100,000.00), which shall constitute reimbursement to Landlord for costs incurred by Landlord prior to the date hereof in connection with Landlord&#8217;s Work (as defined in <font style="text-decoration:underline;">Exhibit B-1</font> attached to the Lease) related to the Original Premises. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Security Deposit</font><font style="font-weight:bold;">. </font>Landlord and Tenant acknowledge that, as of the date hereof, Tenant has not delivered to Landlord a letter of credit in the amount of One Hundred Seventeen Thousand Forty-Eight and 75/100 Dollars ($117,048.75) as required pursuant to Section 9.19 of the Lease. In connection with this First Amendment, the amount of the security deposit required under the Lease shall be increased from One Hundred Seventeen Thousand Forty-Eight and 75/100 Dollars ($117,048.75) to Two Hundred Fifty Thousand and 00/100 Dollars ($250,000.00), and in connection therewith, the Lease is hereby amended as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)<font style="margin-left:36pt;"></font>Section 1.1 of the Lease is hereby amended by deleting the definition of &#8220;Security Deposit&#8221; contained therein and replacing it with the following:</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:15.38%;width:85.77%;">
<tr>
<td style="width:30.96%;"></td>
<td style="width:54.81%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Security Deposit:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$250,000.00&#8221;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:16.03%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)<font style="margin-left:36pt;"></font>Section 9.19 of the Lease is hereby amended by deleting the first sentence of such Section 9.19 in its entirety and replacing it with the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>&#8220;Concurrently with the execution of the First Amendment, Tenant shall pay to Landlord a security deposit in the amount of Two Hundred Fifty Thousand and </p>
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-style:italic;;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">00/100 Dollars ($250,000.00) and Landlord shall hold the same, throughout the Term of the Lease (including the Extended Term, if applicable), unless sooner returned to Tenant as provided in this Section 9.19, as security for the performance by Tenant of all obligations on the part of T</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enant to be performed under the</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Lease.&#8221;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Right of First Offer</font><font style="font-weight:bold;">.</font> Landlord and Tenant acknowledge and agree that Tenant shall have no right of first offer under the Lease and Section 2.9 of the Lease is hereby deleted in its entirety and of no further force and effect. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0.32%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Brokerage</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)<font style="margin-left:36pt;">Tenant warrants and represents that Tenant has not dealt with any broker in connection with the consummation of this </font>First Amendment; and in the event any claim is made against Landlord relative to dealings by Tenant with brokers, Tenant shall defend the claim against Landlord with counsel of Tenant&#8217;s selection first approved by Landlord (which approval will not be unreasonably withheld) and save harmless and indemnify Landlord on account of loss, cost or damage which may arise by reason of such claim.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)<font style="margin-left:36pt;">Landlord warrants and represents that Landlord has not dealt with any broker in connection</font> with the consummation of this First Amendment; and in the event any claim is made against Tenant relative to dealings by Landlord with brokers, Landlord shall defend the claim against Tenant with counsel of Landlord&#8217;s selection first approved by Tenant (which approval will not be unreasonably withheld) and save harmless and indemnify Tenant on account of loss, cost or damage which may arise by reason of such claim.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Defined Terms</font><font style="font-weight:bold;">.</font> Except as otherwise expressly provided herein, all capitalized terms used herein without definition shall have the same meanings as are set forth in the Lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Ratification</font><font style="font-weight:bold;">.</font> Except as herein amended the Lease shall remain unchanged and in full force and effect.&nbsp;&nbsp;All references to the &#8220;Lease&#8221; shall be deemed to be references to the Lease as herein amended.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Authority</font><font style="font-weight:bold;">. </font>Each of Landlord and Tenant hereby represents and warrants to the other that all necessary action has been taken to enter this First Amendment and that the person signing this First Amendment on its behalf has been duly authorized to do so.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Electronic Signatures</font><font style="font-weight:bold;">.</font> The parties acknowledge and agree that this First Amendment may be executed by electronic signature, which shall be considered as an original signature for all purposes and shall have the same force and effect as an original signature.&#160;Without limitation, &#8220;electronic signature&#8221; shall include faxed versions of an original signature or electronically scanned and transmitted versions (e.g., via pdf) of an original signature.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 4</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-style:italic;;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXECUTED as of the date and year first above written.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:44.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WITNESS:</p></td>
<td valign="top"  style="width:9.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:46.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">/s/ Patrick Kimble</font></p></td>
<td valign="top"  style="width:9.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:46.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BP BAY COLONY LLC, a Delaware </p></td>
</tr>
<tr>
<td valign="top"  style="width:44.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:46.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limited liability company</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BP BAY COLONY HOLDINGS LLC, a Delaware limited liability company, its sole member and manager</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.22%;">
<tr>
<td valign="top"  style="width:44.18%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:16.06%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:33.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BOSTON PROPERTIES LIMITED PARTNERSHIP, its sole member and manager</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:105.36%;">
<tr>
<td valign="top"  style="width:42.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:21.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.86%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4.86%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:25.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BOSTON PROPERTIES, INC., its general partner</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:46.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David C Provost</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David C Provost</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SVP, Leasing</p></td>
</tr>
<tr>
<td valign="top"  style="width:46.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.44%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:19.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:44.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WITNESS:</p></td>
<td valign="top"  style="width:9.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:46.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:46.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">/s/ Noah Oshry</font></p></td>
<td valign="top"  style="width:9.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:46.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARSANIS, INC., a Delaware corporation</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.28%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.3%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael Gray</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Gray</p></td>
</tr>
<tr>
<td valign="top"  style="width:44.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:9.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:0.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:39.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Operating and Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 5</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-style:italic;;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="text-decoration:underline;">EXHIBIT A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Relocated Premises </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Attached]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gnoz4kbhq1ug000001.jpg" title="" alt="" style="width:678px;height:508px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 6</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-style:italic;;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="text-decoration:underline;">Exhibit B-1</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Work Agreement</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc74635730"></a><a name="_Toc77744144"></a><a name="_Toc100466465"></a><a name="_Toc100466583"></a><a name="_Toc198116527"></a><a name="_Toc198116905"></a><a name="_Toc198117033"></a><a name="_Toc198353358"></a><a name="_Toc198353742"></a><a name="_Toc198353865"></a><a name="_Toc198354289"></a><a name="_Toc201049247"></a><font style="text-decoration:underline;">Condition of Premises</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall accept the Premises in their as-is condition without any obligation on the Landlord&#8217;s part to perform any additions, alterations, improvements, demolition or other work therein or pertaining thereto. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Toc74635731"></a><a name="_Toc77744145"></a><a name="_Toc100466466"></a><a name="_Toc100466584"></a><a name="_Toc198116528"></a><a name="_Toc198116906"></a><a name="_Toc198117034"></a><a name="_Toc198353359"></a><a name="_Toc198353743"></a><a name="_Toc198353866"></a><a name="_Toc198354290"></a><a name="_Toc201049248"></a><font style="text-decoration:underline;">Quality and Performance of Work</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All construction work required or permitted by the Lease shall be done in a good and workmanlike manner and in compliance with all applicable laws, ordinances, rules, regulations, statutes, by-laws, court decisions, and orders and requirements of all public authorities (&#8220;Legal Requirements&#8221;) and all Insurance Requirements (as defined in Section 5.12 of the Lease). All of Tenant&#8217;s work shall be coordinated with any work being performed by or for Landlord and in such manner as to maintain harmonious labor relations. Each party may inspect the work of the other at reasonable times and shall promptly give notice of observed defects. Each party authorizes the other to rely in connection with design and construction upon approval and other actions on the party&#8217;s behalf by any Construction Representative of the party named in Section 1.1 of the Lease or any person hereafter designated in substitution or addition by notice to the party relying. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;text-indent:0%;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Page 7</a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-style:italic;;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>asns-ex103_186.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
asns-ex103_186.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.3</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:65%;">
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Materials omitted and filed separately with the</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities and Exchange Commission. Double asterisks denote omissions.</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="g332r24s0lwy000001.jpg" title="" alt="" style="width:258px;height:51px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(AMENDMENT 2 TO GRANT AGREEMENT)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investment ID OPP1170296<font style="font-weight:bold;"><br /><br /></font><font style="text-decoration:underline;font-weight:bold;">AGREEMENT SUMMARY &amp; SIGNATURE PAGE</font><font style="font-weight:bold;"><br /></font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  BGCOLOR="#C0C0C0" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">GRANTEE INFORMATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: </p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis, Inc</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Status:</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not exempt from federal income tax under U.S. IRC &#167; 501(c)(3)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You confirm that the above information is correct and agree to notify the Foundation immediately of any change.</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenditure Responsibility:</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement is subject to "expenditure responsibility" requirements under the U.S. Internal Revenue Code.</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mailing Address: </p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">890 Winter Street</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite 230</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waltham, MA 02451-1472<br />United States</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact:</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  BGCOLOR="#C0C0C0" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FOUNDATION INFORMATION</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mailing Address:</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P. O. Box 23350, Seattle, WA&nbsp;&nbsp;98102, U.S.A.</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact:</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  BGCOLOR="#C0C0C0" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AGREEMENT AND AMENDMENT INFORMATION<font style="font-weight:normal;"> </font></p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement to be Amended and Restated:</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant agreement between the Bill &amp; Melinda Gates Foundation and Arsanic, Inc., effective February 20, 2017 and bearing Investment ID OPP1170296 (&#8220;<font style="font-style:italic;">Original</font> <font style="font-style:italic;">Agreement</font>&#8221;) as amended on May 3, 2018</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Respiratory Syncytial Virus (RSV) Program Proposal</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">"Charitable Purpose":</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To fund pre-clinical development of monoclonal antibodies (mAbs) for the prevention of respiratory syncytial virus (RSV) infection in newborns</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">"Start Date":</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 20, 2017</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">"End Date":</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 31, 2019</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment Purpose:</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amend and restate the Original Agreement </p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amended and Restated Agreement includes and incorporates by this reference: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement Summary &amp; Signature Page and:<br />&#9679; Grant Amount and Reporting &amp; Payment Schedule (Attachment A)<br />&#9679; Terms and Conditions (Attachment B)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679; List of Developing Countries (Attachment C)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679; Project Information (date submitted January 13, 2017)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679; Project Plan (date submitted February 8, 2017)<br />&#9679; Budget (date submitted February 3, 2017)</p></td>
</tr>
<tr>
<td valign="top"  style="width:23.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:76.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">THIS AMENDED AND RESTATED AGREEMENT<font style="font-weight:normal;"> (&#8220;</font><font style="font-weight:normal;font-style:italic;">Agreement</font><font style="font-weight:normal;">&#8221;) is between Arsanis, Inc. ("</font><font style="font-weight:normal;font-style:italic;">You</font><font style="font-weight:normal;">" or "</font><font style="font-weight:normal;font-style:italic;">Grantee</font><font style="font-weight:normal;">") and the Bill &amp; Melinda Gates Foundation ("</font><font style="font-weight:normal;font-style:italic;">Foundation</font><font style="font-weight:normal;">"), and is effective as of the date of last signature. This Agreement amends, restates, and replaces entirely the above-referenced Original Agreement in its entirety as of the date of last signature. Each party to this Agreement may be referred to individually as a "</font><font style="font-weight:normal;font-style:italic;">Party</font><font style="font-weight:normal;">" and together as the "</font><font style="font-weight:normal;font-style:italic;">Parties."</font><font style="font-weight:normal;"> As a condition of this grant, the Parties enter into this Agreement by having their authorized representatives sign below.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0%;width:100%;"></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a> of 20</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0%;width:100%;">
<tr>
<td valign="top"  style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:40.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:42.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:47.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BILL &amp; MELINDA GATES FOUNDATION</p></td>
<td valign="top"  style="width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:42.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARSANIS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:24pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:42.8%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:24pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jacqueline Kirchner</p></td>
<td valign="top"  style="width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:24pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:24pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:42.86%; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:24pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Mike Gray</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:40.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jacqueline Kirchner</p></td>
<td valign="top"  style="width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42.86%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mike Gray</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:40.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Program Officer</p></td>
<td valign="top"  style="width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:42.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial and Chief Business Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:40.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:42.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td rowspan="2" valign="top"  style="width:7.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:40.5%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 1, 2018</p></td>
<td valign="top"  style="width:2.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:42.86%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 8, 2018</p></td>
</tr>
<tr>
<td valign="top"  style="width:40.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top"  style="width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:42.86%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-top:12pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a> of 20</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED AGREEMENT</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(AMENDMENT 2 TO GRANT AGREEMENT)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investment ID OPP1170296</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="text-decoration:underline;">ATTACHMENT A</font><br /><font style="font-weight:normal;">GRANT AMOUNT AND REPORTING &amp; PAYMENT SCHEDULE</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">GRANT AMOUNT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foundation will pay You up to<font style="color:#C0504D;"> </font>the total grant amount specified in the Reporting &amp; Payment Schedule below. The Foundation&#8217;s Primary Contact must approve in writing any Budget cost category change of more than 10%.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">REPORTING &amp; PAYMENT SCHEDULE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the avoidance of doubt, the Foundation will make the first payment in full subject to the applicable milestone and compliance with this Agreement, but the subsequent payment is an &#8220;up to&#8221; amount and may be reduced in the Foundation&#8217;s discretion based on its assessment of Your completion of, or progress against, targets and milestones.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">REPORTING </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will submit reports according to the Reporting &amp; Payment Schedule using the Foundation's templates or forms, which the Foundation will make available to You and which may be modified from time to time. For a progress or final report to be considered satisfactory, it must demonstrate meaningful progress against the targets or milestones for that investment period. If meaningful progress has not been made, the report should explain why not and what adjustments You are making to get back on track. Please notify the Foundation's Primary Contact if You need to add or modify any targets or milestones. The Foundation must approve any such changes in writing. You agree to submit other reports the Foundation may reasonably request.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;">Accounting for Personnel Time</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>You will track the time of all employees, contingent workers, and any other individuals whose compensation will be paid in whole or in part by Grant Funds. Such individuals will keep records (e.g., timesheets) of actual time worked on the Project in increments of sixty minutes or less and brief descriptions of tasks performed. The Foundation acknowledges that You have offered the Foundation the opportunity to review copies of the records maintained by such individuals for work on the Project through June&#160;30, 2018, and the Foundation agrees that the descriptions of tasks performed in such records comply with the foregoing requirements. You </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-top:12pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 of 20</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will report actual time worked consistent with those records in Your progress and final budget reports. You will submit copies of such records to the Foundation upon request.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.46%;width:91.54%;">
<tr>
<td colspan="5" valign="top"  BGCOLOR="#C0C0C0" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">REPORTING &amp; PAYMENT SCHEDULE</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investment Period</p></td>
<td valign="top"  style="width:36.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Target, Milestone, or Reporting Deliverable</p></td>
<td valign="top"  style="width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Due By</p></td>
<td valign="top"  style="width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Payment Date</p></td>
<td valign="top"  style="width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Arial;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Payment Amount (U.S.$)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Paid</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[**]</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Start Date to End Date </p></td>
<td valign="top"  style="width:36.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly Financial &amp; Progress Updates </p></td>
<td valign="top"  style="width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:34.15pt;">
<td valign="top"  BGCOLOR="#D9D9D9" style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Global Access Strategy<font style="font-weight:normal;"> satisfactory to the Foundation</font></p></td>
<td rowspan="4" valign="top"  style="width:14.78%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="4" valign="top"  style="width:16.1%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td rowspan="4" valign="top"  style="width:16.86%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$[**]</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:19.3pt;">
<td valign="top"  BGCOLOR="#D9D9D9" style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Updated Financial Statements</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Product Development Summary and Status - Candidate Target Product Profile, Revised Budget, including Sub-award Budget</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[**]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:36.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[**]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:36.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:36.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[**]</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:15.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Start Date to End Date</p></td>
<td valign="top"  style="width:36.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Final Report </p></td>
<td valign="top"  style="width:14.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:16.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="4" valign="top"  BGCOLOR="#C0C0C0" style="width:83.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Amended Total Grant Amount</p></td>
<td valign="top"  style="width:16.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$9,330,878.00</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">GO/NO-GO MILESTONE(S) </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will provide the results of the &#8220;go/no-go&#8221; milestone(s) identified in the Reporting &amp; Payment Schedule by the applicable due date. During the course of the project The Foundation will then determine, in its sole discretion, whether to provide continued funding under this Agreement. If the Foundation determines that it will not continue funding, the Foundation will terminate this Agreement in accordance with its terms.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.46%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-top:12pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a> of 20</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED AGREEMENT</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(AMENDMENT 2 TO GRANT AGREEMENT)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investment ID OPP1170296</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="text-decoration:underline;">ATTACHMENT B</font><br /><font style="font-weight:normal;">TERMS &amp; CONDITIONS</font><br /></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement is subject to the following terms and conditions. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#C0C0C0" style="width:20%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PROJECT SUPPORT</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.46%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PROJECT DESCRIPTION AND CHARITABLE PURPOSE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foundation is awarding You this grant to carry out the project described in the Project Plan and Project Information Sheet (collectively, "<font style="font-style:italic;">Project</font>") in order to further the Charitable Purpose.<font style="font-size:11pt;"> </font><font style="color:#000000;">The Foundation, in its discretion, may approve in writing any request by You to make non-material changes to the Proposal Narrative and/or Results Framework and Tracker.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#C0C0C0" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">MANAGEMENT OF FUNDS</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">USE OF FUNDS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may not use funds provided under the Agreement (&#8220;Grant Funds&#8221;) for any purpose other than the Project. You may not use Grant Funds to reimburse any expenses You incurred prior to the Start Date; provided, however, that the Foundation hereby approves using Grant Funds to reimburse expenses specifically included in the Budget incurred by You prior to the Start Date. At the Foundation&#8217;s request, You will repay any portion of Grant Funds and/or Income that the Foundation determines in its discretion was used or committed in material breach of this Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INVESTMENT OF FUNDS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You must invest Grant Funds in highly liquid investments with the primary objective of preservation of principal (e.g., interest-bearing bank accounts or a registered money market mutual fund) so that the Grant Funds are available for the Project. Together with any progress or final reports required under this Agreement, You must report the amount of any currency conversion gains (or losses) and the amount of any interest, or other income generated by the Grant Funds (collectively, <font style="font-style:italic;">"Income"</font>). Any Income must be used for the Project.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SEGREGATION OF FUNDS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You must maintain Grant Funds in a physically separate bank account<font style="font-size:11pt;"> </font>or a separate bookkeeping account maintained as part of Your financial records and dedicated to the Project. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#C0C0C0" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">GLOBAL ACCESS</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">GLOBAL ACCESS COMMITMENT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will conduct and manage the Project and the Funded Developments in a manner that ensures Global Access. Your Global Access commitments will survive the term of this Agreement. &#8220;<font style="font-style:italic;">Funded Developments</font>&#8221; means the products, services, processes, technologies, materials, software, data, other innovations, and intellectual property resulting from the Project (including modifications, improvements, and further developments to Background Technology). &#8220;<font style="font-style:italic;">Background Technology</font>&#8221; means any and all products, services, processes, technologies, materials, software, data, or other innovations, and intellectual property created by You or a third party prior to or outside of the Project used as part of the Project. &#8220;<font style="font-style:italic;">Global Access</font>&#8221; means: (a) the knowledge and information gained from the Project will be promptly and broadly disseminated; and (b) the Funded Developments will be made available and accessible at an affordable price (i) to people most in need within developing countries, or (ii) in support of the U.S. educational system and public libraries, as applicable to the Project.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">GLOBAL ACCESS MILESTONES</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>To further define Your Global Access commitments, You are required to complete a Global Access Strategy and any other Global Access<font style="font-weight:bold;"> </font>activities and documentation listed in the Reporting &amp; Payment Schedule. The Global Access Strategy should address the following concepts with respect to all Funded Developments: (a) identification of Background Technology at the outset of the Project and any Funded Developments created during the Project and specific strategies to ensure access to such Funded Developments and Background </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0.4%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technology; (b) agreements and/or procedures for transfers of materials and data among Project Collaborators or third parties relevant to the Project; (c) reporting processes for the creation of Funded Developments to both the Project management team and to the Foundation as well as the publishing and dissemination of the knowledge and information gained from the Project; (d) strategies to secure, manage and allocate intellectual property rights associated with the Funded Developments or Background Technology in a way that ensures Global Access while providing incentives for future potential private sector participation; and (e) anticipated development, commercialization and sustainability strategies during and after the Project to ensure that Global Access can be met.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may not materially change the plans and strategies contained in any Global Access documents after they have been approved by the Foundation without the Foundation&#8217;s prior written approval. You will provide the Foundation with updates to the Global Access Strategy during each year of the Project describing any new or modified approaches with respect to Funded Developments and Background Technology, and related agreements, taking into account any new product, technology, and commercialization developments and/or market information. &#8220;<font style="font-style:italic;">Global Access Strategy</font>&#8221; means a written document, subject to the Foundation&#8217;s approval, describing how You intend to achieve Global Access given the particular circumstances of the Project. &#8220;<font style="font-style:italic;">Project Collaborators</font>&#8221; means all current and future subgrantees, subcontractors, partners, agents, affiliates, or other parties who provide any input to the Project.<font style="font-size:11pt;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LICENSE TO THE FOUNDATION</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purpose of achieving Global Access, You grant the Foundation a nonexclusive, perpetual, irrevocable, worldwide, royalty-free, fully paid up, sublicensable license to: make, use, sell, offer to sell, import, distribute, copy, modify, create derivative works, publicly perform and display the Funded Developments, and any Background Technology incorporated into a Funded Development or required to use a Funded Development; in each case, for the sole benefit of people in Developing Countries.&nbsp;&nbsp;You and the Foundation agree and acknowledge that the license granted in this section does not include the right to sell Funded Developments for end use outside of the Developing Countries and that no such sales are authorized under this license.&nbsp;&nbsp;In the event You demonstrate to the satisfaction of the Foundation that Global Access can best be achieved without such a license (or a license of different scope) such as by the provision of a Global Access Strategy satisfactory to the Foundation, the Foundation and You will make good faith efforts to modify or terminate this license, as appropriate.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PUBLICATION </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with Your Global Access commitments, if the Project description specifies Publication or Publication is otherwise requested by the Foundation, You will seek prompt Publication of any Funded Developments consisting of data and results. &#8220;<font style="font-style:italic;">Publication</font>&#8221; means publication in a peer-reviewed journal or other method of public dissemination specified in the Project description or otherwise approved by the Foundation in writing. Publication may be delayed for a reasonable period for the sole purpose of seeking patent protection, provided the patent application is drafted, filed, and managed in a manner that best furthers Global Access. If You seek Publication in a peer-reviewed journal, such Publication shall be under &#8220;open access&#8221; terms and conditions consistent with the Foundation&#8217;s Open Access Policy available at: <font style="text-decoration:underline;color:#0000FF;">www.gatesfoundation.org/How-We-Work/General-Information/Open-Access-Policy</font>, which may be modified from time to time. Nothing in this section shall be construed as requiring Publication in contravention of any applicable ethical, legal, or regulatory requirements. You will mark any Publication of any Funded Development subject to this clause with the appropriate notice or attribution, including author, date and copyright (<font style="font-style:italic;">e.g.</font>, &#169; 20&lt;&gt; &lt;Name&gt;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INTELLECTUAL PROPERTY REPORTING</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of this Agreement and for 5 years after, You will submit upon request annual intellectual property reports related to the Funded Developments, Background Technology, and any related agreements using the Foundation&#8217;s templates or forms, which the Foundation may modify from time to time.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#C0C0C0" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SUBGRANTS AND SUBCONTRACTS</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SUBGRANTS AND SUBCONTRACTS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may not make subgrants under this Agreement. You have the exclusive right to select subcontractors to assist with the Project. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0.4%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RESPONSIBILITY FOR OTHERS</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You are responsible for (a) all acts and omissions of any of Your trustees, directors, officers, employees, subgrantees, subcontractors, contingent workers, agents, and affiliates assisting with the Project, and (b) ensuring their compliance with the terms of this Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#C0C0C0" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PROHIBITED ACTIVITIES</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANTI-TERRORISM</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You<font style="font-weight:bold;"> </font>will not use funds provided under this Agreement, directly or indirectly, in support of activities (a) prohibited by U.S. laws relating to combating terrorism; (b) with persons on the List of Specially Designated Nationals (<font style="text-decoration:underline;color:#0000FF;">www.treasury.gov/sdn</font>) or entities owned or controlled by such persons; or (c) in or with countries or territories against which the U.S. maintains comprehensive sanctions (currently, Cuba, Iran, Sudan, Syria, North Korea, and the Crimea Region of Ukraine), including paying or reimbursing the expenses of persons from such countries or territories, unless such activities are fully authorized by the U.S. government under applicable law and specifically approved by the Foundation in its sole discretion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANTI-CORRUPTION; ANTI-BRIBERY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will not offer or provide money, gifts, or any other things of value directly or indirectly to anyone in order to improperly influence any act or decision relating to the Foundation or the Project, including by assisting any party to secure an improper advantage. Training and information on compliance with these requirements are available at <font style="text-decoration:underline;color:#000000;">www.learnfoundationlaw.org</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">POLITICAL ACTIVITY AND ADVOCACY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may not use Grant Funds to influence the outcome of any election for public office or to carry on any voter registration drive. You may not use Grant Funds to support lobbying activity or to otherwise support attempts to influence local, state, federal, or foreign legislation. Your strategies and activities, and any materials produced with Grant Funds, must comply with applicable local, state, federal, or foreign lobbying law.<font style="color:#C0504D;"> </font>You agree to comply with lobbying, gift, and ethics rules applicable to the Project. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#C0C0C0" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PUBLICITY</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PUBLICITY BY THE FOUNDATION</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foundation may include information about the award of<font style="font-size:11pt;"> </font>this grant, including Your name, in its periodic public reports and<font style="font-size:11pt;"> </font>may make such information available on its website and as part<font style="font-size:11pt;"> </font>of press<font style="font-size:11pt;"> </font>releases, public reports, speeches, newsletters, tax returns, and other public disclosures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PUBLICITY BY YOU</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You must obtain the Foundation&#8217;s prior written approval before: (a) issuing a press release or other public announcement regarding this grant; and (b) any other public use of the Foundation&#8217;s name or logo. Please email Your request to: <font style="text-decoration:underline;color:#0000FF;">grantee.comms@gatesfoundation.org</font> two weeks in advance to provide the Foundation an opportunity to review and comment. Detailed guidelines are available at: <font style="text-decoration:underline;color:#0000FF;">www.gatesfoundation.org/grantseeker/documents/guidelines_communications_for_grantees.doc</font><font style="text-decoration:underline;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PUBLICITY BY OTHERS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You and Your subgrantees, subcontractors, contingent workers, agents, or affiliates may not state or otherwise imply to third parties that the Foundation directly funds or otherwise endorses their activities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#C0C0C0" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OTHER</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk511044924"></a>LEGAL ENTITY AND AUTHORITY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You confirm that: (a) You are an entity duly organized or formed, qualified to do business, and in good standing under the laws of the jurisdiction in which You are organized or formed; (b) You are not an individual (i.e., a natural person) or a disregarded entity (e.g., a sole proprietor or sole-owner entity) under U.S. law; (c) You have the right to enter into and fully perform this Agreement; and (d) Your performance will not violate any agreement or obligation between You and any third party. You will notify the Foundation immediately if any of this changes during the term of this Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0.4%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COMPLIANCE WITH LAWS</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In carrying out the Project, You will comply with all applicable laws, regulations, and rules and will not infringe, misappropriate, or violate the intellectual property, privacy, or publicity rights of any third party.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COMPLIANCE WITH REQUIREMENTS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will conduct, control, manage, and monitor the Project in compliance with all applicable ethical, legal, regulatory, and safety requirements, including applicable international, national, state, local, institutional, and school district or school network standards (&#8220;<font style="font-style:italic;">Requirements</font>&#8221;). You will obtain and maintain all necessary approvals, consents, and reviews before conducting the applicable activity. As a part of Your annual progress report to the Foundation, You must report whether the Project activities were conducted in compliance with all Requirements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Project involves: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:7pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:7pt;"><font style="font-size:10pt;">any protected information (including personally identifiable, protected health, or third-party confidential), You will not disclose this information to the Foundation without obtaining the Foundation&#8217;s prior written approval and all necessary consents to disclose such information; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:7pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:7pt;"><font style="font-size:10pt;">children, students, or vulnerable subjects, You will obtain any necessary consents and approvals unique to these subjects; and/or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">any trial involving human subjects, You will adhere to current Good Clinical Practice as defined by the International Council on Harmonisation (ICH) E-6 Standards (or local regulations if more stringent) and will obtain applicable trial insurance. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any activities by the Foundation in reviewing documents and providing input or funding does not modify Your responsibility for determining and complying with all Requirements for the Project.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RELIANCE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You acknowledge that the Foundation is relying on the information You provide in reports and during the course of any due diligence conducted prior to the Start Date and during the term of this Agreement. You represent that the Foundation may continue to rely on this information and on any additional information You provide regarding activities, progress, and Funded Developments.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEMNIFICATION</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Project involves clinical trials, trials involving human subjects, post-approval studies, field trials involving genetically modified organisms, experimental medicine, or the provision of medical/health services (&#8220;<font style="font-style:italic;">Indemnified Activities</font>&#8221;), You will indemnify, defend, and hold harmless the Foundation and its trustees, employees, and agents (&#8220;<font style="font-style:italic;">Indemnified Parties</font>&#8221;) from and against any and all demands, claims, actions, suits, losses, damages (including property damage, bodily injury, and wrongful death), arbitration and legal proceedings, judgments, settlements, or costs or expenses (including reasonable attorneys&#8217; fees and expenses) (collectively, &#8220;<font style="font-style:italic;">Claims</font>&#8221;) arising out of or relating to the acts or omissions, actual or alleged, of You or Your employees, subgrantees, subcontractors, contingent workers, agents, and affiliates with respect to the Indemnified Activities. You agree that any activities by the Foundation in connection with the Project, such as its review or proposal of suggested modifications to the Project, will not modify or waive the Foundation&#8217;s rights under this paragraph. An Indemnified Party may, at its own expense, employ separate counsel to monitor and participate in the defense of any Claim. Your indemnification obligations are limited to the extent permitted or precluded under applicable federal, state or local laws, including federal or state tort claims acts, the Federal Anti-Deficiency Act, state governmental immunity acts, or state constitutions. Nothing in this Agreement will constitute an express or implied waiver of Your governmental and sovereign immunities, if any.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INSURANCE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will maintain insurance coverage sufficient to cover the activities, risks, and potential omissions of the Project in accordance with generally-accepted industry standards and as required by law. You will ensure Your subgrantees and subcontractors maintain insurance coverage consistent with this section.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:2pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#C0C0C0" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TERM AND TERMINATION</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TERM<font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk496265981"></a><a name="_Hlk496266957"></a><a name="_Hlk496266957"></a>This Agreement commences on the Start Date and continues until the End Date, unless terminated earlier as provided in this Agreement. The Foundation, in its discretion, may approve in writing any request by You for a no-cost extension, including amending the End Date and adjusting any affected reporting requirements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TERMINATION</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foundation may modify, suspend, or discontinue any payment of Grant Funds or terminate this Agreement if: (a) the Foundation is not reasonably satisfied with Your progress on the Project; (b) there are significant changes to Your leadership or other factors that the Foundation reasonably believes may threaten the Project&#8217;s success; (c) there is a change in Your control; (d) there is a change in Your tax status; or (e) You fail to comply with this Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RETURN OF FUNDS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any Grant Funds, plus any Income, that have not been used for, or committed to, the Project upon expiration or termination of this Agreement, must be returned promptly to the Foundation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk496266168"></a>MONITORING, REVIEW, AND AUDIT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foundation may monitor and review Your use of the Grant Funds, performance of the Project, and compliance with this Agreement, which may include onsite visits to assess Your organization&#8217;s governance, management and operations, discuss the Project and Your finances, and review relevant financial and other records and materials. In addition, the Foundation may conduct audits, including onsite audits, at any time during the term of this Agreement, and within four years after Grant Funds have been fully spent. Any onsite visit or audit shall be conducted at the Foundation&#8217;s expense, following reasonable prior written notice, during normal business hours, and no more than once during any 12-month period.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INTERNAL OR THIRD PARTY AUDIT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:normal;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If during the term of this Agreement You are audited by your internal audit department or by a third party and such audit identifies any deficiencies relevant to the management of the Project, You will provide the audit report to the Foundation upon request, including the management letter and a detailed plan for remedying any deficiencies observed (&#8220;<font style="font-style:italic;">Remediation Plan</font>&#8221;), as relevant to the management of the Project. The Remediation Plan must include (a) details of actions You will take to correct any deficiencies observed, and (b) target dates for successful completion of the actions to correct the deficiencies; in each case, as relevant to the management of the Project.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RECORD KEEPING</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk496266138"></a>You will maintain complete and accurate accounting records regarding Your use of the Grant Funds and copies of any reports submitted to the Foundation relating to the Project. You will retain such records and reports for 4 years after Grant Funds have been fully spent. At the Foundation&#8217;s request, You will make such records and reports available to enable the Foundation to monitor and evaluate how Grant Funds have been used or committed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SURVIVAL</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Party&#8217;s obligations under this Agreement will be continuous and survive expiration or termination of this Agreement as expressly provided in this Agreement or otherwise required by law or intended by their nature.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#C0C0C0" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">GENERAL<font style="font-size:11pt;"> </font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ENTIRE AGREEMENT AND AMENDMENTS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement contains the entire agreement of the Parties and supersedes all prior and contemporaneous agreements concerning its subject matter. Except as specifically permitted in this Agreement, no modification, amendment, or waiver of any provision of this Agreement will be effective unless in writing and signed by authorized representatives of both Parties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-family:Arial;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;">Notices AND approvals</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written notices, requests, and approvals under this Agreement must be delivered by mail or email to the other Party&#8217;s primary contact specified on the Agreement Summary &amp; Signature Page, or as otherwise directed by the other Party.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0.4%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SEVERABILITY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each provision of this Agreement must be interpreted in a way that is enforceable under applicable law. If any provision is held unenforceable, the rest of the Agreement will remain in effect.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSIGNMENT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may not assign, or transfer by operation of law or court order, any of Your rights or obligations under this Agreement without the Foundation&#8217;s prior written approval. This Agreement will bind and benefit any permitted successors and assigns.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">COUNTERPARTS AND ELECTRONIC SIGNATURES</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as may be prohibited by applicable law or regulation, this Agreement and any amendment may be signed in counterparts, by facsimile, PDF, or other electronic means, each of which will be deemed an original and all of which when taken together will constitute one agreement. Facsimile and electronic signatures will be binding for all purposes.<font style="font-size:11pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ATTACHMENT C</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">DEVELOPING COUNTRIES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-weight:normal;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Developing Countries&#8221; means the following list of countries, which includes (i) countries eligible for GAVI support as of 2016, (ii) countries in the process of transitioning out of GAVI support in 2016, and (iii) Botswana, Brazil, Philippines, South Africa and Thailand. &#8220;Developing Countries&#8221; also means any countries reasonably requested by the Foundation that are part of the Foundation&#8217;s strategies to which the Company consents in writing, such consent not to be unreasonably withheld and subject to the consent of Adimab, as applicable.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:0.79%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Afghanistan</p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Congo,Dem Republic of </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kenya </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Angola</p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C&#244;te d&#8217;Ivoire </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kiribati </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Armenia </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cuba </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Korea, DPR </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Azerbaijan </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Djibouti </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kyrgyz Republic </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bangladesh </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eritrea </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lao PDR </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benin </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ethiopia </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesotho </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bolivia </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gambia </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liberia </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Botswana </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Georgia </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Madagascar </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Burkina Faso </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ghana </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Malawi </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Burundi </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guinea </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mali </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambodia </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guinea Bissau </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mauritania </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cameroon </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guyana </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moldova </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Central African Republic </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Haiti </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mozambique </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chad </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">India </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Myanmar </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comoros </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indonesia </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nepal </p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:2pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nicaragua </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sierra Leone </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Timor Leste </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Niger </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Solomon Islands </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Togo </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nigeria </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Somalia </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uganda </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pakistan </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Republic of Sudan </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uzbekistan </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Philippines </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">South Africa </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vietnam </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Papua New Guinea </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">South Sudan </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yemen </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rwanda </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tajikistan </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zambia </p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#227;o Tom&#233; e Pr&#237;ncipe </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tanzania,&#160;United&#160;Republic&#160;of </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zimbabwe</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:32.58%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senegal </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="width:31.42%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thailand </p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:26.88%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0.4%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g332r24s0lwy000002.jpg" title="" alt="" style="width:140px;height:28px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Innovative Technology Solutions</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">The Innovative Technology Solutions (ITS) team has a unique process and approach to making and managing investments. Please note that other foundation investments in which you may also be involved will not use the same process and approach.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">PROJECT INFORMATION - GRANTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">The purpose of this document is for you to provide organizational and project details to support your proposal to the foundation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#F4B083" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#F4B083;"> </font><font style="Background-color:#F4B083;letter-spacing:-0.3pt;"> </font><font style="Background-color:#F4B083;">Foundation</font><font style="Background-color:#F4B083;letter-spacing:-0.55pt;"> </font><font style="Background-color:#F4B083;">Information</font></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:17.35pt;">
<td valign="top"  style="width:24.42%; border-top:solid 2.875pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:8.4pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Opportunity ID</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:22.76%; border-top:solid 2.875pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OPP1170296</p></td>
<td colspan="2" valign="top"  style="width:52.82%; border-top:solid 2.875pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Program Officer</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:22.76%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:24%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6.2pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Program Coordinator</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:28.82%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:5.6pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#F4B083" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#F4B083;"> </font><font style="Background-color:#F4B083;letter-spacing:-0.3pt;"> </font><font style="Background-color:#F4B083;">General</font><font style="Background-color:#F4B083;letter-spacing:-0.25pt;"> </font><font style="Background-color:#F4B083;">Information</font></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:3.5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:17.3pt;">
<td valign="top"  style="width:24.42%; border-top:solid 2.875pt #FFFFFF; border-bottom:solid 3.375pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:8.35pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Investment Title</p></td>
<td colspan="4" valign="top"  BGCOLOR="#FBE4D5" style="width:75.58%; border-top:solid 2.875pt #FFFFFF; border-bottom:solid 3.375pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSV Pre-Clinical Program</p></td>
</tr>
<tr style="height:35.5pt;">
<td valign="top"  style="width:24.42%; border-top:solid 3.375pt #FFFFFF; border-bottom:solid 3.375pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Short Description</p></td>
<td colspan="4" valign="top"  BGCOLOR="#FBE4D5" style="width:75.58%; border-top:solid 3.375pt #FFFFFF; border-bottom:solid 3.375pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:5.5pt;;margin-right:1.39%;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discovery, lead selection, pre-clinical development, and IND-enabling toxicology studies for monoclonal antibodies (mAbs) targeting respiratory syncytial virus (RSV). Goal is to achieve a product profile that supports Global Access objectives (e.g. low-cost, single dose prophylaxis).</p></td>
</tr>
<tr style="height:18.85pt;">
<td valign="top"  style="width:24.42%; border-top:solid 3.375pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Organization</p></td>
<td colspan="4" valign="top"  BGCOLOR="#FBE4D5" style="width:75.58%; border-top:solid 3.375pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis, Inc.</p></td>
</tr>
<tr style="height:27.6pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:6.45pt;;margin-right:7.34%;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Investment Duration (months)</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:23.54%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="top"  style="width:23.24%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:28.8%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:18.9pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:5.75pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Requested Amount (U.S.$)</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:23.54%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$8.8 Million</p></td>
<td colspan="2" valign="top"  style="width:25.16%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total Project Cost (U.S. $)</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:26.9%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:5.75pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$9.4 Million</p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Organization Legal Name<font style="font-size:6pt;">1</font></p></td>
<td colspan="4" valign="top"  BGCOLOR="#FBE4D5" style="width:75.58%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis, Inc.</p></td>
</tr>
<tr style="height:17.3pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #F2EDDE; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Mailing Address</p></td>
<td valign="top"  style="width:23.54%; border-top:solid 0.75pt #F2EDDE; border-bottom:double 2.5pt #FBE4D5; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:25.16%; border-top:solid 0.75pt #F2EDDE; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.9%; border-top:solid 0.75pt #F2EDDE; border-bottom:double 2.5pt #FBE4D5; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:18.9pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #F2EDDE; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:14.15pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Street Address 1</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:23.54%; border-top:solid 0.75pt #F2EDDE; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">890 Winter Street</p></td>
<td colspan="2" valign="top"  style="width:25.16%; border-top:solid 0.75pt #F2EDDE; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact Name</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:26.9%; border-top:solid 0.75pt #F2EDDE; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:5.75pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:17.3pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:14.15pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Street Address 2</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:23.54%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite 230</p></td>
<td colspan="2" valign="top"  style="width:25.16%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact Title</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:26.9%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:5.75pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:14.15pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Street Address 3</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:23.54%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:25.16%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact Email</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:26.9%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:5.75pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:17.3pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:14.15pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">City</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:23.54%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waltham</p></td>
<td colspan="2" valign="top"  style="width:25.16%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact Phone</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:26.9%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:5.75pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:18.9pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:14.15pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State / Province</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:23.54%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MA</p></td>
<td colspan="2" valign="top"  style="width:25.16%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:26.9%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:14.15pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zip / Postal Code</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:23.54%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02451-1472</p></td>
<td colspan="2" valign="top"  style="width:25.16%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Authorized Signer Name</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:26.9%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:5.75pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mike Gray</p></td>
</tr>
<tr style="height:20.35pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:14.15pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Country</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:23.54%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:5pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US</p></td>
<td colspan="2" valign="top"  style="width:25.16%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Authorized Signer Title</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:26.9%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:5pt;margin-bottom:0pt;margin-left:5.75pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFO and CBO</p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Website <font style="font-weight:normal;">(if applicable)</font></p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:23.54%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">www.arsanis.com</p></td>
<td colspan="2" valign="top"  style="width:25.16%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Authorized Signer Email</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:26.9%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:5.75pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mike.gray@arsanis.com</p></td>
</tr>
<tr style="height:25.2pt;">
<td colspan="5" valign="top"  style="width:100%; border-top:solid 0.75pt #F2EDDE; border-bottom:solid 0.75pt #FBE4D5; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:6.45pt;;text-indent:0pt;;font-weight:bold;font-size:4.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1 <font style="font-size:7pt;font-weight:normal;">Legal Name will be used in the agreement and should match the name on the bank account that receives the grant funds (assuming fully executed agreement).</font></p></td>
</tr>
<tr style="height:37.7pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #F2EDDE; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:6.45pt;;margin-right:4.56%;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Tax Status <font style="font-weight:normal;">(if known and applicable)</font></p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:12.2pt;;text-indent:0pt;;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to <font style="text-decoration:underline;">Tax Status Definitions</font></p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:23.54%; border-top:solid 0.75pt #F2EDDE; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Exempt Organization</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8211; C Corporation</p></td>
<td rowspan="2" colspan="2" valign="top"  style="width:25.16%; border-top:solid 0.75pt #F2EDDE; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:6.45pt;;margin-right:3.97%;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Organization&#8217;s Total Revenue for Most Recent Audited Financial Year (U.S.$)</p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:26.9%; border-top:solid 0.75pt #F2EDDE; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.75pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No sales revenue</p></td>
</tr>
<tr style="height:27.85pt;">
<td valign="top"  style="width:24.42%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:6.45pt;;margin-right:0.99%;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">U.S. Employer Identification Number (EIN) <font style="font-weight:normal;">(if applicable)</font></p></td>
<td valign="top"  BGCOLOR="#FBE4D5" style="width:23.54%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.5pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27-3181608</p></td>
<td valign="top"  style="width:26.9%; border-top:solid 0.75pt #F2EDDE; border-bottom:solid 0.75pt #F2EDDE; border-left:solid 2.875pt #FFFFFF; border-right:solid 2.875pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/5/2017 (ITS-Version 1.1)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 12</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g332r24s0lwy000002.jpg" title="" alt="" style="width:140px;height:28px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#F4B083" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#F4B083;"> </font><font style="Background-color:#F4B083;letter-spacing:-0.3pt;"> </font><font style="Background-color:#F4B083;">Charitable Purpose &amp; Public</font><font style="Background-color:#F4B083;letter-spacing:-0.7pt;"> </font><font style="Background-color:#F4B083;">Description</font></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.18%;margin-right:3.97%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Describe the charitable purpose of the project. This statement will be used to inform the public description of this project. Please limit to one sentence, begin with &#8220;to&#8221; and do not include a period at the end. <font style="font-style:italic;font-weight:normal;">Example: &#8220;This grant will be used [to fund new schools and assist other organizations in the design of new&nbsp;&nbsp;schools]&#8221;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.18%;margin-right:3.97%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #BFBFBF; border-bottom:solid 0.75pt #BFBFBF; border-left:solid 0.75pt #BFBFBF; border-right:solid 0.75pt #BFBFBF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This grant will be used to fund pre-clinical development of monoclonal antibodies (mAbs) for the prevention of respiratory syncytial virus (RSV) infection in newborns, which is responsible for over 30 million cases of acute lower respiratory infection and 200,000 deaths per year in the developing world.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#F4B083" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#F4B083;"> </font><font style="Background-color:#F4B083;letter-spacing:-0.3pt;"> </font><font style="Background-color:#F4B083;">Conduct &amp; Control of the</font><font style="Background-color:#F4B083;letter-spacing:-0.5pt;"> </font><font style="Background-color:#F4B083;">Project</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">In answering the questions in this section, please consider all Project activities, such as those involving: confidential or protected information (including personally identifiable information or protected health information); the inclusion of children or vulnerable populations; research involving human subjects; clinical trials; post-approval studies; field trials; experimental medicine; provision of medical services (diagnostic, prophylactic or treatment); product development; use of genetically modified organisms, human tissue, animals, radioactive isotopes, pathogenic organisms, recombinant nucleic acids, select agents or toxins (<font style="text-decoration:underline;">www.selectagents.gov</font>), dual-use technology (<font style="text-decoration:underline;">http://export.gov/regulation/eg_main_018229.asp</font>), or any substance, organism, or material that is toxic or hazardous; use of aircraft, unmanned vehicle systems, drones or satellites; and the import, export, transfer, approvals, consents, records, data, specimens, images, and materials related to any of the forgoing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">Please confirm that your organization:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">will maintain the expertise necessary to conduct, control, manage, and monitor all aspects of the Project in compliance with all applicable ethical, legal, regulatory, and safety requirements, including applicable international, national, local, and institutional standards and policies and is responsible for determining and complying with these requirements and standards;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">will not disclose any confidential or protected information to the Foundation without obtaining prior written approval from the foundation and all necessary consents to disclose such information;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">acknowledges that any activities by the Foundation in reviewing documents, providing input or funding does not modify your organization&#8217;s responsibility for determining and complying with all applicable ethical, legal, regulatory, and safety requirements for the Project in all places;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">will maintain insurance coverage sufficient to cover the activities, risks, and potential omissions of the Project in accordance with generally-accepted standards and as required by law (for instance, general, professional, clinical trial, product liability, medical malpractice, workers' compensation, or otherwise);</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">e)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">will not transfer any biological materials, chemicals, reagents, hazardous materials or the like to the Foundation.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:9.72%;text-indent:-4.86%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Confirmed <font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;X&nbsp;&nbsp; </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Not confirmed<font style="text-decoration:underline;margin-left:36pt;"></font>(please explain)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.86%;width:87.14%;">
<tr style="height:20pt;">
<td valign="top"  style="width:100%; border-top:solid 0.75pt #BFBFBF; border-bottom:solid 0.75pt #BFBFBF; border-left:solid 0.75pt #BFBFBF; border-right:solid 0.75pt #BFBFBF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.2pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">Does the Project involve any of the following: clinical trial, other trial involving human subjects, post-approval study, experimental medicine, genetically modified organism, or the provision of medical/health services?</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">No&nbsp;&nbsp;<font style="text-decoration:underline;">&nbsp;&nbsp; X </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;margin-right:1.59%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Yes<font style="text-decoration:underline;margin-left:36pt;"></font>(If yes, please list all approvals and consents required for each site&nbsp;&nbsp; and describe the timeframe in which your organization will acquire the necessary approvals and consents.)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.86%;width:87.14%;">
<tr style="height:20pt;">
<td valign="top"  style="width:100%; border-top:solid 0.75pt #BFBFBF; border-bottom:solid 0.75pt #BFBFBF; border-left:solid 0.75pt #BFBFBF; border-right:solid 0.75pt #BFBFBF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.2pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.86%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">Please identify the name of the entity that will be the sponsor/responsible party of any clinical trials, studies involving human subjects, experimental medicine studies, post-approval studies, products, or regulatory filings contemplated by the Project. Note that the Foundation will not serve as the sponsor/responsible party nor accept delegation of any of these responsibilities. If the Project will not involve such activities, please indicate not applicable or N/A below.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.86%;width:87.14%;">
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #BFBFBF; border-bottom:solid 0.75pt #BFBFBF; border-left:solid 0.75pt #BFBFBF; border-right:solid 0.75pt #BFBFBF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.2pt;;text-indent:0pt;;color:#3E3E3E;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis, Inc.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/5/2017 (ITS-Version 1.1)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 13</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g332r24s0lwy000002.jpg" title="" alt="" style="width:140px;height:28px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#F4B083" style="width:100%;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Global Access &amp; Open Access</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">In order to establish that the projects we fund are charitable and will have a positive impact on the intended beneficiaries of our work, the foundation requires the projects it funds be conducted and managed in a manner that ensures Global Access and Open Access.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Global Access&#8221; <font style="font-weight:normal;">is a foundation policy requiring that: (a) the knowledge and information gained from the </font><font style="letter-spacing:-0.15pt;font-weight:normal;">project </font><font style="font-weight:normal;">will be promptly and broadly disseminated; and (b) the </font><font style="letter-spacing:-0.15pt;font-weight:normal;">Funded </font><font style="font-weight:normal;">Developments </font><font style="letter-spacing:-0.15pt;font-weight:normal;">will </font><font style="font-weight:normal;">be made available and accessible </font><font style="letter-spacing:-0.15pt;font-weight:normal;">at an </font><font style="font-weight:normal;">affordable price (i) to people most in </font><font style="letter-spacing:-0.2pt;font-weight:normal;">need </font><font style="font-weight:normal;">within developing countries, </font><font style="letter-spacing:-0.15pt;font-weight:normal;">or </font><font style="font-weight:normal;">(ii) in support </font><font style="letter-spacing:-0.15pt;font-weight:normal;">of </font><font style="font-weight:normal;">the U.S. </font><font style="letter-spacing:-0.15pt;font-weight:normal;">educational system </font><font style="font-weight:normal;">and public libraries, as applicable to the</font><font style="letter-spacing:-0.5pt;font-weight:normal;"> </font><font style="font-weight:normal;">project.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Funded Developments&#8221; <font style="font-weight:normal;">means the products, services, processes, technologies, materials, software, data, other innovations, and intellectual property resulting from the project, including modifications, improvements, and further developments to Background Technology.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Background Technology&#8221; <font style="font-weight:normal;">means any and all products, services, processes, technologies, materials, software, data, or other innovations, and intellectual property created by You or a third party prior to or outside of the project used as part of the project.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional information about Global Access (including examples and case studies) can be found at <font style="text-decoration:underline;">http://globalaccess.gatesfoundation.org/.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.46%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&#8220;Open Access&#8221; </font><font style="text-decoration:underline;font-weight:normal;">is a foundation policy that sets the requirements, terms and conditions for </font><font style="font-weight:normal;">publication of Funded Developments in a peer-reviewed journal. Additional Information on the foundation&#8217;s Open Access Policy for peer-reviewed publications and underlying data can be found at </font><font style="text-decoration:underline;font-weight:normal;">www.gatesfoundation.org/How-We-Work/General-Information/Open-Access-Policy</font><font style="font-weight:normal;">. Note: the foundation will pay directly for reasonable fees to effect publication on &#8220;open access&#8221; terms; such fees should </font><font style="text-decoration:underline;font-weight:normal;">not </font><font style="font-weight:normal;">be included in the project budget (See the </font><font style="text-decoration:underline;font-weight:normal;">Open Access Policy FAQs </font><font style="font-weight:normal;">for further detail).</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#818181;font-size:9pt;font-family:Arial;letter-spacing:-0.05pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#818181;font-size:9pt;font-family:Arial;letter-spacing:-0.05pt;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#818181;letter-spacing:-0.05pt;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;"><font style="text-decoration:underline;color:#000000;">Knowledge and</font><font style="text-decoration:underline;letter-spacing:-0.4pt;color:#000000;"> </font><font style="text-decoration:underline;color:#000000;">Information</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Describe how the knowledge and information gained from the project will be promptly and broadly disseminated (including how you will comply with the foundation&#8217;s Open Access Policy, discussed above).</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.86%;width:87.14%;">
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #BFBFBF; border-bottom:solid 0.75pt #BFBFBF; border-left:solid 0.75pt #BFBFBF; border-right:solid 0.75pt #BFBFBF;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.55pt;;margin-right:0.2%;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis will promptly and broadly disseminate the output of Funded Developments in compliance with the Open Access Policy and Arsanis internal policies. Our primary approaches are publication in peer-reviewed journals and presentations (e.g. abstracts, oral sessions) at scientific congresses. In some circumstances, timing of disclosures may be gated by the need to provide for relevant intellectual property protections prior to such disclosures.</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:4.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:4.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#818181;font-size:9pt;font-family:Arial;letter-spacing:-0.05pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#818181;font-size:9pt;font-family:Arial;letter-spacing:-0.05pt;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#818181;letter-spacing:-0.05pt;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;"><font style="text-decoration:underline;color:#000000;">Funded Developments </font><font style="color:#000000;">(Indicate &#8220;not applicable,&#8221; as</font><font style="letter-spacing:-1.45pt;color:#000000;"> </font><font style="color:#000000;">appropriate)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">Describe any Funded Developments that may ultimately result from the project, including any Background Technology that <font style="letter-spacing:-0.15pt;">will </font>be <font style="letter-spacing:-0.15pt;">used or </font>incorporated in <font style="letter-spacing:-0.1pt;">the </font><font style="letter-spacing:-0.15pt;">proposed </font>project. If applicable, briefly explain how the Funded Developments will be made available <font style="letter-spacing:-0.15pt;">and </font>accessible <font style="letter-spacing:-0.15pt;">at </font>an affordable price to the intended beneficiaries. The use <font style="letter-spacing:-0.15pt;">of </font>commonly-available, off-the-shelf products (such as Microsoft Excel, <font style="letter-spacing:-0.15pt;">Adobe, </font>etc.) need <font style="letter-spacing:-0.15pt;">not </font>be disclosed.</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.86%;width:87.14%;">
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #BFBFBF; border-bottom:solid 0.75pt #BFBFBF; border-left:solid 0.75pt #BFBFBF; border-right:solid 0.75pt #BFBFBF;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funded Developments that may ultimately result from the project include:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:18pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;<font style="font-weight:normal;">Monoclonal antibody </font><font style="letter-spacing:-0.15pt;font-weight:normal;">(mAb) </font><font style="font-weight:normal;">drug candidates targeting RSV</font><font style="letter-spacing:-0.4pt;font-weight:normal;"> </font><font style="font-weight:normal;">infection.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:18pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;<font style="font-weight:normal;">Pre-clinical</font><font style="letter-spacing:0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">data</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">and</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">regulatory</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">filings</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">that</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">support</font><font style="letter-spacing:-0.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">the</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">initiation</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:-0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">human</font><font style="letter-spacing:-0.2pt;font-weight:normal;"> </font><font style="font-weight:normal;">studies</font><font style="letter-spacing:0.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">of</font><font style="letter-spacing:-0.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">these</font><font style="letter-spacing:-0.45pt;font-weight:normal;"> </font><font style="font-weight:normal;">mAbs.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:18pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;<font style="font-weight:normal;">Manufacturing know-how for the production of GMP mAb drug</font><font style="letter-spacing:-1.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">product.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:18pt;;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;<font style="font-weight:normal;">Intellectual property (including patents </font><font style="letter-spacing:-0.15pt;font-weight:normal;">and </font><font style="font-weight:normal;">know-how) covering the mAbs.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Background technology that may be incorporated in the project<font style="letter-spacing:-1pt;"> </font>includes:</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/5/2017 (ITS-Version 1.1)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 14</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g332r24s0lwy000002.jpg" title="" alt="" style="width:140px;height:28px;"></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.86%;width:87.14%;">
<tr>
<td valign="top"  style="width:100%; border-top:solid 0.75pt #BFBFBF; border-bottom:solid 0.75pt #BFBFBF; border-left:solid 0.75pt #BFBFBF; border-right:solid 0.75pt #BFBFBF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:32pt;;text-indent:-14pt;;font-weight:bold;font-size:11.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;<font style="font-size:9pt;font-weight:normal;">Arsanis know-how related to the discovery </font><font style="font-size:9pt;letter-spacing:-0.15pt;font-weight:normal;">and </font><font style="font-size:9pt;font-weight:normal;">optimization </font><font style="font-size:9pt;letter-spacing:-0.15pt;font-weight:normal;">of</font><font style="font-size:9pt;letter-spacing:-0.3pt;font-weight:normal;"> </font><font style="font-size:9pt;font-weight:normal;">mAbs.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:32pt;;text-indent:-14pt;;font-weight:bold;font-size:11.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;<font style="font-size:9pt;font-weight:normal;">RSV mAb </font><font style="font-size:9pt;letter-spacing:-0.15pt;font-weight:normal;">sequences </font><font style="font-size:9pt;font-weight:normal;">(patents </font><font style="font-size:9pt;letter-spacing:-0.15pt;font-weight:normal;">and </font><font style="font-size:9pt;font-weight:normal;">know-how) that may be in-licensed by Arsanis from Adimab, LLC upon exercise of the Adimab license described</font><font style="font-size:9pt;letter-spacing:-0.5pt;font-weight:normal;"> </font><font style="font-size:9pt;font-weight:normal;">below.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:32pt;;text-indent:-14pt;;font-weight:bold;font-size:11.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;<font style="font-size:9pt;font-weight:normal;">Technologies (patents and know-how) related to the optimization of RSV mAbs in-licensed by Arsanis from third parties.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:32pt;;text-indent:-14pt;;font-weight:bold;font-size:11.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;<font style="font-size:9pt;font-weight:normal;">Technologies (patents and know-how) related to the manufacture </font><font style="font-size:9pt;letter-spacing:-0.15pt;font-weight:normal;">of </font><font style="font-size:9pt;font-weight:normal;">RSV mAbs in-licensed by Arsanis from third parties.</font></p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:6pt;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">Please <font style="letter-spacing:-0.15pt;">confirm </font>that <font style="letter-spacing:-0.15pt;">you </font>will make the Funded Developments &#8211; including any Background Technology incorporated into <font style="letter-spacing:-0.15pt;">or </font>required to <font style="letter-spacing:-0.15pt;">use </font>the Funded Developments &#8211; available to achieve the proposed project&#8217;s goals and Global Access. If <font style="letter-spacing:-0.15pt;">you </font>foresee any obstacles to achieving Global Access (e.g., third party <font style="letter-spacing:-0.15pt;">rights, </font>broad access, time frame, affordability) please briefly summarize the obstacles and the specific steps that <font style="letter-spacing:-0.15pt;">you will </font>take to address<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.15pt;">them.</font></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.86%;width:87.14%;">
<tr style="height:200pt;">
<td valign="top"  style="width:100%; border-top:solid 0.75pt #BFBFBF; border-bottom:solid 0.75pt #BFBFBF; border-left:solid 0.75pt #BFBFBF; border-right:solid 0.75pt #BFBFBF;">
<p style="margin-top:5pt;margin-bottom:0pt;margin-left:4.55pt;;margin-right:0.2%;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis will make the Funded Developments available to achieve the project&#8217;s goals and Global Access as agreed upon with BMGF.</p>
<p style="margin-top:5pt;margin-bottom:0pt;margin-left:4.55pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential obstacles include:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.5pt;;text-indent:0pt;;font-weight:bold;font-size:11.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;<font style="font-size:9pt;font-weight:normal;"> [**].</font></p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#818181;font-size:11pt;font-family:Arial;letter-spacing:-0.05pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#818181;font-size:11pt;font-family:Arial;letter-spacing:-0.05pt;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#818181;letter-spacing:-0.05pt;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:11pt;"><font style="font-size:9pt;color:#000000;">If one or more of the following </font><font style="font-size:9pt;letter-spacing:-0.15pt;color:#000000;">applies, </font><font style="font-size:9pt;color:#000000;">please click the following link to complete an </font><font style="text-decoration:underline;font-size:9pt;color:#000000;">Intellectual Property (IP)</font><font style="text-decoration:underline;font-size:9pt;letter-spacing:-1.1pt;color:#000000;"> </font><font style="text-decoration:underline;font-size:9pt;color:#000000;">Report</font><font style="font-size:9pt;color:#000000;">:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:9pt;"><font style="font-family:Arial;">Creation of Funded Developments will likely involve </font><font style="font-family:Arial;letter-spacing:-0.15pt;">new </font><font style="font-family:Arial;">IP rights (Note: copyrights in works intended to be published in accordance with the Open Access Policy </font><font style="font-family:Arial;letter-spacing:-0.2pt;">need </font><font style="font-family:Arial;">not be disclosed);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:9pt;"><font style="font-family:Arial;">Use of Background Technology requires access to existing IP rights;</font><font style="font-family:Arial;letter-spacing:-0.95pt;"> </font><font style="font-family:Arial;letter-spacing:-0.3pt;">or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.14%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:4.86%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:9pt;"><font style="font-family:Arial;">For-Profit entities are </font><font style="font-family:Arial;letter-spacing:-0.15pt;">engaged </font><font style="font-family:Arial;">in the</font><font style="font-family:Arial;letter-spacing:0.3pt;"> </font><font style="font-family:Arial;">project.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.14%;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: For login purposes, please use the email address to which this Proposal Narrative was sent. To delegate permissions to another member of your project team, or for any questions regarding the IP Report, please contact <font style="text-decoration:underline;">GlobalAccess@gatesfoundation.org</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/5/2017 (ITS-Version 1.1)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 15</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g332r24s0lwy000002.jpg" title="" alt="" style="width:140px;height:28px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:9pt;font-family:Arial;text-transform:none;font-variant: normal;">Privacy and Non-Confidentiality Notice</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">The foundation is required by the IRS to publish a list of its grants. We may also provide a general description of our grants and contracts on our web sites, in press releases, and in other marketing materials. Subject to the foundation&#8217;s <font style="text-decoration:underline;color:#5291A8;">Privacy Policy</font>, the foundation may also share information you provide to us (either orally or in writing) with third parties, including external reviewers, key partners and co-funders. This document is subject to the foundation&#8217;s <font style="font-size:11pt;">Terms of Us</font>e.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/5/2017 (ITS-Version 1.1)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 16</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g332r24s0lwy000007.jpg" title="" alt="" style="width:112px;height:37px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:16pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#ED7C2F;font-size:16pt;font-family:Arial;text-transform:none;font-variant: normal;">RSV Pre-Clinical Program Proposal</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#7F7F7F;font-size:11pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Prepared by: Arsanis, Inc.</p>
<p style="text-align:right;border-bottom:Solid 1.5pt;padding-bottom:4pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Updated February 8, 2017</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Materials omitted and filed separately with the Securities and Exchange Commission. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A total of 23 pages were omitted. [**]</p>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page <font style="font-weight:bold;">17</font></a> of <font style="font-weight:bold;">20</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARSANIS NON-CONFIDENTIAL REDACTED DRAFT</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><img src="g332r24s0lwy000008.jpg" title="" alt="" style="width:790px;height:479px;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quick start guide this page provides a quick overview of the bmgf budget template to orient you before getting started. As you populate the sheets, you will find direct links to specific instructions with examples throughout the template. The full instruction document can be accessed here, frequently asked questions (FAQ&#8217;s) can accessed here. Grantee input sheets these first three sheets need to be filled out by the grantee for every grant. General information enter the required basic information into this sheet before populating any of the other sheets. Budget details. For each of the 6 expense categories, enter the items that collectively make up the grant budget into this sheet. Financial summary &amp; reporting review the summary tables from the budget detail sheet and add further information (where applicable). This sheet is also used to enter actuals expenditures and projections as part of reporting. Payment &amp; reporting schedule this shee is used by the grantee to review an auto-generated preliminary payment schedule and by bmgf to make any changes before incorporating it into the grant agreement important information for working with the template legend for cell formatting input cells are colored according to the following scheme. At the time of budgeting, populate only light yellow cells. Enter information into light yellow cells. Enter actual expenditures into green cells blue cells will be populated by bmgf cash vs projected actuals (accruals) all actual amounts reported should be based on cash spent, not projected (or accrued) for the remainder of the period. Hints for specific data entry fields for some fields a red triangle in the upper right corner indicates that a hint available when hovering the mouse over the cell. Copying data into the template use paste values whenever transferring data from an external source into the template. If no, the template can become corrupted. Error checking for some cells, an automatic error check will show its value in red if it appears to be populated incorrectly or if the calculation yields a result that is inconsistent with another value.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 18</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><img src="g332r24s0lwy000009.jpg" title="" alt="" style="width:790px;height:479px;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#FFFFFF;font-size:1pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the three sheets described above, there are several additional sheets included in the template, some of them optional and/or hidden. Grantees do not need to use these additional sheets, but for transparency, you will find na overview below. If you would like to include additional information (or are asked for it by bmgf) in this file, it is ok to add extra sheets for this purpose. However, please do not make any changes to the structure, formatting or formulas&nbsp;&nbsp;of the existing sheets. Bmgf work sheets these three sheets are primarily used by bmgf to analyze and manage the grant. Grantees can provide input in the payment &amp; reporting schedule sheet. You may use them yourself, but please do not enter&nbsp;&nbsp;or alter any data or formulas. Payment &amp; reporting schedule this sheet is used by the grantee to review an autogenerated preliminary payment schedule and by bmgf to make any changes before incorporating it into the grant agreement. Analytics contains two analytic features: a set of basic charts and a comparison tool. Budget pivot (typically hidden) excel pivot table that can be used to analyze the data in the budget details sheet. Historic or background information these sheets are used by bmgf to preserve historic information throughout the grant or for administrative purposes. Please do not make any changes to these sheets. Historic budget details if a grant budget revision takes place, the previous version of the budget details sheet can be preserved as a separate sheet for reference historic budget summaries if grant budget revisions take place, this sheet can be used to preserve previous versions of the budget summary for reference. Config (typically hidden) used for administrative purposes to populate dropdown lists etc. throughout the template.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 19</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g332r24s0lwy000010.jpg" title="" alt="" style="width:259px;height:52px;"></p>
<p style="margin-top:30pt;margin-bottom:0pt;margin-right:1.22%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Materials omitted and filed separately with the Securities and Exchange Commission.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.22%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A total of 32 pages were omitted. [**]</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 20</a> of 20</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>asns-ex104_185.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
asns-ex104_185.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk521597821"></a>Exhibit 10.4</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Materials omitted and filed separately with the</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities and Exchange Commission. Double asterisks denote omissions.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gnhmo5dgyo1b000001.jpg" title="" alt="" style="width:258px;height:51px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="GRANT_AGREEMENT"></a>GRANT AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Investment_ID_OPP1189138__AGREEMENT_SUMM"></a>Investment ID OPP1189138</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">AGREEMENT SUMMARY &amp; SIGNATURE PAGE</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:12pt;">
<td colspan="2" valign="top"  BGCOLOR="#C0C0C0" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">GRANTEE INFORMATION</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top"  style="width:23.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:76.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis Inc</p></td>
</tr>
<tr style="height:35.05pt;">
<td valign="top"  style="width:23.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Status:</p></td>
<td valign="top"  style="width:76.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not exempt from federal income tax under U.S. IRC &#167; 501(c)(3)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You confirm that the above information is correct and agree to notify the Foundation immediately of any change.</p></td>
</tr>
<tr style="height:23.4pt;">
<td valign="top"  style="width:23.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenditure Responsibility:</p></td>
<td valign="top"  style="width:76.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement is subject to &#8220;expenditure responsibility&#8221; requirements under the</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Internal Revenue Code.</p></td>
</tr>
<tr style="height:50.35pt;">
<td valign="top"  style="width:23.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mailing Address:</p></td>
<td valign="top"  style="width:76.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">890 Winter Street</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite 230</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;margin-right:47.22%;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waltham, MA 02451-1472 United States</p></td>
</tr>
<tr style="height:23.5pt;">
<td valign="top"  style="width:23.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact:</p></td>
<td valign="top"  style="width:76.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;margin-right:6.35%;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:12pt;">
<td colspan="2" valign="top"  BGCOLOR="#C0C0C0" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FOUNDATION INFORMATION</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top"  style="width:23.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mailing Address:</p></td>
<td valign="top"  style="width:76.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P. O. Box 23350, Seattle, WA&nbsp;&nbsp;98102, U.S.A.</p></td>
</tr>
<tr style="height:23.5pt;">
<td valign="top"  style="width:23.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact:</p></td>
<td valign="top"  style="width:76.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;margin-right:25%;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:12pt;">
<td colspan="2" valign="top"  BGCOLOR="#C0C0C0" style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">AGREEMENT INFORMATION</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top"  style="width:23.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:76.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Respiratory Syncytial Virus (RSV) Program: Optimization Proposal</p></td>
</tr>
<tr style="height:35.05pt;">
<td valign="top"  style="width:23.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Charitable Purpose&#8221;:</p></td>
<td valign="top"  style="width:76.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;margin-right:6.35%;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To optimize and further characterize anti respiratory syncytial virus (RSV) monoclonal antibodies (mAbs) towards the prevention of RSV in infants in the developing world</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top"  style="width:23.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Start Date&#8221;:</p></td>
<td valign="top"  style="width:76.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date of last signature.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top"  style="width:23.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;End Date&#8221;:</p></td>
<td valign="top"  style="width:76.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 31, 2018</p></td>
</tr>
<tr style="height:11.85pt;">
<td rowspan="7" valign="top"  style="width:23.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement includes and incorporates by this reference:</p></td>
<td valign="top"  style="width:76.94%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement Summary &amp; Signature Page and:</p></td>
</tr>
<tr style="height:11.45pt;">
<td valign="top"  style="width:76.94%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:16.65pt;;text-indent:-11.5pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;Grant Amount and Reporting &amp; Payment Schedule (Attachment<font style="letter-spacing:-1.05pt;"> </font>A)</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top"  style="width:76.94%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:16.65pt;;text-indent:-11.5pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;Terms and Conditions (Attachment<font style="letter-spacing:-0.45pt;"> </font>B)</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top"  style="width:76.94%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:16.65pt;;text-indent:-11.5pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;List of Developing Countries (Attachment C)</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top"  style="width:76.94%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:16.65pt;;text-indent:-11.5pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;Proposal Narrative (date submitted April 10,<font style="letter-spacing:-0.8pt;"> </font>2018)</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top"  style="width:76.94%; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:16.65pt;;text-indent:-11.5pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;Results Framework and Tracker (date submitted April 11,<font style="letter-spacing:-0.9pt;"> </font>2018)</p></td>
</tr>
<tr style="height:11.6pt;">
<td valign="top"  style="width:76.94%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:16.65pt;;text-indent:-11.5pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9679;Budget (date submitted April 11,<font style="letter-spacing:-0.55pt;"> </font>2018)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="THIS_AGREEMENT_is_between_Arsanis_Inc_(""></a>THIS AGREEMENT <font style="font-weight:normal;">is between Arsanis Inc (&#8220;</font><font style="font-style:italic;font-weight:normal;">Arsanis</font><font style="font-weight:normal;">,&#8221; &#8220;</font><font style="font-style:italic;font-weight:normal;">You</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="font-style:italic;font-weight:normal;">Grantee</font><font style="font-weight:normal;">&#8221;) and the Bill &amp; Melinda Gates Foundation (&#8220;</font><font style="font-style:italic;font-weight:normal;">Foundation</font><font style="font-weight:normal;">&#8221;), and is effective as of the date of last signature. Each party to this Agreement may be referred to individually as a &#8220;</font><font style="font-style:italic;font-weight:normal;">Party</font><font style="font-weight:normal;">&#8221; and together as the &#8220;</font><font style="font-style:italic;font-weight:normal;">Parties.&#8221; </font><font style="font-weight:normal;">As a condition of this grant, the Parties enter</font><font style="letter-spacing:-1.3pt;font-weight:normal;"> </font><font style="font-weight:normal;">into this Agreement by having their authorized representatives sign</font><font style="letter-spacing:-1.05pt;font-weight:normal;"> </font><font style="font-weight:normal;">below.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BILL &amp; MELINDA GATES FOUNDATION</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARSANIS INC</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">/s/ Lynda Stuart</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">/s/ Mike Gray</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.24%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lynda Stuart</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mike Gray</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deputy Director</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vaccines and Host-Pathogen Biology</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Operating Officer and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/6/2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 8, 2018</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">GRANT AGREEMENT</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment ID OPP1189138</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ATTACHMENT A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GRANT AMOUNT AND REPORTING &amp; PAYMENT SCHEDULE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">GRANT AMOUNT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foundation will pay You the total grant amount specified in the Reporting &amp; Payment Schedule below. The Foundation&#8217;s Primary Contact must approve in writing any Budget cost category change of more&nbsp;&nbsp;&nbsp;&nbsp; than<font style="letter-spacing:-0.25pt;"> </font>10%.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">REPORTING &amp; PAYMENT SCHEDULE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments are subject to Your compliance with this Agreement, including Your achievement, and the Foundation&#8217;s approval, of any applicable targets, milestones, and reporting deliverables required under this Agreement. The Foundation may, in its reasonable discretion, modify payment dates or amounts and will notify You of any such changes in writing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">REPORTING</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will submit reports according to the Reporting &amp; Payment Schedule using the Foundation&#8217;s templates or forms, which the Foundation will make available to You and which may be modified from time to time.&nbsp;&nbsp;For a progress or final report to be considered satisfactory, it must demonstrate meaningful progress against the targets or milestones for that investment period. If meaningful progress has not been made, <font style="letter-spacing:0.2pt;">the </font>report should explain why not and what adjustments You are making to get back on track. Please notify the Foundation&#8217;s Primary Contact if You need to add or modify any targets or milestones. The Foundation must approve any such changes in writing. You agree to submit other reports the Foundation may reasonably request.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ACCOUNTING FOR PERSONNEL TIME</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will track the time of all employees, contingent workers, and any other individuals whose compensation will be paid in whole or in part by Grant Funds. Such individuals will keep records (e.g., timesheets) of actual time worked on the Project in increments of sixty minutes or less and brief descriptions of tasks performed. The Foundation acknowledges that You have offered the Foundation the opportunity to review copies of the records maintained by such individuals for work on the Project through June&#160;30, 2018, and the Foundation agrees that the descriptions of tasks performed in such records comply with the foregoing requirements. You will report actual time worked consistent with those records in Your progress and final budget reports. You will submit copies of such records to the Foundation upon request.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:12pt;">
<td colspan="5" valign="top"  style="width:100%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">REPORTING &amp; PAYMENT SCHEDULE</p></td>
</tr>
<tr style="height:35.05pt;">
<td valign="top"  style="width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Investment</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Period</p></td>
<td valign="middle"  style="width:31.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Target, Milestone, or Reporting</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Deliverable</p></td>
<td valign="middle"  style="width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Due By</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:16.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Payment Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:22.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:22.45pt;;text-indent:-22.45pt;;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">Payment Amount</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:22.45pt;;text-indent:-22.45pt;;font-style:italic;font-size:10pt;font-family:Arial;font-weight:normal;text-transform:none;font-variant: normal;">(U.S.$)</p></td>
</tr>
<tr style="height:46.45pt;">
<td valign="top"  BGCOLOR="#D9D9D9" style="width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Countersigned Agreement</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:16.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;margin-right:1.19%;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within [**] days</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;margin-right:1.19%;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after receipt of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;margin-right:1.19%;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">countersigned</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:6.55pt;;margin-right:1.19%;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement</p></td>
<td valign="top"  style="width:22.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.99%;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,137,292.00</p></td>
</tr>
<tr style="height:35.05pt;">
<td valign="top"  style="width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;margin-right:1.79%;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Start Date to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;margin-right:1.79%;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">End Date</p></td>
<td valign="top"  style="width:31.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:5.15pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Final Report</p></td>
<td valign="top"  style="width:14.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:9.35pt;;margin-right:1.79%;text-indent:-0.1pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within [**]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:9.35pt;;margin-right:1.79%;text-indent:-0.1pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">days of<font style="letter-spacing:-0.25pt;"> </font>End</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:9.35pt;;margin-right:1.79%;text-indent:-0.1pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:16.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#D9D9D9" style="width:22.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:12pt;">
<td colspan="4" valign="top"  style="width:77.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.99%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total Grant Amount</p></td>
<td valign="top"  style="width:22.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.99%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">$1,137,292.00</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 of 22</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="GRANT_AGREEMENT_Investment_ID_OPP1189138"></a><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">GRANT AGREEMENT</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment ID OPP1189138</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ATTACHMENT B</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TERMS &amp; CONDITIONS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement is subject to the following terms and conditions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#C0C0C0" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;PROJECT SUPPORT</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">PROJECT DESCRIPTION AND CHARITABLE PURPOSE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foundation is awarding You this grant to carry out the project described in the Proposal Narrative and Results Framework and Tracker (collectively, &#8220;<font style="font-style:italic;">Project</font>&#8221;) in order to further the Charitable Purpose. The Foundation, in its discretion, may approve in writing any request by You to make non-material changes to the Proposal Narrative and/or Results Framework and Tracker.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#C0C0C0" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;MANAGEMENT OF FUNDS</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">USE OF FUNDS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may not use funds provided under the Agreement (&#8220;Grant Funds&#8221;) for any purpose other than the Project. You may not use Grant Funds to reimburse any expenses You incurred prior to the Start Date; provided, however, that the Foundation hereby approves using Grant Funds to reimburse expenses specifically included in the Budget incurred by You prior to the Start Date. At the Foundation&#8217;s request, You will repay any portion of Grant Funds and/or Income that the Foundation determines in its discretion was used or committed in material breach of this Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">INVESTMENT OF FUNDS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You must invest Grant Funds in highly liquid investments with the primary objective of preservation of principal (e.g., interest-bearing bank accounts or a registered money market mutual fund) so that the Grant Funds are available for the Project. Together with any progress or final reports required under this Agreement, You must report the amount of any currency conversion gains (or losses) and the amount of any interest, or other income generated by the Grant Funds (collectively, <font style="font-style:italic;">&#8220;Income&#8221;</font>). Any Income must be used for the Project.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SEGREGATION OF FUNDS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You must maintain Grant Funds in a physically separate bank or a separate bookkeeping account maintained as part of Your financial records and dedicated to the Project.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#C0C0C0" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;GLOBAL ACCESS</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">GLOBAL ACCESS COMMITMENT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will conduct and manage the Project and the Funded Developments in a manner that ensures Global Access. Your Global Access commitments will survive the term of this Agreement. &#8220;<font style="font-style:italic;">Funded Developments</font>&#8221; means the products, services, processes, technologies, materials, software, data, other innovations, and intellectual property resulting from the Project (including modifications, improvements, and further developments to Background Technology). &#8220;<font style="font-style:italic;">Background Technology</font>&#8221; means any and all products, services, processes, technologies, materials, software, data, or other innovations, and intellectual property created by You or a third party prior to or outside of the Project used as part of the Project. &#8220;<font style="font-style:italic;">Global Access</font>&#8221; means: (a) the knowledge and information gained from the Project will be promptly and broadly disseminated; and (b) the Funded Developments will be made available and accessible at an affordable price (i) to people most in need within Developing Countries, or (ii) in support of the U.S. educational system and public libraries, as applicable to the Project. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>To further define Your Global Access commitments, You will work with the Foundation to develop, by the time of completion of Phase&#160;II clinical trials, and execute a manufacturing and supply plan that will enable to be met the reasonably expected demand in Developing Countries for any Products (defined below).&nbsp;&nbsp;The expected demand will be determined by the Foundation and You based upon review of the Foundation&#8217;s target markets for the applicable product and other relevant considerations, including cost-effectiveness.&nbsp;&nbsp;The price of the relevant Products in Developing Countries will be such that the Products are affordable to low income individuals in the Developing Countries, and in no case would the price charged by You to the relevant procurer or distributor of such Products exceed Actual Production Costs (defined below) plus 10%.&nbsp;&nbsp;For clarity, You will </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4 of 22</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in no event be required to offer the applicable Product to a procurer or distributor at a price that would be less than Actual Production Costs.&nbsp;&nbsp;The manufacturing and supply plan could involve the use of manufacturing partners and support from donors, and the specific level and allocation of funding responsibilities in such plan will be decided as mutually agreed in good faith in writing by the parties based on a fair allocation of the expected benefits between Developing Countries and developed countries.&nbsp;&nbsp;The Foundation will have the right to inspect Your records to verify the Actual Production Costs.&nbsp;&nbsp;These commitments do not apply to sales of Products used outside of the Developing Countries.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of the preceding paragraph, &#8220;<font style="font-style:italic;">Product</font>&#8221; means any anti-respiratory syncytial virus (RSV) monoclonal antibody (mAb) optimized by You or on Your behalf in the course and as a result of performance of the Project (as any such optimized anti-RSV mAb may be further optimized by You or on Your behalf after completion of the Project); and &#8220;<font style="font-style:italic;">Actual Production Costs</font>&#8221; means, with respect to a Product, (a)&#160;Your recognized cost of goods sold as calculated in accordance with Your usual and customary accounting methods, which are in accordance with GAAP, minus (b)&#160;the amount of any funding provided by the Foundation or any Foundation-supported Entity directly allocable to the production, supply and distribution of such Product (except to the extent such funding has been deducted from the cost of goods sold as calculated under the foregoing clause&#160;(a)). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">LICENSE TO THE FOUNDATION</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purpose of achieving Global Access, You grant the Foundation a nonexclusive, perpetual, irrevocable, worldwide, royalty-free, fully paid up, sublicensable license to: make, use, sell, offer to sell, import, distribute, copy, modify, create derivative works, publicly perform and display the Funded Developments, and any Background Technology incorporated into a Funded Development or required to use a Funded Development; in each case, for the sole benefit of people in Developing Countries.  You and the Foundation agree and acknowledge that the license granted in this section does not include the right to sell Funded Developments for end use outside of the Developing Countries and that no such sales are authorized under this license.&nbsp;&nbsp;In the event You demonstrate to the satisfaction of the Foundation that Global Access can best be achieved without such a license (or a license of different scope) such as by the provision of a Global Access Strategy satisfactory to the Foundation, the Foundation and You will make good faith efforts to modify or terminate this license, as appropriate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">PUBLICATION</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with Your Global Access commitments, if the Project description specifies Publication or Publication is otherwise requested by the Foundation, You will seek prompt Publication of any Funded Developments consisting of data and results. &#8220;<font style="font-style:italic;">Publication</font>&#8221; means publication in a peer-reviewed journal or other method of public dissemination specified in the Project description or otherwise approved by the Foundation in writing. Publication may be delayed for a reasonable period for the sole purpose of seeking patent protection, provided the patent application is drafted, filed, and managed in a manner that best furthers Global Access. If You seek Publication in a peer-reviewed journal, such Publication shall be under &#8220;open access&#8221; terms and conditions consistent with the Foundation&#8217;s Open Access Policy available at: <font style="text-decoration:underline;color:#0000FF;">www.gatesfoundation.org/How-We-Work/General-Information/Open-Access-Policy</font>, which may be modified from time to time. Nothing in this section shall be construed as requiring Publication in contravention of any applicable ethical, legal, or regulatory requirements. You will mark any Publication of any Funded Development subject to this clause with the appropriate notice or attribution, including author, date and copyright (<font style="font-style:italic;">e.g.</font>,&nbsp;&nbsp;&#169; <font style="letter-spacing:2.7pt;"> </font>20&lt;&gt; &lt;Name&gt;).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">INTELLECTUAL PROPERTY REPORTING</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of this Agreement and for 5 years after, You will submit upon request annual intellectual property reports related to the Funded Developments, Background Technology, and any related agreements using the Foundation&#8217;s templates or forms, which the Foundation may modify from time to time.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">DATA ACCESS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>The Foundation believes the requirement that the knowledge and information gained from the Project be promptly and broadly disseminated extends to data and datasets generated through the Project. During the term of this Agreement, You will make cleaned datasets available to the Foundation upon request within a reasonable period of time after they are generated, and for internal Foundation use only. Following the End Date, You will make all cleaned datasets available to the Foundation, upon request and for internal Foundation use only.  Unless otherwise agreed with the Foundation, You will make all data generated under the Project available to the public in a manner and under conditions mutually agreed to in good faith between You and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 of 22</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Foundation.</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Public dissemination of data and datasets may be delayed for a reasonable period for the sole purpose of seeking patent protection, provided the patent application is drafted, filed, and managed in a manner that best furthers Global Access</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">othing in this section shall be construed as requiring the dissemination or release of data in contravention of any applicable ethical, legal, or regulatory requirements.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#C0C0C0" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;SUBGRANTS AND SUBCONTRACTS</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SUBGRANTS AND SUBCONTRACTS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may not make subgrants under this Agreement. You have the exclusive right to select subcontractors to assist with the Project.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">RESPONSIBILITY FOR OTHERS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You are responsible for (a) all acts and omissions of any of Your trustees, directors, officers, employees, subgrantees, subcontractors, contingent workers, agents, and affiliates assisting with the Project, and (b) ensuring their compliance with the terms of this Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#C0C0C0" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;PROHIBITED ACTIVITIES</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ANTI-TERRORISM</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will not use funds provided under this Agreement, directly or indirectly, in support of activities (a) prohibited by U.S. laws relating to combating terrorism; (b) with persons on the List of Specially Designated Nationals (<font style="text-decoration:underline;color:#0000FF;">www.treasury.gov/sdn</font>) or entities owned or controlled by such persons; or (c) in or with countries or territories against which the U.S. maintains comprehensive sanctions (currently, Cuba, Iran, Syria, North Korea, and the Crimea Region of Ukraine), including paying or reimbursing the expenses of persons from such countries or territories, unless such activities are fully authorized by the U.S.&nbsp;&nbsp;government under applicable law and specifically approved by the Foundation in its sole<font style="letter-spacing:-1.6pt;"> </font>discretion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ANTI-CORRUPTION; ANTI-BRIBERY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will not offer or provide money, gifts, or any other things of value directly or indirectly to anyone in order to improperly influence any act or decision relating to the Foundation or the Project, including by assisting any party to secure an improper advantage. Training and information on compliance with these requirements are available at<font style="letter-spacing:-0.65pt;"> </font><font style="text-decoration:underline;color:#0000FF;">www.learnfoundationlaw.org</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">POLITICAL ACTIVITY AND ADVOCACY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may not use Grant Funds to influence the outcome of any election for public office or to carry on any voter registration drive. You may not use Grant Funds to support lobbying activity or to otherwise support attempts to influence local, state, federal, or foreign legislation. Your strategies and activities, and any materials produced with Grant Funds, must comply with applicable local, state, federal, or foreign lobbying law. You agree to comply with lobbying, gift, and ethics rules applicable to the Project.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#C0C0C0" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;PUBLICITY</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">PUBLICITY BY THE FOUNDATION</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foundation may include information about the award of this grant, including Your name, in its periodic public reports and may make such information available on its website and as part of press releases, public reports, speeches, newsletters, tax returns, and other public disclosures.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">PUBLICITY BY YOU</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You must obtain the Foundation&#8217;s prior written approval before: (a) issuing a press release or other public announcement regarding this grant; and (b) any other public use of the Foundation&#8217;s name or logo. Please email Your request to: <font style="text-decoration:underline;color:#0000FF;">grantee.comms@gatesfoundation.org </font>two weeks in advance to provide the Foundation an opportunity to review and comment. Detailed guidelines are available at: <font style="text-decoration:underline;color:#0000FF;">www.gatesfoundation.org/grantseeker/documents/guidelines_communications_for_grantees.doc</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">PUBLICITY BY OTHERS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You and Your subgrantees, subcontractors, contingent workers, agents, or affiliates may not state or otherwise imply to third parties that the Foundation directly funds or otherwise endorses their activities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 of 22</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#C0C0C0" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;OTHER</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">LEGAL ENTITY AND AUTHORITY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You confirm that: (a) You are an entity duly organized or formed, qualified to do business, and in good standing under the laws of the jurisdiction in which You are organized or formed; (b) You are not an individual (i.e., a natural person) or a disregarded entity (e.g., a sole proprietor or sole-owner entity) under law; (c) You have the right to enter into and fully perform this Agreement; and (d) Your performance will not violate any agreement or obligation between You and any third party. You will <font style="letter-spacing:0.1pt;">notify </font>the Foundation immediately if any of this changes during the term of this<font style="letter-spacing:-0.85pt;"> </font>Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">COMPLIANCE WITH LAWS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In carrying out the Project, You will comply with all applicable laws, regulations, and rules and will not infringe, misappropriate, or violate the intellectual property, privacy, or publicity rights of any third party.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">COMPLIANCE WITH REQUIREMENTS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will conduct, control, manage, and monitor the Project in compliance with all applicable ethical, legal, regulatory, and safety requirements, including applicable international, national, local, and institutional standards (&#8220;<font style="font-style:italic;">Requirements</font>&#8221;). You will obtain and maintain all necessary approvals, consents, and reviews before conducting the applicable activity. As a part of Your annual progress report to the Foundation, You must report whether the Project activities were conducted in compliance with all Requirements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Project involves:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">any protected information (including personally identifiable, protected health, or third-party confidential), You will not disclose this information to the Foundation without obtaining the Foundation&#8217;s prior written approval and all necessary consents to disclose such information;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">children or vulnerable subjects, You will obtain any necessary consents and approvals unique to these subjects; and/or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:10pt;">any trial involving human subjects, You will adhere to current Good Clinical Practice as defined by the International Council on Harmonisation (ICH) E-6 Standards (or local regulations if more stringent) and will obtain applicable trial insurance.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any activities by the Foundation in reviewing documents and providing input or funding does not modify Your responsibility for determining and complying with all Requirements for the Project.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">RELIANCE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You acknowledge that the Foundation is relying on the information You provide in reports and during the course of any due diligence conducted prior to the Start Date and during the term of this Agreement. You represent that the Foundation may continue to rely on this information and on any additional information You provide regarding activities, progress, and Funded Developments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">INDEMNIFICATION</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Project involves clinical trials, trials involving human subjects, post-approval studies, field trials involving genetically modified organisms, experimental medicine, or the provision of medical/health&nbsp;&nbsp;services (&#8220;<font style="font-style:italic;">Indemnified Activities</font>&#8221;), You will indemnify, defend, and hold harmless the Foundation and its trustees, employees, and agents (&#8220;<font style="font-style:italic;">Indemnified Parties</font>&#8221;) from and against any and all demands, claims, actions, suits, losses, damages (including property damage, bodily injury, and wrongful death), arbitration and legal proceedings, judgments, settlements, or costs or expenses (including reasonable attorneys&#8217; fees and expenses) (collectively, &#8220;<font style="font-style:italic;">Claims</font>&#8221;) arising out of or relating to the acts or omissions, actual or alleged, of You or Your employees, subgrantees, subcontractors, contingent workers, agents, and affiliates with respect to the Indemnified Activities. You agree that any activities by the Foundation in connection with the Project, such as its review or proposal of suggested modifications to the Project, will not modify or waive&nbsp;&nbsp;the Foundation&#8217;s rights under this paragraph. An Indemnified Party may, at its own expense, employ separate counsel to monitor and participate in the defense of any Claim. Your indemnification obligations are limited to the extent permitted or precluded under applicable federal, state or local laws, including federal or state tort claims acts, the Federal Anti-Deficiency Act, state governmental immunity acts, or state constitutions. Nothing in this Agreement will constitute an express or implied waiver of Your governmental and sovereign immunities, if<font style="letter-spacing:-0.75pt;"> </font>any.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">INSURANCE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>You will maintain insurance coverage sufficient to cover the activities, risks, and potential omissions of the </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 of 22</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Project in accordance with generally-accepted industry standards and as required by law. You will ensure Your subgrantees and subcontractors maintain insurance coverage consistent with this section.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#C0C0C0" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;TERM AND TERMINATION</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">TERM</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement commences on the Start Date and continues until the End Date, unless terminated earlier as provided in this Agreement. The Foundation, in its discretion, may approve in writing any request by You for a no-cost extension, including amending the End Date and adjusting any affected reporting requirements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">TERMINATION</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foundation may modify, suspend, or discontinue any payment of Grant Funds or terminate this Agreement if: (a) the Foundation is not reasonably satisfied with Your progress on the Project; (b) there are significant changes to Your leadership or other factors that the Foundation reasonably believes may threaten the Project&#8217;s success; (c) there is a change in Your control; (d) there is a change in Your tax status; or (e) You fail to comply with this<font style="letter-spacing:-0.8pt;"> </font>Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">RETURN OF FUNDS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any Grant Funds, plus any Income, that have not been used for, or committed to, the Project upon expiration or termination of this Agreement, must be returned promptly to the Foundation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">MONITORING, REVIEW, AND AUDIT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foundation may monitor and review Your use of the Grant Funds, performance of the Project, and compliance with this Agreement, which may include onsite visits to assess Your organization&#8217;s governance, management and operations, discuss the Project and Your finances, and review relevant financial and other records and materials. In addition, the Foundation may conduct audits, including onsite audits, at any time during the term of this Agreement, and within four years after Grant Funds have been fully spent. Any onsite visit or audit shall be conducted at the Foundation&#8217;s expense, following reasonable prior written notice, during normal business hours, and no more than once during any 12-month period.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">INTERNAL OR THIRD PARTY AUDIT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If during the term of this Agreement You are audited by your internal audit department or by a third party and such audit identifies any deficiencies relevant to the management of the Project, You will provide the audit report to the Foundation upon request, including the management letter and a detailed plan for remedying any deficiencies observed (&#8220;<font style="font-style:italic;">Remediation Plan</font>&#8221;), as relevant to the management of the Project. The Remediation Plan must include (a) details of actions You will take to correct any deficiencies observed, and (b) target dates for successful completion of the actions to correct the deficiencies; in each case, as relevant to the management of the Project.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">RECORD KEEPING</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You will maintain complete and accurate accounting records regarding Your use of the Grant Funds and copies of any reports submitted to the Foundation relating to the Project. You will retain such records and reports for 4 years after Grant Funds have been fully spent. At the Foundation&#8217;s request, You will make such records and reports available to enable the Foundation to monitor and evaluate how Grant Funds have been used or committed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SURVIVAL</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Party&#8217;s obligations under this Agreement will be continuous and survive expiration or termination of this Agreement as expressly provided in this Agreement or otherwise required by law or intended by their nature.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#C0C0C0" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;GENERAL</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ENTIRE AGREEMENT AND AMENDMENTS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement contains the entire agreement of the Parties and supersedes all prior and contemporaneous agreements concerning its subject matter. Except as specifically permitted in this Agreement, no modification, amendment, or waiver of any provision of this Agreement will be effective unless in writing and signed by authorized representatives of both Parties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">NOTICES AND APPROVALS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>Written notices, requests, and approvals under this Agreement must be delivered by mail or email to the other </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8 of 22</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Party</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s primary contact specified on the Agreement Summary &amp; Signature Page, or as otherwise directed by the other Party.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">SEVERABILITY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each provision of this Agreement must be interpreted in a way that is enforceable under applicable law. If any provision is held unenforceable, the rest of the Agreement will remain in effect.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">ASSIGNMENT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You may not assign, or transfer by operation of law or court order, any of Your rights or obligations under this Agreement without the Foundation&#8217;s prior written approval. This Agreement will bind and benefit any permitted successors and assigns.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">COUNTERPARTS AND ELECTRONIC SIGNATURES</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.76%;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as may be prohibited by applicable law or regulation, this Agreement and any amendment may be signed in counterparts, by facsimile, PDF, or other electronic means, each of which will be deemed an original and all of which when taken together will constitute one agreement. Facsimile and electronic signatures will be binding for all purposes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9 of 22</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="text-decoration:underline;">ATTA</font><font style="text-decoration:underline;">CHMENT </font><font style="text-decoration:underline;">C</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEVELOPING COUNTRIES</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Developing Countries</font>&#8221; means the following list of countries, which includes (i) countries eligible for GAVI support as of 2016, (ii) countries in the process of transitioning out of GAVI support in 2016, and (iii) Botswana, Brazil, Philippines, South Africa and Thailand. &#8220;<font style="font-weight:bold;">Developing Countries</font>&#8221; also means any countries reasonably requested by the Foundation that are part of the Foundation&#8217;s strategies to which the Company consents in writing, such consent not to be unreasonably withheld and subject to the consent of Adimab, as applicable. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Afghanistan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guinea</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pakistan</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Angola</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guinea Bissau</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Philippines</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Armenia</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guyana</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Papua New Guinea</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Azerbaijan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Haiti</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rwanda</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bangladesh</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">India</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S&#227;o Tom&#233; e Pr&#237;ncipe</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benin</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indonesia</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senegal</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bolivia</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kenya</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sierra Leone</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Botswana</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kiribati</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Solomon Islands</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Burkina Faso</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Korea, DPR</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Somalia</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Burundi</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kyrgyz Republic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Republic of Sudan</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cambodia</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lao PDR</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">South Africa</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cameroon</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesotho</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">South Sudan</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Central African Republic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liberia</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tajikistan</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chad</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Madagascar</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tanzania, United Republic of</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comoros</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Malawi</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thailand</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Congo,Dem Republic of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mali</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Timor Leste</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C&#244;te d&#8217;Ivoire</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mauritania</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Togo</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cuba</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moldova</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uganda</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Djibouti</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mozambique</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uzbekistan</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eritrea</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Myanmar</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vietnam</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ethiopia</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nepal</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yemen</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gambia</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nicaragua</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zambia</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Georgia</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Niger</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Zimbabwe</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.4%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ghana</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nigeria</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.42%;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 of 22</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gnhmo5dgyo1b000002.jpg" title="" alt="" style="width:144px;height:29px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#595959;font-size:20pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-weight:bold;color:#595959;font-size:20pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Grant Proposal Narrative</font></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#808080;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">We appreciate your interest in submitting a proposal to the Bill &amp; Melinda Gates Foundation and we thank you for working with us throughout the proposal process. Your designated foundation contact will continue to work collaboratively with you as you prepare your proposal to help you understand the connection between the foundation's relevant program strategy and the proposed project, as well as to respond to any questions you might have over the course of this process. You are encouraged to communicate with your program officer to make sure that your efforts are aligned with the proposal requirements and that you are not expending unnecessary time or energy in this process.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#808080;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Answer all of the questions in this Proposal Narrative template and submit it to your foundation program officer for review and collaborative discussion. Due to tax, legal, and reporting requirements, all proposals must be submitted in English. The proposal must be submitted in Word, as PDFs will not be accepted. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#808080;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This is a proposal shaping document and not a commitment by the foundation to fund the work.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td colspan="4" valign="middle"  BGCOLOR="#8CB7C7" style="width:100%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">General Information</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Proposal Title</p></td>
<td colspan="3" valign="middle"  BGCOLOR="#E7E6E6" style="width:75.6%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Respiratory Syncytial Virus (RSV) Program: Optimization Proposal</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Requested Amount (U.S.$)</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,137,292</p></td>
<td rowspan="2" valign="top"  style="width:17.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Investment Duration (Months)</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Total Project Cost (U.S.$)</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,137,292</p></td>
<td valign="middle"  style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Opportunity ID</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OPP1189138</p></td>
<td colspan="2" valign="top"  style="width:47.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:18pt;">
<td colspan="4" valign="middle"  BGCOLOR="#8CB7C7" style="width:100%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Prospective Grantee Information</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Organization Legal Name<sup style="font-size:85%; vertical-align:top">1</sup></p></td>
<td colspan="3" valign="middle"  BGCOLOR="#E7E6E6" style="width:75.6%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis, Inc.</p></td>
</tr>
<tr style="height:12.6pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Organization Doing Business as</p></td>
<td colspan="3" valign="middle"  BGCOLOR="#E7E6E6" style="width:75.6%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact Name</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:47.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Mailing Address</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact Title</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:17.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Street Address 1</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">890 Winter Street</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact Email</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:17.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Street Address 2</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite 230</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact Phone</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:17.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Street Address 3</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Feedback Contact<sup style="font-size:85%; vertical-align:top">2</sup></p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:17.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; City</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Waltham</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Feedback Email<sup style="font-size:85%; vertical-align:top">2</sup></p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:17.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; State / Province</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Massachusetts</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Authorized Signer Name</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mike Gray</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:17.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Zip / Postal Code</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02451-1472</p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Authorized Signer Title</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFO and CBO</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:17.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Country</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Authorized Signer Email</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mike.gray@arsanis.com</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:47.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Website <font style="font-weight:normal;">(if applicable)</font></p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">www.arsanis.com</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:47.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.9pt;">
<td colspan="4" valign="top"  BGCOLOR="#FFFFFF" style="width:100%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">1 </sup><font style="font-weight:normal;">Legal Name</font> <font style="font-weight:normal;">will be used in the agreement and should match the name on the bank account that receives the grant funds (assuming fully executed agreement).</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:7pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">2 </sup><font style="font-weight:normal;">Feedback Contact/Email: The full name and email of the contact whom foundation staff queries for various surveys.</font></p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Tax Status <font style="font-weight:normal;">(if known and applicable) </font></p>
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:6.5pt;;text-indent:0pt;;color:#808080;font-size:7pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to <font style="text-decoration:underline;color:#5291A8;">Tax Status Definitions</font> </p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Exempt Organization - C Corporation</p></td>
<td rowspan="2" valign="top"  BGCOLOR="#FFFFFF" style="width:17.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Organization&#8217;s Total Revenue for Most Recent Audited Financial Year (U.S.$)</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0</p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">U.S. Employer Identification Number (EIN) <font style="font-weight:normal;">(if applicable)</font></p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27-3181608</p></td>
<td valign="middle"  style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:18pt;">
<td colspan="4" valign="middle"  BGCOLOR="#8CB7C7" style="width:100%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Submission Information </p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Date Submitted</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 April, 2018 </p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:17.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Submitted by same as above</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes</p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Submitted by Contact Name</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:17.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Submitted by Contact Email</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:24.4%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Submitted by Contact Title</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:28.42%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:17.18%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Submitted by Contact Phone</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.1%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 11</a> of 22</p></td>
<td valign="bottom"  style="width:41.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#169; 2016 Bill &amp; Melinda Gates Foundation</p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker &#8211; Short Form 3/31/16</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#595959;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-weight:bold;color:#595959;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Proposal Details</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#808080;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The Foundation is prohibited from conducting or funding any lobbying or political campaign activities, as these terms are specifically defined under U.S. tax law. Unlike many of our grantees/vendors who may engage in limited lobbying, the Foundation cannot lobby or fund any lobbying activities carried out by its grantees/vendors. We request that you please review the information at the following link: <font style="text-decoration:underline;color:#5291A8;">Foundation Funds and Advocacy</font>, to assess whether any of your proposed activities may constitute lobbying as defined by the IRS. If so, you should revise your proposal accordingly prior to submission.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1.Executive Summary</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Provide a brief summary of the investment.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#ED7D31;font-family:Arial Bold;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Program Vision</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis endeavors to collaborate with the Bill &amp; Melinda Gates Foundation (BMGF) to develop and commercialize a safe, effective, globally-accessible parenteral monoclonal antibody product for the prevention of respiratory syncytial virus (RSV) infection in all newborns and potentially adults who could benefit from prophylactic intervention. Our guiding principles for this program will support BMGF&#8217;s Global Access commitments for an RSV monoclonal antibody (mAb).</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Arsanis team is deeply experienced in the research, development, and commercialization of infectious disease products (including RSV therapeutics) and mAbs, and as such is an attractive partner for BMGF&#8217;s RSV initiatives.</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Describe the charitable purpose of this work by completing the statement &#8220;This grant will be used [to &#8230;].&#8221; <font style="font-weight:normal;">Please limit to one sentence, begin with &#8220;to&#8221; and do not include a period at the end. Example: &#8220;This grant will be used [to fund new schools and assist other organizations in the design of new schools]&#8221;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further develop a safe, effective, potent, highly manufacturable, and durable monoclonal antibody for the prevention of respiratory syncytial virus infection.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2.Problem Statement</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Describe the problem, why it is a problem, and who is impacted by the problem. What specific elements of the problem is this investment trying to address?</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The only product approved for the prevention of RSV infection is MedImmune&#8217;s Synagis<sup style="font-size:85%; vertical-align:top">&#174;</sup> (palivizumab), a humanized mAb (IgG) directed against the RSV glycoprotein F. While effective in reducing RSV hospitalization rate in high-risk neonates, the global availability of Synagis is highly-restricted in developed countries and absent in the developing world for a variety of reasons including cost, dosing regimen, manufacturing capacity, and product stability.&nbsp;&nbsp;This is a critical problem in the developing world, where RSV is responsible for over 30 million cases of acute lower respiratory infection and 200,000 deaths per year.</p>
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development of a safe, effective, and globally-accessible product for the prevention of RSV infection has proven to be elusive over the years. Only one mAb product candidate is in clinical development, MEDI8897 (MedImmune), an anti-RSV mAb that targets glycoprotein F, which has the potential to show higher efficacy, and be administered by a more convenient dosing regimen than is currently the case with Synagis.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">3.Scope and Approach </p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Describe the scope and approach of the proposed work. This should be a narrative description of the principal results the investment would achieve and how those results relate to the problem described above (rather than a list of outcomes and outputs.) <font style="font-weight:normal;">Note: You will provide a list of outcomes and outputs in the Results Framework.</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 4 pages were omitted. [**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">4.Risk Mitigation</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">As needed, describe any significant risks to the success of this project and how you plan to address them.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.1%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 12</a> of 22</p></td>
<td valign="bottom"  style="width:41.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#169; 2016 Bill &amp; Melinda Gates Foundation</p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker &#8211; Short Form 3/31/16</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">5.</font><font style="font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">How We&#8217;ll Work Together</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">This question is intended to begin the dialogue on how foundation staff would work with you to achieve the intended outcomes. Topics could include minimal staff support, any specific issues that would likely need on-going discussion, regular communications, or other information to help establish mutual expectations and assist with implementing the proposed work.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Team meetings planned for [**]. Additional ad hoc teleconferences and email communication as needed.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">6.Geographic Areas to Be Served</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">List all countries and sub-regions/states that would benefit from this work and associated dollar amounts. If areas to be served include the United States, indicate city and state. <font style="font-weight:normal;">Add more rows as needed. More information about Geographic Areas to Be Served can be found </font><font style="text-decoration:underline;color:#5291A8;font-weight:normal;">here</font><font style="font-weight:normal;">.</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Location</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Foundation Funding (U.S.$)</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">World</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,137,292</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">7.Geographic Location of Work</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">List all countries and sub-regions/states where this work would be performed and associated dollar amounts. If location of work includes the United States, indicate city and state. <font style="font-weight:normal;">Add more rows as needed. More information about Geographic Location of Work can be found</font> <font style="text-decoration:underline;color:#5291A8;font-weight:normal;">here</font><font style="font-weight:normal;">.</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Location</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Foundation Funding (U.S.$) (DIRECT COST ONLY)</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:49.88%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:50.12%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">8.Global Access and Open Access</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">In order to establish that the projects we fund are charitable and will have a positive impact on the intended beneficiaries of our work, the foundation requires the projects it funds be conducted and managed in a manner that ensures Global Access and Open Access. </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.25%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>&#8220;Global Access&#8221;<font style="font-weight:normal;"> is a foundation policy requiring that: (a) the knowledge and information gained from the project will be promptly and broadly disseminated; and (b) the Funded Developments will be made available and accessible at an affordable price (i) to people </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.1%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 13 of 22</p></td>
<td valign="bottom"  style="width:41.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#169; 2016 Bill &amp; Melinda Gates Foundation</p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker &#8211; Short Form 3/31/16</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.25%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">most in need within developing countries, or (ii) in support of the U.S. educational system and public libraries, as applicable to the project.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.25%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Funded Developments&#8221;<font style="font-weight:normal;"> means the products, services, processes, technologies, materials, software, data, other innovations, and intellectual property resulting from the project, including modifications, improvements, and further developments to Background Technology. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.25%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Background Technology&#8221;<font style="font-weight:normal;"> means any and all products, services, processes, technologies, materials, software, data, or other innovations, and intellectual property created by You or a third party prior to or outside of the project used as part of the project.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.25%;text-indent:0%;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional information about Global Access (including examples and case studies) can be found at <font style="text-decoration:underline;color:#5291A8;">http://globalaccess.gatesfoundation.org/.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.25%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Open Access&#8221;<font style="font-weight:normal;"> is a foundation policy that sets the requirements, terms and conditions for publication of Funded Developments in a peer-reviewed journal. Additional Information on the foundation&#8217;s Open Access Policy for peer-reviewed publications and underlying data can be found at </font><font style="text-decoration:underline;color:#5291A8;font-weight:normal;">www.gatesfoundation.org/How-We-Work/General-Information/Open-Access-Policy</font><font style="font-weight:normal;">. Note: the foundation will pay directly for reasonable fees to effect publication on &#8220;open access&#8221; terms; such fees should </font><font style="text-decoration:underline;font-weight:normal;">not</font><font style="font-weight:normal;"> be included in the project budget (See the </font><font style="text-decoration:underline;color:#5291A8;font-weight:normal;">Open Access Policy FAQs</font><font style="font-weight:normal;"> for further detail).</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;"><font style="text-decoration:underline;">Knowledge and Information</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:3.25%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Describe how the knowledge and information gained from the project will be promptly and broadly disseminated (including how you will comply with the foundation&#8217;s Open Access Policy, discussed above). </p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96.72%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis will promptly and broadly disseminate the output of Funded Developments in compliance with the Open Access Policy and Arsanis internal policies.&nbsp;&nbsp;Our primary approaches are publication in peer-reviewed journals and presentations (e.g. abstracts, oral sessions) at scientific congresses.&nbsp;&nbsp;In some circumstances, timing of disclosures may be gated by the need to provide for relevant intellectual property protections prior to such disclosures.</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;"><font style="text-decoration:underline;">Funded Developments</font> (Indicate &#8220;not applicable,&#8221; as appropriate)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;color:#808080;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;color:#808080;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;"><font style="font-weight:bold;">Describe</font><font style="color:#000000;"> </font><font style="font-weight:bold;">any Funded Developments that may ultimately result from the project, including any Background Technology that will be used or incorporated in the proposed project. If applicable, briefly explain how the Funded Developments will be made available and accessible at an affordable price to the intended beneficiaries. The use of commonly-available, off-the-shelf products (such as Microsoft Excel, Adobe, etc.) need not be disclosed. </font></p></td></tr></table></div>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96.86%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funded Developments that may ultimately result from the project include:</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-18pt;;text-align:left;font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="font-family:Arial;">Monoclonal antibody (mAb) drug candidates targeting RSV infection</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-18pt;;text-align:left;font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="font-family:Arial;">Pre-clinical data and regulatory filings that support the initiation of human studies of these mAbs</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-18pt;;text-align:left;font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="font-family:Arial;">Manufacturing know-how for the production of GMP mAb drug product</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-18pt;;text-align:left;font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="font-family:Arial;">Intellectual property (including patents and know-how) covering the mAbs</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Background technology that may be incorporated in the project includes:</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-18pt;;text-align:left;font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="font-family:Arial;">Arsanis know-how related to the discovery and optimization of mAbs</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-18pt;;text-align:left;font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="font-family:Arial;">RSV mAb sequences (patents and know-how) that may be in-licensed by Arsanis from Adimab, LLC upon exercise of the Adimab license described below</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:36pt;;text-indent:-18pt;;text-align:left;font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="font-family:Arial;">Technologies (patents and know-how) related to the optimization of RSV mAbs in-licensed by Arsanis from third parties</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Technologies (patents and know-how) related to the manufacture of RSV mAbs in-licensed by Arsanis from third parties</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;color:#808080;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;color:#808080;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;"><font style="font-weight:bold;">Please confirm that you will make the Funded Developments &#8211; including any Background Technology incorporated into or required to use the Funded Developments &#8211; available to achieve the proposed project&#8217;s goals and Global Access. If you foresee any obstacles to achieving Global Access (e.g., third party rights, broad access, time frame, affordability) please briefly summarize the obstacles and the specific steps that you will take to address them.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96.86%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis will make the Funded Developments available to achieve the project&#8217;s goals and Global Access as agreed upon with BMGF.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential obstacles include:</p>
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**].</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">Intellectual Property</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-5.77%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Please indicate which, if any, of the following applies to your project:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">__X__</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">Creation of Funded Developments will likely involve new IP rights (Note: copyrights in works intended to be published in accordance with the Open Access Policy need not be disclosed);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">__X__</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">Use of Background Technology requires access to existing IP rights; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:5.77%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">__X__</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;"><font style="text-decoration:underline;"></font><font style="font-weight:normal;">For-Profit entities are engaged in the project.</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.25%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">If any of the above are present, please complete an<font style="color:#5291A8;"> </font><font style="text-decoration:underline;color:#5291A8;">Intellectual Property (IP) Report</font>:&nbsp;&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.1%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 14</a> of 22</p></td>
<td valign="bottom"  style="width:41.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#169; 2016 Bill &amp; Melinda Gates Foundation</p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker &#8211; Short Form 3/31/16</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.77%;text-indent:0%;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: For login purposes, please use the email address to which this Proposal Narrative was sent. To delegate permissions to another member of your project team, or for any questions regarding the IP Report, please contact </font><font style="text-decoration:underline;color:#5291A8;">GlobalAccess@gatesfoundation.org</font><font style="color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.25%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">If none of the above apply, please acknowledge by typing N/A: <font style="text-decoration:underline;">____</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">9.Advocacy and Lobbying </p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">While the foundation funds a broad range of advocacy activities, US law prohibits foundation funds from being earmarked to support direct or grassroots lobbying communications. Describe how this project will be conducted in compliance with these rules, as summarized in the <font style="text-decoration:underline;color:#5291A8;">Advocacy Guidelines Handout</font>, and any other relevant local, state, or non-US lobbying laws. If foundation grant funds will be earmarked to influence policies, budgets, innovations, frameworks, action plans, etc., that could require a legislative vote, explain how such &#8220;legislative&#8221; activities will be conducted in accordance with the applicable rules and exceptions. Your explanation should address both direct and grassroots communications. If this investment does not include advocacy activities, indicate in the space below.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis will not use Foundation funds for this program to support direct or grassroots lobbying communications. All funds will be used for the project as described in this grant proposal.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">10.Conduct and Control of the Project</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In answering the questions in this section, please consider all Project activities, such as those involving: confidential or protected information (including personally identifiable information or protected health information); the inclusion of children or vulnerable populations; research involving human subjects; clinical trials; post-approval studies; field trials; experimental medicine; provision of medical services (diagnostic, prophylactic or treatment); product development; use of genetically modified organisms, human tissue, animals, radioactive isotopes, pathogenic organisms, recombinant nucleic acids, select agents or toxins (<font style="text-decoration:underline;color:#5291A8;">www.selectagents.gov</font>), dual-use technology (<font style="text-decoration:underline;color:#5291A8;">http://export.gov/regulation/eg_main_018229.asp</font>), or any substance, organism, or material that is toxic or hazardous; use of aircraft, unmanned vehicle systems, drones or satellites; and the import, export, transfer, approvals, consents, records, data, specimens, images, and materials related to any of the forgoing.&#160; &#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">Please confirm that your organization:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.49%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">will maintain the expertise necessary to conduct, control, manage, and monitor all aspects of the Project in compliance with all applicable ethical, legal, regulatory, and safety requirements including applicable international, national, state, local, and institutional, school district or school network standards and policies and is responsible for determining and complying with these requirements and standards;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.49%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">will not disclose any confidential or protected information to the Foundation without obtaining prior written approval from the foundation and all necessary consents to disclose such information; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.49%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">acknowledges that any activities by the Foundation in reviewing documents, providing input or funding does not modify your organization&#8217;s responsibility for determining and complying with all applicable ethical, legal, regulatory, and safety requirements for the Project in all places;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.49%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">is a government agency, public institution or multilateral organization or will otherwise maintain insurance coverage sufficient to cover the activities, risks, and potential omissions of the Project in accordance with generally-accepted standards and as required by law (for instance, general, professional, clinical trial, product liability, medical malpractice, workers' compensation, or otherwise);</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.49%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">e)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">will not transfer any biological materials, chemicals, reagents, hazardous materials or the like to the Foundation. </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.49%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Confirmed <font style="text-decoration:underline;">__X__</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:6.49%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Not confirmed <font style="text-decoration:underline;">____</font> (please explain)</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96.76%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.25%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Complete if you are a Global Health Applicant</font>: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">Does the Project involve any of the following: clinical trial, other trial involving human subjects, post-approval study, experimental medicine, field trial of genetically modified organisms, or the provision of medical/health services?&nbsp;&nbsp;</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.49%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">No <font style="text-decoration:underline;">__X__</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:6.49%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="text-decoration:underline;">____</font> (If yes, please list all approvals and consents required for each site and describe the timeframe in which your organization will acquire the necessary approvals and consents.)</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96.96%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.1%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 15</a> of 22</p></td>
<td valign="bottom"  style="width:41.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#169; 2016 Bill &amp; Melinda Gates Foundation</p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker &#8211; Short Form 3/31/16</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Please </font><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">identify the name of the entity that will be the sponsor/responsible party of any clinical trials, studies involving human subjects, experimental medicine studies, post-approval studies, products, or regulatory filings contemplated by the Project.&#160; Note that the Foundation will not serve as the sponsor/responsible party nor accept delegation of any of these responsibilities. If the Project will not involve such activities, please indicate not applicable or N/A below</font><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td></tr></table></div>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96.7%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;text-align:left;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis, Inc.</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.25%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Complete if you are a U.S. Program Applicant</font>: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">&nbsp;</p></td>
<td valign="top" style="width:3.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#808080;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:9pt;">Does the Project involve regulated human subject research?&nbsp;&nbsp;</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:6.49%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">No <font style="text-decoration:underline;">__X__</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:6.49%;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="text-decoration:underline;">____</font> (If yes, please identify the name of the entity that will be conducting such research and please describe any consents, approvals or waivers needed or obtained to the extent such are necessary for compliance with applicable law.)</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96.6%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#CE6B29;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Delete this text before sending:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#CE6B29;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">OPTIONAL QUESTIONS (11-21)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#CE6B29;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PO to select which optional questions below (11-21) to include. At a minimum, include any questions identified by the Risk Profile, Investment Development Plan, and GCM/Business Partner feedback. PC to remove questions that are not applicable before sending, but remember the Reporting &amp; Payment Schedule will need to be completed and discussed with grantee prior to sending them the grant agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">11.Data Access</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">We anticipate this investment, if funded, would generate datasets that may be of interest to the foundation and/or to the field if made publicly available.&nbsp;&nbsp;Please describe any datasets that will be generated as part of this investment. Specifically address when and how the datasets would be made available to the foundation and/or to the public, in what form or format, and any anticipated costs to your organization. <font style="font-weight:normal;">Additional information about Data Access can be found </font><font style="text-decoration:underline;color:#5291A8;font-weight:normal;">here</font><font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#595959;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Budget Narrative</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#808080;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The purpose of the budget narrative is to supplement the information provided in the excel-based budget template by justifying how the budget cost elements are necessary to implement project activities and accomplish target outcomes. The budget narrative is a tool to help foundation staff fully understand the budgetary needs of the project and is an opportunity to provide descriptive information about the costs, drivers, and risks that can&#8217;t be easily communicated in the budget template. Together, the budget narrative and budget template should provide a complete quantitative and qualitative description that supports the proposed budget. The description provided in the budget template should be very brief. Please use this budget narrative to provide a thorough description of your budget and only complete questions that are relevant to your grant proposal. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#808080;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">For Global Development, Global Health and Global Policy and Advocacy related grants</font>: If your proposal includes any sub-contracts and/or sub-grants greater than $1 million USD, please complete a separate budget template and narrative for each organization. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#808080;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">For U.S. Programs, Communications and Family Interest related grants</font>: If your proposal includes any sub-contracts and/or sub-grants greater than $250,000 USD, please complete a separate budget template and narrative for each organization.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1.Summary</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Please explain the major cost drivers and how costs relate to planned activities and target outcomes. Also explain any potential risks in spending as budgeted and any plans to mitigate those risks.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">If budgeting by outcomes, or additional dimension, please explain the major cost drivers per outcome or other relevant dimension.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2.Personnel and Benefits</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Personnel</font>: Provide a brief explanation of personnel budgeted, including responsibilities as they relate to the grant. Also include assumptions made for any staff budgeted which are to-be-hired, including salary estimates for these personnel.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.1%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 16</a> of 22</p></td>
<td valign="bottom"  style="width:41.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#169; 2016 Bill &amp; Melinda Gates Foundation</p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker &#8211; Short Form 3/31/16</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</font><font style="color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Benefits</font>: Describe the components of the benefits (column R of the &#8220;Budget Details&#8221; sheet) included with the salary costs. For example: pension, health insurance, expatriate costs, etc.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#222222;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">[**].</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">3.Travel</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Provide rationale for the travel budgeted and assumptions used to determine appropriate number of trips and personnel required. Also include a brief rationale for how travel costs were estimated.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In person meeting with Foundation in [**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">4.Consultants</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Provide a brief description of the work to be performed by consultants in support of the overall project and describe any expenses that have been included.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">5.Capital Equipment</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Provide a brief justification and description of any items required for the project with a unit cost of greater than $5,000 (USD) <font style="text-decoration:underline;">and</font> a useful life of more than one year.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">6.Other Direct Costs</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Provide a brief description and rationale for other direct costs required, including cost assumptions used to develop the budget for these costs.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct costs include [**].</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">7.Sub-awards</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">List all sub-grantees or sub-contractors involved in this investment. <font style="font-weight:normal;">Add more rows as needed.</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18.75pt;">
<td valign="top"  style="width:30.2%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="top"  style="width:32.22%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Corporate Entity Name <font style="font-weight:normal;">(if applicable)</font></p></td>
<td valign="top"  style="width:37.58%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Mailing Address</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top"  style="width:30.2%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:32.22%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:37.58%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top"  style="width:30.2%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:32.22%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:37.58%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top"  style="width:30.2%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:32.22%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:37.58%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top"  style="width:30.2%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:32.22%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:37.58%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top"  style="width:30.2%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:32.22%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:37.58%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top"  style="width:30.2%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:32.22%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:37.58%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:18.75pt;">
<td valign="top"  style="width:30.2%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:32.22%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="middle"  style="width:37.58%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">If separate budgets are required (see above), please also submit a separate budget template and narrative for each sub-award. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.1%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 17</a> of 22</p></td>
<td valign="bottom"  style="width:41.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#169; 2016 Bill &amp; Melinda Gates Foundation</p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker &#8211; Short Form 3/31/16</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Describe the work each organization is going to perform as well as the rationale for each organization chosen to participate on this project as a sub-grantee or sub-contractor. If organizations are TBD, include the assumptions used to estimate cost for the sub-award and the process </font><font style="text-decoration:underline;">and</font><font style="font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> timeline you will be using to select these organizations.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: You will be required to submit the sub-award budget once final.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">8.Indirect Cost Rate</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Briefly explain the indirect cost rate being charged on this project and the rationale and assumptions behind it.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The indirect cost rate applied to this project is [**].</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">9.Currency Exchange</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Briefly describe any foreign currency exchange exposure with this investment. Which costs included in the budget are exposed to exchange risk? How much do these costs total?</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximately $[**].</p>
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">10.Other Sources of Support for this Project</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">If you are requesting funding from the foundation for only a portion of this project and will depend on funds from other sources, please describe your contingency plans if full project funding does not become available. If you have applied for funding from other sources which overlap with the funding requested in this proposal, please indicate the nature and timing of that potential funding. Any expected in-kind contributions (e.g. drug donations, personnel time) should be included in the description. </p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOTE: Names of the other sources and their expected dollar (U.S.$) contributions should be included on the &#8216;Financial Summary &amp; Reporting&#8217; sheet of the budget in the Funding Plan table.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">11.Other</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Please feel free to use this section to provide any other commentary or information that helps to describe and justify the budget request presented. This may include assumptions and rationale behind indirect costs, risks, anomalies or other assumptions foundation staff should be aware of when reviewing the budget.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total project spend incurred in Q1&#8217;18 was approximately $[**]. By category:</p>
<p style="margin-bottom:6pt;margin-top:2pt;margin-left:36pt;;text-indent:-18pt;;font-size:9pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;<font style="color:#404040;font-family:Arial;">[**]</font></p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Privacy and Non-Confidentiality Notice</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foundation is required by the IRS to publish a list of its grants. We may also provide a general description of our grants and contracts on our web sites, in press releases, and in other marketing materials. Subject to the foundation&#8217;s <font style="text-decoration:underline;color:#5291A8;">Privacy Policy</font>, the foundation may also share information you provide to us (either orally or in writing) with third parties, including external reviewers, key partners and co-funders. This document is subject to the foundation&#8217;s <font style="text-decoration:underline;color:#5291A8;">Terms of Use</font>.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.1%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 18</a> of 22</p></td>
<td valign="bottom"  style="width:41.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#169; 2016 Bill &amp; Melinda Gates Foundation</p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker &#8211; Short Form 3/31/16</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#595959;font-size:20pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a><font style="font-weight:bold;color:#595959;font-size:20pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker </font><font style="font-size:14pt;">(Short Form)</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-style:italic;color:#808080;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use this form to capture and report on investment outputs. The Results Framework &amp; Results Tracker will be developed collaboratively by you and your foundation program officer to finalize an agreed upon outputs schedule.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td colspan="4" valign="middle"  BGCOLOR="#8CB7C7" style="width:100%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">General Information</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  style="width:21.2%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Investment Title</p></td>
<td colspan="3" valign="middle"  BGCOLOR="#E7E6E6" style="width:78.8%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Respiratory Syncytial Virus (RSV) Program: Optimization Proposal</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  style="width:21.2%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Program Officer</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:26%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:22.8%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Opportunity/Contract ID</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OPP1189138</p></td>
</tr>
<tr style="height:18pt;">
<td colspan="4" valign="middle"  BGCOLOR="#8CB7C7" style="width:100%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Prospective Grantee Information</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:21.2%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Organization Legal Name</p></td>
<td colspan="3" valign="middle"  BGCOLOR="#E7E6E6" style="width:78.8%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis Inc</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:21.2%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact Name</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:26%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:22.8%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact Email</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:21.2%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact Title</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:26%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:22.8%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Primary Contact Phone</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
<tr style="height:18pt;">
<td colspan="4" valign="middle"  BGCOLOR="#8CB7C7" style="width:100%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Submission Information </p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:21.2%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Date Submitted</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:26%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 April 2018</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:22.8%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Submitted by same as above</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes</p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:21.2%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Submitted by Contact Name</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:26%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:22.8%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Submitted by Contact Email</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:15.9pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="width:21.2%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Submitted by Contact Title</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:26%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:22.8%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0.7pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Submitted by Contact Phone</p></td>
<td valign="middle"  BGCOLOR="#E7E6E6" style="width:30%; border-top:solid 3pt #FFFFFF; border-bottom:solid 3pt #FFFFFF; border-left:solid 3pt #FFFFFF; border-right:solid 3pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:1.62%;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">1.Primary Investment Outcomes</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Define the ultimate or overall change(s) in technologies, systems, populations or behaviors the investment seeks to achieve in the context of the project timeframe; tell us what success is for this investment. <font style="font-weight:normal;">(If section is pre-populated, edit as needed.)</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: Primary investment outcomes may not be applicable for all investments. In these cases, please leave the space below blank.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary investment outcome for the project timeframe is [**]. The long-term objective of the program is the development of a safe, effective, potent, highly manufacturable, and durable monoclonal antibody for the prevention of respiratory syncytial virus infection.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2.Investment Outputs </p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Provide a list of outputs (the goods, services, deliverables, or events produced during an investment) that will be tracked. This is not meant to be an exhaustive list of activities, but rather outputs that inform whether the project is on track. The Foundation and grantee/vendor will determine together which outputs will be tied to payments. <font style="font-weight:normal;">(If section is pre-populated, edit as needed.)</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:11.82%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Output Number</p></td>
<td valign="top"  style="width:40.56%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Output Description</p>
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Assuming a January 1<sup style="font-size:85%; vertical-align:top">st</sup>, 2018 start date</p></td>
<td valign="top"  style="width:16.78%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Target Completion Date</p></td>
<td valign="top"  style="width:16.04%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Actual Completion Date</p></td>
<td valign="top"  style="width:14.8%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Payment Contingency</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:11.82%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top"  style="width:40.56%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:16.78%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:16.04%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.8%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:11.82%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="top"  style="width:40.56%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:16.78%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
<td valign="top"  style="width:16.04%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.8%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:11.82%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top"  style="width:40.56%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:16.78%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:16.04%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.8%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:21.6pt;">
<td valign="top"  style="width:11.82%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="top"  style="width:40.56%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:16.78%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:16.04%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:14.8%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"></table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.1%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 19</a> of 22</p></td>
<td valign="bottom"  style="width:41.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#169; 2016 Bill &amp; Melinda Gates Foundation</p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker &#8211; Short Form 3/31/16</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:18pt;">
<td valign="middle"  BGCOLOR="#8CB7C7" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:-18pt;;font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><font style="font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">3.</font><font style="font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;color:#404040;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Grantee/Vendor Comments</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Use this section to provide comments about the outputs/deliverables above including variances on completion dates, additional context, etc. Be sure to include the date and specific deliverable referred to in the comment.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:21.6pt;">
<td valign="top"  style="width:100%; border-top:solid 1.5pt #D9D9D9; border-bottom:solid 1.5pt #D9D9D9; border-left:solid 1.5pt #D9D9D9; border-right:solid 1.5pt #D9D9D9;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#404040;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[**]</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#808080;font-size:9pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Privacy and Non-Confidentiality Notice<font style="margin-left:36pt;"></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#808080;font-size:9pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foundation is required by the IRS to publish a list of its grants. We may also provide a general description of our grants and contracts on our web sites, in press releases, and in other marketing materials. Subject to the foundation&#8217;s <font style="text-decoration:underline;color:#5291A8;">Privacy Policy</font>, the foundation may also share information you provide to us (either orally or in writing) with third parties, including external reviewers, key partners and co-funders. This document is subject to the foundation&#8217;s <font style="text-decoration:underline;color:#5291A8;">Terms of Use</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.1%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 20</a> of 22</p></td>
<td valign="bottom"  style="width:41.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#169; 2016 Bill &amp; Melinda Gates Foundation</p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker &#8211; Short Form 3/31/16</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><img src="gnhmo5dgyo1b000003.jpg" title="" alt="" style="width:672px;height:608px;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.1%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 21</a> of 22</p></td>
<td valign="bottom"  style="width:41.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#169; 2016 Bill &amp; Melinda Gates Foundation</p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker &#8211; Short Form 3/31/16</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 10 pages were omitted. [**]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:13.1%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Page 22</a> of 22</p></td>
<td valign="bottom"  style="width:41.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#169; 2016 Bill &amp; Melinda Gates Foundation</p></td>
<td valign="bottom"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results Framework and Tracker &#8211; Short Form 3/31/16</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#A6A6A6;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>asns-ex105_184.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
asns-ex105_184.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.5</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORBEARANCE <font style="text-transform:uppercase;">agreement</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Forbearance Agreement (this<font style="font-weight:bold;"> </font>&#8220;<font style="font-weight:bold;">Agreement</font>&#8221;) is entered into this _<font style="text-decoration:underline;">8th</font>_ day of __<font style="text-decoration:underline;">August</font>__, 2018<font style="font-family:Palatino;"> </font>by and between <font style="font-weight:bold;">SILICON VALLEY BANK</font> (&#8220;<font style="font-weight:bold;">Bank</font>&#8221;) and <font style="font-weight:bold;">ARSANIS, INC.</font>, a Delaware corporation (&#8220;<font style="font-weight:bold;">Borrower</font>&#8221;) whose address is 890 Winter Street, Suite 230, Waltham, Massachusetts 02451.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Recitals</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">Bank and Borrower have entered into that certain Loan and Security Agreement dated as of December 7, 2012, as amended by that certain First Amendment to Loan and Security Agreement dated as of February 19, 2016, between Borrower and Bank, and as further amended by that certain Second Amendment to Loan and Security Agreement dated as of August 17, 2016, between Borrower and Bank (as the same may from time to time be further amended, modified, supplemented or restated, the &#8220;</font>Loan Agreement<font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="font-weight:normal;margin-left:36pt;">Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">Borrower has requested that Bank forbear from exercising its rights and remedies with respect to the Stated Default (as defined below).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;">Bank has agreed to so forbear from exercising its rights and remedies with respect to the Stated Default (as defined below), but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Agreement</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Now, Therefore,<font style="font-weight:normal;font-variant: normal;"> in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">1.<font style="margin-left:72pt;"></font><font style="text-transform:none;color:#000000;">Definitions.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;Capitalized terms used but not defined in this Agreement shall have the meanings given to them in the Loan Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>2.<font style="margin-left:72pt;"></font><font style="text-transform:none;color:#000000;">Acknowledgment of Defaults; Forbearance by Bank</font><font style="font-weight:normal;text-transform:none;color:#000000;">.&nbsp;&nbsp;Borrower acknowledges that it is currently in default under the Loan Agreement by (i) its failure to comply with Section 7.1 of the Loan Agreement (with respect to dispositions) by entering into (a) that certain Option and License Agreement by and among Borrower, BB100, LLC and Bravos Biosciences, LLC dated as of March 30, 2018 and (b) that certain Option and License Agreement by and among Borrower, BB200, LLC and Bravos Biosciences, LLC dated as of June 8, 2018 without obtaining the prior written consent of Bank and&nbsp;&nbsp;(ii) its failure to comply with Section 6.2(b) of the Loan Agreement as a result of delivering Compliance Certificates that did not disclose the violation of Section 7.1 of the Loan Agreement ((i) and (ii) collectively, the &#8220;</font><font style="text-transform:none;color:#000000;">Stated Default</font><font style="font-weight:normal;text-transform:none;color:#000000;">&#8221;).&nbsp;&nbsp;As a result of the Stated Default, Bank may, at its option, declare all of the Obligations to be immediately due and payable in full and exercise its other rights and remedies under the Loan Documents and </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;color:#000000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;color:#000000;">applicable law.&nbsp;&nbsp;In consideration of Borrower&#8217;s performance hereunder, Bank hereby agrees to forbear from exercising its rights and remedies with respect to such defaults until the earlier to occur of (i) an Event of Default under the Loan Agreement (other than the Stated Default) or (ii) </font><font style="font-weight:normal;text-transform:none;color:#000000;">October</font><font style="font-weight:normal;text-transform:none;color:#000000;"> 31, 2018.&nbsp;&nbsp;Borrower hereby acknowledges and agrees that except as specifically provided herein, nothing in this section or anywhere in this Agreement shall be deemed or otherwise construed as a waiver by Bank of any of its rights and remedies pursuant to the Loan Documents, applicable law or otherwise.&nbsp;&nbsp;The foregoing waiver shall apply only to the Stated Default and is not intended to be and shall not be construed as a waiver or agreement to waive any other defaults or Events of Default.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="text-transform:none;color:#000000;">Representations and Warranties.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;To induce Bank to enter into this Agreement, Borrower hereby represents and warrants to Bank as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.1<font style="margin-left:108pt;"></font><font style="font-weight:normal;color:#000000;">Immediately after giving effect to this Agreement (a)&#160;the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b)&#160;no Event of Default has occurred and is continuing;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.2<font style="margin-left:108pt;"></font><font style="font-weight:normal;color:#000000;">Borrower has the power and authority to execute and deliver this Agreement and to perform its obligations under the Loan Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.3<font style="margin-left:108pt;"></font><font style="font-weight:normal;color:#000000;">The organizational documents of Borrower delivered to Bank on the 2016 Amendment Date remain true, accurate and complete and have not been amended, supplemented or restated, except for Borrower&#8217;s certificate of incorporation for which a copy was furnished in connection with that certain Second Amendment to Loan and Security Agreement dated as of August 17, 2016, and are and continue to be in full force and effect;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.4<font style="margin-left:108pt;"></font><font style="font-weight:normal;color:#000000;">The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement, have been duly authorized; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.5<font style="margin-left:108pt;"></font><font style="font-weight:normal;color:#000000;">The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement do not and will not contravene (a)&#160;any law or regulation binding on or affecting Borrower, (b)&#160;any contractual restriction with a Person binding on Borrower, (c)&#160;any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d)&#160;the organizational documents of Borrower; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.6<font style="margin-left:108pt;"></font><font style="font-weight:normal;color:#000000;">The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.7</font><font style="margin-left:108pt;"></font><font style="font-weight:normal;color:#000000;">This </font><font style="font-weight:normal;color:#000000;">Agreement</font><font style="font-weight:normal;color:#000000;"> has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&#8217; rights.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">4.<font style="margin-left:72pt;"></font><font style="text-transform:none;color:#000000;">[Reserved]</font><font style="font-weight:normal;text-transform:none;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">5.<font style="margin-left:72pt;"></font><font style="text-transform:none;color:#000000;">No Defenses of Borrower</font><font style="font-weight:normal;text-transform:none;color:#000000;">.&nbsp;&nbsp;In consideration of the foregoing, Borrower hereby acknowledges and agrees that it has no offsets, defenses, causes of action, suits, damages, claims, or counterclaims against Bank, SVB Financial Group, or any of their respective officers, directors, employees, attorneys, representatives, predecessors, successors, and assigns (collectively, the &#8220;</font><font style="text-transform:none;color:#000000;">Bank Released Parties</font><font style="font-weight:normal;text-transform:none;color:#000000;">&#8221;) with respect to the Obligations, the Loan Documents, the Collateral, any Bank Services Agreement, any contracts, promises, commitments, or other agreements to provide, to arrange for, or to obtain loans or other financial accommodations to or for Borrower, or otherwise, and that if Borrower now has, or ever did have, any offsets, defenses, causes of action, suits, damages, claims, or counterclaims against one or more of the Bank Released Parties, at law or in equity, whether known or unknown, from the beginning of the world through this date and through the time of execution of this Agreement (collectively, the &#8220;</font><font style="text-transform:none;color:#000000;">Released Claims</font><font style="font-weight:normal;text-transform:none;color:#000000;">&#8221;) all of them are hereby expressly WAIVED and Borrower hereby RELEASES the Bank Released Parties from any liability therefor.&nbsp;&nbsp;Borrower hereby irrevocably agrees to refrain from directly or indirectly asserting any claim or demand or commencing (or causing to be commenced) any suit, action, arbitration or proceeding of any kind, in any court or before any tribunal or arbiter or arbitration panel, against any Bank Released Party as to any of the Released Claims.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">6.<font style="margin-left:72pt;"></font><font style="text-transform:none;color:#000000;">Integration</font><font style="font-weight:normal;text-transform:none;color:#000000;">.&nbsp;&nbsp;This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.&nbsp;&nbsp;All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">7.<font style="margin-left:72pt;"></font><font style="text-transform:none;color:#000000;">Counterparts.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;This Agreement may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">8.<font style="margin-left:72pt;"></font><font style="text-transform:none;color:#000000;">Effectiveness</font><font style="font-weight:normal;text-transform:none;color:#000000;">.&nbsp;&nbsp;This Agreement shall be deemed effective upon (a) the due execution and delivery to Bank of this Agreement by each party hereto and (b)&#160;Borrower&#8217;s payment to Bank of Bank&#8217;s legal fees and expenses incurred in connection with this Agreement.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Signature page follows.]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;color:#000000;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;color:#000000;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">In Witness Whereof,</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;font-variant: normal;">the parties hereto have caused this </font><font style="font-weight:normal;font-variant: normal;">Agreement</font><font style="font-weight:normal;font-variant: normal;"> to be duly executed and delivered </font><font style="font-weight:normal;font-variant: normal;">as a sealed instrument under the laws of the Commonwealth of Massachusetts </font><font style="font-weight:normal;font-variant: normal;">as of the date first written above.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BANK</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BORROWER</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SILICON VALLEY BANK</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARSANIS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Lauren Cole</p></td>
<td valign="top"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael Gray</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lauren Cole</p></td>
<td valign="top"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Gray</p></td>
</tr>
<tr>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President</p></td>
<td valign="top"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:37%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Operating Officer and Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>asns-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
asns-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, <font style="color:#000000;">Ren&#233; Russo</font>, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Arsanis, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 13, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Ren&#233; Russo</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ren&#233; Russo, PharmD</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>asns-ex312_6.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
asns-ex312_6.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Michael Gray, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Arsanis, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 13, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Michael Gray</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Gray</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Operations Officer and</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(principal financial and accounting officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>asns-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
asns-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report of Arsanis, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, <font style="color:#000000;">Ren&#233; Russo, Chief Executive Officer of the Company,</font> certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 13, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Ren&#233; Russo</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ren&#233; Russo, PharmD</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>asns-ex322_8.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
asns-ex322_8.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report of Arsanis, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Michael Gray, Chief Operating Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 13, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Michael Gray</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Gray</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Operating Officer and</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(principal financial and accounting officer)</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g332r24s0lwy000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332r24s0lwy000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "- :8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7):EJ5S+>2*LKI&C%553CI76UCWN@I<W#312^6
M7.6!7(S656,FO=.K"SIPDW,-!OIKF.2*9BYCP0QZX-<1XQ\0W[ZU-907$L%O
M;D*%C8J6..22*]#T_3X]/B*JQ9V.68C&:PO$/@N'6KS[9#<?9YV $F5W*^.
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M]P>:\#T&>72?%=C)G#PW2H^/3.UA^1-&P;GT31113$9'B77H/#FC2WTH#O\
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M&'YBO*=9^%%["[2:/<I<1=1%,=KCVST/Z5R<^@^(M&D,CV%];E?^6L:M@?\
M EX_6E<=CZ'HKP*Q\<^)-.<!=2EE4'E+C]YG\3S^M=_X<^)UGJ4JVNJQ+93M
MPLH.8F/OGE?QR/>BX6.^HHHIB"FR21PQM)*ZHBC)9C@#\:PO%?BBW\,::)G4
M2W,N5@AS]X^I]A7CDUWXA\:ZGY>9KN4G*Q)Q'&/IT4>Y_.E<=CV2Y\:^&[1B
MLNKVY(Z^63)_Z"#4,7C_ ,+RG"ZL@_WXG7^:UPMI\)=3EC#7=_;0,1]U 7(^
MO05:E^$$P_U6LQMQ_';E?_9C1J&AZ/9:OINI#_0K^VN#Z1RAB/J.M>'^//\
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J:#*MP%:ZNUZ2S8^7_=7H/KR?>NIII";"BBBF(**** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gnoz4kbhq1ug000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gnoz4kbhq1ug000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '] J<# 2(  A$! Q$!_\0
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MM1H10NT* OICBH_LMO\ \\(_^^14U% QCPQ2 !XU8#ID4JHB+M50%] *=10
M@ 48 P!VH"JN< #/)QWI:* $"@$D 9/4TM%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#=W45E:O<
M3,%C09))KF;3Q1=&"^G>V6X6"=E(BD V( ,9]>M=3)%',A25%=#U5AD5DMX<
MM1:7UO QA^V/O=D49'L* (?^$E,5PL5U9& O$TJEI1@@?XU9;49+SPU+J$(,
M#F!Y$R0V, X_E1)H:37$<TDY8I;F  H#P>_UJ2/21%H1TM;A]OEF/S-HS@T
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MP^E8O_"+W'_0Q:O_ -_A_A7144 <[_PB]Q_T,6K_ /?X?X4?\(O<?]#%J_\
MW^'^%=%10!SO_"+W'_0Q:O\ ]_A_A1_PB]Q_T,6K_P#?X?X5T5% '._\(O<?
M]#%J_P#W^'^%'_"+W'_0Q:O_ -_A_A7144 <[_PB]Q_T,6K_ /?X?X4?\(O<
M?]#%J_\ W^'^%=%10!SO_"+W'_0Q:O\ ]_A_A1_PB]Q_T,6K_P#?X?X5T5%
M'._\(O<?]#%J_P#W^'^%'_"+W'_0Q:O_ -_A_A7144 <[_PB]Q_T,6K_ /?X
M?X4?\(O<?]#%J_\ W^'^%=%10!SO_"+W'_0Q:O\ ]_A_A1_PB]Q_T,6K_P#?
MX?X5T5% '._\(O<?]#%J_P#W^'^%'_"+W'_0Q:O_ -_A_A7144 <[_PB]Q_T
M,6K_ /?X?X4?\(O<?]#%J_\ W^'^%=%10!SO_"+W'_0Q:O\ ]_A_A1_PB]Q_
MT,6K_P#?X?X5T5% '._\(O<?]#%J_P#W^'^%'_"+W'_0Q:O_ -_A_A7144 <
M[_PB]Q_T,6K_ /?X?X4?\(O<?]#%J_\ W^'^%=%10!SO_"+W'_0Q:O\ ]_A_
MA1_PB]Q_T,6K_P#?X?X5T5% '._\(O<?]#%J_P#W^'^%'_"+W'_0Q:O_ -_A
M_A7144 <[_PB]Q_T,6K_ /?X?X4?\(O<?]#%J_\ W^'^%=%10!SO_"+W'_0Q
M:O\ ]_A_A1_PB]Q_T,6K_P#?X?X5T5% '._\(O<?]#%J_P#W^'^%'_"+W'_0
MQ:O_ -_A_A7144 <[_PB]Q_T,6K_ /?X?X4?\(O<?]#%J_\ W^'^%=%10!SO
M_"+W'_0Q:O\ ]_A_A1_PB]Q_T,6K_P#?X?X5T5% '._\(O<?]#%J_P#W^'^%
M'_"+W'_0Q:O_ -_A_A7144 <[_PB]Q_T,6K_ /?X?X4?\(O<?]#%J_\ W^'^
M%=%10!SO_"+W'_0Q:O\ ]_A_A1_PB]Q_T,6K_P#?X?X5T5% '._\(O<?]#%J
M_P#W^'^%'_"+W'_0Q:O_ -_A_A7144 <[_PB]Q_T,6K_ /?X?X4?\(O<?]#%
MJ_\ W^'^%=%10!SO_"+W'_0Q:O\ ]_A_A1_PB]Q_T,6K_P#?X?X5T5% '._\
M(O<?]#%J_P#W^'^%'_"+W'_0Q:O_ -_A_A7144 <[_PB]Q_T,6K_ /?X?X4?
M\(O<?]#%J_\ W^'^%=%10!SO_"+W'_0Q:O\ ]_A_A1_PB]Q_T,6K_P#?X?X5
MT5% '._\(O<?]#%J_P#W^'^%'_"+W'_0Q:O_ -_A_A7144 <[_PB]Q_T,6K_
M /?X?X4?\(O<?]#%J_\ W^'^%=%10!SO_"+W'_0Q:O\ ]_A_A1_PB]Q_T,6K
M_P#?X?X5T5% '._\(O<?]#%J_P#W^'^%'_"+W'_0Q:O_ -_A_A7144 <[_PB
M]Q_T,6K_ /?X?X4?\(O<?]#%J_\ W^'^%=%10!SO_"+W'_0Q:O\ ]_A_A1_P
MB]Q_T,6K_P#?X?X5T5% '._\(O<?]#%J_P#W^'^%'_"+W'_0Q:O_ -_A_A71
M44 <[_PB]Q_T,6K_ /?X?X4?\(O<?]#%J_\ W^'^%=%10!SO_"+W'_0Q:O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC^P;R20HS6L_( _A:I?NNY2U5C?JG?:C%9%$96>63[B*.30MQ<F-91 KHPR
MC<XK/UJZM&TX7+3K%+$VY-QP<CMBB4M- 2U)?LM_J/-U)]GA/_+*,\GZFM"W
ML[>TCV0QJH[^IJ/3;U-0L8[A#]X?,/0U;H26X-O8IW.E65VA$L"9/\0&"*33
MIYH_W>_;=VC JWKCH:NU0OU:"1+Z,<Q\2 ?Q)_\ 6HDD";/;_#^KQZUI$-VO
M#XVR+_=8=:U*\G\&ZV-+U=4=_P#0[S"DYX5NQKUBO'K4_9SL>I2GSQN%%%%9
M&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4]0U6RTJ S7MPD
M2]@3R?H* +E9NL^(-+T"U-QJ=Y%;IV#'EOH*\Q\0_%N\N99K+P]9F+8VQKJY
M&,'V%<3_ &7=ZM=?;-4N);J8G.^<Y ^BUT4\-.>YC.O&)V&O_%G4-2W6_AVV
M^SPGC[7..3_NBN!2SNY]:5]7N);AY^4FG.2#Z =JZBWLH;< JN6_O'K4>IV?
MVRT*KQ*GS1MZ$5W0P\8*ZW..5=R=B2"SAMQ\JY;^\>M6*IZ;>?;+1688D7Y7
M7T(JY70K6T,'>^H4444Q!5/5'B33Y!,A=&^7 '<]*N5#=+$]LZSD"-A@DFD]
MAK<U?A1J$VAS2:9=W"M:W,A\I0<^4_IGWKV6OE&[2YA0S:;<3RF.02,Z_*G'
M3ZU]$^!O$T?BCPU!=[A]H0;)E]&%>3B(<LKH].C.ZLSI:***YS8**** "BBB
M@ HHHH **K7M_::=;M<7EQ'#$HR6=L5Y?XB^,2>:]GX<M3</C'VEQA ?8=ZJ
M,'+83DEN>G:AJ=EI5LUQ?7,<$2C[SMBO*]>^,GVAI+7PS;&5@2IN)!P#["N+
MGM=7\17/VK6KR27)R$8_*/H*!9PZ'J,<T:?Z/-\CDC[K>M=E/"VUD<L\2MHB
M2:?J>O7'VK6[N29F.=KG@?05L6MC;VB@11@'U[U8ZC-%=T81CL<<IREN(P#*
M5(R",$5DV!.GW\FGN?W;?/ 3Z=Q6O5#5;1KBV$D7$\)WH?Z4Y=T)=B_15:QN
MUO;1)AP2,,/0]ZLU2=Q!7.:I%-9;C&KF MN8@<<^OT-='5>\DC2W*.A?S/E"
M#JU3)70XNS)+<EK:-F8,2HR1WJ2N/L-4E2:.TED>*!7*G!PR\\<^U=(T4]NO
MF0S/(HY*.<Y^AI1E=#E&S+E9VM):RZ?)'=2I&"/E+'O6?)K&H:A(8=)LRHZ-
M<3C"K]!WJ6T\.1"876HS/>W(Y!?[J_04-\VB!1Y=6)X7FN&L'AGC8+$V(V(^
M\M79-%L)M0^VRP!YL8&[D#WQZU?  &   .PI::CI9B<G>Z,E;2ZL]2D:TC0V
M\PRP8X"M5QI+N(;FBC=1U"$YI]U>V]E'ON)4C';<>M<ZTFL:XS+&#:6A. >A
M84FU'1#2;U9OOJ-K';B=YE"'IZU2:YO=2!2UB\F \&64<D>PIVGZ#:V*J2#+
M(/XGY_2M6G9O<5TMC+T]&M-VFS2%]HW1.>I'_P!8U[+X-UO^U]($<S9N[;$<
MOOZ'\:\BU"!I(EFB_P!="=R>_J*UO#>N?V9J-OJ49/D.-DZ_[)_J#7/B*7/#
M3=&]"IRRUV9[5138Y%EC61&#(PRI'<4ZO*/1"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KS[XG:9LL1K:+(_P!G0I*J<G:>A ]J]!J.X@CNK>2"
M90T<BE64]P:J$G"7,B914E9GS9X:0W0DO7=6S\NTCD>Y]ZZ.L'5=/?P1XUFT
MZ3(LYSNB)[J>A_"M[J,BO8HR4HW1YE6+C+4****U,C'GSIFJ+<#BWN#MD_V6
M]:UC(@(!=1GIDU'=VR7=J\#]&'7TKG]!*K<W&F7J[[B([D=^K+47Y7;N7:ZN
M=-37=8U+.P51U)-4)TNK/'V)/-5N-C-]SWSZ5F/I>J:A<-]LD58P>,'(_*FY
M/L)17<T)-6:9S%I\)G<=7/"C\:1-)>X<2ZC,9F[1CA!^%.LK./3[P0PLQ#1Y
M?)[YZUITDK[C;ML,$,8B,00!",;0.*I>#=;D\%^-1;29_LZ^.UB3PI[&M"LG
M7].^W6!*#]]%\R&HK4U.%BJ-3DE<^B58,H92"",@CO2UP/PM\5?V[H LKE_]
M-LQL<'J5[&N^KQVK.QZB=PHHHI#"BHKBY@M(6FN)4BC49+.< 5YOXC^+UC:,
M]KH<)OK@<>9_ I_K51BY.R$Y);GH]U>6]C T]U,D,:C)9VP*\O\ %7QDMK2.
M6#P_;F\G7K,P^0?XUP=TWB#Q3-Y^LWKM&3D1CY4 ],=ZT+72;2TCVK&#QC)%
M=E/"-ZR.6IB4M(F9+_;/BR1;W5KYY(W^94SA1]!6K::;;6:@1QC([D54L"=/
MOY-/<_NW^> GT[BM>NVG",5HCDG.3>H5#=VR7=L\+]&'7T-345H9F;I%R[1/
M:S_Z^ [3[CL:TJR=31K2YCU*(?=^68#NM:B.LD:NIRK#(-3'L4^XZBBBJ),?
M_D%ZMZ6UT?P5_P#Z];%5K^T6]M'A/!/*GT/:JUAJ*?8F^UR+')!\LI8X_&I6
MCL4]5<TJJ'!U0!NT65_/FLJ3Q!/?.8=%M6G/0SN,1K_C5K3]*N(YEN]0NVN+
MD9QMX50>P%'-?8?+;<HZUH5Q<7RSV6P"3B0$XQ[UNV<4D-G%%,X>1% 9AWJ>
MBA12=Q.3:L   P!BBBJNI27$-A+):@&51D9%4]!+4LDX!)[5@2ZKJ.HR&'2;
M;;'T-S,, ?0=ZN:)J;:A:$3%?/CX?'0^XJS88V2E?N&1MOTJ;\VQ7P[F?:>'
M($F%S?RO>W77=(?E'T%;8  P!@444TDMB6V]PHHHIB"LQK>\MYI4M%C,,OS9
M<\(>_%:=%)JXT['6_"KQ/+J%A/H>HN/M]BQ _P!I.V/I7H]?/=J;RV\:V%YH
M^TWB-LF1FVAE]#[XKWRRNX[ZSBN8B"KC/!Z'N*\>O!1FTCU:4G*";+%%%%8F
M@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <)\4?"@\0>'FNK>,&^
ML@7C('++W6O)=%UV Z>([J3;+%\N#U(KZ4(# @C(/!%>"^/-'M/"VK7$-N8X
M/MI,\!QR>?F7\Z[,+4L^4YL1"ZN3*RN@93E2,@BEJCI,5Q#8*EQ@'.54'.T>
ME7J]):H\]Z,*P;R!8/$EO>3?ZMQL1AQAO>MZL[4X_MR&R3AV&XO_ ,\_?ZTI
M*Z'%ZFC4%Y.UM:23)&9&1<A1WJ2)#'"B,Q<J "Q[T\@$$'H:H13T[;-"+O>'
M>8 DCH/:KE8]F3INIO9-Q!-EX3Z'N*V*F.PY;A1115$F'9WLG@WQE;ZO"#]F
MF.V50>,'K7T5:745[:17,#!HI5#*1Z&O!=3L4U"QD@8<D94^AJ3PK\3[CPSH
M<FCW%F]U=0L1!D\ >]>=BJ+YKQZG?AZONV?0]XFGBMXFEFD6.-1DLQP!7G?B
M3XMZ;IS/:Z/&;^Z'&Y?N*?K7G.IZAXB\8R[]2NGCMLY6&,[4'^-6;+1K2R4;
M4#,.Y%*EA&]9#J8E+2)D:SJOB'Q%J,,VL7;K9RG:(U)5%/;BMFRTBTLE&Q 6
M'<BI[RU2[M'@8<$<'T-5M)NGE@:WF_X^(#L<>OH:[84XP=D<DYRFKFC1116I
MD4-5M&N+821<3PG?&?Z5-8W:WMHDR\$C##T/>K-8X_XE>KXZ6UT>/17_ /KU
M+T=REJK%^^:5;5FA."#EL#G'?%9^F79-V\0#E6)ZG.#ZY]ZV>M1Q0QPC$:*H
M]A0T[W!/2PZ1%EC9'&588(K%M;U-)DDL;ICA3^Y.,E@>U;E8WB*P%W8&9<"6
M'YE-$KVN@C;9E_[:J\RQ2QJ?XF7@5.TT21>:TBB/&=Q/%9^AW_\ :6F*S\NG
MR/GN144WA^"ZF)N99)+<-N2#.%7_ !HNVKH=DG9D,OB![J0P:/;-=2=#*>(U
M_'O3H/#XG8S:HRSS/C>BC"?E6Q#!%;QB.&-40= HQ4E'+?X@YK?",CBCAC"1
M(J(.@48%/HHJB HHHH *",C!HHH YK[!]DUX()6BBF!VE>_JM='&BQ1JB#"J
M, 54U.S^UVA"<2H=\;>A%.TV\%[9K(1B0?*Z^A%1%6=BV[JY;HHHJR HI;6*
MYU&X^SZ=;274N<'8/E7ZGH*Z6Q\'P)(/[6F:]N.UC:_='^\U8U,1"GON;4Z$
MYG)_:[<'YY-J#@R$';GTSZU-9+J&KS>3HEB\AS@W$@^4>XKU$^&HM0M([6_@
M@ALD8,MI"O&1ZGO6W!;VNG6NR")(84&<*,  5P5,5.>BT.R&'A'5ZGF]G\/?
ML]U&M[>O-?W?,FSC8@ZG/KVK4\*2OX;UZY\,W+'R6)EM'8]1Z5U&E*;AY=2D
M!W3G$8/\*#I^?6LGQOHTE[I\>HV0(O[$^9&1U('45RG0=5165X=UF+7=&@O$
M(WD8D7^ZPZBM6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^>O
MB!.OB?XC/:[B8+/$0*GICDU[OK-^FEZ+>7SD 0Q,_/KCC]:^=/# EO)[O4[@
M?O97.?J3DUTX6'-,PQ$N6)H?8+^W_P"/:^+*/X)1FE^WW]OQ=6)8#^*$YK4H
MKU.7L>=S=RC#J]E,=OF[&/\ #(-IJO)>-!?SB&!YWE"^7L^[P.Y[5H36MO<
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MPZ8K#\.:T9IEF?RDM;UMJ!6Y64=<^F: .OHHHH **** "BBB@ HHHH ****
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MR#D&B@ KDT_XIOQ04/RZ=J1ROI'+Z?C765C^)[:UN=#G6ZE6$*-Z2'^%AT-
M&Q17$Z%XNN-2DMM-18ENO+.Z:4G:Y'ICOCFNA:_N[%@=0AC,!.#/"3A?J#_.
M@#5I&8*I9B HZDGI7-:AXSLXKHV.EPR:E?=HX!E1]6Z"H8M"UC6I/.U^]\N
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M-<0VZ[II4C7U8XKGVU&]O&9(Y&/;9:IG\W/3\*?#HUU(_F.(H3_>D/G/^O%
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M"R/L6F6ZH/)MXAP!PM5SJ_G';96LUP?[V-J?F:D@TBSA;?Y7FR?WY3N/ZU>
M & ,4 9GD:I=?ZZY2V3^[",D_B:EATBSB?S&C,TG]^4[C^M7J0D $DX ZDT
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M Y!&0169K^D1ZUI$UHX&XC*-Z-VK'\$ZO)/:2Z3>G%[8G80>K+V- '64444
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MOX<L%N;B-Y-[;$5!U/OZ54\+^)_[=$\<\:PW$9R%4Y#*>X- %W7];70[%9S
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M?P'- &A17/\ ]NZA>G;I>DRLIZ37)\M/RZFC^Q]6OL'4M6>-3UAM!L7Z;NM
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M7C2H[F06D1Q&I/:NXM;.VL8%AM84BC7HJ#%3T4 %%%% !1110 4444 %%%%
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M@DC_ +ZE?S%87@R3.@+;G/\ HTKQ#/H#Q70US7AT?9M=URSZ#SQ,@]B.?UH
MZ6BBB@ K/UV2YBT*]DLWV7"1%D;&<$5H4R:,3021-T=2I_$4 >>67@F_U6TB
MNKO6Y2DZ;]L9(Y;K6G#\-=''-S)/.2.<MC-:_A*0MX>AC;[T#O$1Z;6-;E '
M/V7@K0;'_5V0?@ >8<UL16-I!CRK:),="$%6** "BBB@ HHJ.:XAMHR\\J1(
M.I=@!0!)17)7_P 1-$MI#!:-+J%P./+M4+<_7I6-JGB3QG/9_:K;3(M+LRRJ
MTMP=SJ"<9Q0!Z'+-% A>:1(U'5G8 5R^H_$/0+&4V\,[WMSVAM5+D_E5*#X?
M+?E9]>U>[U)CSLW[8_R%3:EHVG^&;G3-3T^SB@B@D\F8(O5&XR?H: *_]L^-
M-<_Y!FDQ:9 >DUX<M_WS6'J&@:II.J1-=W3:C=:@1\X 4+(O08Z8Q7JP((R.
MAK!\76CSZ&\\0)FM6$Z8Z_+UH S;'1M>FMUAO9(8X5.5BWD@#T..M:DMD;.U
M+7>HO' O1(%$>?;CK4W]OV<>B0:C+*H69 RKGECZ"N977;C5;W?86;:A<J?D
M[00?4]S0!J0Z-:RR#4=27RK=/FCCF?/_  )L_P J8_B8W+FT\-:?]J<'!FV[
M(4_'O^%4[KP_=375O<^);PWEO(=CP1Y2*(GH<=Q]:Z#1@MCOTHJJ^1\T1 P&
MC/3\NE &;!X4EOYEN?$-XU[)U$"_+"OX=_QKI888K>)8H8UCC7@*HP!4E<<G
MBN\L_%:Z9J<:)!,Q2-U&-K=N?>@";QAJ4EJL:::C/K"C= H7((/!!]JPK'P7
MK&NS+>>(;MXL\F,-EO\ !?PKM+M4_M_3V4#S-DFXXYVX_P :U* ,_2]%T_1X
M1'96R1^K8RS?4U@:ZC>'_$$&OPC_ $6<B&]4>G9ZZ^L/7]2TQ;&:RNB)C*A4
MQ)R: -I'61%=""K#(([BG5QW@759FMY-&OE>.ZM>8A)U>(_=-=C0 45'--%;
MQ-+-(L<:C)9C@"N7N/%\M_.UIX<LGOI0<-<-\L*?CW_"@#I[BY@M(6FN)4BC
M49+.V *Y:7Q==:G*8/#6GM>$'YKF7Y(A]#WIUOX0EOYEN_$EZU_*#E8%^6%/
M^ ]_QKJ(88K>)8H8UCC48"J, 4 48+NWU2R>WN JR,I2:%^"#CG\*X.^>702
MSP21QWNE?(A;I- W3/J1TKT6XL+6Z.Z>!';UZ'\ZSM2\.V=S8/'!;1K*"&4D
M9R1V)/:@"IX0\1OKEK-#=%/MUN<2!!@,#T8#TK1T4*/MWE@"(W+;<#\ZXNTT
M2[MKF'4!=M:M"QM;J-!DK&3QD^W8UZ%:V\5K;)#",1J./?WH FHHHH ****
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M,3PPJ78E>,\>M,D\1>*_$$3QZ/H'V2"0$>??'&0?:NHTOPSHVC(%L-.@B/\
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M-:]% '"+\./[1F6?Q'K-WJ3J<B,-L0?@*ZG3?#^DZ/&$L+""$#N$&?SK2HH
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M7]R\_P# 9O\ "NBHH YW_A--*_N7G_@,W^%'_"::5_<O/_ 9O\*Z*B@#G?\
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M_P" S?X4?\)II7]R\_\  9O\*Z*B@#G?^$TTK^Y>?^ S?X4?\)II7]R\_P#
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9<$>XHK>2)(D"(BJHZ #BBH<E?8M1=MS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g332r24s0lwy000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332r24s0lwy000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T 0,# 2(  A$! Q$!_\0
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MA[+XE=_+9G5>*]:;0O#UQ=PC==OB&UCQDO*W"@#OZX]JH?#BY:[\!:9([%G
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M+N*-(YHK21LE50'Y0,XX/..U=;INM/J5Q>'[!>V]K B;'N;9XVE8[BVU2,D
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JBJET.:CJJDGO8[ZBBBK.0**** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g332r24s0lwy000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332r24s0lwy000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T 0,# 2(  A$! Q$!_\0
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MOHW]I16L5P@D".CN5//0C@UN#[3]E!(A%QCD G9GZ]:XSXM?\B-+_P!?$?\
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M"J!DDG@"BR:?F4ZDZ<XZ6<?^'_4RO#>DMH^B0V\S;[MR9KJ3^_,YRY]^3CZ
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%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g332r24s0lwy000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332r24s0lwy000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '@ Q<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4\^9QC/MQUKH-#-\T%RU^9S*;B3:)5  3<=NW Z;<=S]:U:* "BBB@ HHHH
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ML+R/J$3MYBL9/LZA<J4^\,\GY#DGG+'Z4^/P+;!%CENO-C0':# N7)!YD/\
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MH [6BLC0+._L+5K:^E$S!BZR^8SDY)X.[T&.>.O2M>@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8DKV  7D\\G''6L__A/'$EQ"=$NC-;KND57!"\<C/J#Q@=<UV5% '%)\02$
MDT2[\WY%/EL"N\C)&3[=/[U:*^+HWT^*[%E*!+<M BLXY"]3GID@<#N>*Z2B
M@#EM)\9KJ]S''#IEPD1D*-.[ *!AB"/480Y]*K+X^$D2RQZ3*T3#=YOGKLP1
ME1N[L<'Y>QX[UV#*KH48!E88((X(H1$CC5$4*BC"JHP /04 <A?^.FM=HCTB
MY+LL@ D^4;T.-N?4G@#OSCI4R>,VDT?[<FDW6XW:6R1<9<MCGK\OH<]*ZNB@
M#CD\?P9<SZ?-$J,48APQ5@,D$#D9Z#/4U,?&$\>F:=<R:3*9KNW:X>&-\B(
M9P6]< ]NHKJ(XHX@PC14W,6;:N,D]3]:?0!R6I^,;C3;ZYC.DRS6]M@R&)LN
M5*QGA?7,F,9Y"DYXJ27Q+J5Q86,VG:4QFN?,9HY2&"JG .01P21SZ=C74T4
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M B:0]0I ^[C!W=#FJ*^/I4O)XY]%N/*$VV$HPW% BLQ8'N"V, G(!/:NVHH
MYF[\7_89K2WGTNX-Q<0><8HV#%"<[5/;G&,]J=;^+!/8WER^G31?9"%E#.,;
MB1M&[I@@AB>PZUTE,CACAW>7&J;F+MM&,D]2?>@#B(_B(6F6-M*? #222!_E
M50&*CIR3\OMR3VK3E\91Q65C<'3K@M=0^=Y61O Z84?Q'O@=!R:Z>B@#E-0\
M6W.EW@2ZTS;"+=9'"R@OYAY9!V) Z <MGC&#31XUE21Q=:+<P(@)9_,# 8!/
M;Z$9KK:* .+_ .%@Q":0#3YWC/F&(@[=P0<$[L##$'!^GK76V=Q]KLX;C84\
MU X4]1D9J>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KD/B@S)\.=69'9&_=#<K$'F5.XKKZX_XI?\DXU;_MC_
M .CDI/8J'Q(\"^?_ )[3_P#?Y_\ &DR__/:?_O\ /_C2FND^S:'<1V=HI5+A
MH4DDE1MN#L)=2S$@DG&  ,5QIR?4^BG&G#[/X'-Y?_GM/_W^?_&C+_\ /:?_
M +_/_C72RZ#I5N\;O?R-;RO*L9#*I;R]V3G&,'Y,?4^E(^B:+]HNECU&3RXX
M2T>9(]Q8.ZD^A'RJ<#GYA3M+N1S4?Y?P.;R__/:?_O\ /_C1E_\ GM/_ -_G
M_P :Z"\TS1H=,O);:XDFN(U&P-.G4,H9@,<@ANG7@TFN:;IUOH>GW-A/;M/L
MVW 68,[,0"&"Y/RYR.Q[8[T>]W&G2;2Y=_(P,O\ \]I_^_S_ .-&7_Y[3_\
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MBGRSMC).!SD%G&#_ ':+2[AST?Y?P.=R_P#SVG_[_/\ XT?/G_73_P#?Y_\
M&KVL6EM9:BT%I*TD04'+.K$'TRO!]?QJB.M)N2>YK&%.2NHK[CZ&^';M)\/=
M#9W9V-JN68DD_B:Z>N7^'/\ R3O0O^O5?ZUU%=J/FI;A1110(*\ ^*#R'XAW
MJ^=,%6V@PJRL ,AL\ U[_7S]\3O^2BW_ /U[6_\ )JSJNT3KP,5*LDSD\O\
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M2J6HRSQK%Y#%<ELD#/;CL>]%V)J*5[&@)9 ,"5Q_P(_Y["F#(.0S@_[Q]_\
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M Z?X4>P?</[3C_+^)\P;E]1^=*&7/WA^=?3W]A:/_P! JQ_\!T_PH_L+1_\
MH%6/_@.G^%'L'W#^TX_R_B8_PX_Y)WH7_7HO]:ZBL#P2 O@[3E4 *$8  < ;
MC6_70>2W=A1110(*^?OB>0/B+?Y('^C6_P#)J^@:Y6QT^RO?&7B%KNSMYV46
MH4RQ*Q \L],BIG'F5C?#U52J*;5SYZWK_>'YT;U_O#\Z^G_["T?_ *!5C_X#
MI_A1_86C_P#0*L?_  '3_"L?8/N>A_:<?Y?Q/F#>O]X?G1O7^\/SKZ?_ +"T
M?_H%6/\ X#I_A1_86C_] JQ_\!T_PH]@^X?VG'^7\3Y@WK_>'YT;E]1^=?3_
M /86C_\ 0*L?_ =/\*/["T?_ *!5C_X#I_A1[!]P_M./\OXGS!N3U'YTYI2Z
MJK2%E084%LA1[>E?3O\ 86C_ /0*L?\ P'3_  H_L+1_^@58_P#@.G^%'L'W
M#^TX_P OXGS!N3U6C<O]X?G7T_\ V%H__0*L?_ =/\*/["T?_H%6/_@.G^%'
ML'W#^TX_R_B?,&]?[P_.C>O]X?G7T_\ V%H__0*L?_ =/\*/["T?_H%6/_@.
MG^%'L'W#^TX_R_B?,&]?[P_.C>O]X?G7T_\ V%H__0*L?_ =/\*/["T?_H%6
M/_@.G^%'L'W#^TX_R_B?,&Y<_>'YU]%_#_\ Y)[X?_Z\(O\ T$5J?V%H_P#T
M"K'_ ,!T_P *H>!P!X'T8 8 M4 'X5I3I\IR8K%*O:RM8WZ***T.,**** .4
MUE0NJS'/W@IZ^U4,CUKK8HDEN[OS8D;#@*67/&T>U6/LMO\ \\(O^^!4.-V=
M,,0HQ2L<5D>M&1ZUVOV6W_YX1?\ ? H^RV__ #PB_P"^!2Y&5]978XK(]:KS
MS21R((]N#RV?3^E=[]EM_P#GA%_WP*3[+;_\^\7_ 'P*.0'B?(\\6^F<_+ <
M8![\<9I#<3F?Y;8 D#,FP\_G7HGV6W_Y]XO^^!2_9;?_ )X1?]\"GR$_6#S_
M .TS-$LB1 Y+97.>,XR/UIGVJZ(_U./F4?=/X_YZ5Z']EM_^>$7_ 'P*/LMO
M_P \(O\ O@4<@?6#SU;JX*%F@"8]SU_SQ5W(]:[7[+;_ //"+_O@4?9;?_GA
M%_WP*7(-8FW0XK(]:3(]:[;[+;_\\(O^^!1]EM_^>$7_ 'P*.1C^LKL<5D>M
M(<;3SVKMOLMO_P \(O\ O@4R6VMQ$Y$$6=I_@%'('UE=A]JNVTA4=HU'Z5+4
M%F2;&W+?>,:Y_*IZT.0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\W; I$C*3M& >0 I;/3\>*L0ZGX8%M)>IH:+!'.B1E84W.YCW=,X "8/)[]
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MW!_NGTJ.Y\;:#:NJRWA&X9&(V)/.", 9R.2?05GG7?#MWH5CJ5UINVTNI-L
M:-3M6,MM8@' '7 _VL=ZK7?B3PW;W*M=Z+(OSAXG\A&+3$N^W@]>"V<X^;G%
M '1)XIT>6SNKN*\#PVHS,RJ3MST&,=?:I=,U_3M8D=+&9I=BABWELJD'T)&#
M^%<S)XD\+F&XLY-. LGB\YP8U'F$' &WKG*]\'(Z=ZU_"VK:3JD<G]EV36PB
M1%?]UM7^(X![X.[T]>] #_!7_(H:?_NM_P"AM6_6!X*_Y%#3_P#=;_T-JWZ
M"BBB@ KGM(_Y'#Q']+7_ -%FNAKD1:W%[KGBNWM9?+FD6U"L6*_P'(R.1D9&
M1R,T ==17)_V'KR21QVE[%96@(S%#*S;5P<HNY3SNQ\V1QD "JG_  C_ (N6
M'RH]:@*M"XD\PEM\C/G=]WCCH.W2@#MZ*Y=--UR.>YCDU=9(C;R)$&DP^YB=
MC-A1C'J/P'',0T?Q/%')$NLHT (6%#\K*H!'+[22?NG..<$<9H ZVBN7GTKQ
M/+J+E=9C2S,2)A1ARPP6;[I )(/X'VJDFC^*XKJ.>YU>.9A,HBV?=0' =F!
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M,XZ5%;^'?$]FAAM-6ABM5@9(X@W(8ONSG;V!(X !P.!0!VM8'@C_ )$C1O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCCGM4R^-$F>^2'3+O_1K8SJ[J 'X!5<=1N#+CCU]*ZGCTI: .,N?'3V_[O\
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MH XN#XAPL$$VEW:$RI&6P,98X.!UX]#R0<U=T[QK!J.H16B:==+OC>1Y."J
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M;U/7 SDX[8'/7I5A?&T!T)-4>PN8TDN/)2-RNXCKNX/0#MUR#]:ZC\*,#TH
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MUU?4U&%U"Z'TE/O_ (FF_P!IZ@7WF^N-WKYI]O\  ?E5K[!:X5VD*HS':=P
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M1BBCFBC5ICN)^7G(7KGC\!^=.>UMUDVBX&,9Y(!Z?7'YU[;_ &+I7_0,L_\
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M[2ZM8YS<71F4KB->R@9]?P_*@"[;+MM85YX11S]*EJ"R)-C;D]3$OIZ>U3T
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M?F7C!E-JB\'!\[V^GU_*K=% #(59(8U<@LJ@$CUI]%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116#JNI:C9:
MJ1;P/-;QVC2B%(B3/)D_(&['&* -ZBN6F\1ZOY),.BR>8Q8 '=E,*,$Y7G).
M0!U /0\5>CU2]%]Y4T6$^P)-_J7'[TD@J6Y'IQU% &W17)#Q-K*J96T&<AXM
MZ0 -O#8SL/&,]>>F<#OFNIMW:6WCD==K,H8KSP2.G- $E%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%8VJWFIVM]"UI");5(FDG&PDG&.%(YSZ#'- &S17'Q^+]1
MFN/(31P9E$?F1^:=R$@%LC;PO(&?4C-:EQJE[!J&HB*!KB"W@5DB$+*QD]%;
MHPP><<CWH W**Y9-9UQ[74[N2S6%88X_LR>5(YD;)W'& 2#@8] 1D5H:1?ZA
M=:EJ45W"4MXY!]F;RBNY<D<Y[\ _CGH10!LT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T1HLC2!%#
;MPS <FG444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gnhmo5dgyo1b000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gnhmo5dgyo1b000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T 0,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#N;?2K27XL
M7^G2+(;,:<)E@$K!5?<@R #Z$_G5_P -O>Z9X]U;P^+F:XTM+=;F 3.7,!)4
M; QYQR>,]OK5.2UN+OXQ7R6U_-9.-*!,D2(Q(W)QAP1WS^%-M;R_\%>,EL]7
M=+ZWUN8;=1V;)=XPH5@.,#(&!@ '/J*R6GWGIR3E'EO=N*T_4Z/QEXBN/"^C
M?VE%:Q7""0(Z.Y4\]".#6X/M/V4$B$7&.0"=F?KUKC/BU_R(TO\ U\1_SKN:
MM/WF<<HI48RMJV_PL<WX1\17?B2VO+B>UAMTMKE[8JDA<EE"DGH..:T/$.I7
M&CZ'=:C;P1SFVC,C1NY7('7!Q7-?"[_D#ZQ_V%YO_04K<\9_\B5K/_7I)_*D
MF^6Y=2$5B.1+2Z+NAWT^IZ)9W]Q%'$US$LRI&Q8*K $ D@<\UH5D>%?^1/T3
M_KP@_P#1:TGB;6_["TD3HF^XFE6WMTVELR-TX') &3@<G%5?2[,G!RJ.,>Y=
MU2^&F:1>7Y4/]F@>786VAMH)QGMG&*DLIY+JPM[B6!K>26)7>%CDQD@$J?<=
M*XJ:P\17/V:74[J66UDN0ZQR0Q 6J!2?,E"\,<CY5.X+D$EB!6EX<N/$]ZEA
M<7LEFU@Z&5I@"LDR.H*?)C"D'KSR#TI*6II*BE"Z:_K^OZ1#\3+N>U\'L+5F
M6XEN84B*?>WAPPQ[Y6MGPQK<?B+P]9ZD@ :5,2J/X7'##Z9Z>V*R_&)\W4O"
M]I_?U5)NG_/-6/\ 6L7P\3X1^(-]X=8!=.U/-U9>BMW4?D1_P%?6IO:1HJ:E
MA[+XE=_+9G5>*]:;0O#UQ=PC==OB&UCQDO*W"@#OZX]JH?#BY:[\!:9([%G
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M+N*-(YHK21LE50'Y0,XX/..U=;INM/J5Q>'[!>V]K B;'N;9XVE8[BVU2,D
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JBJET.:CJJDGO8[ZBBBK.0**** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g332r24s0lwy000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332r24s0lwy000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '@ Q<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% $-UG['-@2$[&P(CACQV/K7)1KXBL(D\IKJ
MXQ;QJ\<XWEI65RS!L\ ':*ZN_NC9V,UPL+S,B_+%&/F=N@4?4X%<WI^O:O\
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MH")CRC(C*)#P&VCKZGYB,Y 'K5S4]>U*TU&-8HXA ;57820R$B0[C@8&3PN
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MY9,D8VXR%1F8\MT&P@_AZUK[&FHV<'?T_P""*[[EP_$*5=/2:[T*23 WJQD
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M><MC.>0.AZ5:O[CP5I\=]-)H^Y;.8P%@X!=QG<%!?/&T]1SCC-0Z-*Z3@_\
M/\?F.[->3QR(XMYTYI,6OVD^5,&#*20-AQ\R\#<W&W(ZU#)X_:*.[9]'E'V:
MT2Y8>>#DL0-N0,=\^I["LLW'A!]/U:YBT)@NGVKW :0X6559DXPQ(RR$<BI-
M%?PEK-\E@F@/'<;&\XD9CC9<Y!8,<C@X(XZ=Z7L:44Y.#T_KN%V7;KXA/;0W
M4AT:<>3M :24*"Q0O@Y&5X!V\?-[9ITWB_4["XLEN=,-PKV,4MTL (=)G#-M
M4'J (VS^%95OJ'@BZFE2/17;RV?>^05V* 2X._YAAAP,GVJ4S^#E^SYT"4M-
M"TX"8;:HS@DA\<[2.O'?%/V5):.#_KYBN^Y?/C^?[*TZZ#,RJ(P<7"X+.6V@
M'&,87.3CEE'>NPM+J.\M4GB.5;WS@@X(_ Y'X5YRFH^!VC5_[$8*]J+E<$$$
M;@H48;DY(^F1G%;&C>)],34+71M)TZ2W@(DEG,F%$("!VXR3GYTYZ<\$UE6H
M)K]W%JW]=V-/N=D\:2 !T# ,&&1G!'0T^N*T[XC6=RD"75C=0W#J))%50ZQH
M5#!B<]-K*3W'7&*TM(\86>K7RVBVMU;N8EDS.J@#<%95.">2&4_IU%<\L/5C
M>ZV*NCHZ***Q&%%%% !1110 4444 %%%% #5C1'=U10SG+$#ECC'/X"G444
M%%%% $$=G;17,MS'!&D\N/,D50&;'3)J>BB@ HHHH *8\4<C(716*-N0D9VG
M!&1[X)_.GT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:_L(-2M&MKD.8F()".
M5/!R.0<]:RY/"&E2AQ+]L<.P=]UY*=S#H3EN2,#!]JO:SJL6BZ3/J$\<DB1
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M ^@Q4L7A/2HKN.Z"7+31LK*SW4C?=^[G+<@>E;=%'MJG\S"R"BBBLQA1110
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MMYK6/]\_VGE2D1.%.[!/?DK@8ZY%:-EJ%MJ$6^WDR02'0C#H02"&4\@Y!ZT
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MT.1US6C)X1TJ2)8RDN S,3OR6W!0V2?78.F#^=21>%M-ACV1B8+Q_P M#V!
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MPF/C[_H7-$_\&#?_ !-'_"8^/O\ H7-$_P#!@W_Q--.N:6J;GOX$^17(=MI
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MUZQ7SQK?_)4_&'_7:W_]%"MJ$%.HHLSJS<(.2.C_ .%K>+_^A=TG_P #6_\
MB:/^%K>+_P#H7=)_\#6_^)KG**]#ZE2\SB^M5#H_^%K>+_\ H7=)_P# UO\
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M/!-;2F*>-HY!U5AR*CJE@J3%]:J'1_\ "UO%_P#T+ND_^!K?_$T?\+6\7_\
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M-'_"U_%W_0O:3_X&/_\ $UAC3[POL6VD8]MHR#UY'M\I_*I/[(U/>4_L^YW
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M.3^0J*DG&-T=&%I1JU.66QV'_"ZO$W_0NZ9_X%O_ /$TG_"ZO$W_ $+NF?\
M@6_^%<II.C7FM32Q6?E;HE#L9'VC!8*/U(IDVCZE;AC+93A5+ MMR/EZ\^U8
M^UGN>E]1P][7U]3K_P#A=7B;_H7=,_\  M_\*/\ A=7B;_H7=,_\"W_PKDI-
M#U:)&9]-NE5068F,\ #)_2F_V-JF'/\ 9]S\@W-^[/ Y_P #^1H]K,/J6'[_
M (G7?\+J\2_]"[IG_@6_^%'_  NKQ-_T+NF?^!;_ .%<Q%X=U*74;RP$<:7%
MFI:8/( % ]_QI-+T&_UBVEN+,1%(WV$.^TEMI; _ &CVDQ/!89*]_P 3J?\
MA=7B;_H7=,_\"W_PH_X75XF_Z%W3/_ M_P#"N/BTC4YMOE:?<OO3>N(SRN0,
M_J/S'K0FDZDZ(ZV%P5=2RMY9 ('4T>UF/ZCA^_XG8?\ "ZO$W_0NZ9_X%O\
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M$:N/^?B+\C1_PC5Q_P _$7Y&@#%I&^XW^Z?Y5M_\(U<?\_$7Y&D?PW<"-O\
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M?\*QU'_H(6G_ 'RU'UJC_,+V%3L<+)_JI/\ </\ *O5OA-_R2OP__P!>Y_\
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M,LGA\1J&.4R[,!QQP.2#G)'! XH ["BN8L==UN;[4USHK1)#:B1<!MTDF <
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MGE^??1QEO0&+!_3-:USX5_LU[B[BUUK&,@F-W; 1R?EW<@-V'N%44 =D&!)
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M " >-V3P,"NPHH YS1+SQ-=W0&JV5M:1 L7V9;H  H.><DYW8[$5T,G^J?\
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M "X"G;QGYL\MSCT/UKKJ* ,"Q?5I++4SJH (3$06/:I&PY(Y/7T/2LOX2_\
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MXM_\%+?XT =_17 ?\+7LO^A5\6_^"EO\:/\ A:]E_P!"KXM_\%+?XT =_17
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MXM_\%+?XT =_17 ?\+7LO^A5\6_^"EO\:/\ A:]E_P!"KXM_\%+?XT =_17
M?\+7LO\ H5?%O_@I;_&C_A:]E_T*OBW_ ,%+?XT =_17 ?\ "U[+_H5?%O\
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M37_OT_\ \31SQ[A]6K_R/[F=#17/?\)QX;_Z":_]^G_^)H_X3GPW_P!!-?\
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M /Q-'/'N'U:O_(_N9T-%<]_PG'AS_H)K_P!^G_\ B:/^$Y\-_P#037_OT_\
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MG8DA5S,,\': >N*W/$?CN?2]&L;BTM;5Y[V)I%D-P'@7:Z*0K #S&._( QD
MGM7:^5&.B+^5*8T*A2BE5Z#' H \SF^+)&J-'%86RV,#2>;/+<D;P%8IM^7A
MB4(((-:UQ\1D@\+Z=K/]DRNUY<26_DK,NV,H7!R_3G8=O3.1TKM3%&<YC0Y.
M3\H_SW/YT&.,IL*+MSG&.* //KKXE7,;J8](CCA5]SM/=8+19N%_N_*Y: @
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M%% !1110!D^*/^13UC_KRF_] -2Z#_R+NF?]>D7_ * *B\4?\BGK'_7E-_Z
M:ET'_D7=,_Z](O\ T 5/VCI_YA_^WOT-&BBBJ.8**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KE/B%_R+*?]?MM_P"C5KJZY3XA?\BRG_7[;?\
MHU:BI\#.G!?[Q#U1U=%%%6<P4444 %8=]XHM-.NIX)[>X/DL%+QJ",E<J.HY
M/('TK<KC]:UNR2YU.SU'1S+:1!1)*C*S/E<C(Z]B* -%/%MC,UNL$,\CS7 M
MRN "ARH)//0;ATS[5'=>-M'M -[R[G>2.,>6<2%#M8@^@;"Y]3Z54EUG3[:'
M3KN/1(PMU&2/EC5T*$!5 [\]#G P*(M=TF6^M8'T1DGNK@GF*,[6POSDCO\
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MC!YXS73U76PLT8,MK K+C!$8!&#G^=6* "BBB@ HHHH R?%'_(IZQ_UY3?\
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M>::*VC629@TC8SDCI],5)/96US;O;RPJT3C#+TS^590\2@C(T?5B#T(MQ_\
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MI_S+[PLS9$4:L65%#'J0.:?6'_PDG_4&U;_P''_Q5'_"2?\ 4&U;_P !Q_\
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M">!CI@\5(FMVNE/?1'0H4@ANY#OC<$M*6D;<V1D$X)SVW#M4\/BJ_:XM$;2
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M-I(Q[U?HH S1H.GAHB8Y6\H *'G=A@'(!!/(!&0#33X>TYYC++"9'\PR#+G
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ME<Q9-#U:4R0VWB#;;%=B)G+C@@Y8<YR1T]*FDT?4_L/E7&L!I!*7WLQ4*I7
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MY*Y%>BJ<ERNZ:OYE"YC<6DQ(X\MN_L:N0_ZB/_='\JCO/^/&X_ZYM_*I(?\
M41_[H_E5&(^BBB@ HHHH **** "BBB@ HHHH **** ,GQ1_R*>L?]>4W_H!J
M70?^1=TS_KTB_P#0!47BC_D4]8_Z\IO_ $ U+H/_ "+NF?\ 7I%_Z *G[1T_
M\P__ &]^AHT4451S!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<I\0O^193_K]MO\ T:M=77*?$+_D64_Z_;;_ -&K45/@9TX+_>(>J.KHHHJS
MF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *0G )]*6B@#BO^$KTA)[6./1E>>ZPD2Q^43R<*"<\9YR
M#T[U+=:SI.G.T[Z0C1W5JMS(556D/##:5ZD +C(X&?>NM\F+(/EID$D':._6
ME,:$@E%) P#CM0!QJ>*-'$:2#1E0)@ %8E9?ER< G.,="/O'@4^3QK8I ]Q+
MI-RI8 #*H2X('7!X^5EZ^N*ZWR8N/W2<  ?*.W2E,4;+M9%(/4$4 <S?ZYI=
MM<RB32XW8*JEG\I&.X!R#N.0,=SP6XZU"OBK3A;M=7&E-#"D86)I-A9P0"%
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M)]+N='^VKJ^H7<:I:V\(SY;C'[S.3MZ;B3Z>]=GK=E%?VDL$KPJ/,W?O4W#
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M:]_X,&H_X0FV_P"@UKW_ (,&KIZ*/9Q[!]=Q'\QS'_"$VW_0:U[_ ,&#4?\
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M0FV_Z#6O?^#!J/\ A";;_H-:]_X,&KIZ*/9Q[!]=Q'\QS'_"$VW_ $&M>_\
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M!%=):6R6=I#;19\N%%C3)R< 8%344U%+8SJ8BK524Y7"BBBJ,0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!@B02&0(H=A@MCD
8CZT^BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gnhmo5dgyo1b000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gnhmo5dgyo1b000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )D J0# 2(  A$! Q$!_\0
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M,91Y78****"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPS<_(JE)&NI@ARW!)]"N3^!KMCX4T(LK'382R]"<Y'TYIW_"+:)_T#XOS/\
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M+X'_ !*NW_/S+_\ %4?\(!X7_P"@5_Y,R_\ Q5 'LM%>-?\ " >%_P#H%?\
MDS+_ /%4'P#X549.F #IS<RC_P!GH ]EHKQK_A /"_\ T"O_ "9E_P#BJ/\
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MR/D\1&M#$SE"+W?0UX-2\*EE-Q9$;""=MOGS./FW'/KWIO\ :/A8JRBP56
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M-OYB"1=C/+GA<9R00?TJBFK::?!;:3(9EN=QD&$RI?.>OIC'O5+_ (1?7O\
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MM=G7&?%G_DEGB#_KW'_H:T =DOW%^E<W?:MKZ:I<P6.EK);P.A5G1AYJE?F
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M#/"__@;/_P#&Z/M/Q*_Z!GA?_P #9_\ XW0!V=%<9]I^)7_0,\+_ /@;/_\
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M$K_H&>%__ V?_P"-T =G17&?:?B5_P! SPO_ .!L_P#\;H^T_$K_ *!GA?\
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M,A=F96)))Y7IWK&^T_$K_H&>%_\ P-G_ /C='VGXE?\ 0,\+_P#@;/\ _&Z
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M9_Z"5I_X!'_XY1=]@]E'^=?C_D:5%9OV;6?^@E:?^ 1_^.4?9M9_Z"5I_P"
M1_\ CE%WV#V4?YU^/^1I45F_9M9_Z"5I_P" 1_\ CE'V;6?^@E:?^ 1_^.47
M?8/91_G7X_Y&E16;]FUG_H)6G_@$?_CE'V;6?^@E:?\ @$?_ (Y1=]@]E'^=
M?C_D:5%9OV;6?^@E:?\ @$?_ (Y1]FUG_H)6G_@$?_CE%WV#V4?YU^/^1I45
MF_9M9_Z"5I_X!'_XY1]FUG_H)6G_ (!'_P".47?8/91_G7X_Y&E16;]FUG_H
M)6G_ (!'_P".4?9M9_Z"5I_X!'_XY1=]@]E'^=?C_D:5%9OV;6?^@E:?^ 1_
M^.4?9M9_Z"5I_P" 1_\ CE%WV#V4?YU^/^1I45F_9M9_Z"5I_P" 1_\ CE'V
M;6?^@E:?^ 1_^.47?8/91_G7X_Y&E16;]FUG_H)6G_@$?_CE'V;6?^@E:?\
M@$?_ (Y1=]@]E'^=?C_D:5%9OV;6?^@E:?\ @$?_ (Y1]FUG_H)6G_@$?_CE
M%WV#V4?YU^/^1I45F_9M9_Z"5I_X!'_XY1]FUG_H)6G_ (!'_P".47?8/91_
MG7X_Y&E16;]FUG_H)6G_ (!'_P".4?9M9_Z"5I_X!'_XY1=]@]E'^=?C_D:5
M%9OV;6?^@E:?^ 1_^.4?9M9_Z"5I_P" 1_\ CE%WV#V4?YU^/^1I45F_9M9_
MZ"5I_P" 1_\ CE'V;6?^@E:?^ 1_^.47?8/91_G7X_Y&E16;]FUG_H)6G_@$
M?_CE'V;6?^@E:?\ @$?_ (Y1=]@]E'^=?C_D:5%9OV;6?^@E:?\ @$?_ (Y1
M]FUG_H)6G_@$?_CE%WV#V4?YU^/^1I45F_9M9_Z"5I_X!'_XY1]FUG_H)6G_
M (!'_P".47?8/91_G7X_Y&E16;]FUG_H)6G_ (!'_P".4?9M9_Z"5I_X!'_X
MY1=]@]E'^=?C_D:5%9OV;6?^@E:?^ 1_^.4?9M9_Z"5I_P" 1_\ CE%WV#V4
M?YU^/^1I45A:E)K.GZ?+="_LW*8^4V;#.2!_ST]ZW1G'/6A.^@IT^6*DFFGZ
M]/5+N%%%%,R"BBB@ HHHH **** "J&N?\B_J7_7K+_Z":OUGZ[_R+VI?]>LO
M_H!I2V9K0_BQ]44HO"NG>:]P3.9)9!*V7XSNW^G3('Y"JUMX+LHVF6>:::!B
M D); "A-HSW)&6Y]^E=)'_JU^@IU3[.-MC;Z[B%=*;U,-/"NGKYA+W#R21/$
MTK.-Q#*%SP."%4 8IB^$K 79NI)KJ60[/]9("!M96 Z=,J.*WZ*?)'L3]<K_
M ,[,FW\/6ELDR1R3XF@,#9<="6)(XZY8U73PCID<'DJ9PF&&-XZ,%![>B ?G
M6]6$OB[24TS^T+R<6<!N9+93-U+HQ4],\?*3[#K1R1["6*KIMJ3U'?\ "+:<
M;GSF\YL2>8B,_P J'>'( QT+ $YSTH_X173]X?=<;@P;=YG.0S/G./[S$_@*
MA;QSX95RC:O "&"Y(;!R2,@XP5X/S#CCK4-UX_\ #MOI\]W'>_:/*SB*)&WO
M@9X!'3C[W3WHY(]A_6Z_\S)5\&Z<MNT(FNR'W[V,@W/N !R<>BC]:GB\*Z;%
M(C+YQ$;AHE+\1@/OVCCINYYR:AE\9:7;:O<6%TSP>0D;-*ZG:2X) &.3@#)/
M058_X2S0_P"SWOQ?J;59C;^8$8AG'4+Q\W0\C(X/I1[./8;QN(:UFQ[>'+![
M"ULG$K06RNJJ7Z[E*G/KPQHL?#UG8WBW:-+)<*K*9)&!)R%'. .@4#CM69??
M$#0[5-UM.;[$IC<6Y!VG!.><9'!Y&:L2>,M*@UF]TZZ=X&M#&K2R*=K,R[N,
M=@,$GH,T^17O8CZS6<6N9V?Z[BCP9HW]H7%ZT,CS3B0/N?CY^N/3'./3)]:D
M7PKIX\PN\\DDD;QO(SC<0P4'MCHH'':JQ^('A=6VG55Z$Y\F3!P2.#MP>5;I
MZ&F:G\0/#VER>7+<RR2!2Y6&!W(787!X'0@<$<4E3CV*>-Q#WF_O+<7A/38)
M(F0S 0D>6N_A0'+@#CIN/Z"J]EX42QUB&YBFQ:P'>D7)+/LV[F/K@GI3X?&^
M@R2".6^2&0DX60$<#/).,+T/!P>*U=+U>QUFW>>PG\Z-'\MCL92K8!P0P!Z$
M?G1[-=A_7J]FG+?0S7\':2^HSWY2;[1-YFYO,Z;Q@X^G./0DT#PCIH1X]]P8
MV5D"EQA0P4'''H@'YUOT4E"*Z!]=Q'\[T,V[T2UO+Y;N5Y=R[,(K#;\C%EXQ
MZFJUEX4TRPOHKR%',L:!!O(;H" W3(.">E;=%/ECO8A8FLH\BD[;&#)X1TR:
MZ%Q)YKR!G;YB"/F;=W'8\CO4%YX-LYK%H()IHG*A [-G VA#_P".@_B2:Z6B
ME[.%K6+CCL1%IJ;T.?D\'Z?*&+3W?F,#OD$N&;)!.>,?PJ.G04U_!>E2)&C&
M<I'LV*6! VILZ$=QU_I7144<D>P+'8A;38U$6.-8T4*B@*H X %.HHJSE"BB
MB@ HHHH **P/$'B_3O#<PCOLAFMY)T^91OVE1L&2,L=W ]JK2?$#0(;4RR71
M,JJ&:&-&=N3@ 8&"><X!SBA:AY'445S]SXQTJ+1+K5;9Y+R&VE$+"&-LERP7
M R!W/7I4L'B[0[BY@MH[]6N)I/*CC5&)9L9...1U^;IP>: -NBL&3QIX>B+!
M]20;96A)\MR-Z_>&<8XQR>@H'C3PXP8IJT#XE\KY,GYOP'W>/O=/>@#>HKDK
M3XA:1<W<L3[H88ER9WY5VP#M0#EOO#IZUH:AXNTG3TLB9FF>\,?DI$I)*NP4
M,?09/?\ #FBP=+F[17-_\)WX?^T21BZE*Q1-++(+>0K&%8*P;Y<@@GN*N7GB
MK0M/>)+K4X(FFA\^/.3NCQG/'KV]>U &Q17,_P#"?^'!<&(WDF BL'^SR$$L
M6&T87.[Y3QBGZEXTTNQTY;R!FO5:=( (!P&9=XR3P!MYH Z.BN:/CO0<($O8
MY&W*LH1N(@RD[B>A Q@XSS4FC>-=&UN^DLK::07*R.BQ/&P+*O\ 'T^4'MNP
M>*=F&QT-%%%( HHHH **** "BBB@ HHHH ***YB\\;6%AKMYIMRHB2S17GGD
MF084KNRJ9WM^ H Z>BL&+QIX>F^[J(&)#&=\3KAAUSE>,' )/&3CK4I\5Z*-
M/MK[[:/L]T2(&,;#?CN 1T]SQR.: -FBN9LO'WAN[LK:X?48[8W& (YP4920
M#AL]!R.>G/6FCQ]H4EZ]K#<;V%LUPK$%0P&<CGGH,YQC!!S3L!U%%<\/&_AT
MQ2.=20>60'4(Q.>>F!\P&TY(R!@UNP3Q7-O%<0N'BE0.C#HRD9!I 24444 %
M%%% !1110 4444 %%%% !1110!E>(_\ D W/_ ?_ $(5JUE>(_\ D W/_ ?_
M $(5JU/VC:7\&/J_RB%%%%48A1110 4444 %%%% !6?KO_(O:E_UZR_^@&M"
ML_7?^1>U+_KUE_\ 0#2ELS6A_%CZHO1_ZM?H*=38_P#5K]!3J9F]PHHHH$%<
MW+X&T2<,LJ7$D9G:X6-YV9(Y&)+%5)P,[CGZUTE8P\6:%YCQG48ED1@K*P((
M)_#VH#H85A\,]*M[R2>\F>["N#:H5VK;H&8[%&<8^8\8 ]JT)_ 6@3PB,V\R
M 1B+,=PZG9S\N0>ASR._%:3>(M(5K@-?1C[-$)I6P<*AZ'.,<^G6JD_C;PY!
M(T9U6"21"H=(CO*;EW+D#H"*:NQW);[PKI.H3--/ _FMM!=)64X"E=O!Z%20
M1W%#>%=).DPZ:D,D5O!*9H?*E96C8DYVL#D?>8?0XI[>*-$2PM[Y]2@2UN9/
M*AE8X5VYX!/T-,M?%WA^]@NIK;5K:6.U17G*MS&K?=)'7GM2$4X_ 'AR*$PQ
MV)6,R&0*)&&"0<\YSCD_G5R^\*:1J-S+<7$#F69@9&65EW#:$*G!^Z5 !'0T
M/XMT%"<ZG 0" Q4Y RI89/T!_'CK4?\ PFOAGSU@.M6:R/\ =5GQGY=QZ]\<
MT]0&#P3H(CCC%JX6- B 3-P 7..O_31OS]JJP_#GPW;N6CMIPQ0QY-S(3L(9
M=O7IAFX]ZTT\5:(UG:W9U".."[D:*!Y 4$C+G(&1[&G?\)/HV 3?Q@';R58?
M>Z=OQHNPO<H2^!=$EMKB+R92TV"SO*SDL,X)R>?O'K5OPQX?/AW3I;9[V6]F
MEF,TDT@P6) '<GLH[U%_PFOATJ7&IQF,+O+A6V@9 ZX]2*LGQ-HPAFF%_&T<
M+(LC*"0I<@+VZ<]>U&H/S-:BL6Y\6Z):06T\U\!%<Y\IQ&Q!P0#G XY(ZTLO
MBS0XH+F4:A'*MM.MO/Y(,AC=N@(7..O6D!LT5C_\)5HNU6-^@1L88@@'/X?_
M *J27Q7H4(W/J<&W>4W*<@,"!@X[\T ;-%9G_"0Z08FE%_%Y:SBW+9./,/05
M5E\9^'H!(T^J0PI''YK/*"J[=VW.2,'D4 ;M%8DWC#P[;QRR3:Q:QQP_?=GP
MHY Z].I%6[_6]-TQK1;RZ2(W;E(,\^80I;C\!0!H45#:W,-[:0W5NVZ&9 Z-
M@C((R.#4U !1110 4444 9NI:#I^K2,]Y"79K=[8X<CY&(+#C_='-9W_  @V
M@^1Y(M9 N=PQ.^0=NW(.>N*OZAXAT[2[^&SNY6266-I0=A("KU)-(OB71GMW
MN%U"(Q)(L3/S@.V"%^O(H7D!%#X5TJ%+U1'*QO94EG9Y6)9D.5_44VQ\):/I
MVH1WUO;NMQ%N$3&5B$5@?D )P%Y.!T&:D7Q5H3.B#4X-S_=&3ZX_#FHSXOT+
M[+9745\L]M>R-'#- I=,KG<20,*!CDG H S[_P"'VD7^KC4'>X5G9S<*LK#S
M@RE=I(/"\G([YQ4\7@+P];H$M[1X )"Z^3*R$ _>0%2#M/\ =Z5./&GAUX(I
MTU2%X9?N2)EE;C.<@=.#5^XUO3;2SMKNXO(XK>Z=$AD<X#L_W1^-/78/,R_^
M$&T$0I&MM(HC.8V6=PR'"@$'/!&Q<'VJ2^\':/J"VRW$=P1 BQC;<NI=5;<
MY!RV#SSWJ2?QAX=MKZ2RGU>UCN8RP:)WPV5&6^N!Z5%)XVT")());[9'/#YT
M;M&P#+NVCMG)/;K2W#R*9^''APP>3Y%R%;=OQ=2#S,XSNY^;IWJ[=>#-#O)+
M=YK0EH+86J'>?]6.@/T['K2Q^-/#DA11J]NKLRKL9L$%E# $'IP0>:(_&OAR
M6:&)=6M]TT@BBW$J'<D@*,]3Q3UV%H*/"&DIJ"W\44BW*/YJGS6*[\L02N<'
M&YOSJ+3/!VG6'A^#29<SI',]PSC*;I&+9. >!\Q &>F*T=0U>+3IDCDC=BR[
M@5Q53_A)[;_GA+^E9NI%:-E)/=%:+P#X<BCEC2P_=R$,R;SC(!'U[_GS4EEX
M+T>QO+>[C2X>:"5YD>6X=R788+$D\G%2_P#"3VW_ #PE_2C_ (2>V_YX2_I1
M[6/<.5LW**P_^$GMO^>$OZ4?\)-;_P#/"7]*7M8=PY6;E%8?_"3VW_/"7]*/
M^$GMO^>$OZ4>UAW#E9N45A_\)/;_ //"7]*9)XKLX8GEDCD2- 69F(PH'4FC
MVL.X69OT5@1^++.:%)HXY'C=0RL,8(/0UO*VY%8=QFJC)2V"PM%%%4(*P[[P
MGIFH7EU<SFZ!NU5;B-+EUCEVC RH..!6Y6/-XHTFWU&XLI[@Q26^T2,RG:"W
M09_&CJ!%/X/T6Y),MNY#222./-8"3>VYE;GE=P!QTR*DF\+Z7/96-HT<JQ62
M>7#Y<SJVS !4L#D@X&0?2I&\2Z,D$,[:A$(YPYB;GYPOWL<5#)XO\/0K*TNK
M6R+$F^1F; 5< YS]"* ZW*K^ ?#DDL,DFGAVB18UWL6!0*%"D'.1A1^5-7P!
MX?63S3;SO,(O)$KW,C,(\$; 2>%P<8':M&\\3Z)I\/G7>I6\,1B67S&;Y=C'
M"G/3DGBI;77M-O+M;2"Z5IV!94P<D#&2/;D4]0O<P=5^'VG7EG'%83RV$\>0
MLZEG(4EBR]1UWMW]NG%=196J6-A;VD9)2")8E)ZD*,#^543XFT4:BVGG48?M
MBRB%H<G<'(R ?PH/B31@]VG]H0E[-BMP@)+1GC@CKW%*X/>[-6BL3_A+M \M
M9#J<(5C@9!!Z9Z8]*3_A,- ^T20#4HFDC+"0*"=A7&03CCJ/KGB@#<HK'O/%
M6A:>\<=WJ<$,DD/GI&YPS1YQNV]>IHMO%6AW;1+!J,3M*ZI& #EF;. ./8T
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M6EOI=S%$Z-<3)(IVD*0,@;CUSD8_G71:AHFEZK:"UOK""X@&W$<B CY2"!]
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M?:P/0?\ A*;_ ,[R?LFB^;DC9_;'S9'7CRJ:OBV\=E5;;1&9B  -8SDGH/\
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M1BNK!XBI5FU/L-3A+2)T]%%%>B,**** .>US5]:L-6M8-.T<WMJ\3O*XR"K
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M5@RD9!!R"*6N.\*>$+_0-4>YN-2,T'V9(8X(W;8FT*,;2.@VD@Y_B-=C0[=
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M#]JA_O'_ +Y-'VJ'^\?^^33,B:BH?M4/]X_]\FE6XB=P@;YCT!!&: ):***
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M&UOKV/?(S\%. WWE^[T/'/7CK3[[P=8WUW%<FYNHGC$@'EE<'><GJI[UT5%
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M<K\0@3X2F Z[U_K755RGQ$S_ ,(C/@X/F+2 L2P6UIHMG)%9VGF-&F2\(/\
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MI=_^ 4W_ ,31S+N'U>M_(_N9I45F_P!NV/I=_P#@%-_\31_;MCZ7?_@%-_\
M$T<R[A]7K?R/[F:5%9O]NV/I=_\ @%-_\31_;MCZ7?\ X!3?_$T<R[A]7K?R
M/[F:5%9O]NV/I=_^ 4W_ ,31_;MCZ7?_ (!3?_$T<R[A]7K?R/[F:5%9O]NV
M/I=_^ 4W_P 31_;MCZ7?_@%-_P#$T<R[A]7K?R/[F:5%9O\ ;MCZ7?\ X!3?
M_$T?V[8^EW_X!3?_ !-',NX?5ZW\C^YFE16;_;MCZ7?_ (!3?_$T?V[8^EW_
M . 4W_Q-',NX?5ZW\C^YFE16;_;MCZ7?_@%-_P#$T?V[8^EW_P" 4W_Q-',N
MX?5ZW\C^YFE16;_;MCZ7?_@%-_\ $T?V[8^EW_X!3?\ Q-',NX?5ZW\C^YFE
M16;_ &[8^EW_ . 4W_Q-']NV/I=_^ 4W_P 31S+N'U>M_(_N9I45F_V[8^EW
M_P" 4W_Q-']NV/I=_P#@%-_\31S+N'U>M_(_N9I45F_V[8^EW_X!3?\ Q-']
MNV/I=_\ @%-_\31S+N'U>M_(_N9I45F_V[8^EW_X!3?_ !-']NV/I=_^ 4W_
M ,31S+N'U>M_(_N9I45F_P!NV/I=_P#@%-_\31_;MCZ7?_@%-_\ $T<R[A]7
MK?R/[F:5%9O]NV/I=_\ @%-_\31_;MCZ7?\ X!3?_$T<R[A]7K?R/[F:5%9O
M]NV/I=_^ 4W_ ,31_;MCZ7?_ (!3?_$T<R[A]7K?R/[F:5%9O]NV/I=_^ 4W
M_P 31_;MCZ7?_@%-_P#$T<R[A]7K?R/[F:5%9O\ ;MCZ7?\ X!3?_$T?V[8^
MEW_X!3?_ !-',NX?5ZW\C^YFE16;_;MCZ7?_ (!3?_$T?V[8^EW_ . 4W_Q-
M',NX?5ZW\C^YFE16;_;MCZ7?_@%-_P#$T?V[8^EW_P" 4W_Q-',NX?5ZW\C^
MYFE5*^!:6V ZEB/TJ+^W;'TN_P#P"F_^)JO<:S9O)"ZB[/EMDC[%-S_X[1S1
M[A]7K?R/[F4'\+M'?&ZM)$M2XQ/L!_>#Z=!TZXK2O]+^W,JL[+M /R2%3Z=N
MU(?$-H01Y%]R/^?.7_XFJ-U>:5>3B>2WU)90%&Y+:93@'..%]ZS4*:V*]E6_
ME?W,OQZ:T&G26ZR8R1AF;./J35+3] N[35Y+^XOS.'Q\A0 +CT/6H/-TM8I8
MXTU1?, !)MI6QAMV0"N,Y[T))I:*!MU=B!@EH)N?_'::44K7%[&MORO[F6;[
M0[V[^T(NHF..7/R>6IV^E:MA:M8Z7!:LYD,484OC&[WK(M-0T^R&(DU0@G)W
MV\S9^N5JX?$-H1CR+T9_Z<Y?_B:J\>XO85OY7]S-=?NCZ4M9@UVQ  Q=_P#@
M%-_\32_V[8^EW_X!3?\ Q-/F7</J];^1_<S2HK-_MVQ]+O\ \ IO_B:/[=L?
M2[_\ IO_ (FCF7</J];^1_<S2HK-_MVQ]+O_ , IO_B:/[=L?2[_ / *;_XF
MCF7</J];^1_<S2HK-_MVQ]+O_P  IO\ XFC^W;'TN_\ P"F_^)HYEW#ZO6_D
M?W,TJ*S?[=L?2[_\ IO_ (FC^W;'TN__  "F_P#B:.9=P^KUOY']S-*BLW^W
M;'TN_P#P"F_^)H_MVQ]+O_P"F_\ B:.9=P^KUOY']S-*BLW^W;'TN_\ P"F_
M^)H_MVQ]+O\ \ IO_B:.9=P^KUOY']S-*BLW^W;'TN__  "F_P#B:/[=L?2[
M_P# *;_XFCF7</J];^1_<S2HK-_MVQ]+O_P"F_\ B:/[=L?2[_\  *;_ .)H
MYEW#ZO6_D?W,TJ*S?[=L?2[_ / *;_XFC^W;'TN__ *;_P")HYEW#ZO6_D?W
M,9XC_P"0#<_\!_\ 0A6K7-Z]K-I+HMPB+=%CMQFSE'\0_P!FND!R,^M)-.3L
M74A.%&/,K:O\HA1115',%%%% !1110 4444 %%%% !17(6^F^)4\32WAN6CL
M'NMQ@#H5:/# D\9S@1@ $=365+9^.[Q[J*X!BMYIOW2Q3Q_NQGG<3R4QV'S?
M2@#T2BO,+CP_XPO+\W+?:$SPHDGA/.W'( ^YGG;UQUS6O86'C,ZC!+<7TL5I
M&T>86:)B^6'F;L+]W .T YY&::0/8[BBN1L;'Q'%XAED>2=;*2Z>4AY8V39R
M-N,;N0$VXZ<YK'_L3QE;>==6-Q(L\F5:.>9'RGS,<=!G<QV\C '-+H'6QZ-1
M7#:MHGB6_?2A]KFWP6^9YHI$C4R@[A\ISSD*,\CK3)K/Q^K6[V]]"9&5WD$J
MHR(PR%7 (.",=,\GL*8'>45QK0>+E\/V">9)+?B8O,5>./"]D<G((]UYZ>]9
M\6D^.["*VM;"\A\E 6W3[7P^U20W(.PMO QDC@T@/0J*\]@TWQJ%\^XGN6NF
M6-!Y<L2*J[B6!!SST&1S@\<BK7B.S\7W&K&32RXABYC/F1["I4 X!PWF9+')
M.W% '<45Q*VWC',PEEG?+1KNBEA3H.2@(.%)P6W9/4#UK/FT;QJ=6@NUG>2=
M+;Y)FDB$:RDY974#)C &,#GGK0!Z-17!V%AXSGN[!=6E9K83++((VC4( 22K
M\DMR%V[>@SFJUW9>.KS6WD\HPVR2L]L4N(\1M@JI8'DI@\C&>>* /1:*XA;7
MQQC,=RJB0/N%PT;&-@ 05VC[I8$ =0#SS5FWC\07'A*]L;TS/JA7AHRD; ,?
MNALE<@9Y]Q0P.NHKSR/2?'&GVD$%C>!EW>8YF*.5<@L1U'R9..YR,]*U=,M?
M%MMJ4S7=TMS:I:_NEDV#S92N<$KC;ALC.,8Q0!UU%>>+:?$&33F9K@PSJ_RQ
MAXF+*S'.3ZJ ,<]SUK=UN+Q.?[&339%?8X-\X98P_ SD') ZGC)[>] '345Y
MW;67Q(V_O;^V#RB7=N5,0L,%"N,[@QR.<8!-.%EX^&C,\ES))>B,>7$CQ1_.
MS'.X\YV@#'(SGVH ]"HK@6L/&=MX7D%LBMK=U=!YI1.@" (JAL'@@[>@]:R+
MG1?B!<74]T[RF26U:V?R[B)<M\Y!CXPL>=F<_-3L!ZK17E*^'/'5O%9Q6C",
MQ$R8:6)H007QE<;B^!'AOKFM<6WCV/$RRM(L;#R[>2:(,Z'>2)&"XW#Y!E>.
M?:AH#OZ*X+3].\8IIE]=WC ZL;/R+;$B$@^8Y_W<A2O7KCK5 Z3\0(VEOK6=
M8[N:-4DBDF1U(5!R.!\^XMCD#USUHL!Z917G$6G_ !$)E6\U R1#RU3[-Y43
MLNY2?F).' W \8/:M6TMO%C>#]1AO</JLDC"#S)(V^0XZX&T=^/Y=*70#LJ*
MX&72_&@LWM#?37.4(24R1+DE &W_ "\KG=@+@CN:JRZ?X[N+);1PR1B*.-!Y
MT6-ZGYGDQR4(Z!>>.U,$>D45PMI8>,)Y=-CU.5VA\Y99_+:-0@#$E7Y);HNW
M:?K5G2M/\507]W<W=T?)E,Y2V!CV)G'EX(&<DY))-%@.QHKS2VT/QOI]HHL;
MJ53.V;@7$L<C)T4%>@SA03ST.,9KTB(.(D$C!I HW,!@$]SBBP#Z***0!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M);[G0G/0]NM=3X:BU"+0+8:I++)?-N:8RA00Q8G&%XP.WM6M12Z6#K<****
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MDVKM<FXGNW=!<;0PCP ORJ2J\#.!ZUT5 !1110 4444 %%%% !1110 4444
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MUF^M+K7[F"YFN_-*;?+VNV\[0Q&"2&/0]*]4K,O=!T_4#)]JB:02,68%S@Y
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M(R,W0\J<CJ/TZ5M6NGP6ED;2/>82",,V< ]J.@=1D6L:9,Y2._MF<9ROFC.
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M7,BRJ5VCJ<YQCWK.O/">E7PLUFCE"6A8QHDK!23UW#^+\:$\+:<D-]$!(%O
M Q5MI11R I'3G)H L?\ "1Z(%#'5K( ],SJ.Q/KTP"?PJP^J:?$4$E_:H7C\
MU0TRC<G]X<].1S6$? &B$3<WN9E",?M3Y  QP<\>M7_^$6TK[3;3&%R;>.-(
MU+DK\GW21W(]:>@%C^W](^V7%H=3M5N+;_71M* 4X!YS[$?G4D6LZ7<!S#J5
MG)L^_LG5MOUP>.AJG/X6TJYOVO)87:1CN8;SM9NQ(]14,O@W1Y?+_=S1[#G]
MW*5W#T..H/I2 THM8TR9U2/4+5I&<(J>:NXMC.W&<YQSBKM8%GX.TJQOEO(/
MM(E6;SANG8C.W:!SV [5OT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6;XBNIK'PSJUY;/LG@LYI8VP#M94)!P?<5I5C^+?^1,UW_L'W'_ *+:@#PQ
M?B'XQ**?[?EY&?\ CV@_^(IW_"PO&/\ T'Y?_ :#_P"(KF8_]6O^Z*[*UL]
MN=+TRQ>.);^ZAWO<"4)Y;!VSN8D@$J,!=M<JE)]3Z"=&A#>!3_X6%XQ_Z#\O
M_@-!_P#$4?\ "PO&/_0?E_\  :#_ .(K>D\$>'(?WLFNS&!RRQ$-&-S+C=R>
M".5Z>]12>#O#2QJZ^(7.YPFT-&2GS$9;'8X_"G[_ ',O]E_E_ QO^%A>,?\
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MZ55+NJ+C+$ 9-/GEW#ZK1_E1T?\ PL+QC_T'Y?\ P&@_^(H_X6%XQ_Z#\O\
MX#0?_$5OW7ASPG<QQB#48X/LNVVN##*N99"5&_Y^"O+'*\<46G@S0C8F&35(
MI;VY98H?+F20HQ;A@!V.>1@XJ_?[G-_LUKN'X&!_PL+QC_T'Y?\ P&@_^(H_
MX6%XQ_Z#\O\ X#0?_$5NR>%_#+6XABU$*T:E7E:6/?+(K,"H!/RYP.3Q@BL#
M6M"TVPTM;JSOFEE$OEO')+&3WY4+G(&.3G\*EN:UN7&&&D[<OX#O^%A>,?\
MH/R_^ T'_P 11_PL+QC_ -!^7_P&@_\ B*YNBIYY=S;ZK1_E1TG_  L+QC_T
M'Y?_  &@_P#B*/\ A87C'_H/R_\ @-!_\17-T4<\NX?5:/\ *CI/^%A>,?\
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M]B^X?VG'^7\3Y;+1DDEE)/4YHW1CHR_G7U)_9>G_ //C;?\ ?E?\*/[+T_\
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M^%^4<GC)]/>JVG:CXB;4H(+ZQ18#&YED2(@;E Q@[N,DGCD\5)K7_"1[M/\
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M#6K]JM_^>\7_ 'V*R=#D235_$11U8?;D^Z<_\N\-)Z@;=%%% !1110!AZ/\
M\C%XB_Z^(?\ T0E;E8&E311^)/$0>5%/VB'AF _Y8)6U]JM_^>\7_?8H EK-
M7P_I"0/"NG6PC?.Y?+&#GK_,U=^U6_\ SWB_[[%'VJW_ .>\7_?8H SQX:T4
M6L=J-,MA!'C9&$^48(/3\!^52'0M*-]->G3[<W4X EEV#<^.!DU<^U6__/>+
M_OL4?:K?_GO%_P!]B@"A_P (YHWD00_V9;>7!-]HB78,))_>'O3YM"TJXEFE
MFL('>9E:1F3EBO0U<^U6_P#SWB_[[%'VJW_Y[Q?]]B@"E-H&DSF+S;"%O*;<
M@V\ _3O3(_#>BQ6TMM'IELD,I)=%0 ,3G/\ ,UH?:K?_ )[Q?]]BC[5;_P#/
M>+_OL4 5(-#TJVD+P6%O&Q(.50#D8Q_(?E4MQI=A=E3<6D,I63S1N4'Y\8S^
M53?:K?\ Y[Q?]]BC[5;_ //>+_OL4 166G6>FQ&.RMHX$/4(N,U:J+[5;_\
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M_P#"M:B@#)_X1?P__P! +3/_  $C_P */^$7\/\ _0"TS_P$C_PK6HH R?\
MA%_#_P#T M,_\!(_\*/^$7\/_P#0"TS_ ,!(_P#"M:B@#)_X1?P__P! +3/_
M  $C_P */^$7\/\ _0"TS_P$C_PK6HH R?\ A%_#_P#T M,_\!(_\*/^$7\/
M_P#0"TS_ ,!(_P#"M:B@#)_X1?P__P! +3/_  $C_P *T+6SMK& 06EO#;P@
MDB.% BC/7@<5-10 4444 %%%% %:33[*5V>2SMW9\EF:)23G .>/8?D*;_9>
MGY)^PVW))/[E>22"3T[D _@*MT4 5?[,L,Y^PVW_ 'Z7W]O]H_F?6D_LK3AG
M_0+7G&?W*\X&T=O0D?2K=% %7^S+#.?L-M_WZ7V]O]D?D/2D_LO3]V[[#:[O
M7R5SUW>GKS]:MT4 5/[+T_&/L%KC&/\ 4KZ$>GH3^9H.E:<QRUA:GJ.85[C!
M[=P,5;HH J_V;89S]BMLYSGREZY!]/4 _A2?V7IXVXL+7Y2"O[E>",XQQVR?
MSJW10!4_LK3MNW[!:[<8QY*XQC&.GIQ]*&TO3W!#V%JP;J#"ISSGT]0#^%6Z
M* *O]FV.[=]BMLYSGREZYSGIZ\_6D_LO3MNW[!:[<8QY*XQC&.GIQ]*MT4 5
M/[+T_;M^P6N",8\E>F /3T 'T%6Z** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "N:F\>^'+>ZDMYK\+)$SI+\A/
MEE2P(;'3[IQZUTM<%J\-K'J-PMYX9L[RS65DW0LQE(8;G." "<OT!Y)/I0!N
M#QOX?"S-+?>2L3LA,L;+G: 2>G3G\3Q4]CXKT34-X@O5S'&TC"1&0A5/).0/
MKCKBN'?5?#YL8)#X-=F>)9%MQ+&2-S>6,_-M' !R3^M;=]=:9IOB&:UMO#R3
MW#P W#JX!,;D[ACGGIUZYQ3:$;,GC+0TL[JZ2\,J6L(GE6.-MRJ3M&01P<@\
M'GBHX?'/AR6-&;4DB9HUE\N12&"DE0<?4'I7*QZWI(M)K"#P?.L%TDB2"2:-
M5=(VPI8[B>2Q]QWI[/X4@TVROF\,QEKR<VRHC;FPC<MGH>1GW]31H,Z>'QUX
M;FMXYQJ2!)"ZC*-U3.[/'&,&IH_&'A^569-2CPO)W*R_S'^>E<A'#X:F6ZOK
MWPU-IT>DRB(IYPV2&3ALHK<XSGYAWR*2YU'PY/>E)?"CR[IV9Y%=<(43=N/(
M]>5&>Y(HT#4Z^'QCH-S):1V]\)GNY3%$$C8Y8>O'RCW/7M59_'_AR-<F]<L'
M5&00N64DXR>.G<GL*Q8[S183I-__ ,(]$KM'+<QM'+S$%X4CH&R%Z]N/6HM1
MN]*L=1M+:W\-0N9[9[IU?(89!P,#/7;SZ<4.P;_U_7D=%-X\\,P,BRZJBEP"
M!Y3\9SU^7@\'@\\4V?Q[X<@F2$7WFR,%.V*-FVJ5+ GC@8!KEO[1TN'R8T\+
M0^63'D%F+N0N7VY'S%2QY)Z<U-)%ING:5!J%]X1@BGN96WQ"3;L55.&.>.^#
M]:&@.OA\6:'/<P6\6HQM-<.8XE"M\S#'MQU&">#GC-;-<*;O1=/O88;/PX9+
MGRENMD9&^-F((!!Z8P/88 ITGQ&\NPM;C^P;LR7$9D6 31[A\^P9.[:,]<DC
MTZT6 [BBN3U#QJ]A#-(=#O92C+L560;U+;<DD@+\P(Y/OWJ?5/%4FFW4\;::
M[QQ1AQ)Y@&3MW,I],#'.<9XI =+17'0^.GEG\H:/,789C"2@[N!CJ!@9R">W
M'K5N+Q7)+I,UY_9S>9'*L(@$@+%B,D'CY?;/7@T =-17&1^.+O[;Y,N@S*KK
M^Z"S NS ?,,8Q@' SGWI9_'K6D1DN=%N8P75(_WBMO)(';IQSSUH [*BN.A\
M=2R3/$=%F\P1;T"2@[B>@SCIDX)Z U:N_%D]M<6R+I,DD<D"3RD2C=&&SQC'
M./KSF@#IZ*Y#_A/(HGD2ZTRYA=6VJNX,6;&=O'0XYQZ<U##\05GM/MD6EO):
M,,)-'.K(S9]1QMQCYO4XH [6BN8@\8I=R,MO82E8TE:4R.%*,BYVX]>GTS4-
MCXTN+F_L;.;0[B.2[DP'69&1$QG<2<9^@!/>G8#K:*XQ_B';_9K^YBT^26"S
MD:-Y%E4@L" %XSAB3T[=ZN6_BZ2>63=I,\4"0O/O:0;F0 8PH[DYX[4O,#IZ
M*Y1_%UV^B2:C:Z-(Y5T0*\P ;/+$$ Y 7G..<TYO&:QZ!<ZO+ILR0P[ H+@^
M:S=E([<CGH: .IHKCE\=2323"VT6XF6-@I_>JK+QSD'H1Z4LGCAXH)IFTB41
MHI=7:0 .!DGKTXQU]Z .PHKBYO'S6X1I='EVR3^3&5F!W'KZ=AR:>?'4D=E%
M*VAW3S221KY<4B[0'.%.]L#L?R'K3L%SL:*YF[\9VEGJ=Q9O;R,(I%A\Q2#F
M0C(7'8^GK55O'82:6)M)GW(RKQ(I^]TSZ$CH.YXI+4#L**XM_B$BF7;I%PRQ
MQS2%_-0+A&V@<GDD^F<<5J:KKU[!;V+Z7IXO9+@%Y%WX$:+C<2?J<4 =!17%
M1?$)6=$FT>ZB=KCR!N=><+N9NO 'HV#CFK.G^.%OH;R8Z5<Q16MHERSEU(8L
M,[1SG_@6,=?2@#K**Y:P\8F]BN&&FRAHK<3 +(#O)/RK^.1@]#SZ46?C![S4
M8K,:5+$Q.)6DD'[OY23]>G'J.: .IHKCYO'9M8O,N=&N8@TR1Q#>#YFXXSQT
MP.<&K&G^,3>W_P!EDTFZ@"VSW$DKE<(%.,;<[B3[#TH ZBBN/L_'J7<$5P-)
MN5@E^57#J=SEL!0.ISD'/O[5=OO%,EI>36\>FO,8'190)0& 9<DA<<@<<]SD
M46 Z.BN(/Q'MQ8R7K:;,EI&75IY)51 0<#)/0'U[5:T_QR+^[A@_LFY@$MRM
MNKRR(,Y3<3@$GCW ZYHL!UM%<Q:^+FN)M0B.FR(;2*27/F@API./IN'?ZCM5
M-?'<R20QW&A7*-(KN669-BHJ[LY)&<^@'O0!V=%<G:^-UN;+4[HZ5<1QV-ND
MQ9Y4 D++G:.<CZD 'M44GCJ2&>*-]#NW6:3"/$ZD; I);YL<\'"C)/6@#L:*
MX_3O'1O;BR272GM8[K&&DN$8I\I8DA<\8 Y![]J["G8 HHHI %%%% !1110
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M@B5>1@GU] ?R->"@D'(X.<Y_$G^;-_WT?6FJBHBHJA5 "J ,   @ >V&8?\
M CZT_J,NX?7%V/?/M]@"<7=L">O[Q?;_ !7\Q2C4;$]+VW/..)5ZY QU]2!]
M37@F#U(//?'^[_\ $K_WR/2D4;?NC');@=RP8GZ[@#]0#2^HON'UQ=CWS^T;
M'&?MMOZ_ZU?<^OH#^1I/[2L!NS>VWR_>_>KQQGU].?I7@F!C&!C&,>V"/Y,P
M_P"!'UH* AR5R'^\<?>^7;S_ ,!X^G%/ZB^X?7%V/?/[0LLX^V6^<XQYHZY
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M-1L6 *WMN01D$2KR.??V/Y&C^T++_G\M_P#OZOM[^X_,5Q*Z?8QJJK9VZJH
M $8  &<#_P >;_OH^M'V"R(_X](.?^F8]O\ XE?^^1Z4_8ON'M#MO[1LCTO+
M?J1_K5Z@@$=?4@?C1_:%E_S^6_\ W]7W]_8_D:XG[!9+DBTMQEBQ/ECJ2&)^
MI(!^H%'V&R'_ "ZP#'_3,>__ ,4W_?1]:/8ON'M#MO[1L>?]-M^.O[U>.,^O
MIS]*7^T++./M<&>G^L'L/7U(_,5Q']G6/S?Z';_-][]V.?EV_P#H)(^AQ2_8
M;,G=]E@)SG.P=<@_S53^ ]*/8ON'M$=HM_89VK=VV3S@2+SDX_4\?6@:A8 9
M%W; 'YLB1>>"<]?0$_A7%"PLE8,+2 ,  #Y8R &W#\FY^O-']GV.W:+.WVXP
M!Y8QC!7'Y$CZ$T>Q?</:';'4;%3AKRW'4\RKVZ]^U+]OL\X^UP9SC'F#KG'\
M^*XAM/LG.7L[=B0P),8/###?F ,^M.^Q6F[=]EAW9W9V#.=V[/UW 'Z\T>Q?
M</:':#4;$[<7EO\ ,0%_>KSGICFC^T;';N^VV^W&<^:O3&?7TY^E<2-/LALQ
M:6_R$%,1CY2!@8], G\Z/[.L=FS[';[<;=OEC&-NW'TV\?3BCV+[A[0[9M1L
M5!+7EN,=<RKQSCU]>*FCECF7=%(KJ"1E3D9'!%<&^GV4@8/9P,&.6W1@YYW?
MSY^M=!X2CCCTNY6-$0&]G)"J!DER2>">2?7!]A4SARH<9\QOT445F6-:-'V[
MT5MIW+D9P?44ZBB@"I<W.G.LD%U-:LHX>.5U(XP>0?J#^(I1J-AR!>VW!*D>
M:O!! (Z]B0/Q%?/'B*:5O$VKYD8YO)@>>OS8[$]E4=>PX'09OFR98^8V68L>
M>I)!)^I*J3[@>E 'TU_:-CG'VRW_ ._J^_O['\CZ4G]IV'/^FVW&,_O5XR-W
MKZ GZ5\S^?*#D2OGUW?[W_Q3?]]'UIHD<9P[#.,\]<*5'_CI*_0XH ^F_P"T
M;'_G\M_^_J^WO_M#\QZT?VE8EMHO;?=Z>:OKM]?7CZU\R^=+G/FOG_>_W?\
MXE?^^1Z4"60/O$C!L ;L\\-N'_CWS?7F@#Z9_M*QQG[;;8QG_6KZ$^OH#^1H
M.I6"G#7ML.IYE7L,GOV'-?,WF2[<!WV@8ZG &"/Y,P_X$?6D:1W.6=F.&')S
M]X!6_,  ^H% 'TW_ &A99Q]LM\YQCS5ZY ]?4@?C2?VE8G;B]MOF("_O5Y)Z
M8Y[X/Y5\T&:?=N,D@8G=DDYSD-G\P#]0*:)9 4(D8;"K)S]TKG:1Z8R<?4T
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M&22.2$[2S,HRA/&5"_\ ?+-[X/%8XNI"5.T7?4UPL)1G=H[NBBBO-.\****
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MI0!OT5C0:_Y]PD7V.5 \HB#,P],YQU_,41:^&^TF2V:-8%9MVX8.#@?3/^-
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MJ:SY5RA)7 R.3^ -:$.AV-OYOEH0)0P8>N3DT0:)90+*$C)\Q=C$G/R^GTH
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MQ.!TYXQ_6I9O"]G(HV33HP(RVX$GUZCOTJU;:)96:L($9 P8<'!^;&>?PZT
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gnhmo5dgyo1b000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gnhmo5dgyo1b000002.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[@ .061O8F4 9      "_^$,N$5X:68
M $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    '    '(!,@ "    %    (Z':0 $
M 0   *(   #" 2P    !   !+     $  $%D;V)E(%!H;W1O<VAO<"!#4S(@
M5VEN9&]W<P R,# U.C Y.C V(#$Q.C Q.C U   "H ( !     $   @TH ,
M!     $   &D          8! P #     0 &   !&@ %     0   1 !&P %
M     0   1@!*  #     0 "   " 0 $     0   2 " @ $     0  "Y
M        2     $   !(     ?_8_^  $$I&248  0(  $@ 2   _^T #$%D
M;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5
M#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  @ * # 2(  A$! Q$!_]T
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M64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M      $  /;6  $     TRU!1$)%
M                               *9&5S8P   /P   !T8W!R=    7
M   K=W1P=    9P    403)",    ;   *(&03)",@   ;   *(&03)",0
MH[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@  CBT9V%M
M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D("A35T]0*2!V
M,@
M                                              !T97AT     $-O
M<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B        "U
M6@  O&<  )(P;69T,@     $ PD   $                    !
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MY^@VZ8;JV.PK[8#NU_ Q\9#R[_1-]:KW!/A:^:OZ]OPZ_7O^N____P"  (
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M-^Z!@X L$GB#(("FWH2!2HVKR4Z X8O>LU& AXHOG&> 48C#A-2 ,H>,;(:
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MACN;:[$I=B*8>*U&94&5JJFN4[23*J<.02^1$J4Z+0Z/?9YV% *0#(V'  "
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M?#2G38T-;1ZCP8NT74&@8HJ!3(F=3(F).HV:P8CL)I29,8C_#3^:7(<]  "
M&H  BA"J09;$>ZZFEI3-;)BC!9+L7+J?H9$Y3 F<A8_1.C*9W8[T)EN8/X];
M#4*9)XCW  "  (  B:BIGI\@>T"E^)RK;":B9)I&7$B>_9@82Z&;WI9<.>.9
M+I6&)C:77I3<#4J8$8C\  "  (  B4NI-*>G>P6EBJ2]:^>AY*'.6_B>8I\C
M2TJ;.9TY.8J8F9RL)?.6RYER#4J7.8C\  "  (  B0.HZ+"">KRE,ZTJ:Y6A
M@JG 6Z.=]J:]2O^:Q:3Z.4Z8'Z+$)<B649F,#4.6H(CW  "  (  ?W*Y_VUL
M<>&UP&YI8[&QO6]Q5*NMZ7" 1)FJ8'&-,P&GDW)X'KNFT7+!!;VG/W-M  "
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M<$^PK9) 8@BL<9"74P*H8H\F0R6DJHX2,?ZAG8VU'H&@(XW@!R&>HX32  "
M (  ?9^T:9OF< NP$IFV8<:KR9>94KZGKY7$0N*C]I2",=*@WI1Z'GZ?+I*G
M!TZ=>(3Q  "  (  ?6JSZ:/E;]BOCJ%089"K/9[-4H:G&YRI0JRC7)MP,9R@
M2IKB'F:>?)2-!WF<=H4.  "  (  ?3:SFZQ';]"O*ZE6882JP:9=4F2F@J/K
M0I"BK:+#,92?CY_S'G:=R929!Z";Q84H  "  (  <J_%2&S>9:7 K&VT6!V\
M.6Z?2=.W[&^5.G6T 7"!*5.Q-'$M%):QZ7"X  "K*71[  "  (  <J+$=W1P
M9<._L72+6#J[!'352?&VAG5 .I:R=G6_*8VO?W8A%16OQ'6[  ^IZ7CG  "
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M93^Z8I;@5ZZU?Y4*26.PSY.-.C^LD)+"*;:I.),'%F"H+8\A D>AM(&*  "
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M*02"@753!3R#NW:-NDR O72SJ1" C76-EK. 9796@T^ 2W<7;N6 0G?=67"
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MEY:#^I=^AH&#,)5<=&^"@),S88R!\9$P3:J!AH]X.$6!18Y2'K6!6(W=  "
M((  IN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R-\> =I2Z
M'E& ;))7  "  (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!* EY]63%.
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MBH>,6ITP>GF*S9JU:7J)7I@]5ZV((98*1-6'')1;,%Z&5Y/T%O^&LH^-  "
M (  F1R-:*C,B?6+V*7I>=R*1*+-:-R(R9^W5Q*'B)T/1$"&BYM)+^:%O9HI
M%KZ%X8]A  "  (  F+V-"+)6B82+>Z[Q>5:)W*LY:$Z(4J>05I&'!J240]6&
M!*+V+X:%.)\=%FN%2(\H  "  (  D-B>X6C,@M><3&J-<]^: FPT8\27[VW%
M4H>6"V])/^R4AG"Q*TJ3Z'&S$&R6WG$O  "  'W0D$"=C7%C@DB;$')1<SR8
MPW,Z8R:6HW0B4?"4MG4,/V63*G7I*M.2=79Z$#B4]77R  "  (  CYB<(7G9
M@769NGH2<GV7;7I-8F"54WJ543V3:GKI/LN1X7M *EF1''MQ$ :3+WLE  "
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M?B*54J)#;P"3 Y^37O:0S9SQ3AV.W)K4/":-3YG<*&N,.)@:#TN,K(I7  "
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M=)"B.H  9E^?3G^V5TZ<C'^"1QR:&']I-8N8*7]?(:&7=7]8"*Z7BW^3  "
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M<GV>MZ;L9"Z;IJ0R5/J8K:&E10*6#: M,]F3_)Y\()F2V)8*"..1.X8"  "
M (  =K2SP6=_:?6P.&D(7("LY6J,3ABIO&P"/H>FXFU<+3VDZVYK&+FEEVYL
M 8FBJG "  "  (  =EJRT&]2:<JO*' =7%>KIG#Y3?FH5''=/G"E7G*\+3JC
M27-J&..CIW-& ?Z@-W5A  "  (  =@RQ?';H:6"MV'<;7 *J1W=@3:"FZW?#
M/BBC['@M+1"AQWB$&.ZAZ7A4 EZ=^7I8  "  (  =:RP'7Y=:.FL?7X66W>H
M\WW=332EE'W#/<>BF7W&+-"@:GW1&.>@6GV\ JR;^GZO  "  (  =42N](7A
M:'^K6(4N6P6GSX2'3+>D;8/S/7*A9(./+)"?,H-K&-F>]X._ NV:.X'[  "
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M7<Z[0&@.4..WEFEP0R.T!6K&-"JPZ&OT(Q^O/FRB#B&Q2&OC  "?!'.P  "
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M71ZU'(G)4$2Q (C<0IZM#8@0,_RID8>2(YVG.H? #^:GJX:X  "9D(    "
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M6G0[-<""?74X&\B#;W5F  "  'JYH(N!V7;5D6:!B'>+@5V!.W@K<!*! WC
M7<" WGE52CB UWGD-06 \WI/&S>!FGHL  "  'XZGV: &8 ED#-_W8 B@!=_
MIX #;Q-_>7_>7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "  (  GCM^L(E]
MCR1^?8C/?P=^4(?_;>1^*X<=6]9^'H9*2)%^,H69,[)^0H4-&CE^684,  "
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MAO*-G67Q=_",>6@@9Y^+B6HG5AN*NVP50SV**FWA+G:**6]'$\B,FV\4  "
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M@E2&2HZR<T.%8(UW8R*$A8PG4B2#S(KP/_*#1(H *]*"_8F>$A^#9X@Z  "
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M><^5'VT":YF3:6YG7$61VV^_2[R0>W$&.;Z/@7(G)7B/=G+("RZ1&')%  "
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M=?&.W9/P9[R-.Y)B6(:+J)#%2&N*38]H-Q2)0HZ8(YZ(LH[&"L:('8=)  "
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M;.Z=0G,A7YV:]'/F42&8T72L08*6\G5H,$25L77^'#:6!77[!%*3Q7=-  "
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M:DN8!IB#7-V5KI;+3G.3894,/QZ199/6+F./^Y/2&S"/C)$]!-6,'(-%  "
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M8*^F WA34_VC+'B<1FJ@>GCO-XF>,WE!)MV<W'EL$I>>,GCU  "4,'QC  "
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M7U:AI)RH4IF>F)KW1-B;HIE6-C.9%YC/)?R7:I;G$JJ7J8R>  N/BH (  "
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M5.FOK'R_2+ZL77RM.[FI-'R<+8ZFE7RB'1FECGR9">JEB'T9  ".P8    "
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ME )S'W-N@^1T#G1T<FAT^'5F7^QUX'933$9VQW<V-Q%WA7?M'9UWDG@'  "
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MCHIKXZ!7?EAM!9V1;35N'9J\6S9O0I@K2#!P4I89,]%PU)4?&SIO-9%Z  "
M (  G51I\:R7C@AK/:ER?<%L5*7R;)=M7Z)K6J5N?9]-1[5OBIT#,U9O_YMX
M&L1N1Y(9  "  (  F%!_EUY:BDE_<&%&>QA_>&/X:I9_GF9V6-A_UVC51<:
M+FL-,.6 OFS>%K6"/6TT  "  '9<EU-]&V>8B49].6FD>@%]9&N':9%]G&U-
M5^U]XV[^1/M^07"/,#E^O7')%C9_LW&[  "  'IGECEZUW"^B %[('(!>.5[
M8G,G:'A[L'0W5OI\"'4Z1"]\<'8I+Y=\VW;8%<5]2':%  "  'WSE05XQ'GG
MAKQY*GIR=Y=YA7K;9WEYX7LY5A!Z3GN.0W%ZP'O<+PE[&WP*%69['7NF  "
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M@KISCZ6*<WUS]**38U5T49^/4E-TQIS]0#-U.9MJ+&QU,YF,$XMTM(TW  "
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M>?V &X"C:\)_WX"67(M_IH!N3&=_>X!).JA_?8 M)MQ_CH 0#5)__G_H  "
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M<=J0D6 :9&F/<6*F5;J.@V4'1;Z-PV<Y-!^-<FD;']*.5FH7!DZ.F6H4  "
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M;;F(%H7[8%Z'*H6'4@N&0H3X0KJ%?(1Q,?*$]X0@'FZ$^80[!I&$/(+;  "
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M96>81V9O6+26HFA 2N&5(VGX.[:3ZFN#*J^3;FRK%C"5%VR4 "^0OFZV  "
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M8?60U8JA552/18GD1[.-OXD5.0:,=HAV*,^+G8A1%76+XX@$ 0.'WX"O  "
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M60R@N&NX31F>E&SQ/_B<FFX>,7^;$6\:(-":P6^5#'V<;&\&  "*>W>B  "
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M5LR:2HZ;2M.8'(V^/=B5_8S;+ZZ41(QV'XN3?HRO#(F3)8AZ  "%(8    "
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M3-^J)F_]05>GJ'"Y-.>E57%M)M^CO''L%@JD3G&K!(2A7'+\  "%07Z*  "
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M3 RD>I(B0*>ANI%5-"Z?(Y"D)F>=+Y"9%B:<]HWD!6J8<(.I  "!@(    "
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MBZ-N[F4/?#%P06=I:Z-QC&FA6>5RT6N^1N9T!VVZ,CAT]6]@&-)TR6_<  "
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MA65D9I#8=D9F-H]F9B%G[8WB50UIDHQ]0M9J](M6+Q5K:HJL%IUK(XG'  "
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M?KUT"6QY<'MTXVX=8.5UNV^B4#)VCW$2/AIW77)=*@MW[7-%$#UY$'++  "
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M><UK6)9$:Y5L?)2!7%UMB9*I3"-NCI$/.JIO6X_V)X!O)X_L#P!Q4(HE  "
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M<@YZ#7+W9)9Z:'0%5BYZNW3W1EM[('73-1=[AW:((71[U';0"+)]<'<+  "
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M;E=S)YK]8/-SFYD04I-S\I<.0S5T296!,G1T>I42'X%SMI+6""QW"H6&  "
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M9;F!'7B160Z ZGDB2UV MWF8/)F DWG\*^B J7I"&$B _WH3 FZ!1'O   "
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M7="32%GW4:Z255S%1%&1E5]B-7F1)6&P)'*1HF-5#T^4C&,G  "("6F:  "
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M6>Z),'U+3@"(9WU[00F'GWV-,MZ'!'V9(MF&S'VC#PN'$GVU  " &X    "
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M4:R;65]51C>9]&%Y.968P&-R*U&8%&4,&E"9$66T!M^8W67C  ""$'(Q  "
M (  6U^:A61#4/69&V7\19^7O6>B.066A&DF*NJ5Q6I6&B:6AVJU!Q>5G&KD
M  " EW<4  "  (  6K:80&M:4#B6YVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4
M,V_.!RZ2L7 C  "  'ME  "  (  6@R63'*!3Y*5!'-;1#"3MW0<-\:2?'2W
M*@*1JW4M&922''4A!S&0*G7>  "  '\N  "  (  67.4MWG(3P:3?7I#0[&2
M+GJ5-U&0Z7K#*9B0!'K?&7&0+7K,!SN-^'O1  "  (    "  (  6/"3:X$3
M3I:2/H$[0TR0ZH$C-NV/EX#L*2Z.I8#.&2".J8#K!U",'(#@  "  (    "
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M12VDEF...D&BZV48+A&A?F9Y(!.A!V=6#M&BX6<*  ":WFGN  "  'H\  "
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M0TJ<<X1Q.(&:MH0R+)F9"(/?'PJ8$H/D#JJ8=X-[ +60F8![  "  (    "
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MB'5777M?>4E::GN]:1Y=/GP*6 )?ZGQ618YB*'RD,:UC&WSE&;!C1'SN  "
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M@YYK3%<O=/-L\%K,91MND%XW5!!P(V%X0:QQF&2 +75RI6<)$]%SQF?'  "
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M?-)<:H(';J)>\H'?7V5A1H&@3R=C9X%D/9UE"X$[*DUE)($L$>9H]X$[  "
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M=S=O,%\#:8%PA&'.6J5QS61S2H)S!F;M..%T(FDD)0MTR&JV"XUW]VJJ  "
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M<5YB6H?*9 ]D3(<T5:YF#8:&1CUGF(7K-7!HDX6"(J1GI(6*"LMNSX1#  "
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M:K!T%V747?QU"6?S3_QUZFGK0+EVOVNX+\5W?6TU'!!WRVW6!)Q[Q6ZY  "
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M9@!I0XRQ67AJEHO-2^1KL(K./2ALDXH&+-QLWXFZ&BMK]HG,!)EX.H,<  "
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M7DYZ!&NA4E%ZA6TM14MZ]VZ8-K][:&_.)DQ[VW"A$CE\CW!(  "  '3^  "
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M6KYQ*)#J3NMQX(_;0A-R2XZS- MR?HX")"]R(8XV$1%S/XKP  "  (    "
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M4DZ!$G!Q1O2!''&%.HN!%7)O+,"!)W,M'&>!CG-C"6&!XW.*  "  'RL  "
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M2HR5\5-5/XF53U9*,R:5 ECZ),^5=UL6$N^84ENH 8*4I5V-  "  &T4  "
M (  4YZ3_5<_2;R31%G@/L62IUQ=,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I
M  "  ''X  "  (  4LN1#%X_2-R0>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1
MI&6. @:-RV=G  "  ';D  "  (  4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA
M(U2- 6K0$DJ.DVJ= A^*\&RD  "  'L\  "  (  43F+R&Q51T2+:6V6/&N*
M]VZU,'2*CV^>(N.*BG ]$?Z+OF_F BV(>'):  "  '\&  "  (  4(*)JW.
M1IF)9W1<.]*(_74-+^J(C'6/(FF(:'77$>*)'W6( D6&57A*  "  (    "
M (  3^*'XGJI1@R'N'LM.UB'5'MU+X"&U7N7(@2&DWNF$:B&Y7N+ G"$@GU7
M  "  (    "  (  3V"&8X'$18B&4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%
M&('# F&#$8%U  "  (    "  (  3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4
M(>V#@X@:$>2#'8<D M>!M('L  "  (    "  (  2%BB<4Y?/M^A/%%"-&F@
M9U/V*%F@*%9.&<.A<U>_"*.C&UAE  "1E%_D  "  '!Z  "  (  1T>?YE3^
M/?B>[%=W,WB>&EG%)X^=KUN\&46>H5S8"*>?<UU9  ".W&1^  "  '51  "
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M.L^36G<Y,(*2KG>6)/B2 7>\%VB2'G>9"(*/TGB;  "$LGW*  "  (    "
M (  0\F207V0.FV1]GWM,#*13WWX),.0B'W:%T*0<WW("%*-\'YX  "#18
M  "  (    "  (  0X"1!(3&.B60SH3T+_&0,H2S))F/681E%TJ/!82'"(6,
M68-8  ""<8    "  (    "  (  GOM3U4W5C\A7"%(=@ 1:(E90;UQ=+%IC
M7:5@&5Y12K]BM6(1-G%D8V6!'E]CEF?T 7M]@&L9G-%.A5@(CA12+EMO?H15
MLEZ^;@A9$6'R7&]<0V4&2:M?!V?V-8!@F&J?':U@,FQV 8M]9&_/FMI)K&(^
MC#M-P&2Y?.]1G&<B;(I506E[6R!8J&N^2(U;BFWH-)I<\V_:'0Y=2G$D 9I]
M2W3BF.A%/&QDBFM)LVWY>S)-U&^(:Q]1N7$-6=I55G*%1WY83G/P,\A9A74T
M'']:VG8& :9]-GF+EPI!-G9XB,M&"G<X>;Y*>7?U:;U.CWBJ6-A27'E>1IQ5
M:'H0,Q=69GJS' I8TWLJ ;%])'V(E6<]J8!^AVM"U(!L>)M'BX!<:,-+W(!+
M5^]/QH ^1?=2WH!#,I%3H(!8&ZM7*8"H ;I]%(#EE HZEHIQADI #XF(=[%%
M!HBG: %)B8?45SM-DX<515Q0K89[,BY1-88A&V=5RH:2 <)]"($PDO4X!I0_
MA64]P))V=OE"[9#$9VY'F(\U5KE+NXW61-Q.U(RV,<-/&(P;&S%4KXO+ <A\
M_8$TDC,V#YVTA+X[\IL'=G%!0IB&9P1&"99+5FQ*/Y1C1*5-69+C,8E-7I)0
M&O=3SX_P <U\]8$XDX-:ODWNA4-=85(@=EM?_58Y9GUBBEHO58%D^5W[0SUG
M%V&/+T]H0&2Q%JII=694  "  &W2D7E5F5>9@]58NUK^=2U;MEY*97]>C6%V
M5*-A,61X0H!C:F=*+KED76FW%DYF8&K:  "  '*PCYI0Y&%)@@)4;6/7<YE7
MN6909 ):SVBO4U9=I6KR06-?\6T0+=%@G6[:%;%CX&^*  "  '=BC<I,DVKK
M@$=0<VRG<?54 6Y68K174F_R4BE:67%X0&I<KW+G+1-="G08%3AAN'1S  "
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M>QQ##)@6;59'BI7U7H9+DI/R3J!/"I)%/8)119$=*N%0K9$3$]]>:8U   "
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M=*I3]'.J9T%7*72Y6-1:#W6R25Q<GW:=.$Q>2W=Q)6==@W@)#7YI,7@Z  "
M (  ?^M-(7NG<X!0X7P79C941WQO5]]75GRU2'M9]GSY-[);D'U#)/9:S'V)
M#5)I?'X)  "  (  ?N%*382T<HY./(1X95M1RH095QA4^(.P1\!7I8-9-QE9
M)H,I)*98D8-$#3QIH8,3  "  (  ?A-']8VE<=),"HS#9*I/MHNR5G=2^(J<
M1R=5JHFX-H17"HDK)#=6PHEB#25IR(<V  "  (  ?8)&()9G<4A*4Y3R9!].
M$9,V5?-16Y%Z1KI4"Y 7-C%53X]1(]]54(]D#.%J/(BU  "  (  ?)5I<TX3
M< 9K#5'\8KILMU725&%N6%F#1,9OW5S[,X]Q*V 3']1QK&(Y!S-WMF,0  "
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M:4)8:7G'7+!;*WI.3Q%=EGJ\0%1?B7LB, =@6'N#'4]@B7N[!M9T<GSJ  "
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M8[MN:ED35U]OW%PN2>EQ-E\A.PUR:F'0*E)S6F0#%D-T"637 ,Y^I&<A  "
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M7>U=XW[T4AM@'W\,139A\G\+-QMC*W\3)T=BWG\O%'%FNW]F 21^$W_Z  "
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M5UUR[E\72^YT$F&0/R]U#V/7,/IUYF70((%V>&<>#'QY06<:  "  &]6  "
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M4J1D;8-!1WUF(8,'.T-G3(*S+:MGLX**'>QFZH*W"XIN7()[  "  (    "
M (  7&)@;8KL4B9BJHJE1O]D;HGU.LQEE8DM+4MEV(C,':AE)HDJ"UEM/H:J
M  "  (    "  (  6/.#7$Q@3JN#ED_=0X2$!%,^-PJ$FE9A*+R%@%D"%U:'
MB5I<!'&'U5NB  "  &DU  "  'X:5WA_3E-\381_U5:*0GF 8%EQ-BR \5P;
M*!.!L5Y)%O&#,U]#!(V$"&!N  "  &WQ  "  (  5DA[6EJS3%1\'UU 07M\
MR5^J-3Y]7V'7)U-^ F.1%FM^^V0O!(J MF56  "  ',D  "  (  52MWHF'U
M2S%XDF/]0%9Y567D-%AY]V>:)HAZ?VCF%=-Z^&DO!'-]W&IO  "  '@@  "
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M1V]L 8;I/-QM089X,3EMSH7S)!%M9(7;%!!NI(6X!%%XM8+K  "  (    "
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M/R=_CV?.-,)__FDW*1Z 3VI7&Y6 P6KX"SN!8&K]  "  '!Y  "  'Z^  "
M (  1[I[XFU,/DU\L&YP,_Y]-F]H*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95
M  "  (    "  (  1OAY,71=/95Z+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\
M-G9L  "  'M'  "  (    "  (  1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P
M&?IXA'O["FUZ;WRM  "  ']X  "  (    "  (  1=-TVX*\/(=V1(+@,F]W
M((*?)SIW.8)+&B1V<H);"LYXM8(&  "  (    "  (    "  (  0)F914BK
M-[*8K4OE+:.8E$[4(:J945$[$GF<,E)3 U*9OE1@  "$LE^*  "  ' -  "
M (  /S>5O$\$-E25CE'9+"R5F51B($N60%9F$6Z8H5<O PF5%5D_  "!KF1
M  "  '4!  "  (  /D&2%E5X-3J2&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0
MSUXN  "  &DC  "  'ET  "  (  /6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H
M#_^0UV$J JJ-!F,Z  "  &Y6  "  'U8  "  (  /)J+%&*:,W2+:60F*42+
MK65T'9F,(F9+#Z>-$&9G IF)Q6B'  "  '0$  "  (    "  (  .\N'\FE=
M,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)I&O6 J:' VXP  "  'D[  "  (    "
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MA:''[);8JF"T_I0BI=>AKI&2H7"."X\YG3%Z3(T)F0)FEXKXE,Y3-HCPD'1
M,(;OB],M_X38AL'&^Y9DL[^T().NKE:@UY$?J06-08[(H]%YGHRAGJ=F"HJ3
MF6-2QHB"D^(_YX:/C@TMV(2,A[O&+I8#O1FS99-.ML2@(9# L'R,DHYIJD1X
M_HQ&I!%EB8I$G;I2:X@VEQ8_JH9!D LMN(1,B)#%A96OQG&RS9+\OQR?B9!R
MM\:+_HX=L'=X>XO[J2AE((G^H;)2&H?]F>P_<(81D<(MGX0:B4"_(*2'>JVL
MR:#Z>HV:?YU\>I:(%)H?>MAU<I;>>U9BM).E? Q0*I!;?.D]X8SN?B L:HD[
M?].]HJ.<@W"KXI_R@GR9SIQS@;6';ID?@25TQ97O@-)B"I+'@*Y/B8^/@*8]
M;HPU@-PL28B7@5F\@Z*IC#:JW)\&BFZ8[)N%B,^&C)A!AW5S\Y4<AE!A4I(#
MA5!.\X[9A%L]"HN0@X4L+(@%@L2[@J'=E.RIT)Y$DEN7V9K,C_F%E9=^C<)S
M$Y1DB\U@F)%4B>9.9HXTA_H\LHK[AA L$X>$A!&ZI:$:G<.HZ9V.FF66YYHA
MES2$H9;:E"9R/).ID3]?YI"ICFM-X8V4BWT\88IOB'8K_8<5A3VYO*"/IIJH
M'IS]HFF6))F,GF"#WY9)FG]QB),KEJ]?39 BDMI-=HT5CN,\(HG^BK<KZH:W
MAD6X[: @KUJG8)R*JEB5;ID:I7&#-97;H*IP]Y+$F^M>UX^_EQ5-'HRGD@L[
M\(F;C, KVX9HARJX-Y_'N FFP9PMLB>4UIB\K%B"I95^IIQP<Y)KH.1>;8]P
MFPQ,UXQ9E/,[QXE+CHPKSX8HA^NWH)]YP+2F/IO9N=Z45IAJLPZ"*94PK$IP
M")(@I8E>&H\JGJ1,F8P@EX$[GXD<D!0KQ87TB(FPG:XH>B:?BJG->@F.CJ5^
M>AM]@*%(>FIL2ITA>OA;!9CP>\!*"92@?+$Y:I 1??\IT(L<?\2O7*U2@F:>
MU*C9@8*.!J2$@-!\_J!0@%IKOYPR@"):?9@/@!U)C9/*@#8Y(8]+@),IX(IK
M@3FN=ZQKBI^> J?WB/>-4J.=AWM\1Y]SAD=K$YM=A4A9Z9=%A'-)&I,+@ZXX
MY(Z;@Q I[HG/@I&MM*N;DL^=+J<TD&J,<Z+CCC)[>YZQC#5J7)JCBG!95):2
MB,%(L))@AQ(XKXW^A6XI^HE'@\FL[:K]FO6<:J:6E]2+JJ))E.=ZM)X9DBQI
ML)GYCX-8S97RC/A(5)'%BE8X@HUQAZ4J!(C1A."L1*IBHS>;R:7]GU*+"Z&P
MFYEZ&IV$F AI(YEFE(585I51D05( I$PC6LX6HSPB:\J#8ANA=2KGJGOJUZ;
M1*6 IJB*CJ$MHAAYG9T G:]HLYCOF517_93FE.5'Q9"[D$TX/HR(BX<J%(@<
MAJ6K!JF7LVB:PZ4?K=J*&:#*J&QY,9R>HQ]H5)B3G=M7L)25F'Q'DY!JDNPX
M*HPUC24J&8?8AU2J@ZE,NV2:5Z3)M.B)M*!UKH5XU9Q-J$%H!YA&H@E7>)1+
MF[5';I OE3,X%XP#CH(J'H>CA^.BX;?\><>3 ;+,>:.#/*VJ>;AS=:B6>A%C
MF:-]>JQ3OYY(>X-$1IC??(8U2I,<?><G?XS9?[:AY+<M@8V2=['H@+""UJR\
M@ QS$:>C?ZAC*Z*,?X=36)U=?YY#\9?Z?]8U+))$@%4GO(P9@1RA/[9&B4*1
MV[$)A[""3ZO8ADURA*;"A3EBJ*&NA%Q2ZYR&@ZY#I9<J@Q0U%I&#@J@G\HMP
M@F*@M[5RD.:11+ ^CJ6!J:L2C)5Q[*7RBL1B(*#GB2U2@9O&A[%#8)9QACHU
M!9#9A-HH(8K>@XB@++3'F(>0MZ^2E92!&:IIDMEQ6Z5,D$]AIJ SC>E2(YL<
MBYM#)Y7.B4 T^)!#AN0H2(IAA(V?F[1"H"60-Z\$G'F HZG6F0)P[J2ZE;QA
M1)^DDHE1U9I^CU5"^94XC!0T[8^_B,$H:8GWA6Z?+K.ZI["/UJYZHT" 2:E,
MGP-PG*0UFO)@_9\EENY1H9H"DMM"UI2KCJHTY8]&BF8HA8F@AB^>M[-<KQF/
MC:X,J<V #JC2I+1P7J.QG\U@PIZEFOI1<9F:EA%"O)14D04TY8[NB]HHFXE9
MAL^>3;,*MF>//*VNL#1_RZASJC!P**-7I&1@G)Y0GK116YE(F.]"M)00DPTT
MZHZVC1(HK8D@AU&5[,']>7^',KOR>5!XD;7X>6)I_*__><);9ZGK>FA,[*.A
M>T\^ZYT.?&(QA98%?=,E=(YO?ZF5/,$F@-B&T;L8?_EX1;44?UQIKJ\/?P=;
M%:CS?OQ,IJ*G?RP^O9P3?X QDY46@!\EW(V=@0&4V< RB ^&:[HSAHMWZ[0K
MA3MI3:XBA$%:O*@#@X1,8J&\@OH^FILM@HDQI91 @DLF-HSF@CB4D;]0CRZ&
M%+E4C0AW@K-/BQEH[:T\B6U::*<EB ),):#EAK4^?II?A70QN).$A%,FA(Q(
M@TZ40KZ3EDB%QKB2DWEW,[**D.IHF:QZCI-:):98C&5+^* GBE0^:YFLB#PQ
MRY+BAC,FQXO"A$*3Y+W]G5V%>[?PF=QV];'AEIMH9JO2DY)9]J6UD*5+UI]]
MC<$^7YD-BM,QW9)5A^8F_HM2A163B;V#I$Z%.K=HH ]VQ+%1G!!H/ZM!F$M9
MV*4OE*)+Q)[\D/$^6)B#C2TQ[)'<B64G+(KUA<:33;T!JQ.%#K;EI@IVI[#-
MH49H+*J_G+]9R:2SF%)+NIZ1D]4^59@9CT0Q^I%QBJ\G48JIAEJ3 +RBL;6$
M\K9TJ[]VG[!1IA)H)ZHYH+E9S*0LFXY+QYX2EE<^;I>ZD1$R&)$PB\8G;XIN
MAM&)E<PD>7![]<4V>2AN9KYH>2]@[+>.>8]3D+!X>CQ&::D)>RXYVJ$W?$PN
M!IC4?<DCI(_A?YR)2<LJ@&5[O\1B?W9N+[V.?M5@M+:<?HA36Z]P?HM&2:?V
M?M$YV: =?SPN0Y?'?_0D,X[\@.F),\H:AR)[E\-JA:!N"+R3A%=@A[65@W!3
M-*YA@LM&-J;J@F YY9\7@A(N@);6@?PDL(XV@A.)+\D=C;Y[B<)GBZ=MZ+N0
MB<]@:K2(B$!3'ZU<AOI&,*7PA=<Y]YXLA,4NN98%@]TE&XV-@QJ)(\A"E%![
M@L& D9IMYKJ?CRY@7[.:C0)3':QJBP5&.J42B2HZ$9U@AU$N[I51A94E=8S]
MA ")"<>$FMA[>\"VEW=M\+G-E&1@=;+)D953+ZNDCN=&4*1-C$DZ+YROB:LO
M'Y2YAR EP8R%A,6([,;AH2][=L *G1AM_;D:F51@CK(8E=I32ZL DG]&;J.U
MCR<Z4)P9B\@O2Y0YB'DE_XPBA6J(S<94IU![<;]WHG9N#;B"G?A@JK& F<I3
M:ZIPE<)&CZ,YD;8Z<INJC:0O=)/1B:$F,HO2A?.(L<70K3)[<;[QIX=N);?Z
MHCU@TK#YG5=3FZGPF*-&PZ+%D^XZI)M+CS<OH9.'BI8F6HN3AF'RSWMC>;#;
MW7N\>=+$J'P<>@>M)7R#>EZ5<7SW>MU]K7U\>X)E\'X5?#Y.1'[9?30VRW_I
M?GWPLGFYA,_:+7HT@\K#*GJS@NBKSWL[@C*4-'O0@:I\B'QV@4)DX7TN@.--
M57X0@)\V 7\Z@&CNS'A9D +8:GCEC=K!GWEXB]*J7GH9BA"2ZGK)B'U[9'N+
MAP5CY'Q?A89,?7U;@_XU3'Z;@C_M!G<SFS'6KG?(E^^_^'AHE-BHX'D9D?*1
MF'GACU1Z07J[C,-B\GNGBAI+N'RYAT<TK7X,@_WK:79'IE75&W;>H@.^<G>%
MG=ZG=WA!F>R037D6EAUY*'H&DG)B#7L&CI9+ GPLBF\T)'V-A9WJ!'63L6_3
MOW8GK!&]'G;-IM>F-W>/H<^/+WANG.9X'WEIE_UA.7I\DNM*7WNRC6TSKWT?
MAQ?HVG4%O'O2G765M@Z[_W8WK[JE)';[J92./7?DHXUW47CJG7-@@7H&EPQ)
MU'M+D#,S37S"B&CGYW2<QW'1L'4GO^Z[$'7"N'ND-W:"L2N-8'=QJ?AVFWB#
MHJY?\GFJFOQ)7GKVDKLR_'QTB8SG)W15TD'0]G39R9NZ3'5JP/^C;G8DN(",
MHG<3L!5U]'@KIXA?:GE;GHY(^7JQE/HRO'PVBH'BF801>!O-C8.%>'BX'(,.
M>.&B.(*K>62,"8)<>@QUO((?>ME?@('P>\-)58'B?.PS?(($?G7@X8*.@JG,
M7((7@>:W$H&S@3^A*(%E@,&*Z8$K@&MTH($)@#E><X#^@!E(=8$5@!\RX(%:
M@$G?48%!C4'*P8#9BVZUEH""B;B?Q8!-B#Z)LH NAO!SE( IA;Y=CX UA(I'
MNH!D@U@R5H"_@@?=OX HE\7))7_'E/2T 7]\DD*>7']0C[F(=']+C6YRAW]<
MBS%<MW]_B.-'$W_%AG0QW8 T@ZS<1']"HD''LW[BGGNRFGZ@FM*=!WZ ETJ'
M07Z"D]UQB7ZJD)-;[W[@C2!&>W\YB6TQ='^ZA3#:^GZ0K+[&='XQJ 2Q8WWN
MHUB;XWW3GL6&/7W?FDAPGGX,E=!;.7Y6D39%]'["C#LQ&W]1AH[9Z'X"MS+%
M;'VDL7ZP7'U>J\>:Y'U#IB&%7GU:H)%OYGV2FO):GGWAE1=%@7Y<CM$PT'[Y
MA\/9#7V7P9C$EGTZNN*O?WSMM!::!GS-K4V$D7SGIIMO.7TMG]=:&GV'F,-%
M(7X(D2LPDWZOB,[89GU*R^[#[GSNQ">NQ7R8O#691'QOM#N#X'R(K%ANIGS5
MI&!9K'T[G!1$TWW(DSTP8WYTB:W2[XSK=MF_DHM\=U>KO8HM=]V77XC^>'R"
MJ8?F>4-MT8;>>C19&(7>>T9$>X3Q?*$P6H0:?FO1=8N4@,&^9(HU@#RJHXCT
M?]&66H?5?X:!KX;2?V5LZ(7C?V=80(3]?WM#S(0L?[HO[H-N@"K0)HI4BKF]
M%HD%B36I@X?)A\J5-(:_AI. FX70A8-K\83YA)%7;80L@Z)#*X-W@K\OC8+4
M@=+.SHE"E*6[M(?XDC>H$(;.C^*3Z87+C;-_=H3UB[1J^H0SB<)6JH-\A\-"
MG8+;A:\O.8)+@UW-@8AIGH2Z:(<BFS2FR88 E_J2LH4&E-E^9(0QD<YJ%H.%
MCMI5^H+>B\1"'X)0B'DN\8'3A,;,6X>^J&FY3(9ZI#:EM(57H F1K(1BF^U]
M>8.5E]]I1X+ID\Y578)4CYQ!LH'8BQ<NLX%LA@O+9H<SLD2X7H7RK2>DQX3.
MI_^0R8/:HM]\LH,7G<IHI()SF*!4V8'=DSU!5X%RC7XN@($6AR?*H(;'O ^W
MG(6*M@&D (1CK]60!(-JJ:%[_(*JHW=H"X(4G3)4:8&'EJ5!"X$>CZ<N5H#.
MB!K*"H9UQ<VW X4\OL"C6800MWV/68,2L"5[8H)1J-1GC8' H6A4!H$_F;!
MQ8#AD8@N-("5B.3#NY7X==ZQRI.R=G*?;Y&0=Q",E(^1=\EY7(VI>*IE_HO+
M>;A2RXGK>NH_Q(@-?&LM:88D?F#"?)3!?S2PT)*#?MB>A)!M?I.+MHYZ?G)X
MA8RB?GEE-8K9?J52%(D/?N<_.X='?ULM*X5T@ S!69.BB'^OHI%OAT"=>X]:
MAA**KXUWA1MWEHNPA$1D98G\@XI1:(A&@M<^P8:4@C8L](37@9W 19*3D=BN
M?)!LC[J<2XYEC:J)IXQ]B\=VGHK,B@UCD8DIB&)0PH>'AJ\^4(7OA/(LQ81+
M@Q"_)Y&^FR:M=(^8F#&;/(V7E5&(BXO DHEUJ(H.C]=BQ8B C350*8;MBG8]
M[85DAY LG(/2A&*^)Y$;I'.L=H[XH*N:0HSXG.B'H8LEF35TUXEXE8MB$H?G
MD=Q/IH9BC@X]F83KB?XL>8-KA8Z]3I"8K:ZKI8YXJ0V9<XQVI&"&VHJDG[9T
M*(C^FQ)AA8=SEEA/.87ID6P]582"C#4L7(,5AI*\GY QMMFJ^HX3L5>8PXP0
MJ[6&+8HYI@=SB(B6H%I@_X<7FI1.VX64E(X]&X0LCBXL18+.AW"\&8_?O_>J
M<HW&N8:8+HO LMN%EHGEK!=S 8A!I5-@DX;&GG1.AH5/EU4\X8/SC]\L,H*5
MB">U#I\]=3*D8YPH=<Z38IDW=GJ!\99E=T5P+).C>#I>1I#A>5Y,G8X1>J@[
M-HLL?$0JK8@>?E2T!YXI??RCHYL4?;>2KI@G?8Z!1)5;?8IO?I*D?;)=HX_R
M?@%,"HTR?FHZU(I@?PLJG8=E?^ZS'9T7AKRBK9H-A:"1T9<@A*" 9)1B@]%N
MLI&Y@RE<\X\9@I]+?HQI@A\Z?8FI@;LJCX;!@6NR*9PICV*AJIDEC7^0PI9!
MB[Q_>Y-^BA1MW9#DB)Q<18Y1ARU*_8NQA;PZ,8D$A$HJ@X8Q@LBQ3)M+F!^@
MQ9A1E72/UY5VDN)^CY*[D&)M%Y 4C?M;H(V4BZ5*A8L#B3@Y[(ALAK(J>86T
MA .P=)JKH-J@!I>PG66/'932F?I]SI(9EJ%L8H^ DU);"HS\C_]*&XIWC)$Y
ML(?OB/(J<(5*A1BONYHNJ7F?49<UI3J.:915H/-])9&=G+)KSH\)F'5:DXR)
ME"9)Q8G]CZPY@H>$BODJ:83RA@BO(9G.L?Z>O9;4K.N-U)/RI[Y\DY$VHHAK
M2(ZDG51:(XPNF =)>HFEDH<Y6X<KC,0J8X2JAM*NJIF!NG:>1I:(M(&-5).C
MKEE\$I#CJ!QJUXY0H>%9RXO=FXY)-HEAE0HY,(;RCDDJ7H1PAWBG :BZ=,&7
M?J3<=5N'N*$>=@QWFYUU=N)G.9G.=^96Q)89>1Q&H9)%>G@VX(Y$?"HH+XG^
M?DBF,J?$?0J6\Z/@?,^'-J =?+=W&IQS?,EFM9C1?0M6294G?7A&-Y%>?@$V
MJ(UM?L@H2XDX?]&E?Z:_A3V6,Z+DA#J&C9\>@UAV:IM\@JQF%)?C@BI5P91'
M@<I%T9",@7HV>(RK@4PH9(B*@3NDQJ7/C5N59J'\BYZ%L9X^B@!UJIJ9B(YE
M9Y<.AT95-Y-]AA!%<8_0A-LV3(O_@Z\H>H?R@H6D!*41E6J4IJ$_DOB$[IV%
MD*5TYYGCCG%DR)9*C$I4N9+(BCM%'8\EB!@V*(MDA>HHC8=P@ZNC8Z1CG8^4
M!Z"8FF"$3YS>ET-T3ID\E#ED/)6FD3=42I(9CCA$U(Z#BR<V"(K9A_4HG(<!
MA*RBSZ/EI9:3BJ 7H:2#U)Q6G;1SSYBOF<YCQI4BE?)3[9&?D@E$EXX"C@ U
M[XIGB<\HJ8:FA8FB3J.(K7J3$9^WJ,"#79ORH_5S79A&GRMC7Y2ZFF=3F)%!
ME9!$8(VGD)8UVXH+BVXHM(9;AD*AZ*,_M4B2KI]JK[B"]INAJ?]R^)?RI#YC
M"91EGH=35Y#NF+]$,XU?DM<UQ(G/C,HHO(8?AMF9K+)L=&F+/*W'=/I\G:DZ
M=:UMOJ2S=HQ>L* :=YU/HIM@>.) _I9V>D\RW)%$?!0E]HNW?CR9&K&+?#R*
MY:S<? %\2JA">_1M::.Q?!A>5I\7?')/49IC?/M OY6 ?:,RT9!;?HPF/(KC
M?[:8H;")@^J*7:OB@O9[TJ="@BILZ**T@9U=X9X@@3Y.\YEW@09 @I2?@.(R
MQX^*@.<F>HHI@1"8(J^6BWN)R:KTB=M[+J9:B&)L6:''AQM=8IT_A@-.DIBA
MA0% 1Y/4A 8ROX[2@Q\FKXF(@D>7F*[.DP.)/*HOD+IZG*67CI=KQZ$&C)9<
M[9QUBK%..I?DB.% $Y,AAP<RN(XNA2\FW(C^@UN7$*XUFH:(OJF3EY!Z(Z3W
ME+1K5:!ED?1<AYO4CT)-\)<UC)$_ZI)]B=@RLXV>AQ G HB*A$N6JZVEH?"(
M6JD&GD5YPJ1JFJAJ^9_8EQU<.)M*DYE-N):ND L_S9'FC&HRL(T<B+HG(8@J
MA1>61ZU&J3>(&JB@I,QYAJ/UH%EJM9]1F_%;]9K"EYE-?I8ZDS@_JY&#CL$R
MKXR[BC(G.X?<A<*5]*S\L&&'T*A-JREY/:.<I=1J<9[UH(9;OYIEFU%-6I7>
MEA0_F)$TD,<RKXQYBVPG3X>=ADR-$;Q2=!Q_HK;C=*!R%K&$=5%D9*P7=C=6
MG*9_=U1(ZZ"N>*L[O)J8>BHO,)0C? (D 8U)?C",O[MX>X)_?;8!>T)Q\+"-
M>SMD.:L->V]6;:5L>]](QI^=?(4[JYF+?4PO4I,C?E<D;HQD?YZ,A+IN@K)_
M+K3_@<=QJ:^$@0QCZ:H"@)I6)J1C@%U(E)Z<@$T[F)B5@%0O<)(_@(PDS8N=
M@.F,0;ELB;Y^U;0!B#5Q/ZZ*AMICCJD"A;I5UZ-NA-!(7YVRA $[A9>W@S\O
MBI%U@IPE'XKQ@A&+[[B5D+Y^@K,JCIAPYZVRC*!C,J@KBM)5E**0B2A(,9SC
MAY@[=I;TA@8OHI#&A(,E9(I?@Q6+E[?QE[A^-+)_E/!PH:T!DDMB\Z=XC\E5
M6Z'>C5Y(#IPIBO\[:I9'B)POMI MACPEGXGD@_:+1;=PGHQ]\['WFQMP::QO
ME[YBOZ;@E']5,*%,D59'])N<CBL[996OBO<OR(^HA\,ESHE_A+2+$+;VI3)]
MQ;%\H0]P/ZOQG/9BFZ9?F/-5$*#-E0-'VILID0T[7)4\C1 OV8\UB1,E]8DM
MA5**U+:FJ[U]L;$>IM-P,:N!H=IBA:7;G/I5 J _F$-'V9JADY [:I33CMXO
M\([KBB\F%(CKA=&!#<9D<_9TBL T=&1G_KH%=0M;:;.L=?-.W*T'=QI"@J8+
M>'\VPYZT>@XKRI;E>_4B18ZV?B6!!\5_>OETF;]/>J=H!+D&>IY;9[*1>MM.
MV*O<>UY"BZ3<?!TVXYV'?0 L&I7)?BHBUXW ?X>!$,1@@;!TA[X[@,%G\+?L
M@ U;2K%M?[%.PZJV?Y!"B:.^?Z4V_IQT?]8L8)3-@#LC58SJ@,6!#\-$B#=T
M<+T@AKIGQK;2A71;*;!0A'1.K*FB@[1"A:*W@Q4W%IM]@HHLGI/P@B4CP(PS
M@=^ ^\)3CJ]T6[PJC*-GL+77BL];#*]6B2U.H*BFA[E"B:'-AF4W+YJDA1@L
MUI,P@^8D'(N8@M: W,&4E1]T2[M@DGYGJK4$D E;#:Z!C<).H*?6BYA"E*#\
MB8,W2IGFAW4M!Y*,A7LD:(L6@ZJ O<#YFV)T0+JZF"-GJK13E05;$ZW.DA!.
MJ:<KCS5"I*!:C&0W99E#B9<M,Y(!AMTDIXJLA%R G\!^H7)T.;HSG8QGK[/"
MF;M;'*TUE@Y.LZ:7DH%"LI_7COHW?)C*BWDM6)&0B XDVHI5A.^ A\ 9IU!T
M.+G HK-GNK-$GAY;+:RRF;1.R:85E7)"SY]=D3TWFIACC1,M>)$]B0@E HH1
MA67FMW:Q<VC157>3=$N[AGAP=32E.GE(=BJ.H7HD=SEW[WL/>&5A3WP/>:I*
MSWT]>R@TKWZ[?/_DM737?G//LW7A?BNZ#W;@??JC[7?;?>>-<'C;??1VVGGJ
M?AI@4WL.?DI)]WQ??I8T!GW[?OSBY7--B8K-\71IB!JXA75_AL2B?7:5A:B,
M*W>SA*]UOWCB@\M?9'HF@N))-'N5@?4S<'U,@.3A*''\E(W,,W,CD@BVU'1&
MCZ6@_75QC6N*V':LBVITH'?WB7->?7E7AVE(@'KAA3PR['RO@K+?E'#HGWK*
MIG(3F_.U2W-!F(B?C'1XE4*)CW7$DA=SBW<JCPI=HGBBB]5'VWI#B%\R>GPD
MA%[>07 3JE7)67$_I=>T G)NH6&>3G.LG0:(<'4$F,!RAW9WE'Q<UW@&D!A'
M1GF\BU8R&7NMA>/=*V]MM1G(2G"8KZ6R[W'"JB"=07,"I*F'?W1EGT=QNW7F
MF=5<)W>!E"5&R'E*CA4QR7M'ASO<4F[SO[K'=G ;N4VR$7$^LK:<7')YK!F&
MI'/AI8YQ W5PGO);FG<8F !&7'CKD)0QAGKSB&;;LVZERB/&VF_&PK*Q87#=
MNP*;G'(.LSN%ZG-UJWYP8'4*HZ=;$W:]FW=%]WB<DL8Q47JOB6'7('\5<AK#
MFG\9<SFO@'\H=$Z:R7] =6B%JG]D=I=P8G^6=^5;,W_8>4Y&'H ^>O4Q?H#>
M?/W5HWUF?)G"<GV+?)JN:'VS?*.9N'WB?,&$GGX>?/MO:7YM?4]:47[1?;)%
M9G]=?C<Q ( A?N34(WOSAQ3 UWPHA@2L[7Q@A0*84GRIA"B#97T!@VMN7'UP
M@L)9<7WQ@AA$N'Z8@7 PD7]U@+32GGJRD72_1'KOCVFK8'LUC6Z6]7N,BXR"
M+GP!B=1M57R)B"58GWTEAF9$'7WGA(LP+W[<@F?1+GFHF\:]W7GJF,VI_GHY
ME=V5HGJ=DOR!!7L=D"UL6WO C717W7QSBI=#D'U,AX$OVGY5@_?/^7C9IA*\
MK'D=HC"HTGEMGD*4@WG8FEJ  GIDEGUK=WL0DIQ7+7O9CIY#$WS(BDDODGWB
MA6'._7@UL$R[LWAZJWVGUWC'IHR3CGDTH91_)WG+G*9JP7J$EZ56F'M6DFU"
MJWQ7C-DO5WV!AI_..7>\NFBZ[W@ M*JG"'A'KJZ2O'BOJ)M^87E+HHYJ&7H3
MG&U6&'KQE@1"4GOZCRDO)GTPA['-KW=JQ%ZZ7'>LO::F7W?HMI22"'A%KUI]
MN7C@J"1IB7FOH-95I'J:F3Q!_WNPD2XN_WSOB)7("8?2<06V.H;H<D:CMX8?
M<W:0=H5O=*=\P83.=?!HWX0[=UQ5)8.Q>.I!AX-#>KPN>X+Y?/G&W(9'>N6U
M-(5^>Q^BIX3)>UJ/=(0I>Z5[S8.;? IH 8,A?(M47X*T?2! [H)F?=PN)X(Z
M?LO%LX3AA,JT (0MA *AHH.!@T*.6H+U@IYZQ8)Y@AIG&X(7@:Q3GX'*@41
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MD/98@'5OC4=$/W>UB4HPG'H[A,'14&F!K9>]RVM)J0VIOVT"I%B536[%GYV
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M@M+$SG+<GSFRQW._G"2@)G2AF/&-!'64E;9YIW:GDGYF.G?=CT-3&'DUB_!
M.GJZB%4N(7QUA$;#W7(:J3*QUW, I3J?,W/AH0N,%G38G,=XT77XF(1EB7<^
ME#!2CGBBCZX_WGH^BN M]'P+A8W#)W&)LP6Q'7)OKBB>:W-+J/B+3'0_HY]X
M$'5FGD9DY7:]F-I2%'@QDS$_CWG8C2HMSGNTAJ;"KG$JO*6PEG(,MMF=S7+<
ML)R*H7/&JB=W;W3MHZYD779,G2%1HG?.EE,_/7F%CR0ML7MNAY"]8()[:U*L
MW8(>;3^;B8'<;PN)7H&N<,AVK8&,<I1CR(%X=']1$8%R=HL^AX&->-TLLX'8
M>YN\28"V=1NKR8"'=@":8X!?=MJ(2X!&=[9ULH [>*)B[H!$>:=06X!=>L$^
M!(":? 0L>8$&?8"[)G\7?MFJC'\&?L:96'[Q?K"'-G[O?J-TN7[[?JMB''\@
M?L5/M']:?N8]D'^\?Q0L1H!)?TFYTWVMB'2I-GVEAX67YGVDAHJ%]WVTA9%S
MG7WAA*]A,'XE@]1._WY[@O0]&G[Z@@0L&7^B@/*XDGQ_D?RG]GQ_D#F6JWR+
MCF"$S'RJC'MRHGSDBIQ@7GU%B,A.8GVUAMX\MGY/A,PK\G\1@G:WAGN3FX&F
M['N:F.J5IGNIEB>#TGO0DT]QP7P6D'-?HWR C9)-V'T*BIL\77V\AV,KTGZ5
M@]"VKWK8I.ZF$GKDH7^4R7KRG<V"^WL;F?=Q 'MNEAU?!GOFDC%-97QXCAX\
M%7U B<(KMWXMA/ZV#'I+KCBE9GI:J>V4$7IDI42"0WJ(H&9P4WKAFX)><'MK
MEHI,]GP*D6 [UGS;B^ KH'W7A@&UH7GLMU>DYGG\LBJ3>GGZK'V!I'H4IHQO
MPGIKH)1=^7K[FHA,EGNJE$8[DWR+C;$KCWV3AM>O9HL[:K*@3HGT;*B068C@
M;GY_@X?N<$=N*8<'<B-<H(8I="-+5X51=DDZ0(20>+LI^X/L>YRNBHF2<^J?
M:HA_=.F/78>$==Q^E(:?=M1M3X7(=^%;XX4 >0E*N81!>DHYV8.=>[LIYX,3
M?6VMDX@*?/^>2(<3?2..6X8E?3Y]D856?6)L;X24?9E;+(/F?>5*+8-$?CLY
M@H*_?J0IUH)2?R"L@H:EA@N=*(6ZA6"-*83AA*%\F(0>@^=KEH-Q@T1:A(+;
M@JE)L8)8@@TY-8'V@6DIQH&H@+&K8X5_COZ<+(2:C92,+X/-C M[C(,6BG%J
MK8)ZB-Q9OX(#AU5)(X&6A;PXYH%*A 0IN8$6@ARJ=H2=E_&;.8/ E<"+/X+U
MDUYZKX)#D-UIZ(&QCEA9(H$^B]-(LX#IB3TXI("VAF\IKH"8@U^IMH/JH,>:
M=H,5G<V*>X)(FHIY[H&7EQEI.8$.DZ-8F("GD")(68!4C(,X;X XB*(II8 P
MA'>I)8-DJ8"9VX*5I;B)U('#H8IY2($)G1QHGX"#F*I8#( NE"A'\W_ICX8X
M07_2BI<IGG_;A66HQ(,&LA>99((\K7V)18%@J%5XLX"8HMQH'H .G6)7J'^^
ME]U'J'^)DC0X$G^#C$,IF'^6ABFAY904:DZ3[Y(";#^%+9 M;AAUG(YV;^QE
MEXS!<=55;8L)<^9%EHE,=AXV"8>7>*8G=H7I>YNA-9*:<P&3/I"U= B$98[N
M=0MTX(TZ=AEDZHN-=S]4VHGF>(5%'X@]>>8UQX:?>WXGB(4(?5F@;)$I>XV2
M28]@>\6#AHVC>_YT 8O_?$5D*(ID?*-4/(C5?1A$JH=$?9PUC(7 ?CPGEX1
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M@[3%6V,FIA*S-66/HEN@?6?<GG*-46HNFGAY_6REEH9FI6]$DHA3GW(,CF1
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MGO=II8(3FJ];4X%/EF1-(X#'DA0_@X!9C;4R;8 >B2TFIH  A*F,*)<#9*V
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M@LW"SV@.8."Q2FI.8[^?46QY9HR,PFZ9:4UYPW##;!-FEG,(;O!3GW5R<?)
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M<R%G/(*-=(%938([=?%+2X']=WD]NH'/>1HPMH'$>N4E 8':?-R,[8'O>'"
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MA'EFI')U@]A8_W07@S1+4W7N@I@^('?U@?\Q?WHZ@5XF.7RC@+.,6FS.C7R
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M9(T*=(XV,HK5=H<MJHBD>)HEW(:1>M@?8X2R?1MC<Y-7=#-:L)&B=4E1FH_
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MPDZ.ER2%(5--E()UXE@0D=IF1%T3CS=6GV)EC(U'A&?[B<\X^6WFANLKO70
M@^FA*TAPHH&3-TU[GO>$H%)+FUQU<%<AE\5EYUP[E#A66&&JD)U'1&=BC.0X
MRFURB/HKN7.KA/N@U6/S5362U&9I63J$26CG72=U&6MX809E<6XL9.Y5HG$0
M:/E&+W0H;3<W*W>5<=8I6WM8=PJ?*V P7N61HV,/8?N#167@90)T/&B\: )D
MM&N]:PI5"F[U;C%%PW)E<8(V\W8O=2HI8WI+>4F=BES.:'F0 6  :J6!VV,;
M;,=R[F9!;N=CFVF/<1-4*FT9<UI%(7#==<(VGG3X>&LI:GE;>V6;ZEG$<>6.
M;UT]<S2 76"7='IQP&/]=;MBEF>8=P=37VMM>&A$EV]^>>$V6'/E>X8I;WB)
M?5N::%<;>S6-#UK0>Z]_%UYG?!EPC6(%?'EAN&7;?-]2JFGX?5A$'6Y.?=PV
M'7+V?G8I='?3?R69*%3?A&J+[5C$A ]^$UR+@YIOHV!>@Q5@Z&1F@I%2&6BV
M@AA#NFU)@:8UZW(K@30I>7<X@+Z8)E,!C7"+ E</C#Q]/UK[BN)NY5[WB71@
M/F,PB A1E6>NAIU#;FQLA3 UQW& @[,I?':W@B.78E&%EC&*356PE")\E5FW
MD=YN35W0CX-?LV(LC2Q1&F;6BM-#&VN]B' UIW#SA>XI?W9-@U66W5!JGH^)
MRE2GFZ-\$EB]F'-MTUSGE2I?3V%:D>I0T&8ACJ9"V6LIBT\U>G"#A]0I@77Y
MA%*56VLU55:(E&T$659[)V[J73UM!'#G819>9W,#9/M/J75,:0=!4W?$;4DS
M=GJ-<?$FV7VB=RN3YF>C7FJ'8FG789!Z"&P)9*-L#FY,9[!=F7"Q:LE/"'-)
M;@1 XW83<6LS1GDO=2<F^'R->5&2@61A9WB&"6;J:<9X_FEA; =K%VOD;D)<
MTVZ-<(I.=7%P<NY B'2(=70S(W?R>#PG$WN8>U.1!V%T<&&$GV1 <>-WE&;T
M<U=I^6FT=,);W&RH=C5-MV_3=[] "7,T>6(RZW;C>S$G*GK!?2Z/K5[I>2Z#
M6V'J>>MV9F35>I!HXV?,>R5;&&KW>\!-&6YG?&P_I'()?28RPW7U??@G/GH(
M?MZ.CUS&@>2"4E_R@=MU=V,)@:QH"68Q@6=:66F,@2),F6TK@.D_4G$&@+DR
MH'4I@(LG3WEK@%V-J5K^BFF!>UY-B9ATL6&&B)%G5V34AVU9NFA=ADE,(6PH
MA2D_%' JA PRBG1]@N(G77CH@:N,^5F0DJR U%SZD1)T$&!,CR]FQ&.UC2=9
M,V=@BR%+JVM5B1P^R6]]AQ0R='/OA/4G:7A]@L:,?UA\FI6 65OYF#=SD%]9
ME79F2F+2DH98T&:2CYM+9&JBC+(^BF[LB< R2W."AK8G<G@G@[&*!W*V58!^
M3'/>67%QYW4I74]DT':.82-71G@+90A)IGFL:1D\>GMU;6$OUWV%<A$D@7_4
M=T>(N6]/7@5]-7#982]PY7)L9$IC]70.9V)6EG7-:HI)(W>W;=<\)WG+<5(O
MPGPF=2(DMWZU>5:'?6PT9GM[\&X.:.-OWF_>:S]C!W&^;9=5VG.^;_U(FW7N
M<H([V'A*=2HOKWKL>!,DYGVX>T"&-FEB;N-ZL&M]<(UNKFV(<B=B-&^><[Y5
M+''?=5I()711=PX[FG;Q>-TOI'G5>MHE#WS<?0*$_6;U=S%YI&E">"5MK6M_
M>/]A+VW&><E4<' \>IE'BW+P>WP[.77,?&XOA'CH?7HE,GP=?IF#^F3J?V=X
MKF=>?Z1LS&G"?[=@9&PW?[)3PV[9?ZY'''&W?[<Z]G3*?\LO<'@;?^4E3WM]
M@ "#*6,VAVEWZV7*AN]L&6A-ACA?PFKDA5]3,VVOA(=&LG"W@[0ZR'/M@N@O
M9W=L@A0E:'KW@3>"AF'5CRMW462$C?MK@V<>C'9?.FG-BL12MVRXB1-&1F_G
MAV8ZAG- A;TO6W;<A $E>WJ*@C^"$6#'EIMVW6.*E+QK"V8RDF=>R&COC]=2
M6VOMC4I&!F\VBL(Z3G*PB#@O.79OA: EBWHS@QA^TGI\59]T!'L!67UHFWNP
M75%<CWQS8250('U#91!#J'XL:2HWL7\T;7LL5X!U<C0B6('G=U]]IG=*79US
M$W@K8,=GOWD68^A;W7H-9PU/EWL6:D=#2WQ ;:DWA'V+<3HL8G\1=1\BI("]
M>5A\C'1298]Q\G6 : 9FTG:F:G=;"'?3;.A.\'D8;VU"UGJ$<A,W1WP1=-XL
M8WW5=^DBYW^W>RQ[<'&D;6=PV',*;S-EO71E</1:1G7#<K).37=(='Q":GCQ
M=E\W$GJ^>%XL9'R^>HHC(7[3?-=Z7&],=35OTG#B=E1DSG)J=V!9;'/V>%Y-
MT'6H>6="$7>->H,VZWF2>[$L;'O)?/LC4WX/?E=Y<6U9?.]O$&\7?6AD(W#!
M?;I8P')S??--,W1-?C%!K79:?H$VL7B0?MTL87KZ?T(C?'UJ?ZAXL6NWA'1N
M6FV3A$5C?&]:@]E8*G$L@TM,KW,I@L!!3W5<@D VC7>R@<@L8GI(@4PCGGSA
M@,MX&FIDB[5MS6Q:BN%B]6XVB;57LG =B%M,0W(WAP- \'2.A;(V6'<$A&HL
M8GFU@Q8CNGQR@<%WJ6E<DJYM8&MFD3MBAVU1CTU73&]%C2!+\W%PBO5 O'/>
MB-0V+'9UAK<L2WE'A)4CSWP9@HISS(*,59IIWX)Q66=?;()[7314;(*/80U)
M&X*A900]T8*_:3 S%H+Q;9$I"X-/<E0@8X/4=W-ROG^271QI#'_*8$9>KX &
M8V]3V8!#9J5(LH"$:?8]E(#;;70S"H%)<1\I-('C=1L@QH*=>5EQRGR^9)!H
M$GT\9Q9=YWVL:9U3)WX9;"Q(+GZ0;M(]07\B<9XR[7_,=) I4("@=[\A&X&-
M>QAPTWHM:^YG&7K>;=5<]'M];[=2=7P;<9Y'GGS+<Y8\XWV7=:LRQ7Y[=]PI
M8'^&>CHA98"A?*YOZ'?R<SAF07C-=(-<*GF4=<!1LWI;=O9','LS>#D\EGPW
M>90RIWU0>P$I<GZ.?(DAI'_6?AEO%'8+>G-E?7<.>R%;>W?W>[!1)GC>?"Q&
MO7G;?+ \:7L ?4LRFGQ(??,IA'VX?J4AV7\L?U=N9G1X@7YD\'6@@95; G:B
M@7)0MW>=@2]&5'BZ@/4\''H#@,PRAGMH@*\ID'T"@(TB!'Z?@&AMW',RB$ID
M;W1SA\E:B76*AO%03G:7A>Q%^G?,A/$[SWDVA ,R7'JV@R(IF7QL@C@B)WXM
M@4UM<G(PCM)D"G.%C<!:)W2LC#!/^'7&BF-%NG<)B*$[J'B'ANTR0WHEA44I
MDWO[@YLB0WW1@@AI((KD55Q@#(HC61Q6C8E]7.E,F8C08,U"98@/9-HX28=-
M:2 NR8:6;9LF"87_<F\>J(61=X-H+H@@7&U?5(>J7YE5Z8<J8M%,'8:;9AY"
M%H8!:8XX*85O;2\NVX3K</TF382*=14?'X1->5AG7X5L8VM>?X4S9@-5083B
M:*-+BX1]:U=!L802;B8W\X.V<2 NVH-I=#TF@8,_=Y4?AH,R>P1FD8+P:E-=
MKX+D;%A4=(*];F!*^(*%<'=!/H)/<J,WLH(I=/ NS((2=UDFIX(<>>P?WX(]
M?(AEQX#'<2Q<\8#C<J!3PH#@= U*5X#*=7I WX"^=P W<X#+>)XNNX#F>DXF
MQ8$@?!D@*H%L?>%E$W[U=_)<37\U>-93,W]/>:-)V7]8>F9 >W]J>S<W4G^4
M?!\NMW_<?14FX8!%?A8@:8"\?PUD=GUD?GU;NWW+?M)2LGX!?OM);7XA?Q%
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M;5MF>DM3?6$_>SQ%$V=;?#\W1&W3?6HJXW1J?KV9*D+N@':,&4BO@&5^>$Y
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M_P  __\  &UF=#$      P0A   !                     0
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M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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MV8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V?^D."K_H45
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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MCCX=_XY++O^543K_F%1'_YA84_Z87E_VE61J[Y)L=>F.=G[DBH"'WX6'CMN
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MESP>_Z(Z)O^J.2[_LSHT^;T\..[(0SGCU5 WU]I22,C265RZRU]MK<5E?*'
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MH9IZA)J6@8N4DHB1CH^0EHF,F9J$BJ*=@8JMGW^*NY]^BLB>?XG)G8"(RIR
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M2SS_G$P\_Y],//^?3#S_GTP\_Y],//^?3#S_GTP\_Y],//^?3+>\ P"IRP(
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M7T+SS&!!\^=@0?/H8$'SZ&!!\^A@0?/H8$'SZ&!!\^A@0?/H8-ZG @#+M@4
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M9I"5>FR*DH%RA9")=X"-D7Q[BYM_=XJE@G2)LH-RB<*#<HK:@W.)WH%TA]^
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M'P+$S# +N,@^&:W%2"BCP5$VF+U80H^Y7TV&MF56?[-K77BQ<F1RKWEI;*V
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M,2[_I3(M_Z\S+/^W,RS_MS,L_[<S+/^W,RS_MS,L_[<S+/^W,ZNX  ">Q0
MD-(  (/@  !]_P\!<O\6 FC_'@1A_R<(6O\O#%3_-Q!._SX32?]$%D7_2AA!
M_T\9/O]5&SO_61PY_U\=-O]D'C3_:1\R_W @+_]W(2W_?R(K_X<C*/^0)"?_
MF24F_Z$F)?^G)B7_IR8E_Z<F)?^G)B7_IR8E_Z<F)?^G)I_   "1S0  @]L
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M1$#JS41 ZN1$0.CU1$#G^$- Y_A#0.?X0T#G^$- Y_A#0.?X0\VC  "]K@$
ML+@! *3$ @"9T 4 C^$* (GQ&@&!\2@%>/(R#'#R.Q-I\D,98O)*'USS4"-6
M\U<G4O->*T_S92U,]&PP2?1S,D;T>S1#](0V0?6.-S[UF3D]]J0Z._:P.SKW
MOSPY^,\\./?H/#CW[#PX]^P\./?L/#CW[#PX]^P\./?L/+^J  "QLP  I+\
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M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;(?^M&YJ^  "+R@  ?M<  '#C  !G_P0
M7O\- %;_$@%/_QD"2?\@ T/_)P0__RX%.O\T!C?_.@<S_S\',/]$""[_20DL
M_TX)*?]3"B?_6 HE_UX+(_]D"R'_; P?_W0-'?]]#AO_APX9_X\/&/^9#QC_
MFQ 8_YL0&/^;$!C_FQ 8_YL0&/^;$/],*@/_2#,%_T\T!O]4-PC_6D$._UQ*
M%O]:5!W_5V D_U1K*O]0>"__380S_TJ/-O]'F3G_1J$[_T6I//]$L#[_0[<_
M_T+ /_]"R4#_0=5!_T'D0?]![D+_0?9"_T']0O]"_T'Y1/]!]$;_0N]'_T+O
M1_]"[T?_0N]'_T+O1_]"[T?_0O]-*0/_2C($_U$R!O]7-@C_7#\._UY)%O]=
M4QW_6EXD_U=I*O]3=2__4($T_TV--_]*ESK_2)\\_T>G/?]&KC__1;5 _T2]
M0?]$QD+_0]%"_T/B0_]#[$/_0_5#_T/\0_Q$_T/U1_]#[TC_1.M)_T3K2?]$
MZTG_1.M)_T3K2?]$ZTG_1/]-*0/_3# $_U0Q!?]9- C_7ST._V%'%O]@4AW_
M75PD_UIG*_]6<S#_4W\T_T^*./]-E#O_2YT]_TJD/_](K$#_2+-!_T>[0O]&
MPT/_1LY$_T7?1/]%ZD7]1?-%^T7[1?=&_T3P2?]%ZDK_1N5+_T?E2_]'Y4O_
M1^5+_T?E2_]'Y4O_1_].*0/_3RX$_U<N!?]=,@?_8SL._V5&%O]E4!W_85DD
M_UUD*_]:<##_5GPU_U.'.?]0D3S_3IH__TVB0/]+J4+_2K!#_TJW1/])P$7_
M2,I&_4C;1OI(YT?X2/)']4CZ1O%)_T?J2_](XTS_2=Y-_TK>3?]*WDW_2MY-
M_TK>3?]*WDW_2O]/* /_4BP$_UHL!?]A+P?_9SH._VI$%?]J3AS_9U<D_V)A
M*_]>;3'_6W@V_U>#.O]4C3W_4I9 _U">0OY/I43\3JU%^TVT1_I,O$CY3,=(
M]DO42?-+Y4GP2_!)[4SY2.E,_TKA3O]+VD__3--0_TW34/]-TU#_3=-0_TW3
M4/]-TU#_3?]0* /_52H$_UTI!?]E+0?_;#@-_V]"%/]O2QS_;%4C_VA>*O]C
M:3'_7W0V_5Q_._M9B3_Y5I)"]U2:1/53HD;T4JE(\E&Q2?%0N4KO3\-+[D_/
M2^M/XDOG3^Y+Y$_X3=]/_D[54?]/SE+_4,E3_U#)4_]0R5/_4,E3_U#)4_]0
MR5/_4/]1)P/_6"<$_V$G!/]J+ ;_<38,_W1 $_]T21K_<E(B_VY;*?UH9##Y
M97 V]F%[._->A4#P6XY#[EF61NQ7GDCJ5:9*Z%2M3.=3M4WE4[].XU/,3N%3
MWT[=4^U/V%+W4=%3_5+*5/Y3Q%;_4[]7_U._5_]3OU?_4[]7_U._5_]3OU?_
M4_]2)P/_6R4#_V4D!/]N*@;_=C0+_WH]$?]Z1AC_>$\@^W18*/9O82_Q:VPV
M[6=V/.EC@$#F8(I%Y%V22.%;FDK?6:)-W5BJ3]I7LE#85KQ1U57(4M)5VU/.
M5NM3RU;V5<96_5:_6/U6NEG]5[9:_5>V6OU7MEK]5[9:_5>V6OU7MEK]5_]3
M)@/_7R(#_VDA _]S* 7_>S(*_W\[$/^ 1!;[?DP>]'M4)>YV72WI<6@TY&UR
M.^!I?$'<985&V&*.2M1?EDW179U0SERE4LQ:K53)6;96QUG"5\99T%?"6>98
MOUGS6;M:^UFU6_M:L%W[6JU=^UFM7?M9K5W[6:U=^UFM7?M9K5W[6?]6) /_
M8B #_VT@ _]W)@3_?S (_X0Y#?V&013UA4D;[H)1(N=]6BKA>&0RW'-N.M1N
M=T'0:H!'S&:)3,ADD5#%8IA3PV"@5<!>J%B^7;%9NUV\6[E<R5RW7.!<M%WO
M7+!>^5VK7_E=J&#Y7*5A^5RE8?E<I6'Y7*5A^5RE8?E<I6'Y7/]8(@/_91X#
M_W$? _][) /_A"X'_XDV"_B+/A'OBT87Z(A.'N&$5R;9?F$QT7AJ.LMS<T+&
M;WQ(PFR$3;YIC%&[9I-5N&2;6+5CHUJS8:Q<L&"W7JY@Q%^L8-A?J6'K7Z=A
M]U^B8_=?GV3W7YUD^%Z=9/A>G63X7IUD^%Z=9/A>G63X7O];( +_:!P"_W0=
M O]^(P/_B"L%_8TT"?.0.P[JD$,4XH]*&MJ*5"70@UTPR7YG.L-X;T*^='A(
MN7& 3K5NB%*R:X]6KVF76JQGGURI9:A?IF2R8:1DOV*B9-!BH&3G8IYE]6*:
M9O5AF&?V8)9H]F"6:/9@EFCV8)9H]F"6:/9@EFCV8/]='P+_:AH"_W<< O^"
M(0+_BRD$^9$Q!^^5. OFEC\0W91'%]*.423*B%LOPH-D.;Q^;$&W>71(LG5\
M3JYRA%.J;XM7IFV36Z-KFUZ@:J1@G6BN8YMHNF29:,MEEVCC9)5I\V23:O1C
MD6OU8I!K]6&0:_5AD&OU89!K]6&0:_5AD&OU8?]?'0+_;1@"_WH; O^%'P+_
MCB<#]94N!>N9-0CAG#L,UIA#%LR33R+$C5@NO8=A.+:":4&P?G%(JWIY3J=W
M@%.C=(A8GW&06YMOF%^8;J%BE6VK9))LMV:0;,9FCVS?9HYM\66,;O-DBV[T
M8XIN]&**;O1BBF[T8HIN]&**;O1BBF[T8O]A' +_;Q8"_WP: ?^('@'_D20"
M\IDK!.>>,07=H#8)T9Q!%<>732&_D58MMXQ?-[&'9T"K@FY(I7YV3J![?5.<
M>(58F':-7)1TE5^1<IYBCG&H98MPM&>)<,-HAW#;9X9Q[F:&<O)EA7+S9(1R
M]&.$<O1CA'+T8X1R]&.$<O1CA'+T8_]C&@+_<14!_W\8 ?^*' '\E"$"[IPG
M N.B+ /8I#((S)] %,.:2R"ZE54LLY!=-ZR+93^EAVQ'H(-S39N >U.6?8)7
MDGJ*7(YXDF"*=IMCAW6E9H1TL6>"=,!H@'35:(!U[&=_=O)F?W7S97]U\V1_
M=?-D?W7S9']U\V1_=?-D?W7S9/]E&0+_=!0!_X$7 ?^-&@'YEQX!ZZ C =^F
M)@+2IS 'R*,^$[^>21^VF5,KKI1;-J>/8S^@BVI&FX=Q396$>%*0@7]7C'^'
M7(A]D&"$>YEC@'JC9GYYKVA[>;UI>GG1:7EZZFAZ>O)F>GGR97IY\V1Z>?-D
M>GGS9'IY\V1Z>?-D>GGS9/]G%P+_=A0!_X06 ?^0%P'UFQH!YZ0= =NK'P'.
MJB\&Q*8]$KJA2!ZRG5$JJIA9-**483Z<D&A%EHQO3)")=E*+AGU7AH2%6X*"
MC5]^@)=C>G^A9G=^K&AU?;MI<W[.:7-^Z&AT?O%F='WR975\\V1U?/-D=7SS
M9'5\\V1U?/-D=7SS9/]I%@'_>!,!_X<4 /^3%0#QGA4 XZ@6 -6N&P'*K2T&
MP*D[$;:E1AVMH5 II9Q8,YZ87SR7E&9$D)%M2XN.=%&&C'M6@8F#6WR'BU]X
MAI1B=(2?97&#JF=O@[AI;8/+:6V#YFAN@_)F;X+R97"!\V1P@?-D<('S9'"!
M\V1P@?-D<('S9/]K% '_>Q(!_XH2 /^6$@#MHA  WJT. -"Q&0#%L"L%NZTY
M#[*I1!NII4XGH*%6,IF=7CN2FF1#BY=K2H:4<E" DGE5>X^ 6G>-B5YRC))A
M;HJ<9&N)J&=IB;9H9XG(:&>)XV=HB?)F:8?S96J&\V1JAO-D:H;S9&J&\V1J
MAO-D:H;S9/]N$@'_?A  _XT0 />:#@#;IPH T[ + ,JT%@# M"D$MK$W#JVN
M0QJDJDPEFZ95,).C7#F,H&-!AIUI2(":<$Y[F'=3=I9^6'&4AEQLDI!@:)&:
M8V60IF5CD+1F89#&9F&0X69AD/)E8X[S9&2,]&-DC/1C9(ST8V2,]&-DC/1C
M9(ST8_]Q$ '_@@\ _Y$- -Z?"0#3J@D S+,) ,2X$P"ZN"8#L;8U#*>S01B>
MKTHCEJQ3+HZI6C>'IF$_@*1G1GJA;DQUGW51<)U\56N<A%IFFHY=8YF88%^8
MI&)=F+)D6YC#9%N8WF-;F/!C7)7U8EZ3]6)>D_5B7I/U8EZ3]6)>D_5B7I/U
M8O]U#@#_A@T ZY8( -6C!P#,K0@ Q;8' +V\$0"TO2,"J[LR"J&Y/Q68MD@@
MD+-1*XBP6#2 KE\\>JMF0W2I;$AOJ'-.:J9Z4F6E@E9AHXQ:7:*67%JBHE]7
MH;!@5J'!8%6BW&!5H>]@5I_W7U><]U]7G/=?5YSW7U><]U]7G/=?5YSW7_]Z
M# #]BPD VIL$ ,ZG!@#$L 8 O+D$ +7!#@"LPB !I,$P")J_/!.1O48=B;I/
M)X&X5C!ZMETX<[1D/VZR:D1HL7%)9+!Y35^N@5%;K8I46*V55U2LH5E2K*];
M4*S 6U"LVEI/J^Y;3ZKZ6U&F^EM1IOI;4:;Z6U&F^EM1IOI;4:;Z6_^ "0#A
MD@$ T: $ ,:K!0"\M 0 L[T# *O'"P"DR1P!G,@L!I/'.0^*Q409@<--(WK!
M5"QSOULS;;YB.6>\:3YBNW!#7KIW1UJY@$M6N8E.4[B44%"XH%)-N*Y43+B_
M5$NYV%1+M^U42K;Y54JS_E9*L_Y62K/^5DJS_E9*L_Y62K/^5OJ' @#6F
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M+S;Q\R\V\?,O-O'S+S;Q\R\V\?,O-O'S+[FG  "KL   G[L  )+&  "&T $
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MFDP?H)=4*9F37#&3D&,XC8UJ/XB*<42#B'A)?H9_37J$B%%V@I%5<X&;6&^
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M6%F4U%=9E.Q769/Y5EN1_E5;D/Y56Y#^55N0_E5;D/Y56Y#^5?]S"0#UA 0
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M04.]_T)#O/]#0[S_0T.\_T-#O/]#0[S_0]:-  #&FP  N*4  *VN  "BM@
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M&RO[ZQLK^^L;*_OK&ZBJ  ":M   C;\  (#)  !TTP  9]X  %[R" !9_A$
M4_\: 4[_(P))_RL#1?\S!$'_.@4^_T$&._]'!SC_3@@U_U0),_]:"3'_80HO
M_VD++/]R#"K_?0TH_X@.)O^5#R7_H1 D_ZX1(_^Z$B+_RA(B_] 2(O_0$B+_
MT!(B_] 2(O_0$IRR  ".O   @<<  '/1  !GW0  6>,  %/]!@!-_PX 2/\6
M $/_'@$__R8".O\M C?_,P,S_SD#,/\_!"[_1 0K_TH%*?]0!2?_5@8D_UT&
M(O]E!R#_;@<=_WD(&_^%"!K_D@D9_YX)&/^H"1?_LPD7_[<)%_^W"1?_MPD7
M_[<)%_^W"9"Z  ""Q0  =-   &?<  !8XP  3?   $?_ @!"_PP //\1 #C_
M& $T_Q\!,/\E 2S_*P(I_S ")?\U B/_.@(@_S\#'O]$ QS_20,9_T\#%_]6
M!!7_7@02_V@$$?]R!0__?@4._XH%#O^4!0W_G@4-_Z(%#?^B!0W_H@4-_Z(%
M#?^B!?\Y+P+_/# #_T$Q _]$- 3_1#H&_T1%"/]%40S_0UT1_T%I%O\^=AG_
M/($<_SJ,'O\YEB#_.)XA_S>E(_\WJR/_-K(D_S:Y)?\VP"7_-<HF_S77)O\U
MY2;_->\F_S7X)O\V_R;^-O\F_#;_)OPV_R?Z-O\H^C;_*/HV_RCZ-O\H^C;_
M*/\Y+P+_/B\#_T0O _]&,@3_2#@&_TA#"/](3PW_1UL2_T1G%O]"<QK_/W\=
M_SV*'_\\DR'_.YLC_SJB)/\YJ27_.; F_SBV)O\XOB?_.,<G_SC3*/\XXRC_
M..TH_CCW*/LX_B?Y.?\G^#C_*?@X_RKV./\J]CC_*O8X_RKV./\J]CC_*O\Z
M+P+_02P#_T8L _]*+P3_3#<%_TU!"/],3 W_2U@2_TAD%_]&<!O_0WP>_T&'
M(/\_D"/_/I@D_SV@)?\]IB;_/*TG_SRT*/\[NRG_.\0I_SO/*?X[X"K[.^LJ
M^#OU*?8\_BGT//\J\SO_*_([_RSO._\M[SO_+>\[_RWO._\M[SO_+?\\+0+_
M1"D"_THI _].+ 3_430%_U(^"/]22@W_4%42_TUA%_]*;1O_2'@?_T6#(O]#
MC23_0I4F_T&=)_] HRC_0*HI_C^Q*OT_N"O\/\$K^C_+*_<_W"SU/^DL\3_T
M*^\__2SM/_\M[#[_+^L^_S#G/_\PYS__,.<__S#G/_\PYS__,/] *@+_2"8"
M_TXF _]2*0/_5C(%_U<\!_]71PS_55$2_U)=%_]0:1S_370@_TI_(_U(B2;[
M1Y$H^D:9*?A%H"KW1*<K]42M+/1#M2WS0[TM\D/(+O!#UR[L0^<NZ43S+>9#
M_##D0O\QXT+_,N%"_S/<0_\TW$/_--Q#_S3<0_\TW$/_-/]#)P+_2R,"_U(B
M O]8)P/_7"\$_UTY!_]>0PS_6TX1_UA8%_Y59!SZ4F\@]U!Z)/1-A"?R3(TI
M\$J5*^])G"WM2:,N[$BJ+^I'L2_I1[HPYT?%,.9'TC#B2.4PWT?R,MM'^S38
M1O\UU4;_-M)&_S?-2/\WS4C_-\U(_S?-2/\WS4C_-_]&) +_3R "_U8? O]=
M) /_82P$_V,U!O]D0 O_8DH0^EY4%O5;7QSQ6&L@[E5U)>M3?RCH48@KYD^1
M+>1.F"_B3: PX4RG,=],KC+=2[<SVTO"--E*SS752^0UT$OP-LU*^SC*2O\Z
MR$K_.L9+_SO!3/\[P4S_.\%,_SO!3/\[P4S_._]*(0+_4QT"_UL< O]B(@+_
M9RD#_VDR!?]J/ GY:$8/\F50%>UA6QKH7F8@Y%MQ)>%8>RG>5H0LVU2,+]A2
ME#+449LTTE"C-=!/JC?.3K(XS$Z\.<I.R3K(3MTZQ$_M.\%.^3V^3O\]O$[_
M/KI/_SZV4/\^ME#_/K90_SZV4/\^ME#_/O]-'@+_5AH!_U\: ?]G( +_;"8"
M_V\N!/EP. ?R;T(,ZVQ+$N5I5QG?96(?VF%L)=1==BK06WXOS5F',LI7CS7(
M5I8WQE2=.<13I3O!4ZT\OU*W/KU2PS^\4M,_N5+H/[52]D&S4O]!L5/_0:]3
M_T&L5/]!K%3_0:Q4_T&L5/]!K%3_0?]0' '_6A<!_V08 ?]L'0'_<2,"_74J
M _-V,P7K=CT*XW-'#]QO4Q?4:UX?SF9G)LIC<2O&8'DPPEZ!-+]<B3>]6I$Z
MNEF8/+A8H#ZV5ZA M%:R0K)6O4.P5<Q#K5;C1*M6\T2H5_Y$IU?_1*58_T2B
M6/]$HEC_1*)8_T2B6/]$HEC_1/]3&0'_710!_V@6 ?]P&@'_=B !]WHF NU\
M+@/D?#@'W'I$#=)U3Q;+<%H>QFQC)L%H;"R]9G4QN6-]-;9AA#FS7XP\L%V4
M/ZY<FT&K6Z1#J5JM1:=:N$:E6<='HUK>1Z%:[T>?6_Q'G5O_1YM<_T::7/]&
MFES_1II<_T::7/]&FES_1O]5%P'_8!(!_VL4 ?]T%P#_>AP!\G\B >>!*0+>
M@C,$TW] #,MZ3!7$=E8>OG%@);EN:"RT:W$RL6AY-JUF@#JJ9(@]IV*/0*5@
MET.B7Z!%GUZI1YU>M$F;7<)*F5W62I=>[$J67_I)E5__29-@_TB28/]'DF#_
M1Y)@_T>28/]'DF#_1_]8%0'_8Q$!_VX2 /]W%0#[?A@ [8,= .*'(P'6ARX#
MS(,]"\5_212]>U,=MW9=);)S92RM;VTRJ6UU-Z9J?#NB:(0^GV:,09QEE$29
M8YQ'EV*F291BL$N28;Y,D&'03(]BZ$R.8_A+C6/_2HQD_TF+9/])BV3_28MD
M_TF+9/])BV3_2?]:$P'_9A  _W$1 /]Z$@#W@A0 Z(<7 -V+' #0BRP#QX@[
M"K^$1Q.X?U$<L7M:)*QW8BNG=&HQHW%R-I]O>3N;;8 _F&N(0I5ID$62:)E(
MCV:B2HQFK4R*9;I-B&7,3H=FYDZ&9_9,AF?_2X5H_TN$:/]*A&C_2H1H_TJ$
M:/]*A&C_2O]<$@'_: \ _W00 /]]$ #SA1  Y(L1 -:/%P#+CBH"PHPX";J(
M1!*SA$\;K']8(Z=\8"NA>&@QG75O-IES=CN5<7T_DF^%0HYMC46+;)9(B&N@
M2X5JJDV#:;=.@6G(3X!JXT^ :_1.?VO_3']K_TM_:_]+?VO_2W]K_TM_:_]+
M?VO_2_]>$ '_:PX _W8. /N #0#JB T VX\, -"2%0#'DB<"OH\V"+:,0A&N
MB$T:J(16(J* 7BJ<?64PEWIL-9-W<SJ/=7L^C'."0HARBT:%<)-)@F^=3']N
MJ$Y];K5/>VW&4'INX%!Y;_).>6_^37EO_TQY;_]+>6__2WEO_TMY;_]+>6__
M2_]@#P#_;0T _WD, .Z#"P#;BPD U)$* ,R5$P#"E24"N9,T![&/01"JC$L9
MHXA4(9V$7"F7@6,ODGYJ-8Y\<3F*>G@]AGB 0H-VB$5_=9%)?'.;3'ERIDYV
M<K-0=7+#4'-RW5!T<_!/='/]371S_TQT<_],='/_3'1S_TQT<_],='/_3/]B
M#@#_;PP _'L* -Z&!@#5C@@ SY0) ,>8$0"^F",!M98R!JV3/P^FD$D8GXQ2
M()B)6BB3AF$NCH-H-(F!;SF%?W8]@7U^07U[AD5Z>8])=GB93'-WI$YQ=[%0
M;W;!4&YWV5!N=^]/;G?\3FYW_TUO=_],;W?_3&]W_TQO=_],;W?_3/]D#0#_
M<@H \'X& -J(!0#0D < RI<( ,*;$ "YFR$!L9HP!JF7/0ZAE$<7FI%0'Y2-
M6">.BU\MB8AF,X2&;3B A'0]>X)[07B A$5T?XU(<7V72VU\HDYK?*]/:7N^
M4&A\U5!H?.U/:7S[3FE\_TUJ>_],:GO_3&I[_TQJ>_],:GO_3/]F"@#_=0@
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M2%&7_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@
MJZ@  *&P  ":LA$ E+,B 8VR, 6%L3P,?J]&%'BN3AMRK%8A;:M<)VBI8RQD
MJ&HP8*=Q-%RF>3A8I8([5:2,/E&CF$!/HZ5"3:.T0TRCR$-,H^1#2Z'T0TN@
M_T1+H/]$2Z#_1$N@_T1+H/]$2Z#_1.-]  #/BP  PI8  +>?  "MI@  HZT
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M+CS%_RX\Q?\N/,7_+L23  "VGP  J:8  )VN  "2MP  AK\  'O' P!PSP<
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M"9BP  "*N@  ?,0  &_-  !BV   5=X  $GD  !$^P4 /_\. #O_%0 X_QP
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M1'9JU$5V:^U#=FO[0G9K_T%V;/] =FS_0'9L_T!V;/] =FS_0/]="@#_:0<
M['0# -I\! #0@P8 R8@' ,.*#P"ZBR !LHHO!*N(/ JDA4<2G8%0&9A^6!^3
M?%\ECGEF*HIW;2Z&=70R@G1\-G]RA#E\<8T]>7"60'9OH4)T;JY$<FZ]17!N
MT45P;^M$<&_Z0W%O_T%Q;_] <7#_0'%P_T!Q</] <7#_0/]?" #_:P0 X78
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M0F!]_T%A??] 87W_0&%]_T!A??] 87W_0/]G  #C=   TG\  ,>( 0"^CP(
MMI4! *Z8!@"FFA4 GYHF IB9,P:1ES\,BY5(%(634!I_D5@@>H]?)7:-92IR
MBVPN;HIS,FJ(>S9FAX0Y8X:./&"%F3]=A*9!6X2T0EJ$QT-:A.-"6H/T05N#
M_T!;@_] 6X/_/UN#_S];@_\_6X/_/_]J  #>>   S8,  ,*,  "YDP  L)@
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M.4F;_SE)F_\Y29O_.=MZ  #(AP  O)(  +&:  "FH   G*8  )&L  "'L0@
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M&K.9  "FH0  FJD  (ZQ  "!N0  =<   &K'  !>S0, 5-0( $S=#0!*W1@
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M!!G^F 08_Z@$%_^W!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP
M>,   &K)  !=T@  4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F
M_R< (_\M "#_,P >_SD!'/\_ 1G_10$7_TT!%?]5 1/_7P$1_VH"$/]X @[_
MAP(._Y8"#?^D @S_L (,_[X"#/_" @S_P@(,_\("#/_" H>V  !YOP  :\D
M %[3  !0VP  0^   #CE   O\   *_\  "?_"  D_PX (?\3 ![_&0 ;_QX
M&/\C !7_*  3_RT $?\R !#_.  ._S\ #/]& 0K_3P$'_UD!!/]E 0'_<@$
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M-H=:UC:&6^TVA5O[-85<_S2$7/\SA%S_,X1<_S.$7/\SA%S_,_]3"@#_708
M]68$ -]M P#5<@8 T'4) ,EV$0# =R( N'8Q [%T/@>K<4D.IFY2%*%L6QF=
M:6(=F6=J(I9F<2639'@HD&-_*XUAARZ*8) PB%^9,X5?HS6#7J\V@5Z^.(!>
MT3A_7^HW?E_Z-GY@_S5^8/\T?F#_-'Y@_S1^8/\T?F#_-/]5" #_8 0 Z&D
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M.&UK_S=M:_\V;6O_-FUK_S9M:_\V;6O_-O];  #K9P  V7$  ,QY  ##?@(
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M-5A^_S58?O\U6'[_->EH  #4=   QGX  +N'  "RC0  J)$  )Z4  "6E@X
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M8;0S EZT/01:M$8'5K-."E.S50U0LUP03;)C$TJR:Q9'L7081;%^&D*PBAU
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M#C'+L@\PS,</,,OE#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@
ME:4  (FM  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [
MUS$ .=@[ #C910$VV4T!-=E6 C/:7@(QVF@#,-MS!"[;?P4LVXT%*MR=!BG<
MK08HW<$&*-W>!B?;[P<FV?D()MC^"2;8_@DFV/X))MC^":2=  "8I0  BZT
M 'ZT  !QO   9<,  %G)  !-S0  0],! #K9!@ UY T ,^06 #'D(  PY2H
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M 03_K@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0
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M))]*WB2=2O DFTK])9E+_R292_\DF$O_))A+_R282_\DF$O_)/](# #_3P@
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M+7I<_RQY7/\K>ES_*GI<_RIZ7/\J>ES_*O]1  #R6P  WF0  ,]J  #';@(
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M+&5K_RQE:_\L96O_+/1;  #=9@  RV\  ,!V  "W>P  KWX  *9^ 0"??Q
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M'3Z?LAX]G\8>/9_C'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB
MJ9   )Z6  "3FP  AY\  'ND  !OJ   8ZP$ %^M$0!<K1\ 6JXK %>N-@%4
MKD #4:U(!4ZM3P=+K5<)2:U>"T:L9@U$K&X/0:QX$3^KA!,\JY$5.JN@%CFK
ML!<XJ\,7.*KA%S>I\Q@WI_X9-J;_&C:F_QHVIO\:-J;_&KJ$  "NCP  HI8
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M B#3ZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN
M8+X  %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @
MX#< '^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13G
MW0$3Y>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8
M $C*   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT
M%.\U !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )
M]MD "/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2
M   QV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI
M  K^,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L
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M#KTVY@ZY-O00MS;_$;4V_Q*T-O\3LS;_$[,V_Q.S-O\3LS;_$_\Y$ #_/0L
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M'HM+_QZ+2_\=BDO_'8I+_QV*2_\=BDO_'?]%  #_30  Y50  -E9  #/6P,
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M(F];_R%O6_\A;UO_(?I/  #A6@  SV(  ,1G  "[:P  LVP  *QJ! "D:Q(
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M($M]L2%*?<0B2GWA(4M\]"%+>_\@2WO_($M[_R!+>_\@2WO_(-!G  # <@
MM'L  *J"  "@A@  E8@  (>(  !\B@  =HP. '*-&@!NCB< :HXR 6:-/ -C
MC40%8(Q,"%R+4PI:BUH-5XIA$%2):!)1B'$53XAZ%TR'A1I*AI(<2(:@'4:&
MKQY%A<(>187?'D6$\AY%@_X>18+_'D6"_QY%@O\>18+_'LIM  "Z>   KX$
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M#S.D[@\RHOL0,J'_$3*A_Q$RH?\1,J'_$;2"  "HC   G9(  )*7  "&G
M>:$  &VE  !AJ0  5:P  $NO!0!'L!  1; < $2Q)P!"L3( 0;([ #^R0P$]
MLDL!.[)3 CFR6P,WLF0$-;)N!3.R>08QLH<'+[&6""ZRI@@MLK@)+++0""RP
M[ DKK_D**Z[_"RJM_PLJK?\+*JW_"ZV+  "@D@  E9@  (F=  !]HP  <:@
M &2M  !9L0  3;0  $*X   [N@H .+L3 #>\'@ UO"D -+TR #.].P RO40
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M  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=O   4,$  $3%   XR0
M+LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH&0 ,Z"$ "^DI  KJ,0 )
MZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG  #KO   Z](  .OI  #L
M[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0  0\D  #?-   MT0  (]8
M !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #]A@  /4>  #U)0  ]2X
M /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #WIP  ][<  /C'  #XT
M^-   /C0 'NO  !MN   8,   %+(  !$S0  -]$  "O7   AW   &.   !'D
M   ,YP  !^\   3Z   !_P,  /\(  #_#0  _A   /X4  #_&@  _R$  /\I
M  #_,P  _SX  /]+  #_6P  _VP  /^   #_D@  _Z$  /^M  #_LP  _[,
M /^S /\<)@#_'"0 _QHE /\5)P#_$2X _Q Z /\.1P'_#5,!_PM? ?\*:P'_
M"G4!_PI_ ?\*AP'_"HX!_PJ5 ?\*FP'_": !_PFE /\)JP#_";$ _PFX /\)
MP0#^"<P _ G> /D)ZP#U"?8 \PG_ /(*_P#Q"O\!\0O_ ?$+_P'Q"_\!\0O_
M ?\?(P#_'R$ _QXA /\9) #_%RP _Q4W /\31 #_$5 !_Q!< ?\.9P'_#G(!
M_PY[ ?\.A '_#HL!_PZ2 ?\.F '_#IT!_PZC ?X.J '\#JX!^PZU /H.O@#X
M#LD ]0[; /(.Z@#N#O4 [ [_ >L/_P'J#_\!ZA#_ >D0_P'I$/\!Z1#_ ?\B
M'P#_(AP _R$< /\?( #_'RD _QPT /\:0 #_%TP!_Q58 ?\48P'_$VX!_Q-W
M ?X3@ '\$X@!^A*. ?D2E0'X$IH!]A*@ ?42I@'T$JP!\Q*S ?$2O 'P$L<!
M[1+8 >D3Z 'F$_4!Y!3_ >(4_P+A%?\"X17_ N 5_P+@%?\"X!7_ O\E&P#_
M)A< _R06 /\E' #_)B4 _R0P /\A.P#_'T@ _QU4 ?T;7P'Y&FD!]QIS ?09
M? 'R&80!\1F+ >\9D0'N&9<![!F= >L9HP'I&:H!Z!FQ ><9N@'E&<4!XQG5
M =\:Z '<&_4"V!O_ M4<_P/4'/\#TQS_!-(<_P32'/\$TAS_!/\I%P#_*A,
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M#:4V_PZC-_\.HC?_#J(W_PZB-_\.HC?_#O\W!P#_.P( _T # /)"!0#I0@D
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M%WU+_Q9]2_\6?4O_%O]#  #F3   UE,  ,E8  # 60  NE@! +16"0"L5Q8
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M&U=FL!Q69L,=5F;?'59F\QQ79O\;5V;_&E=F_QI79O\:5V;_&MM9  #'8@
MNFH  *]P  "F<P  FG,  (]P  "'<04 @7(1 'QS'@!X<RH =',U 7!S/P-M
M<D<%:G%.!V=Q50ED<%P+8F]C#E]O:A!=;G(26FU\%5AMAA=6;),95&R@&U)K
MKQQ1:\$<46O<'%%K\1M2:_X:4FK_&E)J_QE2:O\94FK_&=1<  ##9@  MFX
M *QT  "B=P  EG8  (EU  "!=@$ >G</ '9X&P!R>2< ;WDR 6MX/ )H>$0$
M97=,!F)W4PA?=EH*775A#%IU: ]8=' 157-Y$U-SA!91<I 83W*>&4UQK1I,
M<;\;2W'9&TQQ\!I,</T:37#_&4UO_QE-;_\936__&<Y@  "^:@  LG(  *AX
M  "=>P  D'H  (1Z  !Z>P  ='P, &]^%P!L?B0 :7\O 69_.0)B?T(#7WY)
M!5U]4 =:?5<)5WQ>"U5\90U2>VX/4'IW$DYZ@A1+>8X627F<%TAXJQA&>+T9
M1GC5&49W[QA'=OP81W;_&$=U_Q='=?\71W7_%\EE  "Z;P  KG<  *1]  "8
M?P  BW\  'Y_  !S@0  ;(,) &B$$P!EA2  8H8L %^&-@%<AC\"685& U>%
M3@54A54'4H1<"4^#8PM-@VL-2X)T#TB"?Q%&@8P31(&:%4* J19!@+H60(#2
M%D%_[19!?OL607W_%D%]_Q9!??\607W_%L)J  "U=0  JGT  )^"  "2@P
MA80  'F%  !JB0  9(H# &",$ !=C1L 6XXG %B.,@!5CCL!4XY# E".2@-.
MC5(%3(U9!DF,8 A'C&@*18MR#$*+?0Y BHD//HJ8$3R*IQ([BK@2.HK/$CN(
MZQ([A_H3.X;_$SN&_Q,[AO\3.X;_$[QQ  "O>P  I8,  )F'  ",B   ?XD
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M!26G_P4EI_\%):?_!:>)  ";CP  D90  (29  !XG@  :Z(  %^F  !3J@
M2*T  #VP   TLP, +[4. "VU%@ LM2  *[8I "JV,@ IMSH *+=# ">W3  F
MN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G  1RXWP$<MO(!&[7\ ANT
M_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@  8JL  %:P  !*LP  /[8
M #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :PR\ &<0X !C$00 7Q$H
M%L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'U  0QNX $,3Z !##_P 0
MP_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0  $NX  ! NP  -;X  "O!
M   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$ #-$J  S1-  +TCX "M))
M  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !U=P  =7M  '5]@ !U?8
M =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_    TPP  *L<  "'*   9
MS@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@  #>*   WS$  . \  #A
M1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$  .75  #FYP  YN<  .;G
M (.D  !UK   :+,  %J[  !-P0  0,0  #/(   HS   ']   !?4   0V0
M"]T   7A    Y    .4'  #F#0  YQ$  .@6  #I'0  ZB4  .LN  #M.0
M[T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[  #TR   ],@  /3( '>M
M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@  %-P   [@   (XP   >8
M  #J    [@   .X   #O!   \ H  /$.  #S$@  ]!@  /8@  #X*@  ^C4
M /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_L   _[   /^P /\6(P#_
M%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!= /\ : #_ '( _P![ /\
M@P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P ^0"S /< NP#U ,4 \P#1
M /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M /\ [0#_ /\9( #_&!T
M_Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$9 #_!&X _P-W /\#@ #_
M X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P /$!N #O <( [0'/ .L!
MXP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\ Y@;_ /\<&P#_&QD _Q<8
M /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_"VH _0MS /L+? #Y"H,
M]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)M@#H"<  Y@G- .0)X@#B
M"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_ ?\?%P#_'A, _QL2 /\<
M&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8 \Q!O / 0=P#N$'\ [!"&
M .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@#[X W@_, -H0X0#5$?
MTA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B$@#_(@\ _R$/ /\B% #_
M(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J .06<@#B%GH X!:" -X6
MB #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L SA?) ,P8W@#(&>X!Q1K[
M <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_)0L _R@, /\I$ #_*!8
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M"I(W_PJ2-_\*DC?_"O\S  #V.@  Y#\  -A"  #.0@$ R3X& ,0[#P"[/AT
MM3\L +$_.@"M/T4!J3]/ :8^6 *C/5\#H3UG!)\\;06=/'0&G#M[!IH[@@>8
M.XH(ECN3"94ZG J3.J8+D3JR"Y [P R..]4,C#SL#8H\^PV)//\-B3S_#(@\
M_PR(//\,B#S_#/\W  #J/P  W$4  ,Y)  #%20  OT8" +I## "S1!D K44G
M *A&-0"D14$!H$5+ IU$4P*:0UL#F$-B!99":0:407 'DD%V")! ?@F.0(8*
MC4"."XM F R)0*(-AT"N#H5 O ^$0,\/@D'I#X%!^0^ 0?\/@$+_#H!"_PZ
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M$.Q#  #93   R%,  +U7  "T6   K%<  *52 0">4P\ F%0< )-4*0"/5#4
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M%&)5KQ5A5<$68%7;%F!6\15@5OX48%;_$V%6_Q)A5O\285;_$N!-  #+5@
MO5T  +)A  "H8P  G6$  )5=  "-7@D AUX3 (-?( !_7RP >U\W 7=>0 )T
M7D@#<5U/!&]<5@5L7%P':EMC"6A;:PMF6G,-9%I\#V):AQ%@69,27EF@%%U9
MKA5;6;\66UG8%EM9[Q5;6?T47%G_$UQ9_Q)<6?\27%G_$MQ0  #'60  NF
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M%$QFZQ1-9OL336;_$DYE_Q).9?\23F7_$LQ:  "\8P  L&H  *5O  "8;@
MC&T  (!L  !W;0  <6X+ &UO% !I<"$ 9G$L &1Q-@%A<3X!7G%& EQP30-9
M<%0%5W!;!E5O8@A3;VH*4&YS#$YN?@Y,;8H02FV8$4ELIQ)(;+@31VS-$T=L
MZA-(:_H22&O_$DAJ_Q%(:O\12&K_$<=>  "X9P  K&X  *%R  "3<@  AW$
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M##: _PPV@/\,-H#_#+9O  "J>   GW\  )!^  "#?P  =X   &N"  !>AP
M58H  $Z,!@!*CA  2(\: $>/)0!%D"\ 1) X $*00 ! D$<!/Y!/ 3V05@([
MD%\".9!H S>/<P0UCX %,X^.!C&/G@<PCJ\'+X[#!R^.X0<OC/0(+XO_""^*
M_P@OBO\)+XK_";!V  "E?P  F(0  (J$  !]A0  <(<  &6*  !:C@  3Y(
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M 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%K   .[   #&R   GM0
M(+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]-P 0OD$ #KY,  Z^5P -
MOF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P  B]^@ (O?P "+W\ ).4
M  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@  ,;@  ">[   ?O@  %\$
M !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #RC8  LI   #+3   RUD
M ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,[P  S/$  ,SQ (J:  !\
MH0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$  !W$   5R   #\L   K.
M   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH  -DT  #:/P  W$L  -Q:
M  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@  WN(  -[B '^B  !QJ0
M9+   %:W  !)O   /,   "_$   DQP  &\L  !//   -T@  !]8   #;
MW@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G  #H,0  ZCT  .Q+  #L
M6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8  .[& '2J  !FL@  6+D
M $O    ]Q0  +\D  "3-   9T0  $=8   O;   #W@   .$   #E    Z
M .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T(P  ]RX  /D[  #[2@
M_%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO /\0'P#_#AT _PH= /\!
M( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X _P!W /\ ?P#^ (8 _ ",
M /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R +T \0#) .\ W #N .L
M[0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3' #_$1D _PT9 /\&' #_
M R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S /H >P#W (, ]0") /0
MCP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H Z #& .< U@#E .@ Y #U
M ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_$Q0 _P\4 /\-&0#_"R(
M_P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /( =P#O 'X [0"% .L BP#J
M )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP## -T T0#; .8 V0#S -<
M_0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1  _Q(/ /\2%0#_$1T _PXH
M /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F!7H Y 6! .(%AP#@!HT
MWP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - 'SP#.".4 S GT ,H+_P#(
M#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@- /\8$0#_%Q@ _Q0B /L1
M+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74 V U\ -4-@@#3#8D T0V/
M - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##$.8 P!'U +T2_P"\$O\
MNQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?#0#_'1( ^!H; .X6)@#F
M%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W ,<5?0#&%80 Q!6* ,,5
MD0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.( LQGR ;$:_P&O&_\!KAO_
M :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W(0P [!T2 .$:' #8&BH
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M!_0R  #C.P  TD$  ,9$  "]0P  MS\  +$["0"J.Q0 I3PB * ], "=/3L
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M"V]$KPQN1, ,;479#6Q%[PQK1?T+:T;_"VM&_PIK1O\*:T;_"N5   #/20
MP4\  +52  "K4@  H4\  )M*  "42@P CTL7 (M,) "'3"\ A$PZ (%,0P%^
M2TL!>TM2 GE*6 -W2E\$=4EF!7-);09Q274';TE^"&U(B EK2),+:DB?#&A(
MK0UG2;T-9DG4#F5)[0UE2OP,94K_"V5*_PME2O\+94K_"^!$  #+30  O5(
M +)6  "F50  G%(  )5.  ".3@D B4\4 (50( "!4"P ?E W 'M00 %X4$@!
M=4]/ G-.50-Q3EP$;TYC!6U-:@9K37(':4U["&=-A0IE39$+9$R=#&)-JPUA
M3;L.8$W1#F!-[ Y@3?L-8$W_#&!-_PM@3?\+8$W_"]Q'  #'4   N58  *Y9
M  "B6   F%8  )!1  ")4@8 @U,1 ']3'0![5"D >%0T '54/0%R4T4!<%-,
M FU24P)K4ED#:5)@!&=19P9E46\'8U%X"&)1@PI@48\+7E";#5U0J0Y;4;D.
M6U'.#UI1Z@Y;4?H-6U'_#%M1_PQ;4?\+6U'_"]9*  ##4P  MED  *M<  ">
M6@  DUD  (M4  "$5@, ?E80 'I7&@!V5R8 <U@Q '!7.@!M5T(!:E=) FA6
M4 )F5E<#9%9>!&)5905@56T'7E5V"%U5@0I;58T+652:#5A4IPY65;@/5E7,
M#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  # 5@  LUP  *=>  ":70
MCUP  (98  !_60  >5H- '1;%P!Q6R, ;ELN &M;-P!H6T !95M' 6-:3@)A
M6E4#7UI<!%U:8P5<6FL&6EET"%A9?PI668L+5%F8#5-8I@Y26;8.45G*#U%9
MYPY16/@-4EC_#5)8_PQ26/\,4EC_#,U1  "\60  L%\  *-A  "68   BU\
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M"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  "):0  ?6D  '%I  !G:@
M8FP! %UM#0!9;A8 5V\A %5P*P!3<#4 47 ] %!P10%.<$P!3'!3 DIP6@-(
M<&($1F]K!41O=09";X('0&Z/"3]NG@H];J\*/6[""CQNX H];?0*/6S_"CUK
M_PH^:_\*/FO_"KI@  "M:0  H&X  )%M  "$;0  >&T  &QN  !A<   6W(
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M!*IT  ">>P  CGH  (!Z  !T>P  :'X  %V!  !2A0  28D  $&,   YD 4
M-9$/ #.2%P RDB$ ,9(I #"3,@ NDSH +9-! "R32@ KE%( *I1< "B49P G
ME',!)92" 224DP$BDZ0!(9.W 2"3SP$ADNP!()#Z B"/_P(@C_\"((__ J1\
M  "7@   AW\  'N   !N@@  8H4  %>)  !-C@  0I(  #J6   RF0  *IP)
M "B=$0 FG1D )9TB "2>*@ CGC( (IXZ "&>0@ @GDL 'Y]5 !Z?8  <GVT
M&Y]\ !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;_P$7F_\!%YO_ 9V#  "/
MA@  @H8  '2'  !GBP  6X\  %"3  !&F   /)P  #.@   KHP  (Z8  !RH
M"P :J1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD, $ZM- !*K6  1JV4 $*MT
M  ZKA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -J/\ #:C_ ):*  ")C
M>HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ   CK@  &[   !2S 0 /
MM0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#  :W3P $MUL  [=J  *W
M>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<  +7W (^1  "!E   <I<
M &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :N   $[L   Z]   )P 4
M \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$1   Q%   ,1>  #%;P
MQ8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N (:8  !YG@  :Z,  %VI
M  !0K@  1+,  #>V   LN0  (KP  !F_   1P@  #,4   ;(    RP   ,P'
M  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.   U$0  -12  #580  U7,
M -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@  !NI@  8*T  %.S  !%
MN   .+P  "N_   AP@  %\8  !#)   *S    M    #4    UP   -@   #:
M!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38  .=#  #G4P  Z&0  .EW
M  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !BKP  5;8  $>\   YP
M+,0  "#(   6S   #M    ?4    V0   -T   #A    XP   .0   #F
MYP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S  #W0P  ^%0  /EF  #Y
M>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD _P 9 /\ ' #_ "4 _P R
M /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[ (( ^@"( /@ C0#W )(
M]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P T0#K .8 Z0#S .@ _@#H
M /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4 /\ & #_ "( _P N /\
M.P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X \@"$ /  B0#O (\ [@"4
M .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A .( WP#P -X ^P#> /\
MW0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"%0#_ !X _P I /\ -@#_
M $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_ .< A0#E (L Y "0 .(
ME@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T T0#M -  ^0#/ /\ S@#_
M ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_!QD _P(D /\ , #V #P
M[P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L @0#9 (8 U@", -0 D@#2
M )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J ,, ]P#" /\ P0'_ , "
M_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0 _PH> /4&*0#K!#8 XP-"
M -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*!8( R06( ,<%C@#&!90
MQ 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+^ "U#/\ M S_ +0,_P"T
M#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5 .@,(0#>"BX U@L[ - ,
M1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T O0Z# +P.B@"Z#I$ N0Z8
M +<.H "V#JD M ^T +(/P0"Q$-0 KA'K *L2^@"I$O\ J!/_ *<3_P"G$_\
MIQ/_ /\:  #_&P  ^1L  .L9  #E% 8 Y1 . -D.%P#/$28 R!(T ,030 "_
M%$L O!14 +D570"W%60 M15K +05<0"R%7@ L19^ *\6A0"N%HP K!:4 *L7
MG "I%Z8 IQBP *88O0"D&,\ HAKG )\:]P"=&_\!G!O_ 9P;_P&;&_\!FQO_
M ?\=  #W(0  Z"0  -TE  #4(0$ SQL( ,H7$0#"&B  O!PM +<=.@"S'D4
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M X,OL@."+\(#@3#: W\P[P-],?X#?3'_ WPQ_P-\,?\#?#'_ ^TO  #;-P
MR3T  +X^  "S/   K#@  *<S! "B,A$ G30= )DU*@"5-34 DC5  (\U20"-
M-5  BS57 (DU7@&'-60!A31K 80T<@*"-'D"@#2" GXTBP-]-)8#>S6A!'DU
MK@1X-;X%=S;4!78V[05T-_P%=#?_!'0W_P1T-_\$=#?_!.<U  #2/0  PT(
M +A$  "L0@  I#X  )\Y  ":. X E#H9 ) Z)@"-.S$ BCL[ (<[1 "$.TP
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M"&!$Y@A?1?@'7T7_!V!%_P9@1/\&8$3_!M9!  ##20  MDX  *=/  ";30
MDDL  (Q'  "%1P0 @$<0 'Q(&@!X2"8 =4DP '-).@!P24( ;DE) 6Q(4 %J
M2%8!:$A= F9(9 )E2&P#8TAU!&%'?P5@1XH&7DB7!UU(I0A;2+0(6TC'"5I(
MY A:2?8(6DG_!UI(_P9:2/\&6DC_!M%%  "_3   LE(  *-1  "74   C4X
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M!TQ3_P=-4_\&35/_!L5.  "V5@  IUH  )A9  "+6   @5<  '=4  !P50
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M!;1>  "G90  E64  (9D  !Z90  ;V4  &1F  !9:   4FH  $UL! !);@X
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M;0  B6P  'QM  !P;0  9FX  %MQ  !0=0  2'@  $%[   Z?@4 -G\. #2
M%@ S@2  ,H$H #"!,  O@C@ +H)  "V"2  L@E  *X): "J"9  H@G  )H)_
M 26"CP$D@J !(X*R 2*"R0$B@><!(G_W 2)^_P(B??\"(GW_ J5Q  "3<0
M@W$  '9Q  !L<@  8'4  %9X  !,?   0X   #N#   SA@  +8D* "J*$0 I
MBQD )XLB ":+*@ EC#$ )(PY ".,0@ BC4H (8U4 ""-7@ ?C6L '8UY !R-
MB@ ;C9P &8VN !B,Q  8C., &8KU !F)_P$9B/\!&8C_ 9UW  ",=@  ?78
M ')W  !E>0  6GP  %"   !&A   /(D  #2,   MD   )9," !^5#  =EA(
M')8: !N7(@ :ERH &9<R !B8.@ 7F$, %IA- !686  4F&0 $YAS !&8A  0
MF)8 $)BI  Z8OP .E]T #Y;R !"5_  0E/\ $)3_ )5]  "%?   >'P  &M^
M  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@  'IT  !>@ P 2H@P $*,2
M !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *I%P ":1J  >D>P &HXX
M!*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#  !_@@  <80  &2'  !8
MC   39$  $*6   XF@  +YX  ":B   >I0  %Z@  !&K   ,K@< !Z\-  .O
M$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,  +!A  "P<0  L(,  *^7
M  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !XB@  :HX  %V3  !1F
M19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV   %N0,  +H*  "Z#@
MNA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6  "^90  OG<  +Z,  "^
MGP  O;,  +['  "^W@  O>L  +WK '^2  !PE0  8IH  %6?  !)I0  /:L
M #*O   HM   'K8  !6Y   .O   ";\   +"    Q    ,4$  #&"@  Q@X
M ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/60  SVH  ,]^  #/DP
MSZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<  $ZN  !!M   -+<  "BZ
M   =O0  $\    W$   &QP   ,H   #.    T    -$   #2 @  TP@  -4,
M  #6$   V14  -L<  #=)   X"\  .(\  #C2P  Y%P  .1O  #E@P  Y9@
M .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y   UO   *,   !S$   2
MR   #,L   //    TP   -@   #<    WP   -\   #A    XP   .0#  #F
M"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T  /5?  #V<P  ]X<  />9
M  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_ ", _P O /\ / #_ $@
M_P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8 B #U (X ] "3 /( F #Q
M )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q .8 _0#E /\ Y #_ .0
M_P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\ _P K /\ -P#_ $0 _@!/
M /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K (H Z@"/ .@ E #G )H
MY0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@ ^0#6 /\ U@#_ -< _P#8
M /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F /P ,@#W #\ ] !* /$
M50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4 W@"+ -P D #; )8 V "<
M -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#( /\ R #_ ,@ _P#( /\
MR #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$ + #L #D Z0!% .4 3P#A
M %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"& ,P C #+ )( R0"8 ,<
MH #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T NP#_ +H _P"Z /\ N@#_
M /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A #( W  _ -8 20#1 %,
MS@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,  AP"^ (X O "4 +L G "Y
M *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_ *T#_P"M _\ K0/_ /\0
M  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL S ,W ,@$0P#$!$T P016
M +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R!HD L :1 *\'F0"M!Z$
MJP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-_P"A#?\ H W_ /\1  #\
M$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP +P-/ "X#48 M0U/ +(.
M5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4 I0^- *0/E@"B$)\ H!"I
M )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5%/\ E!3_ /\5  #M&P
MX!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4-0"L%4  J15) *854@"D
M%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>( )@7D0"6&)L E!BF ),9
ML@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\ B1S_ /0=  #D)0  TRD
M ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A'CH GAY$ )L>3 "9'E0
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M F\PY0)N,?<";3'_ FTQ_P)M,?\";3'_ M\R  #).0  NSX  *P]  "A.@
MFC<  )4S  "0,0H C#$4 (<R( "$,RL @3,U '\S/@!],T8 >S-- 'DS5 !W
M,UH =C-A '0S9P%R-&\!<31W 6\T@0%N-(P";#28 FHUI0)I-;,#:#7& V<V
MX@-F-O4#9C;_ F8V_P)F-O\"9C;_ M@W  #$/@  M4(  *9!  ";/P  DSP
M (TX  "(-@< A#<1 ( W' !\."< >C@Q '<Y.@!U.4( <SE) '$Y4 !P.5<
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M U1#_P-40_\#5$/_ \A"  "X20  ITL  )A*  "-20  @T<  'U#  !V0P
M<40* &U$$@!J11T 9T4G &1%, !B13@ 8$4_ %]%1P!=14T 6T54 %I&6P%9
M1F,!5T9L 59&=@)41H$#4T:. U)'G 101ZL$4$>]!$]'U@5/1^\$3T?]!$]'
M_P-/1_\#4$?_ \1%  "U30  HTT  )5,  ")2P  ?TH  'A&  !Q1P  ;$<'
M &A($ !D2!H 84DD %])+0!=234 6TD] %E)1 !724H 5DE1 %5*60%42F$!
M4DII 5%*= )/2G\#3DJ, TU*FP1,2ZH$2TN\!$I+TP5*2^X$2TO]!$M*_P-+
M2O\#2TK_ \%(  "R4   H$\  )%/  "%3@  >TT  '-)  !L2@  9TL$ &),
M#@!?3!< 7$TA %I-*@!833( 5DTZ %1-00!33D@ 4DY/ %!.5P%/3E\!3DYG
M 4Q.<@)+3GT"24Z+ TA.F01'3Z@$1D^Z!$9/T01&3^T$1D[\!$9._P-'3O\#
M1T[_ [U,  "N4@  G%$  (U1  "!40  =U   &Y,  !G3@  8D\  %U0#0!:
M4!0 5U$> %51)P!343  45(X %!2/P!.4D8 35)- $Q350!*4UT!25-E 4A3
M;P)&4WL"15.) T-3EP-"4Z<$05.X!$%3SP1!4^P$05+[ T)2_P-"4O\#0E'_
M [I/  "J5   F%0  (E4  !]4P  <U,  &E1  !B4@  7%,  %A4"@!451(
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M 3-CD0(R8Z$",6.S C%CR (Q8N<",6'X C%A_P(R8/\",F#_ JY<  ";70
MBET  'Q=  !P70  9ET  %Q>  !28   3&(  $5E  !!9@H /F<1 #QH&@ [
M:"( .6DK #AI,@ W:CH -FI! #5J20 T:E( ,VI; #%J90 P:G !+FI^ 2UJ
MC@$L:I\!*VJP 2IJQ@$J:>4!*FCV BMG_P(K9_\"*V?_ JEA  "58   A&
M '=@  !L80  8F$  %AC  !.9@  1V@  $!K   Z;@4 -F\. #1P%0 S<!X
M,G$F #!Q+@ O<34 +G(] "UR10 L<DT *W)7 "IR80 I<FT )W)[ "9RBP D
M<IP!(W*N 2-RPP$C<>(!(W#T 2-O_P$C;O\!(V[_ :%E  ".9   ?V0  ')D
M  !H90  7F8  %1I  !);   0F\  #MR   T=0  +G@* "MY$0 J>1@ *7HA
M "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @>V@ 'WQV !U\A@ <>Y@
M&WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI  "(:0  >6D  &UI  !C
M:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$# "*##0 @A!( 'X0: !V$
M(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF, %89Q !2&@0 2AI, $8:F
M !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!;0  =&X  &EN  !=<
M4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-!@ 5CPT $Y 3 !*0&@ 2
MD"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J  N1>@ *D8T ")"?  >0
MLP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P  ;W,  &-U  !7>   37T
M $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .F@@ "YP.  F<$P (G!H
M!YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<<@  G(0  )R7  ";J@
MF[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H  %Q^  !1@@  1H<  #R,
M   RD0  *94  "&9   9G0  $J    ZC   )I@4  Z<,  "G$   IQ4  *@<
M  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:   J7H  *F.  "IH0  J+4
M *C+  "GY   I^\  *?S 'V   !O@0  880  %6)  !)C@  /I0  #29   J
MG@  (:(  !FF   2J0  #:P   >O    L@   +,'  "S#   LQ   +05  "T
M&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X  +B"  "XEP  N*H  +>^
M  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"G   -Z(  "RG   BJP
M&:\  !&S   +M@  !+D   "\    O@   +X   "_!@  P L  ,$/  #"$P
MPQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU  #)B@  R9\  ,JQ  #*
MP0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP  +[   "2U   9N   $+P
M  J_   !P0   ,0   #(    R@   ,H   #,    S0,  ,X(  #0#0  T1
M -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@?   X)$  ."D  #@L@
MX+X  .## &:?  !9I@  _^+P $E#0U]04D]&24Q%  0*3*T  #^T   RN
M)+P  !B_   0PP  ",<   #*    S0   -$   #5    V    -D   #;
MW0   -\   #A!   XPH  .4.  #G$P  ZAP  .TG  #P-0  \48  /)8  #S
M:P  \X   /24  #THP  ]*X  /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L
M /\ .0#_ $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D
M\0". /  DP#N )D [0"? .P I@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B
M /\ X0#_ .$ _P#A /\ X0#_ /\ $ #_  X _P - /\ $@#_ !L _P H /\
M- #^ $$ ^P!, /< 5@#T %\ \0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"*
M .4 CP#C )4 X0"; .  H@#> *H VP"T -D P #6 -  TP#H -( ]P#1 /\
MT0#_ -  _P#0 /\ T #_ /\ #0#_  D _P * /\ #P#_ !8 ^P B /< +P#T
M #L \ !' .T 40#I %H Y0!B .( :0#@ &\ W@!U -P >@#: (  V "% -4
MBP#3 )$ T0"7 ,\ G@#- *8 RP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_
M ,$ _P#" /\ P@#_ /\#!@#_  $ _P & /\ # #Y !$ \0 = .L *0#G #8
MXP!! -\ 2P#; %0 U0!< -( 8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#%
M (P PP"3 ,$ F@"_ *( O0"K +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0
M_P"T /\ M #_ /\$  #_    _P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [
M ,T 10#* $X Q@!7 ,0 7@#! &0 OP!J +T < "\ '4 N@![ +D @0"W (<
MM0". +, E0"R )X L "G *X L@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F
M /\ I@#_ /\&  #_!0  \0,  .@   #A  < U0 0 ,T &P#' "< PP S +\
M/@"\ $@ N0!1 +8 6 "T %\ L@!E +  :@"O '  K0!V *P ? "J (( J0")
M *< D0"E )H HP"D *$ K@"@ +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\
MF07_ /\*  #Q#@  Y!   -D/  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P
M!4( K09* *H&4@"H!UD I@=? *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)
MC@":"9< F JA )8*K "5"[H DPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_
M /81  #F%P  UAL  ,<9  "^%0  N1   +<*#0"Q"Q< K TD *@., "E#CL
MH@Y$ )\/3 "=#U, FP]: )H/8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/
M$90 C1&? (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:
M  #<(0  RB4  +LB  "Q'P  JQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^
M )061P"2%DX D!95 (X76P",%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9
M@1F; ( :IP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0
M*0  ORP  + J  "G)P  H",  )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>
M00"''TD A1]0 (,?5@""'UP @!]B '\?:0!]('  ?"!X 'H@@0!Y(8P =R&7
M '4BI !T(K( <R/# '(CWP!P)/, ;R3_ &\D_P!N)/\ ;B3_ -TI  #(,
MMS(  *@P  ">+@  ERH  ),G  "0(PH C",3 (@D'P"$)2H @B4T ( F/0!]
M)D0 ?"9+ 'HF4@!X)E@ =R9> '4F90!T)VP <B=T '$G?0!O*(@ ;BB4 &PH
MH0!K*:\!:BG  6DJVP%G*O$!9RO_ 68K_P%F*O\!9BK_ =0O  #"-@  KS8
M *$U  "6-   D#   (HM  "'*@8 @RD0 '\J&@!\*R4 >2LO '<L. !U+$
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M E,ZSP)3.NL"4SK[ 5,Z_P%3.?\!4SG_ <0\  "R00  H$   ))   "&/P
M?CT  '@Z  !S.   ;CD( &HY$0!G.1H 9#HD &(Z+ !@.C0 7CH\ %T[0P!;
M.TH 6CM0 %@[5P!7.U\ 5CQG %0\<0%3/'P!4CV) 5$]EP%//:8"3CZW DX^
MS0)./ND"33[Z DX^_P%./?\!3CW_ < _  "N0P  G$,  (Y#  ""0@  >D
M ',]  !M/   :#T% &0]#@!A/A< 7CXA %P^*0!:/C$ 6#XY %<^0 !5/T8
M5#]- %,_50!20%P 4$!E $] ;P%.07H!34&' 4M!E@%*0:4"24*U DE"RP))
M0N@"24+Y DE!_P))0?\!24'_ ;U#  "J10  F$4  (I%  !_10  =D,  &]
M  !H0   8T$! %]!#0!<010 64(= %=")@!50BX 4T(V %%"/0!/0D, 3T-+
M $Y#4@!-1%H 3$1C $I$;0%)17@!2$6% 4=%E %%1:,"14:T D1&R0)$1N<"
M1$7X D1%_P)%1?\"147_ ;I&  "F2   E$@  (9(  ![1P  <D8  &I"  !C
M0P  7D0  %I%"P!611( 5$8; %%&(P!/1BL 3D8S $Q'.@!+1T$ 2D=) $E(
M4 !(2%@ 1TAA $9):P!$278!0TF# 4))D@%!2:("0$FS C]*QP(_2N4"/TGW
M D!)_P) 2/\"0$C_ ;9)  "B2@  D4H  (-*  !W2@  ;DD  &5%  !>1P
M64@  %5)" !12A  3TH8 $Q*(0!*2RD 24LQ $=+. !&3#\ 14Q& $1,3@!#
M358 0DU? $%-: ! 370!/DV! 3U-D $\3: !.TZQ CI.Q@(Z3N0".TWV CM-
M_P$[3/\!/$S_ ;--  ">3   C4P  '],  !T3   :DP  &!*  !92P  5$P
M %!-!0!,3@X 24\5 $=/'@!%3R8 1% N $)0-0!!4#T 0%%$ #]12P ^45,
M/5)< #Q29@ Z4G( .5)_ 3A2C@$W4IX!-E*O 352Q $U4N(!-E+U 391_P$V
M4/\!-U#_ :Y/  "93P  B4\  'M/  !P3P  9D\  %Q.  !43P  3U$  $I2
M 0!&4PP 0U02 $%4&P! 52, /E4K #U6,@ \5CH .U9! #I620 Y5U$ .%=:
M #978P U5V\ -%=\ 3-7C $Q5YP!,%>M 3!7P@$P5^ !,%;T 3%6_P$Q5?\!
M,57_ :A2  "54@  A%(  '=2  !L4@  8E(  %A3  !/5   258  $17  !
M60@ /5H0 #M:%P Y6R  .%LG #=<+P V7#8 -5P^ #1<1@ S74X ,5U7 #!=
M80 O76P +EUZ "Q=B0 K79H!*EVK 2I=OP$I7=X!*ESR 2I;_@$K6_\!*UK_
M :-5  "/50  ?U4  ')5  !G5@  7E8  %17  !,60  15L  #]=   Z7P0
M-F - #1A$P R8AP ,6(C #!B*P O8S( +F,Z "UC0@ L8TH *F13 "ED70 H
M9&D )V1V "9DA@ E9)< )&2I "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8
M  ")6   >ED  &Y9  !C60  6EH  %!<  !(7@  06   #IC   T9@  +V@*
M "QI$  J:1< *6H? "AJ)@ G:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4
M'VQR !YL@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#
M7   =5P  &E=  !?70  5EX  $QA  !#9   /&<  #5J   O;0  *' $ "-R
M#0 A<A( (',: !]S(0 ><R@ '70P !QT.  ;=$  &G1* !ET5  7=6  %G5N
M !5U?@ 4=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8
M;V$  &5A  !;8@  460  $AG   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7
M?0X %GT3 !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_
M>  ,?XH "WZ=  I^L  )?<8 "GWD  I\]  +>_T "WK_ (9E  !W90  :F4
M &%F  !6:   3&L  $)O   Y<P  ,7<  "IZ   C?@  '($  !6$   0AP@
M#8D.  R)%  ,B1L "XDC  J)*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !
MB8,  (F6  "(J0  A[X  (?:  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML
M  !0<   1G0  #QX   S?0  *H$  ".%   <B   %8P  !"/   ,D@8 !I,,
M  *3$0  E!8  )0=  "4)   E2P  )4U  "50   E4P  )99  "6:0  E7H
M )6.  "4H0  E+4  )/,  "2Y@  DO(  )+W 'AP  !M<   8'(  %1U  !)
M>0  /WX  #6#   LB   (XT  !N1   4E   #Y<   J:   $G0,  )X)  "?
M#@  GQ(  * 7  "@'0  H24  *(M  "B-P  HT,  *-0  "C7P  HW$  *.$
M  "BF0  HJT  *'"  "AW   H>L  *#R '-V  !F=P  67L  $V   !"A0
M.(L  "Z0   DE0  &YH  !2>   .H0  ":0   *G    J@   *L$  "K"@
MK T  *T1  "M%@  KAP  *\D  "P+0  L3D  +%&  "R50  LF8  +)Y  "R
MC@  L:,  +*W  "QR@  L>   +'I &Q^  !?@@  4H<  $:-   [DP  ,)D
M ":>   <HP  $Z<   VK   'K@   +(   "U    MP   +@   "Y @  N0@
M +H,  "[$   O!0  +T;  "_(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@
MQ)<  ,2K  #$O   Q,L  ,3: &6)  !8C@  2Y4  #^;   SH@  **@  !VM
M   4L0  #;8   :Y    O    +\   ##    Q    ,4   #&    QP   ,D$
M  #*"0  RPT  ,T1  #/&   TB$  -4M  #6/   V$T  -E?  #:<P  VHH
M -N>  #;K@  V[H  -S# %Z6  !1G   1*,  #BJ   LL0  (+<  !6[   -
MO@  !,(   #%    R0   ,T   #0    T@   -(   #5    U@   -D   #;
M    W@4  . *  #B#P  Y18  .@@  #L+0  [3X  .U1  #N90  [WH  .^/
M  #PGP  \*L  /"S /\ $ #_  X _P . /\ $@#_ !T _P I /\ -0#_ $$
M_P!- /X 5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K
M )4 Z@"; .@ H@#F *H Y0"S ., P #A -( X #J -\ ^0#= /\ W0#_ -T
M_P#> /\ W@#_ /\ #0#_  H _P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !(
M /0 4@#P %H [0!B .L :0#I &\ YP!U .4 >@#C '\ X@"% .  B@#> )
MW "6 -H G0#8 *4 U0"O -( N@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+
M /\ RP#_ /\ " #_  , _P % /\ # #\ !0 ]P ? /( *P#O #< ZP!" .<
M3 #D %4 X != -T 9 #: &H V !P -4 =0#2 'H T "  ,\ A0#- (L RP"2
M ,D F0#' *$ Q0"J ,, M0#! ,, OP#: +X [@"] /P O #_ +P _P"\ /\
MO #_ /\   #_    _P   /D !P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2
M %  S@!7 ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H
ME "Y )P MP"E +4 L "S +T L0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_
M /\   #_    _0   .X  0#C  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H
MOP!2 +P 60"Z %\ N !E +8 :@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K
M )@ J0"A *< JP"E +@ HP#( *( X@"A /, H #^ *  _P"@ /\ H #_ /\
M  #V    Z@   .    #3  8 R0 / ,( & "] "0 N0 O +8 .@"T $, L0!,
M *X 4P"L %D J@!? *D 9 "G &H I@!O *0 =0"C 'L H0"" *  B@"> ),
MG "= )H IP"8 +0 E@## )4 W "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J
M"P  W T  ,L*  #"!0  O  * +8 $0"Q !P K@ H *H ,P"G #T I !% *(
M30"@ %, G@!9 )P 7P"; &0 F@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9
M (X"I ", K$ BP/  (D%U@"(!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%
MRA4  +P2  "S$   K@P  *L&#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5
M"4X DPE4 )$*6@"0"E\ C@IE (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,
MH@"!#;  @ W  '\-V !]#N\ ? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T
M *\<  "F&0  H14  )X0! "=#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@
MB!!/ (<050"%$%L A!%A ((19P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W
M$ZX =1.^ '04U0!S%>X <1;] '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C
M  "<(0  EAX  )(9  "1% L C104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=*
M 'P74 !Z%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL
M:QR[ &H<T !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3
M*   C24  (@B  "&'08 @QL0 '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?
M2P!Q'U$ ;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X
M &$CS0!@).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0
MA2H  ( H  !])   >B(- '8C%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H
M)4T 9B54 &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJ
MR@!9*N< 6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\
M 'DM  !U*@  <B@* &\H$@!K*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH
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M 4<X_P%'./\!1SC_ ;<[  "B/   D3P  (,\  !X/   <#H  &HW  !D-@
M8#8  %PV"P!9-Q( 5C<: %0W(P!2-RL 4#<R $\X.0!-.$  3#A' $LX3@!*
M.54 23E> $@Z: !'.G, 1CN  $4[C@!$/)X 0SRN 4(\P@%"/=\!0CSS 4(\
M_P%"//\!0CO_ ;,]  ">/@  C3X  '\^  !U/@  ;#T  &8Z  !@.0  6SH
M %<Z" !3.Q  43L8 $X[( !,.R@ 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/5,
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M *9$  "210  @D8  '5&  !J1@  844  %E$  !11   3$8  $A'  !$1PH
M04@0 #])&  ]22  /$DG #I*+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S
M3&H ,DQW #%,A@ P3)< +TVH "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'
M  ".2   ?D@  '%(  !F20  74@  %5(  !,20  1TH  $)+   _3 8 .TT.
M #E.%0 W3AT -D\D #5/*P S3S, ,E Z #%00@ P4$H +U%2 "Y17  M46<
M+%%U "M1A  J4I4 *5*F "E2N0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")
M2@  >DL  &U+  !C3   6DP  %%,  !(30  0T\  #U0   Y4@( -5,, #-4
M$@ Q5!D ,%4A "Y5*  M52\ +%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R
M "57@0 D5Y( (U>D ")7MP B5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@
M=4X  &E.  !?3P  5D\  $U0  !%4@  /U,  #E6   S6   +UH( "M;#P J
M6Q4 *%P= "=<)  F7"L )5PS "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>
M?@ =7H\ '%ZA !M>M  :7<P &UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$
M &12  !;4@  4E,  $I4  !!5P  .UD  #5;   N7@  *& # "1B#  B8Q$
M(6,8 !]D(  >9"< '60N !QD-@ ;93X &F5' !EE40 895T %V5J !9E>@ 5
M98L %&6> !-EL0 29<@ $F3G !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6
M  !75@  3U<  $99   ]7   -E\  #!B   I9   (V<  !UJ!P 9; X &&P3
M !9M&@ 5;2$ %&TI !1M,  3;3D $FY" !%N3  0;E@ #VYE  YN=0 -;H<
M#6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_ ()9  !R60  9ED  %Q:  !4
M6@  2EP  $%?   Y8P  ,68  "II   D;   '6\  !=R   2=0D #W</  YW
M%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (=U( !W=?  5W;P $=X   W>4
M  %VIP  =KL  775  %TZP "=/8  G3\ 'M=  !M70  8EX  %E>  !.8
M16,  #QG   S:P  *VX  "1R   >=0  %WD  !)\   -?P8 "8$,  6!$0 #
M@18  H$=  &!)   @2T  ((V  ""0   @DP  ()9  "":   @GD  (*-  "!
MH   @+0  (#+  !_YP  ?O(  '[Y '1B  !H8@  7F(  %-D  !)9P  /VL
M #9P   M=   )7@  !Y\   7@   $8,   V&   (B00  HL*  "+#@  BQ,
M (P8  ",'P  C28  (TO  "..0  CD0  (Y1  ".8   CG$  (Z%  ".F0
MC:T  (S#  ",WP  B^X  (OV &YH  !D9P  6&D  $UL  !"<0  .'8  "][
M   F?P  'H0  !:(   0C   #(\   :2    E0   )8'  "7#   EP\  )@3
M  "9&   FA\  )LF  ";,   G#L  )Q(  "<5P  G&@  )Q[  "<D   FZ4
M )NZ  ":T   FN<  )KQ &IM  !>;P  47(  $9W   [?   ,8(  ">'   >
MC   %I$  !"5   *F0  !)P   "@    H@   *,!  "C!@  I L  *4.  "F
M$@  IQ<  *@>  "J)@  JS$  *L^  "L30  K%T  *QP  "LA0  K)L  *NO
M  "KPP  J]D  *KH &1U  !7>0  2WX  #^$   TB@  *9   !^6   6FP
M$)\   FC   !IP   *H   "N    L    +    "Q    L@,  +0(  "U#0
MMA   +<5  "Y'0  NR8  +PS  "]00  O5(  +UD  "^>0  OI   +VD  "]
MMP  O<8  +W7 %Q_  !0A0  1(L  #B2   LF0  (9\  !>D   0J0  ":X
M  "R    M@   +D   "]    OP   +\   #     P0   ,,   #$!0  Q@H
M ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7  #2:P  TX(  -.7  #3J0
MTK@  -+$ %6,  !)DP  /9H  #"B   EJ   &JX  !&T   )N0   +T   #!
M    Q    ,@   #+    S0   ,T   #/    T    -(   #4    V    -H&
M  #=#   X!$  .,:  #F)P  YS@  .A*  #I70  ZG(  .N(  #KFP  [*@
M .RR /\ #0#_  L _P + /\ $ #_ !H _P F /\ ,@#_ #T _P!( /L 4@#X
M %H ]@!B /, :0#Q &\ \ !U .X >@#L '\ ZP"$ .D B@#H )  Y@"6 .0
MG0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8 /\ V #_ -< _P#7 /\ U #_
M /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H + #W #@ ] !# /  30#M %4
MZ@!= .< 9 #D &H X@!P .  =0#> 'H W0!_ -L A0#9 (L U0"1 -, F0#1
M *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_ ,8 _P#& /\ QP#_ /\
M  #_    _P   /\ "@#X !$ \0 < .P )P#I #( Y@ ] .( 1P#= %  V0!8
M -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D ?P#' (4 Q0", ,, E #! )P
MOP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_ +8 _P"V /\ M@#_ /\   #_
M    _0   /, !0#I  X X0 6 -L (0#5 "T T0 W ,X 00#* $H QP!2 ,0
M60#" %\ P !E +X :@"\ &\ NP!T +D >@"W (  M@"' +0 C@"R )< L "@
M *X J@"M +< JP#( *D XP"H /4 IP#_ *< _P"G /\ I@#_ /\   #^
M\0   .4   #7  H S0 1 ,< ' #" "8 OP Q +P .P"Z $0 MP!, +0 4P"R
M %D L0!? *\ 9 "M &D K !O *H = "I 'H IP"! *8 B0"D )$ H@"; *
MI0"> +( G0#! )L V@": .\ F0#] )@ _P"8 /\ F #_ /T   #P    X0
M -$   #&  0 O0 - +< %0"S "  L  K *T -0"K #X J !& *8 30"D %0
MHP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![ )@ @P"6 (P E0"6 ), H0"1
M *T CP"[ (T SP", .D BP#X (P _P", /\ C #_ /,"  #B!P  S <  +\$
M  "W    L0 ( *L $ "G !D I  D *  +@"> #< G !  )H 1P"8 $X E@!4
M )4 60"3 %X D@!D )  :0"/ &\ C0!V (L ?@"* (@ B "2 (8 G0"% *D
M@P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-  #0$   OA   +$.  "H
M#0  HP@  * "# "< !, F  = )4 )P"2 #$ D  Y (X!00", 4@ B@). (D"
M5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^!(0 ?06. 'L%F@!Y!J< > :U
M '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5  #$%P  L1<  *46  "<$P
MEA$  )0-! "3" T C@<5 (L)( "("2H A0HS (,+.P"!"T( @ M) 'X+3P!]
M#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8  <@V, ' -F0!O#J8 ;0ZU &P.
MR0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y'@  J!X  )L=  "2&P  BQD
M (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W$3T =A%$ '012@!S$5
M<1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.) &83E@!E%*, 8Q6S &(5Q@!B
M%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0  )(C  ")(@  @B   'X=
M  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N%S@ ;!<_ &L710!I&$L :!A1
M &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<&Z$ 6QRP %H<PP!9'>
M6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@  (LH  "")P  >R4  '8C  !S
M(   <1P) &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ &(>00!@'D< 7QY- %X>
M5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4(IX 4R*N %(CP !1(]T 423R
M %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M  !\+   ="H  &\H  !K)0
M:2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V %HC/0!9)$, 5R1* %8D4 !5
M)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL $LIO@!+*=H 2BGQ $HI
M_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W+P  ;RX  &HK  !E*@  8R<!
M %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H.0!2*4  4"E& $\I30!.*50
M32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ $4NO !%+M8 12[O $4N_@!%
M+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P  :S$  &4O  !@+0  72P  %DL
M"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P 2BU# $DM2@!(+E$ 1RY9
M $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _,M, /S+N $ R_0! ,O\
M0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4  &$R  !<,   5S   %0P!@!1
M, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%  $,R1P!",D\ 03-7 $ S
M8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z-M$ .C;M #LV_  [-O\ .S;_
M *8V  "2-P  @C@  '4X  !K.   8S<  %TV  !7,P  4S0  $\T P!+- P
M2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8] #XV1  ]-TP /#=5 #LX7@ Z
M.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL #8Z^P V.?\ -SG_ *(X
M  "..0  ?CH  '([  !H.P  7SH  %DY  !3-@  3C<  $HX  !&. H 1#D0
M $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X.TH -SM3 #8\7  U/&<
M-#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^^@ R/?\ ,CW_ )X[  "+
M/   >SP  &X]  !D/0  7#T  %4\  !..@  23L  $4\  !!/0< /CT. #P]
M%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S0$@ ,D!0 #% 6@ P064 +T%R
M "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M0?\ +4'_ )D]  "'/@
M=S\  &L_  !A0   63\  %(_  !)/@  1#\  $!    \000 .4(- #="$@ U
M0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144 +45. "Q%6  K1F, *D9O "E&
M?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H1?\ *$7_ )5   ""00  <T(
M &="  !>0@  54(  $Y"  !%0@  /T0  #M%   W1@  -$<* #%($  O2!8
M+DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+ "9+50 E2V  )$MM "-+?  B
M2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\ (DK_ )!#  !^1   ;T0  &1%
M  !:10  4D4  $I&  !!1P  /$@  #=)   R2P  +DT' "M.#@ I3A, )T\:
M "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!04@ ?45T 'E%J !U1>0 <48H
M&U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__ (I&  !Y1P  :T<  &!(  !6
M2   3D@  $=)   ^2P  .4P  #-.   N4   *%," "14"P B51  (%46 !]6
M'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 85UD %UAF !58=0 46(< %%B:
M !-7K  25\( $E?A !-6]  45?\ %%7_ (1)  !T2@  9DL  %Q+  !32P
M2TP  $1-   \3P  -5$  "]4   I5@  )%D  !Y;!P :70T &%T2 !==&0 6
M7B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4 $%]B  ]?<0 .7X, #5^6  U?
MJ0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N3@  8DX  %A/  !/3P  2%
M $!2   X5   ,%<  "I:   D70  'U\  !EB 0 390D $68/ !!F%  /9AL
M#F<B  UG*0 -9S( #&<[  MG10 *9U  "6==  =G;  &9WT !6>0  1FHP "
M9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@  75(  %12  !,4P  0U4  #M8
M   S6P  *UX  "5A   ?9   &6<  !-J   /;08 "W ,  AP$0 '<!8 !7 =
M  1P)  #<"P  G U  !P/P  <$H  '!7  !P90  <'8  '"*  !OG@  ;[(
M &[(  !MY0  ;?(  &WY '!6  !C5@  658  %%7  !'6   /EL  #9?   N
M8@  )F8  !]J   9;0  $W    YS   +=@0 !7@+  %X#P  >1,  'D9  !Y
M'P  >B8  'HO  !Z.0  >D0  'I0  !Z7P  >G   'J#  !ZF   >JP  'G"
M  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"8   .6,  #!H   H;
M('   !ET   3=P  #GL   E^   $@0(  (((  "##0  @Q   (04  "%&0
MAB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[  "'D   AJ4  (6Z  "%
MTP  A.H  (3T &5@  !<8   46$  $9D   \:0  ,FT  "ER   A=P  &7L
M !*    -@P  "(<   **    C0   (X$  "."0  CPT  ) 0  "1%   DAD
M ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5B   E9T  )2R  "4R
MD^(  )/N &%E  !69@  2FH  #]N   U=   *WD  "%_   9A   $8D   R-
M   &D0   )0   "8    F@   )L   "< @  G0<  )X+  "?#@  H1(  *(8
M  "C(   I2D  *8V  "F1   IE4  *9H  "F?0  II0  *6I  "DO0  I-$
M *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-   1D@  "Y<   2<
MH    *,   "F    J    *D   "J    K    *T$  "N"0  L T  +$1  "S
M%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@  +B=  "XL0  M\(  +?0
M %1V  !(?   /((  #&)   FD   &Y<  !*=   ,H@   Z<   "K    K@
M +(   "V    N    +@   "Z    NP   +T   "^    P 4  ,$+  ##$
MQA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1  #-I   S;0  ,W  $V#
M  !!B@  -9$  "F9   >H   $Z8   RL   #L0   +8   "Z    O@   ,(
M  #&    R    ,@   #*    RP   ,T   #.    T    -(!  #5"   V0X
M -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #GE@  YZ4  .:P /\ "0#_
M  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!# /D 30#U %4 \@!= /
M8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L XP"1 .$ F0#? *$ W "J
M -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/ /\ R@#_ /\  0#_
M_P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P 2 #H %  Y0!8 .( 7@#?
M &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ", ,X DP#, )P R0"E ,<
ML #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\ O@#_ /\   #_    _P
M /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5 $L T0!2 ,X 60#+ %\
MR0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T C@"[ )8 N0"@ +< J@"V
M +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_ /\   #_    ]P   .H
M @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4 OP!- +P 4P"Z %D N !?
M +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L )$ J@": *@ I0"F +$
MI #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\   #W    Z    -D   #+
M  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!' *P 30"K %0 J0!9 *<
M7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L FP"5 )D GP"8 *P E@"Z
M )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G    TP   ,8   "[  (
MLP , *T $@"J !P IP F *0 , "C #@ H !  )X 1P"< $X F@!3 )D 6 "7
M %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/ (L F@"* *< B "U (8
MQP"% .0 A #U (0 _P"# /\ @P#_ .P   #3    P0$  +0   "L    I@ '
M *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/ $@ C0!- (P 4P"+ %@
MB0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X E@!] *, >P"P 'H P@!Y
M -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P  *8+  "="   F00  )4
M"@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $( @@!( (  3@!_ %, ?0!8
M 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q )\ < "M &X O@!M =8
M;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1  "1$   BPX  (D+ P"'
M!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1# '4%2 !T!4X <P54 '$%
M60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T 90FL &0)O !C"M0 8POL
M &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'%@  @10  'T1  !\#@8
M? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,1 !K#4H :0U/ &@-50!G
M#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K %L0O0!:$-8 61'P %D1
M_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0  >!L  '08  !Q%0  <1$)
M &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B$44 8!)+ %\240!=$E@
M7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6N@!1%M( 41?M %$7_0!1
M%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$  &P>  !I&P  9Q@$ &85
M#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$ 6!A' %8830!5&%0 4QA<
M %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*'<\ 21WK $D=^P!)'?\
M2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C  !B(0  8!X  %X<"P!;
M&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U# $\=2@!-'E$ 3!Y8 $L?
M80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP 0R/I $,C^@!#(_\ 0R+_
M *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<)0  62,  %<A!P!5(0\
M4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B1@!'(TT 12-5 $0D7@!#
M)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH #TH^0 ])_\ /B?_ *(J
M  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*   5"8  %$F! !.)0T 3"43
M $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P! )TL /RA3 #XI7  ]*68
M/"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L^  X+/\ ."S_ )TL  "*
M+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H  $PJ  !)*@L 1BH1 $0J
M%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@ .BQ0 #DM60 X+F0 -RYP
M #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S,/\ -"__ )DO  "',0
M=S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N  !$+@@ 02X. #\N%  ]
M+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%. #0Q5P S,F( ,C)N #$S
M?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\ +S/_ )4Q  "#,P  =#0
M &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _,@4 /#(- #DS$@ X,QD
M-C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V50 N-F  +3=L "PW>P K
M-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_ )(T  !_-0  <38  &4W
M  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@( -S<+ #0W$  R-Q8 ,3@=
M "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I.UX *#MJ "<[>0 F/(D
M)3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV  !\.   ;3D  &(Y  !8
M.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL( "\\#@ M/10 +#T: "H]
M(0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L (D!H "% =@ @0(< 'T&9
M !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X.@  :3L  %X\  !5/
M33P  $<\  ! /   .#T  #0^   P0   +4$% "I"#  G0A$ )D,8 "1#'@ C
M0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E !M%=  :184 &4:7 !E&
MJ0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0  9CX  %L_  !2/P  2C\
M $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A2 \ ($D4 !Y)&P =22(
M'$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+<0 42X( $TN4 !)+IP 2
M2[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$  %="  !.0@  1T(  $%"
M   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT &% 1 !=0%P 64!X %5 E
M !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .4GX #5&1  U1I  ,4;@
M#%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%  !+10  1$4  #Y&   V
M2   +TH  "E,   D3P  'U$  !I3   45@D $5<. !!8$P 06!D #U@@  Y8
M*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D !EB,  58GP $6+, !%?*
M  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(2   04D  #I*   R30
M*U   "52   @50  &E@  !5:   0708 #& ,  I@$  )8!4 "& <  =@(P %
M8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&  !?F@  7ZX  %_$  !>
MX@  7O   %[X &Q*  !?2P  54L  $Q,  !%3   /4X  #50   N4P  )U8
M "!9   :7   %5\  !!B   -900 "&<+  -G#@  :!,  &@8  !H'P  :28
M &DN  !I.   :4,  &E/  !I70  :6T  &F   !IE   :*D  &B_  !GW
M9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0  #!7   H6P  (5X  !IB
M   490  $&@   QK   ';@,  7 )  !P#0  <1   '$4  !R&@  <R$  ',H
M  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@  <Z,  '*Y  !QT@  <>L
M '#T &%3  !64P  3U,  $55   [6   ,EP  "I@   B9   &V@  !1L   /
M;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1  !]%0  ?AL  '\B  "
M*@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T  '^R  !^R@  ?N4  'WQ
M %Q8  !46   25H  #]=   U80  +&4  "-J   ;;P  %',   YW   )>P
M W\   ""    A    (8!  "&!@  B H  (D-  "*$   BQ4  (P;  ".(@
MCRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK  "-P0  C=P  (SK %E=
M  !.7P  0V(  #AF   N;   )'$  !QW   4?   #H$   B%    B0   (T
M  "0    D@   ),   "4    E@,  )<(  "8#   F@\  )L3  "=&@  GR,
M * N  "@/   H$P  *!>  "@=   GXP  )^B  "?MP  GLL  )[@ %-D  !'
M:   /&T  #%S   G>0  '7\  !2%   -BP  !I    "4    F    )P   "?
M    H0   *(   "D    I0   *<   "H!   J@D  *P-  "M$@  L!D  +(C
M  "R,0  LD(  +)4  "R:0  LH   +*8  "QK   LK\  +'. $QN  ! <P
M-7H  "J!   ?B   %8X   Z5   &F@   )\   "D    J    *P   "O
ML0   +$   "S    M0   +8   "X    N@   +P&  "^#   P!$  ,,9  #%
M)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\  ,B\ $9Z   Y@0  +HD
M "*0   7F   #Y\   >E    J@   *\   "S    MP   +P   "_    P0
M ,(   #$    Q0   ,<   #)    RP   ,T   #/ P  T@H  -80  #<&@
MW2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M /\  @#_    _P # /\
M# #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %  \ !7 .T 7@#K &0 Z !I
M .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9 )P U@"F -, L0#1 ,
MSP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\   #_    _P   /\ " #[
M !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2 -T 60#9 %\ U@!D -,
M:0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8 Q "@ ,( JP#  +D O@#-
M +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_    _@   /0 ! #K  T
MY  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,< 4P#% %D PP!? ,$ 9 "_
M &D O0!N +L <P"Z 'D N "  +8 B "T )  L@": +$ I0"O +( K0#$ *P
MX0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]    [@   .(   #5  H S0 1
M ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R %, L !9 *\ 7@"M &,
MK !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$ GP"? *P G@"[ )P T@";
M .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@   ,L   #!  4 N0 - +0
M% "Q !X K@ G *L , "J #D IP!! *0 2 "B $T H0!3 )\ 6 "> %T G0!B
M )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0 *8 C@"T (T R ", .8
MBP#Y (H _P"* /\ BP#_ /    #;    QP   +H   "P    J  * *0 $ "@
M !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!- )$ 4@"/ %< C@!< (P
M80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *  @ "O '\ P !^ -T ?0#R
M 'T _P!] /\ ?0#_ .    #&    M0   *H   "B    FP % )4 #0"2 !,
MD  < (T ) "+ "T B@ T (@ .P"& $( A0!' (, 30"" %( @0!7 '\ 7 !^
M &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J '( N@!Q -$ < #L '
M^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!   C@   (H " "&  \ A  6
M ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V $P =0!2 ', 5P!R %T
M<0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &< M@!F ,L 90#G &4 ]P!E
M /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L  'X' 0!\ 0L >0 1 '<
M& !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $< :@!- &D 4@!H %@ 9@!?
M &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!< \< 6P3D %L%] !;!OX
M6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.  !R# 0 <0<- &X$$@!L
M!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=) %\'3@!>"%4 70A< %L)
M8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,< 4@SD %$-]0!1#?\ 40W_
M *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G$0  9PX' &8,#@!C#!4
M80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-2P!6#E$ 50Y9 %,.80!2
M#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E $D1]P!)$O\ 21'_ *49
M  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P  7A0! %X1"@!;$!$ 61$8
M %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.$DX 3!)5 $L37@!)$V<
M2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7]@!"%_\ 0A?_ )\=  ",
M(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD  %46!@!4%0X 4144 $\6
M' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH 11A2 $,86@!"&60 01EP
M #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 ['/\ /!S_ )HA  "'(P
M>"0  &PE  !C)0  7"0  %<C  !3(   41X  $\< @!-&PP 2QH1 $@;& !'
M&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/ #T>6  \'F( .A]M #D?
M>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\ -B'_ )8C  "#)@  ="<
M &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'( D 1!\/ $(?%0! (!P
M/R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B50 V(U\ -"-K #,D>0 R
M)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_ )$F  !_*   <2H  &4J
M  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4 /R0- #TD$@ [)!D .20?
M #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P)UT +RAI "XI=P M*8<
M+"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH  !\*@  ;2P  &(M  !9
M+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+ #<H$  U*!8 ,R@< #(H
M(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L *BQG "DM=0 H+84 )RV7
M "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X+0  :BX  %\O  !6+P
M3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L#@ P+1, +BT: "TM(  K
M+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E "0Q<P C,8, (C*5 "$R
MIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P  9S   %PQ  !3,0  2S$
M $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K,1$ *3(7 "@R'@ G,B0
M)3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U<0 >-H$ '3:3 !PVI0 ;
M-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,  %DT  !0-   230  $(S
M   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q  )#<5 "(W&P A."( (#@H
M !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8.G\ %SN1 !<[I  6.[<
M%3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V  !--@  1C8  $ V   Z
M-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2 !T]&  </1\ &SXE !H^
M+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P $D"/ !% H@ 10+8 $$#.
M !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*.0  0SD  #TY   W.0
M,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#%0 51!L %$0B !-$*0 3
M1#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,  U%GP ,1;( "T7)  Q%
MY0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/   0#P  #H\   T/   +CX
M "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 02A@ #TL>  Y+)0 -2RT
M#4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+F@ $2ZX !$K$  5*X  %
M2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X  #<_   Q0   *D(  "1%
M   ?1P  &DD  !5,   13@4 #E$+  M1$  *410 "5$;  A1(@ '42D !5$R
M  12.P #4D8  5)2  !27P  4F\  %*!  !1E@  4:D  %&_  !0W   4.X
M %#W &A   !;00  4$$  $A!  !!00  .T(  #1#   M10  )D@  "!+   ;
M30  %E   !%3   .500 "E@*  98#@ "6!(  %D7  !9'0  624  %DM  !9
M-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4  %BZ  !8U0  5^P  %?V
M &-$  !610  344  $5%   _10  -T<  "])   H3   (D\  !M2   650
M$5@   U:   )70, !%\)  !@#0  8!   &$4  !A&0  8B   &(G  !B,0
M8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V  !ASP  8.H  &#U %U(
M  !220  2D@  $-(   Z2@  ,DT  "I0   C4P  '%<  !9:   170  #6
M  AC   #9@$  &<&  !H"P  :0X  &H1  !K%0  ;!L  &TB  !M*@  ;30
M &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !KR   :^8  &KS %A-  !.
M30  2$P  #Y.   U40  +%0  "18   =7   %F   !!D   ,9P  !VL   %N
M    <    '(#  !R!P  <PL  '4.  !V$0  =Q8  '@<  !Y(P  >BT  'HY
M  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0  =]\  '?O %11  !,40
M0E(  #A5   O60  )EX  !YB   69P  $&L   MO   %<P   '<   !Z
M?    'X   !_ @  @ 8  ($*  "##0  A!$  (85  "('   B24  (HP  "*
M/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$  (;H %)6  !'5P  /%H
M #)?   H9   'VD  !9O   0=   "GD   )]    @0   (4   "(    B@
M (P   "-    CP   ) $  "2"   DPP  )40  "7%0  F1T  )LG  ";-
MFT0  )I6  "::@  F8(  )J:  "8L   F,<  )?> $M<  ! 8   -64  "MJ
M   A<0  %W<  !!]   )@P   8@   ",    D0   )4   "8    F@   )L
M  "=    GP   *    "B    I 4  *8*  "H#@  JA0  *T=  "M*@  K3D
M *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F   Y:P  +G$  "-X   9
M?P  $(8   F-    DP   )@   "=    H0   *4   "H    JP   *L   "N
M    KP   +$   "S    M0   +<!  "Y!P  O T  +\3  #"'P  PBX  ,)
M  #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R>   )X   !R(   2D
M"I<   "=    HP   *@   "M    L@   +8   "Y    NP   +P   "^
MP    ,(   #$    Q@   ,@   #+    S@4  -$-  #6%   UR,  -@U  #9
M20  VEX  -MU  #;C   W)\  -RK /\   #_    _P   /\ "0#_ !  _P 9
M /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G %\ Y !D .( :0#@ &X
MW@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P K #* +L R #2 ,8 [@#&
M /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P   /X !0#W  X \@ 5 .X
M'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D S@!> ,P 8P#* &@ R0!M
M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y +0 MP#( +8 Y@"U /L
MM #_ +0 _P"S /\ K@#_ /\   #_    ^    .T   #E  L W0 1 -< &@#2
M "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9 +H 7@"X &, M@!H +4
M;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T I@"^ *4 VP"D /0 I #_
M *, _P"C /\ H@#_ /\   #V    Y@   -<   #+  8 Q  . +X %0"[ !\
MN0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *< 6 "F %P I !A *, 9P"A
M &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V )4 S "4 .L DP#] ),
M_P"3 /\ DP#_ /<   #D    T    ,$   "W  ( KP + *L $0"G !D I0 B
M *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6 %< E0!; ), 80"2 &8
MD !M (\ = "- 'T C "' (H DP"( *  AP"O (4 P@"% .( A #W (0 _P"$
M /\ A #_ .4   #-    O    *\   "F    G@ ' )H #@"6 !0 E  = )(
M)0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$ A@!6 (0 6P"# &  @0!G
M (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V -, =@#O '8 _@!U /\
M=0#_ -    "[    JP   )\   "7    D  " (L "P"( !  A@ 7 (0 ( ""
M "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0 '< 50!V %L = !A ',
M:0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D :0#H &D ^0!I /\ :0#_
M ,    "L    G (  ) "  "(    @P   '\ !@![  T >0 2 '< &@!V "(
M=  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L 4 !J %8 : !< &< 9 !E
M &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A %X ] != /\ 70#_ +0'
M  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D ;P / &T %0!K !P :0 C
M &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !? %( 7@!8 %T 7P!; &@
M6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %, [P!4 /L 5 #_ *D-  "6
M#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+ &0 $ !B !< 8  > %X
M)0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X 50)4 %,"7 !2 V4 40-O
M $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*!_D 2@?_ *$0  ".$@
M?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)#0!:!A( 6 <9 %8'( !5
M!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1 $L*60!*"F( 2 MM $<+
M>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L 0@W_ )H4  "'%@  >!@
M &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3#0X 40T4 $\-&P!-#2(
M3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.5P!"#V$ 01!L #\0>0 ^
M$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_ ),8  "!&@  <QP  &<=
M  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L 2A 0 $@1%P!&$1X 11$D
M $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [$UX .11I #@4=@ W%84
M-A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;  !\'0  ;A\  &,@  !:
M(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4. $$5$P _%1H /A4@ #T5
M)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L ,QEF #(9<P P&H, +QJ4
M "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X(   :B(  %\C  !6(P
M3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9$0 Y&18 -QH= #8:(P U
M&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD "P><0 K'X$ *A^2 "D?
MI  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P  9R0  %PE  !3)0  3"4
M $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S'A, ,1X: # >(  O'B8
M+A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B;P E(W\ )".0 ",CH@ B
M)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8  %DG  !0*   22<  $,G
M   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$ +"(7 "HB'0 I(B, *",J
M "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @)WT 'R>/ !XHH0 >*+0
M'2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I  !-*@  1BH  $$I   \
M*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4 "4G&@ D)R$ (R@G "(H
M+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL &BR- !DLGP 8++( &"S)
M !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*+   0RP  #XK   Y*P
M-"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L&  ?+!X 'BTE !TM+  <
M+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+ !0PG@ 4,+$ $S#' !,P
MY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@  02X  #LN   V+0  ,2T
M "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :,AP &3(B !@R*0 7,S$
M%C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! UG  0-;  #C7&  \TY  0
M-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C   #@P   S,   +S   "DQ
M   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D $S@? !(X)@ 2."X $3DV
M ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +.:P "CG!  HYW@ +.?$
M##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S   Q,@  +#,  "<T   A
M-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<  X^(P -/BH ##XS  P^
M/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@  SZ\  0^UP %/NP !3[W
M &DS  !;-   4#4  $<U   _-0  .34  #0U   N-0  *3<  ",X   >.P
M&CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$(  '1"< !D0O  5$.  #
M14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y  !$T0  1.H  $/U &0V
M  !7-P  3#@  $,X   \.   -S@  #$X   K.0  )3L  " ]   :0   %D(
M !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'   2R,  $LK  !+-   2SX
M $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*S@  2ND  $KU %\Z  !2
M.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$  !Q#   61@  $DD   Y+
M   +3@, !U (  )1#   41   %(3  !3&   4Q\  %,F  !3+P  4SD  %-%
M  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@  4><  %'T %D^  !./@
M13X  #X^   X/@  ,$   "E"   C1   '4<  !=*   230  #E    M3   &
M50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA  !<*@  7#0  %P_  !<
M30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0  %GS %1"  !*0@  0D(
M #Q"   T0P  +$8  "5)   >3   %T\  !)3   .5@  "ED   5;    7@
M & $  !A"   8@P  &,.  !D$0  918  &8<  !G(P  9RT  &<Y  !G1@
M9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P $]&  !'1@  0$4  #='
M   O2@  )DT  !]1   850  $ED   U<   (8    F,   !F    :    &H
M  !K!   ; @  &T,  !O#@  <!(  '(7  !S'0  ="8  '0R  !T/P  =$X
M '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*  !%2@  .TL  #).   I
M4@  (%8  !A;   27P  #60   =H    :P   &\   !R    =0   '8   !W
M    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X  (0I  "$-@  A$4  (16
M  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _4   -5,  "M7   B7
M&6(  !)G   ,;   !7$   !U    >0   'T   "!    @P   (4   "&
MB    (D   "+!   C0@  (\-  "2$   E!8  )8@  "6+   ECL  )9,  "5
M8   E78  )20  "3IP  DKT  )+5 $15   Y60  +UT  "1C   ::0  $F\
M  QU   $>P   (    "%    B0   (T   "1    DP   )0   "6    F
M )H   "<    G@   * &  "B"P  I1   *@7  "I(P  J3$  *E#  "I5@
MJ&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH  !UP   3>   #'\   .%
M    BP   )$   "6    FP   )\   "B    I    *4   "G    J0   *L
M  "M    L    +(   "U @  MPD  +L0  "^&   OB8  +XX  "^2P  O6$
M +QZ  "[E   NJD  +JY #=J   K<   ('@  !:    -B   !8\   "6
MG    *(   "G    K    +    "S    M@   +<   "Y    NP   +T   "_
M    P@   ,4   #(    R@   ,X(  #2$   U1L  -4L  #40   U%<  --N
M  #4A@  U)L  -.K /\   #_    _P   /\ !0#_  X _P 5 /P ( #Y "H
M]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X 8P#< &@ V0!N -4 <P#3
M 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#, ,  [ "_ /\ O@#_ +T
M_P"W /\ L@#_ /\   #_    _P   /H  0#S  L [0 2 .@ &P#E "4 Y  N
M -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$ &, P@!G ,  ;0"_ ',
MO0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X XP"N /H K #_ *T _P"I
M /\ I@#_ /\   #_    \@   .8   #=  < T@ . ,T %@#* "  R  I ,4
M,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T L !B *X 9P"L &P J@!S
M *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"= /( G #_ )T _P"< /\
MF0#_ /P   #N    W0   ,P   #!  ( N@ , +8 $@"R !H L  C *\ + "M
M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!; )P 8 ": &8 F0!L )<
M= "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@ BP#] (P _P", /\ C #_
M .T   #8    Q0   +<   "L    I@ ( *$ #@"? !4 G0 > )L )@": "X
MEP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L 6@"* &  B0!F (< ;0"%
M '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U 'P _P!\ /\ ? #_ -D
M  #!    L0   *0   "<    E  # )  # "- !$ BP 8 (D ( ") "@ AP O
M (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![ %H >0!@ '@ 9P!V '
M=0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X _@!N /\ ;@#_ ,0   "O
M    H    )0   ",    A@   ($ " !^  X ?  4 'L &P!Y "( >  I '<
M, !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0 ; !; &L 8@!I &H : !T
M &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A /\ 80#_ +0   "@
MD0   (8   !^    >0   '4  P!Q  L ;P 0 &T %@!L !T :P D &L *@!I
M #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6 %\ 70!= &4 7 !O %H
M>@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\ 5@#_ *@!  "4!0  A0<
M 'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A !@ 8  ? %\ )0!> "L
M70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4 6 !3 &$ 4@!J %  =@!/
M (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_ )T)  "+"P  ? T  ' -
M  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !, 5P 9 %8 ( !5 "8 4P K
M %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!* %T 20!G $< <P!& (
M10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-  "##P  =!   &D1  !@
M$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5 $X!&P!, 2$ 2P$G $H"
M+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H 0 5D #\%<  ^!GX /0:.
M #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\$@  ;A0  &(5  !:%0
M5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(%@!%"!T 1 @C $((* !!
M"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC #@,;P V#'X -0R. #0-
MGP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0  :1<  %X8  !5&   3Q@
M $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _#1@ /0T? #P-)  [#2H
M.0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0;@ O$'T +A". "T1H  L
M$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H  %D;  !1&P  2QL  $8:
M  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4 -Q ; #41(0 T$2< ,Q$M
M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I%'L *!2, "<5G@ F%;
M)17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>  !-'@  1QX  $(=   ^
M'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07 "\4'0 M%", +!4J "L5
M,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D (AF* "$9G  @&:\ 'QG$
M !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*(   1"   #X?   Z'@
M-QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8&@ G&"  )ADF "49+0 D
M&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V( !P>FP ;'JT &A[# !H>
MX  :'?, &QW_ '<=  !G(   6B$  % B  !((@  02(  #LB   W(0  ,R
M # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A'1T (1TD " >*@ ?'C(
M'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<BF0 6(JP %2+! !4BWP 5
M(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0  #DD   T(P  ,"(  "PB
M   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL &R(A !LB*  :(R\ &2,X
M !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1)JL $2;  ! FW0 1)?$
M$B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F   Q)0  +24  "DD   F
M)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<? !8G)0 5*"T %"@U !,I
M/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD #2J]  TJUP -*NX #BG[
M &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O*   *R<  "<G   B*
M'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M(P 0+2H $"TR  \N/  .
M+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY  @NT  )+ND "B[W &@G
M  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@  *2H  "0J   @*P  &RT
M !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -,B< ##(O  LS.  *,T(
M"3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (SS0 #,^< !#+S &0J  !6
M+   2RT  $(M   Z+0  -"T  "\L   K+   )BP  "(M   =+P  &3$  !4R
M   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0 !C@L  0X-  #.#X  CE*
M   Y5P  .64  #EW   YBP  .)\  #BS   XR@  ..8  #?R %\M  !2+@
M2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q   :,P  %34  !(W   /
M.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH   ^,0  /SL  #]&   _
M4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0  #WR %HP  !.,@  1#(
M #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6.   $CL   \]   ,/P,
M"$$(  1##   0PX  $02  !%%@  11T  $4D  !%+0  1C8  $9"  !&3@
M1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R %4T  !*-0  034  #DU
M   S-   +C0  "@U   B-P  '3H  !<\   2/P  #T$   Q$   (1@$  T@&
M  !)"@  2@T  $L0  !,%   31D  $X@  !.*   3C(  $T]  !.2@  3E@
M $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X  !&.   /3@  #<X   Q
M-P  *CD  "0[   >/0  &$   !-#   /1@  "TD   =+   "3@   % $  !1
M"   4@L  %,.  !4$0  514  %8;  !7(P  5RP  %<X  !71   5U(  %9C
M  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"/   .SL  #4[   M/
M)C\  !]"   910  $T@   Y+   +3P  !5$   !4    5P   %@!  !:!0
M6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q  !B/@  84P  &%=  !A
M<   8(@  &"@  !?MP  7M0  %WN $=    _/P  .C\  #%    I0P  (48
M !I*   33@  #E$   I5   $6    %L   !>    80   &,   !D 0  900
M &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O-@  ;D4  &Y5  !N:
M;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40  "M'   C2P  &T\  !-4
M   .6   "%P   )@    9    &<   !K    ;0   &\   !P    <@   '0"
M  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@  ?ST  'Y-  !]80  ?7<
M 'R0  ![J   >L   'G? $-'   Y20  +TP  "50   <50  %%L   Y@   '
M90   &H   !N    <@   '8   !Y    ?    'X   !_    @0   (,   "%
M    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,  ))$  "15P  D&T  (^&
M  ".GP  C;4  (S- #U.   R40  *%8  !Y<   58@  #F@   =N    =
M 'D   !^    @@   (8   ")    C    (X   "0    D@   )0   "6
MF    )L   ">!@  H0P  *01  "F&P  IBD  *8Z  "E30  I6(  *1[  "C
ME   H:L  *&_ #97   L7   (6(  !=I   /<   !W<   !^    A    (H
M  "/    E    )@   ";    G@   )\   "B    I    *8   "H    JP
M *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[0P  NE@  +EP  "WBP
MMZ$  +>S #!B   E:0  &G   !!X   )@    (@   "/    E@   )L   "A
M    I@   *H   "N    L    +$   "T    M@   +@   "[    O0   ,
M  ##    QP   ,L#  #/#   TQ4  -(E  #2.   T4X  -!E  #/?@  S98
M ,RI /\   #_    _P   /\  P#_  L _  1 /D &P#W "4 \P O .X . #I
M $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H -  ;0#. ', RP!Z ,@
M@@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\ N #_ +$ _P"J /\ IP#_
M /\   #_    ^P   /8   #M  < YP / .( %@#? "  W@ I -D ,P#1 #L
MS !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H 9P"Y &T MP!T +4 >P"R
M (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_ *, _P"= /\ FP#_ /T
M  #V    ZP   -\   #1  , R@ , ,4 $@## !L P  D +X + "Y #4 M@ \
M +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F &< I !M *( = "@ 'T
MG@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4 _P"0 /\ C@#_ /,   #F
M    T0   ,(   "X    L0 ( *T #P"J !8 J  > *@ )P"F "\ H@ V )\
M/ "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &  D0!F )  ;@". '8 C "!
M (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"# /\ @0#_ .0   #+
MN@   *P   "B    G  $ )@ # "6 !$ E  9 ), (0"2 "@ CP P (T -@"+
M #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@ '\ 9P!^ &\ ? !Z 'H
MA@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\ = #_ ,L   "V    I@
M )H   "2    B@   (8 " "#  X @0 4 ($ &P"  ", ?P J 'T , ![ #8
M>@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '  80!N &D ;0!S &L ?P!I
M (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_ +@   "D    E0   (H
M  "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T <  D &X *@!M #  :P U
M &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A &, 8 !M %X >0!= (<
M6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@   "5    AP   'L   !S
M    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ? &( )0!A "H 7P P %X
M-0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X 5 !H %, <P!1 ($ 4 "1
M $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")    >P,  ' #  !H P
M8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %< ( !6 "4 50 J %, , !2
M #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C $D ;P!' 'P 1@", $4
MG0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P  <0H  &8*  !>"@  60D
M %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!, "  2P F $H *P!) #
M2  U $< .@!& $  10!& $, 3@!" %8 00!? $  :P ^ '@ /0"( #P F0 \
M *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X  %\.  !7#@  40X  $T,
M  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P 0P A $( )@!! "L /P Q
M #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V '4 -0"% #0 E@ T *@
M,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1  !1$0  2Q$  $<0  !$
M#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(= #H#(@ Y R@ . ,M #<#
M,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W, +@># "T'E0 L!Z< *P>Z
M "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,%   1A0  $(3   ^$@
M/!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)'P R"20 ,0DI # )+P O
M"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR# "8-E0 E#:< ) V[ ",-
MT@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P  0A8  #T6   Y%0  -Q,
M #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L#2$ *PTG "H-+0 I#C0
M* X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0E@ >$*D '1"] !P0V  =
M$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD  #H8   U%P  ,A8  # 5
M   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X )1 D "00*@ C$3$ (A$Y
M "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8%*< %Q2[ !<3U  7$^X
M&!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;   R&@  +QD  "P8   J
M%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =%"X '!4V !L5
M/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8 $ABZ !(7T@ 2%^P $Q?Z
M &P9  !=&P  41T  $<=   _'@  .1T  #0=   O'   *QL  "@:   F&0
M)!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/0 5
M&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY  X<T  .&^H #QOX &D;
M  !:'0  3A\  $4?   ](   -A\  #$?   M'@  *1T  "4=   C'   (!L
M !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3'2D $AXQ !$>.@ 1'T4
M$!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@R@ +(.4 #!_T &4=  !7
M'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\  ",?   @'@  '1X  !D@
M   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8 #B,O  XC-P -(T$ #"1-
M  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &(^, !R/Q &(?  !4(0
M22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A   >(0  &B$  !8C   3
M) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K  DH-  (*#X !RA)  8H
M50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$  2?P %XB  !1)   1B4
M #TE   U)0  +R4  "HD   F)   (B,  !\C   ;)   &"4  !0F   1* ,
M#RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M,  "+3H  2U%   M4@
M+F   "YQ   MA   +9D  "VM   LP@  +.   "SP %HD  !-)@  0R<  #HG
M   S)P  +2<  "@F   D)@  (28  !TF   9)P  %2D  !$K   /+ , #2X'
M  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0  ,C8  #-"   S3@  ,UT
M #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G  !**0  /RH  #<J   P
M*@  *RD  "<H   C*   'BD  !HJ   6+   $BX   \P   -,0( "C0'  4U
M"P "-@X  #<0   X%   .!H  #@B   X*@  .3,  #D^   Y2@  .5D  #EI
M   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&+   /"P  #0L   N+
M*BL  "4K   @+   &RT  !<O   3,0  $#,   TU   )-P( !3H&  $["@
M/ T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z  ! 1@  0%0  $!E   _
M>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P  .2\  #(O   M+@  *"X
M "(O   =,   &#(  !,U   0-P  ##H   D\   %/@   $$$  !""   0PL
M $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(00  2$\  $A@  !'<P
M1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(  # Q   K,0  )3(  !\T
M   9-@  $SD  ! \   ,/P  "$(   -$    1@   $@"  !*!0  2P@  $P+
M  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/   44H  %%:  !1;0  4(0
M $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T   G-0  (3@  !H[   4
M/@  $$$   Q$   '1P   DH   !-    3P   %$   !3 @  5 4  %4(  !7
M"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0  %Q4  !;9P  6WX  %J7
M  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C/   '#\  !5#   01P
M"TH   5.    40   %0   !7    6@   %P   !=    7P   & $  !B!P
M9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-  !I7P  :'4  &>/  !F
MJ   9<(  &3C #T]   W/   +CT  "5    =1   %DD  !!-   *40  !%4
M  !:    70   &    !C    9@   &@   !J    :P   &T   !O @  <08
M '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X60  >&T  '>&  !VGP
M=;<  '32 #Q!   R0@  *$4  "!*   73@  $%0   I9   "7@   &,   !G
M    :P   &\   !R    =0   '<   !Y    >P   'T   !_    @@   (0#
M  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@  BV,  (I\  "*E0  B*T
M (?% #9'   L2P  (D\  !E5   06P  "F$   %G    ;0   '(   !W
M>P   '\   "#    A@   (@   "*    C0   (\   "1    E    )<   ":
M 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED  *!P  "?BP  G:(  )VW
M #!0   E50  &UL  !)B   +:0   7    !W    ?0   (,   "(    C0
M )$   "5    F    )H   "<    GP   *$   "C    I@   *D   "L
ML    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E  "V?@  M98  +.K "E;
M   >8@  %&D   QQ   ">0   ($   ")    CP   )8   ";    H    *0
M  "H    JP   *P   "O    L@   +0   "V    N0   +P   #     Q
M ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-<P  RXT  ,JA /\   #_
M    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J .L ,P#F #L X@!# -X
M20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X Q@!U ,, ?0#! (8 O@"2
M +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P"> /\ FP#_ /T   #W
M\@   /    #G  , X0 , -P $@#8 !L U@ D -( +0#, #8 Q@ ] ,( 0P"_
M $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N *\ =@"L '\ J@"* *@
MEP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\ CP#_ /,   #L    XP
M -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S "\ KP W *P /0"J $,
MJ !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P ;P": '@ EP"# )4 D "3
M )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_ .<   #=    Q@   +@
M  "N    J  $ *4 # "A !( H0 9 *  (@"? "D FP P )@ -P"6 #T DP!"
M )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "' '  A0![ (, B "! )8
M?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8   #     KP   *,   "9
M    DP   (\ "0"-  X BP 4 (H ' "* ", B  J (4 , "# #8 @@ [ (
M0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D =0!S ', @ !Q (X ;P"?
M &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K    FP   (\   "'
M@    'P ! !Z  P >  1 '@ %P!X !X =P D '4 *@!S #  <0 U '  .@!N
M #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M &0 > !B (< 8 "7 %\
MJ@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9    B@   '\   !W    <0
M &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E "H 8P O &( - !A #D
M8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %< <@!5 ($ 5 "1 %, HP!2
M +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?    '$   !I    9    &
M  !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4 5P J %8 +P!5 #0 5  X
M %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!* 'H 20"+ $@ G0!' +$
M1P#, $8 \ !' /\ 1P#_ )    !^    <    &8   !>    60   %8   !3
M  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E $P *@!* "X 20 S $@
M. !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4 /P"% #X EP ] *L /0##
M #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5!@  4 8  $P$  !* 0
M20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $( )0!! "H 0  O #\ -  ^
M #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"! #4 DP T *8 - "[ #0
MW0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#   2 L  $0*  !""   0 4!
M #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y "4 -P J #8 ,  U #4
M-  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T CP L *( + "V "P T  L
M .X + #\ '<*  !G#   6@X  % .  !)#@  0PX  #X-   [#   .0L  #@)
M P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "( ,  G "\ +  N #( +0 X
M "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E )\ )0"R "4 R@ E .@
M)0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0   V#P  ,PX  #$- 0 P
M"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C "@$*0 G!"\ )@4U "4%
M/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT '@>P !T&Q@ =!N, '07S
M &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q$0  +A   "P/   J#@,
M*@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "())@ A"2P ( HS !\*.P >
M"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP !8,Q0 6#.$ %@OP &D0
M  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P  *A(  "@1   F$ $ )! $
M ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <#2H &PTR !H..@ 8#D0
M%PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /R0 0#^0 $0_R &42  !7
M%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0  "03   B$P  (!(# !X1
M!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@ %1$P !01.0 3$4, $A).
M !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,$N$ #1+Q &(4  !4%@
M21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6   ?%0  '!0" !H3!  9
M$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M ! 4-@ /%4$ #A5,  X6
M5P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT "17N %\6  !1&   1AH
M #T:   U&P  +QH  "H:   E&0  (A@  !\8   <%P  &18! !<6 P 5%@0
M$Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9,P ,&3P "QI'  H:4P )
M&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL %P8  !.&@  0QP  #H<
M   S'   +!P  "<<   C&P  (!H  !T9   :&0  %Q@! !48 @ 2&00 $!L'
M  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P ''CD !AY#  0>4  #'UX
M A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:  !+'   01X  #@>   P
M'@  *AX  "4=   A'   'AP  !L;   8&P  %AL! !,; @ 1' 0 #AX'  P?
M"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4  ")    C30  (UH  "-K
M   C?@  (Y,  "*G   BO   (=<  "'M %4=  !('P  /B   #4@   N(
M*"   ",?   @'@  '1T  !H=   6'0  $QX  !$? @ .( 0 #2('  HD"P &
M)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]   G20  *%<  "AG   G
M>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0  .R(  #(B   L(@  )B$
M "(A   >(   &Q\  !@@   4(   $2(   \C   -)0, "B8&  8H"@ #*0T
M "L/   L$@  +!<  "P>   L)@  +2\  "TY   M1@  +50  "UD   M=P
M+(T  "RD   KN@  *]8  "KN $TB  !!)   ."0  # D   I)   )",  "$B
M   =(@  &2(  !4C   2)   #R8   TH   **@( !BP%  (N"0  +PL  # .
M   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@  ,U   #-@   S<P  ,HH
M #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG   H)@  (R4  !\D   ;
M)0  %B8  !(H   0*@  #2P   HN   &, $  C($   T!P  -0H  #<,   X
M#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP  #I<   Z;P  .88  #B>
M   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F*   (B<  !TH   8*0
M$RL  ! N   -,   "3(   4U   !-P   #D"   [!0  / @  #X+   _#0
M01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7  !":@  08$  $":   _
ML@  /L\  #[O #\L   V+   +RP  "HK   E*@  'RL  !DM   4+P  $#(
M  TU   (.   !#H    \    /P   $$   !# @  104  $8(  !("P  2@X
M $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+9   2WL  $J4  !)K0
M2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$  !4T   0-P  #3H   @]
M   "0    $,   !&    2    $H   !,    3@$  $\$  !1!P  4PL  %4.
M  !8$@  61D  %@B  !8+@  5SP  %=+  !67@  5G,  %6-  !4IP  4L(
M %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\   ,0   !T0   !'
M2@   $T   !0    4P   %4   !7    60   %H   !< P  7@<  &$+  !D
M#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L  &*%  !AGP  8+D  %[<
M #4W   P-0  *#<  " Z   8/0  $4(   Q&   &2@   $\   !3    5@
M %D   !<    7P   &$   !D    90   &<   !I    ; $  &X&  !Q"P
M= \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[  !RE0  <*\  &_) #4Z
M   K.P  (C\  !I#   22   #$T   52    5P   %P   !@    9    &@
M  !K    ;@   '$   !S    =0   '<   !Z    ?    '\   ""!   A@H
M (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%BP  @Z4  (*\ "]    E
M1   '$D  !-.   -5   !%H   !A    9@   &L   !O    =    'D   !]
M    @    (,   "%    AP   (H   ",    CP   )(   "6    F0(  )X)
M  "B$   HAH  *$I  "@.P  GU   )UG  ":@0  FID  )FO "E)   ?3@
M%50   Y;   %8@   &D   !P    =P   'T   ""    A@   (L   "/
MDP   )4   "7    F@   )T   "@    HP   *8   "J    K@   +(   "W
M"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X  *^D ")4   86P  $&(
M  =J    <P   'L   ""    B0   )    "5    F@   )\   "C    I@
M *@   "K    K@   +    "S    M@   +H   "]    P@   ,<   #, 0
MTPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6 /P   #V    \@   /$
M  #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8 W@ ^ -D 1 #4 $H T0!/
M ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\ ($ N0"- +8 F@"S *L
ML0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0   #L    Z    .<   #?
M    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W +P /@"Y $0 MP!) +4
M3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H I0"% *( DP"@ *( G0"V
M )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?    V0   ,D   "_
MN  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8 . "D #T H@!# *  2 ">
M $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!] (\ BP"- )H BP"L (D
MQ0"( .X A@#_ '\ _P!Z /\ > #_ -D   #-    NP   *X   "E    GP
M )P "0"9  \ F0 5 )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8
MB !+ (8 4 "% %4 @P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V
M .  =0#_ '( _P!N /\ ; #_ ,<   "U    I0   )D   "/    B0   (4
M! "$  P @@ 1 (( %P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$
M '4 20!S $\ <@!5 '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P
M90#U &0 _P!A /\ 8 #_ +0   "@    D    (4   !]    =P   ',   !P
M  @ ;P . &\ $@!O !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4
M0P!C $@ 8@!. &$ 50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J
M %< _P!6 /\ 5 #_ *$   ".    ?P   '4   !L    :    &0   !A  0
M8  + %\ #P!? !, 7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6
M $, 50!) %, 4 !2 %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H
M^@!* /\ 2@#_ )(   "     <@   &<   !?    6@   %<   !5  $ 4P '
M %( # !2 !  4@ 4 %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T
M20!# $@ 2@!& %( 10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!
M /\ 0 #_ (4   !T    9P   %T   !5    3P   $P   !*    2  $ $<
M"@!'  T 1@ 1 $8 %0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^
M #T 10 \ $X .P!7 #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X
M-@#_ 'P   !K    7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]
M  L /0 . #P $0 \ !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0
M00 S $D ,@!3 #$ 7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_
M ',!  !D!0  5P<  $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @
M-  , #0 #P T !( ,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K
M $4 *@!/ "D 6@ H &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&
M  !>"0  4@L  $@,  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 *
M "P #0 L !  *P 3 "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $(
M(@!+ "( 5P A &0 ( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9
M#   30T  $,.   \#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$
M"P E PX ) $0 "0!%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %)
M !L!5  : 6$ &@%P !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@
M20\  $ 0   X$   ,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?
M!PP '@8. !X%$0 <!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&
M4@ 5!U\ % =N !,'@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A
M #P1   U$0  +Q$  "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH
M&0H- !@)$  7"1( %@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0
M#%\ #PQN  X,@  .#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3
M   R$P  +!,  "<2   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+
M !,,#0 2#!  $@P4 !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX
M"P]M  H/?P )#Y, "0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P
M%   *10  "44   A$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .
M#  .#@X #@\2  T0&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J
M  82?  %$I  !!*D  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@
M)Q8  "(5   >%   &Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,
M$@X "Q(1  H2%0 )$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5
M>@  %8X  !6C   4MP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<
M "$6   <%@  &14  !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T
M"!80  86$P %%AD !!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P
M&8P  !BB   8MP  %\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8
M   ;%P  &!8  !45 @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.
M  (;$@ !&Q8  !L=   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H
M !R@   <M@  &]   !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9
M&0  %Q@  !07 P 2%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @
M$   (!0  "$:   A(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?
M   @M@  ']$  !_M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@
M%AD! !,9 0 1&0$ #AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@
M)A(  "88   G'P  )R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   E
MM   )-$  "/N $0=   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P
M !$<   .'0  #1\   HA   &(@$  R0$   F!@  * @  "H+   K#0  +1
M "T5   M'   +20  "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@
M*M   "GO $ @   V(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A
M   -(@  "B0   8F   "*    "L"   M!   +P8  # )   R#   - X  #42
M   U&   -2   #4J   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T
M ##O #PC   R)   *B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )
M*0  !2L   $N    ,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^
M%   /AP  #XF   ^,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM
M #<G   O)P  *"8  ",E   ?)   &24  !0F   0*   #2L   DN   %,
M #,    U    .    #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0
M21<  $@A  !(+   1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J
M   L*@  )R@  "(G   <*   %BH  !$M   -,   "3,   ,V    .0   #P
M   ^    00   $,   !&    2    $H   !, P  3@8  % *  !3#@  5!,
M %0<  !3)P  4S0  %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K
M+   )BL  !\L   8+@  $C(   TU   (.0   CT   !     0P   $8   !)
M    3    $X   !1    4P   %4   !7    60$  %P&  !?"@  8@X  &,5
M  !C'P  8BP  &$\  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P
M(C   !HS   3-P  #CL   @_   !1    $@   !,    3P   %(   !5
M6    %L   !=    8    &(   !D    9@   &D   !M!0  < L  '00  !T
M&   <R4  '(T  !R10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@
M !0\   .00  !T<   !,    40   %4   !9    70   &$   !E    :
M &L   !M    ;P   '(   !T    =P   'H   !^    @@0  (8+  "*$0
MB1P  (@K  "&/0  A%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](
M   (3@   %0   !:    8    &0   !I    ;@   '(   !V    >@   'T
M  "     @@   (4   "(    BP   (X   "2    E@   )L#  "@#   HA,
M * A  "?,P  G4<  )I>  "8=P  EX\  )6G "-#   92   $4X   E5
M7    &,   !J    <0   '8   ![    @    (8   "*    C@   )$   "3
M    E@   )D   "<    H    *,   "G    JP   +    "V!   O T  +H7
M  "Y*   MSP  +12  "R:@  KX4  *V< !Q.   35   "UP   %D    ;
M '0   !\    @P   (D   "/    E    )H   "?    H@   *0   "G
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M____________________________________________________
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M%!46%Q@9&AL<'1X?("$B(R0E)B<H*2HK+"TN+S Q,C,T-38W.#DZ.SP]/C]
M04)#1$5&1TA)2DM,34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM
M;F]P<7)S='5V=WAY>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:
MFYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'
MR,G*R\S-SL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T
M]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0                    $
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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M@:>,SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MKWRHRZ]\J,O_LA<)_[(A'O^O+SK_JCQ9[*1)>MB;6IG&EG&RQ)AXM<*9@;G
MFXB\OI>*O[R4B\*ZD(W%N8R.Q[>(D<FVA93+M8.7S;2!FLZT?Y_/LWZDSZY]
MILZK?:C,JWVHS*M]J,RK?:C,JWVHS*M]J,RK?:C,JWVHS*M]J,RK?:C,JWVH
MS*M]J,S_LA8)_[,A'O^P+CK_JSM9[*1(>M><69K&EV^RQ)EVML*;?[G G(>]
MO9J)P+N6BL.YDHO&MXZ-R;:*C\RTAY+.LX26T+*!FM&R@)_2KG^CTJI_I<^F
M?Z?-IG^GS:9_I\VF?Z?-IG^GS:9_I\VF?Z?-IG^GS:9_I\VF?Z?-IG^GS:9_
MI\W_LQ8)_[,@'O^P+3K_JSI9[*5'>M:<69K&F&VRQ)ITML*<?;F_G86]O9R(
MP;N8B<6XE(K(MI"+R[2,CLZSB)'1L865T["#FM2P@J#5JH&BTZ:!I="C@:?-
MHX&GS:.!I\VC@:?-HX&GS:.!I\VC@:?-HX&GS:.!I\VC@:?-HX&GS:.!I\W_
MLQ4(_[0@'O^Q+3K_K#E9ZZ5&>]:<6)O&F6NRQ)QRML*=>[F_GX.^O)Z(PKJ:
MB,:WEHG*M9**S;..C-"QBH_3KX>4UJZ%FMBK@Y_7IH.BU**#I-"?@Z;-GX.F
MS9^#ILV?@Z;-GX.FS9^#ILV?@Z;-GX.FS9^#ILV?@Z;-GX.FS9^#ILW_M!4(
M_[0?'O^Q+#K_K#E9ZZ9%>]6=6)O'FFFRQ)UPML*?>;J_H(*^O)^(PKF<B,>V
MF(C+M)2)S[&0B].OC([6K8F3V:R'F]NFAI[9HH6AU9Z%I-&<A:;.G(6FSIR%
MILZ<A:;.G(6FSIR%ILZ<A:;.G(6FSIR%ILZ<A:;.G(6FSIR%IL[_M!0(_[0?
M'?^Q+#K_K3A9ZZ9%>]6=5YS'FV>RQ)YNML*@=[J_H8"^NZ&(P[B>A\BUFH?-
MLI>(T;"3BM6MCXW9JXR3W:B*F]ZBB)[9GHBAU9N'I-&9AZ;.F8>FSIF'ILZ9
MAZ;.F8>FSIF'ILZ9AZ;.F8>FSIF'ILZ9AZ;.F8>FSIF'IL[_M!0(_[4>'?^R
M*SK_K3A:ZZ9$>]6=5YS'G&6RQ)]LM<*A=;J^HGZ_NZ.'Q+B@A\FTG8?.L9F(
MTZZ6B=BKDXS<J)"2X:..FM^>C)[:FHNAU9>*I-&6B:;.EHFFSI:)ILZ6B:;.
MEHFFSI:)ILZ6B:;.EHFFSI:)ILZ6B:;.EHFFSI:)IL[_M!0(_[4>'?^R*CK_
MK3=:ZZ=#?-6>59W'G6.RQ*!JM<*C<[J^I'R_NZ2%Q+>BA\JSGX?0L)V'U:R:
MB=NIF(S@I9>3YIZ4FM^9D9W:EH^@UI2-H]*3C*7/DXRESY.,I<^3C*7/DXRE
MSY.,I<^3C*7/DXRESY.,I<^3C*7/DXRESY.,I<__M1,(_[4>'?^S*CK_KC9:
MZZ=#?-6?4YW'GF"RQ:)HM<*E<+J^IGJ_NZ:#Q;>EA\NSHH?1KZ"'UZJ>B=RD
MFXO@G9F.XYJ;F>"5EIS;DY.@UY&1H].0CZ7/D(^ESY"/I<^0CZ7/D(^ESY"/
MI<^0CZ7/D(^ESY"/I<^0CZ7/D(^ESY"/I<__M1,(_[8='?^S*3K_KC9:ZZA"
M?-6@49W'GUZQQ:1DM<*G;;F^J7>_NZF!Q+:HB,NQI8?1JZ*'UZ6?B-N>G8C=
MEYN+X)*;D]^2G)S<CYB?UXZ5HM.-DZ30C9.DT(V3I-"-DZ30C9.DT(V3I-"-
MDZ30C9.DT(V3I-"-DZ30C9.DT(V3I-#_M1,(_[8='?^T*3K_KS5:ZJA!?-6B
M3IS'H5JQQ:9@M,*J:;F_K7.^NZY]Q+2JA\NMI8;1IZ*&U:"@AMB9GX;;DIV)
MW8V=CMV,GIC;C)Z?V(N:HM2*EZ31BI>DT8J7I-&*EZ31BI>DT8J7I-&*EZ31
MBI>DT8J7I-&*EZ31BI>DT8J7I-'_MA((_[<<'?^T*#G_L#1:ZJE ?=6D29S(
MI%6PQJI;L\.O8[? LVR]MJY\Q;"IA\RIIH;0HZ2%U)RBA-:5H878CY^'VHJ?
MB]N'GY+:B*&<UXB?H=2'G*31AYRDT8><I-&'G*31AYRDT8><I-&'G*31AYRD
MT8><I-&'G*31AYRDT8><I-'_MA((_[<;'?^U)SG_L#-:ZJH^?=:H1)O)J$^O
MQ[!3LL6X6;6YLVV_L:U]QJRJALNEIX7/GZ:$T9BDA-/_XO  24-#7U!23T9)
M3$4 !0J2HX35C**&UXBABM>%H8[7@Z*6UH2DG]2$HJ/1A**CT82BH]&$HJ/1
MA**CT82BH]&$HJ/1A**CT82BH]&$HJ/1A**CT82BH]'_MQ$'_[@:'/^V)3G_
ML3%:ZJL\?M>L.YG*K42MR;E%KKVX6;BRLF_ K*Y^QJBKA<JAJ83-FZ>#SY6F
M@]"/I832BJ2&TX:CB-2#HXS4@:.1U("DF=. IJ'1@*:AT8"FH=& IJ'1@*:A
MT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH='_N! '_[D9'/^W)#G_LR]:
MZ:TY?MFT+Y;,N#*IPKU L+.V7;JLL7'!IZY^Q:2LA<B=JX/*EZF#S)*HA,Z-
MIX3/B:>&T(6FB-""IHO1@*:.T7ZFE-!]IYK/?:>:SWVGFL]]IYK/?:>:SWVG
MFL]]IYK/?:>:SWVGFL]]IYK/?:>:SWVGFL__N0\'_[H7'/^Y(CG_M2U:[+,P
M>MW 'Y#)PR&HM;I(M*NU8KRFLG/ HZ]^PZ"NA,:9K(/(E*N$R8^JA,J+JH7+
MB*F&S(6IB,V"J(K-@*B-SGZHD<U\J9;-?*F6S7RIELU\J9;-?*F6S7RIELU\
MJ9;-?*F6S7RIELU\J9;-?*F6S7RIELW\NPX'_+P5&_Z['SC_MRE:\+TD=-_3
M#H:YP2JJJKE/MJ2U9;R@LG2_GK%_PINOA,.6KH3%D:V$QHVMA<>*K(;(AZR'
MR86KB,F"JXK*@*N,RGZKC\I\JY+*?*N2RGRKDLI\JY+*?*N2RGRKDLI\JY+*
M?*N2RGRKDLI\JY+*?*N2RGRKDLKQO0P&^;X2&OJ^&S?\NB5:Y\X3:,C9"XFM
MPS*GH;A6N)VU:+N;LW6^F;)_P)BQA,&3L(7"CZ^%PXROAL2)KH;%AJZ'Q82N
MB,:#K8K&@:V+QG^MCL=]K9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0
MQWVMD,=]K9#'?:V0QWVMD,??P @%]<(/&?;"%C;NR!50S=P,9K7:#XBBR3:@
MFKY6L)>W:KF5M7:\E+1^OI2SA+^0LH7 C;&&P8JQAL&(L8?"AK"(PH2PB<*#
ML(K#@;"+PX"OC<-^KX_#?J^/PWZOC\-^KX_#?J^/PWZOC\-^KX_#?J^/PWZO
MC\-^KX_#?J^/PWZOC\/9P@<%Y,<+&._($#31V@M%NND.:*;>&(*8T3>5D<A3
MH8_"9:F.OG*NC;Q[LHRZ@;6)N(*WA[B$N(6WA;F#MH:Z@K:'NH&UB+N M8F[
M?K6*O'VTC+Q\M(V]?+2-O7RTC;U\M(V]?+2-O7RTC;U\M(V]?+2-O7RTC;U\
MM(V]?+2-O7RTC;W4Q <$ULL)%=/4"R>]X@Q)J?0499GF)7B.W#F&B-1/D(;/
M8)>$S&V<@\EUH'_'>*)]QGND>L5]IGG$@*=WPX&H=L*#J77"A*ITP8:K<\&'
MJW+ B:QQOXNM<;^+K7&_BZUQOXNM<;^+K7&_BZUQOXNM<;^+K7&_BZUQOXNM
M<;^+K7&_BZW/Q@<"T,T)$L#9"2RL]P](F_H>7(_O,6N&YT)V@.)0?G[=7X5[
MV6F*=]5NCW33<Y)QT7>4<-!ZEF[/?9=MSG^9;,V!F6O-@YIJS(6;:<R'G&C+
MB9UGRHR=9\J,G6?*C)UGRHR=9\J,G6?*C)UGRHR=9\J,G6?*C)UGRHR=9\J,
MG6?*C)W*R @!PM('$Z[F"2V=_Q5!D?\H4(?Z.5R!\TAF?.U4;G?H7G5QY&5Z
M;>%K?FK?<(%HWG6$9MQXA67;>X=CVGZ(8MJ!B6'9@XI@V86*8-B'BU[8BHQ>
MUHV-7M:-C5[6C8U>UHV-7M:-C5[6C8U>UHV-7M:-C5[6C8U>UHV-7M:-C5[6
MC8W$R@<#L=H$%9__#2B2_QTWB?\N0X+_/4Y\_4M7=_A67V_S765H\&)J9.UI
M;F'K;W%?Z7-S7>AW=5SG>W9;YGYW6N: >%GE@WE8Y85Z6.2(>E?DBWM6XXY\
M5N..?%;CCGQ6XXY\5N..?%;CCGQ6XXY\5N..?%;CCGQ6XXY\5N..?%;CCGS_
MJAP%_ZHG%_^G-B__HD1*^IU29>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.
MD+K BI*\OX>4O;Z$EK^^@IG O8";P;U^GL&\?:'"O'NDPKQZJ,.\>:W#N'FO
MPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\+_JAP%
M_ZHG%_^G-B__HD1*^IU29>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K
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MG'JXP)R#N[Z<B;^[EXG#N9.+Q[>.C<NTB9#.LH26T;&!G=.L@*+3IX"ET*2
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MJ,N$FJC+A)JHRX2:J,N$FJC+A)JHRX2:J,O_L!0$_[$?%?^O+"[_JSE+^*E
M9^NO.WO>MC./TKHTH<S".:J[NE6UL+1JO:JP><.GK83'GZJ$RYBH@\V0IX30
MB:6&TH2DBM. I)#3?Z67TG^FH-!_I:;.@*"HRX"@J,N H*C+@*"HRX"@J,N
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MN<PGG*>]3+&@MV*YG;1QO9NR?+^:L83!E+"$PX^OA<6*KH;&AJV'QX.LB<>
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MA5K=C85:W8V%6MV-A5K=C85:W8V%6MV-A5K=C85:W8V%6MV-A5K=C87+Q 8
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MC=62=9S-D7^HQY&'LL21CK;#C9"XP8F3NL"&EKR_@IF]OW^<OKY]H+^]>Z7
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M_Z<F#_^D-27_H$,^_YU05?>?46CKH%-[X*!7C=2>7Y[*FVNLQ9MUM,.;?KC
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MP[>:B,JRDXK2K(N4VZ"'G]B:AJ31EX:GS)6&JLB4AZS%DX>NPY*'L,"2A[#
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MIJC-<JFIS'&MJLQPLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ''
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M^K=!9/.]1&_NQ4EWY<Y2?-W68G_,SFB2O,5NI*N[=K2:L7_!BJJ*RW^GG<^
MGZC,@IFKQX.5K<2$DZ_!A9&QOX:/L[V'CK2[AXZTNX>.M+N'CK2[AXZTNX>.
MM+N'CK2[AXZTNX>.M+O_G1 !_Z(F"O^@-1S_H#\P_Z<]/?^N/$K_M3Q5^KT]
M8/#&0F?FT4ILWMY.=LW:5X>^T&*6KL5NI:&\>;*5M(.]AJV(QGNJE,IXJZC)
M>Z*KQWZ<K<2 F:_"@9:PP(*4LKZ#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[R#
MDK.\@Y*SO(.2L[S_GA !_Z(F"O^A-!S_HCPN_ZHZ._^R.$?\NS=1\L4Z6.;1
M05S;WD)IS>)&?+[748RNS%^;H<-MJ)B\>;*1M82[A;&)PGRND<5XKI_%=:VL
MQ7BEKL1ZH*_"?)RPP'Z9L;Y_EK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKU_EK*]
M?Y:RO7^6LKW_GA !_Z,E"?^B-!S_I3DM_ZXU./^X,T+TPS-*Y] X3MG>.5K+
MYCUNON!"@*[44)"ARU^=F,-MJ)&]>;&+N(.X@[2(O7VQD,%YL9K!=;&EP7*O
MK\)UJ*_!=Z.PP'F?L;][G+*]>YRRO7N<LKU[G+*]>YRRO7N<LKU[G+*]>YRR
MO7N<LKW_H! !_Z0D"?^C,AS_J#0K_[,O-/F_+3SIS2] V=XO2LKG-%^]ZCIS
MK]Y!@Z'349&7RV"=D,1NIHR_>JV&NX&S?[B'N'JVC;MWM96\=;6?O'*TJ+UN
ML[*^<:RROG2GLKYVH[*]=J.RO7:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO7:C
MLKW_H1 !_Z4C"?^D,1S_K2XG_[DI+^[()C/:W"8WRN<L3[WR,F.OZ#EUH=U"
MA);44Y"/S6*:BL=PHH;#>JB OX"M>[V%L7:[B[1SN9*U<;F:MG"YH[5MN:NV
M:KBTN&NRMKANK+:X;JRVN&ZLMKANK+:X;JRVN&ZLMKANK+:X;JRVN&ZLMKC_
MHQ !_Z<B"?^E+QO_LR<B],(A)MW8'23+YR,\O?(J4Z_S,F:AYSMVE=Y&@XW6
M5HV'T&26A,MQG'_(>*%ZQ7ZE=L*#J7+!B:MOOX^M;+^6KFN^G:YJOZ:N:+^N
MKF6]N+!EN;NP9;F[L&6YN[!EN;NP9;F[L&6YN[!EN;NP9;F[L&6YN[#_I1 !
M_Z@@"/^L)A?\NQT:X]$3&<SE&2F]\B)!K_TJ5:'S-&:6Z3]TC.%+?X7;68B
MU6:/?-%OE'?.=IESRWR<<,F!GVW(AZ%JQXRC:,:2I&;%F:5DQ:"E9,6HI6/&
MLJ1@Q+NF8,2[IF#$NZ9@Q+NF8,2[IF#$NZ9@Q+NF8,2[IF#$NZ;_J!  _ZH>
M"/^S'1'LR0X/SN,.%;[R&"VO_B)#H?\M59;T.62,[$5OA.51>7[@7(!YW&>&
M=-ENBG#6=(YLTWF1:=)_DV?0A)5DSXJ78LZ/F&#-E9E?S9R:7LVBFUW-JYM<
MS;2:7,VTFES-M)I<S;2:7,VTFES-M)I<S;2:7,VTFES-M)K_JP\ _ZT:!_+
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MAQ(!_XDA!O^*-13_B$8E_XI2-?^.6D/_CV%1_HYH7O:+;VKOAWAUZ82!?N2
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MC44F_Y9-,_^94$'_FE5/_YI:7?>88&GOE6AUZ))P@.&/>XK<BX23UH:,FM*
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MA! !_X,: _^+*@S_G#$2_Z4T&O^L-B'^LSHH\[M +>G#2#'ARU$WTL=62\7
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M*2C_HBHG_ZTK)O^Y+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP
MFL4  (O3  !]X@  =?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[
M_ST--_]##S/_21$P_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__
MD1H>_YP;'O^E'!W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X
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M^5;<4_E6W%/Y5MQ3^5;<4_E6W%/Y5MQ3^5;_7AL"_UHE _]4,0;_6#<(_V%
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MDWINCX^#=HB+CGR"B)F!?(:GA7F&N89WA]>%>(7=@WJ#WH%Z@N!_>X'A?7R
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M>&V,Y7AMC.5X;8SE>&V,Y7C_;A,!_WL1 ?^-$ #_G1  ^JP1 -J["P#5R0L
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M1#?_ZD4V_/U%._+_1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP
MO:P  *ZU  "BP@  E<\  (K= P"$_Q(!>_\> W3_*@EL_S,/9/\[%EW_0QM7
M_TH@4?]1)$S_6"=(_V J1/]H+$#_<2X\_WLQ.?^(,C7_EC0S_Z0V,?^V-R__
MT#@N_^\Y+?__.3'__SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$
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M$1/_NA$3_\,2$__#$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP
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M:7A\\&EX?/!I>'SP:7A\\&G_8!<!_VX2 ?]^$ #_C!$ _YD1 /&D$P#CKA8
MUK8< <NT, C!L#\7MZM+):VF5#.DH5U G)UE2I28;%.,E71;AI%]8G^.AVAY
MC))M=(J><7"(K71MB,%T;8GD<V^'ZG%PA.QO<H/M;7.![FMT@/!I=(#P:72
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M4T?(]U5(P/Q82KC[64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P
MW),  ,JB  "\K $ L;4  *C  P"?RP8 EMD+ )'@&P&*WRP&@M\Y#GG>0Q=Q
MW4T@:MQ6*&/;7R]=VF<U6-EQ.E/9>SY/V8A"2]F614C9ID=&VKI(1=O;1T38
M]$E"T_]-1,G_3T7"_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL
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M*BS__RHO^?\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0
M@=$  '7>  !M^@D 9?\1 5[_&@)7_R,#4O\L!4S_- =(_SP*0_]$##__3 X\
M_U,0./];$C7_8Q0R_VP6+_]W%RS_A!DI_Y,:)_^B'"7_M!TD_\P>(__M'B+_
M_1\B__\?(O__'R+__Q\B__\?(O__'R+__Q^LJP  G;8  (_"  " S@  <]P
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M&P+_9QL"_VXB _]S*@3_=S4)_WA $/EW2ACR<U0@[&]>*.=K:C#B9W4VWF.
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M6(-O_%B#;_Q8@V_\6(-O_%C_5A@!_V01 ?]R#@#_?A  _X@1 /61% #HF!D
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M75:=ZUQ7FOI;6I7Z6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H
M_WP  -R,  #-F   PZ,# +JJ @"SLP$ K+P* *:]'0&>O"\&EKH\$8VX1QR%
MM5 G?;-9,':Q8#AOKV@_::UP16.K>4I>JH1/6JF04E6HGE52IZ]74:C&5U"G
MZE=0I?Q74Y_]5U6:_597EOY66)7^55B5_E58E?Y56)7^55B5_E7_;P0 YH(
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M0$##_T)!O?]#0KG_1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP
MH+0  )6^  "+R , @-$' 'CA#0!TX1T!;N$K VC@-PAAX$(.7.!-%%?@5AE3
MX%\=3^!I(DO@<R5'X'XH1."+*T+@FBT_X:LO/N+!+S[BY2\\W_HQ.=[_-#G9
M_S8ZT/\X.\S_.3O,_SD[S/\Y.\S_.3O,_SG-D@  O*   *VH  "AL0  E;L
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M$Q[__Q,>__\3'O__$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4  &#?  !4YP
M3O\$ $G_#@!#_Q0 /_\= 3K_)0(V_RP",O\S R__.@,K_T$$*/](!"7_3P4B
M_U<%(/]@!AW_; <:_WD'&/^*"!;_FP@5_ZT)%/_#"1/_XPD3__@)$___"A/_
M_PH3__\*$___"A/__PJ:L0  B[T  'S(  !MU   7^   %'F  !']0  0?\
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M5F=_XU5H@/I3:7[_46I\_T]K>_]-;'G_3&QY_TQL>?],;'G_3&QY_TS_7@P
M_VP! .9Z  #6A@  RX\" ,27! "^G00 N*(. +&C(0&IHC('H9\_$9F<2AN2
MF5,EBY9<+8638S5_D6L[>HYS076,?$9PBH5+:XB13V>'G5)DAJQ48H:_56&&
MX51AAOE28X3_4&6!_T]F?_]-9W[_3&=^_TQG?O],9W[_3&=^_TS_80H _V\
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M25"9_TE2EO](5)+_1U22_T=4DO]'5)+_1U22_T?_;@  WG\  ,J-  "^F
MLZ   *JG  "AK@  E[8  )&Z$ ",NB,!A;DR!GZX/@YWMDD7<;52'FNS6B5E
MLF(K8+%J,%NP<S57KWTY4ZZ)/4^MED!,K:5"2JVY0TFNV$)(J_5#1ZK_1$FE
M_T1+H/]$39S_1$V<_T1-G/]$39S_1$V<_T3J=0  TH8  ,.3  "WG0  K*0
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M+3;*_RTVRO\M-LK_+3;*_RW%D   MIT  *BE  "<K0  C[8  (.^  !WQP
M;,\" &+6!P!:Y X 6.0< %3D*0%0Y#4#3.4_!4CE20=%Y5,*0N9<#3_F9@\\
MYG$2.N=^%#?GC!8UYYP7,^BN&3+IQADRZ.H9,>7^&2_D_QPNY/\>+>+_("WB
M_R MXO\@+>+_("WB_R"ZF@  JJ,  )VK  "0M   @[T  '?&  !KSP  7]8
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M!0[__P65KP  AKH  '?%  !HT   6ML  $SA  ! YP  -_,  #+_   N_P<
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M4@X _UT# /UI  #A<@  UGH" ,Y_!0#*@P@ Q882 +R')@&UAC8&KH-##Z>
M3ABA?%@@FWE@)Y9W:2V2=' SCG)Y-XIP@3R&;HL_@VV50W]LH45\:ZY'>FN_
M2'AKW4AX;/9&>&S_1'=L_T)W:_] =VK_/W=J_SYW:O\^=VK_/G=J_S[_5 P
M_U\  /)L  #==@  T'T" ,F#! #$AP8 OXH0 +>,(P&PBC0%J8A!#J*%3!><
M@54?EG]>)I%\9BV,>6XRB'=V-X1U?SN =(@_?'*20WAQGD9U<*Q(<V^]27%P
MV4EQ</1'<7'_1')P_T)R;_]!<F[_/W)N_SYR;O\^<F[_/G)N_S[_5@H _V(
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M1&!__T)A??]!8GO_/V-Z_S]C>O\_8WK_/V-Z_S__7@  Z6T  -9Y  #(A
MOHP  +:3  "NEP  IIL$ *"=%P":G2D"DYPW"(R:0Q"&F$T8@)95'WJ4729U
MDF4L<)!L,6R.=39GC7XZ8XN)/E^*E4%<B:-$6HFT15B)RT58B.U$6(C_0UF&
M_T%;@_] 78'_/EV _SY=@/\^78#_/EV _S[_8@  Y'$  ,]^  ##B   N9$
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M-TF:_S=)FO\W29K_-TF:_S?B=   RH,  +R/  "PF   I9X  )ND  "0JP
MA;$  'JX! !VN10 <KDE 6VY,P1HN#\(8[A)#EZW4A-:MEH85K9B'%*U:R!.
MM'4D2[2 )TBSCBI%LYTL0K.N+4&SQ2Y!L^DM0+#^+S^O_S$^K?\R0*C_,D&F
M_S)!IO\R0:;_,D&F_S+5?   PHH  +66  "HG0  G:,  )*J  "'L0  ?+<
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M%BC:_Q:SF   I:   )FG  "+L   ?K@  ''   !ER   6<X  $[3  !$VP0
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M 0O_B@(*_Y\""?^U @C_U0('__0"!___ @?__P('__\"!___ @?__P*1K0
M@K@  '/"  !DS   5M4  $C=   [X@  ,.<  "?N   C_P  (/\$ !S_#  9
M_Q$ %O\6 !/_&P 1_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0  /]B 0#_
M<P$ _X<! /^= 0#_L@$ _\H! /_J 0#_\P$ __,! /_S 0#_\P&$MP  =,$
M &7,  !6V   1]\  #GE   MZ@  (^X  !S]   8_P  %?\  !'_!  /_PL
M#?\.  G_$0 &_Q4  _\:  #_(   _R8  /\N  #_-P  _T$  /]-  #_7
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M4A&L9EP8J&1E':1B;2*A8'4FGEY^*9M=ABV87(\OE5J9,I-9I#206; VCEG
M-HQ9VS>*6?,VB5K_-(A;_S.'6_\QAEO_,(5;_R^%6_\OA5O_+X5;_R__2PP
M_U0  /M>  #B90  V&L! ,]N!0#,< @ QG(2 +YS)@&W<S8$L7!$"JMN3Q&F
M:UD8H6EA'9UG:B*997(GEF-Z*I-B@RZ08(PQC5^5-(I>H#:'7JTXA5V\.8-=
MU#F"7O X@5__-H!?_S2 7_\S?U__,7Y?_S!^7_\P?E__,'Y?_S#_30D _U8
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M.6UL_S=N;/\U;FO_-&YJ_S)N:O\R;FK_,FYJ_S+_4P  ]%\  -YJ  #-<P
MPWH  +M^  "U@0  KH,) *B%&@"BA2L"FX0Z!Y6"10Z0?T\5BGU8&X9[7R"!
M>6<E?7=O*GIV=RYV=( R<W.+-6]RECAL<:,Z:7"R/&APQCQG<.<[9W'\.6AQ
M_S=H</\U:6__-&EN_S-I;O\S:6[_,VEN_S/_5@  ZV(  -AN  #)=@  OWT
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M,UE]_S)9??\R67W_,EE]_S+O8   VVX  ,=Z  "[@P  LHL  *B0  "?DP
ME)8  (V9#@")FAX A)HN GZ9.@=YET4-=)9.$V^55AAJDUX=9I)E(6*1;29>
MCW8J6XZ!+5>-C3!4C)HS48RJ-4^,O35/C-XU3XOW-$^*_S-0B?\R48;_,5*$
M_S%2A/\Q4H3_,5*$_S'J90  TG,  ,)_  "VB   K)   **4  "8F   C)P
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M)CND_R;,>@  NX@  *Z2  "BF0  EYX  (RD  " J@  =:\  &FT  !>N08
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M!2C9L08GVLT&)]?O!B;4_PDETO\+)-'_#"/0_PTCT/\-(]#_#2/0_PVNE@
MH)T  )2D  "&K   >;0  &R[  !@P@  5,8  $C+   ^T   -=4$ "W="@ L
MX1, *^(? "GC*@ HY#4 )^0_ ";E2@ DYE4 (^9A 2'G;@$@YWX"'NB0 AWI
MI (;Z;P"&NKB AKF_ (9Y?\#&>3_!!CC_P48X_\%&./_!1CC_P6CG0  EJ0
M (BL  !ZM0  ;+T  %_$  !3R@  1\X  #S3   RV@  *M\  "7N"0 C\!$
M(?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>  1#XE $/
M^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP  BZP  'RU
M  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9_PX %_\3
M !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_@  !_Y8
M /^M  #_R@  __   /__  #__P  __\  /__  #__P"-JP  ?;4  &Z_  !@
MR   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@ #O\.  S_
M$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0  _WX  /^5
M  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\  &')  !2TP
M0]L  #7A   IY@  'NH  !7N   0^   #O\   O_   (_P  !/\&  #_"@
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M'Z=&X""D1O0@H4;_(9]'_R">1_\@GD?_'YM'_QZ:1_\>FD?_'II'_Q[_0 T
M_T8$ /],  #X4@( Z%4$ .%5" #B50T U549 ,Q7+ #%5SP"OU9*!KI550JV
M4U\.LE)H$J]0<16L3WD8JDZ!&JA-BAVE3)(?HTR<(*%+IB*?2[$CG4O ))M+
MV"692_ EEDS_))5,_R243/\CDTS_(I%-_R&13?\AD4W_(9%-_R'_0@H _TD
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M+'M:_RI[6_\H>UO_)WM:_R9Z6O\E>EK_)7I:_R7_20  ^U(  .-<  #28P
MQV@  ,!K  "Z:P( M6L- *YM'0"H;BX!HVT\!9UK2 J9:E$/E&A:%)!F8AB-
M96H<BF-R((=B>B.$88,F@6",*7Y?ERM[7J,M>5ZQ+W==Q"]U7N(O=5[Y+75?
M_RMU7_\I=5__*'5>_R9U7O\F=5[_)G5>_R;_2P  \%4  -Y?  #-9P  PVP
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M*65J_RAE:O\H96K_*&5J_RC]4P  XU\  ,YI  #!<0  MW<  *][  "G?0
MGGT  )A^$0"3@"( CH Q HE_/@:$?4@,?WQ1$7MZ619W>6 :<W=H'F]V<"%L
M=7@E:72"*&9SCBMC<IHN8'&H+UYQNC!=<=0P77'R+EYQ_RQ></\K7W#_*6!O
M_RA@;O\H8&[_*&!N_RCQ50  WF(  ,IM  "]=0  LWL  *N   "B@@  F($
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M)DZ!_R;A8P  R7   +M[  "PA   IHH  )N.  "1D0  A),  'J5 @!UEQ(
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M%SJFKQ@YIL<8.:7J&#BC_QHWH?\;-Z#_'#>?_QPWG_\<-Y__'#>?_QS$>
MM84  *F/  "=E0  DIH  (:?  !ZHP  ;J@  &*L  !5L   4+(. $ZR&P!-
MLR@ 2[,U $FS/P%&LTD"1+-2!$&S6P8_LV0(/+-O"CJS>PPWLXH.-;*:#S.S
MK1 RL\40,K+I$#&P_A(PKO\4+ZW_%2^L_Q8OK/\6+ZS_%B^L_Q:[@0  KHX
M *&5  "6F@  B:   'VF  !QJP  9:\  %FT  !.MP  0[P% $"]$0 _O1X
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M !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I  !VL0
M:+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4 %.D. !+J%  1
MZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J  !?*Z  3Q
MY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !IN@  6\(
M $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ#P )^Q4
M!_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD  #\P0
M_.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q   3LP  #_1
M   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0  _PX  /\2
M  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_I@  _\(
M /_G  #__   __\  /__  #__P!\LP  ;+P  %W&  !.SP  /]8  #'=   E
MX@  &N8  !'J   ,[@  !?(   #_    _P   /\   #_    _P4  /\*  #_
M#@  _Q(  /\8  #_(0  _RL  /\Y  #_2@  _UT  /]S  #_C   _Z0  /^Y
M  #_U   _]X  /_>  #_W@#_&"P _QDI /\9* #_%2L _Q P /\+. '_ T0!
M_P!1 ?\ 7@'_ &P!_P!X ?\ @@'_ (P!_P"4 ?\ G #_ *( _P"H /\ KP#_
M +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_&RD _QTF /\<)0#_&2< _Q,L /\.- #_"T !_PA.
M ?\%6P'_ V@!_P)T ?\"?P'_ H@!_P*1 ?\"F '_ I\!_P&E /\!K #_ ;(
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M!L@MYP?$+?<)P2W_"K\M_PN]+?\,O"W_#+PL_PR[+/\,NRS_#+LL_PS_,1$
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M&X]'_QJ.1_\9CD?_&(U'_QB-1_\7C4?_%XU'_Q?_/@( _T,  .M+  #=40
MT50  ,I4 0#&4@4 P5$1 +E3(@"S53,!KE1! JI43 6F4U8(HE%?#)]09P^=
M3V\1FDYW%)A.?Q:638@8DTR1&9%,FQN/2Z8=C4NS'HM+Q1Z)2^(>ATSW'H9,
M_QV%3/\<A4W_&H5,_QF%3/\9A4S_&85,_QG_0   _$<  .50  #55@  RED
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M'G!:_QUP6O\<<%K_''!:_QS_2   YU(  --;  #%8@  NV8  +-H  "L:
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M'EMJ_Q[K4P  TV   ,)I  "V<0  K'8  *-Y  "9>0  C7<  (=Y"P"#>Q@
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M'DF!K!](@,$@1X#C'T=_^AY(?O\>2'W_'4E\_QQ)?/\<27S_'$E\_QS680
MPFX  +1X  "J@   GX4  )2'  "(AP  >XD  '",  !KC@T :(\: &:/*0!B
MD#4!7X\_ UR/2 59CE (5HY8"U.-8 Y0C&@038QR$TJ+?19(BHH818J9&D.*
MJAM"BK\;08KA&T&(^1M!AO\;087_&T*%_QI"A/\:0H3_&D*$_QK-9P  O'0
M *]^  "EA@  FHH  (Z,  ""C0  =9   &>4  !AE0@ 7I<4 %R7(P!:F"\
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M$S.9_Q.]=P  KX,  *.+  "8D0  C94  (&9  !SG   9Y\  %NB  !/I@
M1ZD( $2J$@!#JA\ 0:LK $"K-P _K$$ /:Q* 3NL4P(YK%P#-ZQG!#6L<P4R
MK($&,*R1!RZLHP@MK+@)+*S9""RJ]0HKJ/\+*J;_#"JE_PTJI?\-*J7_#2JE
M_PVU@   J(L  )R1  "1E@  A9P  'B@  !KI0  7Z@  %.L  !(KP  /;(
M #:U"P TM14 ,[8A #*V+  QMS< ,+=! "^X2P NN%4 ++A@ 2JX;0$IN7L"
M)[F- B6YGP,DN;0#([G2 R.W] 0BM?\%(;3_!B&S_P<ALO\'(;+_!R&R_P>M
MB@  H)$  )67  "(G0  >Z,  &ZH  !AK0  5;$  $JT   _MP  -+L  "N^
M P DP@P (L(4 "+#'P APRH (,0T !_$/P >Q4H '<96 !S&8P ;QW, &L>%
M !G'F0 8R*X %\C+ !?&\0$7Q/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0
MF)@  (N>  !]I0  <*L  &*Q  !6M@  2KD  #Z]   TP   *L0  "+(   9
MS 0 $] * !'2$0 0TAH $-,E  _3,  .U#P #M1(  W55@ -U64 #-9X  S6
MC0 +V*0 "MB^  G9Y@ *UOX "]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\
M ("F  !RK0  9+0  %>Z  !)OP  /<(  #+&   HR0  '\T  !?1   1U@
M#-L%  C>"P &WQ$ !=\:  3@)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P
MYI(  .:J  #GR   Y_   .C_  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O
M  !EMP  5[X  $G#   \QP  ,,L  "7/   <U   %-D   [=   )X0   N4
M  #I!@  Z0T  .D1  #J&   ZR$  .TK  #O-P  \44  /)6  #S:   \WX
M /27  #UL   ]M   /?S  #W_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8
MP0  2L@  #O,   NT0  (]8  !G<   1X   #.,   3G    Z@   /4   #T
M    ]04  /4+  #V#P  ]A0  /@=  #Z)P  _#0  /]#  #_50  _VD  /^!
M  #_F@  _[(  /_/  #_[0  __D  /_Y  #_^0!XL   :+H  %G#  !+RP
M.]$  "W8   AW0  %N(   [F   (Z@   .T   #P    ^    /\   #_
M_P   /\   #_!@  _PP  /\0  #_&   _R(  /\P  #_0   _U,  /]I  #_
M@0  _YD  /^O  #_PP  _]4  /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M
M /\ -0#_ $$ _P!/ /\ 7 #_ &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T
M_P"D /\ J@#_ +  _P"W /\ P #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\
M, #_ #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@
M /\ I@#_ *T _P"T /\ O #^ ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\
M^ #_ /@ _P#Y /\ ^0#_ /D _P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_
M!SD _P-& /\ 4P#_ &  _P!K /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\
MHP#^ *D _ "P /H N0#W ,0 ]0#2 /, Y@#R /0 \0#_ /  _P#O /\ [P#_
M .\ _P#P /\ \ #_ /  _P#_'AT _QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0
M_PQ! /\*3@#_"%L _P=F /\&<0#_!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V
M!J8 ] :M /(&M0#P!<  [07. .L%Y #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+
M_P'D"_\!Y O_ >0+_P'_(1@ _R$3 /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\
M /\120#_$%4 _ YA /D.:P#V#G4 ] Y^ /(.A@#P#HX [@Z5 .T.FP#K#J(
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M!;4E_P7_+ T _RT% /\N 0#_,04 _S$+ /TO$ #Q*Q@ YRDE -\H,P#8*$(
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M#IL[Q0Z9.^ .ECOT#Y0\_P^2//\/DCS_#I$\_PV1//\-D3S_#9$\_PW_-0
M_SD  .I!  #=1@  T$<  ,E&  #&004 P$ 1 +E"(0"S1#( KT5  :M%2P*G
M154#I$1>!:%$9@>?0VX(G4-V"IM"?@N90H8-ET&/#I5!F0^30:01D4&P$I!!
MP!*.0=D2BT'Q$HE"_Q*(0O\1B$+_$(="_Q"'0O\/AT+_#X="_P__.   \ST
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M&G!1_!AP4?\7<%'_%7!1_Q1Q4/\3<5#_$W%0_Q/U0   Y$L  ,]4  #!6@
MMUT  *]>  "G6P  H5@# )M9$@"66R( DEPQ 8Y</0**7$<$AUM0!H-:6 F!
M66 ,?EEG#GM8;Q!Y5W<3=E: %716BQ=R5989;U6C&FU4LAML5,8;:E7F&VI5
M^QEJ5?\7:E7_%FI5_Q5K5?\4:U7_%&M5_Q3R0P  WT\  ,M8  "]70  LV$
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M%UMA_Q9;8?\56V'_%5MA_Q7G30  SUD  +]B  "S:   J6T  )YM  "3:P
MB6D  (-K"0!_;14 ?&XE 'AN,@%U;CT"<6Y&!&YM3P=K;%8):&Q>#&5K90]C
M:FT18&EV%%UI@19;:(T86&>;&E9GJAM59[T<5&?<'%1G]AI49O\856;_%U5E
M_Q969?\55F7_%59E_Q7B40  RET  +MF  "O;   IG$  )EP  ".;P  @VX
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M$T1V_Q/-7P  NVL  *YT  "D?   EWX  (I]  !_?@  <G\  &:#  !AA @
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M!S&9G0@OF; (+IG*""Z8[0@NEO\*+93_"BV3_PLMDO\++9+_"RV2_PNV=0
MJH$  )Z(  "3C0  AHX  'B/  !KD@  7Y4  %29  !)G0  0*   #JB#0 X
MHQ< -Z,B #:D+0 UI#< -*1! #.E2P QI50!,*5> 2ZE:@$LI7@"*J6( RBE
MF@,GI:T$)J7& R:DZP0EHO\%):#_!B2?_P8DGO\'))[_!R2>_P>O?@  HX@
M )>.  "-DP  ?I4  '"8  !CFP  5Y\  $RB  !"I@  .*D  "^L P JK@X
M*:X8 "BO(P GKRT )K W "6P00 DL$L ([%6 "*Q8P AL7$ '[&" !ZRE $<
MLJD!&[+! 1NQYP$;K_X"&JW_ AJL_P,:J_\#&JO_ QJK_P.HB   FX\  )&4
M  "$F@  =I\  &BB  !;I0  3ZD  $2M   YL   +[,  ":V   >N04 &+L.
M !>[%@ 7O"  %KPJ !6]-0 4O4  $[Y+ !*^6  2OF< $;]X !"_C  0P*(
M#L"Z  [ X0 /O?L #[S_ !"Z_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !Y
MH0  :Z<  %ZL  !2L0  1;0  #JV   ON0  );P  !V_   5PP  #\8%  O*
M#0 )RA0 ",H=  ?*)P 'RC( !LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK
M  #-R   S.T  ,S_  #+_P !RO\  <K_  '*_P"7E@  BIP  'RC  !NJ@
M8+   %*V  !%N0  .;P  "Z_   CPP  &\8  !/*   -S0  "-$   '4"0
MU X  -45  #6'@  V"<  -DQ  #;/@  W$L  -U;  #>;@  WH0  -^;  #?
MM   WMD  -_W  #?_P  W_\  -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H
M $6_   XP@  +,8  "')   8S0  $-$   O5   $V@   -X   #@ 0  X0D
M .(.  #D$P  Y1L  .<D  #I+P  ZSP  .U+  #N70  [G$  .^)  #PH@
M\+P  /#C  #O^0  \/\  /#_  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(
M   JS   ']   !75   .V@  !]X   #B    Y@   .D   #J    [    .X%
M  #O#   \1   /,7  #U(   ^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8
M /_   #_X0  __4  /_U  #_]0!TK@  9;<  %;   !'R   .,T  "K2   =
MV   $]T   SB   #Y@   .D   #L    \    /,   #T    ]@   /@   #Z
M    _0<  /\-  #_$@  _QL  /\H  #_-P  _TH  /]>  #_=@  _X\  /^F
M  #_N@  _]$  /_1  #_T0#_#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X
M_P!, /\ 60#_ &4 _P!P /\ >@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_
M *L _P"R /\ N@#_ ,4 _P#3 /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X
M_P#^ /\ _@#_ /X _P#_$2$ _Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!(
M /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *<
M_@"N /T M@#\ ,  ^P#- /D X@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U
M /\ ]0#_ /4 _P#_%1T _Q,: /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\
M4 #_ %P _P!G /\ <0#_ 'H _@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J
M /0 L@#R +L \0#( .\ W #N .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\
MZ@#_ .H _P#_&!D _Q85 /\3$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_
M %< _P!B /P ; #X '4 ]0!^ /( A0#Q (P [P"3 .X F0#L *  ZP"F .D
MK@#G +< Y@## .0 U #B .D X0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_
M -T _P#_&Q, _QH0 /\6#@#_$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$
M]P)< /("9@#N G  Z@)X .<"@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;
M!+0 V 7  -8%T #3!N< T CX ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+
M_P#_'Q  _QX+ /\:!P#_&0L _Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6
M .4,80#B#&H W@US -L->P#9#8, U@V* -0-D0#2#9D T Z@ ,\.J0#-#K,
MRPZ_ ,H/T #&$>D PA+Y +\3_P"]$_\!O!/_ ;P3_P&\$_\!NQ/_ ;L3_P'_
M(@P _R$$ /\@  #_(04 _Q\, /\<$0#V&!P [!4H .43-@#?$D, V1-/ -,4
M6@#0%60 S19M ,L6=0#)%WT QQ>% ,48C #$&)0 PAF< , 9I0"^&:\ O1J[
M +L:RP"X&^4!M!SV ;(=_P*P'?\"KQW_ JX=_P*N'?\"KAW_ JX=_P+_)@8
M_R4  /\F  #[)P  \24# / A"P#H'!( WAD= -0;+0#-'3P R!]) ,4@50#!
M(5\ OR)H +PB< "Z(W@ N2-_ ;<CAP&U(X\!M"27 ;(DH &Q)*H"KR2V JTE
MQ@*K)=\"J";S Z4F_P.C)O\#HB;_!*$F_P.A)O\#H2;_ Z$F_P/_*0  _R@
M /8M  #G,   WR\  -DK! #6(@H SB,6 ,8F)P# *#8 NRI$ +@K3P"U+%D
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M"X,\^PN"//\*@3S_"H$\_PF!//\(@3S_"($\_PC_,P  [#H  -I#  #*1P
MOTD  +='  "Q0@  K3X* *9 %P"B0B< GD,U )I$0@&71$P!E$15 I%#70./
M0V0%C4-K!HM"<P>)0GL(AT*$"H5!C@N#09D,@4&E#7]!LPY^0<8.?$'D#GI"
M^0UY0O\,>$+_"WA"_PMX0O\*>$'_"GA!_PKV-@  YD   -%(  ##30  N4X
M +%-  "I20  I$4& )]&$P":2", EDDR ))*/@&/2D@"C$I1 XI)602'26 %
MA4EH!X-(;PB!2'<*?T> "WU'B@UZ1Y4.>$:B#W9&L!!U1L(0<T;@$')']P]Q
M1_\.<4?_#7%'_PQQ1_\+<4;_"W%&_POS.0  X$0  ,Q,  "^40  M%,  *I2
M  "B3@  G4H! )=+$0"332  CT\N (Q/.@&(3T4"A4]. X-/5@2 3ET&?DYD
M!WQ-; EY370+=TQ]#'5,APYS3)(/<4N?$6]+K1)M2[\2;$O<$FM,]1%J3/\/
M:DS_#FI+_PUJ2_\,:DO_#&I+_PSP/0  VT@  ,=0  "Z50  L%@  *56  "<
M4P  ET\  )%0#@",4AP B50K (54-P""5$(!?U1+ WQ44P1Z4UH&>%-B"'52
M:0ES4G$+<5%Z#6Y1A ]L4) 0:E"<$FA0JQ-F4+P395#8$V10\Q)D4/\09%#_
M#V10_PYE3_\-94__#&5/_PSL00  U$P  ,-4  "V60  K%P  *!:  "75P
MD50  (M5# "&5QD @U@G (!9- !]63\!>EE( W=84 1T6%@&<E=?!V]79@EM
M5FX+:U9W#6A5@0]F58T19%2:$F)4J1-@5+H47U33%%Y4\A->5/\17U3_#U]4
M_PY?4_\-7U/_#5]3_PWG1   SU   +]8  "S70  J%\  )Q=  "26P  BU@
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M#5!@_PW93P  PUH  +1C  "I:0  FV@  (]G  "$9P  >64  '-G  !O:0X
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M#$%UG0X_=:X./G7%#CUUZ X^<_T-/G+_#3YQ_PP_<?\,/W#_##]P_PS%7@
MM6D  *EQ  "<=0  C70  (!T  !U=   :78  %YY  !8? $ 5'T. %)^&@!1
M?R8 3W\Q $V .P!,@$,!2H!+ DA_5 )&?UP$0W]E!4%_< 8_?GP(/'Z*"3I^
MF@HY?JP+-W[#"S=]Y@LW>_P+-WK_"S=Y_PHX>/\*.'C_"CAX_PJ^9   L&\
M *5X  "6>0  AWD  'MY  !P>@  9'P  %B   !0@P  2X4* $B&% !'AR
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M 1Z>W0$>G/@"'IK_ AZ9_P,>E_\#'I?_ QZ7_P.J?0  GH4  ).+  "%B@
M=8L  &B.  !;D0  4)4  $:9   [G0  ,J   "JC   BI@D 'Z<1 !ZG&@ =
MJ"0 '*@M !NH-P :J4$ &:E, !BI6  7JF8 %JIV !6JB0 4JIX $ZNT !*K
MTP 2J/4 $Z?_ 1.E_P$3I?\!$Z3_ 1.D_P&CA@  EXP  (V1  !]D@  ;94
M &"8  !4G   2*   #ZD   TIP  *JL  "&N   9L0  $K,'  ^U$  .M1<
M#K4A  VU*P -M38 #+9!  NV3@ *MEP ";9L  BV?P 'MI0 !K:J  6VQ0 &
MMNH ![7_  BT_P (L_\ ";+_  FR_P":C0  D),  (28  !TG   9:   %>D
M  !+J   0*P  #6P   JLP  (;4  !BX   1NP  #+X"  ; "P "P!$  <$9
M  #!(@  PBL  ,(V  ##0@  PU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H
M ,3V  ##_P  P_\  ,/_  ##_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!
MM0  -;<  "FZ   ?O0  %L   !##   *Q@   \H   #,!0  S P  ,T1  #.
M&   SB$  - J  #1-0  TT,  -12  #48P  U7@  -6/  #5IP  UL(  -;I
M  #6_0  UO\  -;_  #6_P"*FP  >Z(  &RI  !>L   4+8  $*Z   TO0
M*,$  !W$   4QP  #<L   ;.    T@   -<   #9    V@4  -P+  #=$
MWQ4  .$=  #C)P  Y3,  .="  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K
M[P  Z_X  .O_  #K_P!]HP  ;JL  %^R  !1N@  0L   #3#   GQP  &\L
M !+/   +TP   M@   #=    X0   .0   #E    YP   .D   #K!P  [0T
M .\1  #Q&0  ]"0  /<Q  #Y00  ^E4  /IJ  #[A   ^YT  /RV  #\T@
M_>T  /WT  #]] !QK   8;4  %*]  !$Q   -,D  ";-   :T@  $-@   C=
M    X0   .4   #H    [    .\   #Q    \P   /4   #W    ^0$  /L(
M  #^#@  _Q4  /\A  #_+P  _T$  /]6  #_;0  _X<  /^@  #_M@  _\H
M /_4  #_U #_"R  _P<> /\ '0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_
M &( _P!M /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\
MM0#_ +X _P#+ /\ X0#_ /  _@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_
M /D _P#_#1T _PL: /\$&0#_ !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X
M_P!H /\ <@#_ 'H _P"" /\ B0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y
M +D ^ #& /8 V0#U .L ] #Y /, _P#R /\ \P#_ /, _P#S /\ \P#_ /,
M_P#_$!D _PX5 /\(% #_ !0 _P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C
M /X ;0#\ '4 ^@!] /D A #W (L ]@"1 /0 EP#S )X \@"D /  K #N +0
M[0#  .L SP#I .8 Z #U .8 _P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_
M$A0 _Q 0 /\,#P#_ Q  _P 5 /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0
M9P#Q '  [P!X .T ?P#K (8 Z@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z
M -T R0#; .  V #P -< _@#5 /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1
M_Q(, /\."0#_"PP _PD2 /\#&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E
M &H X@!R .  >@#> (  W "' -H C@#8 )4 U "< -( HP#0 *P S@"V ,P
MQ #* -D R #M ,< ^P#% /\ Q '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4%
M /\0  #_$ 8 _P\- /\,% #\!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0
MT@-L ,\#= #-!'L RP2" ,H$B0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]
M"-4 NPGL +@+_0"V#/\ M0W_ +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7
M  #_%@  ^Q,& /H0#@#N#!8 XPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG
M ,(.;P#!#G8 OPY^ +T/A0"\#XT NA"5 +@0G0"W$*< M1&R +,1P "R$=4
MKA/N *L4_@"I%?\ IQ7_ *<5_P"F%/\!IA3_ :84_P'_'P  _QP  /H>  #K
M'@  XQP  -\5!0#>#@T TPX8 ,L1* #%$S< P!1$ +P63P"Y%UD MQ=A +08
M:0"S&7$ L1EX *\:@ "N&H@ K!N0 *L;F0"I&Z, IQRN *8<O "D'<\ H1[J
M 9X>_ &<'_\!FQ__ 9H?_P&:'O\!F1[_ 9D>_P'_(@  _R$  .PG  #@*@
MU"D  ,TD  #*' @ Q!D2 +T<(@"W'C$ LR ^ *\A20"M(E, JB-< *@D9 "F
M)&P I"1S *,D>@"A)8(!H"6+ 9XEE &=)9X!FR:J 9DFMP&8)LD"E2?F I(G
M^0*0*/\"CRC_ HXG_P*.)_\"CB?_ HXG_P+_)@  \BD  .,Q  #2-   R#0
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M!G(\_P5R//\%<CO_!7([_P7Q,@  WCT  ,E$  "\2   L$D  *9&  "?00
MFST! )4]$ "1/QT C4$K (I". "'0T( A$-+ 8)#4P& 0UL"?D)B WQ":01Z
M0G$%>$)Z!G9!A =T08\(<D&;"'!!J0EO0;D*;4'0"FQ![@EK0O\(:D+_!VI!
M_P9J0?\&:D'_!6I!_P7M-P  UD(  ,1)  "W30  JTT  *!*  "81P  DT(
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M!UE._P??0P  QTT  +A4  "L60  G5<  )%5  "(5   @5   'M2! !W4Q$
M=%0> '%5*P!O5C8 ;%9  6I62 %H5E "9E97 V167@1B568%8%5O!UU5> A;
M5(0*6521"U=4H Q54[ -5%/%#5-3Y@Q34_P+4U/_"512_PA44O\(5%+_!U12
M_P?:1@  PU   +58  "H6P  F5H  (U8  "$5P  >U0  '96 0!Q5P\ ;ED;
M &Q:* !I6C, 9UL] 65;10%C6TT"85I5 U]:7 1=6F0%6UEL!EA9=@A668()
M5%B/"U)8G@Q06*X-3UC##4Y8Y Q.6/L+3U?_"4]7_PA/5O\(4%;_!U!6_P?3
M2@  P%0  +)<  "C7@  E5T  (E<  !_6P  =ED  '!:  !K7 T :%T8 &9>
M) !D7S  8E\Z &!?0P%>7TL"7%]2 EI?6@-87V$%55YJ!E->= =177\)3UV-
M"DU=G M+7:P,2EW!#$E=XPQ)7/H*25O_"4I;_PA*6O\(2EK_!TI:_P?.3@
MO%@  *Y@  "?80  D6   (5?  ![7P  <%T  &I?  !E80H 8F(4 &!C(0!>
M9"T 7&0W %ID0 %89$@!5F10 E1D5P-29%\$4&1G!4YC<09,8WT(26*+"4=B
MF@I&8JH+1&*_"T1BX0M$8?D*1&#_"41@_PA%7_\'15__!T5?_P?(4@  N%P
M *MD  ";9   C&,  (!C  !V8P  :F(  &-D  !?9@8 6V<1 %EH'0!7:2D
M5FHS %1J/ !2:D4!4&I, 4YJ5 ),:EP#2FIE!$AI;P5&:7H'1&F("$)HF E
M:*D*/VB]"CYHW@D^9_<)/F;_"#]E_P<_9?\'/V3_!S]D_P?#5P  LV$  *=I
M  "6:   AV<  'MG  !Q9P  96@  %QJ  !8; $ 5&X. %)O& !0;R0 3G N
M $UP. !+<4$ 2G%) 4AQ40%&<5D"1'!B T)P; 1 <'@%/G"&!CQOE0<Z;Z8(
M.&^["#AOVP<X;O8'.&W_!SAL_P8Y:_\&.6K_!CEJ_P:]7   KV8  *)M  "1
M;   @FL  '=K  !L;   86X  %=P  !0<P  3'4* $EV$P!'=Q\ 1G<I $5X
M,P!#>#P 0GA$ $%X30$_>%4!/7A> CMX: (Y>'0#-WB"!#5XDP4S=Z0%,G>Y
M!3%XUP4Q=O4%,73_!3%S_P4Q<O\%,G+_!3)R_P6W8P  JFT  )QQ  "+<
M?7   ')P  !G<0  7',  %%W  !*>@  0GT# #]^#@ ]?Q@ /'\C #N +0 Z
M@#8 .8$_ #B!2  V@5  -8%: 3.!9 $Q@7 !+X%_ BV!CP,L@:$#*H&V RF!
MT@,I?_,#*7W_ RE\_P,I>_\#*7O_ RE[_P.Q:@  I70  )5V  "%=0  >'4
M &UU  !A=P  5WH  $Q^  !#@0  .X4  #6("0 RB1$ ,8D; #"))0 OBB\
M+HHX "V+00 LBTH *HM4 "F+7P HBVL )HMZ 22+BP$CBYX!(HNS 2&,S@$A
MBO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@  H7P  (][  " >@  <WH  &9\
M  !;?P  4((  $:&   \B@  -(T  "R1   FDPP ))03 ".4'  BE28 (94O
M ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7A@ 8EYD %Y>N !67R0 6E>X
M%I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!  ![@   ;((  %^$  !4
MB   28L  #^0   UE   +9<  "6:   =G@$ %J , !2A$@ 4H1L $Z$E !*A
M+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -HY( #*.G  JBP  +HN8 #*#^
M  V?_P -GO\ #9W_  V=_P">A   DHD  (.(  !SB   98L  %B.  !,D@
M09<  #>;   NG@  )*(  !RE   5J   #ZL$  JN#  'K1( !JT;  6M)  $
MKBX  JXY  &N10  KE(  *YA  "N<P  KH<  *Z=  "NM   KM4  *WT  "M
M_P  K/\  *O_  "K_P"6BP  C)   'N0  !KD@  798  %":  !$GP  .:,
M "^G   EJP  '*X  !2Q   .M   ";<   &X"0  N X  +D4  "Y'   NB4
M +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1  "\J0  O,0  +SK  "[_@
MN_\  +O_  "[_P"0D@  @Y@  '.;  !CGP  5:,  $>H   [K0  ,+$  "6T
M   ;MP  $KH   R]   %OP   ,,   #$ @  Q0H  ,4.  #&%   QQL  ,@D
M  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.FP  S;4  ,[:  #.]@  S?\
M ,W_  #-_P"&F0  =Z   &FF  !:K   3+(  #ZV   PN0  )+P  !F_   1
MP@  "L4   +)    S    -    #1    T@$  -,(  #5#0  UQ$  -H8  #<
M(0  WRP  .$Z  #B2@  XUT  .1R  #DBP  Y:4  .7   #EY@  Y?@  .7_
M  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_   CPP  %\<   _*   'S@
M -$   #6    W    -\   #@    X@   .0   #F P  Z D  .D.  #L%0
M[AX  /$K  #T.@  ]4T  /9A  #W>0  ^),  /BM  #YQ@  ^>0  /GS  #Y
M\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6S@  #=(   38    W0   .$
M  #D    Z    .L   #M    [P   /$   #S    ]@   /@#  #Z"P  _1$
M /\;  #_*0  _SL  /]/  #_9@  _W\  /^9  #_KP  _\,  /_6  #_U@#_
M!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@ _P!& /\ 4P#_ %X _P!I /\
M<@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_ *$ _P"H /\ KP#_ +D _P#%
M /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H _P#T /\ \ #_ /  _P#_!Q@
M_P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!" /\ 3@#_ %H _P!D /\ ;0#_
M '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T ^0"C /@ JP#W +0 ]0"_ /0
MS@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N /\ Z@#_ .H _P#_"Q0 _P81
M /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\ 20#_ %0 _@!? /L : #Y '
M]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"? .P I@#J *X Z "Y .< QP#E
M -X XP#P .( _@#@ /\ X #_ .$ _P#A /\ X0#_ .$ _P#_#1  _PD- /\!
M# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V $X \@!9 .\ 8@#L &L Z@!R
M .@ >0#F (  Y "& .( C #A ), WP": -T H0#; *H V "T -4 P #2 -,
MT #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_ ,P _P#_$ P _PP' /\# @#_
M  @ _P . /\ %@#V "( \  O .P / #I $@ Y0!3 .$ 7 #> &4 VP!L -<
M<P#4 'H T@"  -  AP#. (X S "5 ,H G0#( *4 Q@"O ,0 NP#" ,L P #E
M +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P _P#_$04 _PX  /\*  #_" $
M_P0* /@ $ #I !H XP H -X -0#9 $$ TP!, ,\ 5@#+ %\ R0!F ,8 ;@#$
M '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$ N "K +8 MP"T ,< L@#@ +$!
M\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_%   _Q   /\/  #R#0  Z@H
M .D#"0#= !( U  ? ,T!+0#( CH Q -% , #4 "]!%D NP5A +D%: "W!F\
MM09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH *H*M0"H"L4 I@O? *0-] "B
M#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P  _Q,  .\8  #D&0  VQ8  -(0
M @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q#E, KQ!; *T08P"K$&H J1%Q
M *@1> "F$8  I1&( *,2D0"A$IL H!.F )X3LP"<$\, FQ3> )<6] "5%O\
ME!?_ ),7_P"2%_\ DA;_ )(6_P#_&@  ]!T  .4C  #5)0  RB0  ,(=  "^
M%@0 NQ 0 +03'0"O%2L JQ8X *<80P"E&4T HAE6 * :70">&V4 G1ML )L<
M<P":''L F!R# )<=C0"5'9< DQZB )(>KP"0'K\ CQ_8 (P@\0&)(/\!B"#_
M 8<@_P&'(/\!AB#_ 88@_P'Z'@  ZR8  -HM  #*,   OBX  +4H  "P(@
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M F,[_P+E-0  S3\  +U&  "N1P  GT4  )5#  ".0   B3P  (0\"@" /10
M?3XB 'H_+@!X0#@ =4%" '-!2@!R05$!<$%9 6Y!8 )L06<":D%P VA!>0-G
M080$94&1!6-!GP5A0:X&8$'"!EY!X@9>0?D%74'_!%U _P-=0/\#74#_ UU
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M!5=*F@952JH'5$J]!U-*W =22O8&4DK_!5))_P122?\#4DC_ U-(_P/400
MP$L  +)1  "@4   DD\  (=.  !^3   >$@  ')*  !N2PT :TT8 &A.) !F
M3B\ 9$\Y &)/0@!A4$D!7U!1 5U06 );3V "64]H U=/<@153WT%4T^*!5).
MF 903J@'3DZ[!TU.V0=-3O4&34[_!4U-_P1-3?\$3DS_ TY,_P/.1   O$X
M *Y4  "<4P  CE(  (-1  !Z4   <DT  &Q/  !H4 L 95$5 &-2(0!A4RP
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M!CY=T 8]7/$%/EO_!#Y:_P0^6O\#/EG_ S]9_P/!4   L5H  *%=  "07
M@EL  '9;  !M6P  85L  %M=  !67@  4F - %!A%P!.8B( 36(L $QC-0!*
M8SX 26-& $=C3@!&8U8!1&-> 4)C: ) 8W,#/F.! SQCD 0Z8J$$.6*T!3AC
MS04X8N\$.&'_!#A@_P,X7_\#.5[_ SE>_P.\50  K5\  )Q@  "+7P  ?5\
M ')?  !H7P  76   %5B  !/9   2V8* $EG$@!':!T 16@G $1I,0!#:3D
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M 2)V_P$B=?\"(G3_ B-T_P*L:   G6X  (IM  ![;   ;VP  &5L  !:;@
M4'$  $5U   ]>   -GP  "Y_ @ I@0T )X(4 ":"'@ E@B< )((O ".#.  B
M@T( (8-+ ""$5@ ?A&( 'H1Q !R$@@ ;A)4 &H2I !B$P0 8@^8 &('] !F
M_P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V<0  :W$  %YS  !4=@  27D
M #]]   W@0  +X0  ">(   @BP4 &XT. !J-%0 9C1X &(XG !>.,  6CCD
M%8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D  Z/NP -C^  #HWZ  ^+_P 0
MBO\ $(G_ !")_P"A>@  CGD  'YW  !R=P  9'@  %A[  !-?@  0H(  #F&
M   OB@  )XX  ""1   8E0  $I@%  Z:#@ -FA0 #)H=  N:)@ +FC  "IH[
M  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":L0 !F<\  IGP  *8_P $E_\
M!9;_  66_P"9@0  AW\  'I^  !K?@  78$  %"%  !%B0  .XT  #&2   H
ME@  'YD  !B=   1H   #*,"  :E"@ !I1   *46  "F'P  IB@  *8R  "G
M/0  ITH  *=8  "G:   IWP  *>1  "FJ   IL,  *7I  "E_   I?\  *3_
M  "D_P"1AP  @H8  '*&  !CB   58P  $F1   ]E@  ,IH  "B>   ?H@
M%Z8  !"I   +K   !*\   "Q!@  L0P  +(1  "R%P  LQ\  +,H  "T,@
MM3\  +5-  "U70  M7   +6&  "UG0  M;8  +7<  "T]P  M/\  +3_  "T
M_P"+CP  >HX  &J1  !;E0  39H  $"?   UI   *J@  ""L   6L   #[0
M  FW   !N0   +T   "^    O@8  +\,  # $   P18  ,(=  ##)P  Q3(
M ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'  #'[   Q_X  ,?_  #'_P"#
MEP  <9H  &&>  !2HP  1:D  #BN   LLP  (+<  !:Z   .O0  !L    ##
M    QP   ,D   #*    S    ,T#  #."0  T X  -(3  #4&P  V"4  -LR
M  #=0@  W50  -YI  #>@0  WIP  -^U  #?V0  W_,  -__  #?_P!WGP
M:*8  %FM  !*LP  .[@  "V[   ?OP  %,(   S&   #R0   ,P   #0
MU0   -D   #:    W    -X   #@    X@4  .0+  #G$   ZA@  .TD  #P
M,@  \40  /)8  #S;P  ](H  /2D  #TOP  ]-\  /3S  #T] !JJ   6Z\
M $RW   ]O0  +<$  !_&   3R@  "\X   #2    UP   -P   #@    Y0
M .<   #I    ZP   .T   #O    \0   /,   #V!P  ^0X  /P6  #_(@
M_S,  /]'  #_70  _W8  /^1  #_J0  _[X  /_8  #_VP#_ !@ _P 6 /\
M%0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_ %H _P!D /\ ;0#_ '4 _P!]
M /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\ JP#_ +0 _@"_ /T SP#[ .<
M^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .< _P#_ !0 _P 1 /\ $0#_
M !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@ /\ : #_ '  _P!X /T
M?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T *X \@"Y /$ QP#O .  [@#R
M .P _P#L /\ [ #_ .L _P#E /\ X #_ -X _P#_ Q  _P . /\ #0#_  T
M_P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!: /@ 8P#U &L \P!R /$ >0#O
M '\ [@"& .P C #J )( Z0"9 .< H #F *D Y "S .$ P #@ -, W@#K -P
M^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_!PT _P ) /\ !@#_  D _P /
M /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H 70#G &4 Y !L .( <P#@ 'H
MW@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M ,T N0#+ ,D R0#D ,@ ]@#&
M /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$  /\   #_  0 _P + /0
M$@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4 %\ T0!G ,X ;0#, '0 R@!Z
M ,@ @ #& (< Q0". ,, E@#! )X OP"H +T LP"Z ,( N0#; +< \ "U /\
MM@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0  /\   #^    ]@ # .@ #0#@
M !< V0 D -$ ,0#- #P R@!' ,8 40## %D P !@ +X 9P"\ &X N@!T +D
M>P"W (( M0") +, D0"R )H L "D *X KP"L +T J@#0 *@ ZP"G /L I@#_
M *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)  #J"0  X@0  -H !P#/ !$
MR  < ,( *0"^ #4 NP!  +< 2@"T %, L@!; +  8@"N &@ K !O *L =0"I
M 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D G0/, )P$Z ":!OD F0?_ )@(
M_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<%0  SA$  ,8-  #"! L O  4
M +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)7 "B"F, H IJ )\+<0"="W@
MG N  )H,B0"9#), EPR> )4-J@"4#;@ D@W, ) .Z@".$/P C!#_ (L0_P"+
M$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0  OQT  +<7  "S$0  L@L- *L-
M&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6$EX E1-E ),3; "2$W, D!1\
M (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07YP""&/L @!G_ '\9_P!_&?\
M?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8  *HB  "E'   I!4( * 4$P";
M%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D B1U@ (@=9P"&'F\ A1YW (,?
M@ ""'XL @!^7 'X@HP!](+( >R#% 'DAY !W(OD =B+_ '4B_P!T(?\ ="'_
M '0A_P#O(0  VRL  ,<Q  "V,0  J2X  * J  ";)@  F"$! )4>$ "0(!L
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M 6,UF@)A-JD"8#:[ E\VU@)=-O,"73;_ EPV_P%<-?\!7#7_ 5PT_P'<,P
MQ3P  +1!  "B0   E3X  (L\  "$.0  ?S8  'LT! !W-1  =#<< '$X)P!O
M.3( ;3D[ &LZ0P!J.DL :#M2 &<[60!E.V$!8SMI 6([<@%@.WT!7CN* EP[
MEP);.Z<"63NX U@[T@-7._$"5CO_ E8[_P)6.O\!5CK_ 58Y_P'4-P  P$$
M *]$  "=0P  D$(  (5   !^/@  >3L  '0Z  !Q.@X ;3P8 &L]) !I/B\
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M T=)R@-&2>P#1DC_ D9(_P)'1_\"1T;_ D=&_P+&0P  MDP  *),  "13
MA$L  'E*  !P20  :48  &1'  !?208 7$H0 %I+&P!83"4 5DPO %5-. !3
M34  4DU( %%.3P!/3E< 3DY? 4Q.:0%*3G,"2$V  D9-CP-%39\#0TVQ T)-
MR -!3>H#04S_ D%,_P)"2_\"0DK_ D)*_P+"1P  LT\  )Y/  "-3@  @$X
M '5-  !L3   8TH  %Y,  !:30( 5DX. %1/& !24"( 45$L $]1-0!.4CT
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M C%:_P(Q6?\",EG_ 3)8_P&V5   I%D  )!8  " 6   <U<  &E7  !@6
M5%D  $Y;  !(70  0U\$ $!@#@ ^81< /6$@ #MB*0 Z8C( .6(Z #AC0@ W
M8TL -F-4 #1C70 S8V@ ,6-V 2]CA0$N8Y8!+&.I 2MCOP$J8^,!*F+[ 2I@
M_P$K7_\!*U__ 2M>_P&Q60  GEP  (M<  ![6P  ;UL  &5;  !<7   45X
M $E@  !#8@  /&4  #AG"@ U:!( -&@; #-I)  R:2T ,6DU "]J/0 N:D8
M+6I/ "QJ60 K:V4 *6MR "AK@@ F:Y, )&NG "-KO0 B:N  (VGY 2-G_P$C
M9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@  !78   36,  $1F
M   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E<D  )')*
M ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP_P ;;_\
M&V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D  #]L   W
M;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D &'Q# !=\
M3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1>/\ $G?_
M !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET   Q>
M*7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[  V'1@ ,
MAU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\ "8+_  F"
M_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J@0  (H4
M !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3/@  DTL
M )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__  "/_P"-
M=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   BC0  &I$  !.4
M   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?-0  H$(  *!0
M  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<_P"&?0
M>'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@  $IX   VA   &
MI    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<  *]%  "O
M5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!A   <80
M &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P   2O    L@
M +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X  # 2
MP%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0  :)   %F4
M  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL   "^    P0   ,0
M  #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5.@  U4P
M -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X  %&D  !#
MJ@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+    SP   -(   #3
M    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L*@  [3P  .U1
M  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT   ZN@
M*KX  !S"   0Q@  !\H   #.    T@   -8   #<    X    .,   #D
MY@   .@   #K    [0   .\   #R @  ]0H  /@1  #\'   _RP  /\_  #_
M50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_ !0 _P 9
M /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\ ?P#_ (4
M_P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T /< _P#V
M /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \ _P 4 /\
M( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y (  ]P"&
M /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D _@#G /\
MYP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0 /\ &P#_
M "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H Z0"  .<
MA@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2 /\ T@#_
M -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P %@#W "(
M\P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z -, @ #1
M (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\ OP#_ +X
M_P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X $0#G !L X0 G
M -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,  >@"_ (
MO0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_ *T _P"N
M /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3 !4 S  A ,@
M+ #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O 'H K0""
M *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X _P"> /\
MG@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9 +@ )0"T
M #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4 GP!\ )X
MA0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0 /\ CP#_
M (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P '@"H "D
MI0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X )$#@ "0
M!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\ @PO_ (,+
M_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=!R( F0DN
M )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.?0"%#H<
M@PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_ '<2_P#O
M%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L CQ$G (P2
M,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y%X, >!>/
M '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:_P#G(
MT"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB ($;+0!^
M'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\ ;B&+ &PA
MF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@)@  R"\
M +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C*0!U)#,
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M 5$UQ@%0-><!3S7] 4\U_P%/-/\!3S3_ 4\S_P'+-@  N#T  *,\  "2/
MA3L  'LZ  !T-P  ;S4  &PS  !H- H 9343 &(V'@!@-R@ 7C<Q %TX.@!;
M.$$ 6CE( %DY4 !7.5< 5CI? %0Z: !3.G, 43I_ 4\ZC0%..IT!3#JN 4LZ
MPP%*.N4!23K\ 4DY_P%).?\!23C_ 4HX_P''.@  LT   )X_  "./P  @3X
M '<]  !P.P  :C@  &8X  !B.0< 7SH1 %P[&P!:.R4 63PN %<]-P!6/3X
M5#Y& %,^30!2/E4 43Y= $\_9@!-/W  3#]] 4H_BP%(/YL!1S^L 44_P0%$
M/^,!1#[[ 40^_P%$/?\!1#W_ 44\_P'#/@  KT,  )I"  "*0@  ?4$  '-
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M 3I&_P$Z1?\!.T7_ 3M$_P&[10  ID@  ))'  ""1P  =D<  &M'  !C1@
M6T,  %9%  !21P  3D@* $Q)$@!*21P 2$HE $=*+@!&2S8 14L^ $-+1@!"
M3$T 04Q6 $!,7P ^3&H /$QV #M,A0$Y3)4!-TRG 39,O $U3-T!-4OW 35+
M_P$U2O\!-DG_ 39)_P&X20  HDL  (Y*  !^2@  <DH  &A*  !?20  54@
M %!*  !,2P  24P' $9-$ !$3AD 0D\B $%/*P! 4#, /U [ #Y00P \44H
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M "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8   \6P
M-ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-' "-C40 B
M9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\ '&#_ !Q?
M_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>   W8   ,6,
M "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL3  9;%@
M%VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_ !-G_P"9
M70  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R9P  *VH  "1M
M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /=5( #G5?
M  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP_P"18@
M?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P  )'(  !UV   7
M>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL  G]8  %_
M9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")9P  >&<
M &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:    0@P
M#(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0  "+7P
MBW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P"";0  <VP  &AL
M  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",   +CP  !)(
M  "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "95@  F6@
M )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,  &%S  !3
M=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !G    *    "A
M    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I3   J5X  *ER
M  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^  !+@@
M/H<  #*-   GD@  '9<  !2<   .H   !Z0   "H    JP   *X   "O
ML    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(  +ME  "[
M?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#D   -I<
M "J=   ?H@  %:<   VL   %L    +0   "W    NP   +X   "_    P
M ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8  #0;@
MT8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0  +J<  "&M
M   6LP  #K@   :\    P    ,,   #&    RP   ,T   #.    T    -$
M  #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I7P  ZG@
M .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD  !F^   .
MP@  !,4   #*    S0   -$   #8    VP   -\   #@    X@   .0   #F
M    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^3P  _V<  /^"
M  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\ (@#_ "\
M_P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"& /\ C #^
M ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\ \P#_ .D
M_P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_ "H _P V
M /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /( A@#P (T
M[P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_ -X _P#1
M /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0 _0 P /L
M.P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@ (< W@".
M -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L _P#% /\
MOP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X [0 J .H -0#G
M $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (  R "' ,8
MCP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W /\ LP#_
M +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C -( +@#/ #D
MRP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"! +0 B0"R
M )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\ I0#_ *0
M_P#_    _P   /4   #J    W@   -  "@#( !( P@ = +X * "[ #, N0 ]
M +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0 @@"B (P
MH "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_ )< _P#_
M    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P J  V *8
M/P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4 (8 D@"1
M )  G ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_ (@ _P#Y!@
MZ0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P )@ .0"6
M $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($ A0", (0
MF "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q#@  WA4
M ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T",P"* SP
MB 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F) '@)E@!W
M"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@  T!X  +D=
M  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0" #38 ?@X^
M 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1E !L$:(
M:Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0  + D  "@
M(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$ =!4Z '(6
M00!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C&I\ 81JO
M & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I  "8*0
MC"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU &D>/0!H
M'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP 62*L %<B
MP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2+@  A2T
M 'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E.0!@)D$
M7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ % IO@!/
M*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@  @#$  '8P
M  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9+#T 6"Q$
M %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DONP!(+]L
M2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4  '(T  !K
M,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H 4C)" %$R
M20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"--8 0C3T
M $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW  !F-@
M83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_ $LW1@!*
M-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=, /#GS #PX
M_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B.0  73<
M %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\1 !%/$L
M1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR #<\_P X
M._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0  6#L  %,Z
M  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00! 0$D /D%1
M #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #) _P S0/\
M,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0   5#\  $X_  !*
M0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148 .45. #A&
M6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N1/\ +D/_
M "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#  !$10
M048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI, #)*50 P
M2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\ *$C_ "E'
M_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(   _2@  .TL
M #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M04@ J4%P
M*%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_ "--_P"A
M20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [3@  -5   #%2
M!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "163@ B5ED (59E
M !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2_P";30
MADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P  ,54  "M8   F
M6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754 &%UA !==
M<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"440  @%$
M '!1  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL  "5>   ?80,
M&F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=  ]E:P .
M97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50  >E4  &M5
M  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9:   $VL%
M !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N90 $;G8
M FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H  &9:  !<
M60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3<0  #G0#  IW
M"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@  >&\  'B$
M  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>  !97@
M35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X   * "
M@0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@  (1\  "$
MDP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !29   1V<
M #QK   Q;P  *',  "!W   8?   $7\   R#   &AP   (H   ", P  C D
M (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S  "2BP
MD:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0  /W$  #1V
M   J>P  ((   !>%   0B0  "XT   21    E0   )@   "9    F@,  )L(
M  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B@   HIH
M *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX  "R$   A
MB@  %X\  !"4   *F0   9T   "@    I    *<   "H    J0   *H   "L
M!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P  M8X  +6H
M  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4   8F@
M$)\   FD    J0   *T   "P    M    +<   "X    N0   +L   "\
MO@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\  ,J;  #*
MN   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1JP  ";
M  "U    N0   +T   #!    Q@   ,@   #)    RP   ,P   #.    T
M -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,  #FJ
MY<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +O    ,$   #%
M    R0   ,T   #2    U@   -H   #;    W@   .    #B    Y    .<
M  #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]EP  _:\
M /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V /\ 0@#_
M $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T ^@"4 /D
MG #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7 /\ S@#_
M ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\ /0#_ $<
M_@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ". .H E@#H
M )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\ P@#_ +X
M_P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S $$ [P!+
M .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "( -0 D #2 )@
MSP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_ +, _P#_
M    _P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A #L W !% -4
M30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"] )( NP"<
M +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *< _P#_
M_P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^ ,  1P"\
M $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L J "5 *<
MH "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_    _
M .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T 0 "J $@
MJ !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0 F ". )8 F@"5
M *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\    [P   -L
M  #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@": $( F !)
M )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@ E0"& *(
MA0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D  ,<(  "W
M!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P BP!# (D
M20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y )T > "L
M '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0  "I$
MG@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^ 'T 1 !\
M $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH ; .J &L#
MNP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">%@  DQ4
M (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)0 !R"48
M< I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI &$-NP!@
M#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0  B1P  ($:
M  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I$$( 9Q%)
M &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4N@!6%-4
M517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(  'DA  !S
M'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX 7AA% %T8
M2P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.&]  31SQ
M $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F  !L)
M:"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]! %8@2 !4
M($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT 1B/O $4C
M_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F*0  8B8
M %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F10!.)DP
M3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM #\H_P _
M*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0  72L  %HH
M  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(+$D 1BQ1
M $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM_P Z+?\
M.BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\  %4L  !1
M+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4< 03%/ $ Q
M5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U,?\ -3'_
M #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,  % P  !,,0
M23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9, #HV50 Y
M-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\ ,#7_ # T
M_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'-0  1#8#
M $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z4P T.UT
M,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_ "PX_P"D
M.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@  /SL  #P\
M"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N/UH +4!F
M "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]_P"?.P
MBCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@  .3\  #9!"  T
M00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@ )T5C "5%
M<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":/@  A3\
M '1   !G0   7$   %-   !,0   1D   #Y!   X0P  -$4  #!& P M1PT
M*T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA !]*;P =
M2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@  @$(  '!#
M  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F30D )$X0
M ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0:P 64'P
M%%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8  &M&  !?
M1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @4P, '%4, !I6
M$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /5WD #E>,
M  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*  !;2@
M44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60  %5P' !%>#0 0
M7A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G, !5Z&  ->
MFP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !73@  3DX
M $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#  QF"P (9Q
M!F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>   !FE0
M9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@  2U(  $)3
M   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N"0  ;PX  &\2
M  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !QCP  <*<
M &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<  #Q:   R
M70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X!0  > L  'D.  !Z
M$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B   ?*$  'RZ
M  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C   K9P
M(VL  !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8  (4+  "&#P
MB!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD  (JS  ")
MV   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D<P  &G@
M !-]   -@0  !H4   ")    C0   )    "2    D@   )0%  "5"@  EPX
M )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK  ":R0
MFO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0  $H<   R,
M   $D0   )4   "9    G0   *    "A    H@   *0   "E 0  IP<  *D,
M  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "NO@  K>8
M *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@   .=
MH@   *8   "J    K@   +    "Q    LP   +0   "V    N    +H$  "\
M"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP  Q=$  ,/R
M  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N    L@
M +<   "[    OP   ,(   #"    Q0   ,8   #(    R@   ,T   #/
MT@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T  .'B  #@
M] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_    Q    ,@
M  #.    T0   -0   #5    V    -H   #=    WP   .(   #D    YP
M .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$  #XX0#_
M  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@ _P!2 /\
M6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U *  \P"J
M /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,( _P#_  0
M_P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!, /D 5 #W
M %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H X@"D .
ML #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_    _P
M /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@ 3@#D %8
MX0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "= ,8 J #$
M +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_    _P   /\
M  #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #* $\ QP!6
M ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +( H0"P *\
MK@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P   /<   #H
M    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@ L@!/ +
M50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"= *< FP"X
M )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0   #2
MQ0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $( H !) )X 3P"<
M %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$ BP"P (H
MQ0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]    LP
M *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X 20", $\
MB@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J 'L O !Z
M -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0  H@   )L
M  "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^ $D ?0!/
M 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X M@!M ,X
M; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL  (P'  "(
M @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0 <0!* '
M4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A ,D 8 #I
M &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /  !\#0
M>0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-& &8$3 !E
M!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8 5@GG %8*
M^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q$P  ;A
M &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-2 !<#4\
M6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J $T0_0!-
M$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@  9A<  &04
M  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4$DP 4Q-3
M %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46_@!%%O\
M117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT  %P:  !;
M%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@ 2QI0 $H:
M6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^'/\ /AO_
M #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?  !4'0
M4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!- $,@50!"
M(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\ ."'_ #@A
M_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/(@  3"('
M $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF4P \)EP
M.B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_ #,E_P"E
M*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@  1R<$ $0G
M#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V*UH -2ME
M #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ_P"A+
MBRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L  #\L"P ]
M+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@ ,#!C "XP
M<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<+@  AS
M '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ"0 W,1
M-C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A "DU;@ G
M-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0  @S,  '(T
M  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R-@X ,#<3
M "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y;  A.GP
M(#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8  &XW  !A
M-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL *CP1 "D\
M&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;/WD &C^,
M !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY  !>.@
M4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@ )$(. ")"%  A
M0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'< $T2* !)$
MG@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:/0  4#T
M $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@, !M)$0 921<
M&$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'  U*FP ,
M2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60   34   $5
M   _0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 24!, $5 9
M !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!  50E@ #4*L
M E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0  $-#   \
M1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!  "E@5  A8
M'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8D0  5Z<  %?
M  !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'   X2
M,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX  %\2  !?&
M8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(  %^[  !?
MX@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R3@  *U$
M "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</  !H$P  :1D
M &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV  !HW0
M:/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M5@  )%D  !U=
M   68   $&0   QG   &:@   &X   !O P  < @  '$-  !R$   =!0  '4;
M  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !TTP  <_4
M '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P  '6,  !5G   0
M;   "G    1S    =@   'H   !\    ? ,  'X(  !_#   @1   ((4  "$
M&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0  @O$  ('_
M  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU   )>0
M 7X   "!    A0   (@   "*    BP   (T!  ".!@  D L  )$/  "3%
ME1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0  D^H  )+_  "2
M_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$    B0   (X
M  "2    E@   )@   ":    FP   )T   "?    H0,  *,(  "E#0  IQ,
M *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X  "F_P!6
M:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6    F@   )\   "C
M    IP   *H   "K    K0   *\   "Q    LP   +4   "X!0  N@P  +T2
M  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\_@!.=
M0'D  #)_   EAP  &8X  !"5   'G    *(   "G    K    +    "U
MN0   +P   "]    OP   ,$   ##    Q@   ,@   #*    S0(  - +  #5
M$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&@@  .(D
M "N0   =F   $J    JG    K@   +0   "Y    O@   ,(   #(    RP
M ,X   #/    T@   -0   #6    V@   -T   #?    X@   .8   #J"@
M[Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8 _P # /\
M!0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_ %T _P!D
M /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X LP#K ,0
MZ0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P   /\   #_
M  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %< \0!= .X
M8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5 +L T@#4
M ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\   #_
M_P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7 -< 70#4
M &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +( NP#& +D
MZ "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U    ZP !
M .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T 5@"[ %P
MN0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[ *4 V@"C
M /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?    T    ,<
M!P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F %4 I !:
M *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R )( R0"1 .L
MD0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'    N@   +$  @"K
M  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4 $\ D@!4 )
M6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"  .  @ #Y
M '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J    *    "9  <
ME0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!. ($ 5 !_
M %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\ <0#Q '
M_P!P /\ < #_ '$ _P#A    Q    +    "B    EP   )$   "+  ( A@ +
M (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ', 3@!R %0
M< !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H &0 _0!C
M /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^    >P & '<
M#@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F $\ 90!6
M &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@ ^ !8 /\
M6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8  &T "@!K
M !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L 6P!2 %H
M60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !. _\ 3@3_
M $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+ P!C!@P
M8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/ %$(5@!0
M"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\ 10S_ $4,
M_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:#@8 6@P-
M %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.50!(#UX
M1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_ #X0_P"I
M&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P  4A$* % 0
M$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!%%L /Q1E
M #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5_P"C'
MC1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8& $D6#@!'
M%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@ .1IC #<;
M;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"='P  B"(
M '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<# !!'!(
M/QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@ #$@;0 O
M('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@  A"4  ',F
M  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [(1  .2(6
M #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE:P J)7H
M*"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<  &\I  !B
M*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X -"<4 #(G
M&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D*G@ (RJ*
M "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK  !?+
M5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP +BP1 "TL&  L
M+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8 '2^( !PO
MFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;+P  42\
M $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q%0 F,1P
M)3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2& !8TF@ 4
M,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0  3C(  $8R
M  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @-QD 'S<@
M !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$YF  0.:T
M#CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0  $0T   ]
M-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14 &#T< !<]
M(P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +/JD "C[!
M  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W   [-P
M-3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8 !%#'P 0
M1"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4  D.]  -#
MX  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X.@  ,SH
M "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*&P )2B,
M"$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY  !)W0
M2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0  +SX  "E
M   C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1%P  41X  %$F
M  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U  !0V   4/4
M $__  !/_P!L0   74$  %%!  !'00  0$   #E    R00  *D,  "1&   >
M2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P  61D  %HA  !:
M*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0  6/0  %?_
M  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-   84
M$E,   Y6   *60  !%P   !>!   7PD  & -  !A$   8A4  &,;  !D(P
M9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(  &'_  !@
M_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5   260  #5T
M  A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P'0  <28
M '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_  !L_P!:
M3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,9   !F@   !K
M    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]%@  ?QX  ( H
M  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z_P!65
M3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #<@   '8   !Z
M?0   (    "#    A    (8   "' @  B0<  (L,  "-$   D!8  )(?  "2
M+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!560  2%H
M #M=   O80  )&8  !EL   1<@  "G<   )]    @@   (8   "+    C@
M )$   "3    E0   )<   "9    FP   )T$  "?"@  H@\  *06  "F(0
MIC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.80  0&0  #-I
M   G;@  &W4  !%\   +@P   (D   ".    DP   )@   "=    H0   *0
M  "E    IP   *D   "K    K0   +    "R    M0@  +@.  "\%@  O"4
M +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7   "MW   ?
M?P  $X8   N.   !E0   )L   "A    I@   *L   "P    LP   +<   "W
M    N@   +P   "_    P0   ,0   #'    R@   ,T%  #1#@  U!D  -0K
M  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(   7D0
M#9D   .@    IP   *X   "S    N    +T   #"    Q@   ,H   #*
MS0   ,\   #2    U0   -D   #=    WP   .,   #G!0  ZP\  .P?  #M
M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_  D _P .
M /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\ 90#] &L
M^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@ ., ^ #B
M /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_    _P ) /\
M$ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I &0 Y@!J
M .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. ,D \ #' /\
MQ0#_ +L _P"T /\ K0#_ *D _P#_    _P   /\   #_    ^P " /8 #0#Q
M !, [0 > .P * #I #( XP [ -T 1 #8 $L TP!1 -  6 #- %T RP!C ,D
M: #& &\ Q !V ,( ?@"_ (< O "2 +H GP"W *T M0#! +( Y "Q /T KP#_
M *P _P"E /\ H #_ )P _P#_    _P   /L   #N    Y    -P " #3 !
MSP 8 ,L (@#) "L Q@ T ,$ /0"] $0 N@!+ +< 40"U %8 L@!< +  80"N
M &< K !N *H =@"H '\ I@"* *, E@"A *4 GP"V )T T0"< /, FP#_ )P
M_P"6 /\ DP#_ )  _P#_    ]@   .<   #3    Q@   +T  P"X  T LP 3
M +$ ' "O "4 K@ N *D -@"F #T HP!$ *$ 2@"? $\ G0!5 )L 6@": &
MF !F )8 ;@"4 '< D@"! )  C@". )P C "M (H PP") .@ B #_ (D _P"'
M /\ A0#_ (( _P#S    XP   ,P   "\    L    *<   "A  @ G@ / )L
M%@"9 !\ F  G )8 +P"3 #< D0 ] (X 0P", $D BP!. (D 5 "' %D A0!@
M (0 9P"" &\ @ !Z 'X A@!\ )0 >@"D 'D N !X -@ =P#W '@ _P!X /\
M=P#_ '4 _P#F    RP   +<   "H    G@   )8   "/  0 BP , (@ $@"'
M !D A0 A (0 *0"" #  ?P W 'T /0!\ $, >@!( 'D 30!W %, =@!9 '0
M80!R &D <0!S &\ ?P!M (T ; "= &H KP!I ,@ : #M &D _P!I /\ :0#_
M &D _P#2    N    *4   "7    C0   (8   "!    ?  ( 'D #@!W !0
M=@ < '0 (P!S "L <0 Q &\ -P!N #T ; !# &L 2 !J $X : !4 &< 6P!E
M &, 8P!M &( > !@ (< 7P"6 %T J != +X 7 #D %P ^P!< /\ 7 #_ %P
M_P#"    J@$  )@#  ")!   ?P(  '@   !T    <  $ &T # !K !$ :0 7
M &@ '@!F "4 90 L &, ,@!B #@ 8  ] %\ 0P!> $D 7 !/ %L 5@!: %X
M6 !H %< <P!5 ($ 5 "1 %( HP!1 +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V
M!P  GPD  (T+  !^#   <PL  &P*  !H!P  90,  &, !P!A  T 7P 3 %T
M&@!< "$ 6P G %D +0!8 #, 5@ Y %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D
M $T ;P!, 'T 2@"- $D GP!( +( 1P#, $< [P!& /\ 1P#_ $< _P"L#
ME0X  (,0  !U$   :Q   &,/  !>#@  6PP  %H) @!9! H 5P / %4 %0!3
M !P 4@ C %$ *0!/ "\ 3@ U $T!.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#
M;0!# WH 0@.+ $ #G  _ Z\ /@/( #T$Z@ ]!?P /0;_ #X&_P"D$   CA(
M 'P3  !N%   9!0  %P3  !6$@  4Q$  %$.  !0# 4 4 D, $\'$0!-!Q<
M2P@? $D()0!("2L 1PDQ $8). !$"CX 0PI% $(*30! "U4 /PM? #T+:P \
M"WD .@R* #@,G  W#*\ -0S' #4,Z0 U#?T -0W_ #8,_P"=$P  AQ4  '87
M  !I&   7A@  %88  !0%P  314  $H3  !)$0  20X' $@-#@!&#1, 1 T:
M $,.(0!"#B@ 0 XN #\.-0 ^#SP /0]# #L02P Z$%0 .!!> #80:P T$'D
M,A"* #$0G  O$+  +1#) "T1[  M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D
M'   61P  %$<  !,&P  1QH  $08  !#%0  0A," $$2"P! $1  /A(7 #P2
M'@ [$R4 .A,K #@3,@ W$SD -A1  #042  S%%$ ,11< # 5:  N%7< +!6(
M "H5F@ H%:X )Q7' "85Z@ G%?\ *!7_ "D5_P"1&@  ?1P  &T>  !@'P
M5A\  $X?  !('@  0QT  $ <   ^&@  /1@  #L7!P Y%@X .!<4 #87&P U
M&"( ,Q@H #(8+P Q&38 ,!D] "X91@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:
MF0 B&JT (1K% " :Z  A&OX (AK_ ",:_P"-'0  >1\  &DA  !<(@  4B(
M $HB  !$(0  /R$  #P@   Y'@  .!L  #4<!  T' T ,AP2 # =&  O'1\
M+ATE "T>+  K'C, *AX[ "D?0P G'TT )A]7 "0?9  B'W( (!^$ !\?EP =
M'ZL &Q_# !L?YP ;'_T '1__ !X>_P")(   =2(  &4C  !9)   3R4  $<E
M  !!)   /",  #@C   U(@  ,R   # @ 0 N(0H +"$0 "LA%0 J(AP *"(C
M "<B*0 F(S  )2,X ",C00 B)$H (215 !\D80 =)'  &R2" !DDE0 7)*H
M%B3! !4DY0 6)/P %R/_ !DC_P"%(@  <20  &(F  !6)P  3"<  $0G   ^
M)P  .28  #4F   Q)0  +B0  "LE   I)0< )R8. "4F$P D)QD (R<@ "(G
M)P A*"X ("@V !XH/@ =*$@ &RE3 !DI7P 8*6X %BF  !0IE  2*:@ $2G
M !$HY  1*/L $RC_ !0G_P" )0  ;B<  %\H  !3*0  22H  $(I   [*0
M-BD  #(H   N*   *B@  "8I   D*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;
M+2L &BTS !@M/  7+44 %BY0 !0N70 2+FP $2Y^ ! ND@ .+J< #2V]  TM
MWP -+?D #BS_ ! L_P!\*   :BH  %LK  !0+   1BP  #\L   Y+   -"L
M "\K   K*P  )BP  "(N   ?+P  '# ) !HQ#@ 9,1, %S$: !8R(0 5,B@
M%#(P !,R.0 2,T, $3-. ! S6P .,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (
M,O0 "C'_  LQ_P!W*P  9BT  %@N  !-+P  0R\  #PN   V+@  ,2X  "TN
M   I+@  (S   !\R   ;,P  %S4% !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L
M  XX-0 -.#\ ##A*  LX5P ).&4 !SAV  4XB@ #.)\  3>U  $WTP "-_$
M S;_  4V_P!S+@  8C   %0Q  !),0  03$  #DQ   T,0  +S   "LP   E
M,@  (#,  !LV   7.   $SH" ! \"0 -/0X ##T3  L]&0 */2$ "3TI  @]
M,0 &/CL !3Y&  ,^4@ !/F$  #YR   ^A@  /9P  #VR   ]T   //   #S_
M   \_P!M,@  73,  % T  !&-   /C0  #<T   R,P  +3,  "<T   B-@
M'3@  !@Z   4/0  $#\"  U!"  )0PT !D01  -$%@ "1!T  $0D  !$+0
M1#8  $1!  !$3@  1%P  $1M  !$@0  1)@  $.O  !#S0  0O   $+_  !"
M_P!H-@  6#<  $PX  !#.   .S<  #4V   P-@  *3<  ",Y   >.P  &#T
M !-    00@  #44!  A'!P #20P  $D/  !*$P  2QD  $L@  !+*   2S(
M $L]  !,20  3%<  $MH  !+?0  2Y0  $JL  !*R@  2>\  $G_  !)_P!B
M.@  5#L  $D[  ! .P  .3H  #,Y   L.@  )3P  !\_   900  $T0  !!'
M   ,20  "$P   )/!0  4 H  % -  !1$   4A4  %0;  !4(P  5"P  %0W
M  !41   5%(  %1C  !4=P  5(\  %.H  !2Q@  4NT  %'_  !1_P!</P
M3S\  $4_   ^/@  -ST  "\^   G0   ($,  !E&   320  #TP   M/   &
M4@   %0   !7 @  6 <  %D+  !:#@  6Q$  %T6  !>'0  7R8  %\Q  !>
M/0  7DP  %Y=  !><0  78D  %VC  !<P0  6^L  %K_  !:_P!61   2T,
M $-"   \00  ,D(  "E%   A2   &DL  !-.   .4@  "E4   -9    6P
M %X   !@    8@(  &,&  !E"@  9@X  &@1  !J%P  :Q\  &LI  !K-@
M:T4  &M6  !J:@  :H(  &F=  !HNP  9^<  &;_  !E_P!12   2$@  $%&
M   W1P  +$H  "--   ;40  $U4   Y9   (70   6$   !D    9P   &H
M  !L    ;@   '    !R!0  <PD  '4-  !W$0  >A@  'LA  ![+@  >CT
M 'I.  !Y8@  >7D  'B6  !WLP  =>   '3\  !S_P!.30  1TP  #M-   P
M3P  )E,  !Q8   37   #6$   9F    :@   &\   !R    =@   'D   !\
M    ?0   '\   "!    @P(  (8'  "(#   BQ$  (X8  ".)   CC,  (U$
M  ",6   BV\  (J,  ")J@  B,\  (;W  "%_P!-40  05,  #15   I6@
M'E\  !1E   -:@  !7    !V    >P   '\   "#    AP   (H   "-
MC@   )$   "3    E0   )@   ":!0  G0P  * 1  "C&@  HR@  *(Z  "A
M3@  H&4  *"!  ">H   G<$  )ON  ":_P!&60  .5P  "UA   A9P  %FX
M  YU   %>P   ($   "'    C0   )(   "6    F@   )T   "?    H0
M *0   "F    J    *L   "N    L0,  +0+  "X$0  N1X  +DO  "X0P
MMUH  +5V  "TEP  M+4  +'B  "P_  _9   ,6D  "5O   8=P  #W\   :'
M    C@   )0   ":    H    *4   "J    K@   +$   "R    M0   +<
M  "Z    O    +\   ##    Q@   ,D   #."@  TA,  -(C  #1-P  T$\
M ,YJ  #-B@  RJL  ,O+  #+[P W<0  *7@  !V    1B0  ")$   ":
MH0   *<   "M    LP   +D   "^    P@   ,4   #&    R0   ,P   #.
M    T@   -4   #:    W@   .$   #E    Z@L  .L7  #J*P  ZD,  .I>
M  #J>@  ZYD  .NU  #KU0#_    _P   /\  0#_  < _P - /\ $@#_ !L
M_P E /\ +P#_ #H _P!# /\ 2P#_ %, _P!: /T 8 #[ &8 ^@!K /@ <@#V
M '@ ] "  /$ B0#O )( [ "= .D J@#F +P XP#< -\ ]P#= /\ S #_ +X
M_P"U /\ L #_ *T _P#_    _P   /\   #_    _P & /\ #0#_ !0 _P ?
M /\ *0#[ #, ]P ] /, 10#O $T [ !3 .@ 60#E %\ XP!E .  :@#= '$
MV@!X -8 @ #2 (H SP"5 ,P H@#( +( Q0#) ,( [0#  /\ NP#_ +  _P"H
M /\ I #_ *$ _P#_    _P   /T   #Z    ^    /  "0#L !$ Z  9 .<
M(P#E "T W@ V -8 /@#1 $8 S0!, ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P
M +P > "Y ($ MP"- +0 F@"Q *D K@"\ *P X0"J /P J #_ *  _P"9 /\
ME@#_ )0 _P#_    ^0   /(   #G    VP   -$ ! #*  T QP 4 ,0 '0#"
M "8 OP O +L -P"W #\ M !% +$ 2P"N %$ K !6 *H 7 "H &$ I@!H *,
M< "A 'D GP"$ )T D0": *  F "Q )8 S "5 /$ E #_ )$ _P"+ /\ B #_
M (8 _P#W    [    -X   #)    O    +0   "O  H JP 0 *D %P"H "
MIP H *( , "? #@ G  ^ )H 1 "8 $H E@!/ )0 50"3 %H D0!A (\ : "-
M '$ BP![ (D B "' )< A0"H (, O@"! .0 @ #_ (  _P!\ /\ >P#_ 'D
M_P#I    UP   ,$   "Q    I@   )T   "7  4 E  - )( $@"0 !H CP B
M (X *@"+ #$ B0 X (< /@"% $, @P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D
M> !S '8 ?P!U (X <P"? '$ LP!P -  ;P#V &\ _P!O /\ ;0#_ &P _P#:
M    OP   *P   ">    DP   (P   "%    @@ ) '\ #P!^ !4 ?0 < 'P
M) !Z "L =P Q '4 -P!T #T <@!" '$ 2 !O $T ;@!3 &P 6@!K &( :0!L
M &< > !F (8 9 "7 &( J@!A ,( 8 #K &$ _P!A /\ 80#_ &  _P#%
MK0   )L   "-    @P   'P   !W    <@ % '  # !N !$ ;  7 &P '@!K
M "4 :0 L &< ,0!F #< 9  ] &, 0@!B $@ 8 !. %\ 50!= %T 7 !F %H
M<@!9 (  5P"0 %8 HP!5 +D 5 #> %0 ^P!4 /\ 50#_ %4 _P"V    GP
M (T   !_    =0   &X   !I    9@ ! &, "0!A  X 8  3 %\ &0!> "
M70 F %L + !: #( 6  W %< /0!6 $, 50!) %, 4 !2 %@ 40!A $\ ; !.
M 'H 3 "* $L G !* +$ 20#. $D \P!) /\ 20#_ $H _P"J 0  E 4  (('
M  !T"   :@@  &,&  !>!   6P   %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B
M %$ * !0 "T 3@ S $T . !, #X 2P!% $H 3 !( %0 1P!= $8 : !$ '4
M0P"% $$ F !  *L 0 #% #\ Z@ _ /\ 0 #_ $  _P"@"   B@L  'D-  !L
M#0  80T  %H-  !5"P  4@D  % &  !/ @@ 3@ - $P $@!+ !< 2@ > $D
M(P!' "D 1@ O $4 - !$ #H 0@!! $$ 2 !  %  /@!: #T 9  \ '( .@""
M #D E  X *< -P"^ #8 XP V /D -@#_ #< _P"8#0  @PX  '(0  !E$0
M6Q$  %,0  !.$   2@X  $@-  !'"@, 1P<* $4$#@!$ A, 0@(: $$"( !
M R4 /@,K #T$,0 \!#< .P0^ #H%10 Y!4X -P57 #8%8@ T!G  ,@:  #$&
MD@ P!J4 +P6[ "X%W0 N!O4 +0?_ "X'_P"1$   ?1$  &P3  !?%   510
M $X4  !($P  1!(  $$0  ! #@  0 T& $ *#  ^"1  / D6 #L*'  Y"B(
M. HH #<++@ V"S4 -0L[ #,+0P R#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H
M#*4 )PR[ "4,W0 E#?4 )@W_ "<-_P"+$@  =Q0  &<6  !;%P  41@  $D7
M  !#%P  /Q4  #P4   Z$@  .1$! #D/"  X#@T -PX2 #4.&  T#A\ ,@XE
M #$/+  P#S( +Q Z "T00@ L$$L *A!5 "@080 F$&\ )!"  ",0DP A$*<
M'Q"] !X0X  >$?< 'Q#_ " 0_P"&%   <Q<  &,9  !7&@  31L  $4:  !
M&@  .QD  #@8   U%@  -!0  #,2!  R$@L ,1(0 "\2%0 M$AP +!,B "L3
M*0 J$S  *!,W "<4/P F%$@ )!13 "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[
M !@5W@ 8%?@ &13_ !H4_P""%P  ;QH  %\<  !3'0  2AT  $(=   \'0
M-QP  #0;   Q&@  +QD  "X6   L%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D
M&"T (Q@T "(9/0 @&48 'AE1 !T970 ;&FL &1I\ !<:CP 5&J, %!FZ !(9
MVP 3&?8 %!G_ !48_P!]&@  :QT  %P?  !0(   1R   #\@   Y'P  -!\
M #$>   M'0  *QP  "D;   G&P4 )1L, "0<$0 B'!8 (1P= " =(P ?'2H
M'ATR !P>.@ ;'D0 &1Y. !<>6P 6'FD %!]Z !(>C0 1'J( $!ZX  X>V  /
M'O4 $!W_ !$=_P!Z'0  9Q\  %DA  !-(@  1"(  #PB   V(@  ,B$  "XA
M   J(   )R   "0?   B( ( (" * !XA#P =(10 '"$: !LB(0 9(B< &"(O
M !<B.  5(T$ %"-, !(C6  1(V< $"-X  XCBP -(Y\ #".T  LCT  +(O
M#"+_  TA_P!V'P  9"(  %8C  !+)   020  #HD   T)   +R,  "LC   H
M(P  )",  " C   =)   &R4' !DF#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G
M-0 1*#\ $"A*  XH5@ -*&0 #"AT  HHAP )*)L !R>Q  4GS  &)^P !R;^
M  @F_P!Q(@  8"0  %,F  !()P  /R<  #<F   Q)@  +28  "DE   E)0
M(B4  !TG   9*   %BH$ !0K"P 2+!  $2P4 ! L&P 0+"( #BPI  XM,@ -
M+3L "RU&  HM4@ (+6  !BUP  0M@P "+9@  "RN   LR0  +.L  2O\  (K
M_P!M)0  72<  $\H  !%*0  /"D  #4I   O*   *R@  "<G   C)P  'R@
M !LJ   7+   $RX" ! P"  .,0T #3$2  PQ%P +,1X "C$F  @R+@ ',C<
M!3)"  ,R3@ !,EP  #)L   R?P  ,I4  #&L   QQP  ,.H  ##\   P_P!H
M*0  6"H  $PK  !!+   .2P  #(K   M*P  *2H  "4J   @*P  '"P  !<N
M   3,   $#("  XT!P *-PP !S<0  4W%  #-QL  C<B   W*@  .#,  #@^
M   X2@  .%@  #AH   X?   -Y(  #>I   VQ0  -NH  #;]   U_P!C+
M5"X  $@O   ^+P  -BX  # N   K+0  )RT  "(M   =+P  &#$  !0S   0
M-0  #C<!  HZ!P &.PL  CP.   ]$@  /A<  #X>   ^)@  /B\  #XZ   ^
M1@  /E0  #YD   ^=P  /H\  #VG   ]PP  /.D  #S]   [_P!>,   4#$
M $0R   [,@  -#$  "XP   I+P  )#   !XR   9-   %#8  ! Y   -.P
M"CT   5 !0  00H  $(-  !#$   1!0  $4:  !&(@  1BL  $8U  !&00
M1D\  $9?  !&<P  18H  $6D  !$P   0^@  $/^  !"_P!8-   2S4  $$U
M   Y-0  ,C0  "TS   F-   (#4  !HX   4.@  $#T   U    )0@  !$4
M  !' P  2 <  $H+  !+#@  3!$  $X5  !/'   3R4  $\O  !//   3TH
M $]:  !.;0  3H4  $V@  !,O   2^<  $O^  !*_P!3.0  1SD  #XY   W
M.   ,3<  "DW   A.0  &SP  !4_   00@  #$4   =(   "2@   $T   !/
M    400  %('  !4"P  50X  %<1  !9%P  6A\  %DI  !9-@  640  %E4
M  !89P  6'\  %>:  !6MP  5>,  %3]  !4_P!./0  0ST  #P\   U.P
M+#P  "0^   <00  %40  !!(   +2P  !4X   !1    5    %<   !9
M6P   %T"  !>!@  8 L  &(.  !D$@  9Q@  &<B  !F+@  9CP  &9-  !E
M8   97<  &23  !CL0  8=T  &#\  !?_P!)0@  04$  #H_   P0   )D,
M !Y&   52@  $$X   I2   #5@   %H   !=    8    &,   !E    9P
M &D   !K 0  ;04  &\*  !R#@  =1(  '<;  !V)@  =C4  '5&  !T60
M=&\  '.+  !RJ0  <,T  &_W  !N_P!&1@  0$4  #5&   J2   ($P  !=1
M   05@  "5H   %?    8P   &@   !K    ;P   '(   !U    =P   'D
M  ![    ?0   ( #  "#"   A@T  (D3  "*'0  BBL  (D\  "(3P  AF8
M (6!  "$H   @L(  ('P  !__P!&2P  .DP  "Y/   C4P  &%@  !!>   )
M9    &D   !O    =    '@   !\    @0   (0   "'    B    (L   ".
M    D    ),   "6    F0<  )T-  "A%   H"$  * Q  ">1   G5L  )QV
M  "9E@  F;4  );E  "5_@ _4@  ,E4  "9:   ;8   $6<   EM    =
M 'L   "!    A@   (L   "0    E    )<   "9    G    )\   "A
MI    *<   "J    K0   +$&  "U#0  N!8  +<F  "V.0  M5   +1J  "R
MB0  L*H  *[/  "M]0 W7   *V$  !YH   3<   "W@   "     AP   (X
M  "5    F@   )\   "D    J    *P   "M    L    +,   "U    N
M +L   "_    PP   ,<   #+!0  T0X  -$;  #0+@  ST4  ,U?  #+?@
MR9X  ,B^  #%Z0 O:0  (W   !9Y   -@0   8L   "3    FP   *(   "H
M    K@   +0   "X    O0   ,    #"    Q0   ,@   #+    S@   -$
M  #6    VP   -\   #D    Z 8  .L1  #J(P  ZCH  .E4  #G<@  Y9,
M ..S  #CU #_    _P   /\   #_  0 _P + /\ $ #_ !< _P A /\ *P#_
M #4 _P ^ /\ 1P#_ $X _P!5 /P 6P#Z &$ ^ !F /8 ;0#T ', \@![ .\
MA #M (X Z@"9 .8 IP#C +D WP#5 -L ]P#6 /\ P #_ +( _P"J /\ I0#_
M *( _P#_    _P   /X   #\    _  # /X "P#_ !$ _P : /T ) #Y "X
M]  X /  0 #L $@ Z0!. .8 5 #B %H WP!? -P 90#8 &L U !R -  >P#-
M (4 R@"1 ,< G@## *X P #% +T ZP"[ /\ L #_ *0 _P"< /\ F #_ )4
M_P#_    ^@   /0   #Q    \@   .H !0#G  X X@ 5 .$ '@#A "@ V  Q
M -  .0#+ $  R !' ,4 30#" %, OP!8 +T 7@"[ &0 N0!K +8 <P"T 'P
ML0"( *X E0"K *0 J "X *8 W "C /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y
M    [P   .<   #?    SP   ,@   #!  H OP 1 +P & "[ "$ N0 J +0
M,@"Q #H K@!  *L 1@"H $P I@!1 *, 5@"A %P GP!C )T :@"; ', F0!^
M )8 C "4 )L D@"M )  QP". /  C0#_ (8 _P"  /\ ?0#_ 'P _P#M
MX    -$   "_    LP   *H   "F  4 H@ - *$ $P"@ !L GP C )L *P"8
M #( E0 Y ), /P"1 $0 CP!* (X 3P", %4 B@!; (@ 8P"& &L A !V ((
M@@"  )( ?@"C 'P N@!Z .$ >0#_ '< _P!R /\ < #_ &\ _P#=    RP
M +8   "G    G0   )0   ".  $ BP * (D $ "( !4 AP = (< )0"$ "P
M@@ R '\ . !] #T >P!# 'D 2 !X $X =@!4 '4 6P!S &, <0!N &\ >@!M
M (D ; ": &H K@!I ,P : #V &< _P!E /\ 9 #_ &, _P#*    M    *$
M  "3    B0   ((   ![    >  % '8 # !U !$ =  8 ', 'P!R "4 <  L
M &X ,@!L #< :@ \ &D 0@!H $@ 9@!. &4 50!C %T 8@!F &  <@!> (
M70"2 %L I0!: +X 60#I %D _P!9 /\ 6 #_ %@ _P"Y    H@   )    "#
M    >0   '$   !M    :0 ! &8 "0!E  X 9  3 &, &0!C "  80 F &
M+ !> #$ 7  W %L / !: $( 6 !( %< 3P!6 %< 5 !@ %, ; !1 'D 4 "*
M $\ G@!. +0 30#: $T ^P!- /\ 30#_ $T _P"J    E    ((   !U
M:P   &0   !@    70   %H !0!8  P 5P 0 %8 %0!6 !L 50 A %, )P!2
M "P 40 Q $\ -P!. #T 30!# $P 2@!* %( 20!; $@ 9@!& ', 10"$ $0
MEP!# *P 0@#) $( \0!" /\ 0P#_ $, _P">    B0   '@#  !J!   800
M %H#  !5 0  4@   %   @!.  D 30 - $P $0!+ !< 2@ < $D (@!( "<
M1P M $4 ,@!$ #@ 0P ^ $( 10!! $T /P!6 #X 80 ] &X .P!^ #H D0 Y
M *8 . "_ #@ Z  X /\ .0#_ #D _P"5 P  @ <  &\)  !B"@  6 L  %$*
M  !,"   208  $<#  !&  8 1  + $, #P!" !, 00 8 $$ '@ _ ", /@ I
M #T +@ [ #0 .@ Z #D 00 X $D -P!2 #8 70 T &H ,P!Z #( C  Q *$
M, "X "\ W@ O /D +P#_ #  _P","0  > P  &@-  !<#@  4@X  $L.  !%
M#0  00P  #\*   ^" ( /00( #P!#0 [ !  .@ 5 #D &@ X "  -@ E #4
M*P T #  ,P W #( /@ Q $8 +P!0 "X 6@ M &< *P!W "H B0 I )T * "S
M "< T0 G /( )P#_ "< _P"&#   <@X  &,0  !6$0  31$  $41  ! $
M/ \  #D.   W#0  -@L$ #8("@ U!@X - 42 #($%P Q!1P , 4B "\%*  N
M!BX +08T "L&/  J!D0 *0=. "<'60 F!V4 ) =U ",'AP B!YL ( :P " &
MRP ?!>T 'P;^ !\'_P" #@  ;1$  %X2  !2$P  2!,  $$3   [$P  -Q(
M #01   R$   , \! # -!@ P"PL +PH0 "T*%  L"QD *@L? "D+)0 H#"L
M)PPR "8,.@ D#$, (PQ- "$-6  @#64 '@UU !P-B  :#9P &0VQ !@,R@ 7
M#.L %PW\ !@,_P![$0  :1,  %H5  !.%@  118  #T6   X%0  ,Q4  # 4
M   M$P  *Q(  "H0 P J#P@ *0X- "@.$0 F#A8 )0\= "0/(P C#RD (1 Q
M " 0.0 >$$( '1!, !L06  9$&8 %Q!V !40B0 4$)X $A"S !$0S@ 1$.X
M$A#^ !(0_P!W$P  914  %<7  !+&   0AD  #H9   T&   ,!<  "P7   I
M%@  )Q4  "84 0 E$@0 (Q(+ "(2#P A$A0 (!(: !X3(  =$R< '!,N !H3
M-@ 9%$  %Q1* !845@ 4%&0 $A1T !$4AP 0%)P #A2Q  T4R@ -%.L #A/^
M  X3_P!S%0  81@  %,:  !(&P  /QL  #<;   R&@  +1H  "D9   F&
M)!@  "(7   @%@$ 'A8( !T6#0 ;%Q( &A<7 !D7'0 8&"0 %A@K !48-  4
M&#T $AE( !$95  0&6( #AER  T9A  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7
M_P!O&   7AH  % <  !%'0  /!T  #4=   O'0  *AP  "8;   C&P  (1H
M !X:   <&@  &AL% !@;#  6'!  %1P5 !0<&P 3'"( $ATI !$=,0 0'3L
M#AU%  T>40 ,'EX "AYM  D>@  ''I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K
M&@  6QT  $T>  !"'P  .A\  #(?   M'P  *!X  "0>   A'0  'AT  !P=
M   8'@  %1\" !,@"0 2(0X $"$2 ! A&  .(1\ #B(F  TB+@ ,(C< "B)!
M  DB30 '(EH !2)I  ,B?  !(I$  "*H   AP   (>4  "#X   @_P!G'0
M5Q\  $HA  ! (0  -R(  # A   J(0  )B   "(@   ?'P  '!\  !D@   6
M(0  $B," ! D!P .)@P #"80  LF%0 *)AP "28B  @F*@ &)S, !"<]  ,G
M20 !)U8  "=F   G>0  )X\  ":F   FOP  )>0  "7Y   D_P!C(   5"(
M $<C   ])   -"0  "XC   H(P  )"(  "$B   >(0  &B(  !<C   3)
M$"8"  XH!P +*@L ""L.  8K$P $*Q@  BL?  $L)P  +#   "PZ   L10
M+%,  "QC   L=@  +(P  "ND   KO@  *N0  "KZ   I_P!?(P  4"4  $0F
M   Z)@  ,B8  "LF   F)0  (R0  !\D   ;)   %R4  !0G   1*0  #BL"
M  LM!@ '+PL !# .   P$0  ,14  #$<   Q(P  ,BP  #(V   R0@  ,D\
M #)?   R<@  ,8D  #&B   PO   ,.0  "_[   O_P!:)P  3"@  $ I   W
M*0  +RD  "DH   E)P  (28  !PG   8*   %"H  !$L   .+@  "S !  <R
M!0 #- D  #4,   V#P  -Q(  #@8   X(   ."@  #@R   Y/0  .4L  #E;
M   X;@  .(4  #>?   WN@  -N0  #7\   U_P!5*@  2"P  #TL   T+
M+2L  "@J   D*0  'BH  !DK   4+0  $2\   TQ   *-   !S8   (X!
M.@<  #L*   ]#0  /A   $ 4  ! &P  0"0  $ N  ! .0  0$<  $!6  !
M:0  0(   #^;   ^MP  />,  #S\   \_P!0+P  0R\  #DO   R+P  +"T
M "<L   @+0  &B\  !4Q   1,P  #38   DX   %.P   #T   !  0  000
M $,'  !%"P  1@X  $@1  !*%@  2AX  $HH  !*-   24(  $E1  !)9
M2'L  $B7  !'M   1N   $7\  !$_P!*,P  /S,  #8S   P,0  *C   ",Q
M   <,P  %C4  !$X   -.P  "#X   -!    0P   $8   !(    2@   $P$
M  !.!P  3PL  %$.  !4$@  51D  %4B  !4+@  5#P  %1+  !37@  4W0
M %*0  !1K@  4-<  $_[  !._P!%-P  /#<  #4V   O-   )C4  !XW   7
M.@  $3T   Q!   '1    $@   !*    30   %    !3    50   %<   !8
M @  6P8  %T+  !?#@  8A,  &(;  !B)P  8C0  &%%  !@5P  8&T  %^)
M  !=IP  7,P  %KX  !9_P!!/   .CL  #0Y   J.@  (3P  !A    10P
M#$<   9+    3P   %,   !6    60   %P   !?    80   &,   !E
M9P$  &H%  !M"@  < X  ',5  !R(   <BT  '$]  !P3P  ;V4  &Z   !M
MGP  :\$  &GQ  !H_P _0   .3X  "X_   D0@  &D8  !)*   ,3P  !%0
M  !8    70   &$   !E    :    &L   !N    <0   ',   !U    >
M 'L   !^ P  @0H  (4/  "'%P  AB0  (4T  "$1@  @ET  (%V  !_E@
M?K8  'SG  !Z_P _1   ,T4  "A(   =3   $U(   Q7   #70   &,   !H
M    ;0   '$   !V    >@   'X   "!    @P   (8   ")    BP   (X
M  "2    E0$  )D)  ">$   GAH  )TI  "</   FE(  )AL  "6BP  E*H
M )+4  "0^@ X2P  +$X  "!3   560  #6    -G    ;@   '0   !Z
M@    (0   "*    C@   )(   "5    EP   )H   "=    H    *,   "G
M    JP   *\   "T"0  N!   +<>  "U,   LT8  +%@  "O?@  K*   *O!
M  "I[@ Q50  )%L  !AA   .:0  !7$   !Y    @0   (@   "/    E
M )H   "?    I    *@   "I    K    *\   "S    M0   +D   "]
MP0   ,8   #+    T0H  -,4  #1)0  T#L  ,U4  #*<0  R)(  ,6S  ##
MW@ I8@  '&D  !%Q   '>P   (0   "-    E0   )T   "C    J0   *\
M  "T    N0   +P   "^    P@   ,4   #(    S    -    #4    V@
M -\   #D    Z@   .X,  #M&@  ["\  .I)  #H90  YH8  .2E  #BQ@#_
M    _P   /\   #\  $ _  ( /X #@#_ !0 _P = /\ )@#_ #  _P Z /\
M0@#_ $D _@!0 /L 5@#Y %P ]@!B /0 : #R &\ \ !V .T ?P#J (D YP"5
M .0 HP#@ +4 VP#0 -4 ]@#* /\ M@#_ *@ _P"? /\ F@#_ )8 _P#_
M^P   /8   #S    \P   /8 "0#Z  X _0 6 /L ( #W "H \@ S .T .P#I
M $, Y@!) .( 3P#> %4 VP!; -8 8 #2 &< SP!N ,P =@#) (  Q@", ,(
MF@"_ *H NP#! +@ Z0"V /\ IP#_ )H _P"2 /\ C0#_ (H _P#Z    \0
M .H   #G    YP   .0  0#@  L VP 1 -H &@#; ", T0 L ,H - #& #L
MP@!" +\ 2 "\ $X N@!3 +@ 60"V %\ LP!F +$ ;@"N '< K "# *D D0"F
M *$ HP"U *  V "> /L E0#_ (L _P"% /\ @ #_ 'X _P#O    XP   -H
M  #3    Q@   +\   "Y  8 MP . +0 % "T !T LP E *X +0"K #0 IP [
M *0 00"A $8 GP!, )T 40"; %< F0!> )< 90"5 &X DP!Y )  AP". )<
MC "I (D Q "( .\ A0#_ 'P _P!V /\ <P#_ '( _P#@    T    ,8   "V
M    J0   *$   "=  $ F0 * )@ $ "8 !8 EP > )0 )@"1 "T CP T (P
M.@"* #\ B !% (< 2@"% %  @P!6 ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@
M '4 M@!S -\ <@#_ &X _P!I /\ 9P#_ &4 _P#,    O@   *L   "=
MDP   (H   "%    @@ % (  #0!_ !$ ?P 8 (  ( !] "8 >@ M '< ,P!U
M #@ =  ^ '( 0P!P $D ;P!/ &T 5@!L %X :@!H &@ =0!G (0 90"6 &0
MJP!B ,D 80#V &  _P!< /\ 6P#_ %H _P"]    J0   )<   ")    ?@
M '@   !S    ;P ! &T "0!L  X :P 3 &L &0!J "  :  F &8 + !E #(
M8P W &( / !@ $( 7P!( %T 3P!< %< 6@!A %D ;0!7 'L 5@". %4 H@!3
M +L 4@#I %( _P!0 /\ 3P#_ $\ _P"M    F    (8   !X    ;@   &<
M  !C    8    %T !0!<  L 6P 0 %L %0!; !L 6@ A %@ )@!6 "P 5  Q
M %, -@!2 #P 40!" $\ 20!. %$ 30!; $L 9@!* '0 20"% $@ F0!' +$
M1@#8 $8 _ !% /\ 10#_ $4 _P"?    B0   '@   !L    8@   %L   !6
M    4P   %$  @!/  @ 3P - $X $0!. !8 30 < $P (0!* "8 20 L $@
M,0!' #< 10 ] $0 1 !# $P 0@!5 $  8  _ &X /@!^ #T D@ \ *D .P#'
M #L \P [ /\ .P#_ #P _P"3    ?@   &X   !A    6    %$   !,
M20   $<   !%  4 1  + $, #@!# !( 0P 7 $( '0!  "( /P G #X +  ]
M #( .P X #H /P Y $< . !0 #< 6P U &@ - !X #, C  R *( ,0"\ #$
MYP Q /\ ,@#_ #, _P")    =@,  &8%  !9!P  4 <  $D&  !#!0  0 ,
M #X!   \  , .P ( #H #0 Z !  .0 4 #D &0 W !X -@ C #4 *  T "X
M,P T #( .P P $, +P!, "X 5P M &0 + !S "L AP J )P *0"U "D W  I
M /L *0#_ "H _P"!!   ;@@  %\*  !3"P  2@L  $(+   ]"@  .0D  #8(
M   U!0  - (& #, "@ R  X ,0 1 #$ %0 P !H +P ? "X )  L "H *P P
M "H -P I #\ * !) "< 5  F &  ) !O ", @@ B )< (0"N "$ S  A /,
M(0#_ "( _P!["0  : P  %H-  !.#@  10X  #T.   X#0  ,PT  # ,   N
M"P  +0D# "T&"  L! P *P(/ "H!$@ I 1< * $< "< (0 F "< )0 M "0
M-  C 3T (@%& "$!40 ? 5T '@%L !P!?P ; )0 &@"J !H Q0 : .L &0#_
M !H _P!U#   9 X  %4/  !*$   0!   #D0   S$   +P\  "P.   I#@
M)PT! "<,!0 G"@H )@@- "4'$  D!A0 (@89 "$&'P @!R0 'P<K !X',@ =
M!SH ' A$ !H(3P 9"%P %PAK !8(?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%
M_P!Q#@  7Q   %$1  !&$@  /1(  #82   P$@  *Q$  "@1   E$   (Q
M "(.!  A#0< (0P+ " +#@ ?"Q( '0L7 !P,'  ;#"( &@PI !D,,0 8##D
M%@U# !4-3P 3#5P $@UK ! -?@ /#9( #@VG  T,O@ -#.  #0SU  T,_P!M
M$   7!$  $X3  !#%   .A0  #(4   M%   *!,  "43   B$@  (!$  !X1
M P <$ 4 ' \( !L/#  :#A  &0\4 !</&@ 6#R$ %1 H !00,  2$#D $1!$
M ! 04  .$%T #1!K  P0?  +$)  "1"E  @0O  '$-\ !Q#T  </_P!I$0
M6!0  $L5  ! %@  -Q8  # 6   J%@  )A4  "(5   ?%   '1,  !H3 @ 9
M$@0 %Q(& !82"@ 5$@X %!(2 !(2&  1$QX $1,E ! 3+@ .$S< #11   P4
M2P +%%@ "11G  <4>  &%(T !!2C  ,3NP "$]T  1+T  (2_P!E$P  518
M $@7   ]&   -!@  "T8   H&   (Q<  " 7   =%@  &A4  !@5 @ 6%00
M%!4% !(6"  1%@T $!<0  X7%0 .%QL #1<B  P7*0 +&#( "1@\  <81P %
M&%0 !!AC  (8=0 !&(L  !>A   7N0  %]T  !;U   6_P!A%@  4A@  $4:
M   [&@  ,AH  "L:   E&@  (1D  !X8   ;&   &!<  !87 @ 4%P, $A@%
M ! 9!P .&PL #!L/  L;$P *&Q@ "!P?  <<)@ %'"\ !!PX  (<1   '5$
M !U@   =<@  '(@  !R@   ;N0  &]X  !KV   :_P!>&   3QH  $(<   X
M'   +QT  "D<   C'   'QL  !P:   9&0  %QD! !09 @ 2&@, $!L$  X=
M!P ,'@L "1\.  8@$0 %(!8  R <  $A(P  (2L  "$U   A0   (4X  "%=
M   A;P  (88  "">   @N   ']X  ![X   >_P!:&P  2QT  #\>   U'P
M+1\  "<>   B'0  'AT  !L<   8&P  %1L  !(<   0'0( #A\$  PA!@ )
M(@H !2,-  (D$   )1,  "49   F(   )B@  "8R   F/0  )DH  "9:   F
M;   )H,  "6<   EMP  )-\  "/Y   C_P!5'@  1R   #PA   R(0  *R$
M "4@   @'P  '1X  !H=   6'@  $QX  ! @   .(0  #","  @E!0 %)PD
M "@+   J#@  *Q$  "P6   L'0  +"4  "PN   L.@  +$<  "Q6   L:0
M+(   "N:   JM0  *=\  "G[   H_P!1(@  1",  #@D   O)   *",  ",B
M   ?(0  '"   !<@   3(0  $",   XD   +)@  ""@   0J!   + <  "X)
M   P#   ,0\  #,3   S&0  ,R$  #,J   S-0  ,T,  #-2   S90  ,GL
M #*7   QLP  ,-X  "_[   N_P!,)0  /R8  #4G   M)@  )R4  "(D   >
M(P  &2,  !0D   1)@  #B@   LJ   '+    R\    Q @  ,P0  #4'   W
M"@  .0T  #H0   [%0  .QT  #LF   [,0  .SX  #M.   [8   .G<  #F2
M   XL   -]L  #;\   U_P!'*0  .RH  #(J   K*0  )2<  "$F   ;)P
M%2@  !$J   .+   "B\   8Q   !-    #8    X    .P$  #T$   _!P
M00H  $,.  !%$0  11@  $4A  !%+   1#D  $1(  !$6P  0W$  $*-  !!
MJP  0-(  #_Z   ^_P!"+0  ."X  "\M   I*P  )"H  !TJ   7+   $2X
M  TQ   )-   !#<    Z    /    #\   !!    1    $8   !( P  2@<
M $P+  !.#@  4!,  % <  !0)P  3S0  $]#  !/50  3FH  $V&  !,I
M2LH  $GX  !(_P ^,@  -3$  "XO   I+@  ("X  !DQ   2,P  #C<   DZ
M   "/0   $    !$    1P   $D   !,    3P   %$   !3    50$  %@&
M  !:"P  70X  %\5  !>(   7BP  %T\  !<3@  6V,  %I^  !8G0  5\
M %7R  !4_P Z-@  ,S0  "TR   D,P  &S8  !,Y   ./0  "$$   !%
M20   $P   !0    4P   %8   !9    6P   %T   !@    8@   &4   !H
M!0  :PL  &\0  !O&   ;B4  &TT  !M1@  :UL  &IU  !HE   9K8  &3I
M  !B_P X.0  ,C<  "@Y   >.P  _^+P $E#0U]04D]&24Q%  <*%3\   Y$
M   '20   $T   !2    5@   %H   !>    8@   &4   !H    :P   &T
M  !P    <P   '8   !Y    ?00  ($+  "%$0  A!T  ((L  " /@  ?E0
M 'YK  ![B@  >JH  '?6  !U_0 X/0  +#X  ")!   71@  #TL   =1
M5P   %P   !B    9@   &L   !O    =    '@   ![    ?@   (    "#
M    A@   (H   "-    D0   )8#  ";#   G1,  )LA  ":,P  ETD  )1B
M  "3?P  D*   ([%  ",\P Q1   )4@  !I-   04P  "%H   !A    :
M &X   !T    >0   '\   "$    B0   (T   "1    DP   )8   "9
MG0   *    "D    J    *P   "R P  MPT  +<7  "U*   LCX  +!6  "L
M<P  JI0  *FT  "EY0 J3P  'E0  !);   *8@   &H   !S    >P   ((
M  ")    C@   )0   ":    GP   *0   "F    J0   *T   "P    LP
M +<   "[    P    ,4   #+    T00  -4.  #3'0  T#(  ,U+  #*9@
MQH<  ,*I  #!RP B6P  %F(   QK   !=    'T   "'    D    )<   ">
M    I    *L   "Q    M@   +H   "\    P    ,0   #(    RP   ,\
M  #4    V@   .    #F    ZP   /$&  #P$P  [B<  .P_  #J6P  YWH
M .2;  #@NP#_    ^P   /8   #S    ]  % /8 # #Z !$ _P 9 /\ (@#_
M "P _P U /\ /0#_ $4 _ !, /H 4@#W %@ ]0!> /, 9 #Q &H [@!R .P
M>@#I (4 Y0"1 .$ H #= +( V #. -( ]@#! /\ K0#_ )X _P"6 /\ D #_
M (P _P#Z    \@   .P   #I    Z0   .P !0#R  P ^  2 /< &P#U "4
M\  N .L -P#F #X X@!% -T 2P#8 %  TP!6 -  7 #- &( R@!J ,@ <@#%
M 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\ G0#_ )  _P"( /\ @P#_ (
M_P#P    Y0   -X   #:    VP   -P   #8  < T0 . -$ %0#2 !X RP G
M ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +( 50"P %L K@!A *P :0"I ',
MIP!_ *0 C0"A )X G@"R )L U0"9 /P C #_ (( _P![ /\ =@#_ '0 _P#B
M    TP   ,H   #'    O    +8   "P  $ KP + *P $0"M !@ K0 @ *@
M* "D "\ H  V )T / "; $( F0!' )< 30"5 %, DP!9 )$ 80"/ &H C !U
M (H @P"( )0 A@"G (, P@"" /  ? #_ ', _P!M /\ :@#_ &@ _P#/
MP0   +D   "M    H    )@   "4    D0 & )  #0"0 !( CP 9 (X (0"+
M "@ B  O (8 -0"$ #H @@!  (  10!^ $L ? !2 'H 60!X &( =@!L '0
M>0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@ /\ 7@#_ %P _P"^    L0
M *    "2    B0   ((   !\    >@ ! '@ "0!W  X >  4 '< &@!T "$
M<@ G '  +0!N #, ;  X &L /@!I $0 : !* &8 40!D %H 8P!D &$ < !?
M '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_ %$ _P"P    GP   (T
M  !_    =    &X   !J    9@   &4 ! !C  L 8P 0 &, %0!C !L 80 A
M %\ )P!= "P 7  R %H -P!9 #T 5P!# %8 2P!5 %, 4P!< %( : !0 '<
M3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_ $< _P"B    C0   'P   !N
M    90   %X   !9    5P   %4  0!4  < 4P - %, $0!4 !8 4@ ; %$
M(0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !' $P 1@!6 $0 80!# '  0@"!
M $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4    ?P   &\   !C
M60   %$   !-    2@   $@   !'  0 1P * $8 #@!& !$ 1P 6 $4 ' !$
M "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $< .@!0 #D 6P X &D -P!Z #8
MCP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(    =    &4   !8    3P
M $@   !#    /P   #T    \  ( /  ' #L #  [  \ .P 2 #H %P Y !P
M-P A #8 )@ U "P -  R #, .0 Q $$ , !+ "\ 5@ N &, +0!S "P B  L
M *  *P"[ "L Z@ K /\ *P#_ "P _P!_    ;    %T!  !1 @  2 ,  $ #
M   [ @  -P   #0    S    ,@ % #( "0 R  T ,0 0 #$ $P P !@ +P =
M "T (@ L "@ *P N "H -0 I #T * !& "< 40 F %X )0!N "0 @@ C )D
M(P"S "( W@ B /\ (P#_ "0 _P!W    900  %8&  !+!P  0@@  #H(   U
M!P  , 8  "T%   L P  *P # "H !P I  L *0 . "D $0 H !4 )P 9 "8
M'@ E "0 )  J ", ,0 B #D (0!# "  3@ ? %H '@!I !T ?  < ), &P"L
M !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*  !&"P  /0L  #4+   P"P
M*PH  "@)   E"   ) <" ",$!@ C @D (@$, "( #P A !( (  6 !\ &P >
M "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F !8 >  5 (\ %0"F !0
MPP 4 .X % #_ !4 _P!K"   6PL  $T,  !"#0  .0T  #$-   L#0  )PT
M ",,   A#   'PL! !X*!0 =" @ '08+ !P%#0 <!!  &P04 !D$&  9!!X
M& 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C !$#=0 0 HH $ &B  \ O  /
M .4 #P#^ !  _P!G"P  5PT  $D.   ^#P  -0\  "X/   H#P  ) X  " .
M   =#@  &PT! !D-!  8# < & L) !<)#  7"0X %@D2 !4)%@ 4"1L $PDA
M !()*  2"3  $0DZ ! )10 /"5( #@EA  T)<P ,"(@ "PB?  H'MP *!ML
M"@7V  H$_P!C#0  4PX  $80   [$0  ,A$  "L1   E$   (1   !T0   :
M#P  & \! !8.!  5#@< % T) !,-"P 3# T $@P0 !$,%  0#!D $ P?  \,
M)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &#88 !0V=  0,M  ##-(  @SQ
M  (+_P!?#@  4!   $,1   X$@  +Q(  "@2   C$@  'A$  !L1   8$0
M%1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.  X/$@ -#Q< #! =  P0)  *
M$"P "1 V  @000 &$$X !1!=  ,0;P !$(0  !"<   /M   #M0   [S   .
M_P!<$   31(  $ 3   V%   +10  "84   A$P  '!,  !D2   6$@  %!$#
M !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2$0 *$A4 "1(:  @2(0 &$RD
M!1,S  ,3/@ "$TL  !-:   3;   $X(  !*;   2M   $=<  !'U   1_P!8
M$@  210  #T5   S%@  *Q8  "05   ?%0  &A0  !<4   4$P$ $Q($ !$2
M!P 0$@D #A()  T2"0 +$PH "10-  <5#P &%A, !!88  ,6'P "%B<  !<P
M   7.P  %T@  !=8   7:@  %H   !:9   5M   %=D  !3W   3_P!5%
M1A8  #H7   P&   *!@  "(7   =%@  &18  !85   3% , $A,& ! 3!P /
M$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$  !H6   ;'   &R0  !LM   ;
M.   &T8  !Q5   ;9P  &WT  !N7   :LP  &=L  !CY   7_P!1%@  0Q@
M #<9   N&@  )AH  " 9   ;&   &!<  !46 0 3%04 $14$  \5!  -%@0
M"Q<%  D9!@ &&@@  AP*   >#0  (!   " 3   @&0  ("$  "$J   A-0
M(4(  "%2   @9   ('H  !^5   ?L0  'ML  !WZ   <_P!-&0  /QL  #0<
M   K'   )!P  !X;   :&@  %Q@  !07 @ 2%P( $!@!  T9 0 +&@( "!P#
M  4=!  "'P8  "$(   C"P  )0X  "81   F%@  )AX  "<G   G,@  )S\
M "9.   F8   )G<  "62   DKP  (]H  "+[   A_P!('0  /!X  #$?   H
M'@  (AX  !T<   9&P  %AH  !(:   0&P  #1P   L=   ('P  !"$   $C
M @  )00  "<&   I"0  + P  "X/   N$P  +AH  "XC   N+@  +CL  "Y*
M   M7   +7(  "R.   KK   *M0  "G[   H_P!$(   ."$  "XA   F(0
M("   !P>   8'0  %!T  ! >   .'P  "R$   <C   #)0   "<    I
M+ $  "X#   P!@  ,PH  #4-   V$0  -A<  #8?   V*0  -C8  #9%   U
M5P  -6T  #2)   RJ   ,<\  ##Z   O_P _)   -"0  "LD   D(P  'R$
M !L@   6(   $2$   XC   *)0  !B@   (J    +0   "\    R    -
M #<    Y P  .P8  #X*  ! #@  01(  $$:  ! )0  0#$  $!    _4@
M/F<  #V"   \H@  .L<  #GX   X_P Z*   ,"@  "DG   C)0  'R,  !@D
M   2)0  #B@   HJ   %+0   #     S    -@   #@    [    /@   $
M  !"    10(  $<&  !*"@  30X  $T5  !,'P  3"L  $LZ  !*3   26$
M $A\  !'FP  1;\  $/S  !"_P V+   +2L  "<I   C)P  &R@  !0J   .
M+0  "C    0S    -P   #H    ]    0    $,   !&    2    $L   !-
M    4    %,!  !6!@  60L  %L0  !;&0  6B4  %DT  !81@  5UH  %5T
M  !4DP  4K4  %#J  !/_P S,   +"X  "<L   >+0  %B\  ! R   *-@
M SH    _    0@   $8   !)    3    $\   !2    50   %@   !:
M70   &    !C    9P8  &L,  !L$@  :QX  &LL  !I/0  9U(  &9J  !D
MB0  8:L  %_<  !=_P Q,P  +#$  "(R   9-0  $3D   H]   "0@   $<
M  !,    4    %0   !8    6P   %\   !B    90   &@   !K    ;@
M '$   !U    >0   'T&  ""#0  @A8  ( D  !^-0  ?$D  'MA  !X?P
M=I\  '/&  !P]P Q-@  )C@  !P[   20   "T4   )+    40   %8   !;
M    8    &4   !I    ;@   '(   !V    >0   'P   !^    @@   (4
M  ")    C@   ),   "8!@  G X  )L:  "8*P  ED   ))9  "1<P  C94
M (NU  "(Z  K/@  ($$  !5'   -30   E0   !;    80   &@   !N
M<P   'D   !^    @P   (@   ",    CP   )(   "5    F0   )T   "A
M    I0   *H   "P    MP<  +@1  "U(0  LC4  *]-  "J:0  J(@  *:H
M  "BT0 C2   &$X   Y4   $7    &0   !M    =0   'P   "#    B0
M (\   "5    FP   *    "C    I@   *D   "M    L0   +4   "Y
MO@   ,0   #*    T@   -H*  #6%@  TBD  ,Y!  #*7   Q7P  ,*=  #!
MO0 <50  $5P   =E    ;@   '<   !_    B    )    "8    GP   *4
M  "M    LP   +@   "Z    O@   ,(   #&    R@   ,X   #3    V@
M .    #G    [0   /,   #T#@  \AX  .\V  #L40  Z&X  .20  #?L0
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M________________________________________
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MW^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     #!"$
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MG8G=D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=_Z8E!O^E, [_JCH7_[5#(O_
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MH=6A@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=6A@J'5_Z B!?^>+0S_H3<4_ZQ
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MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
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MI9N]=:^1N'NVB+6 O(&RAL![L(W#=JZ6Q7.NH<9RK:W$<JFPP'*IL,!RJ;#
M<JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# _YD; _^8)@C_
MI"X+_[$V$?Z]/QGTR$<EZ]1--N7C4$G9XU=?R=]>=+K79(:LSVF6G<=MHY'
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M_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRE#_XLI_X,< _^
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M.!'_N4 9^,)')N[+337DT%1&U<M;6\?#8FZZNVA^KK1NBZ.N<Y::J7J?DJ6
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M44__PU%/_\-13__#44__PU%/_\-13__#44__PU%/_\-1VJ\" ,:\!0"YR04
MK=L( */_%P2:_RL+CO\Q$H/_.!IY_T @</]')FG_3RMC_U@O7_]B,ES_:S1:
M_W(V6/]X.%;_?SE4_X8[4O^-/%'_E3U/_YP^3O^C/DW_JC]+_[- 2O^Y04K_
MN4%*_[E!2O^Y04K_N4%*_[E!2O^Y04K_N4%*_[E!R+4" +C!! "KT , G^L)
M 9;_&@6+_R8*?_\M#W7_-15L_ST:9?]$'E[_3")8_U0E5?]=)U+_92E0_VPJ
M3O]S*TW_>2Q,_W\M2O^%+DG_C"](_Y(P1_^9,$7_H#%$_ZDR0_^N,D/_KC)#
M_ZXR0_^N,D/_KC)#_ZXR0_^N,D/_KC)#_ZXRN+H" *K(  "=V0  DO\, HG_
M&@1]_R$(<O\H#&C_,!!@_S@46O] %U3_2!I/_T\<3/]7'4G_71Y'_V,@1?]I
M($3_;R%"_W0B0?]Z(D#_@",__X8D/O^,)#W_DB4\_YDE._^>)CO_GB8[_YXF
M._^>)CO_GB8[_YXF._^>)CO_GB8[_YXFJ\$  )W0  "/X0  AO\. GK_%0-N
M_QP&9/\C"5S_*PQ5_S,/3_\[$4G_0A-&_TD40O]/%D#_518^_UH7//]?&#O_
M9!@Y_V@9./]M&3?_<AHV_W<:-?]\&C3_@1LS_X@;,O^-&S+_C1LR_XT;,O^-
M&S+_C1LR_XT;,O^-&S+_C1LR_XT;_W > _]L*0;_:3,)_W(W#?]Y/A+_?4<9
M_X!1(?]^7RG_?&TR_WE[.?]VB$#_<Y-%_W"=2O]NID[_:ZU1_VFT4_]HNU7_
M9L-7_V/'6?MAS%OW7]-<\U[=7?!<XU[K6^E?YUGO8.59\5_E6?%?Y5GQ7^59
M\5_E6?%?Y5GQ7^59\5_E6?%?_W > _]L*0;_:3,)_W(W#?]Y/A+_?4<9_X!1
M(?]^7RG_?&TR_WE[.?]VB$#_<Y-%_W"=2O]NID[_:ZU1_VFT4_]HNU7_9L-7
M_V/'6?MAS%OW7]-<\U[=7?!<XU[K6^E?YUGO8.59\5_E6?%?Y5GQ7^59\5_E
M6?%?Y5GQ7^59\5_E6?%?_W > _]L*0;_:3,)_W(W#?]Y/A+_?4<9_X!1(?]^
M7RG_?&TR_WE[.?]VB$#_<Y-%_W"=2O]NID[_:ZU1_VFT4_]HNU7_9L-7_V/'
M6?MAS%OW7]-<\U[=7?!<XU[K6^E?YUGO8.59\5_E6?%?Y5GQ7^59\5_E6?%?
MY5GQ7^59\5_E6?%?_W > _]L* ;_:S$)_W4V#?][/!+_?T89_X-0(?^!7BK_
M?FLS_WMX._]XAD+_=9)(_W*;3?]PI%'_;:Q4_VNR5_]IN5K_9\%<_&7'7OAB
MS%_U8--A\%[=8NQ<Y&/H6^EDXEKO9.!:\&+@6O!BX%KP8N!:\&+@6O!BX%KP
M8N!:\&+@6O!B_W$= _]M* ;_;C )_W@T#/]_.Q+_@T09_X=.(?^&6RO_@V@T
M_W]U/?]\@D7_>8Y,_W:94O]RH5;_;ZE:_FVP7OQJMV'[:+YC^6;&9?1CS&?P
M8=-IZU_>:^9=Y6S@6^EMV5SN:-9<[V?67.]GUESO9]9<[V?67.]GUESO9]9<
M[V?67.]G_W(= _]N* ;_<2X)_WLR#/^#.A'_AT,8_XI,(?^*62O_AV4U_X-R
M/_]_?DC_?(M0_WF65O]UGUS]<J9@^FZM9/ALM&CV:;QK]&?%;?!DS'#K8=-R
MY5_?<]Y<Y7367.AQSU[M;,U>[FO-7NYKS5[N:\U>[FO-7NYKS5[N:\U>[FO-
M7NYK_W,< _]O)P;_="T(_WXQ#/^&.1'_BT(8_XY+(?^.5BO_BV,V_X=O0?^#
M>TO_?X=3_GR26_QXG&'Y=*1G]G"K:_-MLF_Q:KIS[VC#=NMES'CF8M5ZWE_?
M?--=XWO-7^9VQV#J<,9@[&[&8.QNQF#L;L9@[&[&8.QNQF#L;L9@[&[&8.QN
M_W0< _]P)P;_=BL(_X$O"_^).!#_CD 8_Y))(?^35"S_D& W_XQL0_^'=TW[
M@X-7^'^.8/9ZEV?S=J!N\'*H<^UNKWCK:[A\Z&C"?^9FS8+?8MB$T5_<A<I@
MX'_%8>-ZOV/H=+YCZ7*^8^EROF/I<KYCZ7*^8^EROF/I<KYCZ7*^8^ER_W0<
M _]P)@;_>2H(_X4N"_^--Q#_DC\7_Y9((/^74BS_E5XX_I%I1/J,=%#UAW];
M\H*)9>Y]DV[J=YMUYW*C?.1NJX'A:K.&WF>]BMIERHW28M2.R&+8BL)CW(2\
M9>!^MV;E>+9FYG:V9N9VMF;F=K9FYG:V9N9VMF;F=K9FYG:V9N9V_W4; _]Q
M)@;_?"@'_X@M"O^0-@__ECX6_YI'(/^<4"O_FELX^9=F1?22<%+OC'M?ZH6%
M:N5^C73@>)5]VW*=A=1MI(O0:JV.S6BWD,MHPY'(9]&2OV74C[EGV8FT:-V"
ML&GB?*YJY'FN:N1YKFKD>:YJY'FN:N1YKFKD>:YJY'FN:N1Y_W8; _]R)@7_
M?R<'_XHL"O^3-0[_F3T6_YY&'_^A3BO[H%DX]9QC1N^8;53HD'=BXHA_;]J
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MA966EH*>FI* IYV/?[.>C8#"GHN S)J+@=*2BH#8B8F VX:)@-N&B8#;AHF
MVX:)@-N&B8#;AHF VX:)@-N&_WD: O][(03_BR(%_Y@H!_^C, K_JS@0^;)
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M=4_3YW1/T^=T3]/G=$_3YW1/T^=T3]/G=$_3YW1/T^=T_X\/ ?^D#@#;N @
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M?UZGY7A>I^5X7J?E>%ZGY7A>I^5X7J?E>%ZGY7A>I^5X_WH5 O^.$@'_GQ,
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M9U>O\6=7K_%G5Z_Q9U>O\6=7K_%G_W\. ?^3"P#AI04 TK,' ,F^!P#"RP@
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MAA(E_Y 3)/^9$R/_HQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4G+X
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M7VB2]U]HDO=?:)+W7VB2]U]HDO=?_V\1 ?^!#@#_D0X \J , -JM"0#3N H
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MTRL&F= Z$H_.11^%RTXJ?<E6-'7'73UNQ65$:,1L26/"<TY>P7M36<&$5E7
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MJRH]_+DK._W+*SO]XBLZ_/0K.OSW*SK\]RLZ_/<K.OSW*SK\]RLZ_/<KO:@
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M#AS_H0X;_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@
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M47F!_U%Y@?]1>8'_47F!_U%Y@?]1_V43 ?]U#@#_@PX _Y . /6;#@#HI@X
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MLTA&RLA(1LKF1T?)]T5'R/]#2,?_0DC'_T)(Q_]"2,?_0DC'_T)(Q_]"WHT
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M(C;YXR(V^/,B-O?\(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0
MD,0  (//  !WVP  ;_8* &?_$P%@_QT"6O\G U3_, 5/_S@(2O] "D;_2 Q#
M_T\.0/]6#SW_7A [_V42./]N$S;_=Q0T_X(5,O^/%C#_FQ<O_ZD7+O^W&"W_
MR!@L_^$8+/_O&"S_[Q@L_^\8+/_O&"S_[Q@L_^\8JZL  )ZU  "0P0  @LP
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MX&%Y,]Q>@CC87(L\TUJ4/]!8G$+.5Z-$RU6L1LE5M4?'5,!)Q5302<)3YDG
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M1(AT_T.(=/]#B'3_0XAT_T.(=/]#_UT2 ?]K#@#_> X _X,/ /V,$ #ME!(
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M2&:/_T=FC_]'9H__1V:/_T=FC_]'_VP( /Y\  #>B@  T)8" ,B?! # IP0
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M/4NT_SU+M/\]XH,  ,V2  #!GP  M*<  *JO  "@N   EL # (S*!P"&S10
M@<TF GK,-0ASRT$/;,I*%V;)4QUAR%LC7,=B*%C&:BQ4QG(P4,5\,TW%AC9*
MQ)(Y1\2?.T7$KCQ$Q<$\0\7?/$3$\SM$P_\Y1<+_-T7!_S=%P?\W1<'_-T7!
M_S=%P?\WU8L  ,6:  "WI   JZP  *"T  "6O@  B\<$ ('0" !XV0X ==D@
M 6_8+P1IV#P)8]9&$%[64!59U5@:5=1@'U'4:").U'$F2]-[*4C3A2M%TY(N
M0M2?+T'4KS _U<(Q/]7A,#_3\C _TOTO/]'_+C_0_RX_T/\N/]#_+C_0_RX_
MT/\NRI0  +NA  "MJ0  HK$  ):[  "+Q   @,T# '78" !OY!$ :N0@ 63D
M+0->Y#@'6>1!"U7D2P]1Y%023>1=%DKD91A'Y&X;1>1W'4+D@A] Y(XA/N6;
M(SSEJB0[YKPD.N;3)#GE[B0YX_HC.>+_)#GB_R0YXO\D.>+_)#GB_R0YXO\D
MOYX  *^F  "CK@  E[@  (K"  !^S   <]8" &GE"0!D[Q0 7_ @ 5GP*P-4
M\#4%3_ ^!TOQ1@I'\4X,1/%7#D+Q7Q _\F<2/?)P%#KR>Q4X\X<6-O.4&#7T
MHADS]+$9,O7%&C'UXAHQ]/$9,?'^&3'Q_QDQ\?\9,?'_&3'Q_QDQ\?\9LJ0
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M!A#_G08/_ZD&#O^U!@[_N@8._[H&#O^Z!@[_N@8._[H&CKH  '_%  !PT0
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M2HII^T.+:_\^C&W_.HQN_S>,;O\WC&[_-XQN_S>,;O\W_UD0 /]E"P#_<0L
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M/G5]_SMU??\[=7W_.W5]_SMU??\[_V$* /]O @#H?   V88! ,^.! #(E08
MPYH& +N<%@"SG"H#JIDY"Z*5112;D4X=E(Y7)HZ+7RV)B&8SA(9M.("$=#U[
M@GM!=X"$171_C4AP?9=+;7RC3FI\L$]H?,%09WS=4&I^\TEM@/]#;H'_/V^!
M_SQO@?\\;X'_/&^!_SQO@?\\_V0( /]R  #A?P  TXD! ,J2 P##F 0 O9X$
M +:@$P"NH"<"I9TV"9V:0Q.6ETT<CY-5)(F172N$CF0Q?XQK-WJ*<CMVB'E
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MJ#%!O[HQ0<#2,4&^[C!!O?TO0;S_+D&\_RU!O/\M0;S_+4&\_RU!O/\MSHH
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M/@1"[$<%/^Q/!SWM6 DZ[6 *..UJ##;N= TS[H .,NZ.#S#OG1 N[ZT1+?#
M$2WPWA$L[O$1+.S^$2SK_Q LZ_\0+.O_$"SK_Q LZ_\0K:(  *"I  "3LP
MAKT  'G&  !LSP  8-@  %7>  !.\PH 2O<3 $;X'0!#^"<!/_@P COY. (X
M^4 #-?I'!#/Z3P4P^U<%+OM?!BO\:0<I_'0()_R""27]D DD_: *(_ZP"B+^
MQ LA_^ +(?WR"B#\_ H@_/P*(/S\"B#\_ H@_/P*HJ<  )6Q  "'NP  ><8
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M-Y]8_C*?6O\NGEO_*YY<_RB>7/\HGES_*)Y<_RB>7/\H_U 1 /]9# #_8PP
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M,X%L_R^!;/\O@6S_+X%L_R^!;/\O_UD+ /]C 0#T;P  WW@  -1_! #.@P8
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MI3M/EK0\3I;)/$Z6Z#I/EODV49;_,U*6_S!2EO\P4I;_,%*6_S!2EO\PYG(
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M)CVZZ"8]N/DE/;?_)#VV_R,]MO\C/;;_(SVV_R,]MO\CQX@  +F5  "LG0
MH:0  ):K  "*L@  ?[D  '._ 0!HQ@4 8,H. %[*'0!;RBP!5\HX U3*0P50
MRDP(3<E5"TK)70Y'R6811,EO%$')>18_R(48/,B3&CK(HALYR;,<.,G)'#C(
MZ!PWQ_D<-\7_'#;$_QPVQ/\<-L3_'#;$_QPVQ/\<OI$  +";  "DHP  F*H
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M!1KW_049]O\%&?;_!1GV_P49]O\%GJ8  )&O  "#N0  =<(  &?+  !:TP
M3=H  $+?   XY0  -?L' #'_#P N_Q8 *_\? "G_)@ E_RT (_\T "#_.P$>
M_T,!&_]+ 1G_4P$6_UT"%/]J A+_> (1_X@"$/^: A#_JP,._[X##O_5 P[_
M[0,.__ ##O_P P[_\ ,.__ #DZX  (2X  !VP@  9\P  %K5  !,W   /^$
M #7F   M]   *O\" ";_"P C_Q$ (/\7 !W_'0 9_R, %O\I !3_+P 2_S4
M$/\]  [_10$,_TX!"O]8 0?_90$%_W0! _^% 0+_E@$!_Z8! /^U 0#_Q@$
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M'[Q%_QVZ1O\;N4?_&;A'_QBX1_\7N$?_%[A'_Q>X1_\7_T04 /]+$ #_40X
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M)9%;_R.16_\AD5O_(9%;_R&16_\A_T\+ /]7 @#_80( ZF@! -YM! #8< @
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MI#==>K,X7'K'.5QZY3=>>_@R7WO_+F!\_RMA?/\I87S_*6%\_REA?/\I]6(
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M,4J1X#%,D?4M39'_*DZ0_RA.D/\F3I#_)DZ0_R9.D/\FWG   ,E]  "\B0
MLI(  *>7  "=FP  DY\  (:D  !^I@P >J8; '6F*@%PIC<$;*5!"6>C2@UC
MHE(27Z%9%ENA81E8H&@=5)]P(%&>>B-.G80F2YV1*4B<GBI&G*XL19S!+$6<
MWRM%F_0I1IK_)T>:_R5'FO\D1YK_)$>:_R1'FO\DU'<  ,*$  "VCP  JY8
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M%#*__Q0QOO\4,;[_%#&^_Q0QOO\4N)   *N9  "?H   DZ<  (>N  ![M
M;KL  &/   !8Q0$ 3<H% $3/# !#T!< 0M E $#0,@ _T3T!/=%' 3O14 (Y
MTED#-M)C!#32;@4RTGH',-*(""[2F DMTZD)+-.^"BS3WPDKT?,**L_^"RG.
M_PPIS?\-*<W_#2G-_PTIS?\-KI@  **?  "6I@  B:X  'RV  !OO0  8\,
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M 0;_]@$&__8!CZP  ("V  !ROP  8\D  %;1  !(V   .]T  ##B   FY@
M'_   !S_   9_PD %O\. !3_$P 1_QD #_\>  W_)  +_RL "?\R  ;_.P #
M_T0  /]/  #_7   _VL  /]]  #_D   _Z,  /^T  #_Q@  _]8  /_6  #_
MU@  _]8 @K4  '._  !DR0  5M,  $?;   ZX   +N4  "/I   :[0  %?T
M !+_   0_P( #O\)  O_#0 (_Q  !/\3  '_&   _QX  /\D  #_*P  _S,
M /\]  #_20  _U8  /]F  #_>   _XH  /^;  #_J   _[$  /^Q  #_L0
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M".(L_PG@+/\)WBS_"-XL_PC=+/\(W2S_"-TL_PC=+/\(_S4: /\Z%@#_/10
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M%JA&_Q6G1_\3IT?_$Z='_Q.G1_\3_T0. /]*" #_4 8 _U4* /]8#0#W61$
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M'(1:_QR$6O\<_TX! /]7  #E7P  V&8  ,YJ  #'; , PVL% +QL$@"T;24
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MI2YJ9K,O:6;&,&AFY"]J:/<I:VG_)6QI_R)L:O\@;&K_(&QJ_R!L:O\@_U<
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M4!!U?E<4<7U>&&Y[91MK>FP>:'ET(F5X?25B=X<H7W:3*EQVGRQ:=:XN677
M+EAUW2Y9=O,J6W;_)EQW_R-<=_\@7'?_(%QW_R!<=_\@ZF   -5L  #%=@
MNGX  +&$  "HB   GXD  )2*  "-BA$ B(LA (.*, )^B3L%>8=%"G2&3@YP
MA%42;(-<%FF"8QIF@6H=8H!R(%]_>R-<?H4F67V1*5=\GBM5?*PL4WR^+5)\
MVBU3?/(I57S_)59\_R)7?/\@5WS_(%=\_R!7?/\@Y60  ,]P  #!>@  MH,
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M'D*5_QU#E/\<0Y3_'$.4_QQ#E/\<S'4  +R!  "QC   II(  )N7  "1FP
MA9\  'FC  !JIP  9:<. &.H' !@J"L!7:@V EFG0 16ITD&4Z91"5"F60Q-
MI6 .2J5I$4>D<A1$I'T60J.)&#^CEQH]HZ<;/*.Y'#NCTAL[HN\;.Z#^&CN?
M_QD\G_\8/)__&#R?_Q@\G_\8Q'P  +:)  "JD@  GY<  )6<  ")H0  ?:8
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M!R/'_P<CQ_\'J98  )Z=  "2HP  A:L  'BR  !KN   7[X  %+"  !'Q@
M/<H  #3/!  KU D )MD/ "79&0 EVB4 )-HP "/;.P CVT4 (MQ0 "'=6P @
MW6@ 'MYV !W>AP$<WYD!&M^L 1G?Q $8WN<!&-SX 1C;_P(7VO\"%]K_ A?:
M_P(7VO\"H)P  )2C  "'JP  >;,  &RZ  !?P0  4L8  $;*   [S@  ,=,
M "G9   AW@4 'N@. !WH%0 ;Z1X &>DG !CJ,  6ZCD %>M# !3L3@ 2[%H
M$>UG !#N=P 0[HH #N^>  [PLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,
MZ_\ EZ,  (FK  ![M   ;;P  %_$  !2R@  1<X  #G3   OV   )=T  !WA
M   8[ ( %O<+ !3W$0 1^!< $/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7
M  /]9@ "_G<  /V+  #]GP  _+4  /S1  #\[0  _/P  /S]  #\_0  _/T
MBZL  'VT  !NO0  8,8  %+-  !$T@  -]@  "S=   BX0  &>4  !/J   0
M^@  #O\&  W_#  *_Q  !_\4  3_&@ !_R   /\G  #_,   _SH  /]%  #_
M4P  _V(  /]U  #_B@  _Y\  /^S  #_QP  _^4  /_E  #_Y0  _^4 ?[0
M '"]  !AQP  4]   $/6   VW0  *N(  !_F   6Z@  $.T   SZ   )_P
M!O\   +_!   _PD  /\-  #_$   _Q0  /\:  #_(0  _RD  /\T  #_0
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M ?H-_P'Y#O\!^0[_ ?D._P'X#O\!^ [_ ?@._P'X#O\!_R8C /\H( #_*"
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M!\@L_P?'+/\&QRS_!L<L_P;'+/\&_S42 /\Y#@#_.@T _SX0 /] %@#_/R
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M$)=&_Q"71O\0_T(% /]'  #W3P  Y5,  -U5 0#7508 U5(+ ,M3&0##5"L
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MIR)Y5K4C=U;')'96Y"1V5_<?=UC_&W=9_QEW6?\7=UG_%G=9_Q9W6?\6_TP
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M)F1BVB9D8_(B963_'F9D_QMG9/\99V7_&&=E_QAG9?\8\%,  -U?  #+:
MOV\  +9S  "N=0  IG4  )US!0"6<Q0 D70D (MS,@*&<CX$@7!'"'UO3PMY
M;5<.=FQ>$7-K9!1P:FP7;6IS&FMI?!QH:(8?9F>1(F-GGB1A9JPE8&:])E]G
MUB9?9_$B8&C_'F%H_QQB:/\:8FC_&6)H_QEB:/\9[%<  -EB  #':P  O'(
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M'E%W_QM2=_\94G?_&5)W_QE2=_\9WF(  ,AN  "[=P  L'\  *>$  "=AP
MDH<  (2'  !]APD >(@6 '2()@!PB#(";(<]!&B&1@9EA4X)8855#%Z$7 ];
M@V,268)K%5:!=!=3@'X:4(")'$Y_EAY,?Z4@2G^V(4E_S"%)?NL?2G[\'$M^
M_QI+?O\93'[_&$Q^_QA,?O\8U6<  ,-S  "V?   K(0  **)  "8BP  C8T
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M$3>9_Q$WF?\1OGL  +&'  "ECP  FY0  )"8  "$G   =Z   &ND  !?IP
M4JH  $VK#@!+JQH 2JLG $BK,P!&JST!1*M& 4*K3@) JU8#/JM?!3NK: 8Y
MJG,(-ZJ "32JCPLRJI\,,:JP##"JQPPPJ><,+Z?Z#2^F_PTOI?\-+Z7_#2^E
M_PTOI?\-MH0  *J.  ">E   E)D  (>>  ![HP  ;Z@  &.L  !7KP  2[(
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M?  2UX\ $=BD !#9NP 0V=X $-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H
M )&A  "#J   =;   &BW  !;O0  3L$  $+%   WR   +<P  "30   <U0
M%=H% !#B"P 0XQ$ #N0:  [D(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &
MYH  !>:5  3FJP "YL0  >;F  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I
M  !WL0  :;D  %O   !.Q@  0<H  #7.   JT@  (=8  !G;   2WP  #>,
M  OQ"  )\PX !_,3  3R&@ "\B(  /(J  #R-   \C\  /),  #R7   \FT
M /*"  #RF   \ZT  //&  #TY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !J
MN@  7,(  $[)  ! S@  ,],  "C8   >W0  %>$   _D   *Z   !?,   /]
M 0  _ @  /L-  #[$0  ^Q8  /P>  #\)@  _#   /T\  #^20  _EH  /YM
M  #_@@  _Y@  /^L  #_P   _]@  /_D  #_Y   _^0 >[(  &R[  !=Q
M3\T  $#2   RV0  )MX  !OB   2Y@  #.H   7M    ]    /\   #_
M_P   /\$  #_"0  _PX  /\2  #_&   _R$  /\K  #_-P  _T8  /]8  #_
M:P  _X   /^5  #_I@  _[,  /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G
M /\0+0#_"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H
M_P"@ /\ I@#_ *P _P"R /\ N0#_ ,( _P#- /\ WP#_ .P _P#X /\ _P#]
M /\ _0#_ /T _P#] /\ _0#_ /T _P#] /\ _Q\C /\?(0#_'B$ _QDC /\3
M*0#_#C( _PQ  /\)30'_!UH!_P1G ?\#<P'_ WT!_P.' ?\#CP#_ I8 _P*<
M /\"H@#_ J@ _P*O /\!M@#_ ;X _P') /\!VP#_ .H _ #V /@ _P#W O\
M]P/_ /8$_P#V!/\ ]@7_ /8%_P#V!?\ _R(? /\B' #_(1P _QX? /\8) #_
M%2\ _Q(\ /\020#_#E8!_PQB ?\+;@'_"WD!_PN" ?\+BP'_"Y(!_PJ9 ?\*
MGP#_"J4 _PJK /\*L@#_"KL _0K& /L*U #W"N< \PKT / *_P#O"_\ [@S_
M .T,_P'M#/\![0S_ >T,_P'M#/\!_R4; /\F& #_)1< _R$8 /\@(0#_'BL
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M!;0L_P6T+/\%_S0, /\V!0#_.0, _SP( /\\#0#].Q, \3@= .@U*0#@-#<
MV3-& -$T4@'-,UT!R3-G L8S< /$,G@$P3* !+\RAP6^,H\&O#*6!KHQG@>X
M,:8'MS&P"+4RO BS,LP)L3+E":TS]0FK,_\)JC/_"*@S_P>H,_\'IS/_!Z<S
M_P>G,_\'_S<' /\Z  #_/@  ^D$! /%!!@#Q/PT YCP2 -LZ'P#0.S$ RCQ
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MK!2/0[H5C4/-%8M$Z!6*1?H2B4;_$(E&_PZ(1O\-B$;_#8A&_PV(1O\-_T
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M50B)5UP*AE9C#(-5:@Z!5'$0?U-Y$GU3@11Z4HL6>%*5&'91H1ET4:\;<U'
M&W%1VQQQ4O(9<5/_%7%4_Q-R5/\1<E3_$')4_Q!R5/\0\T@  .-3  #06P
MQ&   +IC  "S8P  K&$  *1>"0"=7Q< F%\G )-?-0&.7D #BEU*!89<4@>#
M6UD*@%I@#'U99PY[6&X0>%AU$G97?A1T5H@7<E:3&&]6GQIN5:P;;%6]'&M6
MU1UK5O ::U?_%VM8_Q1L6/\2;%C_$6Q8_Q%L6/\1\4L  -]6  #,7@  P&0
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M&%QC_Q9<8_\476/_$UUC_Q-=8_\3YE4  ,]?  #!:   MFX  *QR  "D=
MFG,  (YO  "';PT @F\; 'UP*0!Y;S4!=6X_ W)M2 5N;% ':VQ7"FEK7@QF
M:F4.9&EL$6%I=1-?:'\67&B*&%IGEAI89Z0<5F>T'55GRAU59^@;5F?[&%=G
M_Q97:/\46&?_$UAG_Q-89_\3X5@  ,MC  "]:P  LG(  *EV  "@>   EG<
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M$4=X_Q%'>/\1S64  +UP  "Q>0  IX   )R$  "2A@  AH8  '>&  !KA@
M9H<- &.'&0!@B"< 7H@S 5N(/ )8AT4#5H=-!%.&5 90AEL(3H5C"DN$; Q)
MA'8/1H.!$42#CQ-"@YT40(*N%3^#PA4^@N(5/X'W$S^!_Q) @/\10(#_$$"
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MAP4MI)<&+*2I!BNDO08JI-X&*J+U!RFA_P<IH/\(*9__""F?_P@IG_\(L8(
M *6+  ":D0  D)8  (.:  !VGP  :J(  %ZF  !2J0  1JL  #RM   UKPP
M,[ 5 #*P(0 QL"L +[ U "ZQ/@ ML4@ ++%1 "NQ6P IL6<!)[%T 2:Q@P$D
ML90"([&F B*RNP(ALML"(:_S R"N_P,@K?\$'ZS_!!^L_P0?K/\$JHL  )V1
M  "3EP  AYP  'JB  !MIP  8*L  %6O  !)L0  /K0  #.W   JN@, )+P-
M "*]%0 AO2  (;TJ ""],P ?OCT 'KY' !V^4@ <OUX &K]L !F_?  8OXX
M%\"A !; M@ 4P-, %;[Q !6\_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*
MG@  ?:0  &^J  !BKP  5K0  $JW   ^N@  ,[T  "K    AQ   &<<% !/+
M"P 1S!( $<P; !#,)0 /S2\ #LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7
M  G.K  (SL8 ",[H  C-^P )R_\ "<O_  G+_P )R_\ F)@  (V>  !_I0
M<:P  &2S  !7N0  2KT  #[    RPP  *,8  !_*   7S0  $=$   S6!0 (
MV0P !MD2  7:&P $VB0  ]LN  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?
MG0  W[,  -_.  #@[@  W_H  -__  #?_P  W_\ CY\  (&F  !SK@  9;4
M %B]  !*P@  /<4  #')   FS   '=   !34   .V0  "=T   /A    XP<
M .,-  #D$@  Y1D  .8B  #G*P  Z38  .M#  #L4@  [&(  .UV  #NC
M[J$  .^W  #OT0  [^L  /#V  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&
M   \R@  +\X  "32   :V   $MP   S@   %XP   .<   #K    ZP   .T%
M  #N"P  \!   /$5  #S'@  ]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T
M /VC  #^M@  _LD  /_?  #_WP  _]\ =[   &BY  !:P0  3,H  #S/   N
MU   (MH  !?>   0X@  ">8   #I    [    /    #V    ]@   /<   #X
M    ^@<  /L-  #]$0  _QD  /\C  #_+P  _SX  /]/  #_8@  _W<  /^-
M  #_GP  _ZX  /^Z  #_N@  _[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #,
M_P!! /\ 3@#_ %P _P!H /\ = #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_
M *@ _P"N /\ M0#_ +T _P#' /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L
M_P#[ /\ ^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ]
M /\ 2P#_ %@ _P!D /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0
M_P"J /\ L0#] +D ^P## /H T #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S
M /\ \P#_ /, _P#S /\ _QT< /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%
M1@#_ E, _P!? /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G
M /@ K@#U +4 \P"_ /$ RP#P -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\
MZ0'_ .D!_P#I ?\ _R 7 /\?% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_
M#$X _PE: /\(9@#_"'  _@=Y /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&
MJ@#M!K( Z@:[ .@&R #F!MP Y ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_
M -P,_P#<#/\ _R,2 /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD
M_!!5 /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B
M#J\ X ZX -X.Q0#<#MH UA#L -(1^@#/$O\ S1+_ <P2_P'+$_\!RA/_ <H2
M_P'*$O\!_R</ /\G# #_)0D _R8- /\E$P#_(QP _R H /L<-0#U&D( [QA/
M .H76@#F%F4 XQ9N . 6=P#>%G\ W!:' -D6C@#6%I4 U!:< -(7HP#0%ZL
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MM02N*\0$K"O;!*@L[P2F+/X%I"S_!*,M_P2B+?\$HBS_!*(L_P2B+/\$_S(
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M#H8_X Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@
MS$\  ,-0  "\3@  MTD! +%&#@"J2!P I$DL *!).@";244!F$A. I1'5P.2
M1UX%CT9E!HU&; >+17,)B45["H=$@PN%1(T,@T27#H%#H@]_0Z\0?D/ $'Q$
MVA%[1/$/>D7_#7I&_PMZ1O\*>D;_"7I&_PEZ1O\)]3X  .9(  #33P  QU0
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M$693_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@
MGU\  )9:  "/6A  BEL> (5;+ "!6S@!?5M! GI:2@-W65$$=%A8!G%87P=O
M5V8);5=M"VM6=@UI5G\/9U6*$655EQ-C5:04856T%6!5R!9?5><58%;Z$F!6
M_P]A5_\.85?_#6%7_PQA5_\,YTP  -%6  #!7@  MF,  *UF  "D9@  FV0
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M#5)B_PU28O\-V58  ,1@  "W:   K&X  *-Q  ":<P  CW$  ']K  !X:P4
M<FL2 &YL'P!K;"P :&PW 69L0 )C:T@#8&M/!%YJ5@9<:ET'66EE"5=I;0M5
M:7<-4VB"#U!HCQ%.9YT336>L%$MHP!1+:-X42V?U$DQG_P],9_\.36?_#4UG
M_PU-9_\-TEH  ,!D  "S;   J7(  *!V  "6=P  BG8  'EQ  !Q<0  :W$/
M &AQ' !F<B@ 8W(T &!R/0%><D4"6W%- UEQ5 57<%L&5'!C"%)O:PI0;W0,
M36Z #DMNC1!);IL11VVK$D9NOA-%;MP21FWT$49M_P]';?\.1VS_#4=L_PU'
M;/\-S%\  +QI  "P<0  I7<  )Q[  "1?   AGL  '5X  !K=P  97<, &%X
M%P!?>"0 77DP %IY.@%8>4("5GA* E-X4011=U@%3W=@!TQV: A*=G(*2'5]
M#$5UB@Y#=9D/0G6I$$!UO!! ==D00'3S#T!T_PY!<_\-07/_#$%S_PQ!<_\,
MQF0  +=N  "K=@  HGP  )=_  ",@0  @8$  '*   !E?P  77\( %E_$P!7
M@"  58 K %.!-@!1@#X!3X!& DV 3@)+?U4#27]=!49_9@9$?G (0GY["3]^
MB L]?9<,/'VG#3I]N@XZ?M8-.GSQ#3I[_PPZ>_\+.GK_"SIZ_PLZ>O\+P&D
M +)T  "G?   G8$  )*$  "'A@  >X<  &Z'  !@AP  58<! %"(#@!.B!H
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M B2>M0(CGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@
MBY(  '^6  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  G
MJB( )JHL "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JK
ML0 9J\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD
M '6>  !HH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ<
M%[<A !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -
MN<0 #;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF
M  !>JP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45
M  G%'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8
M ,;2  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3
MM   1K@  #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0
M%@  T1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_
M  #6X   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0
M.<$  "W$   BQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P
MWQ0  .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #I
MQ0  Z>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H
M "#.   6T@  #]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT
M .T1  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP
M^L(  /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:
M   -WP  !>,   #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)
M  #Z#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL
M /^Y  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_
M %D _P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\
ML #_ +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_
M /H _P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4
M_P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[
M +0 ^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /
M_P#P /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!<
M /\ 9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +
M\ "X .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E
M /\ _QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X
M8@#Z &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T
M .( OP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\
M_QX0 /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N
M!&8 Z@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%
MNP#0!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$,
M /\@!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6
MW0UI -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$
M$,@ PA#? +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C
M  #_(P  _R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C
M ,@6:P#%%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L(
MM!K6 + ;[0&M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^
M*@  [RH  .<G 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA
M90"W(FT M2)T +,B? "Q(H,!L"** :XBD@&L(YL!JR.D :DCKP&G([P!IB3.
M :,DZ *@)?D"GB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@
MXC0  -HS  #3+@, TB4* ,DE%P#!)R< NRDV +8J0P"R*TX KRM7 *PK8 "J
M*V<!J"MO :8K=@&D*WT!HRN$ J$KC0*?*Y4"GBN? IPKJ@.:*[8#F2S' Y<L
MX@.4+?4$DBW_ Y$M_P.0+O\#D"W_ Y M_P.0+?\#_S   /(S  #D.@  UCT
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M20  KT,  *D^"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X=
M9P.%/VT$@S]U!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\
M"'1 _P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P
MITH  *!$!P":110 E48B )!&, ",1SP B49% 89&3@&#1E4"@45< WY%8P1\
M1&H$>D1Q!7E$>09W1(((=4.-"7-#F0IQ0Z8+<$.U#&Y$R0QM1.<,;47Z"FQ%
M_PAL1?\';$7_!VQ%_P=L1?\'[#\  -A)  #'4   NU0  +%5  "I5   H5
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M"%M1_PA;4?\(WTH  ,E3  "[6@  L%\  *9A  "=80  E%X  (A7  " 5@H
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MB I*8Y<+2&.F#$=CN U&8]$-1F/O#$9B_PI'8O\)1V+_"4=B_PA'8O\(RE@
M +IB  "N:0  HVX  )IQ  "0<@  A'$  '1K  !I:0  8VD+ %]I%0!<:B$
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M!S5XLP<T>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0
MF'X  (V   ""@0  =H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!
M@C( 0(([ #Z"0P ]@DL .X)3 3F"7 $W@F8"-8)Q S."?P,Q@8X$,(&?!"Z!
ML04M@<@%+8'I!"U__ 4M?O\%+7W_!2U]_P4M??\%LVX  *AX  "=?P  DH,
M (B&  !]AP  <(@  &.)  !5B@  2XH  $&* @ [BPX .8L7 #B,(@ WC"P
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M !&B^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@
M6*$  $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .
ML2L #;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P
M[P %K_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL
M $&M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(
M +XK  "^-@  OD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y
MO?8  +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V
M   JN   (+L  !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB
M  #+*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L
M ,[X  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >
MP@  %<8   [)   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<
M'P  WB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J
M  #E\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0
M#-$   35    V@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@
M[1H  .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #W
MWP  ]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\
M  #B    Y0   .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A
M /P6  #_(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP
M_[\ _PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\
M;0#_ '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"]
M /\ R0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\
M_Q 9 /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_
M '( _P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8
MPP#T -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4
M /\/$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T
M^P!V /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H
M ,L YP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1
M#@#_#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P
M .T > #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4
MU@#9 -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_
M#P4 _PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .
M<@#> 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0
M ,4 Z ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%
M_Q,% /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,
M!7, R@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*
MY0"U"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH
M /46!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT
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M HLG_P**)_\"B2?_ HDG_P&))_\!^BD  .PP  #=-@  S3@  ,0W  "^,@
MNBL" +4E#@"N)QT J"DK *0J. "@*D, G2M, )HK50"8*UP EBMC )0K:@&2
M*W$!D"QX 8\L@0&-+(H!BRR4 HHLGP*(+*L"ABRZ H4MS@.#+NH#@2[\ X N
M_P)_+O\"?R[_ GXN_P)^+O\"]"X  .0W  #2/0  Q3\  +L_  "T/   KS4
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M!&8__P1F/_\$Y3T  ,]&  "_3   M$\  *I0  "B3P  F4H  )%$  "*00T
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MB 934)8'4E"E"%!0MPE04,X)3U#M"%!0_P=04/\&4%#_!5!0_P504/\%T$L
M +]4  "R6@  IUX  )U@  "48   B5T  'Q7  !R5   ;%,. &A4&0!E5"0
M8E0O &!4. !>5$  7%1( 5I43P%95%8!5U1= E5490-45&X$4E1Y!5!4A@9.
M5)0'352D"$M4M0A+5,P)2E3K"$M4_@=+5/\&2U3_!4M4_P5+5/\%S$X  +M7
M  "N7@  I&(  )ID  "19   AF(  '=;  !M6   9E@, &)8%@!?6"( 75DL
M %M9-@!963X 5UE& %9930%4650!4EE; E%98P-/66P#35EW!$M8A 5)6)('
M2%BB!T=9LPA&6<H(15GJ"$99_09&6/\&1EC_!4=8_P5'6/\%QU(  +A;  "K
M80  H68  )AH  ".:0  @V<  ')@  !H7@  85T) %Q=$P!:71X 5UTI %9>
M,P!47CL 4EY# %%>2@%/7E(!3EY9 DQ>80)*7FH#2%YU!$9>@@5$79 &0UZ@
M!T%>L0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@
MGFH  )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.
M9#@ 361  $MD2 !*9$\!2&17 49D7P)%9&@"0V1S T%C?P0_8XX%/6.>!CQC
ML 8[9,8&.V3F!CMC^@4[8O\%.V+_!3QA_P0\8?\$OEL  +!C  "E:@  FV\
M )%R  "&<@  >W$  &QM  !@:P  56D  $]H#0!-:1< 2VDA $EJ*P!(:C0
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M B9Z]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P
M;(0  %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 J
MA3X *85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$
M]0$>@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L
M %B,  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38
M'I%  !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4
MCO\ %(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5
M  !%EP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW
M !&>00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X
M"YK_  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \
MH   ,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J
M.  "JD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_
M  "G_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@
M)JL  !VM   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P
MN#D  +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V
M_P  MO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8
M !.X   -NP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX
M ,@Z  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0
MR/T A9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#
M   #QP   ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM
M  #=.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0
M>:$  &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/
MTP   -D   #<    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M
M*P  \#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H
M %ZQ  !0N0  0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@
M .8   #I    Z@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'
M_RD  /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!
M%P#_ !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![
M /\ @P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4
M_ #J /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_
M !, _P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\
M?@#_ (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C
M .\ \P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \
M_P 0 /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T
M '\ \P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$
M[0#? /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P ,
M /\ $@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H
MY0"  ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#,
M /8 R@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\
M#@#_ !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z
M -  @ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$
MNP#^ +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X
M 1  Z  : ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$
M>@"_ ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[
M *L%_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@
MW0,2 -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q
M"'L KPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T.
M_P"<#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+
M ,<+%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78
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M 7@H_P%X*/\![RL  -TS  #*.0  OCL  +0Z  "M-@  IB\  *$H!P";)Q,
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M) !\-R\ >3<Y '<X0@!T.$D <CA0 '$X5P!O.%X ;3AE 6PX;0%J.'4!:#B
M F<XC )E.)D#9#FH V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"
MW3L  ,=#  "Y20  KDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T
M/"L <CPU &\]/@!M/48 :SU- &D]4P!H/5H 9CUA 60]:0%C/7(!83U] F ]
MB0)>/98#73ZE UL^M@1:/LP$6C_L!%D__@-9/_\#63__ ED__P)9/O\"UC\
M ,-'  "U3   JE   *!0  "73P  CDL  (1%  !Z0 8 =3\1 '% ' !M0"@
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M!$M+L 1*2\4$24OF!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P
MH5L  )A<  ".7   @UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!6
M33H 5$U! %-.2 !23D\ 4$Y7 4].7P%-3F@!3$YS DI/?P))3XT#1T^=!$9/
MK@1%3\,$1%#D!$1/^01%3_\#14__ T5._P-%3O\#Q$P  +55  "I6P  GUX
M )5@  "+8   @%X  ')7  !G4P  7E$' %E1$0!741L 5%$E %)2+P!14C<
M3U(_ $Y21@!-4TT 3%-5 $I370%)4V8!1U-P D53?0)$4XL#0E.; T%4K 1
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M S1>]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@
M=FP  &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \
M9$4 .V1- #ED50 X9%\ -F1I 35D=@$S9(4!,665 C!EIP(O9;L"+F7: BYD
M] (N8_\"+V/_ B]B_P(O8O\"LUX  *=F  "<;0  DW$  (AS  !]<P  <G(
M &1P  !8;@  36P  $)J P \:0X .FH6 #EJ(  X:B@ -FLQ #5K.0 T:T$
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M !9[_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B
M/(@  #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3
MBDP $HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&
M_P .AO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(
M "J2   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0
M")=0  :77@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !
MDO\ F((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=
M   9G@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(
M  "D5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\
MD8H  (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1
MJ@  #*P   6N    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R
M3   LEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)
M '^5  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0
M K@   "[    NP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0
MPT\  ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=
M  !EHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4
M  #'    R    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$
M -A3  #99@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9
MK   2[(  #RW   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5
M    U@   -D   #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#
M  #N5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@
M/KP  "_    @Q   %,@   S,   "T    -0   #9    W@   .(   #E
MY@   .@   #I    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_
M1@  _UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7
M /\ '0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4
M_P"+ /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X
M /\ ]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\
M%P#_ "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "&
M /H C #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X
MZ@#_ .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_
M !\ _P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X
MAP#L (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_
M -< _P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D
M^P F /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#<
M (< V@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,,
M_P## /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ?
M .H +0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($
MQ@"' ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R
M /\ L@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H
M)0#3 #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"!
M +0 B "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\
MH@#_ *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$
M "H OP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8
M@P"D (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_
M )0)_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$
ML@8N *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7
M#(8 E@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1
M_P"'$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G
M *$0,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$
MB12+ (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![
M&?\ [R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09
M+0"1&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V&
M 'P>D0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\
MZ"@  -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&
M(C( @R,\ ($C1 !^(TL ?"12 'LD60!Y)%\ =R1F '8E;@!T)7< <R6! '$F
MC0!O)ID ;B:G &TGN !L)\X!:BCM 6DI_P%H*?\!:"G_ 6@H_P%H*/\!X2X
M ,LV  "\.P  L3T  *<]  "?.0  ES,  (\M  "()PP @R<6 '\H(@!\*2T
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M 54XKP)4.<,"4SGD E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20
MI$P  )I,  "12P  AT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>
M.CP 73I# %LZ2@!:.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]
MK )./L$"33[A DT^^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5
M )=1  ".3P  A$L  'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@
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M CY*\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7
M>UD  &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%
M3$8 1$Q. $--5@!"35\ 0$UJ #]-=@$]3H0!/$Z4 3M.I0$Y3[D".4_4 CE/
M\@$Y3O\!.4[_ 3E-_P$Z3?\!NDX  *Q6  "A6P  EU\  (UA  "#80  >%X
M &E8  !?5@  5%(  $Q/"P!)3Q( 1U < $50)0!#4"T 0E U $%1/ ! 440
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M 2A=_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0
M26<  #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H
M950 )V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C
M_P$A8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\
M #IN   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E
M'FY; !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8
M:_\ I&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X
M   K=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6
M !-X8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\
MGW$  )5X  "+?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D
M@@  '((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#
M70 )@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD
M )!^  "&@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0
M%8X   ^/ P *D P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@
MCV4  (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%
M  ""B0  =(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH
M  J;   "G D  )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P
M )UN  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !X
MD   :I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H
M    J00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC
M  "L=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP
M7YP  %&@  !$I   -J8  "JH   >J0  %*L   VN   &L    +(   "U
MM0   +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]
M:P  O8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4
M $:J   XK0  *J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@
M ,,   #$    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@
MTG,  -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS
M   JM@  ';D  !*\   *OP   ,,   #&    R0   ,T   #/    T    -(
M  #4    U@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60
M .I\  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =
MP   $<0   G(    S    ,\   #3    V0   -T   #@    X0   .,   #E
M    YP   .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ
M  #_@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8
M_P T /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_
M ), _P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A /@ \P#W /\ ]@#_ /4
M_P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T _P . /\ % #_ "$ _P N
M /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[ 'L ^0"" /@ B #W (X
M]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H [ #H /P YP#_ .4 _P#F
M /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P ) /\ $ #_ !P _P I /\
M-@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8 [ !\ .H @@#H (@ YP".
M .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4 /8 T0#_ -  _P#0 /\
MSP#_ ,L _P#' /\ _P # /\   #_    _P $ /\ #0#Z !8 ]@ C /, , #P
M #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V -@ ? #4 (( T@"( -
MCP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\ OP#^ +X _P"] /\ O #_
M +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M !$ Z  < ., *0#? #4
MVP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,, =0#! 'L OP"" +X B "\
M )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X *P _P"K /\ K #_ *P
M_P"K /\ _P0  /\   #V    [@   .<   #?  P U@ 5 ,\ (@#* "X QP Z
M ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q '4 KP![ *T @@"K (H
MJ0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T _P"< /\ G #_ )L _P";
M /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0 ,  &@"[ "< MP R +,
M/0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\ H0!U )\ ? "= (0 FP"-
M )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ". /\ C0'_ (T!_P"- ?\
M^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0 $@"N !X J@ J *8 -0"B
M #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O )$$=@"0!'\ C@6( (P%
MD@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\ @ S_ ( ,_P" #/\ \14
M . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B!Q8 G0DC )D*+@"5"S@
MDPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.<0"##GH @@Z$ ( .CP!^
M#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_ '03_P!T$_\ Z!X  -,F
M  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q  D! ; (P1)P")$C( AA,[
M (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W%70 =A9^ '06B@!R%Y8
M<1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;_P!J&_\ X"8  ,HM  "\
M,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6 ($9(@!^&BP >QLV 'D;
M/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G  :QYZ &H>A0!H'Y( 9Q^@
M &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A(O\ URP  ,,T  "V.
MJCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A'0!T(B< <2(Q &\C.0!M
M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U &$E@0!?)HX 7B:= %TG
MK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\ SS(  +XY  "Q/0  IC\
M )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K*", :2@L &8I-0!E*3P
M8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL?0!8+(L 5BV: %4MJ@!4
M+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8  +H]  "M0@  HD0  )A$
M  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\ 82XH %\N,0!=+CD 7"]
M %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1,8@ 4#*7 $XRJ !-,[L
M3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"  "I1@  GDD  )5)  "+
M1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E %@S+0!6,S4 53,\ %,T
M0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4 2C>5 $@WI@!'.+@!1SC3
M 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F2@  G$T  ))-  "(2P
M?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W*@!0-S( 3S@Y $TX0 !,
M.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3 $,\I %"/+8!03W0 4$]
M\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@  F5   (]1  "%4   >TP
M &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+.R\ 23PV $<\/0!'/$0
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M #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^70  <UH  &55  !;4@
M4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*-0 X2ST -TM$ #9+30 T
M3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$[' "Q.Z0 L3?T +4W_ "U,
M_P M3/\ L%   *18  "970  CV$  (9B  ![80  <%\  &);  !86   3E4
M $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R4#H ,5!" #!12@ N45,
M+5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93YP F4_P )U+_ "=1_P G
M4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64  &!A  !57@  2EL  #]8
M   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8 *E<^ "E71P H5U  )EA:
M "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?6/H (%C_ "!7_P A5_\
MJ%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH  !190  1F,  #M@   Q
M7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ "%>0P @7TP 'U]7 !Y?
M8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D &%[_ !E>_P 97?\ I&
M )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,;   06L  #9I   M9P
M(V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG/@ 79T@ %F=3 !5H7P 3
M:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_ !%E_P 19?\ GV<  )9O
M  ",<P  @G8  'AX  !M>   8'<  %-V  !&=   .W,  #%R   G<0  'G$
M !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .<4( #G%.  UQ6P ,<6D
M"W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN_P );O\ FV\  )%U  "'
M>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T  "I\   A?   &'P  !%\
M!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T  WQ(  %\50  ?&,  'QT
M  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P  >/\ EG<  (Q\  "#@
M>8,  &R$  !>A0  488  $6'   YAP  +8<  ".'   :AP  $H<   V( 0 &
MB0H  8D/  ")%   B!L  (@C  ")+   B38  (E"  "(3@  B%T  (AM  "(
M@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\ D'X  (>#  !^AP  <8D
M &.+  !6C0  28\  #R1   PD0  ))$  !J2   2DP  #90   :5    E@8
M )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "61@  EE4  )9E  "6>
ME8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8  (.*  !UC0  9Y   %F4
M  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP  !*    "B    HP$  *,'
M  "C#   HQ   *05  "D'   I24  *8O  "F/   IDL  *9;  "F;@  I80
M *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1  !JE0  7)D  $Z=  !!
MH   ,Z(  ":C   ;I0  $:<   JI   !JP   *T   "O    L    +    "P
M!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\  +=0  "W8@  MW@  +>0
M  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?G0  4*(  $*F   TJ0
M)JL  !JM   0KP  ";(   "T    MP   +H   "\    O0   +X   "^
MP (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#  #+50  S&H  ,R#  #,
MG   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@  1*L  #:P   GL@  &K4
M !"X   'NP   +X   #!    Q    ,@   #+    RP   ,T   #.    T
M -(   #5 P  V H  -L0  #>&   XB0  .,U  #D2   Y5P  .9S  #FC0
MYJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4  "BY   :O   #\    7$
M    QP   ,L   #/    U    -@   #<    W0   -\   #A    XP   .4
M  #H    Z@   .T&  #Q#@  ]18  /@E  #Y.   ^4T  /IC  #[?   _)4
M /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\ %@#_ ", _P P /\ /0#_
M $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P"" /\ B0#_ (\ _P"5 /X
MFP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\ \P#_ /( _P#L /\ X@#_
M -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_ !X _P K /\ . #_ $0
M_P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8 @P#T (D \@"/ /$ E@#O
M )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_ .( _P#@ /\ U0#_ ,X
M_P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D _P E /T ,@#[ #X ]P!)
M /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D (, X@") .  D #> )<
MW "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L _P#* /\ R #_ ,( _P"^
M /\ _P   /\   #_    _P   /L "P#V !, \0 @ .T + #J #@ YP!# .,
M30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P S "# ,H B0#( )$ Q@"9
M ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W /\ M@#_ +0 _P"Q /\
M_P   /\   #_    ]@   .X !0#G  \ X0 9 -L )0#5 #$ T@ \ ,X 1@#*
M $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\ +@ @P"V (H LP"3 +$
MG "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\ I #_ *0 _P"D /\ _P
M /P   #Q    Z    .    #4  L S  3 ,< 'P#" "H OP U +P /P"X $@
MM0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *< ? "E (0 HP", *$ E@"?
M *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_ )4 _P"5 /\ _ $  / %
M  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ", KP N *L . "I $$ I@!*
M *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6 'T E "& )( D "0 )L
MC@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8 _P"& /\ ] P  .00  #1
M$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F )X ,0": #H F !# )4
M2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '< A@"  (0 BP"" )8 @ "C
M 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X!O\ ZA,  -8:  #&'0
MNAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"*0"- S, BP0\ (@%1 "&
M!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\ '@)A@!V"9( = J@ ',*
MKP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\ X1P  ,LC  "\)@  L28
M *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!#2P ?@TU 'P./0!Z#D4
M> Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0@@!K$(\ :1&= &@1K0!F
M$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0  ,,J  "U+@  JB\  * M
M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R< <Q0P '$4. !O%3\ ;15&
M &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A&(L 7QB9 %X9J0!<&;P
M7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ  "O-0  I#8  )LT  "2
M,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK &<;,P!E'#L 9!Q! &(=
M2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X< 5B"6 %4@I@!4(;@ 4R'2
M %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K.@  H#P  )8[  "-.
M@S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B+P!=(C8 6R(] %HC1 !8
M(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3 $XGHP!,)[4 3"C. $LH
M[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P  G$$  ))   ")/@  ?SD
M '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5*#( 5"@Y %(H0 !1*$8
M4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<LH0!&+;, 12W+ $4N[ !$
M+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44  (]%  "%0P  >SX  '$Y
M  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\ 32TV $PM/ !*+4, 22U*
M $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@! ,K$ /S+( #\SZ@ _,_X
M/S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)  "#2   >$0  &T^  !C
M.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R $8Q.0!$,4  0S)' $(R
M3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\ .C?& #DWZ  Y-_P .C?_
M #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  " 3   =4@  &I#  !@/@
M5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U-@ _-CT /C9% #TW30 \
M-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$ #0[Y@ T._L -3O_ #4Z
M_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4   <TT  &=(  !<1   4C\
M $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z.CL .3M" #@[2@ W/%,
M-CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_Y  O/_H ,#__ # ^_P P
M/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(  &1,  !920  3T4  $5
M P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@ -#]  #- 2  R0%$ ,4%;
M #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J0_D *D/_ "M"_P K0O\
MKDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2  !73@  34L  $-'   Z
M0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4] "U%1@ L14\ *T99 "I&
M9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/< )4?_ "5'_P F1_\ JD\
M )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !550  2U$  $!-   U2@<
M,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+0P F2TP )4M6 "1,8@ C
M3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_ !],_P @2_\ IU,  )Q:
M  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P  1U@  #Q5   R4@( *E ,
M "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @44D 'E)3 !U27P <4FT
M&E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1_P 94?\ HUD  )A@  "/
M90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\  #A<   N6@  )5@( "!7
M#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4 %EE0 !596P 466D $UIZ
M !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 16/\ GU\  )5F  ",:P
M@FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E   I8P  (&$! !A@"P 5
M8!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+  YA6  -868 #&)V  MB
MB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\ FV8  ))M  "(<0  ?G,
M '5U  !J=   7',  $]R  !#<   .&\  "UN   D;   &VL  !-K!  .:@P
M#6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K4P $:V$  FMQ  !JA
M:I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT  (US  "$=P  >WH  '![
M  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@  %78   ]V @ )=@H !'8/
M  !V%0  =AP  '8D  !U+   =38  '5!  !U3@  =5P  '5L  !U?@  =),
M '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ  " ?@  =H   &F!  !;
M@@  3H(  $&"   U@P  *8(  !^!   6@0  $((   J"   "@P<  ((-  ""
M$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4  (%E  "!>   @8T  ("B
M  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![A   ;H8  &"(  !2B@
M18L  #F,   LC   (8P  !>,   0C0  "8X   */    D ,  (\)  "/#@
MCQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=  "/<   CX4  (Z<  ".
MLP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP  9(T  %:0  !(DP  .Y4
M "Z6   BE@  %Y<   ^8   (F0   )L   "=    G0   )T#  "="0  G0T
M )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@9@  GWL  )Z3  ">JP
MG<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698  $N9   ]G   ,)X  ".?
M   7H   #J(   >D    I@   *@   "J    J@   *H   "K 0  JP<  *P,
M  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@  L6\  +&(  "QH   L+H
M *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C   QI@  (Z<  !>I   .
MJP  !:X   "P    L@   +4   "W    MP   +@   "Y    N@   +P#  "]
M"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(  ,9Z  #&E   QJT  ,;(
M  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   DKP  %K$   VT   #MP
M +H   "]    P    ,0   #&    Q@   ,@   #)    RP   ,P   #.
MT 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K  #AA0  X9\  .&W  #A
MSP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0  #;P   &_    PP   ,<
M  #*    SP   -,   #6    UP   -H   #<    WP   .$   #C    Y@
M .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X=   ^(\  /FF  #YN
M^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L /\ .0#_ $4 _P!0 /\
M60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H _0"0 /P EP#Z )X ^0"G
M /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F /\ W #_ -( _P#- /\
M_P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\ ,P#_ #\ _P!* /X 5 #[
M %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"* .T D0#L )D Z@"A .@
MJP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\ S #_ ,4 _P#! /\ _P
M /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V #D \P!% .\ 3@#L %<
MZ0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L BP#8 )( U0"; -( I #/
M *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_ +@ _P"U /\ _P   /\
M  #_    _@   /< "0#Q !$ ZP < .< * #D #, X0 ^ -T 2 #8 %$ TP!8
M -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #" (P P "4 +X G@"[ *@
MN0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P _P"I /\ _P   /\   #Z
M    \0   .@  P#@  T V  6 -$ (@#- "T R@ W ,8 00#" $H OP!2 +T
M60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4 K0"- *L EP"I *$ IP"N
M *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"< /\ _P   /<   #K
MX0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0 .@"Q $, K@!+ *L 4@"I
M %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "& )H D "8 )L E@"G )0
MM@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\ ^    .D"  #; P  S $
M ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A #P G@!$ )P 2P": %(
MF !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L B@") )4 AP"A (4 KP"#
M ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H  -P.  #*$   O@X  +4+
M  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4 D  ^ (X 10", $L B@!1
M (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![ (\ >0"< '< J@!U +L
M= #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7  "_&0  LQD  *H5  "C
M$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W (  /@!^ $4 ?0!+ 'L
M40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL ; .8 &L#I@!I!+< : 7.
M &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V(P  JR,  *$@  "9&P
MDA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(. !R"3\ < E% &\*3 !M
M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5 & -I !?#;8 7@W. %P.
M[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P  I"L  )HI  "2)   B1\
M ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G$#D 91!  &001@!C$$T
M81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83H@!5$[0 5!/+ %,4[ !2
M%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(  )4Q  ",+0  @R<  'HA
M  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30 7!4[ %L60@!9%D@ 6!9/
M %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,&K  2QO' $L;Z0!*'/T
M2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W  "'-   ?2\  '0I  !L
M(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW %(</0!1'$0 3QU+ $X=
M4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X 1"'$ $,BY@!#(OP 0R+_
M $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#.@  >34  &\P  !F*@
M7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB.@!)(D  2")' $<B3@!&
M(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?! #TGXP ]*/H /2C_ #TG
M_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P  =CL  &PV  !B,   62H
M %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#)CT 0B=$ $$G2P _*%0
M/BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<LX  W+/@ -RS_ #<L_P X
M+/\ M3H  *=   "<1   D48  (=&  !]1   <T   &@[  !?-@  53$  $PK
M!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD /"M! #LL2  Z+%$ .2U;
M #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q,?< ,C'_ #(P_P S,/\
ML3X  *1$  "92   CTH  (5*  ![20  <$4  &5   !;.P  4C8  $@Q! !"
M+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^ #4P1@ T,4\ ,S%9 #(R
M9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4 +37_ "TT_P N-/\ KD$
M *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !80   3CP  $4W   ],PL
M.3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U1  O-4P +C96 "TV8@ L
M-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_ "@X_P I./\ JT4  )]+
M  "43P  BU(  (%3  !W4@  ;$\  %])  !61@  3$(  $(]   X. @ -#@/
M #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J.DH *3M4 "@[7P G/&T
M)3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]_P C//\ J$D  )U/  "2
M4P  B58  ']7  !U5@  :E,  %U/  !33   2D@  $!$   V0 4 +ST- "T]
M$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@ (T!2 ") 70 A06H ($%Z
M !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >0?\ I4T  )I3  "06
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M !5,5P 43&4 $TUU !)-B  139P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\
MGE<  )1=  "+8@  @64  '=F  !M9@  8V0  %9A  !*7@  /UL  #58   K
M5@  (E0! !I2"@ 64A  %5(6 !12'0 34B0 $E(L !%2-  14CX $%-(  ]3
M5  .4V( #51R  Q4A  +5)@ "52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT
M )%D  "(:   ?FL  '1L  !K;   7VH  %)G  !%9   .F(  #!@   F7@
M'5T  !5;!0 06@P #EH1  Y:&  -6R  #%LG  M;,  *6SH "5M%  =;40 &
M6UX !%MM  -;@  !6Y0  %NH  !;P   6N(  %KV  %:_P "6?\ EV0  (YK
M  "$;@  >W   ')R  !G<0  67   $QN  ! ;   -6L  "II   A9P  &&8
M !%F 0 ,90H !V4/  1E%  #9!L  F0C  !D+   9#4  &1   !D3   9%H
M &1I  !D>P  9(\  &.D  !CNP  8MT  &+T  !B_P  8?\ DVP  (EQ  "
M=0  >'<  &UX  !@=P  4G8  $9U   Y=   +G0  "-R   :<0  $G$   UQ
M   &<0@  ' -  !P$@  <!<  &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D
M  !O=0  ;HH  &V@  !MM@  ;-8  &OR  !K_P  :_\ CG,  (5X  !]>P
M<WT  &5^  !8?@  2WX  #Y^   R?@  )GT  !Q\   3?   #7P   9]
M?04  'P+  !\#P  ?!,  'P9  !\(0  ?"D  'PT  ![0   >TX  'M>  ![
M;P  >H0  'J:  !YL0  >,X  '?O  !V_@  =O\ B7H  (%_  !X@@  :X,
M %V%  !/A@  0H<  #6(   IAP  '8<  !2'   -B   !HD   "*    B@
M (D&  ")#   B0\  (D3  ")&@  BB(  (HL  "*.   BD8  (E6  "):
MB7P  (B4  "'JP  AL8  (7J  "%^P  A/\ A8(  'V&  !OB   88L  %.-
M  !%CP  .)$  "N1   ?D@  %)(   V3   $E    )8   "7    F    )<
M  "7!0  EPL  )@.  "8$P  F1H  )DB  ":+@  FCT  )E-  "97@  F7,
M )B+  "8HP  E[P  );B  "6]P  E?\ @(D  '*,  !DCP  5I,  $B6   Z
MF0  +)H  !^;   4G   #)X   .?    H0   *,   "E    I0   *4   "E
M    I@(  *<(  "G#0  J!$  *D9  "K(P  JS$  *M!  "L4P  K&<  *N
M  "JF@  JK,  *K0  "I[P  J?L =8\  &>4  !9F   2IP  #R?   MH@
M(*,  !.E   +IP   :D   "K    K@   +$   "R    L@   +,   "T
MM0   +8   "X!   N0L  +L0  "]&   OR0  +\U  # 1P  P%L  ,!R  #
MC0  P:8  ,#!  "_XP  OO, :I<  %N<  !-H0  /J4  "^I   AJP  $ZT
M  NP    LP   +4   "X    O    +\   #!    P0   ,,   #$    Q@
M ,<   #)    RP   ,X(  #1#P  U1@  -@G  #9.0  VDT  -MD  #;?@
MW)D  -RP  #<R0  W., 79\  $^E  ! J@  ,J\  "*R   4M0  "K@   "[
M    OP   ,,   #&    RP   ,X   #1    T0   -0   #6    V0   -L
M  #>    X    .0   #G!@  ZPX  .\9  #P*@  \C\  /-5  #T;0  ](@
M /2A  #TM@  ],< _P ) /\ !@#_  < _P , /\ $0#_ !P _P H /\ - #_
M $$ _P!, /\ 50#_ %T _P!E /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D
MD@#W )D ]@"B /0 K #S +D \0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_
M ,D _P#$ /\ _P ! /\   #_    _P $ /\ #@#_ !< _P C /\ +P#_ #L
M_0!& /H 4 #W %@ ] !? /( 9@#P &P [P!R .T > #L 'X Z@"% .D C #G
M ), Y0"< ., I@#A +$ WP#! -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T
M_P"Y /\ _P   /\   #_    _P   /\ "P#\ !, ]P > /0 *@#R #4 [@!
M .D 2@#F %( XP!9 .  8 #> &8 W !L -H <@#7 '@ U !^ -( A0#0 (T
MS@"5 ,P GP#) *H QP"X ,4 S0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M
M /\ _P   /\   #_    ^0   /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -,
M0P#/ $P S !3 ,D 6@#' &  Q0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0".
M +< F "U *, LP"P +$ P@"N .  K #W *L _P"J /\ J #_ *, _P"@ /\
M_P   /\   #U    ZP   .$   #6  P SP 3 ,H '@#& "D P@ S +\ /0"[
M $4 N !- +8 5 "S %H L0!? +  90"N &H K !P *L =P"I '\ IP"' *4
MD0"C )P H "I )X N "< ,X F@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0
M /$   #E    V0   ,T   #$  8 O0 / +< & "S "( L  L *T -@"I #X
MIP!& *0 30"B %, H !9 )\ 7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1
M )4 CP"B (T L "+ ,, B0#C (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,
M  #1    Q0   +T   "V    K@ + *@ $@"D !P H  F )P +P": #< EP _
M )4 1@"2 $P D0!2 (\ 6 "- %T BP!C (H :@"( '$ A@!Y (0 @P"" (\
M?P"; 'X J0!\ +L >@#5 '@ \@!X /\ =P#_ '< _P!W /\ YP<  -$,  ##
M#0  N P  *X(  "H    H@ % )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8
M0 "$ $8 @@!, (  4@!_ %< ?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5
M '  I !N +0 ; #* &L Z@!J /P :@#_ &H _P!J /\ VA   ,84  "X%@
MK14  *02  "<#@  E@<  )  "0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W
M $  =0!& ', 3 !R %$ < !7 &X 7@!M &4 :P!N &D =P!G (, 90"1 &,
MGP!B *\ 8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\
M )L<  "3%P  BQ$  (0,  !^! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H
M:0)  &<#1@!F TP 9 12 &,$60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7
M"*T 5@C! %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E
M  "+(0  @QL  'L4  !T#@, ;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ
M %T+0 !;#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP
M3 _" $P0XP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&
M*0  ?20  '0>  !L%P  91$' %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0
M.P!2$4( 4!%( $\14 !.$5< 3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^
M $,5WP!#%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@-   E34  (LT  "!,0
M>"L  &\F  !F(   7AD! %<4#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)
M%CX 2!9$ $<73 !%%U0 1!== $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;
MVP ['/8 /!S_ #P<_P \'/\ M3   *@V  "<.0  D3L  (<Z  !^-P  <S(
M &HM  !A)P  62$  %$;"0!,&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH
M01Q! $ <2  ^'%  /1U9 #P>9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U
M(?0 -2+_ #4A_P V(?\ LC0  *0Z  "9/@  CS\  (4_  ![/   <#@  &<R
M  !=+0  5"@  $PB!0!&'PX 0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$]
M #DA10 X(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O(
M+R;_ # F_P P)O\ KS@  *(^  "60@  C$,  ()#  !X00  ;CT  &,X  !:
M,P  42X  $@H 0! ) P /2,1 #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F
M0@ R)DH ,2=4 # G7P O*&P +BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_
M "HJ_P K*O\ K#P  )]"  "41@  BD<  (!'  !V10  ;$(  &$]  !7.
M3C,  $0N   \*0D -R@0 #4H%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M
M*T@ +"M2 "LL70 J+&H *"UY "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O
M_P F+O\ J3\  )U%  "220  B$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD
M $$T   X+P8 ,BT- # M$P N+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8
M)S!/ "4P6P D,6@ (S%W "(RB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A
M,O\ ID,  )I)  "030  AD\  'Q0  !S3P  :$P  %Q&  !20P  23\  #\[
M   V-@( +C(, "LR$0 I,A< *#(> "8R)  E,RL )#,R ",T.@ B-$, (35-
M " U6  ?-F4 'C9U !PWAP ;-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\
MHT<  )A-  ".40  A%,  'M4  !Q4P  9E   %I,  !020  1T4  #U!   S
M/0  *CD) "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ
M5@ 9.V, &#MR !8[A0 5/)D %#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L
M )51  "+50  @E@  'E9  !N6   9%8  %A1  !.3P  14L  #I'   P0P
M)T % " ^#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 3
M0&  $D%P !%!@@ 009< #T&L  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6
M  ")6@  @%T  '9>  !L70  8EL  %97  !,50  05$  #9.   L2P  (T@
M !M%"0 71 \ %404 !1%&P 312( $D4I !%%,0 113L $$9%  ]&4  .1UX
M#4=M  Q'?P +1Y, "4>G  A'O@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'
M8   ?6(  '-C  !J8@  8&$  %->  !'6@  /%<  #)5   H4@  'U   !=.
M!  13 P #TP1  Y,%P .3!X #4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI
M  1.>P "3H\  4ZD  !-N@  3=L  4WR  %-_P "3/\ EEL  (UB  "$9@
M>F@  '%I  !H:0  7&<  $]D  !"80  -U\  "U<   C6@  &E@  !)7 0 -
M5@D "54.  =5$P &51H !%4B  -5*@ "530  %4^  !52@  5E<  %9E  !5
M=P  58L  %6@  !5M@  5-0  %3Q  !3_0  4_\ DV(  (IH  " ;   =VX
M &]O  !C;@  5FP  $EJ   ]:   ,F8  "=E   =8P  %6(   YA   )8 @
M V -  !?$0  7Q<  %\>  !?)@  7R\  %\Z  !?10  7U,  %]A  !><@
M7H<  %V<  !=L@  7,\  %SO  !;_0  6_\ D&H  (9O  !]<@  =70  &IU
M  !==   3W,  $)R   V<   *V\  "!N   7;0  $&P   IL   ":P8  &L+
M  !J#P  :A0  &H:  !J(0  :2H  &DT  !I0   :4X  &E<  !I;0  :((
M &B8  !GK@  9LH  &7M  !E_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5
M>P  2'H  #MZ   O>@  (WD  !EX   1=P  "G<   -W    =P(  '<(  !V
M#0  =A   '85  !V&P  =B,  '8N  !U.@  =4<  '56  !U:   ='P  '22
M  !SJ@  <L0  ''I  !P^P  </\ AGD  ']]  !V?P  :($  %J"  !,@@
M/X,  #*$   E@P  &H,  !&#   *@P   H,   "$    A0   (0#  "#"
M@PT  (,0  "#%0  A!P  (0F  "$,@  A#\  (-/  "#8   @G4  (*,  "!
MI   @+T  '_C  !^^0  ?O\ @H   'J$  !LA@  7H@  %"*  !"BP  -8T
M ">-   ;C0  $8X   J.    CP   )$   "2    D@   )(   "2 0  D@<
M )(,  "2$   DQ4  ),=  "4*   E#8  )1%  "35P  DVL  )."  "2G
MD;8  )#8  "/\P  C_\ ?H<  '"*  !AC0  4Y   $63   WE0  *98  !R7
M   1F   "9D   ";    G    )X   "@    H    *    "@    H0   *$$
M  "B"0  HPX  *04  "E'0  IBH  *8Z  "F3   I6   *5X  "ED@  I*P
M *3)  "CZP  HOH <XX  &21  !6E0  1YD  #F<   JG@  ':   !&A   (
MHP   *4   "G    J0   *P   "N    K@   *X   "O    L    +$   "R
M    LP8  +4-  "W$P  N1X  +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[
M  "ZW@  N?( 9Y4  %B9  !*G@  .Z(  "RF   =J   $:H   >L    KP
M +$   "T    N    +L   "\    O    +X   "_    P    ,(   #$
MQ@   ,@#  #+"P  SQ(  -$@  #1,@  TD8  --=  #4=@  U)(  -6K  #5
MQ   U.( 6YT  $RB   ]IP  +ZP  !^O   1L0  ![4   "X    NP   +X
M  #"    QP   ,H   #,    S    ,X   #0    T@   -4   #8    VP
M -\   #B    Y@L  .L3  #L)   [3@  .Y.  #O9P  \((  /"<  #PL@
M\<4 _P # /\  0#_  0 _P ) /\ #P#_ !@ _P D /\ , #_ #P _P!' /\
M40#_ %D _P!@ /T 9P#\ &T ^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"=
M /  IP#N +, [ #$ .L X0#J /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\
M_P   /\   #_    _P   /\ # #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R
M %, \ !; .X 80#L &< Z@!M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T
MH #; *P V "[ -0 T0#3 /  T #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P
M /\   #_    _P   /T " #W !  \P : .\ )@#M #$ Z  [ ., 10#@ $T
MW !5 -D 6P#6 &$ TP!G -$ ; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@##
M *4 P "R +X Q0"\ .4 N@#[ +@ _P"W /\ L #_ *D _P"E /\ _P   /\
M  #^    ]0   .P  P#E  T WP 5 -H ( #4 "H T  U ,L /@#( $< Q0!.
M ,( 50#  %L O@!A +P 9@"Z &P N !R +8 > "U (  LP"( +$ D@"N )X
MK "J *D NP"H -4 I@#S *0 _P"C /\ H0#_ )L _P"8 /\ _P   /L   #P
M    Y0   -@   #.  D QP 1 ,( &@"^ "0 NP N +< . "T $  L0!( *X
M3@"L %0 J@!: *D 7P"G &4 I0!K *0 <0"B '@ H "! )X BP"< )8 F0"C
M )< L@"6 ,< DP#H )( _@"1 /\ D #_ (T _P"+ /\ ^0   .L   #=
MSP   ,8   "\  0 M0 - +  %0"L !X J  H *4 ,0"B #D GP!! )T 2 ";
M $X F0!3 )< 60"6 %X E !D )( :@"0 '$ C@!Z (P @P"* (\ B "< (8
MJ@"$ +P @@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\ [    -H   #)    O@
M +8   "N    IP ) *$ $ "< !@ F  B )4 *@"2 #( D  Z (T 00"+ $<
MB0!- (< 4@"& %@ A != (( 9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U
M +0 <P#, '$ [0!P /\ < #_ '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$
M  "A    FP # )0 # "/ !, B@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!'
M 'D 3 !W %( =@!7 '0 70!R &0 < !M &\ =@!L (( :@"/ &D G0!G *X
M90## &0 Y !C /H 8P#_ &( _P!C /\ T X  +\2  "R$P  IQ(  )T0  "5
M"P  CP,  (D !P""  X ?@ 5 'H '@!V "4 =  M '$ - !O #H ;@!  &P
M1@!J $P :0!2 &< 6 !F %\ 9 !G &( <0!@ 'P 7@") %P F !; *D 60"\
M %@ W !8 /0 6 #_ %< _P!7 /\ QA8  +8:  "J'0  GQP  )49  "-%
MA0\  'X)  !W 0H <@ 0 &X %P!J !\ :  G &4 +@!D #0 8@ [ &  0 !?
M $8 70!, %P 4P!: %H 6 !B %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"
MT@!-!/  307_ $T%_P!-!?\ OQT  + B  "C)0  F24  (\B  "%'0  ?1@
M '42  !N#0( 9P8, &,#$0!? AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$
M4P9' %$&3@!0!U4 3@=> $T(9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$
M#.\ 0PW_ $,-_P!$#?\ N20  *HI  ">+   E"P  (HJ  " )@  =R$  &X;
M  !F%   7P\% %D+#0!5"A, 4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U"
M $@-20!&#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$
M.Q'_ #L1_P \$?\ M"D  *8O  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A
M'0  618  %$1" !,#Q  2A 6 $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 1
M10 ^$DT /1)6 #P280 Z$VT .1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_
M #06_P T%O\ KRX  *(T  "7-P  C#@  ((V  !X-   ;BX  &4J  !<)
M5!X  $P8! !&% T 0A02 $ 4&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W
M%DH -A=3 #477@ S&&H ,AEY # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;
M_P N&_\ K#(  )\X  "4.P  BCP  ( \  !V.0  :S0  &(O  !9*@  4"4
M $<?  ! &@H /!D0 #H9%@ X&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T<
M+QQ0 "X=6P M'6< +!YV "H>B  I'YL *!^N "<@QP F(.H )R#^ "@@_P H
M(/\ J38  )T\  "2/P  AT$  'U   !T/@  :3H  %\U  !6,   32L  $0E
M   [( < -AX. #,>$P R'AD ,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%.
M "DA6  G(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\
MICH  )H_  "/0P  A44  'M$  !R0P  9S\  %TZ  !3-@  2C$  $$L   X
M)@, ,2,, "XB$0 L(A8 *B(= "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F
M5@ B)F, (2=R !\G@P >*)< '2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX
M )A#  "-1P  @TD  'I)  !P1P  9D0  %H_  !1.P  1S<  #XR   U+0
M+"@) "@G#P G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =
M*V  &RMO !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'
M  "+2P  @DT  'A-  !N3   9$D  %A$  !/0   1CT  #TX   S-   *B\&
M "0L#0 A+!( ("P8 !\M'@ >+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X
M%C!M !4Q?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")
M3P  @%$  '92  !M4   8DX  %9)  !-1@  1$,  #L_   Q.@  )S8# !\R
M"P <,A  &S(5 !DR&P 8,B( %S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K
M ! V?0 /-I$ #C:F  TWO  --]T #3;V  XV_P /-O\ FTD  )%/  "'4P
M?E8  '56  !J50  8%,  %5/  !,3   0DD  #A%   N00  )#T  !PZ"  6
M. X %3@2 !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[
M>@ *.XT "3RB  <\N  '/-4 "#SP  D[_P *._\ F$X  (Y4  "%6   ?%L
M ');  !H6@  7E@  %-5  !)4@  /DX  #1+   J1P  (40  !A" P 20 L
M$#\0  X_%0 ./QP #4 C  Q *P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #
M08H  4&?  !!M   0=   4'N  %!_  "0/\ E50  (Q9  "#7@  >6   '!@
M  !F8   75X  %%;  !%5P  .E0  "]1   E3P  '$P  !1*   .2 @ "T<.
M  A'$@ '1QD !D<@  5(*  #2#$  D@[  !(1P  2%,  $AB  !(<P  2(8
M $B;  !(L0  1\P  $?M  !'^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E
M9@  660  $Q@  ! 70  -5L  "I9   @5P  %U4  !!3   +4@< !5$-  %0
M$0  4!8  % =  !0)0  4"X  % X  !00P  4%   %!>  !0;P  4(,  $^8
M  !/K@  3LD  $[K  !-^P  3?\ CV$  (9F  !]:0  =&P  &QM  !A:P
M4VD  $9G   Z9   +V,  "1A   :7P  $EX   Q<   &7 8  %L+  !:#P
M6A,  %H9  !9(0  62D  %DS  !9/P  64P  %E:  !9:P  6'X  %B4  !7
MJP  5\4  %;I  !5^P  5?\ C&@  ()M  !Z<   <G(  &=R  !:<0  3'
M #]N   S;0  *&L  !UJ   4:   #6<   =G    9@,  &8)  !E#0  91$
M &05  !D'   9"0  &0N  !D.@  8T<  &-5  !C9@  8WH  &*0  !AIP
M8,$  %_F  !?^@  7O\ AV\  ']T  !X=P  ;G@  &!X  !2=P  17<  #AV
M   K=@  ('0  !9S   .<P  !W(   !R    <@   '$%  !Q"@  <0X  ' 1
M  !P%P  <!X  ' G  !P,P  ;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P
M &OB  !J^   :?\ @W<  'Q[  !S?0  97X  %=_  !)?P  /'\  "^    B
M?P  %WX   ]^   '?@   '\   !_    ?P   'X   !^!0  ?@H  'X-  !^
M$0  ?A<  'X@  !^*P  ?3D  'U(  !]60  ?&T  'R$  ![G   >K8  'G:
M  !X]0  =_\ @'\  '>"  !I@P  6X4  $V&   _B   ,HD  "2)   8B0
M#XD   >*    BP   (P   "-    C0   (P   ",    C ,  (P(  "-#0
MC1$  (T7  ".(@  CB\  (X_  "-4   C60  (Q[  ",E0  BZX  (K-  ")
M[P  B?\ >X4  &V(  !>B@  4(T  $*/   TD0  )I(  !F3   .E   !I4
M  "6    F    )H   ";    FP   )L   ";    FP   )P   "=!0  G0L
M )X0  "?%P  H"0  * T  "@1@  H%D  )]P  "?B@  GJ4  )["  "=Z
MG/D <(P  &&/  !3D@  1)8  #:9   GFP  &9P   ^=   %GP   *$   "C
M    I0   *@   "I    J0   *D   "J    JP   *P   "M    K@$  + )
M  "R#P  LQ@  +0G  "T.0  M4T  +1D  "T?@  LYH  +.T  "SU0  L_
M9),  %67  !'FP  .)\  "FB   :I   #J8   2H    JP   *T   "P
MM    +8   "X    N    +D   "Z    O    +T   "_    P    ,,   #%
M!P  R0\  ,H:  #++   S$   ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L
M $F@   ZI0  +*D  !RK   /K@  !+$   "T    MP   +H   "^    PP
M ,8   #(    R    ,H   #+    S0   ,\   #2    U0   -D   #=
MX04  .8/  #G'@  Z#(  .E(  #J8   ZWL  .N7  #LK@  [,( _P   /\
M  #_    _P & /\ #0#_ !4 _P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!;
M /H 8@#X &@ ]@!N /4 = #T 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T
MYP"] .4 V #D /, X@#_ .  _P#0 /\ Q #_ +P _P"V /\ _P   /\   #_
M    _P   /\ "0#_ !$ _P < /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@
M7 #F &( Y !H ., ;@#A ', WP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T
M ,P R0#) .D R #_ ,< _P#! /\ MP#_ *\ _P"K /\ _P   /\   #_
M_P   /@ !0#R  X [@ 7 .H (@#F "P X0 W -T 0 #8 $D TP!0 -  5@#.
M %P S !B ,H 9P#( &T Q@!S ,0 >0#" ($ P "* +X E "\ )\ N0"L +8
MO@"T -T LP#W +$ _P"P /\ J #_ *( _P"> /\ _P   /\   #Y    [P
M .8   #?  L U@ 2 -  ' #, "8 R  P ,0 .@#  $( O0!* +L 4 "X %8
MM@!; +4 80"S &8 L0!L +  <@"N 'H K "" *D C "G )@ I0"E *, M "@
M ,L GP#N )T _P"< /\ F0#_ )0 _P"1 /\ _P   /8   #J    W0   ,\
M  #'  8 P  / +L %P"W "  LP J +  ,P"M #L J@!# *< 20"E $\ HP!5
M *( 6@"@ %\ G@!E )T :P"; '( F0![ )< A0"4 )  D@"= )  K ". +\
MC #B (L ^@") /\ B0#_ (8 _P"# /\ ]    .0   #4    R    +\   "U
M  $ K@ + *D $@"E !L H0 C )X + "; #0 F  \ )8 0P"4 $D D@!. )
M4P". %D C0!> (L 9 ") &L AP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/
M 'D \0!X /\ =P#_ '< _P!U /\ Y0   -$   ##    N    *\   "H
MH  & )H #@"5 !4 D0 > (X )@"+ "T B  U (8 / "$ $( @@!' (  30!_
M %( ?0!8 'L 7@!Y &4 > !M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H
MYP!I /T : #_ &@ _P!I /\ U0,  ,,'  "V"   JP8  *(   ";    E
M (T "@"( !  @P 8 '\ ( !\ "< >@ N '< -0!U #L = !! '( 1P!P $P
M;P!2 &T 6 !K %\ :0!F &< < !E 'L 8P"( &( EP!@ *< 7@"[ %T W !<
M /8 7 #_ %L _P!; /\ R0T  +D0  "L$0  H1   )<-  "/"   B    ((
M!0![  T =P 2 ', &@!O "$ ;  H &H +P!H #4 9P [ &4 00!C $8 8@!,
M &  4@!? %D 70!A %L :@!9 '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\
M4 #_ %  _P!0 /\ OQ0  + 8  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q
M  @ :P . &< % !D !L 80 B %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4
M30!3 %0 4@!< %  90!. '  3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[
M $8 _P!% /\ N!L  *H@  ">(@  DR(  (D?  " &@  =Q4  &\0  !H"P
M800* %T $ !9 !8 5@ = %0 (P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !)
M $\ 1P%7 $8!80!$ FP 0P)Y $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'
M_P \!_\ LB(  *4G  "9*0  CBD  (0G  ![(P  <1X  &D8  !A$@  6@T#
M %,(# !/!1$ 3 47 $H&'@!(!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L
M/@E3 #T)70 ["F@ .@IV #@+AP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T
M#?\ K2<  * L  "5+P  BR\  ( N  !W*@  ;24  &0@  !<&@  5!0  $P/
M!@!&# T 0PP2 $$,&  _#!\ /@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0
M #0.6@ S#F8 ,0]T # /A0 N$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\
MJBP  )TQ  "2-   AS4  'TT  !T,0  :BL  & G  !8(0  3QL  $<6  !
M$0D .Q / #D0%  W$!L -A A #00)P S$2T ,A$T #$1.P P$4, +A)- "T2
M5P L$F, *A-Q "D3@@ G%)4 )A2I "45P  D%>, )1;Z "86_P F%?\ IC$
M )HV  "/.0  A3H  'LY  !Q-@  9S$  %TM  !4*   3"(  $,=   [%P4
M-10- #(3$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F
M%V  )!AO ",8@  A&9, (!FG !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z
M  "-/0  @SX  'D]  !O.P  93<  %LR  !2+0  22@  $ C   X'@$ ,!D*
M "P8#P J&!0 *1@: "<8(  F&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X
M'QUL !T=?@ <'9$ &AZE !D>O  8']T &1_V !H?_P ;'O\ H3@  )4]  "+
M00  @4(  '="  !M0   8SP  %DW  !/,P  1BX  #TI   U)   +2 ' "<=
M#0 E'1( (QT7 "$='0 A'20 (!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J
M !@B>P 6(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6(_\ GCP  )-!  ")1
M?T8  '5&  !L1   8D$  %<\  !-.   1#0  #PP   S*P  *B8# ",B"P @
M(1  'B$5 !PB&P ;(B$ &B(H !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F
M>0 2)HT $2>B ! GN  .)]8 $"CT !$G_P 1)_\ G$   )%%  "'2   ?4H
M '1*  !J20  8$8  %5!  !,/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX
M&2<2 !@G&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .
M*XL #2R?  PLM0 ++,\ #"SO  TL_P -*_\ F40  (])  "%3   ?$X  '-/
M  !I3@  7DL  %-'  !*1   0D   #D]   O.   )30  !TP!0 6+0P %"P0
M !,M%0 2+1P $2TC ! M*@ /+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@
M"#&<  8QL0 &,<L !C'K  <P_  (,/\ ET@  (U-  "#40  >E,  '%4  !G
M4@  75   %),  !)2@  0$8  #5"   K/@  (CH  !HW 0 2- D #S,.  XS
M$P -,QD #3,@  PT*  +-#$ "C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9
M   VKP  -L@  #;H   V^0 !-?\ E$T  (I2  "!5@  >%@  &]9  !E6
M6U4  %%2  !'3P  /$P  #%(   G1   'D$  !8_   0/ < "SH-  DZ$0 (
M.Q< !CL>  4[)@ $.RX  CLX  $\0P  /$\  #Q>   \;@  /($  #R7   \
MK   .\4  #OG   [^   ._\ D5(  (A8  !_7   =ET  &U>  !C70  6EP
M $Y8  !"5   -U$  "U.   C2P  &DD  !)&   -1 8 !T,,  -#$   0Q4
M $,;  !#(P  0RL  $,U  !#0   0TT  $-;  !#:P  0WX  $.4  !"J@
M0L,  $'F  !!^0  0?\ CE@  (9>  !]80  <V,  &MD  !B8P  5V$  $E=
M   ]6@  ,E@  "=5   >4P  %5$   Y/   )304  DT+  !,#@  3!,  $L8
M  !+'P  2R@  $LR  !+/0  2TD  $M7  !+9P  2GL  $J0  !)IP  2<
M $CD  !(^   1_\ BU\  (-D  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W
M80  +%\  "%=   86P  $%D   I8   #5P,  %<)  !6#0  51   %45  !4
M&P  5",  %0M  !4.0  5$4  %13  !49   4W<  %.-  !2I   4;T  %#B
M  !0^   3_\ B&<  ']K  !W;@  ;W   &5P  !7;@  2FP  #UK   P:0
M)6@  !IF   19   "V,   1B    8@$  &$&  !@"P  8 X  %\2  !?%P
M7QX  %XH  !>,P  7D   %Y/  !>7P  77(  %V(  !<H   6[D  %K?  !9
M]P  6/\ A&X  'QR  !U=0  :W8  %UU  !/=   0G,  #5S   H<@  '7
M !-O   ,;@  !&X   !N    ;@   &P"  !L!P  :PL  &L.  !K$@  :AD
M &HB  !J+0  :CH  &E)  !I6@  :6P  &B#  !GFP  9K4  &78  !D]0
M9/\ @'4  'IY  !P>P  8GL  %1\  !&?   .7P  "Q\   ?>P  %'H   UZ
M   $>@   'H   !Z    >@   'D   !Y 0  > 8  '@+  !X#@  >!,  '@:
M  !X)0  >#(  '=!  !W4@  =V4  '9\  !UE0  =*\  '/.  !R\0  <?\
M?GT  '6   !G@0  6((  $J#   \A   +H4  "&%   5A0  #84   .%
MA@   (<   "(    B    (<   "'    AP   (<$  "'"0  APX  (@3  "(
M'   B"D  (@X  "'2@  AUT  (9S  "&C0  A:<  (3%  "#[   @OX >(0
M &J&  !<B   38H  #^,   QC@  (X\  !:/   -D    I$   "2    DP
M )4   "6    E@   )8   "6    E@   )<   "7    EP<  )@-  "9$P
MFA\  )HM  ":/P  FE(  )IH  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-
M  !0D   09,  #.6   DEP  %I@   V9   !FP   )T   "?    H0   *0
M  "E    I    *4   "E    I@   *<   "H    J0   *H$  "L#   KA,
M *XA  "N,P  KD<  *Y=  "N=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$
MF   -9P  ":?   7H0  #:,   "E    IP   *H   "L    L    +(   "T
M    LP   +0   "U    MP   +@   "Y    NP   +T   "_ 0  PPL  ,45
M  #%)0  QCD  ,=/  #':   QH4  ,:B  #&O   QMX 59D  $>=   XH@
M*:8  !FH   -JP   *T   "Q    M    +<   "Z    OP   ,$   #$
MPP   ,4   #&    R    ,H   #-    SP   -(   #6    VP   . ,  #A
M&   XRL  .1!  #E6@  YG0  .:1  #EK   Y<0 _P   /\   #_    _P !
M /\ "@#_ !( _P = /\ * #_ #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &,
M\@!I /  ;P#O '0 [0![ .L @0#I (D Z "2 .8 G #D *@ X@"W -\ S0#<
M .X V0#_ -D _P#* /\ O@#_ +4 _P"P /\ _P   /\   #_    _P   /\
M!@#_  \ _  8 /@ (P#T "X \  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C
M -P : #9 &X U@!T -0 >P#1 (( SP"+ ,T E0#* *$ R "O ,4 P0#" .,
MP #[ ,  _P"[ /\ L #_ *@ _P"D /\ _P   /\   #_    ^P   /,  0#M
M  P Z  3 ., '@#@ "@ V@ R -, / #/ $0 S !+ ,D 40#& %< Q != ,(
M8@#! &< OP!M +T = "[ 'L N0"$ +< C@"T )D L@"G *\ MP"M -  JP#R
M *H _P"I /\ H0#_ )L _P"7 /\ _P   /\   #T    Z0   .    #5  @
MS@ 0 ,D & #% "( P0 K +P -0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L
M &$ J@!F *D ;0"F '0 I !\ *( A@"@ )( G@"? )P K@"9 ,, EP#G )8
M_P"5 /\ D@#_ (T _P"* /\ _    /    #C    U    ,@   "_  , N0 -
M +, $P"O !P K  E *D +@"E #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H
MEP!? )8 9@"4 &P D@!U )  ?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@""
M /\ @0#_ 'X _P!\ /\ [0   -T   #,    P0   +@   "N    IP ) *(
M$ "> !< F@ ? )< )P"4 "\ D0 W (\ /0"- $, BP!) (D 3@"( %, A@!9
M (0 7P"" &4 @ !M 'X =P!\ (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\
M< #_ '  _P!N /\ W0   ,D   "\    L0   *D   "A    F0 # ), # ".
M !( B@ 9 (< (0"$ "D @0 P '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0
M6 !R %\ <0!G &\ < !L 'L :@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_
M &$ _P!A /\ S0$  +P%  "O!0  I0(  )P   "4    C0   (8 " "!  X
M?  4 '@ &P!U ", <@ I '  , !N #8 ;0 \ &L 00!I $< : !, &8 4@!D
M %D 8P!@ &$ :0!? '0 70"! %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0
M_P!5 /\ P0P  +(.  "F#P  FPX  )(+  ")!0  @@   'L  @!U  L <  0
M &P %@!H !T 9@ C &, *@!A #  8  V %X .P!= $$ 6P!& %H 3 !8 %,
M5@!; %0 9 !2 &X 40![ $\ B@!- )L 3 "N $L Q@!* .H 20#^ $D _P!)
M /\ N1(  *H6  ">%P  E!8  (H3  "!$   >0L  '$#  !K  8 90 - &$
M$0!= !@ 6@ > %@ ) !6 "H 5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6
M $D 7P!' &D 1@!V $0 A0!# )< 00"I $  OP _ .( /P#X #X _P _ /\
MLAD  *0>  "8'P  CA\  (0<  !Z&   <A(  &H.  !B"   7 $( %< #@!3
M !, 4  9 $X 'P!, "4 2@ K $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\
M6@ ^ &4 / !R #H @0 Y ), . "E #8 N@ V -L -0#T #4 _P U /\ K"
M )\D  "4)@  B28  '\D  !U(   ;!L  &05  !<$   5 P! $X&"@!* @\
M1P 4 $0 &@!" "  0  E #\ *P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U
M!&$ ,P1N #$%?@ P!9  +P6C "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ
M  "0+   ABT  'LK  !R)P  :"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0
M #L&%0 Y!QL . <A #8()@ U""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX
M*PML "D+?  H#(\ )@RB "4,MP D#-, (PWP "0-_P E#?\ I"H  )@O  "-
M,@  @S(  'DQ  !O+@  92D  %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,
M$0 Q#!8 +PP< "X-(@ M#2@ *PTN "H--0 I#3T )PY& "8.4  D#EP (P]J
M "(/>P @$(X 'Q"B !T0MP <$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@
M@#<  '8V  !M,P  8R\  %DJ  !0)0  2"   #\:   X%0  ,!$( "P0#@ J
M$!( *! 8 "<0'@ E$"0 )! J ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3
M>  :$XL &!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL
M '0[  !K.   830  %<O  !.*P  128  #TA   T'   +1<% "83#  C$Q
M(A,5 " 3&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4
M&(D $QB> !(8LP 1&<X $1GO !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_
M  !I/0  7SD  %4U  !,,   0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2
M !H7%P 9&!X &1@D !@9+  7&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(<
M#QV<  X=L0 -'<L #1WL  X=_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H
M0@  7CX  %,Z  !*-@  03(  #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<
M%0 4'1L %!TB !,=*0 2'C( $1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9
M  HBK@ )(L< "2+G  HB^P +(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@
M7$0  %(_  !).P  0#@  #@T   O,   )RP  !XG P 6(PH $B$. !$A$P 0
M(AD $"(@  \B)P .(R\ #20Y  PD1  +)5  "B5>  DF;P ')H( !B:6  0F
MK  #)L0 !";E  0F]P &)O\ E4(  (I'  "!2@  >$P  &],  !E2P  6T@
M %!$  !'00  /SX  #<[   M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8
M#"@=  LH)0 **2T "2DW  <J0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0
M*\$  "OC   K]@  *O\ DD8  (A+  !_3P  =E$  &U1  !C4   6DT  $]*
M  !'1P  /D0  #-    I/   (#@  !<T   1,04 #"\,  DN$  '+A4 !B\;
M  4O(P #+RL  C U   P/P  ,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\
M ##A   P]0  +_\ D$L  (90  !]5   =58  &M6  !B50  6%,  $Y0  !%
M30  .DD  "]%   E0@  '#X  !0[   ..04 "3<+  0V#P !-A,  #89   V
M(   -BD  #8R   W/0  -TD  #=7   W9P  -WD  #>/   VI0  -KT  #;@
M   U]0  -?\ C5   (16  !\6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@
M-4X  "I+   @2   %T8  !!#   +000 !$ *   _#@  /A$  #X6   ^'0
M/B8  #XO   ^.@  /D8  #Y4   ^9   /G8  #V,   ]HP  /+L  #S>   [
M]0  ._\ BE<  ()<  !Y7P  <&$  &AA  !?80  5%X  $=;   Z5P  +U4
M "52   ;4   $DT   Q+   &2@,  $D)  !(#0  1Q   $<4  !&&@  1B(
M $8L  !&-P  1D,  $91  !&8   17,  $6)  !$H   1+@  $/<  !"]0
M0O\ B%T  ']B  !W90  ;F<  &=H  !;9@  3F,  $%A   T7@  *5P  !]:
M   55P  #E8   =4    4P$  %(&  !1"P  40X  % 1  !/%@  3QX  $\G
M  !/,@  3S\  $]-  !.70  3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\
MA64  'QI  !T;   ;6X  &)M  !4:P  1VD  #IG   M90  (F0  !AB   0
M8   "5\   !>    7@   %T#  !<"   6PP  %H/  !:$P  61D  %DB  !9
M+0  63H  %E(  !86   6&L  %>!  !7F0  5K(  %72  !4]   4_\ @6P
M 'EP  !S<P  :',  %IR  !,<0  /W   #)O   E;@  &FP  !%K   ):@
M &H   !I    :0   &@   !G P  9@@  &8,  !F#P  910  &4<  !E)P
M9#0  &1#  !D4P  9&4  &-[  !BE   8:T  &#-  !?\0  7O\ ?70  '=W
M  !N>0  7WD  %%Y  !#>0  -G@  "EX   <=P  $78   IU    =0   '4
M  !V    =0   '0   !T    <P(  ','  !S#   <A   '(5  !R(   <BP
M '([  !Q3   <5\  '%T  !PC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D
M?@  57\  $>    Y@0  *X(  !Z!   2@0  "H$   "!    @@   (,   "#
M    @P   ((   ""    @@   ((   ""!0  @@H  ((/  ""%P  @B,  ((R
M  ""0P  @58  (%L  " A@  ?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0
M2X<  #R)   NB@  ((L  !.+   *BP   (P   "-    CP   )$   "2
MD0   )$   "1    D0   )$   "2    D@(  ),)  "4#P  E!D  )0G  "4
M.   E$P  )-B  "3?   DY@  )*S  "1V   D/8 :H@  %R*  !-C0  /Y
M #"2   AE   %)4   J6    EP   )D   ";    G0   )\   "@    H
M *    "@    H0   *(   "C    I    *4   "F!P  J!   *@<  "H+0
MJ4   *E6  "I;P  J8L  *BH  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<
M   4G0  "I\   "A    HP   *8   "H    K    *X   "O    KP   +
M  "P    L@   +,   "T    M@   +<   "Z    O0<  +\0  "_'P  P#,
M ,!)  # 8@  P'X  ,";  # MP  O]@ 4Y<  $2;   UGP  )J,  !:E   +
MIP   *H   "M    L    +,   "V    NP   +T   #     OP   ,$   #"
M    Q    ,8   #(    R@   ,P   #/    TP   -H'  #;$P  W24  -X[
M  #?4P  X&X  -^,  #=J0  W<( _P   /\   #_    _P   /\ !P#_ !
M_P 9 /\ ) #_ "\ _  Z /D 0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I
M &\ YP!U .8 ? #D (0 X@"- .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\
M_P#$ /\ N #_ *\ _P"I /\ _P   /\   #_    _P   /\  @#[  T ]P 5
M /, 'P#O "D Z@ T .8 /0#B $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D
MS@!N ,P =0#* 'T R "% ,8 D #" )L P "I +X N@"[ -D N0#W +@ _P"T
M /\ J0#_ *( _P"= /\ _P   /\   #_    ]@   .X   #G  H X0 1 -P
M&@#7 ", T  N ,L -P#' #\ Q !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H
M +8 ;@"T '4 L0!^ *\ B "M ), J@"A *@ L0"F ,@ I #M *( _P"B /\
MFP#_ )4 _P"1 /\ _P   /P   #N    XP   -@   #-  4 Q@ . ,$ %0"]
M !X N0 G +4 , "R #@ KP!  *P 1@"J $P J !1 *< 5@"E %L HP!A *$
M9P"? &X G@!V )L @ "9 (P EP"9 )0 J "2 +P D #? (X ^P". /\ BP#_
M (8 _P"# /\ ^    .D   #<    S    ,$   "X    L@ * *P $0"H !@
MI0 A *( *0"> #( G  Y )D /P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "-
M &< BP!O (D > "& (0 A "1 (( H "  +( ?0#, 'P \0![ /\ >@#_ '<
M_P!U /\ Y@   -,   #&    NP   +$   "G    H0 % )L #0"7 !, DP ;
M )  (P", "L B@ R (@ . "& #X A !$ (( 20"! $X ?P!3 'T 60![ &
M>0!H '< <0!U 'P <P") '  F !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G
M /\ TP   ,,   "U    JP   *,   ";    D@   (P "@"' !  @P 6 '\
M'0!] "0 >@ K '@ ,@!V #@ =  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A
M &@ :@!F '0 9 "! &$ D0!? *( 7@"V %P U0!; /< 6P#_ %H _P!: /\
MQ0   +8"  "I @  GP   )8   ".    AP   (  !0!Z  P =0 1 '$ & !N
M !X :P E &D *P!G #$ 9@ W &0 / !C $$ 80!' %\ 30!> %, 7 !; %H
M9 !8 &X 5@![ %0 B@!2 )L 40"N %  R !/ .X 3@#_ $X _P!- /\ NPH
M *P-  "@#0  E0P  (P(  "# @  ?    '4   !N  @ :0 . &4 $P!B !D
M7P ? %T )0!; "L 60 Q %@ -@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!,
M &@ 2@!U $@ A !' )4 10"H $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44
M  "9%0  CA,  (01  ![#0  <P@  &P   !E  , 7P + %L #P!7 !0 5  :
M %$ 'P!/ "4 3@ K $P , !+ #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &,
M/P!O #X ?@ \ )  .P"C #H N  Y -D . #U #@ _P X /\ K!<  )\;  "3
M'0  B1P  '\9  !U%0  ;!   &0,  !=!@  5@ & %$ # !- !  2@ 5 $<
M&@!% "  1  F $( *P!! #$ /P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K
M #0 >@ R (P ,0"> #  LP O ,X +P#O "X _P N /\ IQX  )HB  "/)
MA"0  'HA  !Q'0  9Q@  %\3  !7#@  4 H  $D#" !%  T 00 1 #X %@ \
M !L .@ A #D )@ W "P -@ R #0 .  S #\ ,0!' #  4  N %L +0!G "L
M=@ J (@ * "< "< L  F ,D )0#J "4!^P E ?\ HB,  )8H  "+*@  @2H
M '<H  !M)0  9"   %L;  !2%0  2Q   $,, @ ]!PD .0,. #8!$@ S 1<
M,0$< # !(@ O B< +0(M "P#-  J SL *01# "@$30 F!5@ )05E ",&=  B
M!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\ GR@  ),M  "(+P  ?B\  '0N
M  !J*P  828  %@A  !/'   1Q<  #\2   X#@0 ,0L* "X(#@ K!Q( *0<7
M "@('0 G"", )0@I "0),  C"3< (0I  " *2@ ?"U4 '0MB !L,<@ :#(4
M& R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q  "&-   ?#0  '(S  !H
M,0  7RP  %4G  !,(P  1!T  #P8   T$P  +1 & "8-"P D# \ (@P3 "$,
M&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7#E, %@YA !0/<0 3$(0 $A"8
M !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$.   >CD  ' X  !G-@
M73(  %,M  !**   0B0  #D?   Q&@  *A4! ",1!P =$ T &P\0 !D/%0 8
M$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$ $1)? ! 2;P .$X( #A.6  T3
MJP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""/   >#T  &\]  !E.@  6S<
M %(R  !)+@  0"H  #<E   O(0  *!P  " 8 P 9% H %1(. !02$@ 3$Q@
M$A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<  P7;  +%W\ "1B3  @8J  &
M&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0   =T$  &U!  !D/P  6CP  % X
M  !',P  /C   #8K   N)P  )R,  !\?   7&@@ $A<- ! 7$0 /%Q8 #A@<
M  X8(P -&2P #!HU  L:0  *&TP "1M:  <<:0 %''P !!V1  (=I@ !';P
M AS=  (<\@ #'/\ DSP  (A!  !_1   =44  &Q%  !C1   64$  $\]  !&
M.0  /C8  #4R   N+@  )2H  !TE   4(00 #QT+  T=$  ,'10 "QT:  H>
M(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P  (7D  "&.   AI   (;H  "';
M   A\@  (/X D$   (9%  !]2   =$H  &M*  !B20  6$8  $Y"  !%/P
M/3P  #4Y   K-   (B\  !DK   2* 0 #20*  DC#@ &(Q( !2,9  0D(  "
M)"@  24Q   E/   )4@  "95   F90  )G<  ":,   FH@  )KD  ";9   E
M\@  )?X CD4  (1)  ![30  <T\  &I/  !@3@  5TL  $U(  !$10  /$(
M #$]   G.0  'C4  !4R   /+@, "BP*  4K#@ !*A$  "H6   J'@  *B8
M "LO   K.0  *T4  "Q3   L8@  +'4  "R*   KH   *[<  "O6   J\@
M*O\ C$D  ().  !Z4@  <50  &A4  !?4P  5E$  $Q.  !#2P  -T<  "U#
M   C/P  &CP  !(X   ,-@, !C,)   R#0  ,A   #$4   Q&P  ,2,  #$L
M   R-P  ,D,  #)0   R8   ,G(  #*'   QG@  ,;4  ##4   P\@  +_\
MB4\  (!4  !X5P  ;UD  &99  !>60  55<  $E3   ^3P  ,DP  "A(   >
M10  %4(   Y    (/0(  3P(   [#   .@\  #D2   Y&   .2   #DI   Y
M-   .4   #E.   Y70  .6\  #B%   XG   -[,  #?2   V\@  -?\ AU4
M ']:  !V70  ;5\  &5?  !=7P  4EP  $18   X50  +5(  ")/   83
M$$H   I(   #1@$  $4&  !$"@  0PT  $(0  !!%0  01T  $$F  !!,0
M03T  $%*  !!6@  06P  $"!   _F0  /[$  #[0   ]\@  //\ A%P  'Q@
M  !S8P  ;&4  &1F  !99   2V$  #Y>   R6P  )ED  !Q6   25   #%(
M  11    3P   $X#  !-"   3 P  $L.  !+$@  2AD  $HB  !*+   2CD
M $I'  !*5@  26@  $E^  !(E@  1Z\  $;-  !%\0  1/\ @6,  'EG  !R
M:@  :VP  &!K  !2:0  1&8  #=D   J8@  'V   !5>   -70  !EL   !:
M    60   %@   !7!   5@@  %8,  !5$   5!0  %0=  !4)P  5#0  %1"
M  !34@  4V0  %)Y  !2D@  4:L  %#*  !/[P  3O\ ?FH  '=N  !P<0
M9G$  %AP  !*;P  /&T  "]L   B:@  %VD   YG   &9@   &4   !E
M90   &,   !B    8@0  &$(  !A#0  8!   & 7  !@(0  7RX  %\\  !?
M30  7EX  %YT  !=C0  7*<  %O%  !:[0  6?\ >W(  '5V  !K=P  778
M $]V  !!=0  ,W4  "9T   9<P  $'(   =Q    <0   '$   !Q    <0
M &\   !O    ;@   &X"  !N"   ;0P  &T1  !M&@  ;28  &PU  !L1@
M:U@  &MM  !JA@  ::$  &B^  !GZ   9OX >7H  '!\  !A?   4WT  $1]
M   V?@  *'X  !M]   0?0  !WT   !]    ?0   'X   !_    ?@   'T
M  !]    ?    'P   !\    ? 8  'P,  !\$@  ?!T  'PL  !\/   ?$\
M 'ME  ![?@  >IH  'FV  !XWP  =_H <X   &6!  !6@P  2(0  #F&   K
MAP  '8<  !&'   'B    (@   ")    B@   (P   "-    C0   (P   ",
M    C    (P   ",    C0   (T$  ".#   CA,  (\A  ".,@  CD8  (Y;
M  "-=   C9   (RM  "+S@  BO, :(8  %J(  !+BP  /(T  "V/   >D
M$9$   >2    DP   )4   "7    F0   )L   "<    FP   )L   "<
MG    )T   ">    G@   )\   "A P  H@P  *(6  "C)@  HSH  *-/  "C
M:   HH8  **B  "BP   H>@ 7(T  $V0   _DP  ,)8  "&9   2F@  !YL
M  "=    H    *(   "D    J    *H   "K    J@   *L   "L    K0
M *X   "O    L0   +(   "T    MP$  +D-  "Y&@  NBT  +I#  "Z6P
MNG<  +N4  "[L0  N=( 4)4  $&8   RG   (Z   !.B   (I    *<   "J
M    K    *\   "R    MP   +D   "[    N@   +P   "]    OP   ,
M  #"    Q    ,8   #)    S0   -(!  #4#P  U1\  -<U  #830  V&D
M ->&  #7HP  UKT _P   /\   #_    _P   /\  P#_  T _P 5 /\ ( #\
M "L ^  U /0 /P#P $< [@!. .L 5 #I %H YP!? .4 9 #C &H X0!P -\
M=@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+ .  R0#[ ,< _P"] /\ L0#_
M *D _P"C /\ _P   /\   #_    _P   /P   #V  L \0 1 .T &P#I "4
MY  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L 7@#) &, QP!I ,4 ;P##
M '< P !_ +X B@"[ )4 N "C +8 M "T ,T L@#R +  _P"L /\ HP#_ )P
M_P"7 /\ _P   /\   #Z    \0   .@   #@  8 V0 . -( %@#. !\ R  I
M ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0 6 "R %T L !B *X :0"L &\
MJ@!X *@ @@"F (X I "; *$ JP"? ,  G0#F )L _P": /\ E #_ (X _P"*
M /\ _P   /8   #H    W    ,X   #&  $ OP + +H $0"V !H L@ B *X
M*P"J #0 J  [ *4 00"C $< H0!, )\ 40"> %8 G !< )H 8@"9 &@ EP!P
M )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (< ]P"& /\ A #_ '\ _P!\ /\
M\@   .,   #2    Q0   +H   "Q    JP ' *4 #@"A !0 G@ < )H )0"7
M "T E  T )( .@"0 $  C@!% (T 2@"+ %  B0!5 (@ 6P"& &$ A !I ((
M<@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S /\ <P#_ '  _P!N /\ WP
M ,P   "_    M    *L   "A    F@ " )0 "P"0 !  C  7 (@ '@"% "8
M@P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !. '8 5 !T %H <P!B '  :P!N
M '4 ; "# &H D@!H *, 9@"X &0 W@!C /L 8@#_ &( _P!@ /\ S    +P
M  "O    I0   )T   "4    C    (8 !P"!  T ?  2 '@ &0!U !\ <P F
M '$ +0!O #( ;0 X &L /0!J $( : !( &< 3@!E %0 8P!; &$ 9 !? &X
M70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_ %0 _P!4 /\ O@   +    "D
M    F0   )    "(    @0   'D  @!S  H ;P / &L % !G !H 90 @ &,
M)@!A "P 7P R %X -P!< #P 6P!" %D 1P!7 $X 5@!5 %0 7@!2 &@ 4 !T
M $X @P!, )4 2@"H $D P !( .@ 1P#_ $< _P!' /\ M D  *8+  ";#
MD H  (8%  !^    =@   &\   !H  4 8P , %\ $ !; !4 6  : %8 (0!4
M "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0 $@ 6 !& &( 1 !N $(
M?0!  (X /P"B #T N  ] -T / #X #P _P \ /\ K!   )\2  "4$@  B1$
M '\/  !V#   ;@4  &8   !@  $ 60 ( %4 #0!1 !$ 3@ 6 $L &P!) "$
M2  F $8 *P!% #$ 0P V $( / !  $, /@!+ #T 4P [ %T .0!I #< >  V
M (D - "< #, L0 R ,X ,@#Q #$ _P Q /\ IA8  )H9  ".&@  A!H  'H6
M  !P$@  : X  %\*  !8 P  40 $ $P "@!(  X 1  2 $$ %@ _ !L /0 A
M #P )@ Z "P .0 Q #< -P V #X - !& #, 3P Q %D +P!E "X <P L (4
M*P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P  )4@  "*(0  ?R$  '4?  !L
M&@  8Q8  %H1  !2#0  2P<  $0 !@!   L /  / #@ $@ V !< -  < #,
M(0 Q "< ,  L "X ,P M #H *P!" "H 2P H %4 )@!A "4 <  D ($ (@"5
M "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&*   ?"<  '(E  !I(@
M7QT  %<8  !.$P  1@X  #\+   X!0< -  , #$ $  N !, +  8 "H '0 I
M "( )P H "8 +@ D #8 (P ^ "( 1P @ %( 'P!> !T ;0 < 'X &@"2 !D
MIP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$+0  >2T  ' K  !F*   720
M %0?  !+&@  0Q0  #L0   T#0( +0D) "D%#0 F Q  ) $3 "("&0 A AX
M( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9< !8&:@ 4!WP $P>0 !('I0 1
M![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0  =S(  &XQ  !D+@  6RH  %$E
M  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?"0T '0<0 !L'%0 9"!H & @@
M !<))P 6"2X %0HW !,*00 2"TT $0M: ! +:0 .#'L #@R0  T,I0 ,#;L
M"PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8  &PU  !C,P  62\  % K  !'
M)@  /B$  #8=   N&   )Q,  " 0!0 9#@H %0P. !0,$0 3#!8 $@P< !$-
M(P 0#2L #PTT  X./P -#DH # ]8  L/9P *$'D "!"-  <0H@ &$+@ !1#4
M  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ  !A.   6#4  $XP  !%+
M/2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +  X.#@ .#Q, #1 9  T0(  ,
M$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8  Q.+  $4H   $[8  !/1   3
M[@  $_L D#8  (8[  !\/@  <S\  &H_  !@/0  5SD  $TV  !$,0  /"X
M #0J   L)@  )2(  !X>   6&@( $!4)  P3#@ *$Q( "107  @4'P '%28
M!A4O  06.@ #%D8  1=3   78@  &'0  !B)   8GP  &+4  !?0   7[0
M%_L CCH  (0_  ![0@  <D,  &A#  !?0@  5C\  $P[  !#-P  .S0  #,P
M   L+   )"D  !LD   3'P( #1L)  D9#0 &&1$ !!D6  (9'0 !&B0  !HM
M   ;.   &T0  !Q1   <8   '7(  !V'   <G0  '+,  !S.   ;[0  &_P
MC#X  ()#  !Y1@  <$@  &A(  !>1@  540  $M   !#/0  .SH  #,W   J
M,@  ("T  !<I   0)0( "R()  4@#0 !'Q   !\4   ?&P  ("(  " K   A
M-@  (4$  "%/   A7@  (G   "*%   AFP  (;(  "'-   @[0  '_P BD,
M (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&  !"0P  .D   "\[   E-P
M'#,  !,O   -+ ( !RD(  $G#   )@X  "42   F&0  )B$  "8I   F,P
M)S\  "=-   G7   )VT  ">"   GF0  )K   "7,   E[@  )/T B$@  '],
M  !V4   ;E$  &52  !<40  4T\  $I,  !!20  -40  "M    A/   %SD
M ! V   *,@$  S '   O"P  +@X  "T1   M%@  +1X  "TG   M,0  +3T
M "U*   M60  +6L  "V    LEP  +*\  "O+   J[@  *OX A4T  'U2  !U
M50  ;%<  &-7  !;5@  4U4  $=1   [30  ,$D  "5&   <0P  $S\   T]
M   &.@   #@%   W"0  -@T  #4/   T%   -!L  #0D   T+@  -#H  #1'
M   T5P  -&@  #1]   SE0  ,JT  #'*   Q[@  ,/\ @U,  'M8  !S6P
M:ET  &)=  !;70  3UH  $)6   V4@  *D\  "!,   620  #D<   A$
M0@   $$#   _!P  /@L  #T.   ]$0  /!@  #PA   \*P  /#<  #Q$   \
M4P  /&4  #MZ   ZD@  .JL  #G(   X[0  -_\ @5H  'E>  !Q80  :6,
M &)D  !78@  25X  #Q;   O6   )%4  !E3   040  "D\   %-    3
M $H   !)!   2 @  $<,  !&#P  1A0  $4<  !%)P  13,  $5   !%4
M1&$  $1V  !#CP  0J@  $'&  ! [   /_\ ?F$  '9E  !O:   :&H  %UI
M  !/9@  0F0  #1A   H7P  '5T  !);   +60   E@   !6    5@   %0
M  !3    4@0  %$)  !0#0  4!   $\8  !/(@  3RX  $\\  !/2P  3ET
M $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD  '1L  !N;P  9&\  %5M  !'
M;   .6H  "QI   @9P  %&4   UD   #8@   &(   !A    8    %\   !>
M    70   %P$  !<"0  6PT  %L2  !;'   6B@  %HV  !:1@  65@  %EM
M  !8A0  5Z   %:]  !5Z   4_X >7   '-T  !I=0  6W0  $QS   ^<P
M,'(  "-Q   6;P  #6X   1M    ;0   &T   !M    ;    &L   !J
M:0   &D   !I P  : D  &@.  !H%0  9R$  &<O  !G/P  9E(  &9F  !E
M?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?>@  4'H  $)Z   S>P  )7L
M !AZ   .>0  !'D   !Y    >0   'H   !Z    >@   '@   !X    =P
M '<   !W    =P$  '<(  !W#@  =Q@  '<F  !V-@  =DD  '5?  !U=P
M=),  '.O  !RTP  <?< <7X  &-_  !4@   18(  #:#   HA   &H0   Z#
M   $A    (0   "%    A@   (@   ")    B    (<   "'    AP   (<
M  "'    B    (@   "(!P  B1   (D<  ")+   B#\  (A5  "(;0  AXD
M (:G  "%QP  A.\ 9H0  %>&  !(B   .8H  "J,   ;C0  #XT   2.
MD    )$   "3    E0   )<   "8    E@   )<   "7    EP   )@   "8
M    F0   )H   ";    G0<  )T1  "=(0  G3,  )U)  "<8@  G'\  )R<
M  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5   0E@  !)@   ":    G
M )X   "A    I    *8   "G    I@   *<   "G    J    *D   "J
MK    *T   "O    L0   +,)  "S%0  M"<  +0]  "U50  M7   +2.  "T
MK   M,P 39(  #^6   OF@  ()T  !&?   %H0   *,   "F    J0   *P
M  "O    LP   +4   "W    M@   +<   "X    N@   +L   "]    OP
M ,$   #$    QP   ,L   #-#   SAH  ,\O  #/2   T&(  -"   #0G0
MT+@                       $#! 4&" D*"PT.#Q$2$Q06%Q@:&QP='R A
M(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$149'24I+34Y/4%)35%576%E;
M7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]?H"!@H.%AH>(BHN,CH^0D9.4
ME9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6VN+FZN[V^O\'"P\3&Q\C)R\S-
MS]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P\?+T]?;W^?K[_/[_________
M_____________________________________________P
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M5%565UA96EM<75Y?8&%B8V1E9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^
M@8*#A(6&AXB)BHN,C8Z/D)&2DY25EI>8F9J;G)V>GZ"AHJ.DI::GJ*FJJZRM
MKJ^PL;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.S]#1TM/4U=;7V-G:
MV]S=WM_@X>+CY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$
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M_______/=#4+    "E*G______________________________^6-
M $^G______________________________9I'0  "0P&"5*Q____________
M_________________\L[#A,U3%M-3%[#____________________________
M_ZE@-F"&G[:LJ;C9_____________________________^"7C;[E________
M_______________________________M^?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________Z]G*O,?_________
M_________________________\^:@6U:1HCJ________________________
M________Q'P^)A   %2P_______________________________@@SP
M "Z'[?____________________________^L4Q       !=MUO__________
M__________________N ,0        EAS/__________________________
M_]): @        !=S/___________________________Z@U          !<
MT____________________________WT-          !4UO______________
M____________[GU%          !$U/___________________________*ID
M+P(   0B-TE8SO___________________________^FD:T$H/V-_E:>ZVO__
M____________________________U;*LLLSD^O______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________Y;N7=V+(_________________________________]N>9S8*
M  *,________________________________R'\_!0    !>S___________
M___________________9@3D        \JO__________________________
M__^>3          CD/___________________________]QO&@         0
M??G__________________________Z](            ;^[_____________
M_____________X03            9.;_________________________[%$
M            5][_________________________N!4             2-;_
M________________________=!0             .,__________________
M_______YHEH3            (\7_________________________WYM<+
M        #;K__________________________^^Q?54Y(A$' 0(1(K+_____
M_________________________]^_I9F8FJ"LO=K_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^.^G8!\^___________
M______________________*WA%<P#@ =K/__________________________
M____THI,%0      <O/____________________________6?S8
M2\G___________________________J1/@          +ZO_____________
M_____________\!:            &I7__________________________XTD
M            "(3_________________________YUX              '?_
M________________________M"4              &K_________________
M________?0               %OT_______________________]*P
M         $SK______________________^E                 #SA____
M__________________\P#                "W9____________________
M_YF*82<              "?7_______________________MOHE5)P
M     "7<__________________________[*G79=2CPR+2PP.4?>________
M_______________________]YMW6TM#3V>3_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________[]2[UO_________________________________GN(]J2R\5
M;_______________________________Y*%G- <     /,G_____________
M_______________6@CL         $I?__________________________^V%
M,0           &___________________________Z9"             %#A
M________________________[&D              #?)________________
M________LR\              "*V________________________>0
M         !"G_______________________R-                 "9____
M__________________^I                  ",____________________
M__]&                  !______________________]\
M      !T_____________________Y<                   !J________
M_____________\X                   !C______________________\I
M(@$               !A______________________^YHX!7-Q<
M  !H___________________________ZTZZ4AGQU<7!R=X&4____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________]NZG8)I:=/_____________________________
M_\B393T9    '9[____________________________;CDP3         &[_
M_________________________]M\+            $77________________
M_________XLJ             "*T________________________PD0
M          .7________________________?0$               !_____
M___________________G-@                !J____________________
M__^=                  !8______________________]&
M      !'^/___________________^D                    UZ?______
M_____________Y8                    EV____________________[P
M                   8SO___________________^L
M   /PO____________________\                    *N?__________
M__________\G                   *M?____________________]P
M               -N?_____________________@G(QP54(S)AL4#PT.$AHF
MO_____________________________GDV-+.S,O,S];@_/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^O3O./_
M_______________________________2J85E2"P2 87_________________
M___________QJW$\#P       $_@_________________________]5_-0
M         !^R________________________XW4=              ")____
M____________________D",               !G____________________
M___50P                !(]O____________________^*
M       NW?____________________\X                   7R/______
M_____________[X                    $MO___________________YP
M                    I?___________________[H
M    D____________________]P                     @O__________
M__________\                     =/____________________\3
M                :/____________________]"
M8/____________________]Z                    7?______________
M_______1                    8?______________________)
M            9O______________________R:R9B7UV<6QI9V9G:W!ZC/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^+%JI%Y87?_____________________________W:9W4"P,     #'$____
M_____________________^"23A,           "/____________________
M____TG =              !@_______________________N;P\
M       WXO____________________^6'                  4P/______
M______________]                     H____________________ZX
M                    B?___________________YX
M    <O___________________[P                     7___________
M_________]H                     3?____________________H
M                ._____________________\.
M*OG___________________\S                    &^G_____________
M______]>                    #]O___________________^/
M            !M#____________________0                     ,K_
M____________________*P                   ,C_________________
M____@                    ,O_____________________]Q8!!04# 0
M     08-&,O_______________________SKX=C/S,W/T-+4U]SBZO______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________QVL;_____________________
M__________'&HX1H33(8 !6K__________________________^Y?$88
M      !Q________________________UWPO               [X_______
M_______________?9 D                ,M?____________________]T
M P                  C?___________________\45
M    :O___________________YD                     2___________
M_________[8                     ,/W__________________]<
M                &>?___________________8
M!=/___________________\.                     ,'_____________
M______\O                     *____________________]2
M             )[___________________]Y                     ([_
M__________________^E                     (#_________________
M___8                     '3_____________________-@
M         &W_____________________?                    &G_____
M________________UPT                  &C_____________________
M_W                   &'_______________________]0/$9.5%E=861H
M;'!V?HG_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^_5NZ.+<UJ5________
M___________________XOXYD02$%      !2_/______________________
M]YU6&              7P?_____________________E;!8
M    C?____________________]C                    7O__________
M_________YT                     -?S__________________Z$
M                $=G__________________\H
M +O__________________^X                      *'_____________
M______\,                     (K___________________\M
M             ';___________________]-                     &3_
M__________________]O                     %+_________________
M__^4                     $#___________________^\
M         ##____________________J#@                   "+_____
M________________1                    !7_____________________
M@0                    OU____________________R L
M      +L_____________________UX                   #E________
M_____________\D<                  #:______________________^=
M 0             '#A?%________________________U;F\P<?.U=OAYNWT
M^___________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________^-_/_____________________________^S&I8AM5#LA
M!P RWO_______________________]>262D             H/__________
M____________B38                 9_____________________]F
M                ,O;__________________Y4
M \C__________________Z<                      *#_____________
M_____]<                      'S___________________\
M             %[___________________\E                     $/_
M__________________](                     "S_________________
M__]J                     !C___________________^+
M          7S__________________^O                      #A____
M_______________5                      #/____________________
M)                     "^____________________5
M      "N____________________BP                    "?________
M____________RPX                   "2_____________________U<
M                  "&_____________________ZH*
M  !Y______________________]M                  !F____________
M___________W50                !%_________________________VHC
M*S4_2E5@:G5^AY&<____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________HS[:=@VE.N?_________________________L
MLH-<.AT"        >_______________________Q6TI
M0/____________________^#&P                  !\O_____________
M_____Y(                      )C__________________Z0
M             &K__________________]T                      $'_
M__________________\.                     !W_________________
M__\Y                      #H__________________]@
M          #.__________________^%                      "W____
M______________^H                      "C___________________+
M                      "0___________________O%@
M      !]____________________/@                    !L________
M____________:0                    !:____________________F0
M                  !)____________________TA8
M   Y_____________________U@                    I____________
M_________Z(                    9______________________56
M               $______________________^[+P
M^/______________________JRD                 S_______________
M_________\E'      <3("X^4FB$[?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________35
MR?____________________________K2L))W74(H#   2O______________
M_________\5]11<             $=C____________________$4
M             )___________________Z(,                     &C_
M_________________Y0                      #;_________________
M_]H                       ?L__________________\5
M          #$__________________](                      "B____
M______________]U                      "#__________________^=
M                      !I___________________#
M      !2___________________G#P                     ^________
M____________,P                     K____________________6
M                   8____________________@0
M   %____________________K                       ____________
M________WB(                     \O___________________UP
M                W____________________Y\
MS/___________________^A*                    M_______________
M______^@%@                  G/______________________>@(
M            =________________________WH+               %3/__
M______________________^B5VAT@(V<J[S0Y_______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________MX___________________________TJ-Z6#HI(QP6#@8  )__
M____________________K%(.                 &G_________________
M_^1#                     #3__________________WD
M          #C_________________\T                       "R____
M______________\3                      "%__________________]/
M                      !=__________________^#
M       Z__________________^R                       <________
M___________; P                     "____________________*@
M                    ^___________________3P
M    Y___________________=                       U/__________
M________FP                      P/__________________Q <
M                K?__________________\#,
MFO___________________V<                     AO______________
M_____Z,                     <O___________________^-$
M            7/____________________^1!@                  0?__
M___________________K7P                  '?__________________
M____RDL                  /_______________________\M7   ,&"0Q
M/TY@=(NGQ___________________________U^?R____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________Z]3-Q\*^
MNK>SL*VIJ*7____________________=?E,_,",9$0D"          #;____
M_____________W8                       "G_________________[H
M                      !U__________________\'
M      !&__________________].                       :________
M__________^,                        _?_________________!
M                    V__________________Q&0
M    OO__________________1                       I/__________
M________:P                      C?__________________D0
M                >?__________________MP
M9O__________________WB$                     4_______________
M_____TH                     /____________________W<
M            *____________________ZP*                    %O__
M_________________^=%                     /__________________
M__^*                     /_____________________630
M         /W_____________________IRX                  -7_____
M_________________Y@J           &&"U%8.#_____________________
M__^H8W2!CYRKN\WB^O__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________Y\NWJ9V5CHF$@'QX
M='!L:&60_________________[QJ2"T9"@                 Q________
M__________\                        #__________________]"
M                    W/________________^.
M    LO_________________.                        C?__________
M________*0                      :___________________6@
M                3O__________________A@
M-/__________________K@                      'O______________
M____U!<                     "O__________________^CT
M             /___________________V4                      /__
M_________________XX                      /__________________
M_[P9                     .____________________%.
M         -C___________________^+                     +______
M_______________,0P                   *'_____________________
MD1D                  'K_____________________\G0*
M    $5_______________________^AT$Q\L.$538G*%F[32]?__________
M________________U^CT________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______[]_/Q[NSKZ^SQ___________________9LIF'>6UD75912T9!/#@R
M+2@CQ/________________]+)0L                     DO__________
M______^(                        9O_________________7
M                /?__________________,P
M&/__________________;                        /______________
M____G0                       /__________________R0P
M             /;_________________\34                      -__
M_________________UL                      ,O_________________
M_X(                      +?__________________ZD&
M         */__________________],O                     (W_____
M______________]>                     '?___________________^3
M!P                   %[____________________-0P
M     $#_____________________AQ                   !S_________
M____________V%X                   #______________________[].
M       .'"P^4FJ&I<C________________________"?(R:I[;%UNC]____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________NX=?/
MR<.^NK:QK:FGIJ:GKO________________^^AFU;3$ W+R@B'!80"P0
M%/_________________7!0                       /______________
M____-                        /;_________________=@
M             -+_________________L                        ++_
M________________X20                      );_________________
M_U$                      'S__________________WD
M         &;__________________Z                       %'_____
M_____________\<C                     #S__________________^Y+
M                     "?___________________]T
M     !#___________________^C%@                    #_________
M___________83                     #_____________________B \
M                  #_____________________RU,
M  #______________________Z4X           )'31.:XS_____________
M__________^9.4-17VY]CJ"UR^7_____________________________Z_G_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Z\RYK*&9D8N&
M@7QX='!K:&9F:/'_________________844R(Q@.!@               )[_
M________________?@                       '7_________________
MPP                       %+_________________^S<
M         #+__________________VH                      !;_____
M_____________Y8                       #__________________[\;
M                      #__________________^9"
M      #___________________]I                      #_________
M__________^0 @                    #___________________^Y+
M                  #T___________________H7
M  #9____________________D1@                   "\____________
M________RE,                   "=_____________________Y@N
M         ! I1F;$_____________________^Y_'0P:*#=&5VE^E:_,[O__
M_______________________GH*JYR-CI_/__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______WU\.OFXM_;V-32T=#2U^#_________________SIZ*?'%I85M644Q(
M0SXZ-C(O+C'_________________TB41 P                    #_____
M_____________T(                       #__________________WT
M                      #__________________[ +
M      #V_________________]TY                      #<________
M__________]B                      #%__________________^)
M                  "O__________________^O(@
M  "9___________________62                     ""____________
M________<@                    !I____________________H2@
M              !.____________________TUP                    S
M_____________________Y8N               5,E)W________________
M_____^!R$P   0\?+T)8<(NHR.S________________________*;VY^CIZP
MP]CO________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________G@
MTLC NK6PK*BEHI^=FYN<H*?__________________X)D5DM#/#8P*R<B'1@3
M#@D$  #4_________________Y(                       "M________
M_________\P>                      "+__________________M2
M                  !M__________________^
M  !1__________________^I&P                     Z____________
M_______00@                     C___________________U:
M               ,____________________CQ0
M____________________N#X                     ________________
M____Y6T#                    _____________________Y\W
M       0+U!T_____________________]UR%      &%RI!6G64MMK_____
M__________________^\6$149'6&FJ_(X___________________________
M____TLWA\?__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________/OZ^_W______________________^ZYJ)V6
MCXJ&@G][>'9T<G-U>'^0_________________^M/.C H(1L5$ L' @
M   C__________________]I                        ____________
M______^;"@                      ___________________(.0
M                ___________________P8P
M____________________B@X                     ________________
M____L#0                     ____________________U5L
M            _____________________X4:                   #[/__
M_________________[%)               8.5V!____________________
M_^5['@      #"$X4F^/L]G_______________________^[6"DY25IL@)>P
MS>W_____________________________LYZTQ=?K____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________^N_GX=S9UM32T-#0T=/9X.OW__________________^XBGYW<6QH
M9&%>6UE85U=97F5Q__________________^_,1\6$ H%
M___________________M5@                      Z/______________
M____@@0                     S/__________________JR\
M            L___________________TE<                     F___
M________________]WP0                    A?__________________
M_Z(W                  4KE/___________________\MA @
M  PL4':>T?____________________6-,       #2,[5W:9ON7_________
M_______________#8Q@J.TQ?=(VGQN?_____________________________
MJ'^6J+O0Y_____________________________________W_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^(1$$E#0U]04D]&24Q%  H*
M____________________________________________________________
M____________________________________________________________
M____________________________W<[%O[RYMK2SL;*RM;G R=7C________
M____________EVQD7EE544],2DA'1DA+4%EFH?__________________IR8.
M!P(                 5O__________________SE
M    .O__________________]'D+                    (?__________
M_________Y\R                    #O___________________\18
M            "#%:A/___________________^E_'P          !B=+<9K"
MZ?____________________^G20     "%R]*:(JNU?S_________________
M_______3=1XF.$I>=8^KR^______________________________KG*%F*S"
MV_;__________________________________]_O____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________[^RJJ:CH:"?GZ&CIJRTP,W=[/__________
M_________XI:4T]+2$9$0T)!0D-'3EEI??___________________YXN!@
M                 /___________________\-6                   5
M0?___________________^=[&@             )-&"+M/______________
M______^?/P         $)4IQF<+K_______________________&9@\    3
M*D1B@Z?-]?_________________________KCC4K/E%H@9V\WO__________
M____________________OG9_E*G!W/G_____________________________
M_____]+8\___________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________]O+P[^_O\?/X_?______
M______________________BPGYJ7EI:6F)N?I*RVPM'A[O______________
M______Z.4$I'141$1$5&1TM16FB#J?____________________^F00$
M      <V8X^ZX?_____________________&90H       0G3'.<Q.S_____
M___________________EB"\  !,J1&*"ILST________________________
M____JU V2F%[EK36^O______________________________TH=\F+'+Z?__
M_________________________________]3.[?______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________[>7CX^3FZ.WQ^?__________
M___________________]L922DI69G:.ILKS0[?______________________
M____G5-'24U15F!SBJ_6_/__________________________LE8 &C50;8NN
MTO?_____________________________S6\^7WN9M]?Y________________
M________________[I^#IL+A____________________________________
M_^/.Z_______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________P
M
M
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M_+O_ ,_;_P U=;E_/JQT?3+^XMD\I:99/8_5Y'B:WNY_]):=&'V9#RB^)?\
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M=FQ5V;%79L5?B7_S^1_YR%_PIY3TS_G'KR_.RZCYB=-1U7C^QI]N_P"ZC/\
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M );M:_[AC_\ -6;%7?\ 17C_ )QZ_P"6[6O^X8__ #5FQ5W_ $5X_P"<>O\
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MV+35K0-_R7>+-BKY4_,K_G&+\V/R?C>\_,GR=K.EV2?;NY;1WM1_T<1\HO\
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M=FQ5V;%79L5=FQ5V;%79L5?RO?\ /WO\TK3SW^=<7E'2'62W\IZ5%I]PR_\
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M&M+[CX_5+CT_^QG-BK^D#-BKLV*NS8J[-BKLV*NS8J[-BKLV*OC_ /YS[_\
M6>OS#_[8TG_$TS8J_C#S8J[-BK^_S-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J\^_-C_E!_,W_ &QM1_ZAGS8J_A$S8J[-BK^WO_G$_P#\DA^6
MG_@&^7?^Z=#FQ5] YL5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5X]_S
MD'_Y*OSO_P" QK/_ %!2YL5?PR9L5=FQ5_<W_P X^?\ DJ_)'_@,:-_U!19L
M5>PYL5=FQ5V;%79L5=FQ5V;%79L5?QA_\Y]_^M"_F%_VV9/^()FQ5DWY/_\
M.&>N?GO^2NO_ )T?EQZMWYD\M:S+;W&DHO-KNQ^K0R\H /\ =T99FX?[M39?
MC55DV*OAQE*GBV;%5F;%7[D?\^T/^?@\GDZ6Q_YQW_/*]=_+\SI;Z#JUP_\
MO"[[):3LW_'NW^ZG_P!T_8_N:>EL5?T:9L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5?S!?\_J?_)X:#_X!MC_W4;_-BKX!_P"<3_\ R=_Y:?\ @9>7?^ZC
M#FQ5_;WFQ5V;%79L5=FQ5V;%79L5=FQ5_$)_SEA_Y._\R_\ P,O,7_=1FS8J
M^?LV*OZO/^?0_P#ZSU8_]MK4_P#B:YL5?J!FQ5V;%79L5=FQ5V;%79L5=FQ5
MV;%79L5?F3_S\$_YP-TS_G)K1I?/OD6"*T_,[3;?_1Y1Q5-2B3I;3_Y=/[F4
M_9^PY]/[&Q5_*AJNDWNAWEQHVKV\EK?VDKV]Q!,C)+%+$W%T=6W5E;[0S8JE
M&;%7Z*_\^\?^<QKC_G%_SPFA^:+AS^7GF"6.'58JU6UE/P1WJ#_(Z2T^W%_,
MR1YL5?UN03I<(LL3*T3+R5E^RRYL51>;%79L5=FQ5V;%79L5=FQ5V;%6/>9_
M,5AY/T?4?-NORB#2],M+B^NY?Y(;=#)(WT*N;%7\-WYN?F+J'YO>=->_,[7M
MKW7=1N;YTY<O265^21@_RQIQ1?\ )7-BK]-?^<I_^<'[#\IO^<8_('YL:58K
M%YILQ#+YFF4?'(FKKZD?JG_EVD].W7_C(<V*OR S8J_5_P#Y]%?G=_RKC\WY
M/RXU2;T])\[6GU,<CQ07UKREMF/S7UHE_P N5<V*OZG<V*NS8J[-BKLV*NS8
MJ[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS_U_S_
M .*OW\S8J[-BK\8?^?V/_DK/*G_@3#_J"N,V*OYH<V*NS8J_O\S8J[-BKLV*
MNS8J[-BK^7W_ )^^?\Y 0_F1^95E^47EZX]72O)<3I<E?LMJ=Q0SCW])%CC_
M ,F3U5S8J_/C_G'O\B?,7_.1WGC3/RL\DQ_Z7>MSGN70M#:6J$>K<2T_90?\
M&Y6/[3C-BK^SK\H/RLT+\E/)VC_E?Y+B]+2-'MEMXMOBD;K)+)_ER/R=_P#*
M8YL5>GYL5=FQ5V;%79L5=FQ5V;%79L5=FQ5CWFS_ (X6I_\ ,%<?\FCFQ5_!
M)FQ5V;%7]K7_ #A5_P"2%_+G_P !G2_^3*YL5?46;%79L5=FQ5V;%79L5=FQ
M5V;%79L5?PA_FO\ \IOYE_[;.H_]1#YL5>?YL5?U^?\ /KG_ -9C\C?]OG_N
ML7F;%7Z 9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5_-!_S^R_\FGY
M4_\  9'_ %&W&;%7XQ9L5?L[_P ^3?\ R:?FO_P&3_U&V^;%7]+^;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5><?FA^9WEK\FO+.H?F)^85ZEAH>F1>K-*W4_LI'&O[3NU%1/VFS8J_DI
M_P"<C/S^\[_\YY_FE:PZ+97$D<UQ^C_+6@P?%Z44K=6_9]5Z<YY3\.W:*,4V
M*OZ.O^<'O^<.M(_YQ,\F_49_2O/.^K*DVM:BOV>2_9MX?"&*OMZC5=OV538J
M^X\V*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*OYQ/^?W?F'Z
MUYV\C^5.7^\6C7=]Q_YB[CT_^Q?-BK\2;>VDNY4M[=2\LC*BK_,S=,V*O[V-
M%TQ-&L+72(#^ZM;>*W7X>/PQ)Q&;%7\S?_/WO_G'W_E7GYD6GYT:!!QT7SE'
M_I11?@34[=0LGR]:/A)_EN)FS8J_(#-BK+?)7G#5/(&OZ9YV\MR^AJVCW<%]
M:2_RRP.'3\1FQ5_;=^17YMZ5^>WD+0OS9\LD?4]9LTF:+GR]&:O&>%O\J*57
MC_V.;%7L.;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5_'O_P _%/\ G(0?\Y!_
MG)JU]I4OJ^6?+_/1-)*MS1TMW;U9QV_?2\V5O]]>G_+FQ5DG_/LK_G'@_GO^
M<-CJNM6YE\K>40FL:AR'P-,C?Z'#_LY?CX_M1Q29L5?UR9L5?R5_\_8M%_1?
M_.1NNW_&GZ2T_2;O>O[-HEO_ ,R<V*OS7S8J_5#_ )\^^8/T-_SD FF\O^.M
MH&HV?_ >E<_\R<V*OZK,V*NS8J[-BKLV*NS8J[-BKLV*NS8J^/\ _G/O_P!9
MZ_,/_MC2?\33-BK^,/-BKLV*O[_,V*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKS[\V/^4'\S?\ ;&U'_J&?-BK^$3-BKLV*O[>_^<3_ /R2'Y:?
M^ ;Y=_[IT.;%7T#FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7CW_.0
M?_DJ_.__ (#&L_\ 4%+FQ5_#)FQ5V;%7]S?_ #CY_P"2K\D?^ QHW_4%%FQ5
M[#FQ5V;%79L5=FQ5V;%79L5=FQ5_&'_SGW_ZT+^87_;9D_X@F;%7[!?\^2+B
M5_(GG6V=OW2:W;.J_P"4UMO_ ,1&;%7E/_/SK_GW[^CC?_\ .2_Y)67^B-SN
M?,>DVZ_W7[4E_$G\O_+0@^S_ 'WV?4X[%7X)YL5=FQ5_0?\ \^R_^?A U(:?
M_P XV?GA>TNU5;?R[K-S+_>_R6-P[G[?[-N_[7]S]KASV*OWMS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*OYEO^?UEBJ?FYY:U$<O5E\JPQ-_+QBOKHC_ (GF
MQ5^=O_.)_P#Y._\ +3_P,O+O_=1AS8J_M[S8J[-BKLV*NS8J[-BKLV*NS8J_
MB$_YRP_\G?\ F7_X&7F+_NHS9L5?/V;%7]7G_/H?_P!9ZL?^VUJ?_$US8J_4
M#-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BK\!_^?N/_.'J)$?^<J?R\M0K
M*R0^9[>%/M<Z)%>T_P"!BF_YYO\ [\;-BK^?O-BKLV*OZD?^?3'_ #DO)^;7
MY<R?E%YHN/4\R^3%B@@+M\<NE/M;GW] @P_Y*>C_ #9L5?K7FQ5V;%79L5=F
MQ5V;%79L5=FQ5^6/_/VO\ZO^5:?DN_D33I>&K^=+M=.0+]OZE#26Z?Y?W<+?
M\9LV*OYY_P#G$;\H/^5Z_F]Y3_+>>(2V%YJ$<VH*5^'ZE:_O[D?[*-&0?Y3#
M-BK^PS\[_P L;3\Y?R_\Q_E5J)5(M;TRXLD=Q58I63]S+3_BN3@_^QS8J_AU
MUG1KWR_J%WH6L0M!?V4\MM<1-]I)8FX.I]PPS8JB_*GF74/)NLZ=YN\OR^AJ
MFEW<%]:2_P DUNXDC/\ P0&;%7]Q?Y/_ )D6'YP>2=!_-#0O]X]=TZWO43KZ
M32K^\C_UHWY(W^KFQ5Z=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=G_]#\_P#BK]_,V*NS8J_&'_G]C_Y*SRI_
MX$P_Z@KC-BK^:'-BKLV*O[_,V*NS8J[-BKLV*OSE_P"<]_\ G.71_P#G%SRW
M-Y<\K3V]Y^9NI1<+&RYA_J2.O^]=PG@O^ZD;^];_ ".>;%7\K_E;RMYF_./S
M3;^6?+5O=:WYGUN[;BJ$O-<32-R=W<_\')(_V?B=^^;%7];7_.$?_.'6B_\
M.)?E!;!_3O?.NK)%+K6HK^TZC:WA[B&*OSD:LC?LHFQ5]P9L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%6/>;/^.%J?_,%<?\FCFQ5_!)FQ5V;%7]K7_.%7_DA?
MRY_\!G2_^3*YL5?46;%79L5=FQ5V;%79L5=FQ5V;%79L5?PA_FO_ ,IOYE_[
M;.H_]1#YL5>?YL5?U^?\^N?_ %F/R-_V^?\ NL7F;%7Z 9L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5_-!_P _LO\ R:?E3_P&1_U&W&;%7XQ9L5?L
M[_SY-_\ )I^:_P#P&3_U&V^;%7]+^;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%6 _F/\ F/Y=_*7R[J'G_P _
MZA%INB:;$9KBXF/W*HZL['X41?B=OA7-BK^4_P#YRK_YRK\]_P#.>?GNQ\E^
M2[&[_P ._6_J_E_R_;_%+-*VWUBXI\+3,O\ SS@C_P">DDFQ5^ZW_."'_."&
MB?\ .*NB#S-YF$6I?F3J406^OE')+1&W^K6U>BC_ '9)UE/^1Q7-BK]&,V*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J_E2_Y_!^8?TU^
M?[Z;_P!6G0-.LO\ @FEN?^9^;%7P!^3&B?XC_,'RIY?"\_K^O:7:<?M<O6NT
M3^.;%7]UF;%7RG_SF=^0D?\ SDA^4VO?ES BOK0A_2&CN?V-0M06AW/3U/BA
M9NR2-FQ5_%Y=6LME*]I=HT4\3,CHZ\65EZ@C-BJ"S8J_=G_GS1_SD.NE:OJ_
M_.-GF.XI!J?/5M$#MM]8B3_2H5_UXE64=OW4G\V;%7]$>;%79L5=FQ5V;%79
ML5=FQ5V;%79L5?!?_/Q3_G(4_P#./?Y.:M?:7+Z7F;S!ST322K<'1[A&]6<=
M_P!S%S96_P!^^G_-FQ5_'OFQ5_7I_P ^U_\ G'C_ )4#^3FG2ZQ;^EYH\T<=
M9U3E]I%E3_1H?^></'DO[,KR9L5?H1FQ5_,3_P _H]'^J?G'H.LHM$O/*UNC
M'XMWAO;FO_"LF;%7X\YL5?;W_/N37_\ #7_.1OD.^=N*RWUQ9?\ 27:36_ZW
MS8J_L>S8J[-BKLV*NS8J[-BKLV*NS8J[-BKX_P#^<^__ %GK\P_^V-)_Q-,V
M*OXP\V*NS8J_O\S8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*O/O
MS8_Y0?S-_P!L;4?^H9\V*OX1,V*NS8J_M[_YQ/\ _)(?EI_X!OEW_NG0YL5?
M0.;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5>/?\Y!_^2K\[_\ @,:S
M_P!04N;%7\,F;%79L5?W-_\ ./G_ )*OR1_X#&C?]046;%7L.;%79L5=FQ5V
M;%79L5=FQ5V;%7\8?_.??_K0OYA?]MF3_B"9L5?K/_SY!NY'\M_F!8,/W46H
M:7*O^L\4P/\ Q 9L5?N;)&DZ-%*O)&^%E;-BK^97_GY1_P X O\ DQ>7'YZ_
ME!:5\AWLW+4[&%?ATJ>5J50#_CUD8T7_ 'R_P?99,V*OQUS8JO5BIY+FQ5_2
MG_S[8_Y^%)^:$%K^0?YVWJ)YP@1(M&U.;X?TG&H_N)6_Y:E_9;_=_P#QE_O-
MBK]ILV*NS8J[-BKLV*NS8J[-BKLV*NS8J_FG_P"?V,$J?F9Y2N77]T_EO@K?
MY27<Q/\ Q(9L5?FY_P XG_\ D[_RT_\  R\N_P#=1AS8J_M[S8J[-BKLV*NS
M8J[-BKLV*NS8J_B$_P"<L/\ R=_YE_\ @9>8O^ZC-FQ5\_9L5?U>?\^A_P#U
MGJQ_[;6I_P#$US8J_4#-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BJ0>9?+
MFG>;=*O?*_F*W2ZTO4K>6TN[>7=)8I4X.I^:YL5?Q/?\Y+?DC?\ _./'YDZ]
M^4^J%G73K@FUG>G[^TE^.WE_V497E3H_)<V*O \V*OL[_G 7\[F_(?\ .SRY
MYGN9C%HNHW'Z'U3>B?5;T^GS?VBD].;_ )YYL5?V79L5=FQ5V;%79L5=FQ5V
M;%79L5?R@_\ /V'\Z/\ E:'YV77E'3)O4T?R;;II,00_ ;M_WMV_^MS80M_Q
MAS8J^GO^?*?Y1/>ZUYL_.^_BI#8V\.@V+MT,TY$]S3_*1$A^B7-BK^B#-BK^
M2O\ Y^G?DS_RJ?\ //4]>T^'TM(\WQ+KEN5^S]8E^"['^L9E:4_\95S8J_-?
M-BK^DG_GS'^=_P#B'R7K7Y$:M+6\\N7)U'3E;_EBO6_>HH\([CXF_P"8@9L5
M?MGFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=G_T?S_ .*OW\S8J[-BK\8?^?V/_DK/*G_@3#_J"N,V*OYH<V*N
MS8J_03R=_P _.?\ G(KR?:V^EQ>;$U&TMT1$34;&TN'XK_--Z0F?_9R,V;%7
MJ5I_S^'_ #]M(_2F7R]</_/+IS\O^2<RC-BJL_\ S^,_/IT9!#Y;4M^TNG35
M7_IXS8J\K\Y_\_0?^<BO.5LVF_XI32;:5>+_ *+L;>W?Z)N#2K_L'7-BKX1U
MK6K_ ,Q7UQK>NW4]]J5T[2W%S<RM+-*[=6DD<\F;W.;%7Z-_\^^_^<O/RQ_Y
MQ8U*[O?S#\HW=YK.H-Z/^(;29)IK2W_WS':2*G%>7Q2.DO-^G$\0N;%7]+_Y
M/_\ .0'Y?_GWIOZ?_*77K36+=/[Z*)^%Q!_QFMY.,L=>W-/EFQ5[1FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L58]YL_XX6I_\P5Q_R:.;%7\$F;%79L5?VM?\
MX5?^2%_+G_P&=+_Y,KFQ5]19L5=FQ5V;%79L5=FQ5V;%79L5=FQ5_"'^:_\
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MBK^S6+_G +_G'J%5B_Y5_H[!5XU=96;_ (GFQ57_ .A!/^<>O_+>:-_R+?\
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M_"?SF/YW_GGYFUVSF]72-)E_0>G?R^A8\D=D_P F2;U95_U\V*ONC_GRO^4
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MC2]F@_XTS8J^X,V*NS8J[-BKLV*NS8J[-BKLV*OC_P#YS[_]9Z_,/_MC2?\
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M%79L5=FQ5Y]^;'_*#^9O^V-J/_4,^;%7\(F;%79L5?V]_P#.)_\ Y)#\M/\
MP#?+O_=.AS8J^@<V*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J\>_P"<
M@_\ R5?G?_P&-9_Z@I<V*OX9,V*NS8J_N;_YQ\_\E7Y(_P# 8T;_ *@HLV*O
M8<V*NS8J[-BKLV*NS8J[-BKLV*OXP_\ G/O_ -:%_,+_ +;,G_$$S8J^^_\
MGR/*J^>?.T1;XFT2V8+_ *MS_;FQ5_2#FQ5V;%79L5=FQ5XE^?/Y%^5O^<BO
M*%[^6GYA6PN+"Z'.&9/AGM;A?[N>%_V73[F'P/5&89L5?Q]_\Y*_\XX>:O\
MG&#SC<?EYYYC#1[SZ??1#]S>VA>B2QG_ (FG5&V]\V*OG3-BKT'\LOS*\Q_E
M'YDT[\P?(-Z]CKFF3+-;RH=O=''[2./A=/VE^'-BK^O#_G#/_G+[RW_SEKY2
M37-/,5CYLL%5-:TCG5X)>GJQUW:"3]AOV?[MOB7-BK[+S8J[-BKLV*NS8J_
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MKLV*NS8J_A#_ #7_ .4W\R_]MG4?^HA\V*O/\V*OZ_/^?7/_ *S'Y&_[?/\
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MOEW_ )R*\D:C^5?GI&^H7ZJR7$7'U;>X3>.>*M?B4_\ !+5/LL<V*OPEO_\
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M5S8J_<6V_P"?VVK6<*6EG^7%C'!$J(B+J[\55>@_WFS8JB?^BX>N?^6[LO\
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MQS_Z7H_/5=$Y'[5I,_\ I,*_\8Y6]4=SZTG9,V*OW/S8J[-BKR7\[_S6TO\
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M?^Z=#FQ5] YL5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5X]_P Y!_\
MDJ_._P#X#&L_]04N;%7\,F;%79L5?W-_\X^?^2K\D?\ @,:-_P!046;%7L.;
M%79L5=FQ5V;%79L5=FQ5V;%7\4G_ #FM_P"3Z_,;_P ";4_^3S9L5?;_ /SY
M6)_Y7;Y@7]G_  ;??]U&PS8J_I\S8J[-BKLV*NS8J[-BKLV*OD/_ )R^_P"<
M2?+7_.6GE!_+&N<+'S%8EYM&U8)R>UFX_8?N\,G25/DP^-%.;%7\AOYL?E5Y
MC_)7S3J'Y;?F%:/9:WIDQBE0_9=?V)8GVYQR#XD?^7-BKS'-BKZ&_P"<;/\
MG([S3_SC)YSM?S&\BRABO[J^LI786][;M]J*4#[T?JC_ !#-BK^PC\A/SW\J
M?\Y%^3[3\R_R[N?6L+C]W<0-_?6MPJ@R03)^RZ5_V2E76J,IS8J]NS8J[-BK
M\+/^?WUBS^6?(&IC[,6HZG#3_C+#"W_&F;%7XP_\XCVTES^>'Y;10+R=?-^@
MO_L$OHG;\,V*O[<<V*NS8J[-BKLV*NS8J[-BKLV*OXA/^<L/_)W_ )E_^!EY
MB_[J,V;%7S]FQ5_5Y_SZ'_\ 6>K'_MM:G_Q-<V*OU S8J[-BKLV*NS8J[-BK
MLV*NS8J[-BKLV*NS8J[-BK$O/'F6+R9Y<UCSA<_W.DZ?=WS\OY;>%I#_ ,1S
M8J_@[GG>X=IIF9I6;DS-]IFS8JA,V*O[8?\ G#?\OS^5_P"2/D7R7*GI7$&B
M6UQ<)_+<78^M3C_D9*V;%7TWFQ5V;%79L50-U=1643W=VZQ01*S.[-Q557J2
M<V*OXD_^<H?S@E_/C\T_-/YI2,[6NIZC)]2Y]5LH?W5LO_(E$K_E9L5?5G_.
M!7_. :_\Y>V>O>:/,VKW.B:!I4T-E;S6T*2O<73+ZDB?$U%$2<"W_&5:9L5?
MHC_T1$\C_P#4[ZS_ -(EOFQ5W_1$3R/_ -3OK/\ TB6^;%7?]$1/(_\ U.^L
M_P#2);YL5=_T1$\C_P#4[ZS_ -(EOFQ5W_1$3R/_ -3OK/\ TB6^;%7YN?\
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MP3]C-BKY5\H^4]7\]:Q9>3_*5G+J&LZA.D%I:P+R>61CLHS8J_L'_P"<)/\
MG%33_P#G$_\ +^'RGRBNO-.INEYKU]']F6YX?#%'W]* 'A'_ #?'+Q7U"HV*
MOLW-BKLV*NS8J[-BKLV*NS8J\2_YR.U!=)_*;SYJKLR+:^5M9FY+]I>%E*V;
M%7\.&;%79L5?V0_\^Y]5_2W_ #CEY!N>2MPL;BV^'_EWNYHO^-,V*OMO-BKL
MV*NS8J[-BKLV*NS8J[-BJ6:C?)IMK/J,U6B@B>5N/VN*+4YL5?P+9L5=FQ5_
M2G_SY/\ -D5]^6WF[R/RY7.F>8$OBI_92^M$C3_AK5\V*OVIS8J[-BKLV*NS
M8J[-BKLV*OYV?^?MGYCQ_F?^:ODC_G&O0G]4Z9+$]\J'_C[U:6*.*,]?B2)5
M?_GOFQ5_1-FQ5V;%79L5=FQ5_++_ ,_D-2_2'Y\6EKRY?4O+&GV_^KRN+F6G
M_)3-BK\G<V*ONO\ Y]M>:D\H?\Y&^2+RZ;C;WES=Z<_^4;VTFAC_ .2K)FQ5
M_8CFQ5V;%79L5=FQ5V;%79L5?#W_ #\._.6#\E_R+\SZD)0NJ:W;OH.G)RXL
MTU^C1NR>\</JR_[#-BKQ;_GT'Y?_ $+_ ,X^V^I<>/Z6US4[[_6X<+7_ )D9
ML5?J5FQ5V;%79L5=FQ5V;%6/>9?+.D^;],N/+GFNQM]2TN\3TKBTO(DEBE0_
MLNC_  G-BK\C?SR_Y\X_EYYUGEUK\FM5N?*-[)\7U&5/KMAR_P @,ZS1U_XR
M2*/V8\V*OS@\Z?\ /H?\_P#RVS'R];Z/YBB_9.GZBD3,ORO!;_\ $LV*O&YO
M^?;?_.2$+-$WD.[+JW'X+S3V7_@A<9L597Y9_P"?67_.1_F!T^L^5H=+@;_=
MM]J=BH_X&*623_A,V*OLS\K_ /GR;K=S)%>?G)YQM+* '][::'"]P[#P^L7
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M]%?DC^8]]S9&7RGK:HZ_:5WLI43_ (8YL5?Q&9L5=FQ5_5'_ ,^?/.T?F/\
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MN]E<<N9M7^NR5'\@6(CC]E4^'-BK^R+-BKLV*NS8J[-BK^/W_GYKYMC\X?\
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M#_?L-I*W_!O"3FQ5#WW_ #\._P"<B]1XK<>?]33C_OE+>'_DW$N;%7EWF_\
MYRF_.'SY&]IYM\^>8KVTE^W;OJ=PMNW_ #R1PG_"YL5>!,Q8\FS8J_7_ /Y\
MW?E5<>:/S:U#\T)H6_1OE72Y527C_P ?=_\ N8U^F'USFQ5_3UFQ5V;%7C?Y
MO_GWY"_(/3K?S%^;VM0:+87<WH6[RQS2M++QY<5CA1W-!_DYL5?GG^;_ /S]
M_P#R?\JZ3=_\JG-[YI\P>DXLE^J36MEZO8S/<>E+P'^1&6;I\/VLV*OYE/,_
MF*_\X:OJ'FOS!*;C5-4NY[Z[F;J\]PYDD;_9,Q.;%6/9L5=FQ5%P3O;NLT+,
MLJMR5E^TK9L5>^>7?^<L/SG\J(MOH'G[S/!!'QX0_I:Z>)>/_%;NR_AFQ5Z-
M9?\ /P;_ )R(T^3U8/S U5GZ?O?J\J_=)&PS8JF,W_/QK_G(Z=3%)Y]OBK+Q
M^&VLD/WK#7-BK"]8_P"<X/S\UN/ZO>?F)YB1/^7:^>W;_@H.!S8J^==>\RZM
MYJO'U?S-J%UJ5_)]NXO)GGE;_9R$MFQ5./R\\CZE^97F;1_('EF/U=5UF^M[
M*W3CR^.5^-3_ )*_:;_)S8J_NF\MZ#9^5M)L/+&D)PLM-M8;2W3^6*%!&GX#
M-BJ?9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7F'YM?F&?RJ\GZQ^88TN]UG]$V[7'
MU#38_5N)J'HB_3R;P7-BK\9M8_Y_:1_%I^@?EK<MJ//TE2XU8+Q;I]A;0MR_
MR<V*OSD_YR=_YRG_ #H_YS%NK?2_,>DW%IH%DYEM]#TFTN/2Y]/5EKR>63]G
MDWPI^PB<FY;%7R]:?D5^96HQ_6=/\G>8;B*O'G%I-VZ_>(\V*H.]_)OS]ITC
M6^H>5M<@F7[22Z9=(WW%,V*OM7_G&S_G/3\[O^<8](3R?8:>-;\HVP9H[+5K
M6X_T5*\W]"="C1K_ )+^I&.R9L5?=GEG_G]NE]Z5CK7Y;3/>N57_ $#5^?/_
M %8VM:_['DV;%7[@>1O,S>=?+ND^<);&ZTQM4L;:]-E?)PN+<SQB3TIE_9=*
M\6'CFQ5E^;%79L5=FQ5V;%79L56$!AQ;-BK^4'_G-C_G OSA^6?YLOI7Y0^7
MK[5O*OFFY^L:']1MWE2WEE?]Y9R%12/TF^QS^'T>+<OADX[%7]&'_.*/Y"6?
M_.-WY8Z)^5-IPDO;:'ZQJ=P@^&XOKCXIWW_9#? G_%:)FQ5](YL5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5_.C_S\,_YQD_YR>_/+\PKK74T%->\EZ8\L/E_]%S6G
M[JUE?E^\B:19S,?A]1BI7;X/AS8J_-#4O^<+?SXTDM]:_+CS._'_ )9]+N+C
M[O25JYL58A??\XU?F[IC^AJ/D'S5!*R\^,NB7R-Q\:-%FQ5CDWY1>?M.F]";
MRSKD%Q&U.+:==*RM_P !FQ5]Y?E-_P _$_\ G)7\F8(O+NH++YBL+,");?S!
MITTLR*O[/UB/TIR?^,COFQ5]@Z7_ ,_LM3TKA:>??RTX7''D7MM6>'_DE+;,
M?^2F;%7WU_SAU_SG%-_SEMJ&H6-MY&U;R_IEA:&X35;B7ZQ92OZB((!+Z<8]
M5@W-5^+X4?-BK] LV*J#R^FC/]KCV7-BK\;O.7_/X#3-%::S\M?ECYFN;Z!V
MC>'4BECP96I1^"7#+_P.;%7XW_\ .3/YP?FO_P Y@^9E\_\ F;R_?+96<7U/
M3K&QLKA[>UAY\Z5XGE(VWJ/^U\/V5"J-BKP.R_(W\R-37U=-\G>89T7X6:'2
M;MQ_PL>;%5E[^2'YBZ9Q;4_*'F&WY_9]72[M.7RK'FQ5BMSY)\Q64K6]WI.H
M12K]I'M958?05S8JQ3-BKLV*NS8J[-BKLV*OW(_Y\Q_DAJMSYNUO\^M6M)8M
M#L]-?2=/N)4XK/=7$J/*8F_:]*.+B_\ QES8J_HTS8J[-BKLV*NS8J_)W\XO
M^?I^D?E=YCUGR!:?EYYFU'5-'O;FQ=YE2TAF:%^/J1O^]?TWIR1N&Z%6S8J_
M'3_G+7_G)_\ -/\ YS3O[5;CRQ>:;Y;T9W>UTNQ@N;CC+-MZD\O!?4>@XK\"
M!5KQ7[5=BKY#LOR1_,74^9TWRCK]QP^UZ6EW;\?G2/-BJ/\ ^A>_S4_ZDCS/
M_P!P:]_ZI9L58_+^5/G6 ,TOEO645/MEM/N!Q^],V*L9NO+VJ6,;7-W97$4*
M_:9XG51]-,V*I0K-$W)?A9<V*I[_ (MUW_JYWO\ TD2_\U9L50][KFHZ@GHZ
MA=7%Q$&Y<997=>7TYL527-BKLV*OZ1O^?.__ #CQKOD+1O,?YS^=M/GTZ;7O
MJVGZ3%<1O%*]K#62:;@_[$CE G_&)OV>.;%7[;9L5=FQ5V;%7Y'_ )L?\_7=
M)_+K6M5\G:7^7/F:^U32KNXLG^MJEE$[1.4Y A9GXM2NZ5I3-BK\</\ G+7_
M )R;_,__ )S.URR?4_+EUIVB:2LOZ/T:QAN+CB\G]Y+*_ >I)0<>7!%5=E7[
M?+8J^4[+\D_S#U/F--\HZ_<<?M>EI=V_'YTCS8JJ7OY(?F+IG%M3\H>8;?G]
MGU=+NTY?*L>;%7OW_../YY?G!_SA[KTOF+R?I-V+/4$1+_3-1LKCZO=I%T[*
MZNG(\9$;X:_M+\)V*OU>\N_\_E+R95C\V?E3JD+?M/8WS2\ODDEK'3_@SFQ5
M]\_\XK_\YEZ3_P Y4SZI9:!Y8U[0_P!$PPRRSZI B0.TM1Z<<B.?C'6A ^'?
M-BK[2S8J[-BKLV*ORT_.S_GZ!H/Y.^:=9_+C_ GFG4=2T:[>T:4Q16]O-Q_W
M9&_QL8V_8;A\2?'FQ5^9O_.3W_/R;\U/^<AO+][^5ODORA+Y7T#5E^KW?I">
M[OKB)^L/J^E&JI)^VJQ\F'P<^/+EL5?FC9_DE^8FILRZ;Y1U^X9?M>EI=T__
M !&/-BKKW\D_S#TS@-2\HZ_;\OL^KI=VG+Y5CS8J^_\ _G&+_G/[\YO^<7]+
MB_+76O+DWF+RQ9'_ $>QU"*XM[JU1M_3BG"-QC_R)(Y./['$9L5?H5H7_/XS
M1[A5'F7\M/,EJW'XOJ;I=4;_ )Z);YL5?JW^5?G^/\T_*>D?F%;:??:5%JUJ
METMCJ47I74//M(H)_P!CXK\6;%7H^;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%7Y<?\_ O^??NG?\ .2VG2_F1^6\4-E^9UE#L?A2+5(D7:&8[4F%/W,W_
M #SD^#BT6Q5^$7_.&WD75M#_ .<F/)'DGS597%AK&F^88?K=I,G"6*6TY3%6
M!Z4X?\#FQ5_9)FQ5V;%79L5=FQ5V;%7YX?\ .3'_ #\&T;_G&KS2WY>:EY-\
MR:Q>K:0W:7=I#&EI*LO^^Y68EN/1O@^W\.;%7XZ_\Y>_\_!/S%_YRHT(_E;Y
M>\HW'EKRK=31/=PKZUW=7OI/RB1Y!%&JISXOZ:I7FJ_O.V;%7YTVGY-^?M1D
M^K6'E37)Y6_9BTR[=ON"9L55=3_)7\P]&7U=7\IZ]:)\3<KC3+J+[/7[2#-B
MKSR\L+G3I/JU]"\,H_9E3@WXYL50JLT3<E^%ES8J^A?)?_.6GYT?E^J6_E+S
MYYAM;>+[%NVHS36Z_P#/&5GC_P"%S8J][TC_ )^A_P#.2FDCTCYQ6ZB5?L7&
MEZ<__#?5P_\ PV;%6:6W_/W#_G(>")8I=3TF5EZO)I</)O\ @.(S8J@M4_Y^
MQ_\ .1NH+QM-;T^R;BR\K?2K1OI_>I)TS8J\/\W_ /.>/_.0/GA6BUW\P=91
M)/M+I\J:>/NLUAS8J\$TOR]YT_-G4W;1K'6/,NL2M\?U>&XOKAV]^(=LV*OM
M+\K?^?77Y_\ YDLDMWH,/EJP?_CYUZX6W_Y(1^I<?\%%FQ5^KWY%_P#/G;\N
M/)#1:O\ G)J%SYNU)>+?54#V6GHWNL;^M)_R-1?YH\V*OUF\L^5=&\F:;;^6
MO*&GVNEZ3:KP@M+&)+>&)?\ )CC 49L59+FQ5V;%79L5=FQ5^?W_ #DS_P Y
M^:)_SC-YG_P%K7D_S)K%TUHEW%=V5O']4?G^RLKO4\?VZ+\.;%7P5^8W_/XO
MS;<VLMI^4_Y;36=TU.%[K$TUPJ^/^C0Q1_\ )_\ V.;%7X\?F-=_FS^>VO7/
MYD>>[37-=U:\^U=M8S,G!.B1K&GIHB_LH@"KFQ5(H_R!_,^9%F@\D^9'B=>2
MNFD7I5E]CZ>;%7JGY#^:OS;_ .<4O.=O^:GE7R[JD%[9I);7=O?:?=I!<02@
M>I#/\*FE>+#^5U1NV;%7[7>6?^?P^@WEM&?-7Y<>:;74G^%H;$1745?\EY/J
M['_@,V*OUZT#6%U_3+365M[BU%W!%/Z%VGI3Q>HO+A+'^RZU^)>QS8JGV;%7
M9L5=FQ5V;%79L5=FQ5V;%7Y]?\_$OS4\V^1_RRU'R/\ EWY,U;S5=><=.U'1
MYKK3K>6XAT^*:)8GDG$2,_)TE?T?V>2?$W[+;%7\J,_Y0^>K=VAE\LZVLJ-P
M=&TZYY*W_ 9L52.\\C^8].D^K7VCZA!*O[$MI,C?<5S8JF7E^T\V^5-2M?,?
MEB#4[#5;.59K>[MXIHI8G3HR,O0YL5?L!^3G_/W#\W/*5G%I'YP>3O\ %21)
MQ%];I+I]V_\ ER\8I87_ -A'%FQ5^AOY#?\ /R?0?SW\VZ9^6VF>1?-ECJ&H
MR,CW#VT4MK;HJLWJ2R!PRIM\3<,V*OTPS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKL__UOS_ .*OVC_,O\COR_\ SEB@@_-'RYIFO"V#"![ZW25X
M@_VO3?[:U_R6S8J\MM_^<)/R#M8EMXOR[\N.J_SV$3O_ ,$V^;%4]LO^<0OR
M/L4]&'\MO*#(37][H=E*W_!21,<V*LCMO^<<?RFL8EMK3R'Y6BB7[*)HMBJ_
M<(LV*H*]_P"<7_R;U!_6U'\O/*-Q*JTYRZ#I[MQ^F'-BK";[_G!S\@-07T[C
M\N_+RJ/B_=6:1?\ )OCFQ5AU]_S[E_YQPU!I&G\@V*^I]KT;F]B_X'TYUX_[
M'-BK'O\ HES_ ,XQ_P#4C?\ <YUC_LLS8JB;/_GV1_SC/8OZT/D:)G^S^]U3
M595_X&2Z89L5>W^4?^<3OR9\B,EQY4\A^7K6X3[%P=.MY9E_YZR*S_\ #9L5
M>^P0);HL42JL2KQ55^RJYL51>;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5\\>
M9?\ G%/\G/.FIW'F?S5Y$\O:AJ]XWJW%W/IUNTLKMU>1N-6;_*.;%4'8_P#.
M'7Y%Z>6:W_+CRFW+_?VC6DW_ "<1LV*LALO^<:OR@TQ3%IOY?^4[=6^)EBT.
MQ2OT+#FQ56O?^<;_ ,I=0C^K7WD/RM/$W[$NAV+K]QBS8JQ^Y_YQ%_(Z[B:V
MF_+;R@JM_)H=BC?\&D0;-BJ4_P#0E7Y"_P#EN?+/_<+A_P":<V*O1/R]_(G\
MNORGGGO_ ,L_*VC:%=7*".>;3K&&"5U^UQ+HH;C_ ).;%7KV;%79L5=FQ5V;
M%7@WG7_G&;\J/S&U67S7YY\F:%JVM7"JLMW=V,+RR\$XKS<K5J+\._[/MFQ5
M)[+_ )P^_(S3N2VWY;>4VY=?6T6TE_Y.1MFQ5DME_P XW_E+I\?U:Q\A^5H(
ME_8BT.Q1?N$6;%47_P!"^?E7_P!21Y8_[@UE_P!4LV*I1=_\XN_DSJ$GKW_Y
M=^4)Y3^W+H&GLWWF'-BK&9O^<,/R(GD:9_RY\L<F^+X=+MU7[E0#-BK'6_YP
M&_YQ[;XC^7NB_P#(I_\ FO-BJ0M_S[C_ .<<&/)O(-CO_P O-[_U7S8JL/\
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MGHZ+:1?\FXUS8JQN^_YP2_(#4&]:?\O-!5N/&D5MZ2_=&5S8JD5[_P ^\O\
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MJ[-BK'/,7E71?-UHVD^;=.M-4LG^U;WUNEQ$?]A(&&;%7P9^;?\ SZ\_(/\
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M=FQ5V;%79L5=FQ5YMYK_ #?\A^0G:#SSYHT31'7[2ZCJ-M:?\G77-BKRH_\
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M ,Y(_P#4QV/_ '"+'_JEFQ5W_15__G)'_J8['_N$6/\ U2S8JE-S_P _2O\
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MBKLV*NS8J[-BK^<+_G[=_P Y>/YOUL_\XR>1+JNAZ-,LOF"6)J_6+Y-TMO\
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MVM_-]O3=#U.[3_694M_^(S'-BK^K7-BKLV*NS8J[-BKLV*NS8J_G8_Y^>?\
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M%79L5=FQ5V;%79L5=FQ5\4_\_ OSD7\D?R,\T^8+>7TM5U2W_0FG<3Q;ZQJ
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M*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*OBW_GX/Y];\N_\
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MQ5_/%_S_  _^.Y^7?_,%J_\ R=MLV*OP@S8J_6#_ )\W_P#D^[C_ ,!G4/\
MD];9L5?U.9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5_,%_P _J?\
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M=:C-BJ/S8J_+[_G)[_GZ3^6GY"W%QY1\E(?.7FR#X'AL9D2QMW\)KKXJLO\
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M\Y/^?T'DRQTNZL?R,T+4]0UYD9(+O5XXK>RB;]F3@DCRRT_D_=?ZV;%69_\
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MOH4(@TW3;6&SM8E_8A@01QH/DHS8JG^;%79L5=FQ5^7W_.0?_/N]_P#G)?\
M.FU_-3\S?,<LWY?6UC!"FB0\TN%>+[4*2?82&5JR2.O[W]A:;2+L5?HGY/\
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M;;]H!VYO_P 5JV;%7\4M_>W&IW$NH:A(T]U,[2RRNW)G=MV8G-BK^GC_ )]
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M#-BKWK-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J_GB_Y_A_\ '<_+O_F"U?\
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M'W&CK1U4YL5?V&?\XS_\Y%^6?^<G/)%C^9?DN01NX$.H63N&ELKI%_>0R?\
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M5_%!^97YAZU^;'FG5_S'\XW'KZUK-W+>7+C9>3]%4=D1?A1?V44+FQ5]5?\
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MD*.39L5?R2?\_'?^<NF_YR6_,"30O*MQR\A>67FM-,X/\%W-TFO#X\Z<8O\
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M?P]^??.>I_F+YCU;S[YD;U-5UB^N+^Y?_BVX<N:>V_PYL5?HK_SZE_YQZ?\
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M5\BZ1^1>D3<=0\SW'UW4$3_JWV351&_XR7'$C_C"^;%7\YGE7RQJ/G36-/\
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MQB]/1_-2KK]I3[/.X8_6E_Z25D:G\KKFQ5^=F;%79L5?U9_\^I_^<B$_-_\
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M>FZ;Y.T:WTC34BLM(TNT2WA3[,<-O;IQ0>RJBYL5?@+_ ,_ ?^?E3>=/K?Y
M_P#.,MR\MA<,;35-?M.7.[Y?"UK94^+TF^R\R_WOV8OW?QR;%7W;_P ^V/\
MG#F;_G&3R9+YL\\1<//WF>.)[V(_\>5LF\5K_K[\YO\ +^#_ '7R;8J_3#-B
MKLV*NS8J_.'_ )^@?GQ_RIG\E=1T;2I?3U_S>YT2TX-\:0R)RNY/D(?W?^M*
MF;%7\E]G9W&HSQV-DC2W$S+'&B_$S,VP S8J_M?_ .<4OR2@_P"<>/RM\N?E
M:BH+VQM%EU%TW]2^G_>7+5_:'J,53_BM4&;%7S?_ ,YW?\Y[:'_SBUH\OE'R
MG)#J/YG7T/\ HEE]I+%77X;FZ_7'%]J7;_=?Q9L5>^_\X??F3YS_ #>_*3R[
M^8GYNZ>FG>8]2A>5U1/22XAYMZ%P(ZL4$L?%Z?[)1P*YL5?46;%79L5=FQ5_
M!CY\OY=4\RZQJ5S_ 'L^HW<K?ZSRL3FQ5^N__/E?R$FL_F1YI_,&YCYKHFB1
MVD3?R2ZA-LP_RN$$B_[)LV*OZ5\V*NS8J_!;_G\?_P Y+I9V-A_SC#Y5N?\
M2KHQ:IYAX/\ 9A7XK6V?_7;]^R]N$+?MYL5?@AY8\KZIYVU>R\I>5K66^UC4
M;B.TM+>$<GEFE;BB*/?-BK^RO_G#O_G&RP_YQ:_+;3ORZM>$NLR_Z=K-VO\
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M[4S_ +*_Y;(#L5?QU>;_ #;KWYJ>9;WSAYGFEU'S#K=X]Q._#D\LTK=$4?\
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MAB7:MM:\MUBY=6H'E/Q/0<$38JK_ //QS\ZO^5)_D5YAU"PE$6KZ\BZ!I_\
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MV*NS8J[-BKLV*NS8J@YX(KV)K:Y59(9%XLK?$K*V;%7\=_\ SGO_ ,XO3?\
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M?]UHA^-MBK]5LV*OYIO^?UNBZNGYG^5_,4T4OZ#G\MI:6\O^Z_K4-[</.O\
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M5=FQ5V;%79L5=FQ5_#+_ ,Y"?^34\[_^!/K/_4;+FQ5X[FQ5^O\ _P ^5O\
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M_LR13)PD0_ZR[9L5?P]_GO\ E9??DC^8/F/\J=8Y--HFH36RNW^[8?MP2_\
M/2(I)_LLV*O(<V*OZ)O^?,?Y]+J6B:Y_SCKK<W^EZ6[ZSI*.V[6TS!;F-?:.
M7C)_SV?-BK]ULV*NS8J[-BKLV*NS8J[-BKLV*OYKO^?VE\9/S(\G:;^S%Y>>
M7E_QENY5_P"-,V*OQ4S8J_3O_GT=<1Q?\Y#:<DK\7ETG5$0?S-Z7/]2YL5?U
M@YL5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5_*1_P _>;LW/_.0=W S
M<EM]$TR)?\FJO)3_ (;-BK\NLV*OW0_Y\@7XB\T^?M*_:FTS3IO^14TJ_P#,
MS-BK^BS-BKLV*NS8J[-BKLV*J3,L2\F^%5S8J_(7_GU_^;OF'\Z?-?YR^>/,
M.I75]I-YK=C<:9#<3.Z6Z2O>?!$C?83T1 E!_)FQ5^O^;%79L5=FQ5\J_P#.
M;>J_HC\@OS%O/C7EY;O[?X>O^D1&+_C??-BK\X?^?*'YEP7OE/S=^45Q(!=:
M=J4.LVZL?B>*[A6"3C_DH\"U_P",N;%7[D9L5=FQ5V;%79L5=FQ5V;%7Y._\
M_@?S6A\F?DJGY=)*GZ2\WZG;VZQ?M_5;%UNII!_JNL"'_C)FQ5_++FQ5_7'_
M ,^O?R2D_)O\C],OM7B,>M>:IGUZX5OM+%,JI;+_ ,B%1_\ 6D;-BK]&<V*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*OY'/^?I7YH+^97Y_ZY:6S^K8>6K>
MWT&W/^5;_O+C[IY95_V.;%7U+_SY;_)UM9\W>9?SMU"+_1=$LDTFR9A_Q]7?
MQRNOO'$G'Y39L5?T?9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;
M%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5
M=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V
M;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L
M5=FQ5V;%79L5=FQ5V;%79L5=FQ5V?__0_/\ XJ_?S-BKLV*NS8J[-BKLV*NS
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-B
MKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*OCO_G*[_G"[
MR'_SEAI'U;S9#]0\SVT173]<M%'UB'_(D_W]%7K&_P#L&1OBS8J_EW_YR9_Y
MP[_,7_G%G5/J'GVP]?0IG*V6MV@9[*X_V?\ NN3_ (KDXM_+R7XLV*OD_-BK
MLV*OL/\ YQH_YS<_,[_G%R=;?R-J'USRTS^I/H>H<I;)BWVB@J&A<_SQ,O+]
MOGTS8J_?W_G'W_GZE^4/YQ0V^E^>+G_!/F1PJM;ZJX^I,_\ Q5>_#'Q_XS"'
MZ<V*OTKL+ZVU2"*_TZ5)[69.<4L3<T=6[AAFQ5,<V*NS8J[-BKLV*NS8J[-B
MKR/\Y_SD\L_D/Y1U#\R_/]TEMIEA$[*K-1[B6GP01*?M22'X5^_[-<V*OXA?
M-OF2X\XZ[J?F[4OANM4O;F^FX_SW$K2/^+9L58SFQ5^P'_/E8'_E=OF!OV?\
M&WW_ '4;#-BK^GS-BKLV*NS8J[-BJ0>9?,>G>4M*O?-'F*X2UTO3;>6[N[B7
M9(HHDYNQ^2YL5?Q+?\Y'?G%>?GY^9'F/\VM2Y*-6OG>WB?K%:Q_N[:+_ &$2
MHI_RLV*OJG_GU;^7B^?O^<@]$O+A/5M?+MI>:Y*G^5"GH0M_L9YHVS8J_K?S
M8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*OYR?^?T7Y)_H7S/Y=_/C2HC]7UNW.
MC:BZ_P#+7:_';LW^5)#R4?\ &#-BK\.<V*O:?R#_ #BU3\@_/VA?FUY;JUSI
M%TDLL ;BL]NWP3PGVDC+)_PV;%7]K/Y=^?\ 1/S1\MZ9^8/DNX%UHVL6J7=K
M+XHXZ,.S*?A=?V6''-BK.LV*NS8J[-BKLV*NS8J[-BK^6C_G\GKL6K?GQ9Z;
M#UTORQI]I)_KO<7-Q_Q&9<V*OR:S8J^^O^?8VNKH?_.2/DN2=^$-T^HVC_9W
M];3[A8QO_P 6<,V*O[ LV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J_
MD _Y^<Z_'K__ #DCYS: J\-H=.LUX_S1:? '^Z3EFQ5\!9L5?IQ_SZ>_-JR_
M+/\ /6VTC794@LO-6G7&AH[FB+<.\<]O7W=XO27_ "I<V*OZQ,V*NS8J[-BK
MLV*NS8J^ O\ GXK_ ,Y)Z?\ \X^?E-JUG;W2IYN\SVT^E:-;I_>UF3A/<=R%
MAC;ERZ>IZ:_M9L5?-G_/E?R_]2_*7S'YE=>+ZAYFEA7_ %+>T@I_PTCYL5?L
MAFQ5V;%79L5?$O\ S\6N9;/_ )QR\_2VK<6;3[=/]B]W"C_\*<V*OY<_^<4/
M^<A=3_YQA_,C2?S3TM&FLXN5IJ=HII]9LIJ>K'_K"BR1_P#%B)7X<V*O[*/R
MX_,?R[^;7EW3_/\ Y U"+4M$U*(36]Q"?O5AU5U/PNC?$C?"V;%6?9L5=FQ5
MV;%79L58UYJ\T:3Y)TB]\W>;+N*QT?3H'N+NZF;BD42+5G)S8J_CT_YS=_YR
MCO?^<K?S&N/-]N'A\KZ<AL=#M6'Q):JU3*Z_[\F;XV\/@C_8S8JS'_GWU_SB
M/=?\Y0?F# ^NV[CR'H3I=ZU<4^&6AK'9J?YI_P!K^6+FWVN%=BK^O2"!+=%B
MB55B5>*JOV57-BJ+S8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*L+_,#SC9_EWY
M8UGS]K&UAHFGW6HW';X+>)I&^\+FQ5_"WYI\Q7WG/6]1\VZPWJ:CJUW<7URW
M\TUQ*9'/TLV;%7]B7_."/Y&M_P X^?DQY=\E:E#Z.NW4)U;5EI1_K=[\91_\
MJ*/TX?\ GGFQ5]C9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79
ML5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ
M5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%7
M9L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=F
MQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%
M79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=
MFQ5V;%79L5=FQ5V;%79L5=FQ5V?_T?S_ .*OW\S8J[-BKLV*NS8J[-BKLV*N
MS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-
MBKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*
MNS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[
M-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*NS8J[-BKLV*I#Y@\O:9YJ
MTZX\O^9K*WU'3+Q#%<6EW$DL4J']EXWJK#YYL5?C?_SDA_SYW\I^</K'F7_G
M'?4!Y:U5N3_HF^9Y=-=O^*Y/BF@K_P ]D_E1,V*OP\_.K_G%7\T_^<?KAH?S
M2\LWEA:<@%U!$^L63_ZMS%RCK_D,W/\ R<V*OG3-BKLV*O;ORJ_YR+_,W\D)
M1+^5?FG4]&BY\VMX)^5J[>+VTG*%_P#9(<V*OT2_+[_G\S^;WEQ4MO/>D:'Y
MCA'VYO2>RN7_ -G"QB'_ "(S8J^OO*__ #^Z\D77'_&WDG6;#^;]'7=O??\
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M$F4O<_E)YX1E_8M-<M"O_!7-OR_ZA\V*OBSSC_SZA_YR*\JR,--T2QUZ)?\
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MG_G$_P#/_P#+KS?I_FW\TOSFU'S!H%ER];2#]8N%NP4*\)'N7HE&XMR"L_\
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FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V;%79L5=FQ5V?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g332r24s0lwy000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332r24s0lwy000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  L -P# 2(  A$! Q$!_\0
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1AI$=@!P%(   Q7Z&T47 _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>20
<FILENAME>asns-20180630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Instance Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-08-10T21:50:57.2070985+00:00 -->
<!-- Version            : 2.12.6766.32775 -->
<!-- Package ID         : 34e5501d2172469fba6650846da28b53 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<xbrl xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance" xmlns:asns="http://www.arsanis.com/20180630" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="asns-20180630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <unit id="U_shares">
    <measure>shares</measure>
  </unit>
  <unit id="U_iso4217USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="U_iso4217USD_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="U_pure">
    <measure>pure</measure>
  </unit>
  <unit id="U_asnsTranche">
    <measure>asns:Tranche</measure>
  </unit>
  <unit id="U_utrsqft">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="U_asnsEmployee">
    <measure>asns:Employee</measure>
  </unit>
  <context id="C_0001501697_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_20180731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
    </entity>
    <period>
      <instant>2018-07-31</instant>
    </period>
  </context>
  <context id="C_0001501697_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_20171103_20171103">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
    </entity>
    <period>
      <startDate>2017-11-03</startDate>
      <endDate>2017-11-03</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20171120_20171120">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-11-20</startDate>
      <endDate>2017-11-20</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20171120_20171120">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-11-20</startDate>
      <endDate>2017-11-20</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_asnsNewEnterpriseAssociates16LPMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20171120_20171120">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asns:NewEnterpriseAssociates16LPMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-11-20</startDate>
      <endDate>2017-11-20</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20171120">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-20</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20171120">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-20</instant>
    </period>
  </context>
  <context id="C_0001501697_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_asnsNewEnterpriseAssociates16LPMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20171120">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">asns:NewEnterpriseAssociates16LPMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-20</instant>
    </period>
  </context>
  <context id="C_0001501697_20171120_20171120">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
    </entity>
    <period>
      <startDate>2017-11-20</startDate>
      <endDate>2017-11-20</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_asnsAccountingStandardsUpdate201415Member_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">asns:AccountingStandardsUpdate201415Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_asnsAccountingStandardsUpdate201415Member_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">asns:AccountingStandardsUpdate201415Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AdimabOptionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:AdimabLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AdimabOptionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:AdimabLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AdimabOptionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:AdimabLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AdimabOptionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:AdimabLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AdimabOptionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:AdimabLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20170228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FebruaryTwoThousandAndSeventeenGrantAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-02-28</instant>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20170301_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FebruaryTwoThousandAndSeventeenGrantAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-03-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FebruaryTwoThousandAndSeventeenGrantAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FebruaryTwoThousandAndSeventeenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FebruaryTwoThousandAndSeventeenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FebruaryTwoThousandAndSeventeenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FebruaryTwoThousandAndSeventeenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FebruaryTwoThousandAndSeventeenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FebruaryTwoThousandAndSeventeenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20180831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AugustTwoThousandAndEighteenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-08-31</instant>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AugustTwoThousandAndEighteenGrantAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AugustTwoThousandAndEighteenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AugustTwoThousandAndEighteenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AugustTwoThousandAndEighteenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AugustTwoThousandAndEighteenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AugustTwoThousandAndEighteenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapStatementClassOfStockAxis_asnsSeriesDRedeemableConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20170401_20170430">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:GrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">asns:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-04-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20171103_20171103">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:GrantAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-11-03</startDate>
      <endDate>2017-11-03</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:GrantAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:GrantAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:GrantAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:GrantAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:GrantAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_asnsFundingArrangementsWithFFGMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FundingArrangementsWithFFGMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_asnsFundingArrangementsWithFFGMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FundingArrangementsWithFFGMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FFGGrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FFGGrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FFGGrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FFGGrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FFGGrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FFGGrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FFGLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FFGLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FFGLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FFGLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FFGLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:FFGLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_srtStatementGeographicalAxis_asnsAustriaMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">asns:AustriaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtStatementGeographicalAxis_asnsAustriaMember_us-gaapStatementScenarioAxis_us-gaapScenarioForecastMember_20180101_20181231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">asns:AustriaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsResearchAndDevelopmentIncentiveProgramMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsResearchAndDevelopmentIncentiveProgramMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsResearchAndDevelopmentIncentiveProgramMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsResearchAndDevelopmentIncentiveProgramMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsResearchAndDevelopmentIncentiveProgramMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsResearchAndDevelopmentIncentiveProgramMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ResearchAndDevelopmentIncentiveProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TermLoansUnderTwoThousandTwelveLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TermLoansUnderTwoThousandTwelveLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:FFGLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:FFGLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveTermLoanAAdvanceMember_20121206_20121207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandTwelveTermLoanAAdvanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-12-06</startDate>
      <endDate>2012-12-07</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveLoanAgreementMember_20121206_20121207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandTwelveLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-12-06</startDate>
      <endDate>2012-12-07</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveTermLoanBAdvanceMember_20121206_20121207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandTwelveTermLoanBAdvanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-12-06</startDate>
      <endDate>2012-12-07</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveTermLoanAAdvanceMember_us-gaapStatementClassOfStockAxis_asnsSeriesATwoPreferredStockWarrantsMember_20121207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandTwelveTermLoanAAdvanceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">asns:SeriesATwoPreferredStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-07</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveTermLoanBAdvanceMember_us-gaapStatementClassOfStockAxis_asnsSeriesATwoPreferredStockWarrantsMember_20130225">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandTwelveTermLoanBAdvanceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">asns:SeriesATwoPreferredStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-02-25</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapStatementClassOfStockAxis_asnsSeriesATwoPreferredStockWarrantsMember_20121207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">asns:SeriesATwoPreferredStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2012-12-07</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapStatementClassOfStockAxis_asnsSeriesATwoPreferredStockWarrantsMember_20121206_20121207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">asns:SeriesATwoPreferredStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-12-06</startDate>
      <endDate>2012-12-07</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAAdvanceMember_20160219">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandSixteenTermLoanAAdvanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-02-19</instant>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanBAdvanceMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandSixteenTermLoanBAdvanceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAAdvanceMember_20160228_20160229">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandSixteenTermLoanAAdvanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-28</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveLoanAgreementMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandTwelveLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanBAdvanceMember_20160822_20160823">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandSixteenTermLoanBAdvanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-08-22</startDate>
      <endDate>2016-08-23</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAAdvanceMember_us-gaapStatementClassOfStockAxis_asnsSeriesBWarrantsMember_20160229">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandSixteenTermLoanAAdvanceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">asns:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-02-29</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanBAdvanceMember_us-gaapStatementClassOfStockAxis_asnsSeriesBWarrantsMember_20160823">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandSixteenTermLoanBAdvanceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">asns:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-08-23</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapStatementClassOfStockAxis_asnsSeriesBWarrantsMember_20160219">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">asns:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-02-19</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapStatementClassOfStockAxis_asnsSeriesBWarrantsMember_20160218_20160219">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">asns:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-18</startDate>
      <endDate>2016-02-19</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapStatementClassOfStockAxis_asnsSeriesBWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">asns:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapClassOfWarrantOrRightAxis_asnsExercisePriceOneMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">asns:ExercisePriceOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapClassOfWarrantOrRightAxis_asnsExercisePriceTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">asns:ExercisePriceTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAdvanceMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandSixteenTermLoanAdvanceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAdvanceMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandSixteenTermLoanAdvanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveLoanAgreementMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandTwelveLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAdvanceMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TwoThousandSixteenTermLoanAdvanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMinimumMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMaximumMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsFirstAmendmentMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:FirstAmendmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TermLoansUnderTwoThousandTwelveLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TermLoansUnderTwoThousandTwelveLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TermLoansUnderTwoThousandTwelveLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:TermLoansUnderTwoThousandTwelveLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:FFGLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:FFGLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:FFGLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:FFGLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:FFGLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">asns:FFGLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapPlanNameAxis_asnsTwoThousandAndTenSpecialStockIncentivePlanMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">asns:TwoThousandAndTenSpecialStockIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapPlanNameAxis_asnsTwoThousandAndElevenStockIncentivePlanMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">asns:TwoThousandAndElevenStockIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_asnsTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTitleOfIndividualAxis_us-gaapDirectorMember_20180101_20180101">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">asns:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-01-01</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapPlanNameAxis_asnsTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTitleOfIndividualAxis_us-gaapDirectorMember_20180101_20180101">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">asns:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-01-01</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapPlanNameAxis_asnsTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">asns:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapStatementClassOfStockAxis_asnsWarrantsToPurchaseRedeemableConvertiblePreferredStockMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">asns:WarrantsToPurchaseRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapLeaseArrangementTypeAxis_asnsViennaLeaseAgreementMember_20101101_20101130">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">asns:ViennaLeaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-11-01</startDate>
      <endDate>2010-11-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapLeaseArrangementTypeAxis_asnsViennaLeaseAgreementMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">asns:ViennaLeaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapLeaseArrangementTypeAxis_asnsAnimalUseLeaseAgreementMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">asns:AnimalUseLeaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapLeaseArrangementTypeAxis_asnsAnimalUseLeaseAgreementMember_20150701_20150731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">asns:AnimalUseLeaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-07-31</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapLeaseArrangementTypeAxis_asnsWalthamLeaseAgreementMember_20151101_20151130">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">asns:WalthamLeaseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-11-01</startDate>
      <endDate>2015-11-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapLeaseArrangementTypeAxis_asnsLeaseAgreementForOfficeSpaceInWalthamMAMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">asns:LeaseAgreementForOfficeSpaceInWalthamMAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180810_20180810">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-10</startDate>
      <endDate>2018-08-10</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180810">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-08-10</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTransactionTypeAxis_asnsAdimabOptionAgreementMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">asns:AdimabOptionAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapOtherCommitmentsAxis_asnsManufacturingCommitmentsMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">asns:ManufacturingCommitmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapOtherCommitmentsAxis_asnsManufacturingCommitmentsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">asns:ManufacturingCommitmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapOtherCommitmentsAxis_asnsPrepaidClinicalManufacturingExpensesMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">asns:PrepaidClinicalManufacturingExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapOtherCommitmentsAxis_asnsPrepaidClinicalManufacturingExpensesMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">asns:PrepaidClinicalManufacturingExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AdimabOptionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:AdimabLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ServicesAndFacilitiesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:EveliQureBiotechnologiesGmbHMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ServicesAndFacilitiesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:EveliQureBiotechnologiesGmbHMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ServicesAndFacilitiesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:EveliQureBiotechnologiesGmbHMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ServicesAndFacilitiesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:EveliQureBiotechnologiesGmbHMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20180401_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ServicesAndFacilitiesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:EveliQureBiotechnologiesGmbHMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ServicesAndFacilitiesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:EveliQureBiotechnologiesGmbHMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20170101_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ServicesAndFacilitiesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:EveliQureBiotechnologiesGmbHMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ServicesAndFacilitiesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:EveliQureBiotechnologiesGmbHMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:ServicesAndFacilitiesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:EveliQureBiotechnologiesGmbHMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20180808">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">asns:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AugustTwoThousandAndEighteenGrantAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-08-08</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180810_20180810">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AugustTwoThousandEighteenLeaseAmendmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-10</startDate>
      <endDate>2018-08-10</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180101_20180630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AugustTwoThousandEighteenLeaseAmendmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180810">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">asns:AugustTwoThousandEighteenLeaseAmendmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-08-10</instant>
    </period>
  </context>
  <context id="C_0001501697_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_asnsArsanisClinicalDevelopmentOfASN100Member_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180810_20180810">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">asns:ArsanisClinicalDevelopmentOfASN100Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-10</startDate>
      <endDate>2018-08-10</endDate>
    </period>
  </context>
  <context id="C_0001501697_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_asnsArsanisClinicalDevelopmentOfASN100Member_us-gaapStatementScenarioAxis_us-gaapScenarioForecastMember_20180701_20180930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">asns:ArsanisClinicalDevelopmentOfASN100Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <dei:DocumentType id="F_000000" contextRef="C_0001501697_20180101_20180630">10-Q</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001501697_20180101_20180630">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001501697_20180101_20180630">2018-06-30</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalPeriodFocus id="F_000003" contextRef="C_0001501697_20180101_20180630">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="F_000004" contextRef="C_0001501697_20180101_20180630">2018</dei:DocumentFiscalYearFocus>
  <dei:EntityRegistrantName id="F_000005" contextRef="C_0001501697_20180101_20180630">ARSANIS, INC.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000006" contextRef="C_0001501697_20180101_20180630">0001501697</dei:EntityCentralIndexKey>
  <dei:TradingSymbol id="F_000007" contextRef="C_0001501697_20180101_20180630">ASNS</dei:TradingSymbol>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0001501697_20180101_20180630">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="F_000009" contextRef="C_0001501697_20180101_20180630">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="F_000010" contextRef="C_0001501697_20180731" decimals="INF" unitRef="U_shares">14315410</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000011" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">49940000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000012" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">76793000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <asns:GrantAndIncentiveReceivables id="F_000013" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">2178000</asns:GrantAndIncentiveReceivables>
  <asns:GrantAndIncentiveReceivables id="F_000014" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">1608000</asns:GrantAndIncentiveReceivables>
  <us-gaap:RestrictedCashCurrent id="F_000015" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">51000</us-gaap:RestrictedCashCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000016" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">4393000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000017" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">1129000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000018" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">56562000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000019" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">79530000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000020" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">353000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000021" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">421000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCashNoncurrent id="F_000022" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">295000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000023" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">355000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000024" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">948000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000025" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">57210000</us-gaap:Assets>
  <us-gaap:Assets id="F_000026" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">81254000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000027" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">2137000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000028" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">1893000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000029" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">3879000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000030" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">5779000</us-gaap:AccruedLiabilitiesCurrent>
  <asns:UnearnedIncomeCurrent id="F_000031" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">712000</asns:UnearnedIncomeCurrent>
  <asns:UnearnedIncomeCurrent id="F_000032" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">694000</asns:UnearnedIncomeCurrent>
  <us-gaap:LoansPayableCurrent id="F_000033" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">3486000</us-gaap:LoansPayableCurrent>
  <us-gaap:LoansPayableCurrent id="F_000034" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">2314000</us-gaap:LoansPayableCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000035" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">10214000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000036" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">10680000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermLoansPayable id="F_000037" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">7706000</us-gaap:LongTermLoansPayable>
  <us-gaap:LongTermLoansPayable id="F_000038" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">9922000</us-gaap:LongTermLoansPayable>
  <asns:UnearnedIncomeNoncurrent id="F_000039" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">1519000</asns:UnearnedIncomeNoncurrent>
  <asns:UnearnedIncomeNoncurrent id="F_000040" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">1936000</asns:UnearnedIncomeNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000041" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000042" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:Liabilities id="F_000043" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">19446000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000044" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">22547000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000045" xsi:nil="true" contextRef="C_0001501697_20180630" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000046" xsi:nil="true" contextRef="C_0001501697_20171231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000047" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">14000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000048" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">15000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000049" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">152601000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000050" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">150830000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000051" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">177000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000052" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000053" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">-115028000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000054" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">-92265000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000055" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">37764000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000056" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">58707000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000057" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">57210000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000058" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">81254000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000059" contextRef="C_0001501697_20180630" decimals="INF" unitRef="U_iso4217USD_shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000060" contextRef="C_0001501697_20171231" decimals="INF" unitRef="U_iso4217USD_shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000061" contextRef="C_0001501697_20180630" decimals="INF" unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000062" contextRef="C_0001501697_20171231" decimals="INF" unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000063" contextRef="C_0001501697_20180630" decimals="INF" unitRef="U_shares">14315410</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000064" contextRef="C_0001501697_20171231" decimals="INF" unitRef="U_shares">14294383</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000065" contextRef="C_0001501697_20180630" decimals="INF" unitRef="U_shares">14315410</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000066" contextRef="C_0001501697_20171231" decimals="INF" unitRef="U_shares">14294383</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000067" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">8930000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000068" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">3906000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000069" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">17063000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000070" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">8297000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000071" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">3686000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000072" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">1738000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000073" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">6503000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000074" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">3174000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000075" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">12616000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000076" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">5644000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000077" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">23566000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000078" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">11471000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000079" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">-12616000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000080" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-5644000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000081" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-23566000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000082" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-11471000</us-gaap:OperatingIncomeLoss>
  <asns:GrantAndIncentiveIncome id="F_000083" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">516000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000084" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">862000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000085" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">961000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000086" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">1562000</asns:GrantAndIncentiveIncome>
  <us-gaap:InterestExpense id="F_000087" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">259000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000088" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">444000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000089" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">526000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="F_000090" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">1463000</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest id="F_000091" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">225000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="F_000092" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">441000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000093" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-11000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000094" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-11000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:DerivativeGainLossOnDerivativeNet id="F_000095" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">762000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000096" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-462000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000097" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-462000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000098" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000099" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-28000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000100" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-73000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="F_000101" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-29000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000102" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">483000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000103" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-61000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000104" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">803000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="F_000105" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">381000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss id="F_000106" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">-12133000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000107" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-5705000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000108" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-22763000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000109" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-11090000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment id="F_000110" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment id="F_000111" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000112" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">-12133000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000113" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-5718000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000114" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-22763000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000115" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-11110000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000116" contextRef="C_0001501697_20180401_20180630" decimals="2" unitRef="U_iso4217USD_shares">-0.85</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000117" contextRef="C_0001501697_20170401_20170630" decimals="2" unitRef="U_iso4217USD_shares">-11.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000118" contextRef="C_0001501697_20180101_20180630" decimals="2" unitRef="U_iso4217USD_shares">-1.59</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000119" contextRef="C_0001501697_20170101_20170630" decimals="2" unitRef="U_iso4217USD_shares">-21.62</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000120" contextRef="C_0001501697_20180401_20180630" decimals="0" unitRef="U_shares">14304102</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000121" contextRef="C_0001501697_20170401_20170630" decimals="0" unitRef="U_shares">513900</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000122" contextRef="C_0001501697_20180101_20180630" decimals="0" unitRef="U_shares">14299288</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000123" contextRef="C_0001501697_20170101_20170630" decimals="0" unitRef="U_shares">513900</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax id="F_000124" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">270000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax id="F_000125" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-297000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax id="F_000126" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">50000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax id="F_000127" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-379000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000128" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">-11863000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000129" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-6002000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000130" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-22713000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000131" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-11469000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ShareBasedCompensation id="F_000132" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">1618000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000133" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">354000</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000134" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">85000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000135" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">96000</us-gaap:DepreciationDepletionAndAmortization>
  <asns:NonCashInterestExpense id="F_000136" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">397000</asns:NonCashInterestExpense>
  <asns:NonCashInterestExpense id="F_000137" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">1377000</asns:NonCashInterestExpense>
  <asns:AdjustmentOfNonCashRentExpense id="F_000138" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-11000</asns:AdjustmentOfNonCashRentExpense>
  <asns:IncreaseDecreaseInGrantAndIncentiveReceivables id="F_000139" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-635000</asns:IncreaseDecreaseInGrantAndIncentiveReceivables>
  <asns:IncreaseDecreaseInGrantAndIncentiveReceivables id="F_000140" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-547000</asns:IncreaseDecreaseInGrantAndIncentiveReceivables>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000141" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">2394000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000142" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">1708000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000143" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">257000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000144" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-563000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000145" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-1886000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000146" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">1434000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <asns:IncreaseDecreaseInUnearnedIncome id="F_000147" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-336000</asns:IncreaseDecreaseInUnearnedIncome>
  <asns:IncreaseDecreaseInUnearnedIncome id="F_000148" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">1095000</asns:IncreaseDecreaseInUnearnedIncome>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000149" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-25657000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000150" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-9874000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquireProductiveAssets id="F_000151" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">27000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:PaymentsToAcquireProductiveAssets id="F_000152" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">41000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000153" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-27000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000154" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">-41000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock id="F_000155" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">35053000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:ProceedsFromConvertibleDebt id="F_000156" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">4935000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceOfDebt id="F_000157" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">666000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000158" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">152000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:RepaymentsOfLongTermDebt id="F_000159" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">1167000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:RepaymentsOfLongTermDebt id="F_000160" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">1165000</us-gaap:RepaymentsOfLongTermDebt>
  <asns:PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes id="F_000161" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">17000</asns:PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes>
  <asns:PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock id="F_000162" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">197000</asns:PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000163" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">43000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000164" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-1058000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000165" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">39275000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000166" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-120000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000167" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">55000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000168" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">-26862000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000169" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">29415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000170" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">77148000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000171" contextRef="C_0001501697_20161231" decimals="-3" unitRef="U_iso4217USD">3429000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000172" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">50286000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000173" contextRef="C_0001501697_20170630" decimals="-3" unitRef="U_iso4217USD">32844000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <asns:IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes id="F_000174" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">11102000</asns:IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes>
  <us-gaap:LiabilitiesAssumed1 id="F_000175" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">403000</us-gaap:LiabilitiesAssumed1>
  <asns:ExtinguishmentOfConvertiblePromissoryNotes id="F_000176" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">8405000</asns:ExtinguishmentOfConvertiblePromissoryNotes>
  <asns:ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes id="F_000177" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">2234000</asns:ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock id="F_000178" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Nature of the Business and Basis of Presentation &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arsanis, Inc. (the &amp;#8220;Company&amp;#8221;) is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody, or mAb, immunotherapies to address serious infectious diseases. The Company possesses a deep understanding of the pathogenesis of infection, paired with access to what the Company believes to be some of the most advanced mAb discovery techniques and platforms available today. The Company&amp;#8217;s pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including &lt;font style="font-style:italic;"&gt;Staphylococcus aureus&lt;/font&gt; (&amp;#8220;&lt;font style="font-style:italic;"&gt;S. aureus&lt;/font&gt;&amp;#8221;) and respiratory syncytial virus (&amp;#8220;RSV&amp;#8221;). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 28, 2018, the Company announced the discontinuation of its Phase 2 clinical trial of ASN100 for the prevention of &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;font style="font-style:italic;"&gt;S. aureus&lt;/font&gt; pneumonia in high-risk, mechanically ventilated patients following the completion of a planned interim analysis of unblinded trial data for 118 patients by an independent data review committee (&amp;#8220;DRC&amp;#8221;). Based on the results of this analysis, the DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion, and recommended that trial enrollment be discontinued. The Company intends to conduct follow-up visits on patients dosed in the trial per the study protocol and to evaluate the complete dataset from the 154 patients that were enrolled in the trial to better understand the basis for this result. The Company expects to complete this evaluation in the fourth quarter of 2018 and has ceased further clinical development of ASN100, pending the results of this analysis. The Company currently does not expect to incur material costs for this program beyond the fourth quarter of 2018. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In light of the discontinuation of the clinical development of ASN100, the Company is considering strategic options that may potentially result in changes to its business strategy and future operations. Pending any decision to change its strategic direction, the Company&amp;#8217;s current operating plan provides for its ongoing review of the data from the ASN100 clinical trial, the continued development of its ASN500 program, as well as supporting its collaborators across its ASN200 and ASN300 programs, both of which were outlicensed to subsidiaries of Bravos Biosciences, LLC during the first half of 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, the Company&amp;#8217;s ability to successfully execute on its strategic plans, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Any product candidates will require significant research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&amp;#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 3, 2017, the Company effected a one-for-3.4130 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&amp;#8217;s redeemable convertible preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 20, 2017, the Company completed an initial public offering (&amp;#8220;IPO&amp;#8221;) of its common stock, and issued and sold 4,000,000 common shares at a price to the public of $10.00 per share. Concurrent to the IPO, (i) the Company issued an additional 600,000 common shares at a price of $10.00 per share pursuant to the exercise of the underwriters&amp;#8217; over-allotment option and (ii) New Enterprise Associates 16, L.P., or NEA, purchased 2,000,000 shares of the Company&amp;#8217;s common stock at the initial per share public offering price of $10.00 in a private placement. The aggregate net proceeds to the Company from the IPO, inclusive of the over-allotment exercise, and the private placement were $58.1 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. Upon the closing of the IPO, all of the outstanding redeemable convertible preferred stock of the Company automatically converted into 7,180,483 shares of the Company&amp;#8217;s common stock.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had an accumulated deficit of $115.0 million at June 30, 2018. During the six months ended June 30, 2018, the Company incurred a net loss of $22.8 million and used $25.7 million of cash in operations. The Company expects to continue to generate operating losses for the foreseeable future. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on its current operating plan, the Company expects that its cash and cash equivalents of $49.9 million as of June 30, 2018, will be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments for at least 12 months from the issuance date of these condensed consolidated financial statements. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arsanis is incorporated under the laws of the State of Delaware and is headquartered in Waltham, Massachusetts, with a wholly-owned subsidiary that is primarily focused on discovery research in Vienna, Austria. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and include the accounts of the Company and its wholly owned subsidiary, Arsanis Biosciences GmbH. All intercompany balances and transactions have been eliminated. &lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000179" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Summary of Significant Accounting Policies &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Unaudited Interim Financial Statements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed balance sheet at December&amp;#160;31, 2017 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying condensed financial statements as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017 are unaudited. The accompanying unaudited interim financial statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company&amp;#8217;s&amp;#160;audited financial statements and the notes thereto for the year ended December&amp;#160;31, 2017 included in the Company&amp;#8217;s&amp;#160;Annual Report on Form 10-K as filed with the SEC on March&amp;#160;9, 2018. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&amp;#8217;s condensed financial position as of June 30, 2018 and condensed results of its operations for the three and six months ended June 30, 2018 and 2017 and cash flows for the six months ended June 30, 2018 and 2017 have been made. The results of operations for the three and six months ended June 30, 2018 and 2017 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of common stock and stock options. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain assets of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&amp;#8212;Quoted prices in active markets for identical assets or liabilities. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&amp;#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&amp;#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of cash equivalents, other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The carrying value of the Company&amp;#8217;s loan and security agreement with Silicon Valley Bank (&amp;#8220;SVB&amp;#8221;) approximates its fair value because the debt bears interest at a market rate. The carrying value of the loans received under the funding agreements with &amp;#214;sterreichische Forschungsf&amp;#246;rderungsgesellschaft mbH (&amp;#8220;FFG&amp;#8221;) approximates their fair value because the Company records imputed interest expense based on rates that approximate market rates of interest as of the issuance date of each FFG loan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Gain (Loss) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive gain (loss) includes net gain (loss) as well as other changes in stockholders&amp;#8217; equity that result from transactions and economic events other than those with stockholders. Comprehensive gain (loss) included $0.3 million and $(0.3) million for the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $(0.4) million for the six months ended June 30, 2018 and 2017, respectively, of foreign currency translation gain (loss) adjustments. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Income (Loss) per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, options to purchase common stock, redeemable convertible preferred stock, warrants to purchase common stock and warrants to purchase redeemable convertible preferred stock are considered potential dilutive common shares.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s redeemable convertible preferred stock contractually entitled the holders of such shares to participate in dividends but contractually did not require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2014-09, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/font&gt;(&amp;#8220;ASU 2014-09&amp;#8221;), which supersedes most existing revenue recognition guidance under GAAP. The FASB also issued several amendments and updates to the new revenue standard (collectively, &amp;#8220;Topic 606&amp;#8221;). The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance. These judgments and estimates include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&amp;#8217;s financial position, results of operations or cash flows as the Company does not currently have any revenue-generating arrangements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2016, the FASB issued ASU No.&amp;#160;2016-15, &lt;font style="font-style:italic;"&gt;Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt; (&amp;#8220;ASU 2016-15&amp;#8221;), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The Company adopted the standard retrospectively to all periods presented on the required effective date of January 1, 2018, and its adoption had no impact on the Company&amp;#8217;s financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2016, the FASB issued ASU No.&amp;#160;2016-16, &lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory&lt;/font&gt; (&amp;#8220;ASU 2016-16&amp;#8221;), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&amp;#8217;s financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2016, the FASB issued ASU No.&amp;#160;2016-18, &lt;font style="font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Restricted Cash&lt;/font&gt; (&amp;#8220;ASU 2016-18&amp;#8221;), which requires restricted cash to be presented with cash and cash equivalents on the statement of cash flows and disclosure of how the statement of cash flows reconciles to the balance sheet if restricted cash is shown separately from cash and cash equivalents on the balance sheet. The Company adopted this standard on January 1, 2018. The adoption of ASU 2016-18 resulted in the Company&apos;s cash, cash equivalents and restricted cash being included in the beginning and ending amounts for the periods shown on the statement of cash flows and was applied retroactively and reflected in the balances presented for any prior periods. The Company believes that the adoption of this guidance did not have a significant impact on its condensed consolidated financial statements and related disclosures. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The restricted cash as of June 30, 2018 and December 31, 2017 is held as letters of credit for the benefit of the landlords in connection with the Company&amp;#8217;s office leases.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,143&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash &amp;#8211; current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash &amp;#8211; non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;295&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash shown in the statement of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,286&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,844&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2017, FASB issued ASU No.&amp;#160;2017-01, &lt;font style="font-style:italic;"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt; (&amp;#8220;ASU 2017-01&amp;#8221;). The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill and consolidation. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&amp;#8217;s financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2017, the FASB issued ASU No.&amp;#160;2017-09, &lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Scope of Modification Accounting&lt;/font&gt; (&amp;#8220;ASU 2017-09&amp;#8221;), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&amp;#8217;s financial position, results of operations or cash flows. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2018, the FASB issued ASU 2018-05, &lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118&lt;/font&gt; ("ASU&amp;#160;2018-05"). This standard amends ASC 740, Income Taxes (&amp;#8220;ASC 740&amp;#8221;) to provide guidance on accounting for the tax effects of the Tax Cuts and Jobs Act pursuant to Staff Accounting Bulletin No. 118, which allows companies to complete the accounting under ASC 740 within a one-year measurement period from the Tax Act enactment date. This standard was effective upon issuance. &lt;font style="color:#000000;"&gt;The Company will continue to assess the impact that various provisions will have on its business. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the FASB issued&amp;#160;ASU 2018-07,&amp;#160;&lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting &lt;/font&gt;(&amp;#8220;ASU 2018-07&amp;#8221;), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The new standard specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&amp;#8217;s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. ASU 2018-07 is required to be adopted for annual periods beginning after December&amp;#160;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2018-07 will have on its consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2017, the FASB issued&amp;#160;ASU 2017-11,&amp;#160;&lt;font style="font-style:italic;"&gt;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception&lt;/font&gt; (&amp;#8220;ASU 2017-11&amp;#8221;).&amp;#160;Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480&amp;#160;with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU 2017-11 is required to be adopted for annual periods beginning after December&amp;#160;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2017-11 will have on its consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No.&amp;#160;2016-02&lt;font style="font-style:italic;"&gt;, Leases (Topic 842)&lt;/font&gt; (&amp;#8220;ASU 2016-02&amp;#8221;), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASU 2016-02 (Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) (Topic 842) supersedes the previous leases standard, ASC 840, Leases. The standard is effective for public entities for annual periods beginning after December&amp;#160;15, 2018 including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements. &lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000180" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Fair Value of Financial Assets and Liabilities&lt;font style="font-weight:normal;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&amp;#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June&amp;#160;30, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents - Money Market Funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents - Money Market Funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no changes to the valuation methods during the six months ended June 30, 2018 and the year ended December 31, 2017. There were no transfers within the fair value hierarchy during the six months ended June 30, 2018 and the year ended December 31, 2017. &lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <asns:AccruedExpensesTextBlock id="F_000181" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/font&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Accrued Expenses&lt;font style="font-weight:normal;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical trial costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,317&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation and benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,539&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,454&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;563&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;510&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,879&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,779&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</asns:AccruedExpensesTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000182" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Collaboration, License and Funding Arrangements&lt;font style="font-weight:normal;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Adimab Option and License Agreement &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2017, the Company entered into an option and license agreement with Adimab, LLC (&amp;#8220;Adimab&amp;#8221;), a related party (see Note&amp;#160;11) (the &amp;#8220;Adimab Option Agreement&amp;#8221;). Under the Adimab Option Agreement, Adimab has provided to the Company certain proprietary antibodies against RSV (&amp;#8220;RSV antibodies&amp;#8221;) for its evaluation during a specified option period and has granted the Company an exclusive, non-sublicensable license in a specified field under certain Adimab patent rights and know-how during the option period. Under the Adimab Option Agreement, the Company has an exclusive option, exercisable during the option period upon payment of an option fee to Adimab, to require Adimab to assign to the Company all rights in up to a specified number of RSV antibodies selected by the Company and certain patent rights owned by Adimab that cover these antibodies, and to obtain from Adimab a non-exclusive license in a specified field, with the right to grant sublicenses, under certain other patent rights and know-how owned by Adimab. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2017, the Company entered into a grant agreement with the Bill &amp;amp; Melinda Gates Foundation (the &amp;#8220;Gates Foundation&amp;#8221;) pursuant to which the Company has no payment obligations under the Adimab Option Agreement with respect to sales of products based on licensed RSV antibodies to the extent they are sold at cost in developing countries. However, if such products are sold in developing countries for an amount that exceeds cost, then the amount of such excess will be subject to certain royalty payment obligations described in the agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized research and development expenses of $14,000 and $58,000 during the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $0.1 million during the six months ended June 30, 2018 and 2017, respectively, in connection with the Adimab Option Agreement, which consisted of reimbursement for services performed by Adimab. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;February 2017 and August 2018 Amended and Restated Gates Foundation Grant Agreement &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2017, the Company entered into the above-referenced grant agreement with the Gates Foundation, under which the Gates Foundation agreed to provide the Company up to $9.3 million to conduct preclinical development of mAbs for the prevention of RSV infection in newborns (the &amp;#8220;RSV project&amp;#8221;).&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2017, the Company received a payment of $1.6 million from the Gates Foundation under the grant agreement. The funds received from the Gates Foundation were incurred on qualifying expenses attributable to the RSV project, and the Company recognized grant income of $1.6 million under the grant agreement during the year ended December 31, 2017.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the Company entered into an amended and restated grant agreement which replaces the February 2017 grant agreement in its entirety. The amended and restated grant agreement includes amendments to conform to current Gates Foundation audit, reporting, and other administrative requirements, as well as to make the perpetual Gates Foundation license grant described below irrevocable.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized grant income of $0 during the three and six months ended June 30, 2018, and $0.6 million during the three and six months ended June 30, 2017, under the grant agreement with the Gates Foundation upon incurring qualifying expenses. As of June 30, 2018 and December 31, 2017, unearned income under the grant agreement with the Gates Foundation was $0. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;August 2018 Gates Foundation Grant Agreement&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the Company entered into an additional grant agreement with the Gates Foundation pursuant to which the Gates Foundation granted to the Company up to $1.1 million to conduct preclinical development activities for the RSV project that were not included in the February 2017 grant agreement, as amended and restated in August 2018. In return, the Company has agreed to conduct the RSV project in a manner that ensures that the knowledge and information gained from the project will be promptly and broadly disseminated, and that the products, technologies, materials, processes and other intellectual property resulting from the RSV project (collectively referred to as the funded developments) will be made available and accessible at an affordable price to people most in need within developing countries. These obligations survive any expiration or termination of the grant agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To this end, the Company has granted to the Gates Foundation a non-exclusive, perpetual, irrevocable, royalty-free, fully paid up, sublicensable license to make, use, sell, offer to sell, import, distribute, copy, modify, create derivative works, publicly perform and display the funded developments and, to the extent incorporated into a funded development or required to use a funded development, any other technology created outside of the RSV project that was used as part of the RSV project, for the benefit of people in developing countries. The Company has also agreed to seek prompt publication of data and results developed under the RSV project under &amp;#8220;open access&amp;#8221; terms and conditions. This license and these publication obligations survive any expiration or termination of the grant agreements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The August 2018 grant agreement expires on August 31, 2018. The Gates Foundation can modify, suspend or discontinue any payment under the grant agreement, or terminate the grant agreement, if it is not reasonably satisfied with the Company&amp;#8217;s progress on the RSV project; if there are significant changes to the Company&amp;#8217;s leadership or other factors that the Gates Foundation reasonably believes may threaten the RSV project&amp;#8217;s success; if the Company undergoes a change in control; if there is a change in the Company&amp;#8217;s tax status; or if the Company fails to comply with the grant agreement. Any grant funds that have not been used for, or committed to, the RSV project upon the expiration or termination of the agreement must be returned to the Gates Foundation or otherwise used as directed by the Gates Foundation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did not recognize grant income or record any unearned income under the August 2018 grant agreement with the Gates Foundation in any periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Gates Foundation Letter Agreement and Investment&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2017, the Company entered into a letter agreement with the Gates Foundation. In connection with the letter agreement, the Gates Foundation purchased 2,464,799 shares of the Company&amp;#8217;s Series D preferred stock, which converted into &lt;font style="color:#000000;"&gt;722,179 &lt;/font&gt;shares of our common stock in connection with our November 2017 initial public offering after giving effect to a one-for-3.4130 reverse-stock-split. The Company committed to use the proceeds of $8.0&amp;#160;million from the investment by the Gates Foundation solely to advance the development of a specified monoclonal antibody program that involves the monoclonal antibodies ASN-1, ASN-2 and ASN-3 and the Company&amp;#8217;s product candidate, ASN100. Under the letter agreement, in addition to the initial project funded by the Gates Foundation with its initial investment, the Company also agreed to conduct up to four additional projects to be proposed and to be funded by the Gates Foundation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The letter agreement contains certain global access obligations as well as requirements relating to the Company&amp;#8217;s use of the funds received from the Gates Foundation investment. In the event that the Company fails to comply with these obligations or requirements or any related U.S. legal obligations set forth in the letter agreement, the Gates Foundation will have the right, after expiration of a specified cure period, to require the Company to redeem all of the shares owned by the Gates Foundation or to locate a third party that will purchase such shares. For any redemption or purchase resulting from such default, the shares of the Company&amp;#8217;s stock held by the Gates Foundation will be redeemed at an amount equal to the greater of the original purchase price (plus specified interest) or the fair market value of such stock on the date of such redemption. The term of the letter agreement continues in perpetuity.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with this letter agreement, the Company has granted to the Gates Foundation and/or Gates Foundation-supported entities certain licenses, including a non-exclusive, non-terminable, royalty-free (except as required under the Adimab Collaboration Agreement), sublicensable license to products, technologies, materials, processes and other intellectual property developed using funds provided by the Gates Foundation or a Gates Foundation-supported entity, or developed in connection with the Company&amp;#8217;s conduct of any funded project or additional funded project, as well as all of the Company&amp;#8217;s background intellectual property, to utilize and exploit products and services directed at pathogens or other targets subject to any funded project or additional funded project.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The proceeds received from the Gates Foundation in connection with the Company&amp;#8217;s sale and issuance of Series D preferred stock were incurred on qualifying expenses under the letter agreement during the year ended December 31, 2017.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company incurred qualifying expenses of $&lt;font style="color:#000000;"&gt;0&lt;/font&gt; during the three and six months ended June 30, 2018, and $&lt;font style="color:#000000;"&gt;0.7&lt;/font&gt; million during the three and six months ended June 30, 2017, under the letter agreement with the Gates Foundation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Funding Agreements with FFG &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Between September 2011 and March 2017, the Company entered into a series of funding agreements with FFG that provided for loans and grants to fund between 50% and 70% of qualifying research and development expenditures of the Company&amp;#8217;s subsidiary in Austria on a project-by-project basis, as approved by FFG. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;FFG Grants &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For grants under the funding agreements with FFG, the Company recognized grant income of $0 and $0.2 million during the three months ended June&amp;#160;30, 2018 and 2017, respectively, and $0 and $0.3 million during the six months ended June&amp;#160;30, 2018 and 2017, respectively. As of June 30, 2018 and December&amp;#160;31, 2017, the Company recorded grant receivables from FFG of $0.1 million and $0.1 million, respectively, for qualifying expenses incurred that were reimbursable under the funding agreements. As of June 30, 2018 and December&amp;#160;31, 2017, there were no amounts recorded as unearned income in connection with the FFG grants. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;FFG Loans &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loans under the funding agreements with FFG bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged by FFG as additional grant funding from FFG. On the date that FFG loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is recognized as additional grant income over the term of the funding agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized grant income of $0.1 million and $0.2&amp;#160;million during the three months ended June 30, 2018 and 2017, respectively, and $0.3&amp;#160;million and $0.3&amp;#160;million during the six months ended June 30, 2018 and 2017, respectively, related to the recognition of the unearned income recorded for the imputed benefit of FFG loans at below-market interest rates. Unearned income (current) related to the imputed benefit of FFG loans at below-market interest rates was $0.7 million and $0.7&amp;#160;million as of June 30, 2018 and December 31, 2017, respectively, and unearned income (non-current) related to such benefit was $1.5 million and $1.9&amp;#160;million as of June 30, 2018 and December&amp;#160;31, 2017, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Incentive &lt;font style="font-weight:normal;font-style:normal;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses incurred by the Company&amp;#8217;s subsidiary in Austria. Under the program, the reimbursement rate for qualifying research and development expenses incurred by the Company through its subsidiary in Austria was 12% for the year ended December 31, 2017, and is 14% for the year ended December 31, 2018. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes incentive income from Austrian research and development incentives when qualifying expenses have been incurred, there is reasonable assurance that the payment will be received, and the consideration can be reliably measured. Management has assessed the Company&amp;#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each reporting date, management estimates the reimbursable incentive income available to the Company based on available information at the time.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized incentive income of $0.3 million and $0.1 million during the three months ended June 30, 2018 and 2017, respectively, and $0.6 million and $0.5 million during the six months ended June 30, 2018 and 2017, respectively, in connection with the Austrian research and development incentive program. As of June 30, 2018 and December&amp;#160;31, 2017, the Company recorded receivables for amounts due under the program of $2.1 million and $1.5 million, respectively, which amounts were included in grant and incentive receivables in the condensed consolidated balance sheet. &lt;/p&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:DebtDisclosureTextBlock id="F_000183" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/font&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Loans Payable &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate principal amount of debt outstanding as of June 30, 2018 and December 31, 2017 consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term loans under 2012 Loan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,667&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;FFG loans&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,937&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,225&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,437&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current and non-current debt obligations reflected in the condensed consolidated balance sheets as of June 30, 2018 and December 31, 2017 consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term loans under 2012 Loan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,333&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;FFG loans&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized debt discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loans payable, net of discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,486&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,314&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term loans under 2012 Loan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;FFG loans&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,937&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,225&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized debt discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,231&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,637&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loans payable, net of discount and current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,706&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,922&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total loans payable, net of discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,236&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2012 Loan Agreement &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 7, 2012, the Company entered into a loan and security agreement (the &amp;#8220;2012 Loan Agreement&amp;#8221;) with SVB, and borrowed an aggregate of $2.5 million in two separate tranches: $0.5 million in December 2012 (the &amp;#8220;2012 Term Loan A Advance&amp;#8221;), and $2.0 million in February 2013 (the &amp;#8220;2012 Term Loan B Advance&amp;#8221;). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the 2012 Loan Agreement, the Company issued a Series A-2 warrant to SVB, which became exercisable with respect to 2,202 shares of Series A-2 preferred stock on December 12, 2012 in connection with the 2012 Term Loan A Advance, and with respect to 8,811 shares of Series A-2 preferred stock on February 25, 2013 in connection with the 2012 Term Loan B Advance. At the time of grant, the Series A-2 warrant was exercisable at a price of $4.54 per share. The Series A-2 warrant expires on December 6, 2022.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 19, 2016, the Company entered into the First Amendment to the 2012 Loan Agreement (the &amp;#8220;First Amendment&amp;#8221;). The First Amendment provided for an additional borrowing of $3.5 million (&amp;#8220;2016 Term Loan A Advance&amp;#8221;), with a requirement that a portion of the proceeds be used to pay in full, all amounts then outstanding, under the 2012 Term Loan A Advance and the 2012 Term Loan B Advance.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The First Amendment provided for two additional advances not to exceed, in the aggregate, $3.5 million, with each advance being for a minimum of $0.5 million (collectively the &amp;#8220;2016 Term Loan B Advance&amp;#8221;), and total borrowings under the 2012 Loan Agreement not to exceed $7.0 million. The Company borrowed the full $7.0 million available in two separate tranches: $3.5 million under the 2016 Term Loan A Advance, which was borrowed on February 29, 2016, and $3.5 million under the 2016 Term Loan B Advance, which was borrowed on August 23, 2016. Following these borrowings in February and August 2016, no additional amounts were available to be borrowed under the 2012 Loan Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the First Amendment to the 2012 Loan Agreement, the Company issued a Series B warrant to SVB which became exercisable with respect to 7,251 shares of Series B preferred stock on February 29, 2016 in connection with the 2016 Term Loan A Advance, and with respect to 7,251 shares of Series B preferred stock on August 23, 2016 in connection with the 2016 Term Loan B Advance. At the time of grant, the Series B warrant was exercisable at a price of $7.24 per share. The Series B warrant expires on February 18, 2026.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the closing of the IPO in November 2017, the Series A-2 warrant converted into a common stock warrant to purchase up to 3,940 shares of common stock at an exercise price of $12.70 per share. The Series B warrant converted into a common stock warrant to purchase up to 6,474 shares of common stock at an exercise price of $16.22 per share. At June 30, 2018, these warrants to purchase up to 3,940 shares of common stock at an exercise price of $12.70 and 6,474 shares of common stock at an exercise price of $16.22 remained outstanding.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Borrowings under the 2016 Term Loan A Advance and 2016 Term Loan B Advance (collectively, the &amp;#8220;2016 Term Loan Advance&amp;#8221;) bear interest at a rate per annum equal to the greater of 3.25% and The Wall Street Journal prime rate, in each case minus 0.25%; provided, however, that in an event of default, as defined in the 2012 Loan Agreement, the interest rate applicable to borrowings under the First Amendment will be increased by 4.0%. As of June 30, 2018 and December 31, 2017, the interest rate applicable to borrowings under the 2016 Term Loan Advance was 4.75% and 4.25%, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is required to make equal monthly payments of principal as well as accrued interest beginning January 1, 2017 through December 1, 2019 (the &amp;#8220;First Amendment Maturity Date&amp;#8221;), when all unpaid principal and interest become due and payable. The First Amendment also provided that the Company could voluntarily prepay all (but not less than all) of the outstanding principal at any time prior to the maturity date, subject to a prepayment fee, which ranges from 0% to 2% of the outstanding principal if paid prior to the First Amendment Maturity Date. The Company has not accrued for this prepayment fee as it had not intended to prepay the outstanding balance and the prepayment fee is 0% as of June 30, 2018. A final payment of 5.0% multiplied by the principal amount of the borrowings under the 2016 Term Loan Advance is due upon the earlier to occur of the First Amendment Maturity Date or prepayment of all outstanding principal. The final payment is being accreted to interest expense through the First Amendment Maturity Date. In connection with the First Amendment, the Company paid an arrangement fee of $20,000 to SVB and incurred legal costs of $7,000, both of which were recorded as a debt discount. The debt discount is reflected as a reduction of the carrying value of the loan payable on the Company&amp;#8217;s consolidated balance sheet and is being amortized to interest expense over the term of the loan using the effective interest method.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company was in compliance with all covenants under the 2012 Loan Agreement as of December 31, 2017. In March 2018, the Company entered into an Option and License Agreement with BB100, LLC, a subsidiary of Bravos Biosciences, LLC, under which BB100, LLC secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license, to mAbs targeting &lt;font style="font-style:italic;"&gt;E. coli&lt;/font&gt; that were discovered by the Company in its ASN200 program. In June 2018, the Company entered into an Option and License Agreement with BB200, LLC, a portfolio company of Bravos Biosciences, LLC, under which BB200, LLC secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license to selected mAbs targeting &lt;font style="font-style:italic;"&gt;K. pneumoniae&lt;/font&gt; that were discovered by the Company in its ASN300 program, including lead preclinical development candidate, ASN-5. As a result of entering into such Option and License Agreements without obtaining prior written consent of SVB, and subsequently delivering compliance certificates under the 2012 Loan Agreement that did not disclose these violations, the Company is currently in default under the 2012 Loan Agreement. On August 8, 2018, the Company and SVB entered into a Forbearance Agreement (the &amp;#8220;Forbearance Agreement&amp;#8221;), pursuant to which SVB has agreed to forbear from exercising its rights and remedies with respect to such default until the earlier to occur of (i) another event of default under the 2012 Loan Agreement or (ii) October 31, 2018. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to the default in connection with the Option and License Agreements, the Company has discussed with SVB whether its decision to discontinue its Phase 2 clinical trial of ASN100 may be considered a material adverse change in the business, operations or condition (financial or otherwise) of the Company and, accordingly, an event of default under the terms of the 2012 Loan Agreement. To date, SVB has not agreed that the discontinuation of the trial does not constitute an event of default. If the trial discontinuation does constitute a material adverse change in the Company&amp;#8217;s business, operations or condition, SVB will have the right to accelerate the Company&apos;s outstanding obligations under the 2012 Loan Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Because the Company&amp;#8217;s obligations under the 2012 Loan Agreement may be accelerated at the election of SVB upon the expiration of the Forbearance Agreement, or earlier if another event of default occurs, including but not limited to if the ASN100 Phase 2 clinical trial discontinuation constitutes a material adverse change in the Company&amp;#8217;s business, operations or condition, the Company has presented the SVB loan payable as current on the consolidated balance sheet as of June 30, 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized interest expense under the 2012 Loan Agreement, as amended, of $0.1 million and $0.1 million during the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $0.3 million during the six months ended June 30, 2018 and 2017, respectively. As of June 30, 2018 and December&amp;#160;31, 2017, the unamortized debt discount was $14,000 and $26,000, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company made aggregate principal payments in connection with the 2012 Loan Agreement of $0.6 million and $0.6 million during the three months ended June 30, 2018 and 2017, respectively, and $1.2 million and $1.2 million during the six months ended June 30, 2018 and 2017, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;FFG Loans &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the funding agreements with FFG (see Note 5), the Company received loans from FFG. Loans from FFG were made on a project-by-project basis and had an aggregate principal amount outstanding of $9.9 million and $10.2 million as of June 30, 2018 and December&amp;#160;31, 2017, respectively. Amounts due under the FFG loans bear interest at rates ranging from 0.75% to 2.0%&amp;#160;per annum and mature at various dates between June 2020 and March 2023. Interest on amounts due under the loans is payable semi-annually in arrears, with all principal and remaining accrued interest due upon maturity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, the Company has recorded a discount to the carrying value of each FFG loan for the portion of the loan proceeds allocated to grant funding, which is being amortized to interest expense over the term of the loan using the effective interest method. As of June 30, 2018 and December&amp;#160;31, 2017, the unamortized debt discount related to FFG loans was $2.2 million and $2.6&amp;#160;million, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized interest expense of $0.2&amp;#160;million and $0.2 million during the three months ended June 30, 2018 and 2017, respectively, and $0.4&amp;#160;million and $0.3 million during the six months ended June 30, 2018 and 2017, respectively, related to the FFG loans. There were no principal payments due or paid under the FFG loans during the three and six months ended June 30, 2018 and 2017. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may be required to return all or a portion of the FFG loans and/or grants (see Note 5) if it does not comply with the terms of the related FFG funding agreements and related guidelines, including specified requirements as to continued operations with respect to certain locations and funded projects. To date, FFG has not requested the return of any amounts received by the Company under the funding agreements.&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000184" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Common Stock &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2018 and December 31, 2017, the Company had reserved 2,738,039 shares and 2,187,252 shares of common stock, respectively, for the exercise of outstanding stock options, the number of shares remaining available for grant under the Company&amp;#8217;s 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan and the exercise of outstanding warrants to purchase shares of common stock.&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000185" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/font&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Stock-Based Compensation &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s 2017 Equity Incentive Plan (the &amp;#8220;2017 Plan&amp;#8221;) provides for the grant by the Company of incentive stock options, non-qualified options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. Incentive stock options may be granted only to the Company&amp;#8217;s employees, including officers and directors who are also employees. Awards other than incentive stock options may be granted to employees, officers, members of the board of directors, advisors and consultants of the Company. Following the adoption of the 2017 Plan, no further grants will be made under the Company&amp;#8217;s 2010 Special Stock Incentive Plan (&amp;#8220;Special Plan&amp;#8221;) and 2011 Stock Incentive Plan (&amp;#8220;2011 Plan&amp;#8221;).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon its adoption, the number of shares of the Company&amp;#8217;s common stock initially reserved for issuance under the 2017 Plan was the sum of 585,994 shares, plus the number of shares of the Company&amp;#8217;s common stock available for issuance under the Special Plan and the 2011 Plan immediately prior to the effectiveness of the 2017 Plan. In addition, the number of shares of the Company&amp;#8217;s common stock subject to outstanding awards under the Special Plan and 2011 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will be available for future grant under the 2017 Plan. The number of shares of common stock reserved for issuance under this plan will automatically increase on January 1 of each year, through January 1, 2027, in an amount equal to the lowest of 1,025,490 shares of the Company&amp;#8217;s common stock, 4% of the number of shares of the Company&amp;#8217;s common stock outstanding on January 1 of each year and an amount determined by the Company&amp;#8217;s board of directors.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares that are expired, terminated, surrendered or canceled under the 2017 Plan without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;439&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;616&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;614&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,002&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;172&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,618&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2018 and December&amp;#160;31, 2017, total unrecognized compensation cost related to the unvested stock-based awards was $11.4 million and $4.0 million, respectively, which is expected to be recognized over weighted average periods of 3.07 and 2.76 years, respectively.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&amp;#8217;s stock option activity since December&amp;#160;31, 2017 (in thousands, except share and per share amounts): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,403,119&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.81&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,128&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;829,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21,027&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(111,977&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of June 30, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,099,615&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable as of June 30, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;540,178&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.47&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options unvested as of June 30, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,559,437&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average grant-date fair value per share of stock options granted during the three and six months ended June 30, 2018 was $11.66 and $11.77, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000186" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/font&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Net Loss per Share &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss per Share Attributable to Common Stockholders &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,133&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,705&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,763&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,090&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accretion of redeemable convertible preferred stock to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; redemption value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,133&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,718&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,763&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,110&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average common shares&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; outstanding&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,304,102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,299,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; stockholders &amp;#8212; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.85&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s potentially dilutive securities, which include options to purchase common stock, redeemable convertible preferred stock, warrants to purchase common stock and warrants to purchase redeemable convertible preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Three and Six&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Months&amp;#160;Ended June 30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,099,615&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,198,291&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Redeemable convertible preferred stock (as converted to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,729,121&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,414&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase redeemable convertible preferred&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,414&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,110,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,937,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000187" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/font&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/font&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Commitments and Contingencies &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Lease Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2010, the Company entered into a lease agreement for office, laboratory, parking and storage space in Vienna, Austria (&amp;#8220;Vienna Lease&amp;#8221;), which expires on April&amp;#160;30, 2021. The Company has the option to extend the lease agreement for an additional year. The Vienna Lease includes a rent escalation clause based on an inflation index.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2015, the Company entered into a lease agreement for an animal-use facility in Vienna, Austria (&amp;#8220;Animal-use Lease&amp;#8221;). The lease initially had a one-year noncancelable term, which expired in June 2016, after which the lease became cancelable by either party upon six months&amp;#8217; prior written notice. Base rent for the Animal-use Lease is approximately $0.4 million annually, accordingly, rent expense is being recognized on a straight-line basis over the lease term.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2015, the Company entered into a lease agreement for office and laboratory space in Waltham, MA (&amp;#8220;Waltham Lease&amp;#8221;), which expires on January 31, 2019. The Waltham Lease includes a rent escalation clause, and accordingly, rent expense is being recognized on a straight-line basis over the lease term.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the Company entered into a lease agreement for office space in Waltham, MA (&amp;#8220;Lease Agreement&amp;#8221;). The term of the Lease Agreement commences on the earlier of (a) the later to occur of (x) the date on which the premises are ready for occupancy and (y) December 1, 2018, or (b) the date on which the Company commences occupancy (the &amp;#8220;Commencement Date&amp;#8221;) and expires approximately five years from the Commencement Date. The Company currently anticipates that the term will begin on December 1, 2018. The Lease Agreement includes a rent escalation clause, and accordingly, rent expense will be recognized on a straight-line basis over the lease term.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes rent expense over the respective lease period and has recorded deferred rent for rent expense incurred but not yet paid.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded rent expense &lt;font style="color:#000000;"&gt;of $0.3 million and $0.3 million during the three months ended June 30, 2018 and 2017, respectively, and $0.6 million and $0.6 million during the six months ended June 30, 2018 and 2017.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the future minimum lease payments due under the Company&amp;#8217;s operating leases as of June 30, 2018 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.64%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;662&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;881&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;996&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;648&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;479&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;448&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.18%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,114&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 10, 2018&lt;font style="color:#000000;"&gt;, the Company entered into an amendment to the Lease Agreement (&amp;#8220;Amended Lease Agreement&amp;#8221;) with BP Bay Colony LLC (the &amp;#8220;Lessor&amp;#8221;). Under the terms of the Amended Lease Agreement, the Company will relocate its Waltham, MA premises to a new premises with 5,711 square feet of office space as compared to the 10,290 square feet premises in the original Lease Agreement. The annual base rent obligation is approximately $0.3 million, with a total cash obligation for the base rent over the initial five-year term of the Amended Lease Agreement is approximately $1.3 million. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, in accordance with the terms of the Amended Lease Agreement. The Company will provide a security deposit in the amount of $0.3 million as well as a relocation payment of $0.1 million to the Lessor. The entry into this Amended Lease Agreement reduces the minimum lease payments presented in the table above from $4.1 million to approximately $3.2 million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;License Agreements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company entered into the Adimab Option Agreement in February 2017 under which it is obligated to make contingent and non-contingent payments should the Company exercise its option to obtain rights to certain RSV antibodies (see Note 5). If the Company chose to exercise its option, it would be obligated to pay Adimab an option fee of $0.3 million and make clinical and regulatory milestone payments of up to $24.4 million, as well as royalty payments on a product-by-product and country-by-country basis of a mid single-digit percentage based on net sales by the Company, its affiliates, licensees or sublicensees of products based on certain RSV antibodies during the applicable term for such product in that country. The Company may choose to exercise its option under the terms of the Adimab Option Agreement at any time on or before August 31, 2019. As of June 30, 2018 and December 31, 2017, the Company had not exercise its option under the Adimab Option Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Manufacturing Commitments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2016, the Company entered into an agreement with Boehringer Ingelheim International GmbH (&amp;#8220;BI&amp;#8221;), a contract manufacturing organization, for the manufacture and supply of ASN100 drug product for the Company&amp;#8217;s completed Phase 1 and discontinued Phase 2 clinical trials. In March 2016, the Company entered into an agreement with Cytovance Biologics, Inc. (&amp;#8220;Cytovance&amp;#8221;) for process development and the manufacture and supply of ASN100 drug product. Under such agreements, the Company is obligated to pay BI and Cytovance development and manufacturing milestones, in addition to reimbursement of certain material production-related costs. Additionally, the Company is required to make prepayments for process development services and manufacture and delivery of ASN100 material. The terms of these agreements require future delivery and formal acceptance of the clinical material upon delivery from BI and Cytovance. Formal acceptance includes validation of the clinical material and that established specifications and good manufacturing practices, or GMP, standards have been followed during the manufacture. It is only after acceptance that title and risks and rewards of ownership pass to the Company and at that time advance payments will be applied to the purchase of clinical materials required to be produced under the agreements. The purchase of the clinical material will, at the point of delivery, be charged to research and development expense. The Company&amp;#8217;s policy is to expense research and development costs as incurred (i.e., as services are provided by the Company&amp;#8217;s vendors or as qualifying materials are delivered).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did not terminate the agreements with BI and Cytovance following its decision to discontinue the Phase 2 clinical trial for ASN100. Amounts recorded as of June 30, 2018 represent advance payments to BI and Cytovance for the development and manufacturing of ASN100 drug product that is expected to be completed in the second half of 2018. As of June 30, 2018 and December&amp;#160;31, 2017, the Company had committed to minimum payments under this agreement totaling $&lt;font style="color:#000000;"&gt;3.2&lt;/font&gt; million and $4.7 million, respectively. As of June 30, 2018 and December 31, 2017, prepaid clinical manufacturing expenses totaled $2.4 million $0, respectively. &lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000188" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/font&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Related Party Transactions &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Agreements with Adimab, LLC &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company made payments to Adimab of $0.1 million and $0 during the three months ended June 30, 2018 and 2017, respectively, and $0.1 million&amp;#160;and $0 during the six months ended June 30, 2018 and 2017, respectively, under the Adimab Option Agreement. The Company recognized $14,000 and $58,000 during the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $0.1 million during the six months ended June 30, 2018 and 2017, respectively, of research and development expense under the Adimab Option Agreement. As of June 30, 2018 and December 31, 2017, the Company owed $14,000 and $21,000, respectively, to Adimab under the Adimab Option Agreement. The chairman of the Company&amp;#8217;s board of directors is a co-founder of Adimab and currently serves as Adimab&amp;#8217;s Chief Executive Officer. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Services and Facilities Agreement with EveliQure Biotechnologies GmbH &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s wholly owned subsidiary, Arsanis Biosciences GmbH, leases office and lab space in Vienna, Austria from a third party. In February 2015, Arsanis Biosciences GmbH entered into a services and facilities agreement with EveliQure Biotechnologies GmbH (&amp;#8220;EveliQure&amp;#8221;) under which the Company provides certain laboratory services and sublets office and lab space to EveliQure. Tamas Henics, the husband of Eszter Nagy, the Company&amp;#8217;s former Chief Scientific Officer, serves as Chief Scientific Officer at EveliQure. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 28, 2018 and in accordance with the terms of this agreement with EveliQure, the Company provided EveliQure with written notice that the services and facilities agreement will terminate and EveliQure will vacate the sublet space no later than December 31, 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three and six months ended June 30, 2018, the Company received payments from EveliQure under the agreement of $0 and $0.1 million, respectively, and less than $0.1 million and $0.1 million during the three and six months ended June 30, 2017, respectively. During the three and six months ended June 30, 2018 and 2017, the Company recognized other income under the agreement of less than $0.1 million in each period. As of June 30, 2018 and December 31, 2017, amounts due from EveliQure totaled less than $0.1 million and $0.1 million, respectively. &lt;/p&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000189" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="font-weight:normal;"&gt;&lt;/font&gt;Subsequent Events &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;August 2018 Amended and Restated Gates Foundation Grant Agreement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 8, 2018, the Company entered into an amended and restated grant agreement with the Gates Foundation which replaces the February 2017 grant agreement in its entirety. The amended and restated grant agreement includes amendments to conform to current Gates Foundation audit, reporting, and other administrative requirements, as well as to make the Company&amp;#8217;s grant of a perpetual license to the Gates Foundation irrevocable. See Note 5 for further discussion.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;August 2018 Gates Foundation Grant Agreement&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; On August 8, 2018, the Company entered into an additional grant agreement with the Gates Foundation pursuant to which the Gates Foundation granted to the Company up to $1.1 million to conduct preclinical development activities for the RSV project that were not included in the February 2017 grant agreement, as amended and restated in August 2018. In return, the Company has agreed to conduct the RSV project in a manner that ensures that the knowledge and information gained from the project will be promptly and broadly disseminated, and that the products, technologies, materials, processes and other intellectual property resulting from the RSV project will be made available and accessible at an affordable price to people most in need within developing countries. These obligations survive any expiration or termination of the grant agreement. See Note 5 for further discussion.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;August 2018 Forbearance Agreement with Silicon Valley Bank&amp;nbsp;&amp;nbsp; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 8, 2018, the Company and SVB entered into a Forbearance Agreement to address the Company&amp;#8217;s ongoing default under the 2012 Loan Agreement as a result of the Company&amp;#8217;s failure to obtain SVB&amp;#8217;s written consent prior to entering into certain Option and License Agreements. Under the terms of the Forbearance Agreement, SVB has agreed to forbear from exercising its rights and remedies with respect to such defaults until the earlier to occur of (i) another event of default under the 2012 Loan Agreement or (ii) October 31, 2018. See Note 6 for further discussion.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;August 2018 Lease Amendment&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 10, 2018, the Company entered into an amendment to its Lease Agreement (&amp;#8220;Amended Lease Agreement&amp;#8221;) with BP Bay Colony LLC (the &amp;#8220;Lessor&amp;#8221;). Under the terms of the Amended Lease Agreement, the Company will relocate its premises in Waltham, MA to a new premises with 5,711 square feet of office space as compared to the 10,290 square feet premises in the original Lease Agreement. The term of the Amended Lease Agreement commences on January 1, 2019 and expires December 31, 2023. The Company has the option to extend the term for one additional five-year period upon the Company&amp;#8217;s written notice to the Lessor at least nine months and no more than 12 months in advance of the extension. The Amended Lease Agreement terminates the Company&amp;#8217;s one-time right of first offer, subject to certain terms and conditions, for additional space containing approximately 4,000 square feet specified in the Lease Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The annual base rent obligation is approximately $0.3 million, with a total cash obligation for the base rent over the initial five-year term of the Amended Lease Agreement is approximately $1.3 million. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, in accordance with the terms of the Amended Lease Agreement. The Company will provide a security deposit in the amount of $0.3 million as well as a relocation payment of $0.1 million to the Lessor. See Note 10 for further discussion.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;August 2018 Reduction in Force&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; On August 10, 2018, the Company&amp;#8217;s board of directors approved a reduction in workforce to reduce operating costs and better align the company&amp;#8217;s workforce with the needs of its business following the Company&amp;#8217;s discontinuation of the clinical development of ASN100. As part of this reduction in workforce, the Company plans to eliminate 19 positions across the company, representing approximately 44% of its workforce. The Company anticipates that it will substantially complete the implementation of the reduction in workforce by the fourth quarter of 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company currently estimates that it will incur total expenses relating to the reduction in workforce of approximately $0.6 million, which is comprised of notice and severance payments. The Company expects to record these charges in the third and fourth quarters of 2018.&lt;/p&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <asns:UnauditedInterimFinancialStatementsPolicyTextBlock id="F_000190" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Unaudited Interim Financial Statements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The condensed balance sheet at December&amp;#160;31, 2017 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying condensed financial statements as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017 are unaudited. The accompanying unaudited interim financial statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company&amp;#8217;s&amp;#160;audited financial statements and the notes thereto for the year ended December&amp;#160;31, 2017 included in the Company&amp;#8217;s&amp;#160;Annual Report on Form 10-K as filed with the SEC on March&amp;#160;9, 2018. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&amp;#8217;s condensed financial position as of June 30, 2018 and condensed results of its operations for the three and six months ended June 30, 2018 and 2017 and cash flows for the six months ended June 30, 2018 and 2017 have been made. The results of operations for the three and six months ended June 30, 2018 and 2017 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2018.&lt;/p&gt;&lt;/div&gt;</asns:UnauditedInterimFinancialStatementsPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000191" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of common stock and stock options. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. &lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="F_000192" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Certain assets of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&amp;#8212;Quoted prices in active markets for identical assets or liabilities. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&amp;#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&amp;#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of cash equivalents, other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The carrying value of the Company&amp;#8217;s loan and security agreement with Silicon Valley Bank (&amp;#8220;SVB&amp;#8221;) approximates its fair value because the debt bears interest at a market rate. The carrying value of the loans received under the funding agreements with &amp;#214;sterreichische Forschungsf&amp;#246;rderungsgesellschaft mbH (&amp;#8220;FFG&amp;#8221;) approximates their fair value because the Company records imputed interest expense based on rates that approximate market rates of interest as of the issuance date of each FFG loan. &lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000193" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Gain (Loss) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive gain (loss) includes net gain (loss) as well as other changes in stockholders&amp;#8217; equity that result from transactions and economic events other than those with stockholders. Comprehensive gain (loss) included $0.3 million and $(0.3) million for the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $(0.4) million for the six months ended June 30, 2018 and 2017, respectively, of foreign currency translation gain (loss) adjustments. &lt;/p&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000194" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Income (Loss) per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, options to purchase common stock, redeemable convertible preferred stock, warrants to purchase common stock and warrants to purchase redeemable convertible preferred stock are considered potential dilutive common shares.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s redeemable convertible preferred stock contractually entitled the holders of such shares to participate in dividends but contractually did not require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. &lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000195" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2014-09, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/font&gt;(&amp;#8220;ASU 2014-09&amp;#8221;), which supersedes most existing revenue recognition guidance under GAAP. The FASB also issued several amendments and updates to the new revenue standard (collectively, &amp;#8220;Topic 606&amp;#8221;). The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance. These judgments and estimates include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&amp;#8217;s financial position, results of operations or cash flows as the Company does not currently have any revenue-generating arrangements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2016, the FASB issued ASU No.&amp;#160;2016-15, &lt;font style="font-style:italic;"&gt;Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt; (&amp;#8220;ASU 2016-15&amp;#8221;), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The Company adopted the standard retrospectively to all periods presented on the required effective date of January 1, 2018, and its adoption had no impact on the Company&amp;#8217;s financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2016, the FASB issued ASU No.&amp;#160;2016-16, &lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory&lt;/font&gt; (&amp;#8220;ASU 2016-16&amp;#8221;), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&amp;#8217;s financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2016, the FASB issued ASU No.&amp;#160;2016-18, &lt;font style="font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Restricted Cash&lt;/font&gt; (&amp;#8220;ASU 2016-18&amp;#8221;), which requires restricted cash to be presented with cash and cash equivalents on the statement of cash flows and disclosure of how the statement of cash flows reconciles to the balance sheet if restricted cash is shown separately from cash and cash equivalents on the balance sheet. The Company adopted this standard on January 1, 2018. The adoption of ASU 2016-18 resulted in the Company&apos;s cash, cash equivalents and restricted cash being included in the beginning and ending amounts for the periods shown on the statement of cash flows and was applied retroactively and reflected in the balances presented for any prior periods. The Company believes that the adoption of this guidance did not have a significant impact on its condensed consolidated financial statements and related disclosures. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The restricted cash as of June 30, 2018 and December 31, 2017 is held as letters of credit for the benefit of the landlords in connection with the Company&amp;#8217;s office leases.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,143&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash &amp;#8211; current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash &amp;#8211; non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;295&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash shown in the statement of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,286&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,844&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2017, FASB issued ASU No.&amp;#160;2017-01, &lt;font style="font-style:italic;"&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business&lt;/font&gt; (&amp;#8220;ASU 2017-01&amp;#8221;). The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill and consolidation. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&amp;#8217;s financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2017, the FASB issued ASU No.&amp;#160;2017-09, &lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Scope of Modification Accounting&lt;/font&gt; (&amp;#8220;ASU 2017-09&amp;#8221;), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&amp;#8217;s financial position, results of operations or cash flows. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2018, the FASB issued ASU 2018-05, &lt;font style="font-style:italic;"&gt;Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118&lt;/font&gt; ("ASU&amp;#160;2018-05"). This standard amends ASC 740, Income Taxes (&amp;#8220;ASC 740&amp;#8221;) to provide guidance on accounting for the tax effects of the Tax Cuts and Jobs Act pursuant to Staff Accounting Bulletin No. 118, which allows companies to complete the accounting under ASC 740 within a one-year measurement period from the Tax Act enactment date. This standard was effective upon issuance. &lt;font style="color:#000000;"&gt;The Company will continue to assess the impact that various provisions will have on its business. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the FASB issued&amp;#160;ASU 2018-07,&amp;#160;&lt;font style="font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting &lt;/font&gt;(&amp;#8220;ASU 2018-07&amp;#8221;), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The new standard specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&amp;#8217;s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. ASU 2018-07 is required to be adopted for annual periods beginning after December&amp;#160;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2018-07 will have on its consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2017, the FASB issued&amp;#160;ASU 2017-11,&amp;#160;&lt;font style="font-style:italic;"&gt;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception&lt;/font&gt; (&amp;#8220;ASU 2017-11&amp;#8221;).&amp;#160;Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480&amp;#160;with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU 2017-11 is required to be adopted for annual periods beginning after December&amp;#160;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2017-11 will have on its consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No.&amp;#160;2016-02&lt;font style="font-style:italic;"&gt;, Leases (Topic 842)&lt;/font&gt; (&amp;#8220;ASU 2016-02&amp;#8221;), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASU 2016-02 (Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) (Topic 842) supersedes the previous leases standard, ASC 840, Leases. The standard is effective for public entities for annual periods beginning after December&amp;#160;15, 2018 including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements. &lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <asns:FFGLoansPolicyTextBlock id="F_000196" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;FFG Loans &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Loans under the funding agreements with FFG bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged by FFG as additional grant funding from FFG. On the date that FFG loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is recognized as additional grant income over the term of the funding agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, the Company has recorded a discount to the carrying value of each FFG loan for the portion of the loan proceeds allocated to grant funding, which is being amortized to interest expense over the term of the loan using the effective interest method.&lt;/p&gt;&lt;/div&gt;</asns:FFGLoansPolicyTextBlock>
  <asns:ResearchAndDevelopmentIncentivePolicyTextBlock id="F_000197" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Incentive &lt;font style="font-weight:normal;font-style:normal;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses incurred by the Company&amp;#8217;s subsidiary in Austria. Under the program, the reimbursement rate for qualifying research and development expenses incurred by the Company through its subsidiary in Austria was 12% for the year ended December 31, 2017, and is 14% for the year ended December 31, 2018. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes incentive income from Austrian research and development incentives when qualifying expenses have been incurred, there is reasonable assurance that the payment will be received, and the consideration can be reliably measured. Management has assessed the Company&amp;#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each reporting date, management estimates the reimbursable incentive income available to the Company based on available information at the time.&lt;/p&gt;&lt;/div&gt;</asns:ResearchAndDevelopmentIncentivePolicyTextBlock>
  <asns:TwoThousandTwelveLoanAgreementPolicyTextBlock id="F_000198" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;2012 Loan Agreement &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The debt discount is reflected as a reduction of the carrying value of the loan payable on the Company&amp;#8217;s consolidated balance sheet and is being amortized to interest expense over the term of the loan using the effective interest method.&lt;/p&gt;&lt;/div&gt;</asns:TwoThousandTwelveLoanAgreementPolicyTextBlock>
  <asns:ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock id="F_000199" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,940&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,143&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash &amp;#8211; current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash &amp;#8211; non-current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;295&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;340&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash shown in the statement of&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; cash flows&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,286&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,844&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</asns:ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock id="F_000200" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following tables present information about the Company&amp;#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June&amp;#160;30, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents - Money Market Funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,576&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents - Money Market Funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,891&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000201" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Accrued expenses consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical trial costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,317&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation and benefits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,539&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,454&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;563&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;510&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;442&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,879&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,779&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfDebtInstrumentsTextBlock id="F_000202" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The aggregate principal amount of debt outstanding as of June 30, 2018 and December 31, 2017 consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term loans under 2012 Loan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,667&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;FFG loans&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,937&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,225&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,437&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,892&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
  <us-gaap:ScheduleOfDebtTableTextBlock id="F_000203" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Current and non-current debt obligations reflected in the condensed consolidated balance sheets as of June 30, 2018 and December 31, 2017 consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term loans under 2012 Loan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,333&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;FFG loans&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized debt discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loans payable, net of discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,486&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,314&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term loans under 2012 Loan Agreement&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;FFG loans&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,937&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,225&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unamortized debt discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,231&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,637&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loans payable, net of discount and current portion&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,706&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,922&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total loans payable, net of discount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,192&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,236&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
  <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock id="F_000204" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;439&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;616&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;614&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,002&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,053&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;172&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,618&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000205" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table summarizes the Company&amp;#8217;s stock option activity since December&amp;#160;31, 2017 (in thousands, except share and per share amounts): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,403,119&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.81&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,128&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;829,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.19&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21,027&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(111,977&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of June 30, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,099,615&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable as of June 30, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;540,178&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.47&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options unvested as of June 30, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,559,437&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.79&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000206" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Six Months Ended June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,133&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,705&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,763&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,090&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accretion of redeemable convertible preferred stock to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; redemption value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,133&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,718&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,763&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,110&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average common shares&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; outstanding&amp;#8212;basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,304,102&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,299,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; stockholders &amp;#8212; basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.85&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000207" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company&amp;#8217;s potentially dilutive securities, which include options to purchase common stock, redeemable convertible preferred stock, warrants to purchase common stock and warrants to purchase redeemable convertible preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Three and Six&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Months&amp;#160;Ended June 30,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,099,615&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,198,291&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Redeemable convertible preferred stock (as converted to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,729,121&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,414&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase redeemable convertible preferred&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,414&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,110,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,937,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="F_000208" contextRef="C_0001501697_20180101_20180630">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table summarizes the future minimum lease payments due under the Company&amp;#8217;s operating leases as of June 30, 2018 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.64%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;662&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;881&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;996&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;648&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;479&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.18%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;448&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.18%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,114&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000209" contextRef="C_0001501697_20180101_20180630">one-for-3.4130</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000210" contextRef="C_0001501697_20171103_20171103" decimals="4" unitRef="U_pure">0.2930</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000211" contextRef="C_0001501697_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20171120_20171120" decimals="INF" unitRef="U_shares">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000212" contextRef="C_0001501697_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20171120_20171120" decimals="INF" unitRef="U_shares">600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000213" contextRef="C_0001501697_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_asnsNewEnterpriseAssociates16LPMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20171120_20171120" decimals="INF" unitRef="U_shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000214" contextRef="C_0001501697_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20171120" decimals="INF" unitRef="U_iso4217USD_shares">10.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare id="F_000215" contextRef="C_0001501697_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20171120" decimals="INF" unitRef="U_iso4217USD_shares">10.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare id="F_000216" contextRef="C_0001501697_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_asnsNewEnterpriseAssociates16LPMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20171120" decimals="INF" unitRef="U_iso4217USD_shares">10.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="F_000217" contextRef="C_0001501697_20171120_20171120" decimals="-5" unitRef="U_iso4217USD">58100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000218" contextRef="C_0001501697_20171120_20171120" decimals="INF" unitRef="U_shares">7180483</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000219" contextRef="C_0001501697_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_asnsAccountingStandardsUpdate201415Member_20180630" decimals="-5" unitRef="U_iso4217USD">-115000000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:NetIncomeLoss id="F_000220" contextRef="C_0001501697_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_asnsAccountingStandardsUpdate201415Member_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">-22800000</us-gaap:NetIncomeLoss>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000221" contextRef="C_0001501697_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_asnsAccountingStandardsUpdate201415Member_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">25700000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000222" contextRef="C_0001501697_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_asnsAccountingStandardsUpdate201415Member_20180630" decimals="-5" unitRef="U_iso4217USD">49900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000223" contextRef="C_0001501697_20170630" decimals="-3" unitRef="U_iso4217USD">24143000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashCurrent id="F_000224" contextRef="C_0001501697_20170630" decimals="-3" unitRef="U_iso4217USD">8361000</us-gaap:RestrictedCashCurrent>
  <us-gaap:RestrictedCashNoncurrent id="F_000225" contextRef="C_0001501697_20170630" decimals="-3" unitRef="U_iso4217USD">340000</us-gaap:RestrictedCashNoncurrent>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000226" contextRef="C_0001501697_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180630" decimals="-3" unitRef="U_iso4217USD">49576000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000227" contextRef="C_0001501697_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180630" decimals="-3" unitRef="U_iso4217USD">49576000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000228" contextRef="C_0001501697_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180630" decimals="-3" unitRef="U_iso4217USD">49576000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000229" contextRef="C_0001501697_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20180630" decimals="-3" unitRef="U_iso4217USD">49576000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000230" contextRef="C_0001501697_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">70891000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000231" contextRef="C_0001501697_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">70891000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000232" contextRef="C_0001501697_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">70891000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000233" contextRef="C_0001501697_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">70891000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <asns:FairValueTransfersBetweenLevel1Level2OrLevel3Amount id="F_000234" contextRef="C_0001501697_20180630" decimals="INF" unitRef="U_iso4217USD">0</asns:FairValueTransfersBetweenLevel1Level2OrLevel3Amount>
  <asns:FairValueTransfersBetweenLevel1Level2OrLevel3Amount id="F_000235" contextRef="C_0001501697_20171231" decimals="INF" unitRef="U_iso4217USD">0</asns:FairValueTransfersBetweenLevel1Level2OrLevel3Amount>
  <asns:AccruedClinicalTrialCosts id="F_000236" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">1335000</asns:AccruedClinicalTrialCosts>
  <asns:AccruedClinicalTrialCosts id="F_000237" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">2317000</asns:AccruedClinicalTrialCosts>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000238" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">1539000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000239" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">2454000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000240" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">563000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000241" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">510000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000242" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">442000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000243" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">498000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <asns:CollaborationPaymentObligations id="F_000244" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20180630" decimals="INF" unitRef="U_iso4217USD">0</asns:CollaborationPaymentObligations>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000245" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20180401_20180630" decimals="0" unitRef="U_iso4217USD">14000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000246" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20170401_20170630" decimals="0" unitRef="U_iso4217USD">58000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000247" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000248" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
  <asns:GrantsAgreementMaximumAwardAmount id="F_000249" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20170228" decimals="INF" unitRef="U_iso4217USD">9300000</asns:GrantsAgreementMaximumAwardAmount>
  <asns:RelatedPartyTransactionProceedsFromGrants id="F_000250" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20170301_20170331" decimals="-5" unitRef="U_iso4217USD">1600000</asns:RelatedPartyTransactionProceedsFromGrants>
  <asns:GrantAndIncentiveIncome id="F_000251" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">1600000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000252" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20180401_20180630" decimals="-6" unitRef="U_iso4217USD">0</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000253" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">600000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000254" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20180101_20180630" decimals="-6" unitRef="U_iso4217USD">0</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000255" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">600000</asns:GrantAndIncentiveIncome>
  <asns:UnearnedIncome id="F_000256" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20180630" decimals="0" unitRef="U_iso4217USD">0</asns:UnearnedIncome>
  <asns:UnearnedIncome id="F_000257" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsFebruaryTwoThousandAndSeventeenGrantAgreementMember_20171231" decimals="0" unitRef="U_iso4217USD">0</asns:UnearnedIncome>
  <asns:GrantsAgreementMaximumAwardAmount id="F_000258" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20180831" decimals="INF" unitRef="U_iso4217USD">1100000</asns:GrantsAgreementMaximumAwardAmount>
  <asns:GrantAgreementExpirationDate id="F_000259" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20180101_20180630">2018-08-31</asns:GrantAgreementExpirationDate>
  <asns:GrantAndIncentiveIncome id="F_000260" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20180401_20180630" decimals="INF" unitRef="U_iso4217USD">0</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000261" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20180101_20180630" decimals="INF" unitRef="U_iso4217USD">0</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000262" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20170401_20170630" decimals="INF" unitRef="U_iso4217USD">0</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000263" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20170101_20170630" decimals="INF" unitRef="U_iso4217USD">0</asns:GrantAndIncentiveIncome>
  <asns:UnearnedIncome id="F_000264" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20180630" decimals="INF" unitRef="U_iso4217USD">0</asns:UnearnedIncome>
  <asns:UnearnedIncome id="F_000265" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20170630" decimals="INF" unitRef="U_iso4217USD">0</asns:UnearnedIncome>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000266" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapStatementClassOfStockAxis_asnsSeriesDRedeemableConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20170401_20170430" decimals="INF" unitRef="U_shares">2464799</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000267" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapStatementClassOfStockAxis_asnsSeriesDRedeemableConvertiblePreferredStockMember_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20170401_20170430" decimals="-5" unitRef="U_iso4217USD">8000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000268" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20171103_20171103" decimals="INF" unitRef="U_shares">722179</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000269" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20180101_20180630">one-for-3.4130 reverse-stock-split</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000270" contextRef="C_0001501697_srtCounterpartyNameAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20171103_20171103" decimals="4" unitRef="U_pure">0.2930</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <asns:QualifyingExpensesUnderLetterAgreement id="F_000271" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">700000</asns:QualifyingExpensesUnderLetterAgreement>
  <asns:QualifyingExpensesUnderLetterAgreement id="F_000272" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">700000</asns:QualifyingExpensesUnderLetterAgreement>
  <asns:QualifyingExpensesUnderLetterAgreement id="F_000273" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20180401_20180630" decimals="0" unitRef="U_iso4217USD">0</asns:QualifyingExpensesUnderLetterAgreement>
  <asns:QualifyingExpensesUnderLetterAgreement id="F_000274" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsGrantAgreementMember_20180101_20180630" decimals="0" unitRef="U_iso4217USD">0</asns:QualifyingExpensesUnderLetterAgreement>
  <asns:PercentageOfLoansAndGrantsToFund id="F_000275" contextRef="C_0001501697_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_asnsFundingArrangementsWithFFGMember_20180101_20180630" decimals="INF" unitRef="U_pure">0.50</asns:PercentageOfLoansAndGrantsToFund>
  <asns:PercentageOfLoansAndGrantsToFund id="F_000276" contextRef="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_asnsFundingArrangementsWithFFGMember_20180101_20180630" decimals="INF" unitRef="U_pure">0.70</asns:PercentageOfLoansAndGrantsToFund>
  <asns:GrantAndIncentiveIncome id="F_000277" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20180401_20180630" decimals="-6" unitRef="U_iso4217USD">0</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000278" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">200000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000279" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20180101_20180630" decimals="-6" unitRef="U_iso4217USD">0</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000280" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">300000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveReceivables id="F_000281" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20180630" decimals="-5" unitRef="U_iso4217USD">100000</asns:GrantAndIncentiveReceivables>
  <asns:GrantAndIncentiveReceivables id="F_000282" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20171231" decimals="-5" unitRef="U_iso4217USD">100000</asns:GrantAndIncentiveReceivables>
  <asns:UnearnedIncome id="F_000283" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20180630" decimals="0" unitRef="U_iso4217USD">0</asns:UnearnedIncome>
  <asns:UnearnedIncome id="F_000284" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGGrantsMember_20171231" decimals="0" unitRef="U_iso4217USD">0</asns:UnearnedIncome>
  <asns:GrantAndIncentiveIncome id="F_000285" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20180401_20180630" decimals="-5" unitRef="U_iso4217USD">100000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000286" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">200000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000287" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">300000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000288" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">300000</asns:GrantAndIncentiveIncome>
  <asns:UnearnedIncomeCurrent id="F_000289" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20180630" decimals="-5" unitRef="U_iso4217USD">700000</asns:UnearnedIncomeCurrent>
  <asns:UnearnedIncomeCurrent id="F_000290" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20171231" decimals="-5" unitRef="U_iso4217USD">700000</asns:UnearnedIncomeCurrent>
  <asns:UnearnedIncomeNoncurrent id="F_000291" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20180630" decimals="-5" unitRef="U_iso4217USD">1500000</asns:UnearnedIncomeNoncurrent>
  <asns:UnearnedIncomeNoncurrent id="F_000292" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsFFGLoansMember_20171231" decimals="-5" unitRef="U_iso4217USD">1900000</asns:UnearnedIncomeNoncurrent>
  <asns:ReimbursementRateForResearchAndDevelopment id="F_000293" contextRef="C_0001501697_srtStatementGeographicalAxis_asnsAustriaMember_20170101_20171231" decimals="2" unitRef="U_pure">0.12</asns:ReimbursementRateForResearchAndDevelopment>
  <asns:ReimbursementRateForResearchAndDevelopment id="F_000294" contextRef="C_0001501697_srtStatementGeographicalAxis_asnsAustriaMember_us-gaapStatementScenarioAxis_us-gaapScenarioForecastMember_20180101_20181231" decimals="2" unitRef="U_pure">0.14</asns:ReimbursementRateForResearchAndDevelopment>
  <asns:GrantAndIncentiveIncome id="F_000295" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsResearchAndDevelopmentIncentiveProgramMember_20180401_20180630" decimals="-5" unitRef="U_iso4217USD">300000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000296" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsResearchAndDevelopmentIncentiveProgramMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">100000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000297" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsResearchAndDevelopmentIncentiveProgramMember_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">600000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveIncome id="F_000298" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsResearchAndDevelopmentIncentiveProgramMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">500000</asns:GrantAndIncentiveIncome>
  <asns:GrantAndIncentiveReceivables id="F_000299" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsResearchAndDevelopmentIncentiveProgramMember_20180630" decimals="-5" unitRef="U_iso4217USD">2100000</asns:GrantAndIncentiveReceivables>
  <asns:GrantAndIncentiveReceivables id="F_000300" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsResearchAndDevelopmentIncentiveProgramMember_20171231" decimals="-5" unitRef="U_iso4217USD">1500000</asns:GrantAndIncentiveReceivables>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000301" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20180630" decimals="-3" unitRef="U_iso4217USD">3500000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000302" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20171231" decimals="-3" unitRef="U_iso4217USD">4667000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000303" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180630" decimals="-3" unitRef="U_iso4217USD">9937000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000304" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20171231" decimals="-3" unitRef="U_iso4217USD">10225000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000305" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">13437000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentCarryingAmount id="F_000306" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">14892000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:LoansPayableCurrent id="F_000307" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20180630" decimals="-3" unitRef="U_iso4217USD">3500000</us-gaap:LoansPayableCurrent>
  <us-gaap:LoansPayableCurrent id="F_000308" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20171231" decimals="-3" unitRef="U_iso4217USD">2333000</us-gaap:LoansPayableCurrent>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent id="F_000309" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">14000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent id="F_000310" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">19000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:LongTermNotesPayable id="F_000311" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20171231" decimals="-3" unitRef="U_iso4217USD">2334000</us-gaap:LongTermNotesPayable>
  <us-gaap:LongTermNotesPayable id="F_000312" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180630" decimals="-3" unitRef="U_iso4217USD">9937000</us-gaap:LongTermNotesPayable>
  <us-gaap:LongTermNotesPayable id="F_000313" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20171231" decimals="-3" unitRef="U_iso4217USD">10225000</us-gaap:LongTermNotesPayable>
  <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent id="F_000314" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">2231000</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
  <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent id="F_000315" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">2637000</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
  <us-gaap:LoansPayable id="F_000316" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">11192000</us-gaap:LoansPayable>
  <us-gaap:LoansPayable id="F_000317" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">12236000</us-gaap:LoansPayable>
  <us-gaap:ProceedsFromLinesOfCredit id="F_000318" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveTermLoanAAdvanceMember_20121206_20121207" decimals="INF" unitRef="U_iso4217USD">500000</us-gaap:ProceedsFromLinesOfCredit>
  <us-gaap:ProceedsFromLinesOfCredit id="F_000319" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveLoanAgreementMember_20121206_20121207" decimals="INF" unitRef="U_iso4217USD">2500000</us-gaap:ProceedsFromLinesOfCredit>
  <us-gaap:ProceedsFromLinesOfCredit id="F_000320" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveTermLoanBAdvanceMember_20121206_20121207" decimals="INF" unitRef="U_iso4217USD">2000000</us-gaap:ProceedsFromLinesOfCredit>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000321" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveTermLoanAAdvanceMember_us-gaapStatementClassOfStockAxis_asnsSeriesATwoPreferredStockWarrantsMember_20121207" decimals="INF" unitRef="U_shares">2202</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000322" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveTermLoanBAdvanceMember_us-gaapStatementClassOfStockAxis_asnsSeriesATwoPreferredStockWarrantsMember_20130225" decimals="INF" unitRef="U_shares">8811</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000323" contextRef="C_0001501697_us-gaapStatementClassOfStockAxis_asnsSeriesATwoPreferredStockWarrantsMember_20121207" decimals="2" unitRef="U_iso4217USD_shares">4.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <asns:ClassOfWarrantOrRightsExpirationDate id="F_000324" contextRef="C_0001501697_us-gaapStatementClassOfStockAxis_asnsSeriesATwoPreferredStockWarrantsMember_20121206_20121207">2022-12-06</asns:ClassOfWarrantOrRightsExpirationDate>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="F_000325" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAAdvanceMember_20160219" decimals="INF" unitRef="U_iso4217USD">3500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:LineOfCredit id="F_000326" contextRef="C_0001501697_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanBAdvanceMember_20180630" decimals="-5" unitRef="U_iso4217USD">500000</us-gaap:LineOfCredit>
  <us-gaap:ProceedsFromLinesOfCredit id="F_000327" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAAdvanceMember_20160228_20160229" decimals="-5" unitRef="U_iso4217USD">3500000</us-gaap:ProceedsFromLinesOfCredit>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="F_000328" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveLoanAgreementMember_20180630" decimals="INF" unitRef="U_iso4217USD">7000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:ProceedsFromLinesOfCredit id="F_000329" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanBAdvanceMember_20160822_20160823" decimals="-5" unitRef="U_iso4217USD">3500000</us-gaap:ProceedsFromLinesOfCredit>
  <asns:NumberOfTranches id="F_000330" contextRef="C_0001501697_20180101_20180630" decimals="INF" unitRef="U_asnsTranche">2</asns:NumberOfTranches>
  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity id="F_000331" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveLoanAgreementMember_20180630" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000332" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAAdvanceMember_us-gaapStatementClassOfStockAxis_asnsSeriesBWarrantsMember_20160229" decimals="INF" unitRef="U_shares">7251</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000333" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanBAdvanceMember_us-gaapStatementClassOfStockAxis_asnsSeriesBWarrantsMember_20160823" decimals="INF" unitRef="U_shares">7251</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000334" contextRef="C_0001501697_us-gaapStatementClassOfStockAxis_asnsSeriesBWarrantsMember_20160219" decimals="2" unitRef="U_iso4217USD_shares">7.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <asns:ClassOfWarrantOrRightsExpirationDate id="F_000335" contextRef="C_0001501697_us-gaapStatementClassOfStockAxis_asnsSeriesBWarrantsMember_20160218_20160219">2026-02-18</asns:ClassOfWarrantOrRightsExpirationDate>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000336" contextRef="C_0001501697_us-gaapStatementClassOfStockAxis_asnsSeriesBWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630" decimals="INF" unitRef="U_shares">6474</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000337" contextRef="C_0001501697_us-gaapStatementClassOfStockAxis_asnsSeriesBWarrantsMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630" decimals="2" unitRef="U_iso4217USD_shares">16.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000338" contextRef="C_0001501697_us-gaapClassOfWarrantOrRightAxis_asnsExercisePriceOneMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630" decimals="INF" unitRef="U_shares">3940</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000339" contextRef="C_0001501697_us-gaapClassOfWarrantOrRightAxis_asnsExercisePriceOneMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630" decimals="2" unitRef="U_iso4217USD_shares">12.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="F_000340" contextRef="C_0001501697_us-gaapClassOfWarrantOrRightAxis_asnsExercisePriceTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630" decimals="INF" unitRef="U_shares">6474</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000341" contextRef="C_0001501697_us-gaapClassOfWarrantOrRightAxis_asnsExercisePriceTwoMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180630" decimals="2" unitRef="U_iso4217USD_shares">16.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="F_000342" contextRef="C_0001501697_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAdvanceMember_20180101_20180630" decimals="INF" unitRef="U_pure">0.0325</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <asns:PercentageMinusWallStreetJournalPrimeRate id="F_000343" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAdvanceMember_20180101_20180630" decimals="4" unitRef="U_pure">0.0025</asns:PercentageMinusWallStreetJournalPrimeRate>
  <us-gaap:DebtInstrumentInterestRateIncreaseDecrease id="F_000344" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandTwelveLoanAgreementMember_20180101_20180630" decimals="3" unitRef="U_pure">0.040</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="F_000345" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAdvanceMember_20180101_20180630" decimals="4" unitRef="U_pure">0.0475</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="F_000346" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAdvanceMember_20170101_20171231" decimals="4" unitRef="U_pure">0.0425</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <asns:PrepaymentFeePercentageToOutstandingPrincipalAmount id="F_000347" contextRef="C_0001501697_srtRangeAxis_srtMinimumMember_20180101_20180630" decimals="INF" unitRef="U_pure">0.00</asns:PrepaymentFeePercentageToOutstandingPrincipalAmount>
  <asns:PrepaymentFeePercentageToOutstandingPrincipalAmount id="F_000348" contextRef="C_0001501697_srtRangeAxis_srtMaximumMember_20180101_20180630" decimals="INF" unitRef="U_pure">0.02</asns:PrepaymentFeePercentageToOutstandingPrincipalAmount>
  <asns:PrepaymentFeePercentageToOutstandingPrincipalAmount id="F_000349" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTwoThousandSixteenTermLoanAdvanceMember_20180101_20180630" decimals="3" unitRef="U_pure">0.050</asns:PrepaymentFeePercentageToOutstandingPrincipalAmount>
  <asns:PrepaymentFeePercentageToOutstandingPrincipalAmount id="F_000350" contextRef="C_0001501697_20180101_20180630" decimals="INF" unitRef="U_pure">0.00</asns:PrepaymentFeePercentageToOutstandingPrincipalAmount>
  <us-gaap:DebtInstrumentFeeAmount id="F_000351" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFirstAmendmentMember_20180630" decimals="0" unitRef="U_iso4217USD">20000</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:DeferredFinanceCostsNet id="F_000352" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFirstAmendmentMember_20180630" decimals="0" unitRef="U_iso4217USD">7000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:InterestExpenseDebt id="F_000353" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20180401_20180630" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt id="F_000354" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt id="F_000355" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt id="F_000356" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:InterestExpenseDebt>
  <us-gaap:DebtInstrumentUnamortizedDiscount id="F_000357" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20180630" decimals="-3" unitRef="U_iso4217USD">14000000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentUnamortizedDiscount id="F_000358" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20171231" decimals="-3" unitRef="U_iso4217USD">26000000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal id="F_000359" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20180401_20180630" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal id="F_000360" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal id="F_000361" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">1200000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal id="F_000362" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsTermLoansUnderTwoThousandTwelveLoanAgreementMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">1200000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="F_000363" contextRef="C_0001501697_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180101_20180630" decimals="4" unitRef="U_pure">0.0075</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod id="F_000364" contextRef="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180101_20180630" decimals="3" unitRef="U_pure">0.020</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:DebtInstrumentMaturityDateRangeStart1 id="F_000365" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180101_20180630">2020-06-30</us-gaap:DebtInstrumentMaturityDateRangeStart1>
  <us-gaap:DebtInstrumentMaturityDateRangeEnd1 id="F_000366" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180101_20180630">2023-03-31</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
  <us-gaap:DebtInstrumentUnamortizedDiscount id="F_000367" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180630" decimals="-5" unitRef="U_iso4217USD">2200000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DebtInstrumentUnamortizedDiscount id="F_000368" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20171231" decimals="-5" unitRef="U_iso4217USD">2600000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:InterestExpenseDebt id="F_000369" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180401_20180630" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt id="F_000370" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt id="F_000371" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt id="F_000372" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:InterestExpenseDebt>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal id="F_000373" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180401_20180630" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal id="F_000374" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20170401_20170630" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal id="F_000375" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20180101_20180630" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal id="F_000376" contextRef="C_0001501697_us-gaapDebtInstrumentAxis_asnsFFGLoansMember_20170101_20170630" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000377" contextRef="C_0001501697_20180630" decimals="INF" unitRef="U_shares">2738039</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000378" contextRef="C_0001501697_20171231" decimals="INF" unitRef="U_shares">2187252</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000379" contextRef="C_0001501697_us-gaapPlanNameAxis_asnsTwoThousandAndTenSpecialStockIncentivePlanMember_20180101_20180630" decimals="INF" unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000380" contextRef="C_0001501697_us-gaapPlanNameAxis_asnsTwoThousandAndElevenStockIncentivePlanMember_20180101_20180630" decimals="INF" unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized id="F_000381" contextRef="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_asnsTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTitleOfIndividualAxis_us-gaapDirectorMember_20180101_20180101" decimals="INF" unitRef="U_shares">1025490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000382" contextRef="C_0001501697_us-gaapPlanNameAxis_asnsTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTitleOfIndividualAxis_us-gaapDirectorMember_20180101_20180101" decimals="INF" unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000383" contextRef="C_0001501697_us-gaapPlanNameAxis_asnsTwoThousandSeventeenEquityIncentivePlanMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20180630" decimals="INF" unitRef="U_shares">585994</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000384" contextRef="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">439000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000385" contextRef="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">62000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000386" contextRef="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">616000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000387" contextRef="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">124000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000388" contextRef="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">614000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000389" contextRef="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">110000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000390" contextRef="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">1002000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000391" contextRef="C_0001501697_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">230000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000392" contextRef="C_0001501697_20180401_20180630" decimals="-3" unitRef="U_iso4217USD">1053000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000393" contextRef="C_0001501697_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">172000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000394" contextRef="C_0001501697_20180101_20180630" decimals="-3" unitRef="U_iso4217USD">1618000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000395" contextRef="C_0001501697_20170101_20170630" decimals="-3" unitRef="U_iso4217USD">354000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000396" contextRef="C_0001501697_20180630" decimals="-5" unitRef="U_iso4217USD">11400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000397" contextRef="C_0001501697_20171231" decimals="-5" unitRef="U_iso4217USD">4000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000398" contextRef="C_0001501697_20180101_20180630">P3Y0M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000399" contextRef="C_0001501697_20170101_20171231">P2Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000400" contextRef="C_0001501697_20171231" decimals="INF" unitRef="U_shares">1403119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000401" contextRef="C_0001501697_20180101_20180630" decimals="INF" unitRef="U_shares">829500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000402" contextRef="C_0001501697_20180101_20180630" decimals="INF" unitRef="U_shares">21027</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000403" contextRef="C_0001501697_20180101_20180630" decimals="INF" unitRef="U_shares">111977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000404" contextRef="C_0001501697_20180630" decimals="INF" unitRef="U_shares">2099615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="F_000405" contextRef="C_0001501697_20180630" decimals="INF" unitRef="U_shares">540178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="F_000406" contextRef="C_0001501697_20180630" decimals="INF" unitRef="U_shares">1559437</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000407" contextRef="C_0001501697_20171231" decimals="2" unitRef="U_iso4217USD_shares">6.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000408" contextRef="C_0001501697_20180101_20180630" decimals="2" unitRef="U_iso4217USD_shares">17.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000409" contextRef="C_0001501697_20180101_20180630" decimals="2" unitRef="U_iso4217USD_shares">7.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000410" contextRef="C_0001501697_20180101_20180630" decimals="2" unitRef="U_iso4217USD_shares">11.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000411" contextRef="C_0001501697_20180630" decimals="2" unitRef="U_iso4217USD_shares">10.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice id="F_000412" contextRef="C_0001501697_20180630" decimals="2" unitRef="U_iso4217USD_shares">6.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue id="F_000413" contextRef="C_0001501697_20180630" decimals="2" unitRef="U_iso4217USD_shares">11.79</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000414" contextRef="C_0001501697_20170101_20171231">P8Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000415" contextRef="C_0001501697_20180101_20180630">P8Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000416" contextRef="C_0001501697_20180101_20180630">P7Y5M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <asns:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm id="F_000417" contextRef="C_0001501697_20180101_20180630">P9Y5M12D</asns:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000418" contextRef="C_0001501697_20171231" decimals="-3" unitRef="U_iso4217USD">9128000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000419" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000420" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">185000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000421" contextRef="C_0001501697_20180401_20180630" decimals="2" unitRef="U_iso4217USD_shares">11.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000422" contextRef="C_0001501697_20180101_20180630" decimals="2" unitRef="U_iso4217USD_shares">11.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000423" contextRef="C_0001501697_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20180101_20180630" decimals="INF" unitRef="U_shares">2099615</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000424" contextRef="C_0001501697_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20170101_20170630" decimals="INF" unitRef="U_shares">1198291</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000425" contextRef="C_0001501697_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20170101_20170630" decimals="INF" unitRef="U_shares">6729121</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000426" contextRef="C_0001501697_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20180101_20180630" decimals="INF" unitRef="U_shares">10414</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000427" contextRef="C_0001501697_us-gaapStatementClassOfStockAxis_asnsWarrantsToPurchaseRedeemableConvertiblePreferredStockMember_20170101_20170630" decimals="INF" unitRef="U_shares">10414</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000428" contextRef="C_0001501697_20180101_20180630" decimals="INF" unitRef="U_shares">2110029</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000429" contextRef="C_0001501697_20170101_20170630" decimals="INF" unitRef="U_shares">7937826</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:LeaseExpirationDate1 id="F_000430" contextRef="C_0001501697_us-gaapLeaseArrangementTypeAxis_asnsViennaLeaseAgreementMember_20101101_20101130">2021-04-30</us-gaap:LeaseExpirationDate1>
  <us-gaap:LesseeOperatingLeaseOptionToExtend id="F_000431" contextRef="C_0001501697_us-gaapLeaseArrangementTypeAxis_asnsViennaLeaseAgreementMember_20180101_20180630">The Company has the option to extend the lease agreement for an additional year.</us-gaap:LesseeOperatingLeaseOptionToExtend>
  <asns:LesseeOperatingLeaseExpirationDescription id="F_000432" contextRef="C_0001501697_us-gaapLeaseArrangementTypeAxis_asnsAnimalUseLeaseAgreementMember_20180101_20180630">The lease initially had a one-year noncancelable term, which expired in June 2016, after which the lease became cancelable by either party upon six months&#8217; prior written notice.</asns:LesseeOperatingLeaseExpirationDescription>
  <us-gaap:OperatingLeasesRentExpenseMinimumRentals id="F_000433" contextRef="C_0001501697_us-gaapLeaseArrangementTypeAxis_asnsAnimalUseLeaseAgreementMember_20150701_20150731" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
  <us-gaap:LeaseExpirationDate1 id="F_000434" contextRef="C_0001501697_us-gaapLeaseArrangementTypeAxis_asnsWalthamLeaseAgreementMember_20151101_20151130">2019-01-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:LesseeOperatingLeaseDescription id="F_000435" contextRef="C_0001501697_us-gaapLeaseArrangementTypeAxis_asnsLeaseAgreementForOfficeSpaceInWalthamMAMember_20180101_20180630">In June 2018, the Company entered into a lease agreement for office space in Waltham, MA (&#8220;Lease Agreement&#8221;). The term of the Lease Agreement commences on the earlier of (a) the later to occur of (x) the date on which the premises are ready for occupancy and (y) December 1, 2018, or (b) the date on which the Company commences occupancy (the &#8220;Commencement Date&#8221;) and expires approximately five years from the Commencement Date. The Company currently anticipates that the term will begin on December 1, 2018. The Lease Agreement includes a rent escalation clause, and accordingly, rent expense will be recognized on a straight-line basis over the lease term.</us-gaap:LesseeOperatingLeaseDescription>
  <us-gaap:LeaseAndRentalExpense id="F_000436" contextRef="C_0001501697_20180401_20180630" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense id="F_000437" contextRef="C_0001501697_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense id="F_000438" contextRef="C_0001501697_20170401_20170630" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense id="F_000439" contextRef="C_0001501697_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear id="F_000440" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">662000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="F_000441" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">881000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="F_000442" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">996000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears id="F_000443" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">648000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears id="F_000444" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">479000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter id="F_000445" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">448000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="F_000446" contextRef="C_0001501697_20180630" decimals="-3" unitRef="U_iso4217USD">4114000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <asns:CurrentOfficeSpaceUnderLeaseAgreement id="F_000447" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180810_20180810" decimals="0" unitRef="U_utrsqft">5711</asns:CurrentOfficeSpaceUnderLeaseAgreement>
  <asns:OriginalOfficeSpaceUnderLeaseAgreement id="F_000448" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180810_20180810" decimals="0" unitRef="U_utrsqft">10290</asns:OriginalOfficeSpaceUnderLeaseAgreement>
  <asns:AggregateBaseRentObligation id="F_000449" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180810_20180810" decimals="-5" unitRef="U_iso4217USD">300000</asns:AggregateBaseRentObligation>
  <asns:CashObligation id="F_000450" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180810_20180810" decimals="-5" unitRef="U_iso4217USD">1300000</asns:CashObligation>
  <us-gaap:SecurityDeposit id="F_000451" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180810" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:SecurityDeposit>
  <asns:RelocationPaymentToLessor id="F_000452" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180810_20180810" decimals="-5" unitRef="U_iso4217USD">100000</asns:RelocationPaymentToLessor>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="F_000453" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180810" decimals="-5" unitRef="U_iso4217USD">3200000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <asns:MilestonePayments id="F_000454" contextRef="C_0001501697_us-gaapTransactionTypeAxis_asnsAdimabOptionAgreementMember_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">24400000</asns:MilestonePayments>
  <asns:OptionFee id="F_000455" contextRef="C_0001501697_us-gaapTransactionTypeAxis_asnsAdimabOptionAgreementMember_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">300000</asns:OptionFee>
  <us-gaap:PurchaseObligation id="F_000456" contextRef="C_0001501697_us-gaapOtherCommitmentsAxis_asnsManufacturingCommitmentsMember_20180630" decimals="-5" unitRef="U_iso4217USD">3200000</us-gaap:PurchaseObligation>
  <us-gaap:PurchaseObligation id="F_000457" contextRef="C_0001501697_us-gaapOtherCommitmentsAxis_asnsManufacturingCommitmentsMember_20171231" decimals="-5" unitRef="U_iso4217USD">4700000</us-gaap:PurchaseObligation>
  <us-gaap:PrepaidExpenseCurrent id="F_000458" contextRef="C_0001501697_us-gaapOtherCommitmentsAxis_asnsPrepaidClinicalManufacturingExpensesMember_20180630" decimals="-5" unitRef="U_iso4217USD">2400000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent id="F_000459" contextRef="C_0001501697_us-gaapOtherCommitmentsAxis_asnsPrepaidClinicalManufacturingExpensesMember_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:PrepaidExpenseCurrent>
  <asns:PaymentsToRelatedPartyForPriorPeriodExpense id="F_000460" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20180401_20180630" decimals="-5" unitRef="U_iso4217USD">100000</asns:PaymentsToRelatedPartyForPriorPeriodExpense>
  <asns:PaymentsToRelatedPartyForPriorPeriodExpense id="F_000461" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20170401_20170630" decimals="INF" unitRef="U_iso4217USD">0</asns:PaymentsToRelatedPartyForPriorPeriodExpense>
  <asns:PaymentsToRelatedPartyForPriorPeriodExpense id="F_000462" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">100000</asns:PaymentsToRelatedPartyForPriorPeriodExpense>
  <asns:PaymentsToRelatedPartyForPriorPeriodExpense id="F_000463" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20170101_20170630" decimals="INF" unitRef="U_iso4217USD">0</asns:PaymentsToRelatedPartyForPriorPeriodExpense>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="F_000464" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20180630" decimals="0" unitRef="U_iso4217USD">14000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent id="F_000465" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsAdimabLLCMember_us-gaapTypeOfArrangementAxis_asnsAdimabOptionAgreementMember_20171231" decimals="0" unitRef="U_iso4217USD">21000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <asns:CashReceivedFromRelatedPartyTransaction id="F_000466" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20180401_20180630" decimals="INF" unitRef="U_iso4217USD">0</asns:CashReceivedFromRelatedPartyTransaction>
  <asns:CashReceivedFromRelatedPartyTransaction id="F_000467" contextRef="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20170401_20170630" decimals="INF" unitRef="U_iso4217USD">100000</asns:CashReceivedFromRelatedPartyTransaction>
  <asns:CashReceivedFromRelatedPartyTransaction id="F_000468" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20180101_20180630" decimals="-5" unitRef="U_iso4217USD">100000</asns:CashReceivedFromRelatedPartyTransaction>
  <asns:CashReceivedFromRelatedPartyTransaction id="F_000469" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20170101_20170630" decimals="-5" unitRef="U_iso4217USD">100000</asns:CashReceivedFromRelatedPartyTransaction>
  <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty id="F_000470" contextRef="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20180401_20180630" decimals="INF" unitRef="U_iso4217USD">100000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty id="F_000471" contextRef="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20170401_20170630" decimals="INF" unitRef="U_iso4217USD">100000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty id="F_000472" contextRef="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20180101_20180630" decimals="INF" unitRef="U_iso4217USD">100000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty id="F_000473" contextRef="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20170101_20170630" decimals="INF" unitRef="U_iso4217USD">100000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
  <us-gaap:DueFromRelatedParties id="F_000474" contextRef="C_0001501697_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20180630" decimals="INF" unitRef="U_iso4217USD">100000</us-gaap:DueFromRelatedParties>
  <us-gaap:DueFromRelatedParties id="F_000475" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsEveliQureBiotechnologiesGmbHMember_us-gaapTypeOfArrangementAxis_asnsServicesAndFacilitiesAgreementMember_20171231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:DueFromRelatedParties>
  <asns:GrantsAgreementMaximumAwardAmount id="F_000476" contextRef="C_0001501697_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_asnsBillAndMelindaGatesFoundationMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandAndEighteenGrantAgreementMember_20180808" decimals="-5" unitRef="U_iso4217USD">1100000</asns:GrantsAgreementMaximumAwardAmount>
  <asns:CurrentOfficeSpaceUnderLeaseAgreement id="F_000477" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180810_20180810" decimals="0" unitRef="U_utrsqft">5711</asns:CurrentOfficeSpaceUnderLeaseAgreement>
  <asns:OriginalOfficeSpaceUnderLeaseAgreement id="F_000478" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180810_20180810" decimals="0" unitRef="U_utrsqft">10290</asns:OriginalOfficeSpaceUnderLeaseAgreement>
  <asns:LeaseAgreementOriginationDate id="F_000479" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180810_20180810">2019-01-01</asns:LeaseAgreementOriginationDate>
  <us-gaap:LeaseExpirationDate1 id="F_000480" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180810_20180810">2023-12-31</us-gaap:LeaseExpirationDate1>
  <asns:LeaseAgreementExtensionDescription id="F_000481" contextRef="C_0001501697_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180101_20180630">The Company has the option to extend the term for one additional five-year period upon the Company&#8217;s written notice to the Lessor at least nine months and no more than 12 months in advance of the extension.</asns:LeaseAgreementExtensionDescription>
  <asns:AdditionalOfficeSpaceUnderLeaseAgreement id="F_000482" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180810_20180810" decimals="0" unitRef="U_utrsqft">4000</asns:AdditionalOfficeSpaceUnderLeaseAgreement>
  <asns:AggregateBaseRentObligation id="F_000483" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180810_20180810" decimals="-5" unitRef="U_iso4217USD">300000</asns:AggregateBaseRentObligation>
  <asns:CashObligation id="F_000484" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180810_20180810" decimals="-5" unitRef="U_iso4217USD">1300000</asns:CashObligation>
  <us-gaap:SecurityDeposit id="F_000485" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180810" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:SecurityDeposit>
  <asns:RelocationPaymentToLessor id="F_000486" contextRef="C_0001501697_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_asnsAugustTwoThousandEighteenLeaseAmendmentMember_20180810_20180810" decimals="-5" unitRef="U_iso4217USD">100000</asns:RelocationPaymentToLessor>
  <asns:NumberOfEliminatedPositions id="F_000487" contextRef="C_0001501697_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_asnsArsanisClinicalDevelopmentOfASN100Member_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180810_20180810" decimals="INF" unitRef="U_asnsEmployee">19</asns:NumberOfEliminatedPositions>
  <asns:PercentageOfEliminatedPositions id="F_000488" contextRef="C_0001501697_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_asnsArsanisClinicalDevelopmentOfASN100Member_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180810_20180810" decimals="2" unitRef="U_pure">0.44</asns:PercentageOfEliminatedPositions>
  <us-gaap:RestructuringCharges id="F_000489" contextRef="C_0001501697_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_asnsArsanisClinicalDevelopmentOfASN100Member_us-gaapStatementScenarioAxis_us-gaapScenarioForecastMember_20180701_20180930" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:RestructuringCharges>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>asns-20180630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Schema Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-08-10T21:50:57.2070985+00:00 -->
<!-- Version            : 2.12.6766.32775 -->
<!-- Package ID         : 34e5501d2172469fba6650846da28b53 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:asns="http://www.arsanis.com/20180630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arsanis.com/20180630" xmlns="http://www.w3.org/2001/XMLSchema">
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <import schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2018-01-31" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" namespace="http://fasb.org/us-gaap/2018-01-31" />
  <import schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" namespace="http://fasb.org/srt/2018-01-31" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" namespace="http://fasb.org/us-types/2018-01-31" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <import schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd" namespace="http://fasb.org/srt-types/2018-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <import schemaLocation="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2017-01-31" />
  <import schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2018-01-31" />
  <import schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <annotation>
    <appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.arsanis.com/20180630/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="asns-20180630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="asns-20180630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="asns-20180630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="asns-20180630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" id="Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
        <link:definition>100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" id="Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
        <link:definition>100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)(Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" id="Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited">
        <link:definition>100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" id="Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited">
        <link:definition>100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" id="Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
        <link:definition>100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>100060 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilities">
        <link:definition>100080 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100090 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCollaborationLicenseAndFundingArrangements" id="Role_DisclosureCollaborationLicenseAndFundingArrangements">
        <link:definition>100100 - Disclosure - Collaboration, License and Funding Arrangements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayable" id="Role_DisclosureLoansPayable">
        <link:definition>100110 - Disclosure - Loans Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100120 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100130 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100140 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100150 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100160 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100170 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100180 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100190 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables">
        <link:definition>100200 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100210 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableTables" id="Role_DisclosureLoansPayableTables">
        <link:definition>100220 - Disclosure - Loans Payable (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100230 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100240 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100250 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100280 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsMeasuredAtFairValueDetails" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsMeasuredAtFairValueDetails">
        <link:definition>100290 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100310 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCollaborationLicenseAndFundingArrangementsAdditionalInformationDetails" id="Role_DisclosureCollaborationLicenseAndFundingArrangementsAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Collaboration, License and Funding Arrangements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfAggregatePrincipalAmountOfDebtOutstandingDetails" id="Role_DisclosureLoansPayableScheduleOfAggregatePrincipalAmountOfDebtOutstandingDetails">
        <link:definition>100330 - Disclosure - Loans Payable - Schedule of Aggregate Principal Amount of Debt Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfCurrentAndNonCurrentDebtObligationsDetails" id="Role_DisclosureLoansPayableScheduleOfCurrentAndNonCurrentDebtObligationsDetails">
        <link:definition>100340 - Disclosure - Loans Payable - Schedule of Current and Non-current Debt obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableAdditionalInformationDetails" id="Role_DisclosureLoansPayableAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Loans Payable - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseClassificationDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseClassificationDetails">
        <link:definition>100380 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Classification (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100390 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100400 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100410 - Disclosure - Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetails">
        <link:definition>100430 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments Due under Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <element id="asns_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_GrantAndIncentiveReceivables" name="GrantAndIncentiveReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="asns_UnearnedIncomeCurrent" name="UnearnedIncomeCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_UnearnedIncomeNoncurrent" name="UnearnedIncomeNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_GrantAndIncentiveIncome" name="GrantAndIncentiveIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_NonCashInterestExpense" name="NonCashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="asns_AdjustmentOfNonCashRentExpense" name="AdjustmentOfNonCashRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="asns_IncreaseDecreaseInGrantAndIncentiveReceivables" name="IncreaseDecreaseInGrantAndIncentiveReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="asns_IncreaseDecreaseInUnearnedIncome" name="IncreaseDecreaseInUnearnedIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes" name="PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock" name="PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" name="IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_ExtinguishmentOfConvertiblePromissoryNotes" name="ExtinguishmentOfConvertiblePromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes" name="ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_AccruedExpensesTextBlock" name="AccruedExpensesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_CollaborationAbstract" name="CollaborationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_UnauditedInterimFinancialStatementsPolicyTextBlock" name="UnauditedInterimFinancialStatementsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_FFGLoansPolicyTextBlock" name="FFGLoansPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_ResearchAndDevelopmentIncentivePolicyTextBlock" name="ResearchAndDevelopmentIncentivePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_TwoThousandTwelveLoanAgreementPolicyTextBlock" name="TwoThousandTwelveLoanAgreementPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock" name="ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_NewEnterpriseAssociates16LPMember" name="NewEnterpriseAssociates16LPMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_AccountingStandardsUpdate201415Member" name="AccountingStandardsUpdate201415Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount" name="FairValueTransfersBetweenLevel1Level2OrLevel3Amount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="asns_AccruedClinicalTrialCosts" name="AccruedClinicalTrialCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_CollaborationLicenseAndFundingArrangementsLineItems" name="CollaborationLicenseAndFundingArrangementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_CollaborationLicenseAndFundingArrangementsTable" name="CollaborationLicenseAndFundingArrangementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_AdimabLLCMember" name="AdimabLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_AdimabOptionAgreementMember" name="AdimabOptionAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_BillAndMelindaGatesFoundationMember" name="BillAndMelindaGatesFoundationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember" name="FebruaryTwoThousandAndSeventeenGrantAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_AugustTwoThousandAndEighteenGrantAgreementMember" name="AugustTwoThousandAndEighteenGrantAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_GrantAgreementMember" name="GrantAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_SeriesDRedeemableConvertiblePreferredStockMember" name="SeriesDRedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_FundingArrangementsWithFFGMember" name="FundingArrangementsWithFFGMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_FFGGrantsMember" name="FFGGrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_FFGLoansMember" name="FFGLoansMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_AustriaMember" name="AustriaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_ResearchAndDevelopmentIncentiveProgramMember" name="ResearchAndDevelopmentIncentiveProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_CollaborationPaymentObligations" name="CollaborationPaymentObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_GrantsAgreementMaximumAwardAmount" name="GrantsAgreementMaximumAwardAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="asns_RelatedPartyTransactionProceedsFromGrants" name="RelatedPartyTransactionProceedsFromGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="asns_UnearnedIncome" name="UnearnedIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_GrantAgreementExpirationDate" name="GrantAgreementExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_QualifyingExpensesUnderLetterAgreement" name="QualifyingExpensesUnderLetterAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="asns_PercentageOfLoansAndGrantsToFund" name="PercentageOfLoansAndGrantsToFund" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_ReimbursementRateForResearchAndDevelopment" name="ReimbursementRateForResearchAndDevelopment" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" name="TermLoansUnderTwoThousandTwelveLoanAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_ClassOfWarrantOrRightsExpirationDate" name="ClassOfWarrantOrRightsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_TwoThousandTwelveTermLoanAAdvanceMember" name="TwoThousandTwelveTermLoanAAdvanceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_TwoThousandTwelveLoanAgreementMember" name="TwoThousandTwelveLoanAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_TwoThousandTwelveTermLoanBAdvanceMember" name="TwoThousandTwelveTermLoanBAdvanceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_SeriesATwoPreferredStockWarrantsMember" name="SeriesATwoPreferredStockWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_TwoThousandSixteenTermLoanAAdvanceMember" name="TwoThousandSixteenTermLoanAAdvanceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_TwoThousandSixteenTermLoanBAdvanceMember" name="TwoThousandSixteenTermLoanBAdvanceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_SeriesBWarrantsMember" name="SeriesBWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_ExercisePriceOneMember" name="ExercisePriceOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_ExercisePriceTwoMember" name="ExercisePriceTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_TwoThousandSixteenTermLoanAdvanceMember" name="TwoThousandSixteenTermLoanAdvanceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_FirstAmendmentMember" name="FirstAmendmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_NumberOfTranches" name="NumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_PercentageMinusWallStreetJournalPrimeRate" name="PercentageMinusWallStreetJournalPrimeRate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_PrepaymentFeePercentageToOutstandingPrincipalAmount" name="PrepaymentFeePercentageToOutstandingPrincipalAmount" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_TwoThousandSeventeenEquityIncentivePlanMember" name="TwoThousandSeventeenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_TwoThousandAndTenSpecialStockIncentivePlanMember" name="TwoThousandAndTenSpecialStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_TwoThousandAndElevenStockIncentivePlanMember" name="TwoThousandAndElevenStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember" name="WarrantsToPurchaseRedeemableConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_ManufacturingCommitmentsMember" name="ManufacturingCommitmentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_ViennaLeaseAgreementMember" name="ViennaLeaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_AnimalUseLeaseAgreementMember" name="AnimalUseLeaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_WalthamLeaseAgreementMember" name="WalthamLeaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_LeaseAgreementForOfficeSpaceInWalthamMAMember" name="LeaseAgreementForOfficeSpaceInWalthamMAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_PrepaidClinicalManufacturingExpensesMember" name="PrepaidClinicalManufacturingExpensesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_LesseeOperatingLeaseExpirationDescription" name="LesseeOperatingLeaseExpirationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_CurrentOfficeSpaceUnderLeaseAgreement" name="CurrentOfficeSpaceUnderLeaseAgreement" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_AggregateBaseRentObligation" name="AggregateBaseRentObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_CashObligation" name="CashObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_RelocationPaymentToLessor" name="RelocationPaymentToLessor" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_OriginalOfficeSpaceUnderLeaseAgreement" name="OriginalOfficeSpaceUnderLeaseAgreement" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_OptionFee" name="OptionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="asns_PaymentsToRelatedPartyForPriorPeriodExpense" name="PaymentsToRelatedPartyForPriorPeriodExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="asns_EveliQureBiotechnologiesGmbHMember" name="EveliQureBiotechnologiesGmbHMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_ServicesAndFacilitiesAgreementMember" name="ServicesAndFacilitiesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_CashReceivedFromRelatedPartyTransaction" name="CashReceivedFromRelatedPartyTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="asns_AugustTwoThousandEighteenLeaseAmendmentMember" name="AugustTwoThousandEighteenLeaseAmendmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_ArsanisClinicalDevelopmentOfASN100Member" name="ArsanisClinicalDevelopmentOfASN100Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="asns_LeaseAgreementOriginationDate" name="LeaseAgreementOriginationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_AdditionalOfficeSpaceUnderLeaseAgreement" name="AdditionalOfficeSpaceUnderLeaseAgreement" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_LeaseAgreementExtensionDescription" name="LeaseAgreementExtensionDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_NumberOfEliminatedPositions" name="NumberOfEliminatedPositions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="asns_PercentageOfEliminatedPositions" name="PercentageOfEliminatedPositions" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>asns-20180630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-08-10T21:50:57.2070985+00:00 -->
<!-- Version            : 2.12.6766.32775 -->
<!-- Package ID         : 34e5501d2172469fba6650846da28b53 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="asns-20180630.xsd#TemplateLink" roleURI="http://www.arsanis.com/20180630/role/TemplateLink" />
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:href="asns-20180630.xsd#Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantAndIncentiveReceivables" xlink:type="locator" xlink:label="asns_GrantAndIncentiveReceivables" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" />
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncomeCurrent" xlink:type="locator" xlink:label="asns_UnearnedIncomeCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncomeNoncurrent" xlink:type="locator" xlink:label="asns_UnearnedIncomeNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermLoansPayable" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="asns_UnearnedIncomeNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="asns_UnearnedIncomeCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LoansPayableCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="asns_GrantAndIncentiveReceivables" order="10210.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:href="asns-20180630.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantAndIncentiveIncome" xlink:type="locator" xlink:label="asns_GrantAndIncentiveIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="asns_GrantAndIncentiveIncome" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" xlink:href="asns-20180630.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:href="asns-20180630.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
    <loc xlink:href="asns-20180630.xsd#asns_IncreaseDecreaseInUnearnedIncome" xlink:type="locator" xlink:label="asns_IncreaseDecreaseInUnearnedIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="asns-20180630.xsd#asns_IncreaseDecreaseInGrantAndIncentiveReceivables" xlink:type="locator" xlink:label="asns_IncreaseDecreaseInGrantAndIncentiveReceivables" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="asns-20180630.xsd#asns_AdjustmentOfNonCashRentExpense" xlink:type="locator" xlink:label="asns_AdjustmentOfNonCashRentExpense" />
    <loc xlink:href="asns-20180630.xsd#asns_NonCashInterestExpense" xlink:type="locator" xlink:label="asns_NonCashInterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="asns-20180630.xsd#asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock" />
    <loc xlink:href="asns-20180630.xsd#asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes" xlink:type="locator" xlink:label="asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="asns_NonCashInterestExpense" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="asns_AdjustmentOfNonCashRentExpense" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="asns_IncreaseDecreaseInGrantAndIncentiveReceivables" order="10220.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10230.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10240.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10250.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="asns_IncreaseDecreaseInUnearnedIncome" order="10260.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="asns-20180630.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="asns-20180630.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="asns-20180630.xsd#asns_AccruedClinicalTrialCosts" xlink:type="locator" xlink:label="asns_AccruedClinicalTrialCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="asns_AccruedClinicalTrialCosts" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfCurrentAndNonCurrentDebtObligationsDetails" xlink:href="asns-20180630.xsd#Role_DisclosureLoansPayableScheduleOfCurrentAndNonCurrentDebtObligationsDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfCurrentAndNonCurrentDebtObligationsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayable" xlink:type="locator" xlink:label="us-gaap_LoansPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayableCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LongTermLoansPayable" order="10020.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetails" xlink:href="asns-20180630.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10060.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>asns-20180630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-08-10T21:50:57.2070985+00:00 -->
<!-- Version            : 2.12.6766.32775 -->
<!-- Package ID         : 34e5501d2172469fba6650846da28b53 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <roleRef xlink:type="simple" xlink:href="asns-20180630.xsd#TemplateLink" roleURI="http://www.arsanis.com/20180630/role/TemplateLink" />
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <loc xlink:href="asns-20180630.xsd#asns_AccountingStandardsUpdate201415Member" xlink:type="locator" xlink:label="asns_AccountingStandardsUpdate201415Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_NewEnterpriseAssociates16LPMember" xlink:type="locator" xlink:label="asns_NewEnterpriseAssociates16LPMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <loc xlink:href="asns-20180630.xsd#asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_2" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="asns_NewEnterpriseAssociates16LPMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="asns_AccountingStandardsUpdate201415Member" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10800.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10820.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsMeasuredAtFairValueDetails" xlink:href="asns-20180630.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsMeasuredAtFairValueDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsMeasuredAtFairValueDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10500.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCollaborationLicenseAndFundingArrangementsAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureCollaborationLicenseAndFundingArrangementsAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCollaborationLicenseAndFundingArrangementsAdditionalInformationDetails">
    <loc xlink:href="asns-20180630.xsd#asns_ReimbursementRateForResearchAndDevelopment" xlink:type="locator" xlink:label="asns_ReimbursementRateForResearchAndDevelopment" />
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncomeNoncurrent" xlink:type="locator" xlink:label="asns_UnearnedIncomeNoncurrent" />
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncomeCurrent" xlink:type="locator" xlink:label="asns_UnearnedIncomeCurrent" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantAndIncentiveReceivables" xlink:type="locator" xlink:label="asns_GrantAndIncentiveReceivables" />
    <loc xlink:href="asns-20180630.xsd#asns_PercentageOfLoansAndGrantsToFund" xlink:type="locator" xlink:label="asns_PercentageOfLoansAndGrantsToFund" />
    <loc xlink:href="asns-20180630.xsd#asns_QualifyingExpensesUnderLetterAgreement" xlink:type="locator" xlink:label="asns_QualifyingExpensesUnderLetterAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantAgreementExpirationDate" xlink:type="locator" xlink:label="asns_GrantAgreementExpirationDate" />
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncome" xlink:type="locator" xlink:label="asns_UnearnedIncome" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantAndIncentiveIncome" xlink:type="locator" xlink:label="asns_GrantAndIncentiveIncome" />
    <loc xlink:href="asns-20180630.xsd#asns_RelatedPartyTransactionProceedsFromGrants" xlink:type="locator" xlink:label="asns_RelatedPartyTransactionProceedsFromGrants" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantsAgreementMaximumAwardAmount" xlink:type="locator" xlink:label="asns_GrantsAgreementMaximumAwardAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="asns-20180630.xsd#asns_CollaborationPaymentObligations" xlink:type="locator" xlink:label="asns_CollaborationPaymentObligations" />
    <loc xlink:href="asns-20180630.xsd#asns_ResearchAndDevelopmentIncentiveProgramMember" xlink:type="locator" xlink:label="asns_ResearchAndDevelopmentIncentiveProgramMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:type="locator" xlink:label="us-gaap_ScenarioForecastMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_AustriaMember" xlink:type="locator" xlink:label="asns_AustriaMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_FFGLoansMember" xlink:type="locator" xlink:label="asns_FFGLoansMember" />
    <loc xlink:href="asns-20180630.xsd#asns_FFGGrantsMember" xlink:type="locator" xlink:label="asns_FFGGrantsMember" />
    <loc xlink:href="asns-20180630.xsd#asns_FundingArrangementsWithFFGMember" xlink:type="locator" xlink:label="asns_FundingArrangementsWithFFGMember" />
    <loc xlink:href="asns-20180630.xsd#asns_SeriesDRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="asns_SeriesDRedeemableConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantAgreementMember" xlink:type="locator" xlink:label="asns_GrantAgreementMember" />
    <loc xlink:href="asns-20180630.xsd#asns_AugustTwoThousandAndEighteenGrantAgreementMember" xlink:type="locator" xlink:label="asns_AugustTwoThousandAndEighteenGrantAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember" xlink:type="locator" xlink:label="asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember" />
    <loc xlink:href="asns-20180630.xsd#asns_BillAndMelindaGatesFoundationMember" xlink:type="locator" xlink:label="asns_BillAndMelindaGatesFoundationMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_AdimabOptionAgreementMember" xlink:type="locator" xlink:label="asns_AdimabOptionAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_AdimabLLCMember" xlink:type="locator" xlink:label="asns_AdimabLLCMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_CollaborationLicenseAndFundingArrangementsTable" xlink:type="locator" xlink:label="asns_CollaborationLicenseAndFundingArrangementsTable" />
    <loc xlink:href="asns-20180630.xsd#asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:type="locator" xlink:label="asns_CollaborationLicenseAndFundingArrangementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_CollaborationLicenseAndFundingArrangementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="asns_AdimabLLCMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_AdimabOptionAgreementMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="srt_CounterpartyNameAxis" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="asns_BillAndMelindaGatesFoundationMember" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_AugustTwoThousandAndEighteenGrantAgreementMember" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_GrantAgreementMember" order="11410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="11510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="11530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="asns_SeriesDRedeemableConvertiblePreferredStockMember" order="11550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_FundingArrangementsWithFFGMember" order="11690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_FFGGrantsMember" order="11830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_FFGLoansMember" order="11930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="11980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="11990.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="12010.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="asns_AustriaMember" order="12030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="us-gaap_StatementScenarioAxis" order="12040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="12050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="12070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="12090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_ResearchAndDevelopmentIncentiveProgramMember" order="12150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_CollaborationPaymentObligations" order="12230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_GrantsAgreementMaximumAwardAmount" order="12390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_RelatedPartyTransactionProceedsFromGrants" order="12440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_GrantAndIncentiveIncome" order="12460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_UnearnedIncome" order="12590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_GrantAgreementExpirationDate" order="12750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12990.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="13010.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="13030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="13050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="13070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_QualifyingExpensesUnderLetterAgreement" order="13120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_PercentageOfLoansAndGrantsToFund" order="13230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_GrantAndIncentiveReceivables" order="13380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_UnearnedIncomeCurrent" order="13650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_UnearnedIncomeNoncurrent" order="13730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_ReimbursementRateForResearchAndDevelopment" order="13840.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfAggregatePrincipalAmountOfDebtOutstandingDetails" xlink:href="asns-20180630.xsd#Role_DisclosureLoansPayableScheduleOfAggregatePrincipalAmountOfDebtOutstandingDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfAggregatePrincipalAmountOfDebtOutstandingDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <loc xlink:href="asns-20180630.xsd#asns_FFGLoansMember" xlink:type="locator" xlink:label="asns_FFGLoansMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" xlink:type="locator" xlink:label="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_FFGLoansMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10140.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfCurrentAndNonCurrentDebtObligationsDetails" xlink:href="asns-20180630.xsd#Role_DisclosureLoansPayableScheduleOfCurrentAndNonCurrentDebtObligationsDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfCurrentAndNonCurrentDebtObligationsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayable" xlink:type="locator" xlink:label="us-gaap_LoansPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrentAbstract" />
    <loc xlink:href="asns-20180630.xsd#asns_FFGLoansMember" xlink:type="locator" xlink:label="asns_FFGLoansMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" xlink:type="locator" xlink:label="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_FFGLoansMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrentAbstract" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtCurrentAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrentAbstract" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LongTermLoansPayable" order="10640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LoansPayable" order="10680.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureLoansPayableAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <loc xlink:href="asns-20180630.xsd#asns_PrepaymentFeePercentageToOutstandingPrincipalAmount" xlink:type="locator" xlink:label="asns_PrepaymentFeePercentageToOutstandingPrincipalAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
    <loc xlink:href="asns-20180630.xsd#asns_PercentageMinusWallStreetJournalPrimeRate" xlink:type="locator" xlink:label="asns_PercentageMinusWallStreetJournalPrimeRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <loc xlink:href="asns-20180630.xsd#asns_NumberOfTranches" xlink:type="locator" xlink:label="asns_NumberOfTranches" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <loc xlink:href="asns-20180630.xsd#asns_ClassOfWarrantOrRightsExpirationDate" xlink:type="locator" xlink:label="asns_ClassOfWarrantOrRightsExpirationDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <loc xlink:href="asns-20180630.xsd#asns_FFGLoansMember" xlink:type="locator" xlink:label="asns_FFGLoansMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" xlink:type="locator" xlink:label="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" />
    <loc xlink:href="asns-20180630.xsd#asns_FirstAmendmentMember" xlink:type="locator" xlink:label="asns_FirstAmendmentMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandSixteenTermLoanAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandSixteenTermLoanAdvanceMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_ExercisePriceTwoMember" xlink:type="locator" xlink:label="asns_ExercisePriceTwoMember" />
    <loc xlink:href="asns-20180630.xsd#asns_ExercisePriceOneMember" xlink:type="locator" xlink:label="asns_ExercisePriceOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_SeriesBWarrantsMember" xlink:type="locator" xlink:label="asns_SeriesBWarrantsMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandSixteenTermLoanBAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandSixteenTermLoanBAdvanceMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandSixteenTermLoanAAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandSixteenTermLoanAAdvanceMember" />
    <loc xlink:href="asns-20180630.xsd#asns_SeriesATwoPreferredStockWarrantsMember" xlink:type="locator" xlink:label="asns_SeriesATwoPreferredStockWarrantsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandTwelveTermLoanBAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandTwelveTermLoanBAdvanceMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandTwelveLoanAgreementMember" xlink:type="locator" xlink:label="asns_TwoThousandTwelveLoanAgreementMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandTwelveTermLoanAAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandTwelveTermLoanAAdvanceMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TwoThousandTwelveTermLoanAAdvanceMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TwoThousandTwelveLoanAgreementMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TwoThousandTwelveTermLoanBAdvanceMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="asns_SeriesATwoPreferredStockWarrantsMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TwoThousandSixteenTermLoanAAdvanceMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TwoThousandSixteenTermLoanBAdvanceMember" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="asns_SeriesBWarrantsMember" order="10710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="10790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="asns_ExercisePriceOneMember" order="10830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="asns_ExercisePriceTwoMember" order="10870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10900.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TwoThousandSixteenTermLoanAdvanceMember" order="11190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_FirstAmendmentMember" order="11430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" order="11590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_FFGLoansMember" order="11730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="12060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="12120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="asns_ClassOfWarrantOrRightsExpirationDate" order="12180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="12230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="12280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="asns_NumberOfTranches" order="12360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="12380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="12850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="asns_PercentageMinusWallStreetJournalPrimeRate" order="12870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="12890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="asns_PrepaymentFeePercentageToOutstandingPrincipalAmount" order="12980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="13060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="13080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="13130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="13210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="13320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="13430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1" order="13550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeEnd1" order="13590.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandAndElevenStockIncentivePlanMember" xlink:type="locator" xlink:label="asns_TwoThousandAndElevenStockIncentivePlanMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandAndTenSpecialStockIncentivePlanMember" xlink:type="locator" xlink:label="asns_TwoThousandAndTenSpecialStockIncentivePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="asns_TwoThousandSeventeenEquityIncentivePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:type="locator" xlink:label="us-gaap_DirectorMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_DirectorMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="asns_TwoThousandSeventeenEquityIncentivePlanMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="asns_TwoThousandAndTenSpecialStockIncentivePlanMember" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="asns_TwoThousandAndElevenStockIncentivePlanMember" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="10960.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11000.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11220.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseClassificationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseClassificationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseClassificationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="asns-20180630.xsd#Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10220.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" />
    <loc xlink:href="asns-20180630.xsd#asns_OptionFee" xlink:type="locator" xlink:label="asns_OptionFee" />
    <loc xlink:href="asns-20180630.xsd#asns_MilestonePayments" xlink:type="locator" xlink:label="asns_MilestonePayments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:href="asns-20180630.xsd#asns_RelocationPaymentToLessor" xlink:type="locator" xlink:label="asns_RelocationPaymentToLessor" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <loc xlink:href="asns-20180630.xsd#asns_CashObligation" xlink:type="locator" xlink:label="asns_CashObligation" />
    <loc xlink:href="asns-20180630.xsd#asns_AggregateBaseRentObligation" xlink:type="locator" xlink:label="asns_AggregateBaseRentObligation" />
    <loc xlink:href="asns-20180630.xsd#asns_OriginalOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_OriginalOfficeSpaceUnderLeaseAgreement" />
    <loc xlink:href="asns-20180630.xsd#asns_CurrentOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_CurrentOfficeSpaceUnderLeaseAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" />
    <loc xlink:href="asns-20180630.xsd#asns_LesseeOperatingLeaseExpirationDescription" xlink:type="locator" xlink:label="asns_LesseeOperatingLeaseExpirationDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="asns-20180630.xsd#asns_PrepaidClinicalManufacturingExpensesMember" xlink:type="locator" xlink:label="asns_PrepaidClinicalManufacturingExpensesMember" />
    <loc xlink:href="asns-20180630.xsd#asns_AdimabOptionAgreementMember" xlink:type="locator" xlink:label="asns_AdimabOptionAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_LeaseAgreementForOfficeSpaceInWalthamMAMember" xlink:type="locator" xlink:label="asns_LeaseAgreementForOfficeSpaceInWalthamMAMember" />
    <loc xlink:href="asns-20180630.xsd#asns_WalthamLeaseAgreementMember" xlink:type="locator" xlink:label="asns_WalthamLeaseAgreementMember" />
    <loc xlink:href="asns-20180630.xsd#asns_AnimalUseLeaseAgreementMember" xlink:type="locator" xlink:label="asns_AnimalUseLeaseAgreementMember" />
    <loc xlink:href="asns-20180630.xsd#asns_ViennaLeaseAgreementMember" xlink:type="locator" xlink:label="asns_ViennaLeaseAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_ManufacturingCommitmentsMember" xlink:type="locator" xlink:label="asns_ManufacturingCommitmentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="asns_CommitmentsAndContingenciesTable" />
    <loc xlink:href="asns-20180630.xsd#asns_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="asns_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_CommitmentsAndContingenciesTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="asns_ManufacturingCommitmentsMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="asns_ViennaLeaseAgreementMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="asns_AnimalUseLeaseAgreementMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="asns_WalthamLeaseAgreementMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="asns_LeaseAgreementForOfficeSpaceInWalthamMAMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_CommitmentsAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asns_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TransactionTypeAxis" order="10640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_2" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="asns_AdimabOptionAgreementMember" order="10690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="asns_PrepaidClinicalManufacturingExpensesMember" order="10790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_LesseeOperatingLeaseExpirationDescription" order="10920.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" order="10940.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="11040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="11090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_CurrentOfficeSpaceUnderLeaseAgreement" order="11200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_OriginalOfficeSpaceUnderLeaseAgreement" order="11220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_AggregateBaseRentObligation" order="11240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_CashObligation" order="11260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" order="11280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_RelocationPaymentToLessor" order="11300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="11320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_MilestonePayments" order="11390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_OptionFee" order="11410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PurchaseObligation" order="11460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" order="11500.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" />
    <loc xlink:href="asns-20180630.xsd#asns_CashReceivedFromRelatedPartyTransaction" xlink:type="locator" xlink:label="asns_CashReceivedFromRelatedPartyTransaction" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="asns-20180630.xsd#asns_PaymentsToRelatedPartyForPriorPeriodExpense" xlink:type="locator" xlink:label="asns_PaymentsToRelatedPartyForPriorPeriodExpense" />
    <loc xlink:href="asns-20180630.xsd#asns_ServicesAndFacilitiesAgreementMember" xlink:type="locator" xlink:label="asns_ServicesAndFacilitiesAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_EveliQureBiotechnologiesGmbHMember" xlink:type="locator" xlink:label="asns_EveliQureBiotechnologiesGmbHMember" />
    <loc xlink:href="asns-20180630.xsd#asns_AdimabOptionAgreementMember" xlink:type="locator" xlink:label="asns_AdimabOptionAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_AdimabLLCMember" xlink:type="locator" xlink:label="asns_AdimabLLCMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="asns_AdimabLLCMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_AdimabOptionAgreementMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="asns_EveliQureBiotechnologiesGmbHMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_ServicesAndFacilitiesAgreementMember" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="asns_PaymentsToRelatedPartyForPriorPeriodExpense" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="asns_CashReceivedFromRelatedPartyTransaction" order="10870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" order="11030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="11190.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <loc xlink:href="asns-20180630.xsd#asns_PercentageOfEliminatedPositions" xlink:type="locator" xlink:label="asns_PercentageOfEliminatedPositions" />
    <loc xlink:href="asns-20180630.xsd#asns_NumberOfEliminatedPositions" xlink:type="locator" xlink:label="asns_NumberOfEliminatedPositions" />
    <loc xlink:href="asns-20180630.xsd#asns_RelocationPaymentToLessor" xlink:type="locator" xlink:label="asns_RelocationPaymentToLessor" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <loc xlink:href="asns-20180630.xsd#asns_CashObligation" xlink:type="locator" xlink:label="asns_CashObligation" />
    <loc xlink:href="asns-20180630.xsd#asns_AggregateBaseRentObligation" xlink:type="locator" xlink:label="asns_AggregateBaseRentObligation" />
    <loc xlink:href="asns-20180630.xsd#asns_AdditionalOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_AdditionalOfficeSpaceUnderLeaseAgreement" />
    <loc xlink:href="asns-20180630.xsd#asns_LeaseAgreementExtensionDescription" xlink:type="locator" xlink:label="asns_LeaseAgreementExtensionDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="asns-20180630.xsd#asns_LeaseAgreementOriginationDate" xlink:type="locator" xlink:label="asns_LeaseAgreementOriginationDate" />
    <loc xlink:href="asns-20180630.xsd#asns_OriginalOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_OriginalOfficeSpaceUnderLeaseAgreement" />
    <loc xlink:href="asns-20180630.xsd#asns_CurrentOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_CurrentOfficeSpaceUnderLeaseAgreement" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantsAgreementMaximumAwardAmount" xlink:type="locator" xlink:label="asns_GrantsAgreementMaximumAwardAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:type="locator" xlink:label="us-gaap_ScenarioForecastMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_ArsanisClinicalDevelopmentOfASN100Member" xlink:type="locator" xlink:label="asns_ArsanisClinicalDevelopmentOfASN100Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_AugustTwoThousandEighteenLeaseAmendmentMember" xlink:type="locator" xlink:label="asns_AugustTwoThousandEighteenLeaseAmendmentMember" />
    <loc xlink:href="asns-20180630.xsd#asns_AugustTwoThousandAndEighteenGrantAgreementMember" xlink:type="locator" xlink:label="asns_AugustTwoThousandAndEighteenGrantAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_BillAndMelindaGatesFoundationMember" xlink:type="locator" xlink:label="asns_BillAndMelindaGatesFoundationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="asns_BillAndMelindaGatesFoundationMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_AugustTwoThousandAndEighteenGrantAgreementMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_AugustTwoThousandEighteenLeaseAmendmentMember" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" order="10770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="10790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="asns_ArsanisClinicalDevelopmentOfASN100Member" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementScenarioAxis" order="10900.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="10950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_GrantsAgreementMaximumAwardAmount" order="10980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_CurrentOfficeSpaceUnderLeaseAgreement" order="11030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_OriginalOfficeSpaceUnderLeaseAgreement" order="11050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_LeaseAgreementOriginationDate" order="11070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_LeaseAgreementExtensionDescription" order="11110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_AdditionalOfficeSpaceUnderLeaseAgreement" order="11130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_AggregateBaseRentObligation" order="11180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_CashObligation" order="11200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SecurityDeposit" order="11220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_RelocationPaymentToLessor" order="11240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_NumberOfEliminatedPositions" order="11290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_PercentageOfEliminatedPositions" order="11310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringCharges" order="11360.00" priority="2" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>asns-20180630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-08-10T21:50:57.2070985+00:00 -->
<!-- Version            : 2.12.6766.32775 -->
<!-- Package ID         : 34e5501d2172469fba6650846da28b53 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="asns_DocumentAndEntityInformationAbstract" />
    <label xml:lang="en-US" xlink:label="asns_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_DocumentAndEntityInformationAbstract" xlink:to="asns_DocumentAndEntityInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="asns_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Abstract]</label>
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</label>
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</label>
    <loc xlink:href="asns-20180630.xsd#asns_GrantAndIncentiveReceivables" xlink:type="locator" xlink:label="asns_GrantAndIncentiveReceivables" />
    <label xml:lang="en-US" xlink:label="asns_GrantAndIncentiveReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant and incentive receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_GrantAndIncentiveReceivables" xlink:to="asns_GrantAndIncentiveReceivables_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncomeCurrent" xlink:type="locator" xlink:label="asns_UnearnedIncomeCurrent" />
    <label xml:lang="en-US" xlink:label="asns_UnearnedIncomeCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unearned income current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_UnearnedIncomeCurrent" xlink:to="asns_UnearnedIncomeCurrent_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncomeNoncurrent" xlink:type="locator" xlink:label="asns_UnearnedIncomeNoncurrent" />
    <label xml:lang="en-US" xlink:label="asns_UnearnedIncomeNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unearned income noncurrent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_UnearnedIncomeNoncurrent" xlink:to="asns_UnearnedIncomeNoncurrent_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</label>
    <label xml:lang="en-US" xlink:label="asns_GrantAndIncentiveReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant and incentive receivables</label>
    <label xml:lang="en-US" xlink:label="asns_GrantAndIncentiveReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant And Incentive Receivables</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</label>
    <label xml:lang="en-US" xlink:label="asns_UnearnedIncomeCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unearned income</label>
    <label xml:lang="en-US" xlink:label="asns_UnearnedIncomeCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unearned Income Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LoansPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loans payable, net of discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LoansPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermLoansPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan payable, net of discount and current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermLoansPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Loans Payable</label>
    <label xml:lang="en-US" xlink:label="asns_UnearnedIncomeNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unearned income</label>
    <label xml:lang="en-US" xlink:label="asns_UnearnedIncomeNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unearned Income Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 10)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 200,000,000 shares authorized as of June 30, 2018 and December 31, 2017; 14,315,410 and 14,294,383 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</label>
    <loc xlink:href="asns-20180630.xsd#asns_GrantAndIncentiveIncome" xlink:type="locator" xlink:label="asns_GrantAndIncentiveIncome" />
    <label xml:lang="en-US" xlink:label="asns_GrantAndIncentiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant and incentive income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_GrantAndIncentiveIncome" xlink:to="asns_GrantAndIncentiveIncome_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</label>
    <label xml:lang="en-US" xlink:label="asns_GrantAndIncentiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant and incentive income</label>
    <label xml:lang="en-US" xlink:label="asns_GrantAndIncentiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant And Incentive Income</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Gain Loss On Derivative Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Extinguishment Of Debt</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of redeemable convertible preferred stock to redemption value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Accretion To Redemption Value Adjustment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders&#8212;basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding&#8212;basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation gain (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</label>
    <loc xlink:href="asns-20180630.xsd#asns_NonCashInterestExpense" xlink:type="locator" xlink:label="asns_NonCashInterestExpense" />
    <label xml:lang="en-US" xlink:label="asns_NonCashInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash interest expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_NonCashInterestExpense" xlink:to="asns_NonCashInterestExpense_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_AdjustmentOfNonCashRentExpense" xlink:type="locator" xlink:label="asns_AdjustmentOfNonCashRentExpense" />
    <label xml:lang="en-US" xlink:label="asns_AdjustmentOfNonCashRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustment of non cash rent expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_AdjustmentOfNonCashRentExpense" xlink:to="asns_AdjustmentOfNonCashRentExpense_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_IncreaseDecreaseInGrantAndIncentiveReceivables" xlink:type="locator" xlink:label="asns_IncreaseDecreaseInGrantAndIncentiveReceivables" />
    <label xml:lang="en-US" xlink:label="asns_IncreaseDecreaseInGrantAndIncentiveReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in grant and incentive receivables.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_IncreaseDecreaseInGrantAndIncentiveReceivables" xlink:to="asns_IncreaseDecreaseInGrantAndIncentiveReceivables_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_IncreaseDecreaseInUnearnedIncome" xlink:type="locator" xlink:label="asns_IncreaseDecreaseInUnearnedIncome" />
    <label xml:lang="en-US" xlink:label="asns_IncreaseDecreaseInUnearnedIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in unearned income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_IncreaseDecreaseInUnearnedIncome" xlink:to="asns_IncreaseDecreaseInUnearnedIncome_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes" xlink:type="locator" xlink:label="asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes" />
    <label xml:lang="en-US" xlink:label="asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of issuance costs of convertible promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes" xlink:to="asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock" />
    <label xml:lang="en-US" xlink:label="asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of issuance costs of redeemable convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock" xlink:to="asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:type="locator" xlink:label="asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" />
    <label xml:lang="en-US" xlink:label="asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of redeemable convertible preferred stock upon extinguishment of convertible promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:to="asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_ExtinguishmentOfConvertiblePromissoryNotes" xlink:type="locator" xlink:label="asns_ExtinguishmentOfConvertiblePromissoryNotes" />
    <label xml:lang="en-US" xlink:label="asns_ExtinguishmentOfConvertiblePromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Extinguishment of convertible promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ExtinguishmentOfConvertiblePromissoryNotes" xlink:to="asns_ExtinguishmentOfConvertiblePromissoryNotes_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes" xlink:type="locator" xlink:label="asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes" />
    <label xml:lang="en-US" xlink:label="asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes" xlink:to="asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</label>
    <label xml:lang="en-US" xlink:label="asns_NonCashInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</label>
    <label xml:lang="en-US" xlink:label="asns_NonCashInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Interest Expense</label>
    <label xml:lang="en-US" xlink:label="asns_AdjustmentOfNonCashRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash rent expense</label>
    <label xml:lang="en-US" xlink:label="asns_AdjustmentOfNonCashRentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment Of Non Cash Rent Expense</label>
    <label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of debt</label>
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liability</label>
    <label xml:lang="en-US" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of derivative liability</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</label>
    <label xml:lang="en-US" xlink:label="asns_IncreaseDecreaseInGrantAndIncentiveReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant and incentive receivables</label>
    <label xml:lang="en-US" xlink:label="asns_IncreaseDecreaseInGrantAndIncentiveReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Grant And Incentive Receivables</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</label>
    <label xml:lang="en-US" xlink:label="asns_IncreaseDecreaseInUnearnedIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unearned income</label>
    <label xml:lang="en-US" xlink:label="asns_IncreaseDecreaseInUnearnedIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Unearned Income</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Productive Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of redeemable convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Redeemable Convertible Preferred Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Convertible Debt</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of loans under funding agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Debt</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayments of loans payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Debt</label>
    <label xml:lang="en-US" xlink:label="asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of issuance costs of convertible promissory notes</label>
    <label xml:lang="en-US" xlink:label="asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Issuance Costs Of Convertible Promissory Notes</label>
    <label xml:lang="en-US" xlink:label="asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of issuance costs of redeemable convertible preferred stock</label>
    <label xml:lang="en-US" xlink:label="asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Issuance Costs Of Redeemable Convertible Preferred Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of initial public offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <label xml:lang="en-US" xlink:label="asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock upon extinguishment of convertible promissory notes</label>
    <label xml:lang="en-US" xlink:label="asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Redeemable Convertible Preferred Stock Upon Extinguishment Of Convertible Promissory Notes</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAssumed1" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liability in connection with issuance of convertible promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Assumed1</label>
    <label xml:lang="en-US" xlink:label="asns_ExtinguishmentOfConvertiblePromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of convertible promissory notes</label>
    <label xml:lang="en-US" xlink:label="asns_ExtinguishmentOfConvertiblePromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment Of Convertible Promissory Notes</label>
    <label xml:lang="en-US" xlink:label="asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</label>
    <label xml:lang="en-US" xlink:label="asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment Of Derivative Liability In Connection With Extinguishment Of Convertible Promissory Notes</label>
    <label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of redeemable convertible preferred stock to redemption value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</label>
    <loc xlink:href="asns-20180630.xsd#asns_AccruedExpensesTextBlock" xlink:type="locator" xlink:label="asns_AccruedExpensesTextBlock" />
    <label xml:lang="en-US" xlink:label="asns_AccruedExpensesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_AccruedExpensesTextBlock" xlink:to="asns_AccruedExpensesTextBlock_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="asns_AccruedExpensesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</label>
    <label xml:lang="en-US" xlink:label="asns_AccruedExpensesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses [Text Block]</label>
    <loc xlink:href="asns-20180630.xsd#asns_CollaborationAbstract" xlink:type="locator" xlink:label="asns_CollaborationAbstract" />
    <label xml:lang="en-US" xlink:label="asns_CollaborationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_CollaborationAbstract" xlink:to="asns_CollaborationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="asns_CollaborationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration, License and Funding Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loans Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</label>
    <loc xlink:href="asns-20180630.xsd#asns_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:type="locator" xlink:label="asns_UnauditedInterimFinancialStatementsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="asns_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unaudited interim financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:to="asns_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="asns_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unaudited Interim Financial Statements</label>
    <label xml:lang="en-US" xlink:label="asns_UnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unaudited Interim Financial Statements Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted/Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <loc xlink:href="asns-20180630.xsd#asns_FFGLoansPolicyTextBlock" xlink:type="locator" xlink:label="asns_FFGLoansPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="asns_FFGLoansPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">FFG loans.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_FFGLoansPolicyTextBlock" xlink:to="asns_FFGLoansPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="asns_FFGLoansPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FFG Loans</label>
    <label xml:lang="en-US" xlink:label="asns_FFGLoansPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">F F G Loans Policy [Text Block]</label>
    <loc xlink:href="asns-20180630.xsd#asns_ResearchAndDevelopmentIncentivePolicyTextBlock" xlink:type="locator" xlink:label="asns_ResearchAndDevelopmentIncentivePolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="asns_ResearchAndDevelopmentIncentivePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development incentive.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ResearchAndDevelopmentIncentivePolicyTextBlock" xlink:to="asns_ResearchAndDevelopmentIncentivePolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="asns_ResearchAndDevelopmentIncentivePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Incentive</label>
    <label xml:lang="en-US" xlink:label="asns_ResearchAndDevelopmentIncentivePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Incentive Policy [Text Block]</label>
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandTwelveLoanAgreementPolicyTextBlock" xlink:type="locator" xlink:label="asns_TwoThousandTwelveLoanAgreementPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandTwelveLoanAgreementPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2012 loan agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_TwoThousandTwelveLoanAgreementPolicyTextBlock" xlink:to="asns_TwoThousandTwelveLoanAgreementPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandTwelveLoanAgreementPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2012 Loan Agreement</label>
    <label xml:lang="en-US" xlink:label="asns_TwoThousandTwelveLoanAgreementPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twelve Loan Agreement Policy [Text Block]</label>
    <loc xlink:href="asns-20180630.xsd#asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock" xlink:type="locator" xlink:label="asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock" />
    <label xml:lang="en-US" xlink:label="asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of reconciliation of cash and cash equivalents and restricted cash to cash flows.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock" xlink:to="asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</label>
    <label xml:lang="en-US" xlink:label="asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Reconciliation Of Cash And Cash Equivalents And Restricted Cash To Cash Flows [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assets Measured at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Aggregate Principal Amount of Debt Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Debt Instruments [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Current and Non-current Debt obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Debt Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense Classification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments Due under Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</label>
    <loc xlink:href="asns-20180630.xsd#asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <label xml:lang="en-US" xlink:label="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <label xml:lang="en-US" xlink:label="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" />
    <label xml:lang="en-US" xlink:label="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</label>
    <label xml:lang="en-US" xlink:label="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <label xml:lang="en-US" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Equity Method Investment Equity Method Investee Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <label xml:lang="en-US" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investee Name [Domain]</label>
    <loc xlink:href="asns-20180630.xsd#asns_NewEnterpriseAssociates16LPMember" xlink:type="locator" xlink:label="asns_NewEnterpriseAssociates16LPMember" />
    <label xml:lang="en-US" xlink:label="asns_NewEnterpriseAssociates16LPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">New Enterprise Associates 16, L.P.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_NewEnterpriseAssociates16LPMember" xlink:to="asns_NewEnterpriseAssociates16LPMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_NewEnterpriseAssociates16LPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Enterprise Associates 16, L.P.</label>
    <label xml:lang="en-US" xlink:label="asns_NewEnterpriseAssociates16LPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Enterprise Associates16 L P [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments for New Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Adoption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_AccountingStandardsUpdate201415Member" xlink:type="locator" xlink:label="asns_AccountingStandardsUpdate201415Member" />
    <label xml:lang="en-US" xlink:label="asns_AccountingStandardsUpdate201415Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting Standards Update 2014-15.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_AccountingStandardsUpdate201415Member" xlink:to="asns_AccountingStandardsUpdate201415Member_lbl" />
    <label xml:lang="en-US" xlink:label="asns_AccountingStandardsUpdate201415Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2014-15</label>
    <label xml:lang="en-US" xlink:label="asns_AccountingStandardsUpdate201415Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201415 [Member]</label>
    <label xml:lang="en-US" xlink:label="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Line Items]</label>
    <label xml:lang="en-US" xlink:label="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, conversion ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from offerings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</label>
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash used in operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations</label>
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash &#8211; current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash &#8211; non-current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Balance Sheet Grouping [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Financial Assets Balance Sheet Groupings [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</label>
    <loc xlink:href="asns-20180630.xsd#asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount" xlink:type="locator" xlink:label="asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount" />
    <label xml:lang="en-US" xlink:label="asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value transfers between Level 1, Level 2 and Level 3 amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount" xlink:to="asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount_lbl" />
    <label xml:lang="en-US" xlink:label="asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers between fair value levels</label>
    <label xml:lang="en-US" xlink:label="asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Transfers Between Level1 Level2 Or Level3 Amount</label>
    <loc xlink:href="asns-20180630.xsd#asns_AccruedClinicalTrialCosts" xlink:type="locator" xlink:label="asns_AccruedClinicalTrialCosts" />
    <label xml:lang="en-US" xlink:label="asns_AccruedClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trial costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_AccruedClinicalTrialCosts" xlink:to="asns_AccruedClinicalTrialCosts_lbl" />
    <label xml:lang="en-US" xlink:label="asns_AccruedClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial costs</label>
    <label xml:lang="en-US" xlink:label="asns_AccruedClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial Costs</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</label>
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</label>
    <loc xlink:href="asns-20180630.xsd#asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:type="locator" xlink:label="asns_CollaborationLicenseAndFundingArrangementsLineItems" />
    <label xml:lang="en-US" xlink:label="asns_CollaborationLicenseAndFundingArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration, license and funding arrangements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_CollaborationLicenseAndFundingArrangementsLineItems_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_CollaborationLicenseAndFundingArrangementsTable" xlink:type="locator" xlink:label="asns_CollaborationLicenseAndFundingArrangementsTable" />
    <label xml:lang="en-US" xlink:label="asns_CollaborationLicenseAndFundingArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration, license and funding arrangements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="asns_CollaborationLicenseAndFundingArrangementsTable_lbl" />
    <label xml:lang="en-US" xlink:label="asns_CollaborationLicenseAndFundingArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration License And Funding Arrangements [Table]</label>
    <label xml:lang="en-US" xlink:label="asns_CollaborationLicenseAndFundingArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration License And Funding Arrangements [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</label>
    <loc xlink:href="asns-20180630.xsd#asns_AdimabLLCMember" xlink:type="locator" xlink:label="asns_AdimabLLCMember" />
    <label xml:lang="en-US" xlink:label="asns_AdimabLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adimab, LLC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_AdimabLLCMember" xlink:to="asns_AdimabLLCMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_AdimabLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adimab, LLC</label>
    <label xml:lang="en-US" xlink:label="asns_AdimabLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adimab L L C [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Arrangement and Non-arrangement Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrangements and Non-arrangement Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_AdimabOptionAgreementMember" xlink:type="locator" xlink:label="asns_AdimabOptionAgreementMember" />
    <label xml:lang="en-US" xlink:label="asns_AdimabOptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adimab option agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_AdimabOptionAgreementMember" xlink:to="asns_AdimabOptionAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_AdimabOptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adimab Option Agreement</label>
    <label xml:lang="en-US" xlink:label="asns_AdimabOptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adimab Option Agreement [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</label>
    <loc xlink:href="asns-20180630.xsd#asns_BillAndMelindaGatesFoundationMember" xlink:type="locator" xlink:label="asns_BillAndMelindaGatesFoundationMember" />
    <label xml:lang="en-US" xlink:label="asns_BillAndMelindaGatesFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bill &amp; Melinda Gates Foundation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_BillAndMelindaGatesFoundationMember" xlink:to="asns_BillAndMelindaGatesFoundationMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_BillAndMelindaGatesFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gates Foundation</label>
    <label xml:lang="en-US" xlink:label="asns_BillAndMelindaGatesFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bill And Melinda Gates Foundation [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember" xlink:type="locator" xlink:label="asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember" />
    <label xml:lang="en-US" xlink:label="asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">February two thousand and seventeen grant agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember" xlink:to="asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">February 2017 Grant Agreement</label>
    <label xml:lang="en-US" xlink:label="asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">February Two Thousand And Seventeen Grant Agreement [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_AugustTwoThousandAndEighteenGrantAgreementMember" xlink:type="locator" xlink:label="asns_AugustTwoThousandAndEighteenGrantAgreementMember" />
    <label xml:lang="en-US" xlink:label="asns_AugustTwoThousandAndEighteenGrantAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">August two thousand and eighteen grant agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_AugustTwoThousandAndEighteenGrantAgreementMember" xlink:to="asns_AugustTwoThousandAndEighteenGrantAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_AugustTwoThousandAndEighteenGrantAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August 2018 Grant Agreement</label>
    <label xml:lang="en-US" xlink:label="asns_AugustTwoThousandAndEighteenGrantAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">August Two Thousand And Eighteen Grant Agreement [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_GrantAgreementMember" xlink:type="locator" xlink:label="asns_GrantAgreementMember" />
    <label xml:lang="en-US" xlink:label="asns_GrantAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_GrantAgreementMember" xlink:to="asns_GrantAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_GrantAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Agreement</label>
    <label xml:lang="en-US" xlink:label="asns_GrantAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</label>
    <loc xlink:href="asns-20180630.xsd#asns_SeriesDRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="asns_SeriesDRedeemableConvertiblePreferredStockMember" />
    <label xml:lang="en-US" xlink:label="asns_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D redeemable convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_SeriesDRedeemableConvertiblePreferredStockMember" xlink:to="asns_SeriesDRedeemableConvertiblePreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Redeemable Convertible Preferred Stock</label>
    <label xml:lang="en-US" xlink:label="asns_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series D Redeemable Convertible Preferred Stock [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_FundingArrangementsWithFFGMember" xlink:type="locator" xlink:label="asns_FundingArrangementsWithFFGMember" />
    <label xml:lang="en-US" xlink:label="asns_FundingArrangementsWithFFGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding arrangements with FFG.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_FundingArrangementsWithFFGMember" xlink:to="asns_FundingArrangementsWithFFGMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_FundingArrangementsWithFFGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding Agreements with FFG</label>
    <label xml:lang="en-US" xlink:label="asns_FundingArrangementsWithFFGMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Funding Arrangements With F F G [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_FFGGrantsMember" xlink:type="locator" xlink:label="asns_FFGGrantsMember" />
    <label xml:lang="en-US" xlink:label="asns_FFGGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">FFG grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_FFGGrantsMember" xlink:to="asns_FFGGrantsMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_FFGGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FFG Grants</label>
    <label xml:lang="en-US" xlink:label="asns_FFGGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">F F G Grants [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_FFGLoansMember" xlink:type="locator" xlink:label="asns_FFGLoansMember" />
    <label xml:lang="en-US" xlink:label="asns_FFGLoansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">FFG loans.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_FFGLoansMember" xlink:to="asns_FFGLoansMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_FFGLoansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FFG Loans</label>
    <label xml:lang="en-US" xlink:label="asns_FFGLoansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">F F G Loans [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</label>
    <loc xlink:href="asns-20180630.xsd#asns_AustriaMember" xlink:type="locator" xlink:label="asns_AustriaMember" />
    <label xml:lang="en-US" xlink:label="asns_AustriaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Austria.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_AustriaMember" xlink:to="asns_AustriaMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_AustriaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Austria</label>
    <label xml:lang="en-US" xlink:label="asns_AustriaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Austria [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario, Unspecified</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:type="locator" xlink:label="us-gaap_ScenarioForecastMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Forecast [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_ResearchAndDevelopmentIncentiveProgramMember" xlink:type="locator" xlink:label="asns_ResearchAndDevelopmentIncentiveProgramMember" />
    <label xml:lang="en-US" xlink:label="asns_ResearchAndDevelopmentIncentiveProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development incentive program.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ResearchAndDevelopmentIncentiveProgramMember" xlink:to="asns_ResearchAndDevelopmentIncentiveProgramMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_ResearchAndDevelopmentIncentiveProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Incentive</label>
    <label xml:lang="en-US" xlink:label="asns_ResearchAndDevelopmentIncentiveProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Incentive Program [Member]</label>
    <label xml:lang="en-US" xlink:label="asns_CollaborationLicenseAndFundingArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration License And Funding Arrangements [Line Items]</label>
    <label xml:lang="en-US" xlink:label="asns_CollaborationLicenseAndFundingArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration License And Funding Arrangements [Line Items]</label>
    <loc xlink:href="asns-20180630.xsd#asns_CollaborationPaymentObligations" xlink:type="locator" xlink:label="asns_CollaborationPaymentObligations" />
    <label xml:lang="en-US" xlink:label="asns_CollaborationPaymentObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration payment obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_CollaborationPaymentObligations" xlink:to="asns_CollaborationPaymentObligations_lbl" />
    <label xml:lang="en-US" xlink:label="asns_CollaborationPaymentObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration payment obligations</label>
    <label xml:lang="en-US" xlink:label="asns_CollaborationPaymentObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Payment Obligations</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</label>
    <loc xlink:href="asns-20180630.xsd#asns_GrantsAgreementMaximumAwardAmount" xlink:type="locator" xlink:label="asns_GrantsAgreementMaximumAwardAmount" />
    <label xml:lang="en-US" xlink:label="asns_GrantsAgreementMaximumAwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grants agreement maximum award amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_GrantsAgreementMaximumAwardAmount" xlink:to="asns_GrantsAgreementMaximumAwardAmount_lbl" />
    <label xml:lang="en-US" xlink:label="asns_GrantsAgreementMaximumAwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant receivable</label>
    <label xml:lang="en-US" xlink:label="asns_GrantsAgreementMaximumAwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grants Agreement Maximum Award Amount</label>
    <loc xlink:href="asns-20180630.xsd#asns_RelatedPartyTransactionProceedsFromGrants" xlink:type="locator" xlink:label="asns_RelatedPartyTransactionProceedsFromGrants" />
    <label xml:lang="en-US" xlink:label="asns_RelatedPartyTransactionProceedsFromGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction proceeds from grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_RelatedPartyTransactionProceedsFromGrants" xlink:to="asns_RelatedPartyTransactionProceedsFromGrants_lbl" />
    <label xml:lang="en-US" xlink:label="asns_RelatedPartyTransactionProceedsFromGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from related party</label>
    <label xml:lang="en-US" xlink:label="asns_RelatedPartyTransactionProceedsFromGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Proceeds From Grants</label>
    <label xml:lang="en-US" xlink:label="asns_GrantAndIncentiveIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Grant income</label>
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncome" xlink:type="locator" xlink:label="asns_UnearnedIncome" />
    <label xml:lang="en-US" xlink:label="asns_UnearnedIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unearned income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_UnearnedIncome" xlink:to="asns_UnearnedIncome_lbl" />
    <label xml:lang="en-US" xlink:label="asns_UnearnedIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unearned income</label>
    <label xml:lang="en-US" xlink:label="asns_UnearnedIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unearned Income</label>
    <loc xlink:href="asns-20180630.xsd#asns_GrantAgreementExpirationDate" xlink:type="locator" xlink:label="asns_GrantAgreementExpirationDate" />
    <label xml:lang="en-US" xlink:label="asns_GrantAgreementExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreement expiration date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_GrantAgreementExpirationDate" xlink:to="asns_GrantAgreementExpirationDate_lbl" />
    <label xml:lang="en-US" xlink:label="asns_GrantAgreementExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant agreement expiration date</label>
    <label xml:lang="en-US" xlink:label="asns_GrantAgreementExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement Expiration Date</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</label>
    <loc xlink:href="asns-20180630.xsd#asns_QualifyingExpensesUnderLetterAgreement" xlink:type="locator" xlink:label="asns_QualifyingExpensesUnderLetterAgreement" />
    <label xml:lang="en-US" xlink:label="asns_QualifyingExpensesUnderLetterAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Qualifying expenses under the letter agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_QualifyingExpensesUnderLetterAgreement" xlink:to="asns_QualifyingExpensesUnderLetterAgreement_lbl" />
    <label xml:lang="en-US" xlink:label="asns_QualifyingExpensesUnderLetterAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Qualifying expenses related to letter agreement</label>
    <label xml:lang="en-US" xlink:label="asns_QualifyingExpensesUnderLetterAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Qualifying Expenses Under Letter Agreement</label>
    <loc xlink:href="asns-20180630.xsd#asns_PercentageOfLoansAndGrantsToFund" xlink:type="locator" xlink:label="asns_PercentageOfLoansAndGrantsToFund" />
    <label xml:lang="en-US" xlink:label="asns_PercentageOfLoansAndGrantsToFund_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of loans and grants to fund.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_PercentageOfLoansAndGrantsToFund" xlink:to="asns_PercentageOfLoansAndGrantsToFund_lbl" />
    <label xml:lang="en-US" xlink:label="asns_PercentageOfLoansAndGrantsToFund_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of loans and grants to fund</label>
    <label xml:lang="en-US" xlink:label="asns_PercentageOfLoansAndGrantsToFund_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Loans And Grants To Fund</label>
    <label xml:lang="en-US" xlink:label="asns_GrantAndIncentiveReceivables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Grant receivable</label>
    <loc xlink:href="asns-20180630.xsd#asns_ReimbursementRateForResearchAndDevelopment" xlink:type="locator" xlink:label="asns_ReimbursementRateForResearchAndDevelopment" />
    <label xml:lang="en-US" xlink:label="asns_ReimbursementRateForResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement rate for research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ReimbursementRateForResearchAndDevelopment" xlink:to="asns_ReimbursementRateForResearchAndDevelopment_lbl" />
    <label xml:lang="en-US" xlink:label="asns_ReimbursementRateForResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant income</label>
    <label xml:lang="en-US" xlink:label="asns_ReimbursementRateForResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Rate For Research And Development</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</label>
    <loc xlink:href="asns-20180630.xsd#asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" xlink:type="locator" xlink:label="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" />
    <label xml:lang="en-US" xlink:label="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans under two thousand twelve loan agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" xlink:to="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loans under 2012 Loan Agreement</label>
    <label xml:lang="en-US" xlink:label="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans Under Two Thousand Twelve Loan Agreement [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount of debt outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loans payable, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Notes Payable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayable" xlink:type="locator" xlink:label="us-gaap_LoansPayable" />
    <label xml:lang="en-US" xlink:label="us-gaap_LoansPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total loans payable, net of discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LoansPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable</label>
    <loc xlink:href="asns-20180630.xsd#asns_ClassOfWarrantOrRightsExpirationDate" xlink:type="locator" xlink:label="asns_ClassOfWarrantOrRightsExpirationDate" />
    <label xml:lang="en-US" xlink:label="asns_ClassOfWarrantOrRightsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or rights expiration date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ClassOfWarrantOrRightsExpirationDate" xlink:to="asns_ClassOfWarrantOrRightsExpirationDate_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandTwelveTermLoanAAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandTwelveTermLoanAAdvanceMember" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandTwelveTermLoanAAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twelve term loan A advance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_TwoThousandTwelveTermLoanAAdvanceMember" xlink:to="asns_TwoThousandTwelveTermLoanAAdvanceMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandTwelveTermLoanAAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2012 Term Loan A Advance</label>
    <label xml:lang="en-US" xlink:label="asns_TwoThousandTwelveTermLoanAAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twelve Term Loan A Advance [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandTwelveLoanAgreementMember" xlink:type="locator" xlink:label="asns_TwoThousandTwelveLoanAgreementMember" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandTwelveLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twelve loan agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_TwoThousandTwelveLoanAgreementMember" xlink:to="asns_TwoThousandTwelveLoanAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandTwelveLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2012 Loan Agreement</label>
    <label xml:lang="en-US" xlink:label="asns_TwoThousandTwelveLoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twelve Loan Agreement [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandTwelveTermLoanBAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandTwelveTermLoanBAdvanceMember" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandTwelveTermLoanBAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twelve term loan B advance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_TwoThousandTwelveTermLoanBAdvanceMember" xlink:to="asns_TwoThousandTwelveTermLoanBAdvanceMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandTwelveTermLoanBAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2012 Term Loan B Advance</label>
    <label xml:lang="en-US" xlink:label="asns_TwoThousandTwelveTermLoanBAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twelve Term Loan B Advance [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_SeriesATwoPreferredStockWarrantsMember" xlink:type="locator" xlink:label="asns_SeriesATwoPreferredStockWarrantsMember" />
    <label xml:lang="en-US" xlink:label="asns_SeriesATwoPreferredStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A two preferred stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_SeriesATwoPreferredStockWarrantsMember" xlink:to="asns_SeriesATwoPreferredStockWarrantsMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_SeriesATwoPreferredStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2 Warrants</label>
    <label xml:lang="en-US" xlink:label="asns_SeriesATwoPreferredStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Two Preferred Stock Warrants [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandSixteenTermLoanAAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandSixteenTermLoanAAdvanceMember" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandSixteenTermLoanAAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen term loan A advance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_TwoThousandSixteenTermLoanAAdvanceMember" xlink:to="asns_TwoThousandSixteenTermLoanAAdvanceMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandSixteenTermLoanAAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Term Loan A Advance</label>
    <label xml:lang="en-US" xlink:label="asns_TwoThousandSixteenTermLoanAAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Term Loan A Advance [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandSixteenTermLoanBAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandSixteenTermLoanBAdvanceMember" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandSixteenTermLoanBAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen term loan B advance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_TwoThousandSixteenTermLoanBAdvanceMember" xlink:to="asns_TwoThousandSixteenTermLoanBAdvanceMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandSixteenTermLoanBAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Term Loan B Advance</label>
    <label xml:lang="en-US" xlink:label="asns_TwoThousandSixteenTermLoanBAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Term Loan B Advance [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_SeriesBWarrantsMember" xlink:type="locator" xlink:label="asns_SeriesBWarrantsMember" />
    <label xml:lang="en-US" xlink:label="asns_SeriesBWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_SeriesBWarrantsMember" xlink:to="asns_SeriesBWarrantsMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_SeriesBWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</label>
    <label xml:lang="en-US" xlink:label="asns_SeriesBWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Warrants [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</label>
    <loc xlink:href="asns-20180630.xsd#asns_ExercisePriceOneMember" xlink:type="locator" xlink:label="asns_ExercisePriceOneMember" />
    <label xml:lang="en-US" xlink:label="asns_ExercisePriceOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price one.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ExercisePriceOneMember" xlink:to="asns_ExercisePriceOneMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_ExercisePriceOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price One</label>
    <label xml:lang="en-US" xlink:label="asns_ExercisePriceOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price One [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_ExercisePriceTwoMember" xlink:type="locator" xlink:label="asns_ExercisePriceTwoMember" />
    <label xml:lang="en-US" xlink:label="asns_ExercisePriceTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ExercisePriceTwoMember" xlink:to="asns_ExercisePriceTwoMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_ExercisePriceTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Two</label>
    <label xml:lang="en-US" xlink:label="asns_ExercisePriceTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Two [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandSixteenTermLoanAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandSixteenTermLoanAdvanceMember" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandSixteenTermLoanAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen term loan advance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_TwoThousandSixteenTermLoanAdvanceMember" xlink:to="asns_TwoThousandSixteenTermLoanAdvanceMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandSixteenTermLoanAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Term Loan Advance</label>
    <label xml:lang="en-US" xlink:label="asns_TwoThousandSixteenTermLoanAdvanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Term Loan Advance [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_FirstAmendmentMember" xlink:type="locator" xlink:label="asns_FirstAmendmentMember" />
    <label xml:lang="en-US" xlink:label="asns_FirstAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">First amendment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_FirstAmendmentMember" xlink:to="asns_FirstAmendmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_FirstAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Amendment</label>
    <label xml:lang="en-US" xlink:label="asns_FirstAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">First Amendment [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Lines Of Credit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to purchase stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</label>
    <label xml:lang="en-US" xlink:label="asns_ClassOfWarrantOrRightsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</label>
    <label xml:lang="en-US" xlink:label="asns_ClassOfWarrantOrRightsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Rights Expiration Date</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum borrowing capacity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Maximum Borrowing Capacity</label>
    <loc xlink:href="asns-20180630.xsd#asns_NumberOfTranches" xlink:type="locator" xlink:label="asns_NumberOfTranches" />
    <label xml:lang="en-US" xlink:label="asns_NumberOfTranches_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of tranches.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_NumberOfTranches" xlink:to="asns_NumberOfTranches_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <label xml:lang="en-US" xlink:label="us-gaap_LineOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LineOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit</label>
    <label xml:lang="en-US" xlink:label="asns_NumberOfTranches_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranches</label>
    <label xml:lang="en-US" xlink:label="asns_NumberOfTranches_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Tranches</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional amounts available to be borrowed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Remaining Borrowing Capacity</label>
    <loc xlink:href="asns-20180630.xsd#asns_PercentageMinusWallStreetJournalPrimeRate" xlink:type="locator" xlink:label="asns_PercentageMinusWallStreetJournalPrimeRate" />
    <label xml:lang="en-US" xlink:label="asns_PercentageMinusWallStreetJournalPrimeRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage minus Wall Street Journal prime rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_PercentageMinusWallStreetJournalPrimeRate" xlink:to="asns_PercentageMinusWallStreetJournalPrimeRate_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate of loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate During Period</label>
    <label xml:lang="en-US" xlink:label="asns_PercentageMinusWallStreetJournalPrimeRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage minus Wall Street Journal prime rate</label>
    <label xml:lang="en-US" xlink:label="asns_PercentageMinusWallStreetJournalPrimeRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Minus Wall Street Journal Prime Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate increase percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Increase Decrease</label>
    <loc xlink:href="asns-20180630.xsd#asns_PrepaymentFeePercentageToOutstandingPrincipalAmount" xlink:type="locator" xlink:label="asns_PrepaymentFeePercentageToOutstandingPrincipalAmount" />
    <label xml:lang="en-US" xlink:label="asns_PrepaymentFeePercentageToOutstandingPrincipalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment fee percentage to outstanding principal amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_PrepaymentFeePercentageToOutstandingPrincipalAmount" xlink:to="asns_PrepaymentFeePercentageToOutstandingPrincipalAmount_lbl" />
    <label xml:lang="en-US" xlink:label="asns_PrepaymentFeePercentageToOutstandingPrincipalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment fee percentage to outstanding principal amount</label>
    <label xml:lang="en-US" xlink:label="asns_PrepaymentFeePercentageToOutstandingPrincipalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment Fee Percentage To Outstanding Principal Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrangement fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Fee Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Finance Costs Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Debt</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate principal payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Periodic Payment Principal</label>
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate principal loan amount outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan amount maturity start date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date Range Start1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan amount maturity end date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeEnd1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date Range End1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:type="locator" xlink:label="us-gaap_DirectorMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Board of Directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</label>
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="asns_TwoThousandSeventeenEquityIncentivePlanMember" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2017 equity incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="asns_TwoThousandSeventeenEquityIncentivePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Equity Incentive Plan</label>
    <label xml:lang="en-US" xlink:label="asns_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Equity Incentive Plan [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandAndTenSpecialStockIncentivePlanMember" xlink:type="locator" xlink:label="asns_TwoThousandAndTenSpecialStockIncentivePlanMember" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandAndTenSpecialStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2010 special stock incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_TwoThousandAndTenSpecialStockIncentivePlanMember" xlink:to="asns_TwoThousandAndTenSpecialStockIncentivePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandAndTenSpecialStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2010 Special Stock Incentive Plan</label>
    <label xml:lang="en-US" xlink:label="asns_TwoThousandAndTenSpecialStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Ten Special Stock Incentive Plan [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandAndElevenStockIncentivePlanMember" xlink:type="locator" xlink:label="asns_TwoThousandAndElevenStockIncentivePlanMember" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandAndElevenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2011 stock incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_TwoThousandAndElevenStockIncentivePlanMember" xlink:to="asns_TwoThousandAndElevenStockIncentivePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_TwoThousandAndElevenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2011 Stock Incentive Plan</label>
    <label xml:lang="en-US" xlink:label="asns_TwoThousandAndElevenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eleven Stock Incentive Plan [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation arrangement, number of options granted to purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation arrangement, number of additional shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of number of common stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to the unvested stock-based awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period over which unrecognized compensation cost related to unvested awards is expected to be recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Outstanding, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares Granted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Outstanding, Ending Balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Share Options exercisable as of June 30, 2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Share Options unvested as of June 30, 2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Outstanding, Weighted Average Exercise Price, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Granted, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Exercised, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Forfeited, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Outstanding, Weighted Average Exercise Price, Ending Balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Share Options exercisable, Weighted Average Exercise Price as of June 30, 2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number Share Options unvested, Weighted Average Exercise Price as of June 30, 2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value</label>
    <loc xlink:href="asns-20180630.xsd#asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm" />
    <label xml:lang="en-US" xlink:label="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, nonvested, outstanding, weighted average remaining contractual term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm" xlink:to="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Outstanding, Weighted Average Remaining Contractual Term at End of Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Share Options exercisable, Weighted Average Remaining Contractual Term as of June 30, 2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</label>
    <label xml:lang="en-US" xlink:label="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Share Options unvested, Weighted Average Remaining Contractual Term as of June 30, 2018</label>
    <label xml:lang="en-US" xlink:label="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Outstanding Weighted Average Remaining Contractual Term</label>
    <loc xlink:href="asns-20180630.xsd#asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue" xlink:type="locator" xlink:label="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, nonvested, intrinsic value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue" xlink:to="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Share Options Outstanding, Aggregate Intrinsic Value Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Share Options exercisable, Aggregate Intrinsic Value as of June 30, 2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</label>
    <label xml:lang="en-US" xlink:label="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Share Options unvested, Aggregate Intrinsic Value as of June 30, 2018</label>
    <label xml:lang="en-US" xlink:label="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant-date fair value per share of stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock (as Converted to Common Stock)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember" />
    <label xml:lang="en-US" xlink:label="asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants to purchase redeemable convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember" xlink:to="asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Redeemable Convertible Preferred Stock (as Converted to Common Stock)</label>
    <label xml:lang="en-US" xlink:label="asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Redeemable Convertible Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from computation of diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <loc xlink:href="asns-20180630.xsd#asns_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="asns_CommitmentsAndContingenciesLineItems" />
    <label xml:lang="en-US" xlink:label="asns_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_CommitmentsAndContingenciesLineItems_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="asns_CommitmentsAndContingenciesTable" />
    <label xml:lang="en-US" xlink:label="asns_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_CommitmentsAndContingenciesTable" xlink:to="asns_CommitmentsAndContingenciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="asns_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</label>
    <label xml:lang="en-US" xlink:label="asns_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Domain]</label>
    <loc xlink:href="asns-20180630.xsd#asns_ManufacturingCommitmentsMember" xlink:type="locator" xlink:label="asns_ManufacturingCommitmentsMember" />
    <label xml:lang="en-US" xlink:label="asns_ManufacturingCommitmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing Commitments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ManufacturingCommitmentsMember" xlink:to="asns_ManufacturingCommitmentsMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_ManufacturingCommitmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing Commitments</label>
    <label xml:lang="en-US" xlink:label="asns_ManufacturingCommitmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Commitments [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Arrangement, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Arrangement, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Type [Domain]</label>
    <loc xlink:href="asns-20180630.xsd#asns_ViennaLeaseAgreementMember" xlink:type="locator" xlink:label="asns_ViennaLeaseAgreementMember" />
    <label xml:lang="en-US" xlink:label="asns_ViennaLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vienna lease agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ViennaLeaseAgreementMember" xlink:to="asns_ViennaLeaseAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_ViennaLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vienna Lease</label>
    <label xml:lang="en-US" xlink:label="asns_ViennaLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vienna Lease Agreement [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_AnimalUseLeaseAgreementMember" xlink:type="locator" xlink:label="asns_AnimalUseLeaseAgreementMember" />
    <label xml:lang="en-US" xlink:label="asns_AnimalUseLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Animal-use lease agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_AnimalUseLeaseAgreementMember" xlink:to="asns_AnimalUseLeaseAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_AnimalUseLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Animal-use Lease</label>
    <label xml:lang="en-US" xlink:label="asns_AnimalUseLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Animal Use Lease Agreement [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_WalthamLeaseAgreementMember" xlink:type="locator" xlink:label="asns_WalthamLeaseAgreementMember" />
    <label xml:lang="en-US" xlink:label="asns_WalthamLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Waltham lease agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_WalthamLeaseAgreementMember" xlink:to="asns_WalthamLeaseAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_WalthamLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Waltham Lease</label>
    <label xml:lang="en-US" xlink:label="asns_WalthamLeaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Waltham Lease Agreement [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_LeaseAgreementForOfficeSpaceInWalthamMAMember" xlink:type="locator" xlink:label="asns_LeaseAgreementForOfficeSpaceInWalthamMAMember" />
    <label xml:lang="en-US" xlink:label="asns_LeaseAgreementForOfficeSpaceInWalthamMAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement for office space in Waltham, MA.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_LeaseAgreementForOfficeSpaceInWalthamMAMember" xlink:to="asns_LeaseAgreementForOfficeSpaceInWalthamMAMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_LeaseAgreementForOfficeSpaceInWalthamMAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Agreement for Office Space in Waltham MA</label>
    <label xml:lang="en-US" xlink:label="asns_LeaseAgreementForOfficeSpaceInWalthamMAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement For Office Space In Waltham M A [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</label>
    <loc xlink:href="asns-20180630.xsd#asns_PrepaidClinicalManufacturingExpensesMember" xlink:type="locator" xlink:label="asns_PrepaidClinicalManufacturingExpensesMember" />
    <label xml:lang="en-US" xlink:label="asns_PrepaidClinicalManufacturingExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid clinical manufacturing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_PrepaidClinicalManufacturingExpensesMember" xlink:to="asns_PrepaidClinicalManufacturingExpensesMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_PrepaidClinicalManufacturingExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Clinical Manufacturing Expenses</label>
    <label xml:lang="en-US" xlink:label="asns_PrepaidClinicalManufacturingExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Clinical Manufacturing Expenses [Member]</label>
    <label xml:lang="en-US" xlink:label="asns_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="asns_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend the lease agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</label>
    <loc xlink:href="asns-20180630.xsd#asns_LesseeOperatingLeaseExpirationDescription" xlink:type="locator" xlink:label="asns_LesseeOperatingLeaseExpirationDescription" />
    <label xml:lang="en-US" xlink:label="asns_LesseeOperatingLeaseExpirationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of lessee&apos;s operating lease expiration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_LesseeOperatingLeaseExpirationDescription" xlink:to="asns_LesseeOperatingLeaseExpirationDescription_lbl" />
    <label xml:lang="en-US" xlink:label="asns_LesseeOperatingLeaseExpirationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of term of lease</label>
    <label xml:lang="en-US" xlink:label="asns_LesseeOperatingLeaseExpirationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Expiration Description</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Minimum Rentals</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease And Rental Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Remainder Of Fiscal Year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Five Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Thereafter</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Future minimum lease payments due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</label>
    <loc xlink:href="asns-20180630.xsd#asns_CurrentOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_CurrentOfficeSpaceUnderLeaseAgreement" />
    <label xml:lang="en-US" xlink:label="asns_CurrentOfficeSpaceUnderLeaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Current office space under lease agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_CurrentOfficeSpaceUnderLeaseAgreement" xlink:to="asns_CurrentOfficeSpaceUnderLeaseAgreement_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_AggregateBaseRentObligation" xlink:type="locator" xlink:label="asns_AggregateBaseRentObligation" />
    <label xml:lang="en-US" xlink:label="asns_AggregateBaseRentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate base rent obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_AggregateBaseRentObligation" xlink:to="asns_AggregateBaseRentObligation_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_CashObligation" xlink:type="locator" xlink:label="asns_CashObligation" />
    <label xml:lang="en-US" xlink:label="asns_CashObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_CashObligation" xlink:to="asns_CashObligation_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_RelocationPaymentToLessor" xlink:type="locator" xlink:label="asns_RelocationPaymentToLessor" />
    <label xml:lang="en-US" xlink:label="asns_RelocationPaymentToLessor_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Relocation payment to lessor.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_RelocationPaymentToLessor" xlink:to="asns_RelocationPaymentToLessor_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_OriginalOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_OriginalOfficeSpaceUnderLeaseAgreement" />
    <label xml:lang="en-US" xlink:label="asns_OriginalOfficeSpaceUnderLeaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Original office space under lease agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_OriginalOfficeSpaceUnderLeaseAgreement" xlink:to="asns_OriginalOfficeSpaceUnderLeaseAgreement_lbl" />
    <label xml:lang="en-US" xlink:label="asns_CurrentOfficeSpaceUnderLeaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current office space under lease agreement</label>
    <label xml:lang="en-US" xlink:label="asns_CurrentOfficeSpaceUnderLeaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Office Space Under Lease Agreement</label>
    <label xml:lang="en-US" xlink:label="asns_OriginalOfficeSpaceUnderLeaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Original office space under lease agreement</label>
    <label xml:lang="en-US" xlink:label="asns_OriginalOfficeSpaceUnderLeaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Original Office Space Under Lease Agreement</label>
    <label xml:lang="en-US" xlink:label="asns_AggregateBaseRentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent obligation</label>
    <label xml:lang="en-US" xlink:label="asns_AggregateBaseRentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Base Rent Obligation</label>
    <label xml:lang="en-US" xlink:label="asns_CashObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Cash obligation</label>
    <label xml:lang="en-US" xlink:label="asns_CashObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Obligation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</label>
    <label xml:lang="en-US" xlink:label="asns_RelocationPaymentToLessor_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relocation payment to lessor</label>
    <label xml:lang="en-US" xlink:label="asns_RelocationPaymentToLessor_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Relocation Payment To Lessor</label>
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments due</label>
    <loc xlink:href="asns-20180630.xsd#asns_MilestonePayments" xlink:type="locator" xlink:label="asns_MilestonePayments" />
    <label xml:lang="en-US" xlink:label="asns_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_MilestonePayments" xlink:to="asns_MilestonePayments_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_OptionFee" xlink:type="locator" xlink:label="asns_OptionFee" />
    <label xml:lang="en-US" xlink:label="asns_OptionFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_OptionFee" xlink:to="asns_OptionFee_lbl" />
    <label xml:lang="en-US" xlink:label="asns_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</label>
    <label xml:lang="en-US" xlink:label="asns_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</label>
    <label xml:lang="en-US" xlink:label="asns_OptionFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option fee</label>
    <label xml:lang="en-US" xlink:label="asns_OptionFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Fee</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" />
    <label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum payments under agreement with a contract manufacturing organization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</label>
    <loc xlink:href="asns-20180630.xsd#asns_PaymentsToRelatedPartyForPriorPeriodExpense" xlink:type="locator" xlink:label="asns_PaymentsToRelatedPartyForPriorPeriodExpense" />
    <label xml:lang="en-US" xlink:label="asns_PaymentsToRelatedPartyForPriorPeriodExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to related party for prior period expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_PaymentsToRelatedPartyForPriorPeriodExpense" xlink:to="asns_PaymentsToRelatedPartyForPriorPeriodExpense_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</label>
    <loc xlink:href="asns-20180630.xsd#asns_EveliQureBiotechnologiesGmbHMember" xlink:type="locator" xlink:label="asns_EveliQureBiotechnologiesGmbHMember" />
    <label xml:lang="en-US" xlink:label="asns_EveliQureBiotechnologiesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">EveliQure Biotechnologies GmbH.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_EveliQureBiotechnologiesGmbHMember" xlink:to="asns_EveliQureBiotechnologiesGmbHMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_EveliQureBiotechnologiesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">EveliQure Biotechnologies GmbH</label>
    <label xml:lang="en-US" xlink:label="asns_EveliQureBiotechnologiesGmbHMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Eveli Qure Biotechnologies Gmb H [Member]</label>
    <loc xlink:href="asns-20180630.xsd#asns_ServicesAndFacilitiesAgreementMember" xlink:type="locator" xlink:label="asns_ServicesAndFacilitiesAgreementMember" />
    <label xml:lang="en-US" xlink:label="asns_ServicesAndFacilitiesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Services and facilities agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ServicesAndFacilitiesAgreementMember" xlink:to="asns_ServicesAndFacilitiesAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_ServicesAndFacilitiesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services and Facilities Agreement</label>
    <label xml:lang="en-US" xlink:label="asns_ServicesAndFacilitiesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Services And Facilities Agreement [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</label>
    <label xml:lang="en-US" xlink:label="asns_PaymentsToRelatedPartyForPriorPeriodExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to related party</label>
    <label xml:lang="en-US" xlink:label="asns_PaymentsToRelatedPartyForPriorPeriodExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Related Party For Prior Period Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Owed to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current And Noncurrent</label>
    <loc xlink:href="asns-20180630.xsd#asns_CashReceivedFromRelatedPartyTransaction" xlink:type="locator" xlink:label="asns_CashReceivedFromRelatedPartyTransaction" />
    <label xml:lang="en-US" xlink:label="asns_CashReceivedFromRelatedPartyTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash received from related party transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_CashReceivedFromRelatedPartyTransaction" xlink:to="asns_CashReceivedFromRelatedPartyTransaction_lbl" />
    <label xml:lang="en-US" xlink:label="asns_CashReceivedFromRelatedPartyTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments received from related party</label>
    <label xml:lang="en-US" xlink:label="asns_CashReceivedFromRelatedPartyTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Received From Related Party Transaction</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income from related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Other Revenues From Transactions With Related Party</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" />
    <label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due from related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</label>
    <loc xlink:href="asns-20180630.xsd#asns_AugustTwoThousandEighteenLeaseAmendmentMember" xlink:type="locator" xlink:label="asns_AugustTwoThousandEighteenLeaseAmendmentMember" />
    <label xml:lang="en-US" xlink:label="asns_AugustTwoThousandEighteenLeaseAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">August two thousand eighteen lease amendment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_AugustTwoThousandEighteenLeaseAmendmentMember" xlink:to="asns_AugustTwoThousandEighteenLeaseAmendmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="asns_AugustTwoThousandEighteenLeaseAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August 2018 Lease Amendment</label>
    <label xml:lang="en-US" xlink:label="asns_AugustTwoThousandEighteenLeaseAmendmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">August Two Thousand Eighteen Lease Amendment [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Groups Including Discontinued Operations Name [Domain]</label>
    <loc xlink:href="asns-20180630.xsd#asns_ArsanisClinicalDevelopmentOfASN100Member" xlink:type="locator" xlink:label="asns_ArsanisClinicalDevelopmentOfASN100Member" />
    <label xml:lang="en-US" xlink:label="asns_ArsanisClinicalDevelopmentOfASN100Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Arsanis clinical development of ASN100.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_ArsanisClinicalDevelopmentOfASN100Member" xlink:to="asns_ArsanisClinicalDevelopmentOfASN100Member_lbl" />
    <label xml:lang="en-US" xlink:label="asns_ArsanisClinicalDevelopmentOfASN100Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August 2018 Reduction in Force</label>
    <label xml:lang="en-US" xlink:label="asns_ArsanisClinicalDevelopmentOfASN100Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arsanis Clinical Development Of A S N100 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</label>
    <loc xlink:href="asns-20180630.xsd#asns_LeaseAgreementOriginationDate" xlink:type="locator" xlink:label="asns_LeaseAgreementOriginationDate" />
    <label xml:lang="en-US" xlink:label="asns_LeaseAgreementOriginationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement origination date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_LeaseAgreementOriginationDate" xlink:to="asns_LeaseAgreementOriginationDate_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_AdditionalOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_AdditionalOfficeSpaceUnderLeaseAgreement" />
    <label xml:lang="en-US" xlink:label="asns_AdditionalOfficeSpaceUnderLeaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional office space under lease agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_AdditionalOfficeSpaceUnderLeaseAgreement" xlink:to="asns_AdditionalOfficeSpaceUnderLeaseAgreement_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_LeaseAgreementExtensionDescription" xlink:type="locator" xlink:label="asns_LeaseAgreementExtensionDescription" />
    <label xml:lang="en-US" xlink:label="asns_LeaseAgreementExtensionDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement extension description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_LeaseAgreementExtensionDescription" xlink:to="asns_LeaseAgreementExtensionDescription_lbl" />
    <label xml:lang="en-US" xlink:label="asns_LeaseAgreementOriginationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement origination date</label>
    <label xml:lang="en-US" xlink:label="asns_LeaseAgreementOriginationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Origination Date</label>
    <label xml:lang="en-US" xlink:label="asns_LeaseAgreementExtensionDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement extension description</label>
    <label xml:lang="en-US" xlink:label="asns_LeaseAgreementExtensionDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Extension Description</label>
    <label xml:lang="en-US" xlink:label="asns_AdditionalOfficeSpaceUnderLeaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional office space under lease agreement</label>
    <label xml:lang="en-US" xlink:label="asns_AdditionalOfficeSpaceUnderLeaseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Office Space Under Lease Agreement</label>
    <loc xlink:href="asns-20180630.xsd#asns_NumberOfEliminatedPositions" xlink:type="locator" xlink:label="asns_NumberOfEliminatedPositions" />
    <label xml:lang="en-US" xlink:label="asns_NumberOfEliminatedPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of eliminated positions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_NumberOfEliminatedPositions" xlink:to="asns_NumberOfEliminatedPositions_lbl" />
    <loc xlink:href="asns-20180630.xsd#asns_PercentageOfEliminatedPositions" xlink:type="locator" xlink:label="asns_PercentageOfEliminatedPositions" />
    <label xml:lang="en-US" xlink:label="asns_PercentageOfEliminatedPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of eliminated positions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asns_PercentageOfEliminatedPositions" xlink:to="asns_PercentageOfEliminatedPositions_lbl" />
    <label xml:lang="en-US" xlink:label="asns_NumberOfEliminatedPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of eliminated positions</label>
    <label xml:lang="en-US" xlink:label="asns_NumberOfEliminatedPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Eliminated Positions</label>
    <label xml:lang="en-US" xlink:label="asns_PercentageOfEliminatedPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of eliminated positions</label>
    <label xml:lang="en-US" xlink:label="asns_PercentageOfEliminatedPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Eliminated Positions</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total expenses relating to the reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>asns-20180630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-08-10T21:50:57.2080993+00:00 -->
<!-- Version            : 2.12.6766.32775 -->
<!-- Package ID         : 34e5501d2172469fba6650846da28b53 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.arsanis.com/20180630/role/TemplateLink" xlink:href="asns-20180630.xsd#TemplateLink" xlink:type="simple" />
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="asns-20180630.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="asns-20180630.xsd#asns_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="asns_DocumentAndEntityInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:href="asns-20180630.xsd#Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncomeNoncurrent" xlink:type="locator" xlink:label="asns_UnearnedIncomeNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" />
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncomeCurrent" xlink:type="locator" xlink:label="asns_UnearnedIncomeCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantAndIncentiveReceivables" xlink:type="locator" xlink:label="asns_GrantAndIncentiveReceivables" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="asns_GrantAndIncentiveReceivables" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="asns_UnearnedIncomeCurrent" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermLoansPayable" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="asns_UnearnedIncomeNoncurrent" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:href="asns-20180630.xsd#Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:href="asns-20180630.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantAndIncentiveIncome" xlink:type="locator" xlink:label="asns_GrantAndIncentiveIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="asns_GrantAndIncentiveIncome" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" xlink:href="asns-20180630.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:href="asns-20180630.xsd#Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <loc xlink:href="asns-20180630.xsd#asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes" xlink:type="locator" xlink:label="asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes" />
    <loc xlink:href="asns-20180630.xsd#asns_ExtinguishmentOfConvertiblePromissoryNotes" xlink:type="locator" xlink:label="asns_ExtinguishmentOfConvertiblePromissoryNotes" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAssumed1" />
    <loc xlink:href="asns-20180630.xsd#asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" xlink:type="locator" xlink:label="asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="asns-20180630.xsd#asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock" />
    <loc xlink:href="asns-20180630.xsd#asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes" xlink:type="locator" xlink:label="asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="asns-20180630.xsd#asns_IncreaseDecreaseInUnearnedIncome" xlink:type="locator" xlink:label="asns_IncreaseDecreaseInUnearnedIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="asns-20180630.xsd#asns_IncreaseDecreaseInGrantAndIncentiveReceivables" xlink:type="locator" xlink:label="asns_IncreaseDecreaseInGrantAndIncentiveReceivables" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="locator" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <loc xlink:href="asns-20180630.xsd#asns_AdjustmentOfNonCashRentExpense" xlink:type="locator" xlink:label="asns_AdjustmentOfNonCashRentExpense" />
    <loc xlink:href="asns-20180630.xsd#asns_NonCashInterestExpense" xlink:type="locator" xlink:label="asns_NonCashInterestExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="asns_NonCashInterestExpense" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="asns_AdjustmentOfNonCashRentExpense" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="asns_IncreaseDecreaseInGrantAndIncentiveReceivables" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="asns_IncreaseDecreaseInUnearnedIncome" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_LiabilitiesAssumed1" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="asns_ExtinguishmentOfConvertiblePromissoryNotes" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="asns-20180630.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="asns-20180630.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" xlink:href="asns-20180630.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilities" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpenses" xlink:href="asns-20180630.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpenses">
    <loc xlink:href="asns-20180630.xsd#asns_AccruedExpensesTextBlock" xlink:type="locator" xlink:label="asns_AccruedExpensesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="asns_AccruedExpensesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCollaborationLicenseAndFundingArrangements" xlink:href="asns-20180630.xsd#Role_DisclosureCollaborationLicenseAndFundingArrangements" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCollaborationLicenseAndFundingArrangements">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <loc xlink:href="asns-20180630.xsd#asns_CollaborationAbstract" xlink:type="locator" xlink:label="asns_CollaborationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayable" xlink:href="asns-20180630.xsd#Role_DisclosureLoansPayable" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayable">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommonStock" xlink:href="asns-20180630.xsd#Role_DisclosureCommonStock" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommonStock">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="asns-20180630.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShare" xlink:href="asns-20180630.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShare">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="asns-20180630.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="asns-20180630.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureRelatedPartyTransactions">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSubsequentEvents" xlink:href="asns-20180630.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSubsequentEvents">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="asns-20180630.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandTwelveLoanAgreementPolicyTextBlock" xlink:type="locator" xlink:label="asns_TwoThousandTwelveLoanAgreementPolicyTextBlock" />
    <loc xlink:href="asns-20180630.xsd#asns_ResearchAndDevelopmentIncentivePolicyTextBlock" xlink:type="locator" xlink:label="asns_ResearchAndDevelopmentIncentivePolicyTextBlock" />
    <loc xlink:href="asns-20180630.xsd#asns_FFGLoansPolicyTextBlock" xlink:type="locator" xlink:label="asns_FFGLoansPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <loc xlink:href="asns-20180630.xsd#asns_UnauditedInterimFinancialStatementsPolicyTextBlock" xlink:type="locator" xlink:label="asns_UnauditedInterimFinancialStatementsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="asns_UnauditedInterimFinancialStatementsPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="asns_FFGLoansPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="asns_ResearchAndDevelopmentIncentivePolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="asns_TwoThousandTwelveLoanAgreementPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="asns-20180630.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:href="asns-20180630.xsd#asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock" xlink:type="locator" xlink:label="asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" xlink:href="asns-20180630.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="asns-20180630.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpensesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableTables" xlink:href="asns-20180630.xsd#Role_DisclosureLoansPayableTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="asns-20180630.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="asns-20180630.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="asns-20180630.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <loc xlink:href="asns-20180630.xsd#asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <loc xlink:href="asns-20180630.xsd#asns_AccountingStandardsUpdate201415Member" xlink:type="locator" xlink:label="asns_AccountingStandardsUpdate201415Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_NewEnterpriseAssociates16LPMember" xlink:type="locator" xlink:label="asns_NewEnterpriseAssociates16LPMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="asns_NewEnterpriseAssociates16LPMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="asns_AccountingStandardsUpdate201415Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="asns-20180630.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsMeasuredAtFairValueDetails" xlink:href="asns-20180630.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsMeasuredAtFairValueDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsMeasuredAtFairValueDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails">
    <loc xlink:href="asns-20180630.xsd#asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount" xlink:type="locator" xlink:label="asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="asns-20180630.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="asns-20180630.xsd#asns_AccruedClinicalTrialCosts" xlink:type="locator" xlink:label="asns_AccruedClinicalTrialCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="asns_AccruedClinicalTrialCosts" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCollaborationLicenseAndFundingArrangementsAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureCollaborationLicenseAndFundingArrangementsAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCollaborationLicenseAndFundingArrangementsAdditionalInformationDetails">
    <loc xlink:href="asns-20180630.xsd#asns_ReimbursementRateForResearchAndDevelopment" xlink:type="locator" xlink:label="asns_ReimbursementRateForResearchAndDevelopment" />
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncomeNoncurrent" xlink:type="locator" xlink:label="asns_UnearnedIncomeNoncurrent" />
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncomeCurrent" xlink:type="locator" xlink:label="asns_UnearnedIncomeCurrent" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantAndIncentiveReceivables" xlink:type="locator" xlink:label="asns_GrantAndIncentiveReceivables" />
    <loc xlink:href="asns-20180630.xsd#asns_PercentageOfLoansAndGrantsToFund" xlink:type="locator" xlink:label="asns_PercentageOfLoansAndGrantsToFund" />
    <loc xlink:href="asns-20180630.xsd#asns_QualifyingExpensesUnderLetterAgreement" xlink:type="locator" xlink:label="asns_QualifyingExpensesUnderLetterAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantAgreementExpirationDate" xlink:type="locator" xlink:label="asns_GrantAgreementExpirationDate" />
    <loc xlink:href="asns-20180630.xsd#asns_UnearnedIncome" xlink:type="locator" xlink:label="asns_UnearnedIncome" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantAndIncentiveIncome" xlink:type="locator" xlink:label="asns_GrantAndIncentiveIncome" />
    <loc xlink:href="asns-20180630.xsd#asns_RelatedPartyTransactionProceedsFromGrants" xlink:type="locator" xlink:label="asns_RelatedPartyTransactionProceedsFromGrants" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantsAgreementMaximumAwardAmount" xlink:type="locator" xlink:label="asns_GrantsAgreementMaximumAwardAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="asns-20180630.xsd#asns_CollaborationPaymentObligations" xlink:type="locator" xlink:label="asns_CollaborationPaymentObligations" />
    <loc xlink:href="asns-20180630.xsd#asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:type="locator" xlink:label="asns_CollaborationLicenseAndFundingArrangementsLineItems" />
    <loc xlink:href="asns-20180630.xsd#asns_ResearchAndDevelopmentIncentiveProgramMember" xlink:type="locator" xlink:label="asns_ResearchAndDevelopmentIncentiveProgramMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:type="locator" xlink:label="us-gaap_ScenarioForecastMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_AustriaMember" xlink:type="locator" xlink:label="asns_AustriaMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_FFGLoansMember" xlink:type="locator" xlink:label="asns_FFGLoansMember" />
    <loc xlink:href="asns-20180630.xsd#asns_FFGGrantsMember" xlink:type="locator" xlink:label="asns_FFGGrantsMember" />
    <loc xlink:href="asns-20180630.xsd#asns_FundingArrangementsWithFFGMember" xlink:type="locator" xlink:label="asns_FundingArrangementsWithFFGMember" />
    <loc xlink:href="asns-20180630.xsd#asns_SeriesDRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="asns_SeriesDRedeemableConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantAgreementMember" xlink:type="locator" xlink:label="asns_GrantAgreementMember" />
    <loc xlink:href="asns-20180630.xsd#asns_AugustTwoThousandAndEighteenGrantAgreementMember" xlink:type="locator" xlink:label="asns_AugustTwoThousandAndEighteenGrantAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember" xlink:type="locator" xlink:label="asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember" />
    <loc xlink:href="asns-20180630.xsd#asns_BillAndMelindaGatesFoundationMember" xlink:type="locator" xlink:label="asns_BillAndMelindaGatesFoundationMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_AdimabOptionAgreementMember" xlink:type="locator" xlink:label="asns_AdimabOptionAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_AdimabLLCMember" xlink:type="locator" xlink:label="asns_AdimabLLCMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_CollaborationLicenseAndFundingArrangementsTable" xlink:type="locator" xlink:label="asns_CollaborationLicenseAndFundingArrangementsTable" />
    <loc xlink:href="asns-20180630.xsd#asns_CollaborationAbstract" xlink:type="locator" xlink:label="asns_CollaborationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationAbstract" xlink:to="asns_CollaborationLicenseAndFundingArrangementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="asns_AdimabLLCMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_AdimabOptionAgreementMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="asns_BillAndMelindaGatesFoundationMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_AugustTwoThousandAndEighteenGrantAgreementMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_GrantAgreementMember" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="asns_SeriesDRedeemableConvertiblePreferredStockMember" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_FundingArrangementsWithFFGMember" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_FFGGrantsMember" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_FFGLoansMember" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="asns_AustriaMember" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="us-gaap_StatementScenarioAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_ResearchAndDevelopmentIncentiveProgramMember" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsTable" xlink:to="asns_CollaborationLicenseAndFundingArrangementsLineItems" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_CollaborationPaymentObligations" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_GrantsAgreementMaximumAwardAmount" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_RelatedPartyTransactionProceedsFromGrants" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_GrantAndIncentiveIncome" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_UnearnedIncome" order="12580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_GrantAgreementExpirationDate" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="13000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="13040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="13060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_QualifyingExpensesUnderLetterAgreement" order="13110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_PercentageOfLoansAndGrantsToFund" order="13220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_GrantAndIncentiveReceivables" order="13370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_UnearnedIncomeCurrent" order="13640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_UnearnedIncomeNoncurrent" order="13720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CollaborationLicenseAndFundingArrangementsLineItems" xlink:to="asns_ReimbursementRateForResearchAndDevelopment" order="13830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfAggregatePrincipalAmountOfDebtOutstandingDetails" xlink:href="asns-20180630.xsd#Role_DisclosureLoansPayableScheduleOfAggregatePrincipalAmountOfDebtOutstandingDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfAggregatePrincipalAmountOfDebtOutstandingDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <loc xlink:href="asns-20180630.xsd#asns_FFGLoansMember" xlink:type="locator" xlink:label="asns_FFGLoansMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" xlink:type="locator" xlink:label="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_FFGLoansMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfCurrentAndNonCurrentDebtObligationsDetails" xlink:href="asns-20180630.xsd#Role_DisclosureLoansPayableScheduleOfCurrentAndNonCurrentDebtObligationsDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfCurrentAndNonCurrentDebtObligationsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayable" xlink:type="locator" xlink:label="us-gaap_LoansPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:type="locator" xlink:label="us-gaap_LoansPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LongTermDebtCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <loc xlink:href="asns-20180630.xsd#asns_FFGLoansMember" xlink:type="locator" xlink:label="asns_FFGLoansMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" xlink:type="locator" xlink:label="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_FFGLoansMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrentAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtCurrentAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrentAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LongTermLoansPayable" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LoansPayable" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureLoansPayableAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <loc xlink:href="asns-20180630.xsd#asns_PrepaymentFeePercentageToOutstandingPrincipalAmount" xlink:type="locator" xlink:label="asns_PrepaymentFeePercentageToOutstandingPrincipalAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
    <loc xlink:href="asns-20180630.xsd#asns_PercentageMinusWallStreetJournalPrimeRate" xlink:type="locator" xlink:label="asns_PercentageMinusWallStreetJournalPrimeRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
    <loc xlink:href="asns-20180630.xsd#asns_NumberOfTranches" xlink:type="locator" xlink:label="asns_NumberOfTranches" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <loc xlink:href="asns-20180630.xsd#asns_ClassOfWarrantOrRightsExpirationDate" xlink:type="locator" xlink:label="asns_ClassOfWarrantOrRightsExpirationDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <loc xlink:href="asns-20180630.xsd#asns_FFGLoansMember" xlink:type="locator" xlink:label="asns_FFGLoansMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" xlink:type="locator" xlink:label="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" />
    <loc xlink:href="asns-20180630.xsd#asns_FirstAmendmentMember" xlink:type="locator" xlink:label="asns_FirstAmendmentMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandSixteenTermLoanAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandSixteenTermLoanAdvanceMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_ExercisePriceTwoMember" xlink:type="locator" xlink:label="asns_ExercisePriceTwoMember" />
    <loc xlink:href="asns-20180630.xsd#asns_ExercisePriceOneMember" xlink:type="locator" xlink:label="asns_ExercisePriceOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_SeriesBWarrantsMember" xlink:type="locator" xlink:label="asns_SeriesBWarrantsMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandSixteenTermLoanBAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandSixteenTermLoanBAdvanceMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandSixteenTermLoanAAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandSixteenTermLoanAAdvanceMember" />
    <loc xlink:href="asns-20180630.xsd#asns_SeriesATwoPreferredStockWarrantsMember" xlink:type="locator" xlink:label="asns_SeriesATwoPreferredStockWarrantsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandTwelveTermLoanBAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandTwelveTermLoanBAdvanceMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandTwelveLoanAgreementMember" xlink:type="locator" xlink:label="asns_TwoThousandTwelveLoanAgreementMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandTwelveTermLoanAAdvanceMember" xlink:type="locator" xlink:label="asns_TwoThousandTwelveTermLoanAAdvanceMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TwoThousandTwelveTermLoanAAdvanceMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TwoThousandTwelveLoanAgreementMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TwoThousandTwelveTermLoanBAdvanceMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="asns_SeriesATwoPreferredStockWarrantsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TwoThousandSixteenTermLoanAAdvanceMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TwoThousandSixteenTermLoanBAdvanceMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="asns_SeriesBWarrantsMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="asns_ExercisePriceOneMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="asns_ExercisePriceTwoMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TwoThousandSixteenTermLoanAdvanceMember" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_FirstAmendmentMember" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="asns_FFGLoansMember" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="asns_ClassOfWarrantOrRightsExpirationDate" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCredit" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="asns_NumberOfTranches" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="asns_PercentageMinusWallStreetJournalPrimeRate" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="asns_PrepaymentFeePercentageToOutstandingPrincipalAmount" order="12970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="13050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="13120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="13200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="13310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="13420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1" order="13540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeEnd1" order="13580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandAndElevenStockIncentivePlanMember" xlink:type="locator" xlink:label="asns_TwoThousandAndElevenStockIncentivePlanMember" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandAndTenSpecialStockIncentivePlanMember" xlink:type="locator" xlink:label="asns_TwoThousandAndTenSpecialStockIncentivePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="asns_TwoThousandSeventeenEquityIncentivePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:type="locator" xlink:label="us-gaap_DirectorMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_DirectorMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="asns_TwoThousandSeventeenEquityIncentivePlanMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="asns_TwoThousandAndTenSpecialStockIncentivePlanMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="asns_TwoThousandAndElevenStockIncentivePlanMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseClassificationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseClassificationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseClassificationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="asns-20180630.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
    <loc xlink:href="asns-20180630.xsd#asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue" xlink:type="locator" xlink:label="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <loc xlink:href="asns-20180630.xsd#asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="asns-20180630.xsd#Role_DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="asns-20180630.xsd#Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseObligation" xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" />
    <loc xlink:href="asns-20180630.xsd#asns_OptionFee" xlink:type="locator" xlink:label="asns_OptionFee" />
    <loc xlink:href="asns-20180630.xsd#asns_MilestonePayments" xlink:type="locator" xlink:label="asns_MilestonePayments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:href="asns-20180630.xsd#asns_RelocationPaymentToLessor" xlink:type="locator" xlink:label="asns_RelocationPaymentToLessor" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <loc xlink:href="asns-20180630.xsd#asns_CashObligation" xlink:type="locator" xlink:label="asns_CashObligation" />
    <loc xlink:href="asns-20180630.xsd#asns_AggregateBaseRentObligation" xlink:type="locator" xlink:label="asns_AggregateBaseRentObligation" />
    <loc xlink:href="asns-20180630.xsd#asns_OriginalOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_OriginalOfficeSpaceUnderLeaseAgreement" />
    <loc xlink:href="asns-20180630.xsd#asns_CurrentOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_CurrentOfficeSpaceUnderLeaseAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" />
    <loc xlink:href="asns-20180630.xsd#asns_LesseeOperatingLeaseExpirationDescription" xlink:type="locator" xlink:label="asns_LesseeOperatingLeaseExpirationDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="asns-20180630.xsd#asns_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="asns_CommitmentsAndContingenciesLineItems" />
    <loc xlink:href="asns-20180630.xsd#asns_PrepaidClinicalManufacturingExpensesMember" xlink:type="locator" xlink:label="asns_PrepaidClinicalManufacturingExpensesMember" />
    <loc xlink:href="asns-20180630.xsd#asns_AdimabOptionAgreementMember" xlink:type="locator" xlink:label="asns_AdimabOptionAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_LeaseAgreementForOfficeSpaceInWalthamMAMember" xlink:type="locator" xlink:label="asns_LeaseAgreementForOfficeSpaceInWalthamMAMember" />
    <loc xlink:href="asns-20180630.xsd#asns_WalthamLeaseAgreementMember" xlink:type="locator" xlink:label="asns_WalthamLeaseAgreementMember" />
    <loc xlink:href="asns-20180630.xsd#asns_AnimalUseLeaseAgreementMember" xlink:type="locator" xlink:label="asns_AnimalUseLeaseAgreementMember" />
    <loc xlink:href="asns-20180630.xsd#asns_ViennaLeaseAgreementMember" xlink:type="locator" xlink:label="asns_ViennaLeaseAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_ManufacturingCommitmentsMember" xlink:type="locator" xlink:label="asns_ManufacturingCommitmentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="asns_CommitmentsAndContingenciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="asns_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="asns_ManufacturingCommitmentsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="asns_ViennaLeaseAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="asns_AnimalUseLeaseAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="asns_WalthamLeaseAgreementMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="asns_LeaseAgreementForOfficeSpaceInWalthamMAMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TransactionTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="asns_AdimabOptionAgreementMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="asns_PrepaidClinicalManufacturingExpensesMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesTable" xlink:to="asns_CommitmentsAndContingenciesLineItems" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_LesseeOperatingLeaseExpirationDescription" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_CurrentOfficeSpaceUnderLeaseAgreement" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_OriginalOfficeSpaceUnderLeaseAgreement" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_AggregateBaseRentObligation" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_CashObligation" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_SecurityDeposit" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_RelocationPaymentToLessor" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_MilestonePayments" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="asns_OptionFee" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PurchaseObligation" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asns_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetails" xlink:href="asns-20180630.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" />
    <loc xlink:href="asns-20180630.xsd#asns_CashReceivedFromRelatedPartyTransaction" xlink:type="locator" xlink:label="asns_CashReceivedFromRelatedPartyTransaction" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="asns-20180630.xsd#asns_PaymentsToRelatedPartyForPriorPeriodExpense" xlink:type="locator" xlink:label="asns_PaymentsToRelatedPartyForPriorPeriodExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <loc xlink:href="asns-20180630.xsd#asns_ServicesAndFacilitiesAgreementMember" xlink:type="locator" xlink:label="asns_ServicesAndFacilitiesAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_EveliQureBiotechnologiesGmbHMember" xlink:type="locator" xlink:label="asns_EveliQureBiotechnologiesGmbHMember" />
    <loc xlink:href="asns-20180630.xsd#asns_AdimabOptionAgreementMember" xlink:type="locator" xlink:label="asns_AdimabOptionAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_AdimabLLCMember" xlink:type="locator" xlink:label="asns_AdimabLLCMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="asns_AdimabLLCMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_AdimabOptionAgreementMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="asns_EveliQureBiotechnologiesGmbHMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_ServicesAndFacilitiesAgreementMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="asns_PaymentsToRelatedPartyForPriorPeriodExpense" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="asns_CashReceivedFromRelatedPartyTransaction" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="asns-20180630.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.arsanis.com/20180630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <loc xlink:href="asns-20180630.xsd#asns_PercentageOfEliminatedPositions" xlink:type="locator" xlink:label="asns_PercentageOfEliminatedPositions" />
    <loc xlink:href="asns-20180630.xsd#asns_NumberOfEliminatedPositions" xlink:type="locator" xlink:label="asns_NumberOfEliminatedPositions" />
    <loc xlink:href="asns-20180630.xsd#asns_RelocationPaymentToLessor" xlink:type="locator" xlink:label="asns_RelocationPaymentToLessor" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <loc xlink:href="asns-20180630.xsd#asns_CashObligation" xlink:type="locator" xlink:label="asns_CashObligation" />
    <loc xlink:href="asns-20180630.xsd#asns_AggregateBaseRentObligation" xlink:type="locator" xlink:label="asns_AggregateBaseRentObligation" />
    <loc xlink:href="asns-20180630.xsd#asns_AdditionalOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_AdditionalOfficeSpaceUnderLeaseAgreement" />
    <loc xlink:href="asns-20180630.xsd#asns_LeaseAgreementExtensionDescription" xlink:type="locator" xlink:label="asns_LeaseAgreementExtensionDescription" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="asns-20180630.xsd#asns_LeaseAgreementOriginationDate" xlink:type="locator" xlink:label="asns_LeaseAgreementOriginationDate" />
    <loc xlink:href="asns-20180630.xsd#asns_OriginalOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_OriginalOfficeSpaceUnderLeaseAgreement" />
    <loc xlink:href="asns-20180630.xsd#asns_CurrentOfficeSpaceUnderLeaseAgreement" xlink:type="locator" xlink:label="asns_CurrentOfficeSpaceUnderLeaseAgreement" />
    <loc xlink:href="asns-20180630.xsd#asns_GrantsAgreementMaximumAwardAmount" xlink:type="locator" xlink:label="asns_GrantsAgreementMaximumAwardAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:type="locator" xlink:label="us-gaap_ScenarioForecastMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_ArsanisClinicalDevelopmentOfASN100Member" xlink:type="locator" xlink:label="asns_ArsanisClinicalDevelopmentOfASN100Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_AugustTwoThousandEighteenLeaseAmendmentMember" xlink:type="locator" xlink:label="asns_AugustTwoThousandEighteenLeaseAmendmentMember" />
    <loc xlink:href="asns-20180630.xsd#asns_AugustTwoThousandAndEighteenGrantAgreementMember" xlink:type="locator" xlink:label="asns_AugustTwoThousandAndEighteenGrantAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <loc xlink:href="asns-20180630.xsd#asns_BillAndMelindaGatesFoundationMember" xlink:type="locator" xlink:label="asns_BillAndMelindaGatesFoundationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="asns_BillAndMelindaGatesFoundationMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_AugustTwoThousandAndEighteenGrantAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="asns_AugustTwoThousandEighteenLeaseAmendmentMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="asns_ArsanisClinicalDevelopmentOfASN100Member" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementScenarioAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_GrantsAgreementMaximumAwardAmount" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_CurrentOfficeSpaceUnderLeaseAgreement" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_OriginalOfficeSpaceUnderLeaseAgreement" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_LeaseAgreementOriginationDate" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_LeaseAgreementExtensionDescription" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_AdditionalOfficeSpaceUnderLeaseAgreement" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_AggregateBaseRentObligation" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_CashObligation" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SecurityDeposit" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_RelocationPaymentToLessor" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_NumberOfEliminatedPositions" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="asns_PercentageOfEliminatedPositions" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringCharges" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826884512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARSANIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ASNS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,315,410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827342320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 49,940<span></span>
</td>
<td class="nump">$ 76,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantAndIncentiveReceivables', window );">Grant and incentive receivables</a></td>
<td class="nump">2,178<span></span>
</td>
<td class="nump">1,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,393<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">56,562<span></span>
</td>
<td class="nump">79,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">57,210<span></span>
</td>
<td class="nump">81,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,137<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,879<span></span>
</td>
<td class="nump">5,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_UnearnedIncomeCurrent', window );">Unearned income</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable, net of discount</a></td>
<td class="nump">3,486<span></span>
</td>
<td class="nump">2,314<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,214<span></span>
</td>
<td class="nump">10,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loan payable, net of discount and current portion</a></td>
<td class="nump">7,706<span></span>
</td>
<td class="nump">9,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_UnearnedIncomeNoncurrent', window );">Unearned income</a></td>
<td class="nump">1,519<span></span>
</td>
<td class="nump">1,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,446<span></span>
</td>
<td class="nump">22,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized as of June 30, 2018 and December 31, 2017; 14,315,410 and 14,294,383 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">152,601<span></span>
</td>
<td class="nump">150,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(115,028)<span></span>
</td>
<td class="num">(92,265)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">37,764<span></span>
</td>
<td class="nump">58,707<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 57,210<span></span>
</td>
<td class="nump">$ 81,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_GrantAndIncentiveReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant and incentive receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_GrantAndIncentiveReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_UnearnedIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unearned income current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_UnearnedIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_UnearnedIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unearned income noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_UnearnedIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 305<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84242212&amp;loc=d3e2352-115587<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820663504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)(Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">14,315,410<span></span>
</td>
<td class="nump">14,294,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">14,315,410<span></span>
</td>
<td class="nump">14,294,383<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827004576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 8,930<span></span>
</td>
<td class="nump">$ 3,906<span></span>
</td>
<td class="nump">$ 17,063<span></span>
</td>
<td class="nump">$ 8,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,686<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
<td class="nump">6,503<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">12,616<span></span>
</td>
<td class="nump">5,644<span></span>
</td>
<td class="nump">23,566<span></span>
</td>
<td class="nump">11,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,616)<span></span>
</td>
<td class="num">(5,644)<span></span>
</td>
<td class="num">(23,566)<span></span>
</td>
<td class="num">(11,471)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantAndIncentiveIncome', window );">Grant and incentive income</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">862<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
<td class="num">(526)<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(462)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">483<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,133)<span></span>
</td>
<td class="num">(5,705)<span></span>
</td>
<td class="num">(22,763)<span></span>
</td>
<td class="num">(11,090)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (12,133)<span></span>
</td>
<td class="num">$ (5,718)<span></span>
</td>
<td class="num">$ (22,763)<span></span>
</td>
<td class="num">$ (11,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (11.13)<span></span>
</td>
<td class="num">$ (1.59)<span></span>
</td>
<td class="num">$ (21.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding&#8212;basic and diluted</a></td>
<td class="nump">14,304,102<span></span>
</td>
<td class="nump">513,900<span></span>
</td>
<td class="nump">14,299,288<span></span>
</td>
<td class="nump">513,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_GrantAndIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant and incentive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_GrantAndIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826926048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,133)<span></span>
</td>
<td class="num">$ (5,705)<span></span>
</td>
<td class="num">$ (22,763)<span></span>
</td>
<td class="num">$ (11,090)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation gain (loss)</a></td>
<td class="nump">270<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="num">(379)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (11,863)<span></span>
</td>
<td class="num">$ (6,002)<span></span>
</td>
<td class="num">$ (22,713)<span></span>
</td>
<td class="num">$ (11,469)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827549200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,763)<span></span>
</td>
<td class="num">$ (11,090)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">397<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_AdjustmentOfNonCashRentExpense', window );">Non-cash rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(762)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_IncreaseDecreaseInGrantAndIncentiveReceivables', window );">Grant and incentive receivables</a></td>
<td class="num">(635)<span></span>
</td>
<td class="num">(547)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,394)<span></span>
</td>
<td class="num">(1,708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">257<span></span>
</td>
<td class="num">(563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,886)<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_IncreaseDecreaseInUnearnedIncome', window );">Unearned income</a></td>
<td class="num">(336)<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(25,657)<span></span>
</td>
<td class="num">(9,874)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchases of property and equipment</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of loans under funding agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of loans payable</a></td>
<td class="num">(1,167)<span></span>
</td>
<td class="num">(1,165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes', window );">Payments of issuance costs of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock', window );">Payments of issuance costs of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of initial public offering costs</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(1,058)<span></span>
</td>
<td class="nump">39,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(120)<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(26,862)<span></span>
</td>
<td class="nump">29,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">77,148<span></span>
</td>
<td class="nump">3,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 50,286<span></span>
</td>
<td class="nump">32,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes', window );">Issuance of redeemable convertible preferred stock upon extinguishment of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Derivative liability in connection with issuance of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_ExtinguishmentOfConvertiblePromissoryNotes', window );">Extinguishment of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes', window );">Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_AdjustmentOfNonCashRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment of non cash rent expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_AdjustmentOfNonCashRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_ExtinguishmentOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_ExtinguishmentOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_IncreaseDecreaseInGrantAndIncentiveReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in grant and incentive receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_IncreaseDecreaseInGrantAndIncentiveReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_IncreaseDecreaseInUnearnedIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in unearned income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_IncreaseDecreaseInUnearnedIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of redeemable convertible preferred stock upon extinguishment of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_IssuanceOfRedeemableConvertiblePreferredStockUponExtinguishmentOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of issuance costs of convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_PaymentsOfIssuanceCostsOfConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of issuance costs of redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_PaymentsOfIssuanceCostsOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818152128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Nature of the Business and Basis of Presentation </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis, Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody, or mAb, immunotherapies to address serious infectious diseases. The Company possesses a deep understanding of the pathogenesis of infection, paired with access to what the Company believes to be some of the most advanced mAb discovery techniques and platforms available today. The Company&#8217;s pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including <font style="font-style:italic;">Staphylococcus aureus</font> (&#8220;<font style="font-style:italic;">S. aureus</font>&#8221;) and respiratory syncytial virus (&#8220;RSV&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 28, 2018, the Company announced the discontinuation of its Phase 2 clinical trial of ASN100 for the prevention of &nbsp;&nbsp;&nbsp;&nbsp; <font style="font-style:italic;">S. aureus</font> pneumonia in high-risk, mechanically ventilated patients following the completion of a planned interim analysis of unblinded trial data for 118 patients by an independent data review committee (&#8220;DRC&#8221;). Based on the results of this analysis, the DRC determined that the trial was futile, meaning that it was not likely to meet its primary end-point upon completion, and recommended that trial enrollment be discontinued. The Company intends to conduct follow-up visits on patients dosed in the trial per the study protocol and to evaluate the complete dataset from the 154 patients that were enrolled in the trial to better understand the basis for this result. The Company expects to complete this evaluation in the fourth quarter of 2018 and has ceased further clinical development of ASN100, pending the results of this analysis. The Company currently does not expect to incur material costs for this program beyond the fourth quarter of 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In light of the discontinuation of the clinical development of ASN100, the Company is considering strategic options that may potentially result in changes to its business strategy and future operations. Pending any decision to change its strategic direction, the Company&#8217;s current operating plan provides for its ongoing review of the data from the ASN100 clinical trial, the continued development of its ASN500 program, as well as supporting its collaborators across its ASN200 and ASN300 programs, both of which were outlicensed to subsidiaries of Bravos Biosciences, LLC during the first half of 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, the Company&#8217;s ability to successfully execute on its strategic plans, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Any product candidates will require significant research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 3, 2017, the Company effected a one-for-3.4130 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s redeemable convertible preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 20, 2017, the Company completed an initial public offering (&#8220;IPO&#8221;) of its common stock, and issued and sold 4,000,000 common shares at a price to the public of $10.00 per share. Concurrent to the IPO, (i) the Company issued an additional 600,000 common shares at a price of $10.00 per share pursuant to the exercise of the underwriters&#8217; over-allotment option and (ii) New Enterprise Associates 16, L.P., or NEA, purchased 2,000,000 shares of the Company&#8217;s common stock at the initial per share public offering price of $10.00 in a private placement. The aggregate net proceeds to the Company from the IPO, inclusive of the over-allotment exercise, and the private placement were $58.1 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. Upon the closing of the IPO, all of the outstanding redeemable convertible preferred stock of the Company automatically converted into 7,180,483 shares of the Company&#8217;s common stock.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had an accumulated deficit of $115.0 million at June 30, 2018. During the six months ended June 30, 2018, the Company incurred a net loss of $22.8 million and used $25.7 million of cash in operations. The Company expects to continue to generate operating losses for the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on its current operating plan, the Company expects that its cash and cash equivalents of $49.9 million as of June 30, 2018, will be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments for at least 12 months from the issuance date of these condensed consolidated financial statements. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arsanis is incorporated under the laws of the State of Delaware and is headquartered in Waltham, Massachusetts, with a wholly-owned subsidiary that is primarily focused on discovery research in Vienna, Austria. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include the accounts of the Company and its wholly owned subsidiary, Arsanis Biosciences GmbH. All intercompany balances and transactions have been eliminated. </p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633019168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Summary of Significant Accounting Policies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unaudited Interim Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed balance sheet at December&#160;31, 2017 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying condensed financial statements as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017 are unaudited. The accompanying unaudited interim financial statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2017 included in the Company&#8217;s&#160;Annual Report on Form 10-K as filed with the SEC on March&#160;9, 2018. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#8217;s condensed financial position as of June 30, 2018 and condensed results of its operations for the three and six months ended June 30, 2018 and 2017 and cash flows for the six months ended June 30, 2018 and 2017 have been made. The results of operations for the three and six months ended June 30, 2018 and 2017 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2018.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of common stock and stock options. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of cash equivalents, other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The carrying value of the Company&#8217;s loan and security agreement with Silicon Valley Bank (&#8220;SVB&#8221;) approximates its fair value because the debt bears interest at a market rate. The carrying value of the loans received under the funding agreements with &#214;sterreichische Forschungsf&#246;rderungsgesellschaft mbH (&#8220;FFG&#8221;) approximates their fair value because the Company records imputed interest expense based on rates that approximate market rates of interest as of the issuance date of each FFG loan. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Gain (Loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive gain (loss) includes net gain (loss) as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. Comprehensive gain (loss) included $0.3 million and $(0.3) million for the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $(0.4) million for the six months ended June 30, 2018 and 2017, respectively, of foreign currency translation gain (loss) adjustments. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Income (Loss) per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, options to purchase common stock, redeemable convertible preferred stock, warrants to purchase common stock and warrants to purchase redeemable convertible preferred stock are considered potential dilutive common shares.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s redeemable convertible preferred stock contractually entitled the holders of such shares to participate in dividends but contractually did not require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers </font>(&#8220;ASU 2014-09&#8221;), which supersedes most existing revenue recognition guidance under GAAP. The FASB also issued several amendments and updates to the new revenue standard (collectively, &#8220;Topic 606&#8221;). The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance. These judgments and estimates include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows as the Company does not currently have any revenue-generating arrangements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2016, the FASB issued ASU No.&#160;2016-15, <font style="font-style:italic;">Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments</font> (&#8220;ASU 2016-15&#8221;), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The Company adopted the standard retrospectively to all periods presented on the required effective date of January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2016, the FASB issued ASU No.&#160;2016-16, <font style="font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory</font> (&#8220;ASU 2016-16&#8221;), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2016, the FASB issued ASU No.&#160;2016-18, <font style="font-style:italic;">Statement of Cash Flows (Topic 230): Restricted Cash</font> (&#8220;ASU 2016-18&#8221;), which requires restricted cash to be presented with cash and cash equivalents on the statement of cash flows and disclosure of how the statement of cash flows reconciles to the balance sheet if restricted cash is shown separately from cash and cash equivalents on the balance sheet. The Company adopted this standard on January 1, 2018. The adoption of ASU 2016-18 resulted in the Company's cash, cash equivalents and restricted cash being included in the beginning and ending amounts for the periods shown on the statement of cash flows and was applied retroactively and reflected in the balances presented for any prior periods. The Company believes that the adoption of this guidance did not have a significant impact on its condensed consolidated financial statements and related disclosures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The restricted cash as of June 30, 2018 and December 31, 2017 is held as letters of credit for the benefit of the landlords in connection with the Company&#8217;s office leases.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,940</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,143</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash &#8211; current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,361</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash &#8211; non-current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the statement of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; cash flows</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,286</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,844</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, FASB issued ASU No.&#160;2017-01, <font style="font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font> (&#8220;ASU 2017-01&#8221;). The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill and consolidation. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU No.&#160;2017-09, <font style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Scope of Modification Accounting</font> (&#8220;ASU 2017-09&#8221;), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2018, the FASB issued ASU 2018-05, <font style="font-style:italic;">Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118</font> ("ASU&#160;2018-05"). This standard amends ASC 740, Income Taxes (&#8220;ASC 740&#8221;) to provide guidance on accounting for the tax effects of the Tax Cuts and Jobs Act pursuant to Staff Accounting Bulletin No. 118, which allows companies to complete the accounting under ASC 740 within a one-year measurement period from the Tax Act enactment date. This standard was effective upon issuance. <font style="color:#000000;">The Company will continue to assess the impact that various provisions will have on its business. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the FASB issued&#160;ASU 2018-07,&#160;<font style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting </font>(&#8220;ASU 2018-07&#8221;), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The new standard specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&#8217;s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. ASU 2018-07 is required to be adopted for annual periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2018-07 will have on its consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the FASB issued&#160;ASU 2017-11,&#160;<font style="font-style:italic;">Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</font> (&#8220;ASU 2017-11&#8221;).&#160;Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480&#160;with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU 2017-11 is required to be adopted for annual periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2017-11 will have on its consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No.&#160;2016-02<font style="font-style:italic;">, Leases (Topic 842)</font> (&#8220;ASU 2016-02&#8221;), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASU 2016-02 (Accounting Standards Codification (&#8220;ASC&#8221;) (Topic 842) supersedes the previous leases standard, ASC 840, Leases. The standard is effective for public entities for annual periods beginning after December&#160;15, 2018 including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements. </p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818116400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Fair Value of Financial Assets and Liabilities<font style="font-weight:normal;"> </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents - Money Market Funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,576</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,576</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,576</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,576</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents - Money Market Funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,891</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,891</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,891</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,891</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes to the valuation methods during the six months ended June 30, 2018 and the year ended December 31, 2017. There were no transfers within the fair value hierarchy during the six months ended June 30, 2018 and the year ended December 31, 2017. </p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809821600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_AccruedExpensesTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Accrued Expenses<font style="font-weight:normal;"> </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,335</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,317</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and benefits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,539</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,454</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">563</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">510</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,879</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,779</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_AccruedExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_AccruedExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818199456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License and Funding Arrangements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationAbstract', window );"><strong>Collaboration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration, License and Funding Arrangements</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Collaboration, License and Funding Arrangements<font style="font-weight:normal;"> </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Adimab Option and License Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, the Company entered into an option and license agreement with Adimab, LLC (&#8220;Adimab&#8221;), a related party (see Note&#160;11) (the &#8220;Adimab Option Agreement&#8221;). Under the Adimab Option Agreement, Adimab has provided to the Company certain proprietary antibodies against RSV (&#8220;RSV antibodies&#8221;) for its evaluation during a specified option period and has granted the Company an exclusive, non-sublicensable license in a specified field under certain Adimab patent rights and know-how during the option period. Under the Adimab Option Agreement, the Company has an exclusive option, exercisable during the option period upon payment of an option fee to Adimab, to require Adimab to assign to the Company all rights in up to a specified number of RSV antibodies selected by the Company and certain patent rights owned by Adimab that cover these antibodies, and to obtain from Adimab a non-exclusive license in a specified field, with the right to grant sublicenses, under certain other patent rights and know-how owned by Adimab. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, the Company entered into a grant agreement with the Bill &amp; Melinda Gates Foundation (the &#8220;Gates Foundation&#8221;) pursuant to which the Company has no payment obligations under the Adimab Option Agreement with respect to sales of products based on licensed RSV antibodies to the extent they are sold at cost in developing countries. However, if such products are sold in developing countries for an amount that exceeds cost, then the amount of such excess will be subject to certain royalty payment obligations described in the agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized research and development expenses of $14,000 and $58,000 during the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $0.1 million during the six months ended June 30, 2018 and 2017, respectively, in connection with the Adimab Option Agreement, which consisted of reimbursement for services performed by Adimab. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">February 2017 and August 2018 Amended and Restated Gates Foundation Grant Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, the Company entered into the above-referenced grant agreement with the Gates Foundation, under which the Gates Foundation agreed to provide the Company up to $9.3 million to conduct preclinical development of mAbs for the prevention of RSV infection in newborns (the &#8220;RSV project&#8221;).&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, the Company received a payment of $1.6 million from the Gates Foundation under the grant agreement. The funds received from the Gates Foundation were incurred on qualifying expenses attributable to the RSV project, and the Company recognized grant income of $1.6 million under the grant agreement during the year ended December 31, 2017.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company entered into an amended and restated grant agreement which replaces the February 2017 grant agreement in its entirety. The amended and restated grant agreement includes amendments to conform to current Gates Foundation audit, reporting, and other administrative requirements, as well as to make the perpetual Gates Foundation license grant described below irrevocable.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized grant income of $0 during the three and six months ended June 30, 2018, and $0.6 million during the three and six months ended June 30, 2017, under the grant agreement with the Gates Foundation upon incurring qualifying expenses. As of June 30, 2018 and December 31, 2017, unearned income under the grant agreement with the Gates Foundation was $0. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Gates Foundation Grant Agreement&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the Company entered into an additional grant agreement with the Gates Foundation pursuant to which the Gates Foundation granted to the Company up to $1.1 million to conduct preclinical development activities for the RSV project that were not included in the February 2017 grant agreement, as amended and restated in August 2018. In return, the Company has agreed to conduct the RSV project in a manner that ensures that the knowledge and information gained from the project will be promptly and broadly disseminated, and that the products, technologies, materials, processes and other intellectual property resulting from the RSV project (collectively referred to as the funded developments) will be made available and accessible at an affordable price to people most in need within developing countries. These obligations survive any expiration or termination of the grant agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To this end, the Company has granted to the Gates Foundation a non-exclusive, perpetual, irrevocable, royalty-free, fully paid up, sublicensable license to make, use, sell, offer to sell, import, distribute, copy, modify, create derivative works, publicly perform and display the funded developments and, to the extent incorporated into a funded development or required to use a funded development, any other technology created outside of the RSV project that was used as part of the RSV project, for the benefit of people in developing countries. The Company has also agreed to seek prompt publication of data and results developed under the RSV project under &#8220;open access&#8221; terms and conditions. This license and these publication obligations survive any expiration or termination of the grant agreements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The August 2018 grant agreement expires on August 31, 2018. The Gates Foundation can modify, suspend or discontinue any payment under the grant agreement, or terminate the grant agreement, if it is not reasonably satisfied with the Company&#8217;s progress on the RSV project; if there are significant changes to the Company&#8217;s leadership or other factors that the Gates Foundation reasonably believes may threaten the RSV project&#8217;s success; if the Company undergoes a change in control; if there is a change in the Company&#8217;s tax status; or if the Company fails to comply with the grant agreement. Any grant funds that have not been used for, or committed to, the RSV project upon the expiration or termination of the agreement must be returned to the Gates Foundation or otherwise used as directed by the Gates Foundation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not recognize grant income or record any unearned income under the August 2018 grant agreement with the Gates Foundation in any periods presented.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Gates Foundation Letter Agreement and Investment&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2017, the Company entered into a letter agreement with the Gates Foundation. In connection with the letter agreement, the Gates Foundation purchased 2,464,799 shares of the Company&#8217;s Series D preferred stock, which converted into <font style="color:#000000;">722,179 </font>shares of our common stock in connection with our November 2017 initial public offering after giving effect to a one-for-3.4130 reverse-stock-split. The Company committed to use the proceeds of $8.0&#160;million from the investment by the Gates Foundation solely to advance the development of a specified monoclonal antibody program that involves the monoclonal antibodies ASN-1, ASN-2 and ASN-3 and the Company&#8217;s product candidate, ASN100. Under the letter agreement, in addition to the initial project funded by the Gates Foundation with its initial investment, the Company also agreed to conduct up to four additional projects to be proposed and to be funded by the Gates Foundation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The letter agreement contains certain global access obligations as well as requirements relating to the Company&#8217;s use of the funds received from the Gates Foundation investment. In the event that the Company fails to comply with these obligations or requirements or any related U.S. legal obligations set forth in the letter agreement, the Gates Foundation will have the right, after expiration of a specified cure period, to require the Company to redeem all of the shares owned by the Gates Foundation or to locate a third party that will purchase such shares. For any redemption or purchase resulting from such default, the shares of the Company&#8217;s stock held by the Gates Foundation will be redeemed at an amount equal to the greater of the original purchase price (plus specified interest) or the fair market value of such stock on the date of such redemption. The term of the letter agreement continues in perpetuity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with this letter agreement, the Company has granted to the Gates Foundation and/or Gates Foundation-supported entities certain licenses, including a non-exclusive, non-terminable, royalty-free (except as required under the Adimab Collaboration Agreement), sublicensable license to products, technologies, materials, processes and other intellectual property developed using funds provided by the Gates Foundation or a Gates Foundation-supported entity, or developed in connection with the Company&#8217;s conduct of any funded project or additional funded project, as well as all of the Company&#8217;s background intellectual property, to utilize and exploit products and services directed at pathogens or other targets subject to any funded project or additional funded project.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The proceeds received from the Gates Foundation in connection with the Company&#8217;s sale and issuance of Series D preferred stock were incurred on qualifying expenses under the letter agreement during the year ended December 31, 2017.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurred qualifying expenses of $<font style="color:#000000;">0</font> during the three and six months ended June 30, 2018, and $<font style="color:#000000;">0.7</font> million during the three and six months ended June 30, 2017, under the letter agreement with the Gates Foundation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding Agreements with FFG </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Between September 2011 and March 2017, the Company entered into a series of funding agreements with FFG that provided for loans and grants to fund between 50% and 70% of qualifying research and development expenditures of the Company&#8217;s subsidiary in Austria on a project-by-project basis, as approved by FFG. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">FFG Grants </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For grants under the funding agreements with FFG, the Company recognized grant income of $0 and $0.2 million during the three months ended June&#160;30, 2018 and 2017, respectively, and $0 and $0.3 million during the six months ended June&#160;30, 2018 and 2017, respectively. As of June 30, 2018 and December&#160;31, 2017, the Company recorded grant receivables from FFG of $0.1 million and $0.1 million, respectively, for qualifying expenses incurred that were reimbursable under the funding agreements. As of June 30, 2018 and December&#160;31, 2017, there were no amounts recorded as unearned income in connection with the FFG grants. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">FFG Loans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loans under the funding agreements with FFG bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged by FFG as additional grant funding from FFG. On the date that FFG loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is recognized as additional grant income over the term of the funding agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized grant income of $0.1 million and $0.2&#160;million during the three months ended June 30, 2018 and 2017, respectively, and $0.3&#160;million and $0.3&#160;million during the six months ended June 30, 2018 and 2017, respectively, related to the recognition of the unearned income recorded for the imputed benefit of FFG loans at below-market interest rates. Unearned income (current) related to the imputed benefit of FFG loans at below-market interest rates was $0.7 million and $0.7&#160;million as of June 30, 2018 and December 31, 2017, respectively, and unearned income (non-current) related to such benefit was $1.5 million and $1.9&#160;million as of June 30, 2018 and December&#160;31, 2017, respectively.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Incentive <font style="font-weight:normal;font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses incurred by the Company&#8217;s subsidiary in Austria. Under the program, the reimbursement rate for qualifying research and development expenses incurred by the Company through its subsidiary in Austria was 12% for the year ended December 31, 2017, and is 14% for the year ended December 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes incentive income from Austrian research and development incentives when qualifying expenses have been incurred, there is reasonable assurance that the payment will be received, and the consideration can be reliably measured. Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each reporting date, management estimates the reimbursable incentive income available to the Company based on available information at the time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized incentive income of $0.3 million and $0.1 million during the three months ended June 30, 2018 and 2017, respectively, and $0.6 million and $0.5 million during the six months ended June 30, 2018 and 2017, respectively, in connection with the Austrian research and development incentive program. As of June 30, 2018 and December&#160;31, 2017, the Company recorded receivables for amounts due under the program of $2.1 million and $1.5 million, respectively, which amounts were included in grant and incentive receivables in the condensed consolidated balance sheet. </p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_CollaborationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_CollaborationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809831664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loans Payable</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Loans Payable </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate principal amount of debt outstanding as of June 30, 2018 and December 31, 2017 consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term loans under 2012 Loan Agreement</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,667</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FFG loans</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,937</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,225</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,437</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,892</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current and non-current debt obligations reflected in the condensed consolidated balance sheets as of June 30, 2018 and December 31, 2017 consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term loans under 2012 Loan Agreement</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,333</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FFG loans</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loans payable, net of discount</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,486</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,314</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term loans under 2012 Loan Agreement</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,334</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FFG loans</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,937</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,225</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,231</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,637</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loans payable, net of discount and current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,706</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,922</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loans payable, net of discount</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,192</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,236</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2012 Loan Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 7, 2012, the Company entered into a loan and security agreement (the &#8220;2012 Loan Agreement&#8221;) with SVB, and borrowed an aggregate of $2.5 million in two separate tranches: $0.5 million in December 2012 (the &#8220;2012 Term Loan A Advance&#8221;), and $2.0 million in February 2013 (the &#8220;2012 Term Loan B Advance&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the 2012 Loan Agreement, the Company issued a Series A-2 warrant to SVB, which became exercisable with respect to 2,202 shares of Series A-2 preferred stock on December 12, 2012 in connection with the 2012 Term Loan A Advance, and with respect to 8,811 shares of Series A-2 preferred stock on February 25, 2013 in connection with the 2012 Term Loan B Advance. At the time of grant, the Series A-2 warrant was exercisable at a price of $4.54 per share. The Series A-2 warrant expires on December 6, 2022.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 19, 2016, the Company entered into the First Amendment to the 2012 Loan Agreement (the &#8220;First Amendment&#8221;). The First Amendment provided for an additional borrowing of $3.5 million (&#8220;2016 Term Loan A Advance&#8221;), with a requirement that a portion of the proceeds be used to pay in full, all amounts then outstanding, under the 2012 Term Loan A Advance and the 2012 Term Loan B Advance.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The First Amendment provided for two additional advances not to exceed, in the aggregate, $3.5 million, with each advance being for a minimum of $0.5 million (collectively the &#8220;2016 Term Loan B Advance&#8221;), and total borrowings under the 2012 Loan Agreement not to exceed $7.0 million. The Company borrowed the full $7.0 million available in two separate tranches: $3.5 million under the 2016 Term Loan A Advance, which was borrowed on February 29, 2016, and $3.5 million under the 2016 Term Loan B Advance, which was borrowed on August 23, 2016. Following these borrowings in February and August 2016, no additional amounts were available to be borrowed under the 2012 Loan Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the First Amendment to the 2012 Loan Agreement, the Company issued a Series B warrant to SVB which became exercisable with respect to 7,251 shares of Series B preferred stock on February 29, 2016 in connection with the 2016 Term Loan A Advance, and with respect to 7,251 shares of Series B preferred stock on August 23, 2016 in connection with the 2016 Term Loan B Advance. At the time of grant, the Series B warrant was exercisable at a price of $7.24 per share. The Series B warrant expires on February 18, 2026.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO in November 2017, the Series A-2 warrant converted into a common stock warrant to purchase up to 3,940 shares of common stock at an exercise price of $12.70 per share. The Series B warrant converted into a common stock warrant to purchase up to 6,474 shares of common stock at an exercise price of $16.22 per share. At June 30, 2018, these warrants to purchase up to 3,940 shares of common stock at an exercise price of $12.70 and 6,474 shares of common stock at an exercise price of $16.22 remained outstanding.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings under the 2016 Term Loan A Advance and 2016 Term Loan B Advance (collectively, the &#8220;2016 Term Loan Advance&#8221;) bear interest at a rate per annum equal to the greater of 3.25% and The Wall Street Journal prime rate, in each case minus 0.25%; provided, however, that in an event of default, as defined in the 2012 Loan Agreement, the interest rate applicable to borrowings under the First Amendment will be increased by 4.0%. As of June 30, 2018 and December 31, 2017, the interest rate applicable to borrowings under the 2016 Term Loan Advance was 4.75% and 4.25%, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to make equal monthly payments of principal as well as accrued interest beginning January 1, 2017 through December 1, 2019 (the &#8220;First Amendment Maturity Date&#8221;), when all unpaid principal and interest become due and payable. The First Amendment also provided that the Company could voluntarily prepay all (but not less than all) of the outstanding principal at any time prior to the maturity date, subject to a prepayment fee, which ranges from 0% to 2% of the outstanding principal if paid prior to the First Amendment Maturity Date. The Company has not accrued for this prepayment fee as it had not intended to prepay the outstanding balance and the prepayment fee is 0% as of June 30, 2018. A final payment of 5.0% multiplied by the principal amount of the borrowings under the 2016 Term Loan Advance is due upon the earlier to occur of the First Amendment Maturity Date or prepayment of all outstanding principal. The final payment is being accreted to interest expense through the First Amendment Maturity Date. In connection with the First Amendment, the Company paid an arrangement fee of $20,000 to SVB and incurred legal costs of $7,000, both of which were recorded as a debt discount. The debt discount is reflected as a reduction of the carrying value of the loan payable on the Company&#8217;s consolidated balance sheet and is being amortized to interest expense over the term of the loan using the effective interest method.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was in compliance with all covenants under the 2012 Loan Agreement as of December 31, 2017. In March 2018, the Company entered into an Option and License Agreement with BB100, LLC, a subsidiary of Bravos Biosciences, LLC, under which BB100, LLC secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license, to mAbs targeting <font style="font-style:italic;">E. coli</font> that were discovered by the Company in its ASN200 program. In June 2018, the Company entered into an Option and License Agreement with BB200, LLC, a portfolio company of Bravos Biosciences, LLC, under which BB200, LLC secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license to selected mAbs targeting <font style="font-style:italic;">K. pneumoniae</font> that were discovered by the Company in its ASN300 program, including lead preclinical development candidate, ASN-5. As a result of entering into such Option and License Agreements without obtaining prior written consent of SVB, and subsequently delivering compliance certificates under the 2012 Loan Agreement that did not disclose these violations, the Company is currently in default under the 2012 Loan Agreement. On August 8, 2018, the Company and SVB entered into a Forbearance Agreement (the &#8220;Forbearance Agreement&#8221;), pursuant to which SVB has agreed to forbear from exercising its rights and remedies with respect to such default until the earlier to occur of (i) another event of default under the 2012 Loan Agreement or (ii) October 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the default in connection with the Option and License Agreements, the Company has discussed with SVB whether its decision to discontinue its Phase 2 clinical trial of ASN100 may be considered a material adverse change in the business, operations or condition (financial or otherwise) of the Company and, accordingly, an event of default under the terms of the 2012 Loan Agreement. To date, SVB has not agreed that the discontinuation of the trial does not constitute an event of default. If the trial discontinuation does constitute a material adverse change in the Company&#8217;s business, operations or condition, SVB will have the right to accelerate the Company's outstanding obligations under the 2012 Loan Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the Company&#8217;s obligations under the 2012 Loan Agreement may be accelerated at the election of SVB upon the expiration of the Forbearance Agreement, or earlier if another event of default occurs, including but not limited to if the ASN100 Phase 2 clinical trial discontinuation constitutes a material adverse change in the Company&#8217;s business, operations or condition, the Company has presented the SVB loan payable as current on the consolidated balance sheet as of June 30, 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized interest expense under the 2012 Loan Agreement, as amended, of $0.1 million and $0.1 million during the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $0.3 million during the six months ended June 30, 2018 and 2017, respectively. As of June 30, 2018 and December&#160;31, 2017, the unamortized debt discount was $14,000 and $26,000, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made aggregate principal payments in connection with the 2012 Loan Agreement of $0.6 million and $0.6 million during the three months ended June 30, 2018 and 2017, respectively, and $1.2 million and $1.2 million during the six months ended June 30, 2018 and 2017, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FFG Loans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the funding agreements with FFG (see Note 5), the Company received loans from FFG. Loans from FFG were made on a project-by-project basis and had an aggregate principal amount outstanding of $9.9 million and $10.2 million as of June 30, 2018 and December&#160;31, 2017, respectively. Amounts due under the FFG loans bear interest at rates ranging from 0.75% to 2.0%&#160;per annum and mature at various dates between June 2020 and March 2023. Interest on amounts due under the loans is payable semi-annually in arrears, with all principal and remaining accrued interest due upon maturity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company has recorded a discount to the carrying value of each FFG loan for the portion of the loan proceeds allocated to grant funding, which is being amortized to interest expense over the term of the loan using the effective interest method. As of June 30, 2018 and December&#160;31, 2017, the unamortized debt discount related to FFG loans was $2.2 million and $2.6&#160;million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized interest expense of $0.2&#160;million and $0.2 million during the three months ended June 30, 2018 and 2017, respectively, and $0.4&#160;million and $0.3 million during the six months ended June 30, 2018 and 2017, respectively, related to the FFG loans. There were no principal payments due or paid under the FFG loans during the three and six months ended June 30, 2018 and 2017. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may be required to return all or a portion of the FFG loans and/or grants (see Note 5) if it does not comply with the terms of the related FFG funding agreements and related guidelines, including specified requirements as to continued operations with respect to certain locations and funded projects. To date, FFG has not requested the return of any amounts received by the Company under the funding agreements.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818199456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Common Stock </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2018 and December 31, 2017, the Company had reserved 2,738,039 shares and 2,187,252 shares of common stock, respectively, for the exercise of outstanding stock options, the number of shares remaining available for grant under the Company&#8217;s 2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan and the exercise of outstanding warrants to purchase shares of common stock.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818152128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Stock-Based Compensation </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) provides for the grant by the Company of incentive stock options, non-qualified options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. Incentive stock options may be granted only to the Company&#8217;s employees, including officers and directors who are also employees. Awards other than incentive stock options may be granted to employees, officers, members of the board of directors, advisors and consultants of the Company. Following the adoption of the 2017 Plan, no further grants will be made under the Company&#8217;s 2010 Special Stock Incentive Plan (&#8220;Special Plan&#8221;) and 2011 Stock Incentive Plan (&#8220;2011 Plan&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon its adoption, the number of shares of the Company&#8217;s common stock initially reserved for issuance under the 2017 Plan was the sum of 585,994 shares, plus the number of shares of the Company&#8217;s common stock available for issuance under the Special Plan and the 2011 Plan immediately prior to the effectiveness of the 2017 Plan. In addition, the number of shares of the Company&#8217;s common stock subject to outstanding awards under the Special Plan and 2011 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will be available for future grant under the 2017 Plan. The number of shares of common stock reserved for issuance under this plan will automatically increase on January 1 of each year, through January 1, 2027, in an amount equal to the lowest of 1,025,490 shares of the Company&#8217;s common stock, 4% of the number of shares of the Company&#8217;s common stock outstanding on January 1 of each year and an amount determined by the Company&#8217;s board of directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares that are expired, terminated, surrendered or canceled under the 2017 Plan without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">439</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">616</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">614</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,002</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,053</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,618</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2018 and December&#160;31, 2017, total unrecognized compensation cost related to the unvested stock-based awards was $11.4 million and $4.0 million, respectively, which is expected to be recognized over weighted average periods of 3.07 and 2.76 years, respectively.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s stock option activity since December&#160;31, 2017 (in thousands, except share and per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,403,119</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.81</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,128</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">829,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,027</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.25</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111,977</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.06</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of June 30, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,099,615</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.83</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of June 30, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,178</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.06</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.47</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options unvested as of June 30, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,559,437</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.79</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant-date fair value per share of stock options granted during the three and six months ended June 30, 2018 was $11.66 and $11.77, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6630471744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Net Loss per Share </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per Share Attributable to Common Stockholders </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,133</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,705</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,763</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,090</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of redeemable convertible preferred stock to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; redemption value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,133</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,718</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,763</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,110</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,304,102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,900</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,299,288</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,900</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders &#8212; basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.85</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11.13</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potentially dilutive securities, which include options to purchase common stock, redeemable convertible preferred stock, warrants to purchase common stock and warrants to purchase redeemable convertible preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three and Six</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months&#160;Ended June 30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,099,615</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,198,291</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redeemable convertible preferred stock (as converted to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,729,121</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,414</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase redeemable convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,414</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,110,029</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,937,826</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632117552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Commitments and Contingencies </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lease Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2010, the Company entered into a lease agreement for office, laboratory, parking and storage space in Vienna, Austria (&#8220;Vienna Lease&#8221;), which expires on April&#160;30, 2021. The Company has the option to extend the lease agreement for an additional year. The Vienna Lease includes a rent escalation clause based on an inflation index.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, the Company entered into a lease agreement for an animal-use facility in Vienna, Austria (&#8220;Animal-use Lease&#8221;). The lease initially had a one-year noncancelable term, which expired in June 2016, after which the lease became cancelable by either party upon six months&#8217; prior written notice. Base rent for the Animal-use Lease is approximately $0.4 million annually, accordingly, rent expense is being recognized on a straight-line basis over the lease term.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2015, the Company entered into a lease agreement for office and laboratory space in Waltham, MA (&#8220;Waltham Lease&#8221;), which expires on January 31, 2019. The Waltham Lease includes a rent escalation clause, and accordingly, rent expense is being recognized on a straight-line basis over the lease term.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company entered into a lease agreement for office space in Waltham, MA (&#8220;Lease Agreement&#8221;). The term of the Lease Agreement commences on the earlier of (a) the later to occur of (x) the date on which the premises are ready for occupancy and (y) December 1, 2018, or (b) the date on which the Company commences occupancy (the &#8220;Commencement Date&#8221;) and expires approximately five years from the Commencement Date. The Company currently anticipates that the term will begin on December 1, 2018. The Lease Agreement includes a rent escalation clause, and accordingly, rent expense will be recognized on a straight-line basis over the lease term.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes rent expense over the respective lease period and has recorded deferred rent for rent expense incurred but not yet paid.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded rent expense <font style="color:#000000;">of $0.3 million and $0.3 million during the three months ended June 30, 2018 and 2017, respectively, and $0.6 million and $0.6 million during the six months ended June 30, 2018 and 2017.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the future minimum lease payments due under the Company&#8217;s operating leases as of June 30, 2018 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.64%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">881</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">996</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">648</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">479</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,114</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 10, 2018<font style="color:#000000;">, the Company entered into an amendment to the Lease Agreement (&#8220;Amended Lease Agreement&#8221;) with BP Bay Colony LLC (the &#8220;Lessor&#8221;). Under the terms of the Amended Lease Agreement, the Company will relocate its Waltham, MA premises to a new premises with 5,711 square feet of office space as compared to the 10,290 square feet premises in the original Lease Agreement. The annual base rent obligation is approximately $0.3 million, with a total cash obligation for the base rent over the initial five-year term of the Amended Lease Agreement is approximately $1.3 million. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, in accordance with the terms of the Amended Lease Agreement. The Company will provide a security deposit in the amount of $0.3 million as well as a relocation payment of $0.1 million to the Lessor. The entry into this Amended Lease Agreement reduces the minimum lease payments presented in the table above from $4.1 million to approximately $3.2 million.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into the Adimab Option Agreement in February 2017 under which it is obligated to make contingent and non-contingent payments should the Company exercise its option to obtain rights to certain RSV antibodies (see Note 5). If the Company chose to exercise its option, it would be obligated to pay Adimab an option fee of $0.3 million and make clinical and regulatory milestone payments of up to $24.4 million, as well as royalty payments on a product-by-product and country-by-country basis of a mid single-digit percentage based on net sales by the Company, its affiliates, licensees or sublicensees of products based on certain RSV antibodies during the applicable term for such product in that country. The Company may choose to exercise its option under the terms of the Adimab Option Agreement at any time on or before August 31, 2019. As of June 30, 2018 and December 31, 2017, the Company had not exercise its option under the Adimab Option Agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Manufacturing Commitments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2016, the Company entered into an agreement with Boehringer Ingelheim International GmbH (&#8220;BI&#8221;), a contract manufacturing organization, for the manufacture and supply of ASN100 drug product for the Company&#8217;s completed Phase 1 and discontinued Phase 2 clinical trials. In March 2016, the Company entered into an agreement with Cytovance Biologics, Inc. (&#8220;Cytovance&#8221;) for process development and the manufacture and supply of ASN100 drug product. Under such agreements, the Company is obligated to pay BI and Cytovance development and manufacturing milestones, in addition to reimbursement of certain material production-related costs. Additionally, the Company is required to make prepayments for process development services and manufacture and delivery of ASN100 material. The terms of these agreements require future delivery and formal acceptance of the clinical material upon delivery from BI and Cytovance. Formal acceptance includes validation of the clinical material and that established specifications and good manufacturing practices, or GMP, standards have been followed during the manufacture. It is only after acceptance that title and risks and rewards of ownership pass to the Company and at that time advance payments will be applied to the purchase of clinical materials required to be produced under the agreements. The purchase of the clinical material will, at the point of delivery, be charged to research and development expense. The Company&#8217;s policy is to expense research and development costs as incurred (i.e., as services are provided by the Company&#8217;s vendors or as qualifying materials are delivered).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did not terminate the agreements with BI and Cytovance following its decision to discontinue the Phase 2 clinical trial for ASN100. Amounts recorded as of June 30, 2018 represent advance payments to BI and Cytovance for the development and manufacturing of ASN100 drug product that is expected to be completed in the second half of 2018. As of June 30, 2018 and December&#160;31, 2017, the Company had committed to minimum payments under this agreement totaling $<font style="color:#000000;">3.2</font> million and $4.7 million, respectively. As of June 30, 2018 and December 31, 2017, prepaid clinical manufacturing expenses totaled $2.4 million $0, respectively. </p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6631012352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Related Party Transactions </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreements with Adimab, LLC </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made payments to Adimab of $0.1 million and $0 during the three months ended June 30, 2018 and 2017, respectively, and $0.1 million&#160;and $0 during the six months ended June 30, 2018 and 2017, respectively, under the Adimab Option Agreement. The Company recognized $14,000 and $58,000 during the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $0.1 million during the six months ended June 30, 2018 and 2017, respectively, of research and development expense under the Adimab Option Agreement. As of June 30, 2018 and December 31, 2017, the Company owed $14,000 and $21,000, respectively, to Adimab under the Adimab Option Agreement. The chairman of the Company&#8217;s board of directors is a co-founder of Adimab and currently serves as Adimab&#8217;s Chief Executive Officer. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Services and Facilities Agreement with EveliQure Biotechnologies GmbH </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s wholly owned subsidiary, Arsanis Biosciences GmbH, leases office and lab space in Vienna, Austria from a third party. In February 2015, Arsanis Biosciences GmbH entered into a services and facilities agreement with EveliQure Biotechnologies GmbH (&#8220;EveliQure&#8221;) under which the Company provides certain laboratory services and sublets office and lab space to EveliQure. Tamas Henics, the husband of Eszter Nagy, the Company&#8217;s former Chief Scientific Officer, serves as Chief Scientific Officer at EveliQure. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 28, 2018 and in accordance with the terms of this agreement with EveliQure, the Company provided EveliQure with written notice that the services and facilities agreement will terminate and EveliQure will vacate the sublet space no later than December 31, 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three and six months ended June 30, 2018, the Company received payments from EveliQure under the agreement of $0 and $0.1 million, respectively, and less than $0.1 million and $0.1 million during the three and six months ended June 30, 2017, respectively. During the three and six months ended June 30, 2018 and 2017, the Company recognized other income under the agreement of less than $0.1 million in each period. As of June 30, 2018 and December 31, 2017, amounts due from EveliQure totaled less than $0.1 million and $0.1 million, respectively. </p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632583968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Subsequent Events </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Amended and Restated Gates Foundation Grant Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 8, 2018, the Company entered into an amended and restated grant agreement with the Gates Foundation which replaces the February 2017 grant agreement in its entirety. The amended and restated grant agreement includes amendments to conform to current Gates Foundation audit, reporting, and other administrative requirements, as well as to make the Company&#8217;s grant of a perpetual license to the Gates Foundation irrevocable. See Note 5 for further discussion.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Gates Foundation Grant Agreement&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> On August 8, 2018, the Company entered into an additional grant agreement with the Gates Foundation pursuant to which the Gates Foundation granted to the Company up to $1.1 million to conduct preclinical development activities for the RSV project that were not included in the February 2017 grant agreement, as amended and restated in August 2018. In return, the Company has agreed to conduct the RSV project in a manner that ensures that the knowledge and information gained from the project will be promptly and broadly disseminated, and that the products, technologies, materials, processes and other intellectual property resulting from the RSV project will be made available and accessible at an affordable price to people most in need within developing countries. These obligations survive any expiration or termination of the grant agreement. See Note 5 for further discussion.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Forbearance Agreement with Silicon Valley Bank&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 8, 2018, the Company and SVB entered into a Forbearance Agreement to address the Company&#8217;s ongoing default under the 2012 Loan Agreement as a result of the Company&#8217;s failure to obtain SVB&#8217;s written consent prior to entering into certain Option and License Agreements. Under the terms of the Forbearance Agreement, SVB has agreed to forbear from exercising its rights and remedies with respect to such defaults until the earlier to occur of (i) another event of default under the 2012 Loan Agreement or (ii) October 31, 2018. See Note 6 for further discussion.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Lease Amendment</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 10, 2018, the Company entered into an amendment to its Lease Agreement (&#8220;Amended Lease Agreement&#8221;) with BP Bay Colony LLC (the &#8220;Lessor&#8221;). Under the terms of the Amended Lease Agreement, the Company will relocate its premises in Waltham, MA to a new premises with 5,711 square feet of office space as compared to the 10,290 square feet premises in the original Lease Agreement. The term of the Amended Lease Agreement commences on January 1, 2019 and expires December 31, 2023. The Company has the option to extend the term for one additional five-year period upon the Company&#8217;s written notice to the Lessor at least nine months and no more than 12 months in advance of the extension. The Amended Lease Agreement terminates the Company&#8217;s one-time right of first offer, subject to certain terms and conditions, for additional space containing approximately 4,000 square feet specified in the Lease Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The annual base rent obligation is approximately $0.3 million, with a total cash obligation for the base rent over the initial five-year term of the Amended Lease Agreement is approximately $1.3 million. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, in accordance with the terms of the Amended Lease Agreement. The Company will provide a security deposit in the amount of $0.3 million as well as a relocation payment of $0.1 million to the Lessor. See Note 10 for further discussion.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">August 2018 Reduction in Force</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> On August 10, 2018, the Company&#8217;s board of directors approved a reduction in workforce to reduce operating costs and better align the company&#8217;s workforce with the needs of its business following the Company&#8217;s discontinuation of the clinical development of ASN100. As part of this reduction in workforce, the Company plans to eliminate 19 positions across the company, representing approximately 44% of its workforce. The Company anticipates that it will substantially complete the implementation of the reduction in workforce by the fourth quarter of 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently estimates that it will incur total expenses relating to the reduction in workforce of approximately $0.6 million, which is comprised of notice and severance payments. The Company expects to record these charges in the third and fourth quarters of 2018.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814160800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_UnauditedInterimFinancialStatementsPolicyTextBlock', window );">Unaudited Interim Financial Statements</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unaudited Interim Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The condensed balance sheet at December&#160;31, 2017 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying condensed financial statements as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017 are unaudited. The accompanying unaudited interim financial statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s&#160;audited financial statements and the notes thereto for the year ended December&#160;31, 2017 included in the Company&#8217;s&#160;Annual Report on Form 10-K as filed with the SEC on March&#160;9, 2018. In the opinion of management, all adjustments, consisting only of normal recurring adjustments as necessary, for the fair statement of the Company&#8217;s condensed financial position as of June 30, 2018 and condensed results of its operations for the three and six months ended June 30, 2018 and 2017 and cash flows for the six months ended June 30, 2018 and 2017 have been made. The results of operations for the three and six months ended June 30, 2018 and 2017 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2018.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of common stock and stock options. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;text-indent:4.54%;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Certain assets of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of cash equivalents, other current assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The carrying value of the Company&#8217;s loan and security agreement with Silicon Valley Bank (&#8220;SVB&#8221;) approximates its fair value because the debt bears interest at a market rate. The carrying value of the loans received under the funding agreements with &#214;sterreichische Forschungsf&#246;rderungsgesellschaft mbH (&#8220;FFG&#8221;) approximates their fair value because the Company records imputed interest expense based on rates that approximate market rates of interest as of the issuance date of each FFG loan. </p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Gain (Loss)</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Gain (Loss) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive gain (loss) includes net gain (loss) as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. Comprehensive gain (loss) included $0.3 million and $(0.3) million for the three months ended June 30, 2018 and 2017, respectively, and $0.1 million and $(0.4) million for the six months ended June 30, 2018 and 2017, respectively, of foreign currency translation gain (loss) adjustments. </p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) per Share</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Income (Loss) per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period, including potential dilutive common shares. For purpose of this calculation, options to purchase common stock, redeemable convertible preferred stock, warrants to purchase common stock and warrants to purchase redeemable convertible preferred stock are considered potential dilutive common shares.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s redeemable convertible preferred stock contractually entitled the holders of such shares to participate in dividends but contractually did not require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted/Issued Accounting Pronouncements</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2014-09, <font style="font-style:italic;">Revenue from Contracts with Customers </font>(&#8220;ASU 2014-09&#8221;), which supersedes most existing revenue recognition guidance under GAAP. The FASB also issued several amendments and updates to the new revenue standard (collectively, &#8220;Topic 606&#8221;). The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle, and will require companies to use more judgment and make more estimates than under the current guidance. These judgments and estimates include identifying performance obligations in the customer contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows as the Company does not currently have any revenue-generating arrangements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2016, the FASB issued ASU No.&#160;2016-15, <font style="font-style:italic;">Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments</font> (&#8220;ASU 2016-15&#8221;), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The Company adopted the standard retrospectively to all periods presented on the required effective date of January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2016, the FASB issued ASU No.&#160;2016-16, <font style="font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory</font> (&#8220;ASU 2016-16&#8221;), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2016, the FASB issued ASU No.&#160;2016-18, <font style="font-style:italic;">Statement of Cash Flows (Topic 230): Restricted Cash</font> (&#8220;ASU 2016-18&#8221;), which requires restricted cash to be presented with cash and cash equivalents on the statement of cash flows and disclosure of how the statement of cash flows reconciles to the balance sheet if restricted cash is shown separately from cash and cash equivalents on the balance sheet. The Company adopted this standard on January 1, 2018. The adoption of ASU 2016-18 resulted in the Company's cash, cash equivalents and restricted cash being included in the beginning and ending amounts for the periods shown on the statement of cash flows and was applied retroactively and reflected in the balances presented for any prior periods. The Company believes that the adoption of this guidance did not have a significant impact on its condensed consolidated financial statements and related disclosures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The restricted cash as of June 30, 2018 and December 31, 2017 is held as letters of credit for the benefit of the landlords in connection with the Company&#8217;s office leases.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,940</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,143</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash &#8211; current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,361</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash &#8211; non-current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the statement of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; cash flows</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,286</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,844</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, FASB issued ASU No.&#160;2017-01, <font style="font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business</font> (&#8220;ASU 2017-01&#8221;). The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill and consolidation. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU No.&#160;2017-09, <font style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Scope of Modification Accounting</font> (&#8220;ASU 2017-09&#8221;), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. The Company adopted this guidance, effective January 1, 2018, and its adoption had no impact on the Company&#8217;s financial position, results of operations or cash flows. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2018, the FASB issued ASU 2018-05, <font style="font-style:italic;">Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118</font> ("ASU&#160;2018-05"). This standard amends ASC 740, Income Taxes (&#8220;ASC 740&#8221;) to provide guidance on accounting for the tax effects of the Tax Cuts and Jobs Act pursuant to Staff Accounting Bulletin No. 118, which allows companies to complete the accounting under ASC 740 within a one-year measurement period from the Tax Act enactment date. This standard was effective upon issuance. <font style="color:#000000;">The Company will continue to assess the impact that various provisions will have on its business. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the FASB issued&#160;ASU 2018-07,&#160;<font style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting </font>(&#8220;ASU 2018-07&#8221;), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The new standard specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&#8217;s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. ASU 2018-07 is required to be adopted for annual periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2018-07 will have on its consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the FASB issued&#160;ASU 2017-11,&#160;<font style="font-style:italic;">Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</font> (&#8220;ASU 2017-11&#8221;).&#160;Part I applies to entities that issue financial instruments such as warrants, convertible debt or convertible preferred stock that contain down-round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of nonpublic entities contained within ASC Topic 480&#160;with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. ASU 2017-11 is required to be adopted for annual periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that the adoption of ASU 2017-11 will have on its consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No.&#160;2016-02<font style="font-style:italic;">, Leases (Topic 842)</font> (&#8220;ASU 2016-02&#8221;), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASU 2016-02 (Accounting Standards Codification (&#8220;ASC&#8221;) (Topic 842) supersedes the previous leases standard, ASC 840, Leases. The standard is effective for public entities for annual periods beginning after December&#160;15, 2018 including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-02 will have on its consolidated financial statements. </p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_FFGLoansPolicyTextBlock', window );">FFG Loans</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">FFG Loans </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Loans under the funding agreements with FFG bear interest at rates that are below market rates of interest. The Company accounts for the imputed benefit arising from the difference between a market rate of interest and the rate of interest charged by FFG as additional grant funding from FFG. On the date that FFG loan proceeds are received, the Company recognizes the portion of the loan proceeds allocated to grant funding as a discount to the carrying value of the loan and as unearned income, which is recognized as additional grant income over the term of the funding agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company has recorded a discount to the carrying value of each FFG loan for the portion of the loan proceeds allocated to grant funding, which is being amortized to interest expense over the term of the loan using the effective interest method.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_ResearchAndDevelopmentIncentivePolicyTextBlock', window );">Research and Development Incentive</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Incentive <font style="font-weight:normal;font-style:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company participates in a research and development incentive program provided by the Austrian government whereby the Company is entitled to reimbursement by the Austrian government for a percentage of qualifying research and development expenses incurred by the Company&#8217;s subsidiary in Austria. Under the program, the reimbursement rate for qualifying research and development expenses incurred by the Company through its subsidiary in Austria was 12% for the year ended December 31, 2017, and is 14% for the year ended December 31, 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes incentive income from Austrian research and development incentives when qualifying expenses have been incurred, there is reasonable assurance that the payment will be received, and the consideration can be reliably measured. Management has assessed the Company&#8217;s research and development activities and expenditures to determine which activities and expenditures are likely to be eligible under the research and development incentive program described above. At each reporting date, management estimates the reimbursable incentive income available to the Company based on available information at the time.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_TwoThousandTwelveLoanAgreementPolicyTextBlock', window );">2012 Loan Agreement</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2012 Loan Agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The debt discount is reflected as a reduction of the carrying value of the loan payable on the Company&#8217;s consolidated balance sheet and is being amortized to interest expense over the term of the loan using the effective interest method.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_FFGLoansPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>FFG loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_FFGLoansPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_ResearchAndDevelopmentIncentivePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development incentive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_ResearchAndDevelopmentIncentivePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_TwoThousandTwelveLoanAgreementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>2012 loan agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_TwoThousandTwelveLoanAgreementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_UnauditedInterimFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_UnauditedInterimFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818131104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,940</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,143</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash &#8211; current</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,361</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash &#8211; non-current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">340</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the statement of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; cash flows</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,286</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,844</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of reconciliation of cash and cash equivalents and restricted cash to cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_ScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashToCashFlowsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632673072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured at Fair Value</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents - Money Market Funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,576</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,576</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,576</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,576</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents - Money Market Funds</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,891</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,891</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,891</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,891</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809746576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Accrued expenses consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial costs</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,335</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,317</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and benefits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,539</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,454</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">563</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">510</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">442</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,879</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,779</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816023008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Aggregate Principal Amount of Debt Outstanding</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The aggregate principal amount of debt outstanding as of June 30, 2018 and December 31, 2017 consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term loans under 2012 Loan Agreement</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,667</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FFG loans</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,937</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,225</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,437</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,892</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Current and Non-current Debt obligations</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Current and non-current debt obligations reflected in the condensed consolidated balance sheets as of June 30, 2018 and December 31, 2017 consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term loans under 2012 Loan Agreement</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,333</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FFG loans</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loans payable, net of discount</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,486</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,314</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term loans under 2012 Loan Agreement</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,334</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FFG loans</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,937</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,225</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unamortized debt discount</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,231</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,637</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loans payable, net of discount and current portion</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,706</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,922</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.76%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total loans payable, net of discount</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,192</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,236</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6652685488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation Expense Classification</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">439</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">616</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">614</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,002</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,053</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,618</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table summarizes the Company&#8217;s stock option activity since December&#160;31, 2017 (in thousands, except share and per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2017</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,403,119</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.81</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,128</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">829,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.19</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,027</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.25</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(111,977</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.06</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of June 30, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,099,615</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.83</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.16%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable as of June 30, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,178</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.06</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.47</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options unvested as of June 30, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,559,437</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.79</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.30</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6652688928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,133</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,705</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,763</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,090</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of redeemable convertible preferred stock to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; redemption value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,133</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,718</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,763</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,110</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding&#8212;basic and diluted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,304,102</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,900</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,299,288</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,900</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders &#8212; basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.85</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11.13</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s potentially dilutive securities, which include options to purchase common stock, redeemable convertible preferred stock, warrants to purchase common stock and warrants to purchase redeemable convertible preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three and Six</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months&#160;Ended June 30,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,099,615</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,198,291</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redeemable convertible preferred stock (as converted to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,729,121</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,414</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase redeemable convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stock (as converted to common stock)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,414</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,110,029</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,937,826</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818145168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Lease Payments Due under Operating Leases</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table summarizes the future minimum lease payments due under the Company&#8217;s operating leases as of June 30, 2018 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.64%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">662</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">881</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">996</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">648</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">479</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">448</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:62.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,114</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828652496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 20, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Nov. 03, 2017</div></th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-3.4130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from offerings</a></td>
<td class="nump">$ 58,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock into common stock | shares</a></td>
<td class="nump">7,180,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,133<span></span>
</td>
<td class="nump">$ 5,705<span></span>
</td>
<td class="nump">22,763<span></span>
</td>
<td class="nump">$ 11,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,940<span></span>
</td>
<td class="nump">$ 24,143<span></span>
</td>
<td class="nump">49,940<span></span>
</td>
<td class="nump">$ 24,143<span></span>
</td>
<td class="nump">$ 76,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=asns_AccountingStandardsUpdate201415Member', window );">ASU 2014-15</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | New Enterprise Associates 16, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=asns_AccountingStandardsUpdate201415Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=asns_AccountingStandardsUpdate201415Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asns_NewEnterpriseAssociates16LPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=asns_NewEnterpriseAssociates16LPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6801977136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation gain (loss)</a></td>
<td class="nump">$ 270<span></span>
</td>
<td class="num">$ (297)<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="num">$ (379)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827874336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 49,940<span></span>
</td>
<td class="nump">$ 76,793<span></span>
</td>
<td class="nump">$ 24,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash &#8211; current</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; non-current</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 50,286<span></span>
</td>
<td class="nump">$ 77,148<span></span>
</td>
<td class="nump">$ 32,844<span></span>
</td>
<td class="nump">$ 3,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 305<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84242212&amp;loc=d3e2352-115587<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814311872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of Assets Measured at Fair Value (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 49,576<span></span>
</td>
<td class="nump">$ 70,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">49,576<span></span>
</td>
<td class="nump">70,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">49,576<span></span>
</td>
<td class="nump">70,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 49,576<span></span>
</td>
<td class="nump">$ 70,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809694144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount', window );">Transfers between fair value levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value transfers between Level 1, Level 2 and Level 3 amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_FairValueTransfersBetweenLevel1Level2OrLevel3Amount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819992384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_AccruedClinicalTrialCosts', window );">Accrued clinical trial costs</a></td>
<td class="nump">$ 1,335<span></span>
</td>
<td class="nump">$ 2,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,539<span></span>
</td>
<td class="nump">2,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 3,879<span></span>
</td>
<td class="nump">$ 5,779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_AccruedClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_AccruedClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833103392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration, License and Funding Arrangements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 20, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 03, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,930,000<span></span>
</td>
<td class="nump">$ 3,906,000<span></span>
</td>
<td class="nump">$ 17,063,000<span></span>
</td>
<td class="nump">$ 8,297,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantAndIncentiveIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516,000<span></span>
</td>
<td class="nump">862,000<span></span>
</td>
<td class="nump">$ 961,000<span></span>
</td>
<td class="nump">1,562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock into common stock | shares</a></td>
<td class="nump">7,180,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-3.4130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantAndIncentiveReceivables', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,608,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_UnearnedIncomeCurrent', window );">Unearned income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_UnearnedIncomeNoncurrent', window );">Unearned income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=asns_AustriaMember', window );">Austria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_ReimbursementRateForResearchAndDevelopment', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=asns_AustriaMember', window );">Austria | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_ReimbursementRateForResearchAndDevelopment', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember', window );">February 2017 Grant Agreement | Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantsAgreementMaximumAwardAmount', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_RelatedPartyTransactionProceedsFromGrants', window );">Proceeds from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantAndIncentiveIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_UnearnedIncome', window );">Unearned income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=asns_AugustTwoThousandAndEighteenGrantAgreementMember', window );">August 2018 Grant Agreement | Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantAndIncentiveIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_UnearnedIncome', window );">Unearned income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantAgreementExpirationDate', window );">Grant agreement expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=asns_AugustTwoThousandAndEighteenGrantAgreementMember', window );">August 2018 Grant Agreement | Gates Foundation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantsAgreementMaximumAwardAmount', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=asns_GrantAgreementMember', window );">Grant Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_QualifyingExpensesUnderLetterAgreement', window );">Qualifying expenses related to letter agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=asns_GrantAgreementMember', window );">Grant Agreement | Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock into common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-3.4130 reverse-stock-split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=asns_GrantAgreementMember', window );">Grant Agreement | Gates Foundation | Series D Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,464,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=asns_FFGGrantsMember', window );">FFG Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantAndIncentiveIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_UnearnedIncome', window );">Unearned income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantAndIncentiveReceivables', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=asns_FFGLoansMember', window );">FFG Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantAndIncentiveIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_UnearnedIncomeCurrent', window );">Unearned income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_UnearnedIncomeNoncurrent', window );">Unearned income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=asns_ResearchAndDevelopmentIncentiveProgramMember', window );">Research and Development Incentive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantAndIncentiveIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantAndIncentiveReceivables', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asns_AdimabLLCMember', window );">Adimab, LLC | Adimab Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationPaymentObligations', window );">Collaboration payment obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Funding Agreements with FFG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_PercentageOfLoansAndGrantsToFund', window );">Percentage of loans and grants to fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Funding Agreements with FFG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CollaborationLicenseAndFundingArrangementsLineItems', window );"><strong>Collaboration License And Funding Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_PercentageOfLoansAndGrantsToFund', window );">Percentage of loans and grants to fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_CollaborationLicenseAndFundingArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration, license and funding arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_CollaborationLicenseAndFundingArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_CollaborationPaymentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration payment obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_CollaborationPaymentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_GrantAgreementExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant agreement expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_GrantAgreementExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_GrantAndIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant and incentive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_GrantAndIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_GrantAndIncentiveReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant and incentive receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_GrantAndIncentiveReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_GrantsAgreementMaximumAwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grants agreement maximum award amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_GrantsAgreementMaximumAwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_PercentageOfLoansAndGrantsToFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of loans and grants to fund.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_PercentageOfLoansAndGrantsToFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_QualifyingExpensesUnderLetterAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Qualifying expenses under the letter agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_QualifyingExpensesUnderLetterAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_ReimbursementRateForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement rate for research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_ReimbursementRateForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_RelatedPartyTransactionProceedsFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction proceeds from grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_RelatedPartyTransactionProceedsFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_UnearnedIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unearned income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_UnearnedIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_UnearnedIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unearned income current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_UnearnedIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_UnearnedIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unearned income noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_UnearnedIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=asns_AustriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=asns_AustriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=asns_FebruaryTwoThousandAndSeventeenGrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=asns_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=asns_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=asns_AugustTwoThousandAndEighteenGrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=asns_AugustTwoThousandAndEighteenGrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=asns_GrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=asns_GrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=asns_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=asns_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=asns_FFGGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=asns_FFGGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=asns_FFGLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=asns_FFGLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=asns_ResearchAndDevelopmentIncentiveProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=asns_ResearchAndDevelopmentIncentiveProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asns_AdimabLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asns_AdimabLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=asns_AdimabOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=asns_AdimabOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=asns_FundingArrangementsWithFFGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=asns_FundingArrangementsWithFFGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826881424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans Payable - Schedule of Aggregate Principal Amount of Debt Outstanding (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount of debt outstanding</a></td>
<td class="nump">$ 13,437<span></span>
</td>
<td class="nump">$ 14,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember', window );">Term Loans under 2012 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount of debt outstanding</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">4,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_FFGLoansMember', window );">FFG Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount of debt outstanding</a></td>
<td class="nump">$ 9,937<span></span>
</td>
<td class="nump">$ 10,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_FFGLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_FFGLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816723632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loans Payable - Schedule of Current and Non-current Debt obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable, net of discount</a></td>
<td class="nump">$ 3,486<span></span>
</td>
<td class="nump">$ 2,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Unamortized debt discount</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent', window );">Unamortized debt discount</a></td>
<td class="num">(2,231)<span></span>
</td>
<td class="num">(2,637)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loan payable, net of discount and current portion</a></td>
<td class="nump">7,706<span></span>
</td>
<td class="nump">9,922<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Total loans payable, net of discount</a></td>
<td class="nump">11,192<span></span>
</td>
<td class="nump">12,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember', window );">Term Loans under 2012 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable, net of discount</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Loans payable, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_FFGLoansMember', window );">FFG Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Loans payable, non-current</a></td>
<td class="nump">$ 9,937<span></span>
</td>
<td class="nump">$ 10,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_FFGLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_FFGLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833852944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Payable - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 23, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 19, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 07, 2012 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>Tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 25, 2013 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_NumberOfTranches', window );">Tranches | Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_PrepaymentFeePercentageToOutstandingPrincipalAmount', window );">Prepayment fee percentage to outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Aggregate principal loan amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,437,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,437,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,892,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=asns_ExercisePriceOneMember', window );">Exercise Price One | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=asns_ExercisePriceTwoMember', window );">Exercise Price Two | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_PrepaymentFeePercentageToOutstandingPrincipalAmount', window );">Prepayment fee percentage to outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_PrepaymentFeePercentageToOutstandingPrincipalAmount', window );">Prepayment fee percentage to outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=asns_SeriesATwoPreferredStockWarrantsMember', window );">Series A-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_ClassOfWarrantOrRightsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  06,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=asns_SeriesBWarrantsMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_ClassOfWarrantOrRightsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 18,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=asns_SeriesBWarrantsMember', window );">Series B Preferred Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandTwelveTermLoanAAdvanceMember', window );">2012 Term Loan A Advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandTwelveTermLoanAAdvanceMember', window );">2012 Term Loan A Advance | Series A-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandTwelveLoanAgreementMember', window );">2012 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Additional amounts available to be borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate increase percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandTwelveTermLoanBAdvanceMember', window );">2012 Term Loan B Advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandTwelveTermLoanBAdvanceMember', window );">2012 Term Loan B Advance | Series A-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanAAdvanceMember', window );">2016 Term Loan A Advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanAAdvanceMember', window );">2016 Term Loan A Advance | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanBAdvanceMember', window );">2016 Term Loan B Advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from borrowings</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanBAdvanceMember', window );">2016 Term Loan B Advance | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Advance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanBAdvanceMember', window );">2016 Term Loan B Advance | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase stock | shares</a></td>
<td class="nump">7,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanAdvanceMember', window );">2016 Term Loan Advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_PercentageMinusWallStreetJournalPrimeRate', window );">Percentage minus Wall Street Journal prime rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_PrepaymentFeePercentageToOutstandingPrincipalAmount', window );">Prepayment fee percentage to outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanAdvanceMember', window );">2016 Term Loan Advance | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_FirstAmendmentMember', window );">First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Arrangement fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Legal costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember', window );">Term Loans under 2012 Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Aggregate principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Aggregate principal loan amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_FFGLoansMember', window );">FFG Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Aggregate principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Aggregate principal loan amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,937,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,937,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Loan amount maturity start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1', window );">Loan amount maturity end date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_FFGLoansMember', window );">FFG Loans | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=asns_FFGLoansMember', window );">FFG Loans | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_ClassOfWarrantOrRightsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or rights expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_ClassOfWarrantOrRightsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of tranches.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_PercentageMinusWallStreetJournalPrimeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage minus Wall Street Journal prime rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_PercentageMinusWallStreetJournalPrimeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_PrepaymentFeePercentageToOutstandingPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment fee percentage to outstanding principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_PrepaymentFeePercentageToOutstandingPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Latest date the outstanding debt instruments are required to be repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeEnd1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeStart1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earliest date the outstanding debt instruments are required to be repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeStart1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=asns_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=asns_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=asns_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=asns_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=asns_SeriesATwoPreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=asns_SeriesATwoPreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=asns_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=asns_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandTwelveTermLoanAAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_TwoThousandTwelveTermLoanAAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandTwelveLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_TwoThousandTwelveLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandTwelveTermLoanBAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_TwoThousandTwelveTermLoanBAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanAAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanAAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanBAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanBAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanAdvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_TwoThousandSixteenTermLoanAdvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_FirstAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_FirstAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_TermLoansUnderTwoThousandTwelveLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=asns_FFGLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=asns_FFGLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818143824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">2,738,039<span></span>
</td>
<td class="nump">2,187,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827415904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock-based compensation arrangement, number of options granted to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">829,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to the unvested stock-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation cost related to unvested awards is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 26 days<span></span>
</td>
<td class="text">2 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value per share of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.66<span></span>
</td>
<td class="nump">$ 11.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=asns_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock-based compensation arrangement, number of options granted to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">585,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=asns_TwoThousandAndTenSpecialStockIncentivePlanMember', window );">2010 Special Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock-based compensation arrangement, number of options granted to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=asns_TwoThousandAndElevenStockIncentivePlanMember', window );">2011 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock-based compensation arrangement, number of options granted to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Board of Directors | 2017 Equity Incentive Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of common stock outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Board of Directors | Maximum | 2017 Equity Incentive Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Stock-based compensation arrangement, number of additional shares authorized</a></td>
<td class="nump">1,025,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=asns_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=asns_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=asns_TwoThousandAndTenSpecialStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=asns_TwoThousandAndTenSpecialStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=asns_TwoThousandAndElevenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=asns_TwoThousandAndElevenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817010400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense Classification (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,053<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 1,618<span></span>
</td>
<td class="nump">$ 354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 614<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833181568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Beginning Balance</a></td>
<td class="nump">1,403,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Granted</a></td>
<td class="nump">829,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Exercised</a></td>
<td class="num">(21,027)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares Forfeited</a></td>
<td class="num">(111,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending Balance</a></td>
<td class="nump">2,099,615<span></span>
</td>
<td class="nump">1,403,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Share Options exercisable as of June 30, 2018</a></td>
<td class="nump">540,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Share Options unvested as of June 30, 2018</a></td>
<td class="nump">1,559,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Number of Shares Outstanding, Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 6.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Number of Shares Granted, Weighted Average Exercise Price</a></td>
<td class="nump">17.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Number of Shares Exercised, Weighted Average Exercise Price</a></td>
<td class="nump">7.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Number of Shares Forfeited, Weighted Average Exercise Price</a></td>
<td class="nump">11.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Number of Shares Outstanding, Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">10.31<span></span>
</td>
<td class="nump">$ 6.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Number of Share Options exercisable, Weighted Average Exercise Price as of June 30, 2018</a></td>
<td class="nump">6.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Number Share Options unvested, Weighted Average Exercise Price as of June 30, 2018</a></td>
<td class="nump">$ 11.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Number of Shares Outstanding, Weighted Average Remaining Contractual Term at End of Period</a></td>
<td class="text">8 years 9 months 29 days<span></span>
</td>
<td class="text">8 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Number of Share Options exercisable, Weighted Average Remaining Contractual Term as of June 30, 2018</a></td>
<td class="text">7 years 5 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm', window );">Number of Share Options unvested, Weighted Average Remaining Contractual Term as of June 30, 2018</a></td>
<td class="text">9 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Number of Share Options Outstanding, Aggregate Intrinsic Value Ending Balance</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 9,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Number of Share Options exercisable, Aggregate Intrinsic Value as of June 30, 2018</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, nonvested, outstanding, weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6707554608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,133)<span></span>
</td>
<td class="num">$ (5,705)<span></span>
</td>
<td class="num">$ (22,763)<span></span>
</td>
<td class="num">$ (11,090)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (12,133)<span></span>
</td>
<td class="num">$ (5,718)<span></span>
</td>
<td class="num">$ (22,763)<span></span>
</td>
<td class="num">$ (11,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding&#8212;basic and diluted</a></td>
<td class="nump">14,304,102<span></span>
</td>
<td class="nump">513,900<span></span>
</td>
<td class="nump">14,299,288<span></span>
</td>
<td class="nump">513,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted</a></td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (11.13)<span></span>
</td>
<td class="num">$ (1.59)<span></span>
</td>
<td class="num">$ (21.62)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833848000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">2,110,029<span></span>
</td>
<td class="nump">7,937,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">2,099,615<span></span>
</td>
<td class="nump">1,198,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">10,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock (as Converted to Common Stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,729,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember', window );">Warrants to Purchase Redeemable Convertible Preferred Stock (as Converted to Common Stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=asns_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830279024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 30, 2010</div></th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum lease payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=asns_AdimabOptionAgreementMember', window );">Adimab Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_OptionFee', window );">Option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CurrentOfficeSpaceUnderLeaseAgreement', window );">Current office space under lease agreement | ft&#178;</a></td>
<td class="nump">5,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_OriginalOfficeSpaceUnderLeaseAgreement', window );">Original office space under lease agreement | ft&#178;</a></td>
<td class="nump">10,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_AggregateBaseRentObligation', window );">Base rent obligation</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CashObligation', window );">Total Cash obligation</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_RelocationPaymentToLessor', window );">Relocation payment to lessor</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum lease payments due</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=asns_ViennaLeaseAgreementMember', window );">Vienna Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to extend the lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the option to extend the lease agreement for an additional year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=asns_AnimalUseLeaseAgreementMember', window );">Animal-use Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_LesseeOperatingLeaseExpirationDescription', window );">Description of term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease initially had a one-year noncancelable term, which expired in June 2016, after which the lease became cancelable by either party upon six months&#8217; prior written notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=asns_WalthamLeaseAgreementMember', window );">Waltham Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=asns_LeaseAgreementForOfficeSpaceInWalthamMAMember', window );">Lease Agreement for Office Space in Waltham MA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In June 2018, the Company entered into a lease agreement for office space in Waltham, MA (&#8220;Lease Agreement&#8221;). The term of the Lease Agreement commences on the earlier of (a) the later to occur of (x) the date on which the premises are ready for occupancy and (y) December 1, 2018, or (b) the date on which the Company commences occupancy (the &#8220;Commencement Date&#8221;) and expires approximately five years from the Commencement Date. The Company currently anticipates that the term will begin on December 1, 2018. The Lease Agreement includes a rent escalation clause, and accordingly, rent expense will be recognized on a straight-line basis over the lease term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=asns_ManufacturingCommitmentsMember', window );">Manufacturing Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Minimum payments under agreement with a contract manufacturing organization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=asns_PrepaidClinicalManufacturingExpensesMember', window );">Prepaid Clinical Manufacturing Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid Expense, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_AggregateBaseRentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate base rent obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_AggregateBaseRentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_CashObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_CashObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_CurrentOfficeSpaceUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current office space under lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_CurrentOfficeSpaceUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_LesseeOperatingLeaseExpirationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_LesseeOperatingLeaseExpirationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_OptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_OptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_OriginalOfficeSpaceUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Original office space under lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_OriginalOfficeSpaceUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_RelocationPaymentToLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Relocation payment to lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_RelocationPaymentToLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77910348&amp;loc=d3e34039-112682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=asns_AdimabOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=asns_AdimabOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=asns_ViennaLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=asns_ViennaLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=asns_AnimalUseLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=asns_AnimalUseLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=asns_WalthamLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=asns_WalthamLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=asns_LeaseAgreementForOfficeSpaceInWalthamMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=asns_LeaseAgreementForOfficeSpaceInWalthamMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=asns_ManufacturingCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=asns_ManufacturingCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=asns_PrepaidClinicalManufacturingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=asns_PrepaidClinicalManufacturingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633800688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Lease Payments Due under Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases Future Minimum Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2018</a></td>
<td class="nump">$ 662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2021</a></td>
<td class="nump">648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2022</a></td>
<td class="nump">479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum lease payments due</a></td>
<td class="nump">$ 4,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833169728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 8,930,000<span></span>
</td>
<td class="nump">$ 3,906,000<span></span>
</td>
<td class="nump">$ 17,063,000<span></span>
</td>
<td class="nump">$ 8,297,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asns_AdimabLLCMember', window );">Adimab, LLC | Adimab Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_PaymentsToRelatedPartyForPriorPeriodExpense', window );">Payments to related party</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Owed to related party</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asns_EveliQureBiotechnologiesGmbHMember', window );">EveliQure Biotechnologies GmbH | Services and Facilities Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CashReceivedFromRelatedPartyTransaction', window );">Payments received from related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asns_EveliQureBiotechnologiesGmbHMember', window );">EveliQure Biotechnologies GmbH | Services and Facilities Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CashReceivedFromRelatedPartyTransaction', window );">Payments received from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Other income from related party</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related party</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_CashReceivedFromRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_CashReceivedFromRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_PaymentsToRelatedPartyForPriorPeriodExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to related party for prior period expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_PaymentsToRelatedPartyForPriorPeriodExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asns_AdimabLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asns_AdimabLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=asns_AdimabOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=asns_AdimabOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asns_EveliQureBiotechnologiesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asns_EveliQureBiotechnologiesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=asns_ServicesAndFacilitiesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=asns_ServicesAndFacilitiesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833318960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2018 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Employee</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th">
<div>Aug. 08, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=asns_ArsanisClinicalDevelopmentOfASN100Member', window );">August 2018 Reduction in Force | Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total expenses relating to the reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=asns_AugustTwoThousandEighteenLeaseAmendmentMember', window );">August 2018 Lease Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_LeaseAgreementExtensionDescription', window );">Lease agreement extension description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the option to extend the term for one additional five-year period upon the Company&#8217;s written notice to the Lessor at least nine months and no more than 12 months in advance of the extension.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CurrentOfficeSpaceUnderLeaseAgreement', window );">Current office space under lease agreement | ft&#178;</a></td>
<td class="nump">5,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_OriginalOfficeSpaceUnderLeaseAgreement', window );">Original office space under lease agreement | ft&#178;</a></td>
<td class="nump">10,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_AggregateBaseRentObligation', window );">Base rent obligation</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CashObligation', window );">Total Cash obligation</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_RelocationPaymentToLessor', window );">Relocation payment to lessor</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | August 2018 Reduction in Force</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_NumberOfEliminatedPositions', window );">Number of eliminated positions | Employee</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_PercentageOfEliminatedPositions', window );">Percentage of eliminated positions</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | August 2018 Lease Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CurrentOfficeSpaceUnderLeaseAgreement', window );">Current office space under lease agreement | ft&#178;</a></td>
<td class="nump">5,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_OriginalOfficeSpaceUnderLeaseAgreement', window );">Original office space under lease agreement | ft&#178;</a></td>
<td class="nump">10,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_LeaseAgreementOriginationDate', window );">Lease agreement origination date</a></td>
<td class="text">Jan.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_AdditionalOfficeSpaceUnderLeaseAgreement', window );">Additional office space under lease agreement | ft&#178;</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_AggregateBaseRentObligation', window );">Base rent obligation</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_CashObligation', window );">Total Cash obligation</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_RelocationPaymentToLessor', window );">Relocation payment to lessor</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Gates Foundation | August 2018 Grant Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_asns_GrantsAgreementMaximumAwardAmount', window );">Grant receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_AdditionalOfficeSpaceUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional office space under lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_AdditionalOfficeSpaceUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_AggregateBaseRentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate base rent obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_AggregateBaseRentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_CashObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_CashObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_CurrentOfficeSpaceUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current office space under lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_CurrentOfficeSpaceUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_GrantsAgreementMaximumAwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grants agreement maximum award amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_GrantsAgreementMaximumAwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_LeaseAgreementExtensionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement extension description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_LeaseAgreementExtensionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_LeaseAgreementOriginationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement origination date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_LeaseAgreementOriginationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_NumberOfEliminatedPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of eliminated positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_NumberOfEliminatedPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_OriginalOfficeSpaceUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Original office space under lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_OriginalOfficeSpaceUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_PercentageOfEliminatedPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of eliminated positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_PercentageOfEliminatedPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asns_RelocationPaymentToLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Relocation payment to lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asns_RelocationPaymentToLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=asns_ArsanisClinicalDevelopmentOfASN100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=asns_ArsanisClinicalDevelopmentOfASN100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=asns_AugustTwoThousandEighteenLeaseAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=asns_AugustTwoThousandEighteenLeaseAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asns_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=asns_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=asns_AugustTwoThousandAndEighteenGrantAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=asns_AugustTwoThousandAndEighteenGrantAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W$?:]=3OWCXW/@KJ!7W>AOP!02P,$%     @ RD4-39E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M4RFM2 DX4986Q%60A<@&,MJ LXWFV0'GELIL3MUPE;$VL.!!QAMPOBE*6N"
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M?#96_YM[<WDK[YRT.79E7O=_9[M;W93%V$IKI<A^#+_G2_][']M_#],#< S
M1T";^[\": R@GP&V+WYPUI?Z.6NR];(J[[-J>%O7K!L4\$1M9^ZZAWW?]?]K
MJZW;IV_K)%H&;UT[HV0S2' B@8<B:!M_9$ MPP9%.'Y,L)6*R).!U!JHCZ=I
M#;$>;]5XV\?;27S,^V"0Q+WDTDL6B'%$K!)%!F!2H[L)53>AK";1XR,U/A+5
M)"FK9I!$$YL00<)JD2(*K6XD5HW$PLBD(P8CL<B1A,R&E*21[B)17232!3 7
MB:PTC9D-J0&*/:,L58VDT@B?"*E(T@X?/0<8?3H;.9;Y(!TUTS0V0D\:#S5
MI@&>!OY'-2HZG@%E&MYGH^9#FMA;C@X0D 1)R=."CA"0#,&$<]1*IQ'Q\:ZI
M0NL9:: C!$(YUBQW$\H\2%RVU600&P^10$<22":16&4D;S#DLU 1+<+(]ZIT
M+('D$L7<C*3. A*^,FX5&5CR0!)T/H$$%(F1(^FS(-Z#6T75KCVAQXT.*5 H
M%7(W"J8PC.3+4G1I$GNZ!W6@H9%3T\-_U%F%DE6<[AM46(6\'DUD?5LA'6@H
M@9;REXT*T*071>3UHD,/%>BEGA9TZ*&$'AC#G4J>46A"SYQ%'6@H@0:&+S@H
M4653\HQ_U$F%DE1@Q'Y54BB*?(-2AQ!*"($A/A(4O(2>E0UUNJ"D"QB^%*""
M%X!(C#E=YNM@'3 H 0.&KX&H;80\2R#IW""Y$0+#B4ER)[2 U)=(QPM)O(#A
M?"$-'9XI0#HZ2*(##&<'*5AHNY=O[149I1A[WB1YOKI(,<2_-$;11T/(&:&H
M0I\9'46DH CXUP8I6RN,DHC/;T6'J06?(QU9I" +^)<'263%,5CQOJ2,+'I@
M33K92"$;(/<3B0_8T*#8]Y#R;8B)]:SLI".08K'^ /CFA$XW4N@&? =+RK8(
MIE#_F$G'%BG8 HXMDMBRQE.1U;%E%6P![WXKL958XQF>5L>65; %G/A68@O1
MM[^U.K>L\@TG\J 8=LC/3(+)B5;AJF-_^%?/=N7MTG2'1Y.GCP/&Y_Y\D3W?
MP--V.";\V<QP:OE[5AW/EWKV6C9-6?2G8H>R;%QKT7QJI^#)9?O'3>X.37<9
MM]?5<%HXW#3E=3P)#1['L>M_ 5!+ P04    " #*10U-L.R=%[4!  #2 P
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MSW8:L\GPII]_$%N^<?$'4$L#!!0    ( ,I%#4TZ4Z[LLP$  -(#   8
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL?5-ACYP@$/TKA!]PK&C;RT9-;J]I
MVJ1--M>T_<SJJ.1 +.!Z_?<=T+.V]>X+,,.\-V^&(9^,?70=@"=/6O6NH)WW
MPY$Q5W6@A;LQ _1XTQBKA4?3MLP-%D0=05HQ?CB\95K(GI9Y])UMF9O1*]G#
MV1(W:BWLKQ,H,Q4TH<^.!]EV/CA8F0^BA:_@OPUGBQ9;66JIH7?2],1"4]"[
MY'C*0GP,^"YA<ILS"95<C'D,QJ>ZH(<@"!14/C (W*YP#TH%(I3Q<^&D:\H
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MVV<F<1*T@%,@D^W?%T@V3=NH+X"-S_&Q,?F(]L5U )Z\:F5<03OO^R-CKNI
M"W>#/9APTZ#5P@?3MLSU%D2=0%HQOMO=,2VDH66>?&=;YCAX)0V<+7&#UL+^
M/('"L:![^N9XEFWGHX.5>2]:^ +^:W^VP6(+2RTU&"?1$ M-01_WQU,6XU/
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M,BYX;6Q]4]MNW" 0_17$!X1=[%RTLBUE4U6MU$JK1&V>67MLHX!Q *_3O\^
M'==MK;X ,\PY<V88LM'8%]<">/*F5>=RVGK?'QAS90M:N"O30X<WM;%:>#1M
MPUQO0501I!7CN]T-TT)VM,BB[V2+S Q>R0Y.EKA!:V%_'4&9,:=[^N%XE$WK
M@X,562\:> +_HS]9M-C"4DD-G9.F(Q;JG-[O#\<TQ,> GQ)&MSJ34,G9F)=@
M?*URN@N"0$'I X/ [0(/H%0@0AFO,R==4@;@^OS!_CG6CK6<A8,'HYYEY=N<
MWE%202T&Y1_-^ 7F>JXIF8O_!A=0&!Z48([2*!=74@[.&SVSH!0MWJ9==G$?
MIQM^.\.V 7P&\ 5P%_.P*5%4_DEX4636C,1.O>]%>.+]@6-ORN",K8AW*-ZA
M]U+LDR1CET TQQRG&+Z.62(8LB\I^%:*(_\'SK?AR:;"),*3/Q2FVP3I)D$:
M"=+_EK@5<_U7$K;JJ0;;Q&ERI#1#%R=YY5T&]I['-_D=/DW[=V$;V3ER-AY?
M-O:_-L8#2ME=X0BU^,$60T'MP_$6SW8:L\GPII]_$%N^<?$.4$L#!!0    (
M ,I%#4U.U#^FM $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;'U3VV[;, S]%4$?4"5.U@:!;:!I,6S !@0=MCXK-FT+U<63Y+C[^U&RZGJ;
ML1=)I'@.#RDJ'XU]<1V )Z]*:E?0SOO^R)BK.E#<W9@>--XTQBKNT;0M<[T%
M7D>0DBS;;&Z9XD+3,H^^LRUS,W@I-)PM<8-2W/XZ@31C0;?TS?$DVLX'!ROS
MGK?P#?SW_FS18C-++11H)XPF%IJ"WF^/IWV(CP$_!(QN<2:ADHLQ+\'X7!=T
M$P2!A,H'!H[;%1Y RD"$,GXF3CJG#,#E^8W]8ZP=:[EP!P]&/HO:=P4]4%)#
MPP?IG\SX"5(]'RA)Q7^!*T@,#THP1V6DBRNI!N>-2BPH1?'7:1<Z[F.Z.238
M.B!+@&P&'&(>-B6*RA^YYV5NS4CLU/N>AR?>'C/L316<L17Q#L4[]%[+[>XV
M9]= E&).4TRVC)DC&++/*;*U%*?L'WBV#M^M*MQ%^.X/A7?K!/M5@GTDV/^W
MQ+68PU])V**G"FP;I\F1R@PZ3O+".P_L?1;?Y#U\FO:OW+9".W(Q'E\V]K\Q
MQ@-*V=S@"'7XP69#0N/#\0[/=AJSR?"F3S^(S=^X_ U02P,$%     @ RD4-
M3:;OFE^T 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL?5/;
M;MP@$/T5Q <$K]=ITI5M*9NH:J566J5J\\S:8QL%&!?P.OW[ G9<*['R LQP
MSID+0SZB>;8=@",O2FI;T,ZY_L"8K3I0W%YA#]K?-&@4=]XT+;.] 5Y'DI(L
M39)/3'&A:9E'W\F4.0Y."@TG0^R@%#=_CR!Q+.B.OCH>1=NYX&!EWO,6?H+[
MU9^,M]BB4@L%V@K4Q$!3T+O=X9@%? 3\%C#:U9F$2LZ(S\'X5A<T"0F!A,H%
M!>ZW"]R#E$'(I_%GUJ1+R$!<GU_5O\3:?2UG;N$>Y9.H75?06TIJ:/@@W2..
M7V&NYYJ2N?CO< 'IX2$3'Z-":>-*JL$Z5+.*3T7QEVD7.N[C='.3SK1M0CH3
MTH5P&^.P*5#,_($[7N8&1V*FWO<\//'ND/K>5,$96Q'O?/+6>R_E;O\Y9Y<@
M-&..$R9=8Q8$\^I+B'0KQ#%]1T^WZ?O-#/>1OE]'SY)M@6Q3((L"V8<E;F"R
MMT6R54\5F#9.DR45#CI.\LJ[#.Q=?$3V'SY-^P]N6J$M.:/S+QO[WR Z\*DD
M5WZ$.O_!%D-"X\+QQI_--&:3X;"??Q!;OG'Y#U!+ P04    " #*10U-6@O!
M\K(!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q]4V%OW" ,
M_2N('U#N2-95IR12KU/529MTZK3U,Y<X"2K$&9!+]^\'))=F6[0O@(W?\[,Q
MV8CFU;8 CKQIU=F<ML[U!\9LV8(6]@9[Z/Q-C48+YTW3,-L;$%4$:<7X;G?+
MM) =+;+H.YDBP\$IV<')$#MH+<RO(R@<<[JG5\>S;%H7'*S(>M' -W#?^Y/Q
M%EM8*JFALQ([8J#.Z?W^<$Q#? SX(6&TJS,)E9P17X/QN<KI+@@"!:4+#,)O
M%W@ I0*1E_%SYJ1+R@!<GZ_LC[%V7\M96'A ]2(KU^;TCI(*:C$H]XSC$\SU
M?*!D+OX+7$#Y\*#$YRA1V;B2<K .]<SBI6CQ-NVRB_LXW217V#: SP"^ .XB
M@$V)HO)/PHDB,S@2,_6^%^&)]P?N>U,&9VQ%O//BK?=>BGW*,W8)1'/,<8KA
MZY@E@GGV)07?2G'D_\#Y-CS95)A$>/*'PF2;(-TD2"-!^M\2MV+2OY*P54\U
MF"9.DR4E#EV<Y)5W&=A['M_D/7R:]J_"-+*SY(S.OVSL?XWHP$O9W?@1:OT'
M6PP%M0O'C_YLIC&;#(?]_(/8\HV+WU!+ P04    " #*10U-]NYR7K4!  #2
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q]4]MNVS ,_15!'U E
MCM,6@6V@:5%TP 8$+;8]*S9M"]7%E>2X^_M2LNMYF[$72:1X#@\I*AN,?74M
M@"?O2FJ7T];[[L"8*UM0W%V9#C3>U,8J[M&T#7.=!5Y%D)(LV6RNF>)"TR*+
MOI,M,M-[*32<+'&]4MS^.H(T0TZW]-/Q+)K6!P<KLHXW\ +^>W>R:+&9I1(*
MM!-&$PMU3N^VAV,:XF/ #P&#6YQ)J.1LS&LPOE0YW01!(*'T@8'C=H%[D#(0
MH8RWB9/.*0-P>?YD?XRU8RUG[N#>R)^B\FU.;RFIH.:]],]F>(*IGCTE4_%?
MX0(2PX,2S%$:Z>)*RMYYHR86E*+X^[@+'?=AO-DG$VP=D$R 9 ;<QCQL3!25
M/W#/B\R:@=BQ]QT/3[P])-B;,CAC*^(=BG?HO13;=)^Q2R":8HYC3+*,F2,8
MLL\IDK44Q^0?>+(.WZTJW$7X[@^%U^L$Z2I!&@G2_Y:X%G/S5Q*VZ*D"V\1I
M<J0TO8Z3O/#. WL7'Y']#A^G_1NWC=".G(W'EXW]KXWQ@%(V5SA"+7ZPV9!0
M^W"\P;,=QVPTO.FF'\3F;UQ\ %!+ P04    " #*10U-E9+^J[8!  #2 P
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M[_%LIS&;#&_Z^0>QY1N7?P!02P,$%     @ RD4-3>K)IY2T 0  T@,  !D
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M%Q[#+!2>1O@-BA"*>>E1T$+MZ<)-I0C%O/H8:+-0?HI>UP.-$8KY#X""YG\
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MT2C0MD%-#)0IO5^?SMN CX!?#?1V=B:ADBOB2S"^%2E=A81 0NZ"@O#;#1Y
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M[3_89$@H73@>_-D,8S88#MOQ!['I&V?O4$L#!!0    ( ,I%#4W:;D;%M@$
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M3:Z5LN!2V=RX7%HWQ8O!H;9^>^?V>GK+DV%5/X\I6?X5Q6]02P,$%     @
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MQ<.6P!L0A#2!1Q)X+8$_(&!:MA0FHIWXI!.?((BUY>LPX+:@H@6Y-QA[M)^
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MS)B[@%$!<Q:T^0HQFZ"K<_7W_"<S>ZYLLM,.?U$XR%YK!ZB67N'E&?!I+86
MWOGI'<[-?,'FPNDQOAVZ/.#Z/U!+ P04    " #*10U- \%#=@T"  #Z!0
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MDE%"[*0D:EO"AH)K8(S#HY2PI50D00(2(P%J=:CSF $=@23*3?;I"&1W1X!
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M&UY*^_0V1ZEXY5BTE(J^M>^BMN^SX[^$P0'8!> N ,7O!D0N()H:$+N ^%]
M\FX <0&D"\!VAJ#U;A=S115=S 0_>Z+-AX::M$/W1&_7Q@S:W;'?]'I*/7I:
M1'$R"TZ&R&$>6@R^PJ37F.4M!E\C5O]%K $$Z2"!MM%YP: 7;..C*YT93!"!
M!)$EB*\(\H&-%I-83&TQ&<Y)&,+SQ. \\>T\)!PL:(M!N#<10G?Q0,TDU+I%
MI3U0#,LEH%P"R$4#(1!FN+\0)H*%)*"0!" 8>%VVF/QZ09)!2J] 5)K"8E)0
M3 J(&4G7#"3(IJ=K#A+D$](UOTE7DI$\']E_%,*'1 AX348H1LX9--TM@LL;
MX0E^':AO>*0T$7P&(. 0(".)@>#R1O$'O,(EAX!:N?5*)GN%ZPE!!34F%*X"
ME'[ *UP'* -4Y,-_$ !"8UD,EPL"ZB4963 ,%P(.I[O%<"%@!*@8G*8/#M3?
M611B$N=#N4'O/V^N=M^IV!>U]%ZXTE<&^V/?<:Z8)@WO=+H<]&VRZY1LITPS
MU6W17JG:CN*-NRX&W9UU\1=02P,$%     @ RD4-36^H4K1O @  . @  !D
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MO.=RF8@U[6=9O^&DTW,:#'\6\O]02P,$%     @ RD4-3:JAV. 7 P  3@P
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M-4-WLV&T5!\45OM5L_P'4$L#!!0    ( ,I%#4U;V\9<-0,  /0.   9
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M(^#69/48UN=9=:#P)L$J,52)@4J$"1)(D$S/,X4$*1A!;"TXPCC2G$&1V9B
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M$[M^E.?''C4E507M=8"]Z1&L\NBX/QX>#VC8"H#/ G(-$-$TK<7YI&Q\"\>
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MU'N==LWF\"]2>9P"THCJ.Y+U_?65$Q/5M=9^="6BCM,<G:!8K@MD-?:A%11
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MKP[-,/S_X#N@8] [_H\ X[Z&L0S8]<RDY1DX@;Y6:EJ>N;5:QR$NBQY.BB7
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M; :JK)VF<64)T'=:@":#88M8JC3]>2BE@M;1I#]62\I?VWH!=E, 78B[/19
M:>Z_&A+13.%H7 $G&IN=O4@G'K1E ^/H_;=.!J'K^ ZK=^V[@$EP*#= Q>/
M>X6BO$ATG:ZM9*!.XGJW0RQ+@[EB1,#;[HB ?0"R:_#("T#1&F[0Y,+A\(>P
M8-$=5!#>NWFZ7>KWH;2ON$&$=\2RQ&FGH, \_'S7)X?ND^T*+ D7F#:(.+&C
MT29DEWG).R@L UIM>Y6W?D*O'H<?D9%J( 7RL7EO5&MW%$[MI!!L7F-=7S]8
MS!\H2#XN K%FG!,EE[3]<BI_>43.^NBV0(.#[4?R7]!68+%JV,;@;K.+?C-5
M<[*IH\O X2WOXU.Y97G"%5IHM?]U4$X3OGEQ-(K4DCNVTBG9$'J?LF S:D;$
M\427VS@Q7ZDS&:89<M0RS!9($176M#FZ .I!S5ZZI<8I%OM["AGMVL8SDD@7
M1!4SU>-'LV25S (!-1:14]XE)XUCFLH@39%%9:5R]A/<E(I-\?HV^B\$Q7!O
MHY=M@&M[;C> (/G<Y7C:GC.S;,4O;XBN#06?0RM(^-JI!\*TK&.\%RZ]9>'N
MN8O@USSKR4GCK,?]4?-+2XA<9L6FQM96:(FO,#GC+^6F*JA''[4X"A"%06C,
MDQ9,"^RN'=S'H9'?4*%5726A<41&KT;6U#1T/;39:F[\;""38+L+@U(.L)!0
MHQC7$EU+%/RVQI8P(1*K.#L3QX:K(C@:-MP*C:7,(3S6<4CC89&K]00&(21R
MW@LS(IM0[V8!#//+*]O_(9%6<^E11%XZ5<JQP43:8D_W-.:WN>W><6G!IF"&
M]2,'+=8E7:G/7Y2-M)?/D?V<+A+QA"6>NG29UGC9Q(P>6Q$:*N[%ZJUJ))_@
M:7PJK)QS9PJ\4+91 :WP.OZOMA:6X#::\H<?1R*Q%)2/Q]$ZFYWG-G&'-!?E
M.ZL6 <Q/VR_V,<=S1J-3N%#/328F/Y^K,I+'P<<:VR$0'U'Y <N ;7QB6/?-
M+@ZOSB1 0">J<(?)*+_+DV*[<#2([K%!'/E8<2KW_< +PYT>O%0-O5[KAEZ_
M1B]>IVO/:$83^242=UJ-,6R\>%W[WBV[CY\4I=NL'\LJA',=I.KEP?0O,!:T
MUBYH2\JR8],OW-CTME?VV*L?B+XG@6[=)@BQ=EQ3PQ*BSU ,AI8Q*HXNTX>L
MH.+;EYQIL_7U'\,WN?&<#O3>^J2._-YOZ1(_L]NZHQW#P'<=IBL6?+]M:-HJ
MD?V1JU)_Q1%M'7OW,_SZH?0A?_U0^X'OJ]%DZQQ[X$ 8B;[E#+N"2>>/1%:*
M".LRR1J!1E%A)+7X,YWY0L/H/"@U-)\;!I][V1ET;6 [M":RMA.]ML%>:^LX
MNJ];V+F_,"#O^RS,.76CUNG<'PET^ :WHGWP7;"U&2SO<,QOE>CRK9BLU#<T
MI4W_\V):T^$VU);PUOZ;TPQV4$UQ69VK>N.OZG81*MK7I=*Y6S<I#%[P_\Y!
MYO[X5@#WG5+]=C*6[_K";JY:"J>^LL.I[3$;;I[@*GZ3F;JCLE_HH!JZ;IO%
M^D__.IR<-3/>,#!&Z$$CKO,OFUS'J9RTQ*#8 S3L2/;.+AH[ZXY':8\]>;,M
M,KQI4-W)F?XNRX%]8+NF-BN;C!"P^&V+GE#N5RE7S&W7V;'+ZT^LL(2VP[JM
M,I ZJ6K-5XQR&6C*WO#-D0?VRNV^WG2AN.W#FV?8:!%.D2#8#MQ_]N<L+8J$
MLP6:UE1<\;9P& G?8BMDHUZ(G!PVN_ZR3E6'+!=F#2!X]0GQE7*'<72K-G-O
M47QH! =? /XF^1$FU 3W_=I$FE.>@%2+RD//?M3+R#C*.G_F7!QL/W9$9>"*
MLIBA7"$^'QA-Y:@1:#EZ6Q6L/8TC2F&P*OOS\)@"M,0:6GJDZ7,$.@16*:>@
MJ&BS0AN*;H*B>L2L0&J%X2ILD5M(L^L&2#1N-JEQOGY,EF% D3E4AT(U"YG0
MPB^<X[GE&W1/-PCVK<9_=Q%^NR/JOUGF5Z>"D:U_SD'V21!-G)MLUA'#0G3%
M?&_]JGH^IYW9-<3\C:(]"RNAZ@Y\@ 9YQC+D07(H!=?QE-&?/L-^Y_C+ET-3
MQ[2T>SNLJG29U;J_8S)_YCW F[#?V3-QKX/G0Y,^(R9J:HYV,&T;5\'+6J\>
MTFX.?26_T^9>PS"F Q27U*/>IF[G]07*-"R]ZW2YQCAMK>$;#>MUU38I0OA
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ML.9K+8!KX7LM &SABRV ;.&;+0!MX:LM@&WANRT ;N'++8!NX=LM &_AZZU
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MYK/NS\79-U!+ 0(4 Q0    ( ,I%#4T?(\\#P    !,"   +
M  "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,I%#4UF\PM@@@   +$
M   0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ RD4-3=9!D:?O    *P(  !$              ( !F0$  &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ RD4-39E<G",0!@  G"<  !,
M     ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #*10U-
MUM3'.&,"   5"   &               @ 'X"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ RD4-3;9<]]J^ P  /Q$  !@
M     ( !D0L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M ,I%#4WZU_J?]0$  (D%   8              "  84/  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " #*10U-3]D#[^8#  #*$0  &
M            @ &P$0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ RD4-38K@YI-D @  @ <  !@              ( !S!4  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ,I%#4T6Y2BH> 0  )H5
M   8              "  688  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " #*10U-L.R=%[4!  #2 P  &               @ $4'0
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ RD4-33I3KNRS
M 0  T@,  !@              ( !_QX  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( ,I%#4V9Q:U;M $  -(#   8              "
M >@@  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #*10U-
M(BV$0+0!  #2 P  &0              @ '2(@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,I%#4W#90$&LP$  -(#   9
M      "  ;TD  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ RD4-3=/[&(2T 0  T@,  !D              ( !IR8  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #*10U-3M0_IK0!  #2 P
M&0              @ &2*   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( ,I%#4VF[YI?M $  -(#   9              "  7TJ  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ RD4-35H+P?*R
M 0  T@,  !D              ( !:"P  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " #*10U-]NYR7K4!  #2 P  &0
M@ %1+@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,I%
M#4V5DOZKM@$  -(#   9              "  3TP  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ RD4-3>K)IY2T 0  T@,  !D
M         ( !*C(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " #*10U-L"TNW"("   $!P  &0              @ $5-   >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,I%#4V-!S*[M@$  -(#
M   9              "  6XV  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ RD4-308@@P*U 0  T@,  !D              ( !6S@
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #*10U-VFY&
MQ;8!  #2 P  &0              @ %'.@  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( ,I%#4V&,WE4Q0$  #<$   9
M  "  30\  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
MRD4-3?(>V6O& 0  -P0  !D              ( !,#X  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " #*10U-EN4H L$!   W!   &0
M            @ $M0   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( ,I%#4V9*VW*MP$  -(#   9              "  25"  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ RD4-3<,H02!M P
MGP\  !D              ( !$T0  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " #*10U-LXKIR \"  ",!0  &0              @ &W
M1P  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,I%#4U-
M 6M@- (  + &   9              "  ?U)  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ RD4-3?91KSL5 @  "0<  !D
M     ( !:$P  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,I%#4U<!2HZA0(  !()   9              "
M 2Y;  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ RD4-
M3;=;9"_%!@  ;RL  !D              ( !ZET  'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " #*10U-X[H))+<!  #8 P  &0
M        @ 'F9   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( ,I%#4UX=E%DJP(  +\*   9              "  =1F  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ RD4-36^H4K1O @  . @
M !D              ( !MFD  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " #*10U-JJ'8X!<#  !.#   &0              @ %<;
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ,I%#4U.PNWJ
MF0(  +,(   9              "  :IO  !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ RD4-3=7Q>?UI @  3 @  !D
M ( !>G(  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #*
M10U-UIN@/K@#   $$P  &0              @ $:=0  >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ,I%#4W_$N_B_ $  +X%   9
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M  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( ,I%#4WTTT,^> (
M .4.   -              "  2G@  !X;"]S='EL97,N>&UL4$L! A0#%
M  @ RD4-3??\$)&D P  9!X   \              ( !S.(  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( ,I%#4TE&CD\Q $  $\<   :
M  "  9WF  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M ,I%#4VT9AABNP$  &0<   3              "  9GH  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     W #< \PX  (7J      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>165</ContextCount>
  <ElementCount>223</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)(Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)(Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Collaboration, License and Funding Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureCollaborationLicenseAndFundingArrangements</Role>
      <ShortName>Collaboration, License and Funding Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Loans Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayable</Role>
      <ShortName>Loans Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Loans Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableTables</Role>
      <ShortName>Loans Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayable</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAssetsMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of Assets Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Collaboration, License and Funding Arrangements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureCollaborationLicenseAndFundingArrangementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration, License and Funding Arrangements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Loans Payable - Schedule of Aggregate Principal Amount of Debt Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfAggregatePrincipalAmountOfDebtOutstandingDetails</Role>
      <ShortName>Loans Payable - Schedule of Aggregate Principal Amount of Debt Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Loans Payable - Schedule of Current and Non-current Debt obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableScheduleOfCurrentAndNonCurrentDebtObligationsDetails</Role>
      <ShortName>Loans Payable - Schedule of Current and Non-current Debt obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Loans Payable - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureLoansPayableAdditionalInformationDetails</Role>
      <ShortName>Loans Payable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseClassificationDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments Due under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsDueUnderOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Lease Payments Due under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="asns-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arsanis.com/20180630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>asns-20180630.xml</File>
    <File>asns-20180630.xsd</File>
    <File>asns-20180630_cal.xml</File>
    <File>asns-20180630_def.xml</File>
    <File>asns-20180630_lab.xml</File>
    <File>asns-20180630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001564590-18-021372-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-18-021372-xbrl.zip
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MA\97CJOG=EN.]7T2N 80R M?Q5'P\S,-=?A3VP]F+[N=SN5+^/69?- )_3Z
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M>Q@^6 9.R*_"T+<<@"HTAQ^_2!8IRV1? N<67OWB,HOCU#7FL.*E[F*O,D
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M-=W^A06? ZH#L\G&JNLK=<CWM9WY+?\4]&3WO]/N8"W6'@#=9P7#?2WHPZY
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MNL8<O*BTHBO_KNR-^XY/.3AOQ3UR]?6=H@2[V[O,%T$> N:QEWJ*,FYX>/P
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M,A8<,R8(K[LR""RZ*0F9V:$0<0J^BW^'K(RPHY"(FFZ$G:',@0-HPZ H#@O
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M@'!8 ;6H$D-T80A$&GSLI:.!(@9&G>-4$,M:<Z$]_#@"&X;UZJ2*PG@"E'2
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M]:<RHA2FER7YGKN2MW\:4^8$:/QC+@AUR\5-AREP+4/V_;?6KJVB*QP(PN<
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M+)%-=UF5WZG<7NH;  R95M[28ZY#1:0+&#V&"=O&K\QCHLV7J.'&3:J0;ZY
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ME6@.CC]$=T@TH@NPGF<Y2_0?T75TZ5]F64$L5+"@Q83#\CVT,_]@GK"I@F9
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M7I(]B-"^%\8]?#L^=^Q8&&/;#5$($F',1&A$$SL4>),6Q<'H;R/0UVSR"_
M)PEA*QLQ/#2>A$(8MN\8D?O-F,( )I$A8.).^1;.^&I'Q@^6U>KWY:?QQ\'
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M]YTH17((Y\D"]3X)VR>=&/%@][LZT+W/#G3*H6+UVZ_A9$=#_H[H/"&##NM
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MF>Y6(GIA=<UAF^.KZX 5&>ECKJL77LQUC42/CW8['^TZPZ'9N>2B$W6 BXP
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M\8'+P<"1F(:N>ST+7"4BZ0XP\3WPA/!>O14/75(CJ=V:;VM]H"T9*B4]. N
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MU/>E!@XS_:%3Z';R0WO^S7,.\X6&?[MU\BMW ?RLZ/X3MG;Y@E)D2S-@4PO
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ML$XK()O8IU#Z95'2?%UL(GZ<CQPNY#? $D192;.%Q9M+UK0UA<CMDH)H:FL
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M$<.B4Q__7085?[%1VN8$L]+HY^?&R&KU.T0A*EZ\K"HI?[F-]GQ^M&!XL$0
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M.\[7-FIS!WB;[@3?)D:(%2A-]#I;YY:PH2*]ZL,+&HJ38.07)9S(B!YEGF/
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MI(H5)ZE8:X!P^?1^!(B;;O=TS=YEGX@&9LNG+@+*G%DSP+8\Z3-G-A#ALBN
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M]BP2K](?7AN:K]I%4ZZRCJ;6$3N:+E?-!*B20A 7Y2X#$H%+FE0)X,"(84D
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M:-VR'VR#%?'N2<><Q/'+1!BX8+;_F-V!#UY'QBR(X9.N[7F/1KK<1I2MMVF
M@(XFANO+=3>"&2YWA)$%LR0<3>Q(E)HZFT8H'"&F,OP UOI!A+&+/\]",18A
M_#']W%<[A-G$JQ\E;^:7?FK;5TQLF,N=$+XA]+8QQK!OC'@BWY1N'B,8IQ$
MAK\DHB*27Q#CL1C%QM<@\1QX* X(7I6,A/SKXO=:!BPYC"@(A2D_\G6^H("?
M3._@T_#V4FF!8GZ]D43P!0SCL+U1XMDQS">()XNA"TL'OKGYMN&JR47V5 TX
MW2/YBN&?QX'G!5]Q/-EV*8_9Q,6/T#YV<&SP7_B3/0T2A*XX'SLVA W["4;I
M!HXA?,?<"Y,MI@8K+Y^J7@53A1&,;#E",;)A8?6FQF'!YZ8:6KEI)C; !#.
MJ9YG4J%VP"MC[V":9:I8J8C.!A6Q4A5_5]!1BN7EDBCR?7/6!H4G/ _I%::9
M_5L3M_RW-@G4X28S #1[ VEZ]BP2K](?7AN*X0?M8L&K:DJ6]/M@[RQ8&J6&
M)\\?#E;SP]NA8]3[5>.QQ,R3"%P>E81W 0=&#$L"Z/3/J@QO[L('-J"7KNJQ
MW"1%3.Y JS\-W"<@>:.IY,LD%$+2[JW[;14--'LI?H>_3")E0EK]]NOW/AH)
M_TQ\873;)@TM=,1"8V1PJ4>5,1*473^*8/XF#$[&WYU*^=OJMBYW;_W'_(YS
M19</#0'<7OR8XJK&JJ@L]Y(WUJ9TM6FOU=VCDRJK4ZU.!S1$E-7I\4\,SWYS
MK \1S;\F_+CALH7JU;YDQN;#4XO(F9.\7Z\!,AT\K7'@BC07S/9P:/:MJG,!
M68SJ)T8KF(:C-JN'AH6&*C)=>;9E\L'96J8UO#0[0XLL6BQ')"^T^'CZ>:LP
M/..%':5_E[%L>X=/U6MUEM8B*I[>]\V/>7[?)QM59*%A,J"*#!_HRVBI(FMD
MX6)!HHH,LP]9:%AHJ"+#1_H<KKXYZ Q-J[/OD9[EJ&9'>KYQ/A1"_]Z4E$?6
M2\96 UEH6-M118;/K/D]0-OL63VR2+$,445F,_$T4EYJ@ S+#%5D^+1Z2&<I
M2U+-SJNGD5-)ZQ"[J6;,*=]*+[^G)W59?9C\5/8&4/!];I,SQ7Q#$[U.,<GX
MZ0"R<7=D!4HP(8X<7A0DD/FN7G@QWS43O6XI#9P)[UG=Z,QUU*2O^IZ_R[T;
M)]SSEXQ[=[6)PNA4C\XV!LFV54VXFT*-X.WL4P:,VRJLA+QC6F#4M#O<=*@.
M:)$1T,.P(Q_@JU>HS)>-AK>[5Z$W)LR5F _,87=@7G;Z-#1P/0A3(9("0JLJ
M8Q-:$AVJF]"J;D4W29R$XG?7=Z?)]#-,S/8^V8]3^"&Z"<*/,Q'"D_W[WX0=
MB:C< *G8H.CR. V*9+^1E;NP?=1M6-P,<_V*\K8SJJM)E$QA$C!&U;1F+-?<
MF*I%-SQ<6V.F5]UP$F$D\%A5N7]9ZZ,@145]-<)./\$XJV5OX#H;+UP?'A D
MD>T[T<M7>X>)+-OSW/OEH$DZG9:UY>5T=94]=V#E)VCU_R?LT'BO.BZ]$R,A
M^TQU+1KM&<J-'SE<C<PM&%^;U!"N3K_5WT&<&++J(6,)J_?%Y+86R$I?0O,A
M?$)#C2,UGFX^!C7PO9UH7@G9GNS:F& _)LZV7WDS=1:<FB5D;;(,FH\0$/^^
M%^7/#@(3/Q4D6']1188M@ )<EY=<0HP8)'7W#30?H4Z[TZ9J-[,%0 4)UE]4
MD6$+H #7<%AU%!-+$/L :H806 !D[6:V *@@P?J+*C)L 11O 7K[7F2R!-7,
M F ?P $M +)W9VP!4$&"]1=59-@"*,#5&U2=^LL25#,?P-8)":<5Z?YE(D)A
MCV,1DHC#Y42$NIU,N9A:G=';(E6!,ZE+ED?EO@=.6&B"0V*=.<*UNJH_AZTQ
M1QB>ZN'9QASATC!-2X+@BC"'LV-,J_+6:EP-YAD,F;I6@WE"M9:Y C#8&V42
M>+"AHO?_3=SX\;-X@)^%_,/MS'/C8GF7X6[E70"L<X#MO-OJ6=UV82*;W[II
MF'\$<>'3U[+M2^0&_F<L@&,5QFRUUX]Y8%GM;O;#F>&(D0O[*7ISUCLS$M]5
MW_KSKQDL^-DO[59GN'XFZP>V9%H?HB@1SKLD!, ^B= -'%FQ)X)=(_\4%2=C
MK9F,?NIM<A>YCFN'C[<V[A7YDJMO;I1^X,.GC[_+BAIZUIUV]D-Q^A_^N"DM
M0"1'=?9+3PGZW!ILG,539]XYP,P_ A97GA?$*"D?9U@JZ2DKT:]D(;IK%B(*
MXUQ)J/WXNX@G@?,!MF$DI[WX6R'^L*="KI,=^?C2]UA.9Q:ZD;B*HF#DVK&(
MK/YOG_1B;;O<GT+W ;[ZR0,*PE<_9:T[!]EU\H_J2S"XD4C+8Q77M_<L(K9N
MCFX4]#K6X,_;=]ETK7:K--E5 ]]C?A='$20Z\^TW15Z.LJ2?PF DA!-A13G\
ML.V/Q,=0#5@M17%M!QNY=868GU^L&/[9+Q>7UIRH;Q[3#CHU9^2/X^N\D5Y>
M4Z\XOPWE['978P,PC7J7W2W5V,:QEN?]6<2VZPLG+?YW-1HET\2#+>6\$V-W
M5++EK'6VG'[BE?.?1$D!FI6PT>&)0>*C:0F8^/"CVJA1)@SY!VYCVW?LT(G^
MG#DP EBDGG61[VAE(6ZW(\XM&-?<GM@\U_+:_"'B#_XHF(K?@J@(<6>=>7B,
M92A9S%NN1Z=S.;<<I>DMS/S:CB8PT@?7$<[;QS\C 9HL.R1<C6+W0>XFV&+P
MBP1^I_\8^*6EVL+XI+94G8O!XDH]83G*2XL/NO(=_!_40P^@D7!J\((P?(3O
M_<OVDB(7=;8P8HG(7&\XG%NXK2;[Q/599]NBFEV80'<U\CVKUWWJ!#X#W0-7
M@E+!;UTG(7I6B@->9RSN..#+;M^:4W%+7KYN?'\$_FAQB.OLO1V'V.W-*^'E
MK]]F%]S8;BA7_)T;C;P@2DI66V>=U:8?O +/@D'U>^"+Q]_M\&\1WR2^$Y7M
ML6P$;Q^S'__A@J2'H\GC;^)!>,5G91_YX,^2.))_MU8^\'=AXXQ04&]"\=]$
M^*/'I4\K?##ZC+R.-L ZD5V-3F]X,>AOL>.7K/P! %MG"AX>L--;WW6F*&_H
M9UCP+>SC4UZ?[A:&\REHZ('5Z5I; C9H7PZMR@#;PGPGJ*'KL[Y;&/>\H0^Y
MX.M."PU9'SS?O<K^^D7>@XHP>BOBKT+X:D?(_W8^AO)_NU=3/ P6EVG#&66!
M<5;[%L]^@9GL.Z3#36C3B68>H.>?$!S!PP1.09[KNR/;^Q*ZMG<=1''1?=)=
M=Z39D?FM;O=";JOU;]]UA!O=N=OO?/CD8.L1IL+Q?CKS@D<A/@OIR/O-M>]<
M3_EB%LZUW8VM1G98SHONL"2E&P?RA'%ON$/?:9%[%[VGC%O#\BD,QB)"-[/M
MW8AE@^YMN$3?9;$O^F6WS/I![#O@=<;.CJM\8;7W'O#'>")"_86UVZ*WSGK8
M]5S0ZY0&O'X0^PYXDZ]NAQ7N#2]W'K#4*]?8V>4N4,Y9'0'S\<YS[Q><U[TM
MKG6UU'RRP_A1TH ]DH]Y^UC\2^YW=6!F=[_]=ETVR;X\SK!?4P@/^/_+N];>
MMI$E^U>(76"1 6*O2+TQBP'\B+RYB.-<VS-!/M)BVR9 D[HDY<3[Z[>Z24K-
M5[/Z05&>^VDRED3V.5U=75U=CR=F1%1^D%V7GCW%I'+)I[01=S!0<Q<2:FJ"
M 7))-[)HPVXX?VU(F/"6U01Q1SPX69.6VX!1NYHO*TLA&XK$(=R6 Q,W+XBK
M.7[;B9LN>B<.X3X<7.(4[I^J5]E]4(?P# XN<W:+S)FECFG$*QA>FNQ'X?ZB
M09)G/]W8JQTE)B)C+(G3"_I]$F\H.Z6@CW,_"& @UP0L6L^]H@$?*_BNYW*A
M,)VLK<A#O'7CM_N?T7W>H0V>>0?@X*4D9$ :V63>8-P^L1SG-.*XX7ALD1D^
M&"-[',?G5&0G'B^?XT(ZQQ6312"=,YY7-%=5.87Q?0YI^SK_E607^#R;(B/V
M>-DLUGK- ,2RV<*,''<B>_I8N6LW:DYFG9:@$=8Z@DN/DK5VBT8@<>8%3G3
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MW[A!+:A1V#!&K%K5E.*NLH7\L,V![JAC)B@(H@;:.0;0?3AX);1 BT:<'H-
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M+9YH/4:QY8:6NTO>M=Z(&Y_RO'2AYOQ835_F."7).O:S47%,(1)UA4R=A53
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M?>X 1=#"S<E6*HJGAH$;WS!?S<NY92 ;5O(UAT"GV%55G'8S?>(]@BK/9A.
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M]2(LI$#4^UL$0F:"9DJG,X4?)/1&)LB,O"WM(P>J8=6^:(3T3D8JF!":UYH
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M:"D&$R\,P^<_+;/Z<XB\QUW4&G>1)37+I=Z043!+,)C>&"Q! >S1>N4UT3?
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MX6Q![&N/N5!N2L2U)Z&W%^%T#\+WWD,4+WDL#TT4M+P\_9CA>(6M_N-T!6T
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M/ 2XT!!2]700:E:@5S=R^ 2S(GVFW6KP!DYV-WV:MKOK6N2]G(VTG,''),W
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MO_3K5HM("27WQD.9@)8+^(WQD=X4FVM5/P0 UE!/7,I&1GJ>P:)-WUG)ONU
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MK+PG$B4K(]\8)&.%P@!%#X^M. . TN0^16F9PN+GD)Z@@PHVT%6<"%1N0/D
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MQU@S, /T%Q M^");Y3 IX"GD_W43&/>I.G:\/@/? 3*M^(%M@VZ<P5*)IU;
ME*OU(+#3"IPU:U#SMLR <[A-7BC]<PA;?[_#PLELTU52OZ.F/6V+K-B<C9_\
MN)$#/$#1O>@"5&C 2:>#3I?.@)GR!/3Q5/4?$-+=>U>6,%O/_:%&C?8&3 0
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M*B09@BVOH&2B[$,"%G4PY168*OZ "P!J"0 1 7 9P(4"8C^5)%=/<+U#</G
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M(B#SP29<=[T8? 6'EZ4?TJ-,\,R']6'.3,]*O""SJ(6D,VQE#^]7-9(!031
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M=)6[?#A#Z8;Z*%Q?TY*6=%M,>V8<I&$>;P?(>9D+.3^Z]00;CF!;LPPW">I
M@W5U9IHX74.B5**B1SC--D;I6)23&2;IIX1,PS,^.]&%"IOH+T*W%6/^L,_:
M!GGO0T =Z9</H.4$KJ=*/XM?=!Y.C#I%U$-!>Z/0!,33(XFBS'=5G<&3IR1_
M-+OM+/^^Y>7U?5*^"M-7!;<*?N.9'M*5]+8<;0Y0G3.$?9TP  K6T5AD %0V
MWV$ *@ZBHJN?+PE=\F_R+_(#[5WVM_\-4$L#!!0    ( ,I%#4TC'5H+*#D
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M_XZ"^,$!,EPI\FW.KO3<Z6>3"KPUW>'L82?I=NO-#6*YG$@;0<E*QE!'2?-
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M7%2HX40;N:&'./ T*2/2[)25/%X5G*O _DO;0QG97ND?+#_,9MG)INM,SD2
M>B9,40JU()W[;]8OO(I6HY^6[P ?P 0HZ0]D*]!8MP<]9+/6$()BG+LFT.MH
M7.SFV<6+71I 081KZ31BK/+^,@'7"):B#=]J11.5[F"Z01:^M0*6=H41U7T2
MT5XM>E*P[%VV%4C4#2VCT!+CW[U@C6P\Q_3@@Q>T+">B70/8>A_M6 #7L"PF
M 'X<B9A/GP4M;9UOI:.@+UJPP7U%;#.LE\S@#RM"7$% ![N[V<CV!RHN7$X
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M"7O1;2D4:624/WZ;D4;&2OW&D49@HY?!%>ZU@5IM >7!!<8B*BH%V[*4]Z
M>LO/(%EO2=F'(8,K9*MZER/@AT:#ZV>#S0W%K\9Y8?#92(0J']QS>3]*?0)X
M<6)C[S7U;A4%4.V[?G"<>G^I*7?LX2#UQ6XU*0U]$7#BXG 9&W$E#!>T3G-O
MS.SED('+,Y_V17258U;C/\NAZK4 J_9\-KC.?,/U5.S>S@/*^J*KE^,E'K/
M41LDO5@M>7.K8XAK$64EY#64NGA%V)3&<O%*Z,:661)>.T(%X_OBN% .4V5,
M)0=J4 UJ(V)Y=?A>ZP75\<P<I!:R:A1&X__E/6/UF9Z\__[_ 5!+ 0(4 Q0
M   ( ,I%#4TS5=JXW?<  $-)$0 1              "  0    !A<VYS+3(P
M,3@P-C,P+GAM;%!+ 0(4 Q0    ( ,I%#4T4;6Q _Q(  "K.   1
M      "  0SX  !A<VYS+3(P,3@P-C,P+GAS9%!+ 0(4 Q0    ( ,I%#4WJ
MGT!/GPP  %NK   5              "  3H+ 0!A<VYS+3(P,3@P-C,P7V-A
M;"YX;6Q02P$"% ,4    " #*10U-1RK*__TA  ""+@( %0
M@ $,& $ 87-N<RTR,#$X,#8S,%]D968N>&UL4$L! A0#%     @ RD4-3;\F
MCQP^7   XV$% !4              ( !/#H! &%S;G,M,C Q.# V,S!?;&%B
M+GAM;%!+ 0(4 Q0    ( ,I%#4TC'5H+*#D  .LQ!  5              "
M :V6 0!A<VYS+3(P,3@P-C,P7W!R92YX;6Q02P4&      8 !@"* 0  "- !
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
